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A B S T R A C T
Background
Women with a diagnosis of breast cancer may experience short- and long-term disease and treatment-related adverse physiological and
psychosocial outcomes. These outcomes can negatively impact prognosis, health-related quality of life (HRQoL), and psychosocial and
physical function. Physical activity may help to improve prognosis and may alleviate the adverse effects of adjuvant therapy.
Objectives
To assess effects of physical activity interventions after adjuvant therapy for women with breast cancer.
Search methods
We searched the Cochrane Breast Cancer Group (CBCG) Specialised Registry, the Cochrane Central Register of Controlled Trials
(CENTRAL), MEDLINE, Embase, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Physiotherapy
Evidence Database (PEDro), SPORTDiscus, PsycINFO, ClinicalTrials.gov, and the World Health Organization (WHO) International
Clinical Trials Registry Platform, on 18 September 2015. We also searched OpenGrey and Healthcare Management Information
Consortium databases.
Selection criteria
We searched for randomised and quasi-randomised trials comparing physical activity interventions versus control (e.g. usual or standard
care, no physical activity, no exercise, attention control, placebo) after adjuvant therapy (i.e. after completion of chemotherapy and/or
radiation therapy, but not hormone therapy) in women with breast cancer.
Data collection and analysis
Two review authors independently selected studies, assessed risk of bias, and extracted data. We contacted trial authors to ask for
additional information when needed. We calculated an overall effect size with 95% confidence intervals (CIs) for each outcome and
used GRADE to assess the quality of evidence for the most important outcomes.
1Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Main results
We included 63 trials that randomised 5761 women to a physical activity intervention (n = 3239) or to a control (n = 2524). The
duration of interventions ranged from 4 to 24 months, with most lasting 8 or 12 weeks (37 studies). Twenty-eight studies included
aerobic exercise only, 21 involved aerobic exercise and resistance training, and seven used resistance training only. Thirty studies described
the comparison group as usual or standard care, no intervention, or control. One-fifth of studies reported at least 20% intervention
attrition and the average physical activity adherence was approximately 77%.
No data were available on effects of physical activity on breast cancer-related and all-cause mortality, or on breast cancer recurrence.
Analysis of immediately postintervention follow-up values and change from baseline to end of intervention scores revealed that physical
activity interventions resulted in significant small-to-moderate improvements in HRQoL (standardised mean difference (SMD) 0.39,
95% CI 0.21 to 0.57, 22 studies, 1996 women; SMD 0.78, 95% CI 0.39 to 1.17, 14 studies, 1459 women, respectively; low-quality
evidence), emotional function (SMD 0.21, 95% CI 0.10 to 0.32, 26 studies, 2102 women, moderate-quality evidence; SMD 0.31,
95% CI 0.09 to 0.53, 15 studies, 1579 women, respectively; low-quality evidence), perceived physical function (SMD 0.33, 95% CI
0.18 to 0.49, 25 studies, 2129 women; SMD 0.60, 95% CI 0.23 to 0.97, 13 studies, 1433 women, respectively; moderate-quality
evidence), anxiety (SMD -0.57, 95% CI -0.95 to -0.19, 7 studies, 326 women; SMD -0.37, 95% CI -0.63 to -0.12, 4 studies, 235
women, respectively; low-quality evidence), and cardiorespiratory fitness (SMD 0.44, 95% CI 0.30 to 0.58, 23 studies, 1265 women,
moderate-quality evidence; SMD 0.83, 95% CI 0.40 to 1.27, 9 studies, 863 women, respectively; very low-quality evidence).
Investigators reported few minor adverse events.
Small improvements in physical activity interventions were sustained for three months or longer postintervention in fatigue (SMD -
0.43, 95% CI -0.60 to -0.26; SMD -0.47, 95% CI -0.84 to -0.11, respectively), cardiorespiratory fitness (SMD 0.36, 95% CI 0.03
to 0.69; SMD 0.42, 95% CI 0.05 to 0.79, respectively), and self-reported physical activity (SMD 0.44, 95% CI 0.17 to 0.72; SMD
0.51, 95% CI 0.08 to 0.93, respectively) for both follow-up values and change from baseline scores.
However, evidence of heterogeneity across trials was due to variation in intervention components (i.e. mode, frequency, intensity,
duration of intervention and sessions) and measures used to assess outcomes. All trials reviewed were at high risk of performance bias,
and most were also at high risk of detection, attrition, and selection bias. In light of the aforementioned issues, we determined that the
evidence was of very low, low, or moderate quality.
Authors’ conclusions
No conclusions regarding breast cancer-related and all-cause mortality or breast cancer recurrence were possible. However, physical
activity interventions may have small-to-moderate beneficial effects on HRQoL, and on emotional or perceived physical and social
function, anxiety, cardiorespiratory fitness, and self-reported and objectively measured physical activity. The positive results reported
in the current review must be interpreted cautiously owing to very low-to-moderate quality of evidence, heterogeneity of interventions
and outcome measures, imprecision of some estimates, and risk of bias in many trials. Future studies with low risk of bias are required
to determine the optimal combination of physical activity modes, frequencies, intensities, and durations needed to improve specific
outcomes among women who have undergone adjuvant therapy.
P L A I N L A N G U A G E S U M M A R Y
Physical activity for women with breast cancer who have completed active cancer treatment
Review question
What effects do physical activity (PA) interventions have on women with breast cancer who have completed cancer treatment?
Background
After receiving breast cancer treatment, women may experience adverse mental and physical events caused by the cancer and by its
treatment. These adverse events can result in a shorter life after treatment and can have a negative impact on quality of life (QoL) and
on physical and mental health. Some studies suggest that being regularly physically active after treatment might lower the chance that
breast cancer may come back, or that women may die of breast cancer. Regular PA may lead to a wide range of other beneficial effects,
including improved QoL, mental health, and physical function. We wanted to determine whether PA has an effect on risk of recurrence
and dying from breast cancer, QoL, and other aspects of well-being in women who had breast cancer after treatment.
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Study characteristics
We included only studies consisting of women with breast cancer who had completed active cancer treatment. These studies compared
outcomes of women involved in PA interventions versus outcomes of those who were offered usual care or no PA. Participants must
have been assigned to a group in random or somewhat random fashion. The evidence is current to September 2015.
Key results
This review includes 63 trials involving 5761 participants. Most trials (28) consisted of aerobic exercise (e.g. walking, cycling, dance),
whereas seven trials included a resistance training-only group, and 21 trials included a combined aerobic exercise and resistance training
group. One in five participants placed in a PA intervention group dropped out before the end of the study, and on average one-quarter
of target PA sessions were missed by participants. We found no studies that looked at effects of PA after cancer treatment on risk of
recurrence or dying from breast cancer or any other cause. We found that participants performing PA had more favourable values by
the end of the intervention and experienced greater positive changes over the intervention period in terms of QoL, views on their
emotional health and physical ability, social function, feelings of worry, stamina, PA levels, body fat, and strength of muscles, compared
with usual care participants. Researchers found no effects on perceived health, ability to sleep, feelings of pain, sexual function, body
mass index, waist-to-hip girth ratio, and bone health of the upper and lower spine or hip. At least three months after completion of
the intervention, actual values and changes from the start of the intervention in feelings of tiredness, stamina, and self-reported PA
levels remained more favourable in participants given PA intervention than in those given usual care. Both aerobic exercise only and
combined aerobic and resistance training interventions improved QoL and stamina. Aerobic exercise improved views on perceived
emotional health and physical ability, as well as social function and self-reported PA levels, whereas resistance training resulted in greater
improvement in muscle strength. Combined aerobic and resistance training interventions led to reduced feelings of tiredness. Trialists
reported few minor adverse events among those given PA interventions.
Quality of the evidence
We rated the quality of evidence related to various aspects of health as very low, low, or moderate. We noted wide variation among the
interventions that we looked at in terms of types of PA, frequency of sessions per week, levels of effort among participants, and session
and intervention duration. Also, researchers measured aspects of health in many different ways. Other problems with eligible studies
included lack of information on how study authors placed participants in groups at random, whether researchers who were carrying
out the tests knew which group the person being tested belonged to, and how researchers dealt with data missing from their studies.
In many aspects, we could not rule out the chance that positive effects observed were small enough that they were not important. It
is also possible that smaller studies that have not found favourable effects of PA in women with breast cancer after treatment have not
been published, because study authors often find it difficult to publish studies that have not found beneficial effects.
3Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Physical activity versus control for women with breast cancer after adjuvant therapy
Patient or population: women with breast cancer af ter adjuvant therapy
Settings: home-based, facility-based, and combined home and facility-based
Intervention: physical act ivity
Comparison: control
Outcomes Illustrative comparative risks* (95% CI) No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Physical activity




Mean HRQoL at end of in-
tervent ion follow-up ranged
across control groups f rom
- 2.70 to 2.72 standard de-
viation units
Mean HRQoL at end of in-
tervent ion follow-up in the
intervent ion groups was
0.39 standard deviations
higher





SMD 0.39 (0.21 to 0.57) re-
expressed using FACT-G (0
to 104 scale); the interven-
t ion mean HRQoL was 5.9
(3.2 to 8.6) points higher
than control (MID 5 to 6
points)
Emotional function/mental




Mean emotional funct ion/
mental health at end of in-
tervent ion follow-up ranged
across control groups f rom
- 4.80 to 0.21 standard de-
viation units
Mean emotional funct ion/
mental health at end of in-
tervent ion follow-up in the
intervent ion groups was
0.21 standard deviations
higher





SMD 0.21 (0.10 to 0.32) re-
expressed using FACT-EBW
(0 to 24 scale); the interven-
t ion mean emotion funct ion
was 0.7 (0.3 to 1.0) points
higher than control (MID 2
points)
Perceived physical func-




Mean physical funct ion at
end of intervent ion follow-
up ranged across control
groups f rom
- 2.64 to 1.64 standard de-
viation units
Mean physical funct ion at
end of intervent ion fol-








SMD 0.33 (0.18 to 0.49) re-
expressed using FACT-PBW
(0 to 28 scale); the interven-
t ion mean physical funct ion









































































































(0.18 to 0.49 higher)a higher than control (MID 2
points)




Mean anxiety at end of in-
tervent ion follow-up ranged
across control groups f rom
- 1.33 to 1.19 standard de-
viation units
Mean anxiety at end of in-
tervent ion follow-up in the
intervent ion groups was
0.57 standard deviations
lower





SMD -0.57 (-0.95 to -0.19)
re-expressed using PROMIS
(0 to 9 scale); the interven-
t ion mean anxiety was 1.
9 (3.2 to 0.6) points lower
than control (MID 3 to 4.5
points)




Mean depression at end
of intervent ion follow-
up ranged across control
groups f rom
- 0.79 to 2.84 standard de-
viation units
Mean depression at end of
intervent ion follow-up in the
intervent ion groups was
0.34 standard deviations
lower





SMD -0.34 (-0.62 to -0.05)
re-expressed using BDI-II (0
to 63 scale); the interven-
t ion mean depression was
3.8 (7.0 to 0.6) % lower than
control (MID 18%)




Mean fat igue at end of in-
tervent ion follow-up ranged
across control groups f rom
- 1.83 to 1.69 standard de-
viation units
Mean fat igue at end of in-
tervent ion follow-up in the
intervent ion groups was
0.32 standard deviations
lower





SMD -0.32 (-0.47 to -0.18)
re-expressed using FACT-F
(0 to 52 scale); the inter-
vent ion mean fat igue was 2.
8 (4.1 to 1.6) points lower
than control (MID 3 points)
Cardiorespiratory fitness




Mean cardiorespiratory f it -
ness at end of intervent ion
follow-up ranged across
control groups f rom
- 0.51 to 3.59 standard de-
viation units
Mean cardiorespiratory f it -
ness at end of intervent ion









SMD 0.44 (0.30 to 0.58)
re-expressed as VO max
(mL/ kg/ m in); the interven-
t ion mean was 2.1 (1.4 to
2.7) mL/ kg/ m in higher than
control (MID 3.5 mL/ kg/
m in)
* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
BDI: Beck Depression Inventory; CI: conf idence interval; FACT-EBW: Funct ional Assessment of Cancer Therapy Emotional Wellbeing; FACT-F: Funct ional Assessment of Cancer









































































































related quality of lif e; MID: minimal important dif f erence; PROMIS: Pat ient Reported Outcomes Measurement Information System; SMD: standardised mean dif ference; VO
max: maximal oxygen uptake
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aAs a rule of thumb, 0.2 SD represents a small ef fect, 0.5 SD a moderate ef fect, and 0.8 SD a large ef fect.
bWe downgraded by two levels due to evidence of inconsistency supported by presence of substant ial heterogeneity (I² =
50% to 90%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01), and
suspected publicat ion bias (Egger’s test, P < 0.05).
cAll t rials lacked blinding of part icipants (performance bias), and most trials lacked blinding of outcome assessors (detect ion
bias) and had incomplete outcome report ing and/ or high attrit ion (attrit ion bias), but most were at a low risk of select ion bias,
report ing bias, and other bias, and therefore, we did not downgraded based on risk of bias.
dWe downgraded by one level because all t rials lacked blinding of part icipants (performance bias) and most trials lacked
blinding of outcome assessors (detect ion bias), had incomplete outcome report ing and/ or high attrit ion (attrit ion bias), and
half of them had unclear or inadequate randomisat ion and/ or allocat ion concealment procedures..
eWe downgraded by one level due to evidence of inconsistency supported by presence of substant ial heterogeneity (I² = 50%
to 90%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01).
fWe downgraded by three levels due to evidence of inconsistency supported by presence of substant ial heterogeneity (I²
= 50% to 90%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01),
suspected publicat ion bias (Egger’s test, P < 0.05), and imprecision because the 95% conf idence intervals included negligible
ef fects as well as an appreciable benef it (>0.5) and sample size did not meet the ‘‘rule of thumb’’ of approximately 400 (200
per group) part icipants.
gWe downgraded by two levels due to evidence of inconsistency supported by presence of substant ial heterogeneity (I² =
50% to 90%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01),
and imprecision because the 95% conf idence intervals included negligible ef fects as well as an appreciable benef it (>0.5).
All t rials lacked blinding of part icipants (performance bias), had incomplete outcome report ing and/ or high attrit ion (attrit ion
bias), and unclear or inadequate randomisat ion and/ or allocat ion concealment procedures (select ion bias), but because most
were at a low risk of detect ion, report ing, and other bias, we did not downgraded based on risk of bias.
hWe downgraded by one level due to evidence of inconsistency supported by presence of substant ial heterogeneity (I² = 50%
to 90%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01).
iWe downgraded by one level because all t rials lacked blinding of part icipants (performance bias) and most trials lacked
blinding of outcome assessors (detect ion bias), had incomplete outcome report ing and/ or high attrit ion (attrit ion bias), and









































































































B A C K G R O U N D
Description of the condition
Worldwide, breast cancer is the most frequently diagnosed cancer
among women, accounting for one in four of all new female can-
cer cases (1.7 million total cases) in 2012 (Ferlay 2013). Although
incidence rates vary markedly across world regions, breast cancer is
the most common cancer among women in both more developed
and less developed regions, with slightly more cases reported in
less developed (883,000 cases) than in more developed (794,000)
regions (Ferlay 2013). Breast cancer is the most common cause of
cancer death among women in less developed regions (324,000
deaths) and is the second most common cause of cancer death
among women in more developed regions (198,000 deaths). Glob-
ally, researchers reported a 20% increase and a 14% increase in
breast cancer incidence and mortality, respectively, from 2008 to
2012 (Ferlay 2013; Jemal 2011). Although incidence rates remain
highest in more developed regions, mortality rates are relatively
much higher in less developed countries - a fact that can be at-
tributed to lack of both early detection and access to treatment
facilities (IARC 2012).
In 2012, breast cancer was the most prevalent cancer worldwide
with approximately 6.3 million women alive who had received
a diagnosis of breast cancer in the previous five years, represent-
ing a 17% increase from 2008 figures (Bray 2013; Ferlay 2013).
Owing in particular to this rising prevalence, attention to tertiary
prevention among women with breast cancer has increased. In
addition to risk of cancer recurrence, women with breast cancer
often experience numerous short- and long-term disease- or treat-
ment-related adverse physiological and psychosocial outcomes,
such as cardiotoxicity, neurotoxicity, secondary leukaemia, lym-
phoedema, premature menopause, sexual dysfunction, infertility,
weight gain, difficulty sleeping, and fatigue (Azim 2011; Beisecker
1997; Bovelli 2010; de Jong 2002). These adverse effects would
be expected to have a negative impact on health-related quality of
life (HRQoL) and physical function. In addition, these unwanted
effects can be prolonged after completion of active treatment and
may hinder the woman’s return to normal life (Fong 2012).
Description of the intervention
Encouraging women with breast cancer after adjuvant therapy
to adopt a healthy lifestyle, such as low alcohol consumption,
greater fruit and vegetable consumption, and higher physical ac-
tivity levels, may be important for improving quality of life and the
health of survivors and, in turn, may reduce the healthcare burden
(Demark-Wahnefried 2005). In particular, higher levels of physi-
cal activity represent a modifiable health behaviour that could al-
leviate the sequelae related to breast cancer and assist women in
returning to the health status they had before receiving the diag-
nosis and treatment (Fong 2012). Physical activity is defined as
any bodily movement produced by contraction of skeletal muscle
that increases energy expenditure above a basal level, performed as
part of occupation, active transportation, household and garden-
ing chores, and recreational activities. Exercise, a subcategory of
physical activity, is defined as planned, structured, and repetitive
physical activity that is aimed at improving or maintaining one
or more components of physical fitness (Caspersen 1985; Physical
Activity Guidelines 2008). Current recommendations for breast
cancer survivors are to avoid inactivity, return to normal daily ac-
tivities as quickly as possible after surgery, continue these activi-
ties during and after non-surgical treatments, and engage in 150
minutes per week of moderate-intensity aerobic activity (e.g. any
activity, such as brisk walking, that requires a moderate amount
of effort and noticeably increases heart rate) (Schmitz 2010).
How the intervention might work
Evidence from observational data suggests that higher levels of
physical activity in breast cancer survivors or post diagnosis are as-
sociated with reduced risk of dying from breast cancer or from all
causes (Beasley 2012; Ibrahim 2011). Increased physical activity is
also associated with reduced exposure to oestrogen and androgens
and increased concentrations of sex hormone-binding globulin, as
well as improved insulin sensitivity and decreased concentrations
of insulin growth factor-1 and of adipokines and inflammatory
markers, with the exception of a beneficial elevation in adiponectin
concentrations (Lynch 2011). These effects of increased physical
activity may serve as the mechanisms that can explain associated
reductions in all-cause and breast cancer-related mortality. Fur-
thermore, lack of physical activity has been shown to be related
to weight gain post breast cancer diagnosis, which, in turn, has
been linked to poorer survival in some studies (Camoriano 1990;
Kroenke 2005). More active women have been found to possess a
lower body mass index (BMI) and to be less likely to gain weight
after diagnosis, thus improving their survival chances (Holmes
2005; Lahmann 2005).
Evidence suggests that physical activity can promote positive phys-
iological and psychological benefits among cancer survivors after
treatment (Brown 2012; Fong 2012; Galvao 2005; Ingram 2007;
Knols 2005; Speck 2010). A recent meta-analysis revealed that
physical activity was associated with important positive effects on
physical function, body weight and BMI, and quality of life, which
included physical and social functioning domains, among patients
who had completed cancer treatment (Fong 2012). Results re-
ported in a Cochrane review indicate that physical activity may
have beneficial effects on overall HRQoL and on certain HRQoL
domains, including cancer-specific concerns (e.g. breast cancer),
body image and self-esteem, emotional well-being, sexuality, sleep
disturbance, social functioning, anxiety, fatigue, and pain at vary-
ing follow-up periods (Mishra 2012a).
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Why it is important to do this review
Despite benefits derived through physical activity, consensus has
not been reached regarding the magnitude of benefit, the most
effective delivery mode, and prescription of physical activity in
breast cancer survivors. Physical activity interventions in this pop-
ulation typically are delivered under supervised - Courneya 2003;
Milne 2008 - or self-directed, home-based conditions (Pinto 2005;
Vallance 2008). They consist of, or serve as a way to compare,
aerobic exercise training (Cadmus 2009; Herrero 2006), walking
(Matthews 2007; Payne 2008), and resistance training (Schmitz
2009; Winters-Stone 2011). Their duration can vary from less
than 10 weeks - Daley 2007; Fillion 2008 - to six months or
longer (Schmitz 2009; Winters-Stone 2011). Previous systematic
reviews and meta-analyses have included studies involving patients
with all types of cancer (Brown 2012; Cramp 2010; Fong 2012;
Knols 2010; Mishra 2012a; Mishra 2012b; Speck 2010), rather
than focusing on patients with breast cancer; studies of patients
with cancer who received adjuvant therapy (Carayol 2013; Markes
2009; McNeely 2006; Mishra 2012b); studies that focused on a
particular physical activity mode, such as walking (Knols 2010),
yoga (Cramer 2013), dance (Bradt 2011), or resistance training
(Cheema 2014; Cheema 2008; Cramp 2010); or studies that in-
vestigated a particular outcome, such as quality of life - Cramp
2010; Mishra 2012a; Mishra 2012b - and upper limb dysfunction
(McNeely 2010). Therefore, a systematic review and meta-analy-
sis is needed to investigate effects of physical activity on the large
range of outcomes reported in trials including women who have
completed adjuvant therapy for breast cancer.
O B J E C T I V E S
To assess effects of physical activity interventions after adjuvant
therapy for women with breast cancer.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered for inclusion in this review all randomised con-
trolled trials (RCTs), as well as quasi-randomised controlled trials,
investigating effects of physical activity interventions for women
with breast cancer after adjuvant therapy.
Types of participants
We sought trials that included women with a diagnosis of breast
cancer who had completed adjuvant therapy (radiotherapy or che-
motherapy).
We excluded studies including cancers other than breast cancer
unless separate data were available for the breast cancer subgroup.
We also excluded studies including only patients with metastatic
breast cancer (stage IV and above).
We excluded studies including women who were undergoing adju-
vant therapy (radiotherapy and chemotherapy but not endocrine
therapy) for breast cancer during the physical activity interven-
tion.
Types of interventions
We included all trials that reported and evaluated effects of in-
terventions such as physical activity (including exercise), as well
as studies comparing a physical activity group versus a group de-
scribed as receiving no physical activity and no exercise, and given
control, attention control, usual or standard care, or placebo.
We excluded studies that:
• included an additional treatment arm or combined
intervention arm (e.g. physical activity with diet modification)
for which effects of physical activity could not be isolated;
• provided single exercise sessions that measured acute effects;
• investigated effects of physiotherapy; and
• were restricted to stretching or local muscular endurance
(e.g. training of shoulders, back, or legs only) or therapeutic
exercise regimens that addressed only specific impairments
related to the shoulder, the arm, or both.
Types of outcome measures
For selected outcomes, we extracted:
• immediately postintervention follow-up values;
• three-month or longer postintervention follow-up values;
• change from baseline to end of intervention scores; and
• change from baseline to three-month or longer
postintervention scores.
Primary outcomes Breast cancer-related mortality, defined
as time from date randomised to date of death due to
primary breast cancerHRQoL domains, via a validated
questionnaire, including but not limited to physical function
(e.g. performance of self-care and everyday physical
activities), psychological function (e.g. emotional well-being,
anxiety, depression, self-esteem), social and economic role
function (e.g. performance of work or household
responsibilities, social interactions), pain, and fatigue or
vitality (e.g. energy)
Primary outcomes
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• Breast cancer-related mortality, defined as time from date
randomised to date of death due to primary breast cancer
• HRQoL domains, via a validated questionnaire, including
but not limited to physical function (e.g. performance of self-
care and everyday physical activities), psychological function
(e.g. emotional well-being, anxiety, depression, self-esteem),
social and economic role function (e.g. performance of work or
household responsibilities, social interactions), pain, and fatigue
or vitality (e.g. energy)
Secondary outcomes
• All-cause mortality, defined as time from date randomised
to date of death (any cause)
• Breast cancer recurrence, defined as time from date of
randomisation to emergence of local, regional, or distant
recurrence or metastasis
• Cardiorespiratory fitness, defined as ability to engage in
physical activities that rely on oxygen consumption as the
primary source of energy, and measured directly or indirectly to
obtain an individual’s maximal oxygen uptake (VO max)
• Physical activity assessed as an outcome measure, defined as
any bodily movement produced by contraction of skeletal muscle
that increases energy expenditure above a basal level, and
measured by self-report via questionnaires or objectively via
accelerometers
• Body mass, BMI, body composition (e.g. measures such as
body fat percentage, fat-free or lean mass, and fat mass) and
other anthropometric measurements (e.g. waist and hip
circumferences)
• Muscular strength, defined as maximal force (expressed in
Newtons, kilograms, or pounds) that can be generated by a
specific muscle or muscle group
• Bone health-related outcomes such as bone mineral density
and bone mineral content
• Adverse events such as musculoskeletal injuries,
lymphoedema, and illness (such as bronchitis and influenza)
Search methods for identification of studies
Electronic searches
We searched the following databases.
• Cochrane Breast Cancer Group (CBCG) Specialised
Register. Details of search strategies used by the CBCG for
identification of studies and procedures for coding of references
are outlined in the CBCG module (http://
onlinelibrary.wiley.com/o/cochrane/clabout/articles/
BREASTCA/frame.html). We considered for inclusion in the
review retrieved trials using the following terms: ’breast cancer’,
’physical activity’, ’physical activity intervention’, ’exercise’,
’walking’, ’resistance training’, ’weight training’, ’weight lifting’
or ’fitness’.
• MEDLINE (via PubMed); see Appendix 1.
• Embase (via Embase.com); see Appendix 2.
• Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 8) in the Cochrane Library; see
Appendix 3.
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) search portal (http://
apps.who.int/trialsearch/Default.aspx) for all prospectively
registered and ongoing trials; see Appendix 4.
• Clinicaltrials.gov (http://clinicaltrials.gov/); see Appendix 5.
• Cumulative Index to Nursing and Allied Health Literature
(CINAHL) (via EBSCOhost.com); see Appendix 6.
• Physiotherapy Evidence Database (PEDro) (via
PEDro.org.au); see Appendix 7.
• SPORTDiscus (via EBSCOhost.com); see Appendix 8.
• PsycINFO (via OvidSP); see Appendix 9.
Searching other resources
Bibliographic searching
We attempted to identify further studies by reviewing reference
lists of identified relevant trials or reviews. We obtained a copy of
the full article for each reference reporting a potentially eligible
trial. When this was not possible, we attempted to contact trial
authors to request additional information.
We conducted a search for relevant grey literature using OpenGrey
and Healthcare Management Information Consortium (HMIC)
databases.
Data collection and analysis
Selection of studies
We merged results of the searches described above and removed
duplicate records on the same study. We examined titles and ab-
stracts to remove obviously irrelevant reports. Two review authors
(IML and GSM) independently screened and assessed records for
eligibility. We resolved disagreements on study eligibility through
consensus, and, when necessary, we met with a third review au-
thor not involved in the particular assessment (AMN) for discus-
sion. We retrieved full-text articles of potentially relevant reports
and linked together multiple reports of the same study. We exam-
ined full-text reports for compliance of studies with the eligibility
criteria. We corresponded with investigators, when appropriate,
to clarify study eligibility or to seek further information, such as
missing data.
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We recorded in the Characteristics of excluded studies table a list
of studies that were close to inclusion but did not meet the criteria
after further inspection.
We included non-English language trials and translated them,
when necessary, so that we could assess eligibility and subsequently
extract study data.
Data extraction and management
We devised a checklist of items to be considered during data col-
lection. This checklist included the source of the report; confirma-
tion of eligibility or reason for exclusion; methods such as study
design, total duration, sequence generation, allocation sequence
concealment, blinding, and other sources of bias; participant in-
formation such as total numbers, diagnostic criteria, and demo-
graphic information; dates of the study; intervention details; for
each outcome of interest, the definition, unit of measurement and
scales, time points of assessment, results including numbers of par-
ticipants allocated to groups, sample size, missing data, summary
of data for each group, and effect estimates with confidence inter-
vals; and miscellaneous information such as funding sources, key
conclusions, and details of any correspondence.
IML and GSM independently extracted trial data, and AMN ar-
bitrated any conflicts not due to extractor error. We collated mul-
tiple publications for the same trial and used the most complete
report (i.e. the one with outcomes most relevant to the review or
with the most recent outcomes) as the primary reference.
Assessment of risk of bias in included studies
We summarised in the Characteristics of included studies table
data collected from these reports. We used the Cochrane ‘risk of
bias’ tool to assess possible sources of bias in the included reports
(Higgins 2011). Assessment of risk of bias was a two-part process
addressing specific domains such as sequence generation, alloca-
tion concealment, blinding, incomplete outcome data, selective
reporting bias, and ‘other issues’. The first part of the process de-
scribes what was reported to have happened in a study, and the sec-
ond part includes judgement related to the risk of bias for each do-
main in that study. Two review authors (IML and GSM) assessed
risk of bias, and a third review author (AMN) arbitrated conflicts
not due to assessor error. If we found evidence of heterogeneity,
large risk of bias, or low quality of evidence, we interpreted trial
findings cautiously.
We have displayed our assessment of risk of bias in a ‘risk of bias’
table.
Measures of treatment effect
We performed a meta-analysis on an outcome only if at least two
studies assessed that outcome; we did not perform meta-analysis
if outcomes were too diverse, studies were at risk of serious bias,
or evidence suggested serious publication or reporting bias.
We combined continuous outcomes (such as cardiorespiratory
fitness, physical activity, anthropometric measures, muscular
strength, and bone health-related outcomes) using mean differ-
ence (MD) when trials measured an outcome by using the same
measurement method or scale to generate continuous data. We
used standardised mean difference (SMD) when trials used differ-
ent instruments to measure the same outcome.
For dichotomous outcomes (such as meeting physical activity
guidelines), we used risk ratios (RRs) with 95% confidence inter-
vals (CIs). We transformed data presented as odds ratios (ORs)
using the method outlined in Chapter 12 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011).
For this review version, no outcomes were reported as time-to-
event. In future review versions, for time-to-event outcomes such
as mortality and recurrence, we will use hazard ratios (HRs) with
95% CIs. We will report the ratios of treatment effects for re-
sponses, so that HRs less than 1.0 will favour the physical ac-
tivity intervention and HRs greater than 1.0 will favour usual
care or control. To perform meta-analysis of time-to-event out-
comes, we will obtain the log HR (intervention relative to con-
trol) and its standard error (SE). As outlined in Chapter 7 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011), the log hazard ratio is estimated by (O - E)/V,
which has an SE 1/
√
V, where O represents the observed number
of events in the intervention group, E the log-rank expected num-
ber of events in the intervention group, O-E the log-rank statistic,
and V variance of the log-rank statistic. Alternatively, when trial
authors analyse data using a Cox proportional hazards model, they
directly report estimates of the log hazard ratio and its SE.
Unit of analysis issues
For trials that included more than one applicable physical activ-
ity group (Cormie 2014; Dolan 2016; Ergun 2013; Loh 2014;
Martin 2013; Musanti 2012; Portela 2008; Short 2014; Vallance
2007) and more than one relevant control group (Daley 2007),
we created, when possible, a single pair-wise comparison by com-
bining outcome data as recommended in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
We requested missing data from trial authors. If variability was pre-
sented by measures other than standard deviation, we obtained an
estimate of the standard deviation (SD) using standard approaches
for transforming data. We transformed CIs, t values, and P values
to estimate SD using methods described in the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011); if F-
statistics were reported for comparisons of two groups, we trans-
formed F-statistics into T-statistics using the following formula:
T =
√
F, then estimated SD from the T-statistic.
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Assessment of heterogeneity
For each outcome, we first assessed study heterogeneity using
Cochran’s χ² (Chi²) test (Cochran 1954), with P < 0.10 indicating
evidence of heterogeneity.
We evaluated inconsistency of results across studies by using the
I² statistic. I² describes the percentage of variability in point esti-
mates that is due to heterogeneity rather than to sampling error
(Higgins 2003). In accordance with Higgins 2011, we interpreted
I² values of 0% to 40% as ’might not be important’, 30% to 60%
as ’may represent moderate heterogeneity’, 50% to 90% as ’may
represent substantial heterogeneity’, and 75% to 100% as show-
ing ’considerable heterogeneity’. However, the importance of the
observed value of I² depends on the magnitude and direction of
effects and the strength of evidence of heterogeneity (e.g. P value
from the Chi² test, CI for I²).
We used a random-effects model to determine the average effect
of physical activity because, in addition to the presence of random
error (i.e. chance), differences between physical studies after ad-
juvant breast cancer treatment can result from real differences be-
tween study populations, types of adjuvant breast cancer treatment
received, and the training stimulus. The random-effects model
considers these additional sources of between-study variability, as
well as within-study variability. We presented pooled intervention
effect estimates and their 95% CIs for each outcome.
Assessment of reporting biases
To investigate publication bias, we prepared funnel plots and vi-
sually examined them for signs of asymmetry. We followed rec-
ommendations provided in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) regarding statistical test-
ing for funnel plot asymmetry. For example, if a sufficient num-
ber of trials were available in a particular analysis, we examined
publication bias using Egger’s linear regression method, with P <
0.10 taken as an indication of publication bias (Egger 1997). If
we noted evidence of statistically significant asymmetry, we con-
sidered interpretations other than publication bias.
Data synthesis
We have presented pooled intervention effect estimates and their
95% CIs.
For continuous outcomes, we combined data using the inverse
variance random-effects method (DerSimonian 1986).
For dichotomous outcomes, we applied the random-effects model
(DerSimonian 1986), along with the Mantel-Haenszel method
(Mantel 1959; Greenland 1985), to combine data.
For time-to-event outcomes, we combined study results using the
generic inverse variance method. We carried out all analyses using
Review Manager 5 (version 5.3) (RevMan).
IML and GSM assessed the quality of the evidence by using the
GRADE system (Guyatt 2008); we have presented these results in
the ’Summary of findings’ tables.
Subgroup analysis and investigation of heterogeneity
We considered the following important methodological factors,
physical activity programme design components, and participant
characteristics as potential sources of heterogeneity: removal of the
most extreme values; study quality based on risk of bias (low risk
of bias vs moderate unclear/high risk of bias); menopausal status
of participants (premenopausal vs postmenopausal); duration of
intervention (shorter duration, i.e. ≤ 12 weeks, vs longer duration,
i.e. > 12 weeks); measurement type (instrument/method used, e.g.
direct vs indirect, subjective vs objective measurement); and mode
of physical activity (aerobic exercise vs resistance training vs com-
bination of aerobic and resistance exercise vs yoga, tai chi, qigong,
and pilates interventions). When it was possible to inform physi-
cal activity prescription for patients with breast cancer post adju-
vant therapy, we conducted subgroup analyses of treatment effect
based on intervention mode (aerobic exercise vs resistance train-
ing vs combination of aerobic and resistance exercise vs yoga, tai
chi, qigong, and pilates interventions), intensity (light and light-
moderate vs moderate-high and high), duration of intervention
(≤ 12 weeks vs > 12 weeks), format (individual vs group vs com-
bined individual and group), setting (home-based vs facility-based
vs home and facility-based combined), participants’ menopausal
status (premenopausal vs postmenopausal), and treatment regi-
men (chemotherapy vs no chemotherapy).
Sensitivity analysis
We conducted sensitivity analyses to assess the robustness of review
results by removing studies with high or unclear risk of bias.
R E S U L T S
Description of studies
Results of the search
Through a comprehensive literature search, we identified 8454
potentially relevant references and screened them for retrieval. Af-
ter removing duplicates, we excluded a total of 5955 references
upon title and abstract review and retrieved 211 references for
more detailed evaluation. From these, we excluded 86 trials as
they did not meet the inclusion criteria, and identified 63 trials
as appropriate for inclusion in the current review (Figure 1). In
addition, we identified 10 ongoing trials (Deli-Conwright 2014;
Galiano-Castillo 2013; IRCT2014042117379N1; KIlbreath
2011; NCT02057536; NCT02235051; NCT02332876;
NCT02420249; NCT02433067; NCT02527889), as well as
three trials that were awaiting classification (Lahart 2016; Lohrisch
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2011; Luu 2014). We did not include these latter trials in the analy-
sis presented below but will consider them in future updates of this
review. See Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
and Characteristics of ongoing studies.
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Figure 1. Study flow diagram.
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Included studies
Final selection resulted in inclusion of 63 trials in this review
(Banasik 2011; Baruth 2013; Basen-Enquist 2006; Blank 2005;
Bower 2011; Cadmus 2009; Cantarero-Villanueva 2013; Carson
2009; Cerulli 2014; Cormie 2014; Courneya 2003; Cuesta-Vargas
2014; Daley 2007; DeNysschen 2011; Do 2015; Dolan 2016;
Duijits 2012; Ergun 2013; Fillion 2008; Guinan 2013; Hatchett
2013; Heim 2007; Herrero 2006; Irwin 2015; Kaltsatou 2011;
Kiecolt-Glaser 2014; Kim 2015; Ligibel 2008; Littman 2012;
Loh 2014; Loudon 2014; Malicka 2011; Martin 2013; Matthews
2007; McKenzie 2003; Mehnert 2011; Milne 2008; Murtezani
2014; Musanti 2012; Mustian 2004; Naumann 2012; Nieman
1995; Nikander 2007; Payne 2008; Peppone 2015; Pinto 2003;
Pinto 2005; Pinto 2015; Portela 2008; Rahnama 2010; Rogers
2009; Rogers 2013; Rogers 2014; Rogers 2015; Saarto 2012;
Schmitz 2005; Schmitz 2009; Segar 1998; Short 2014; Taleghani
2012; Vallance 2007; Waltman 2010; Winters-Stone 2011) (we
used the earliest main publication of each trial as the trial ref-
erence). We reviewed and included information on trial charac-
teristics and outcome-related data from an additional 125 pub-
lications that were secondary publications of these 63 trials. We
corresponded with, and requested additional data from, nine trial
authors (Baruth 2013; Carson 2009; Daley 2007; Heim 2007;
Loh 2014; McKenzie 2003; Payne 2008; Peppone 2015; Vallance
2007), and four of these trial authors replied to requests for addi-
tional data (Daley 2007; Loh 2014; Payne 2008; Vallance 2007).
Full descriptions of the included studies can be found under
Characteristics of included studies.
Study design
Of the 63 included trials, 60 (95%) were RCTs, and three studies
used a quasi-randomised design to allocate participants to treat-
ment(s) (Cuesta-Vargas 2014; Heim 2007; Segar 1998). Twelve
trials (19%) consisted of more than one exercise intervention
group (Cormie 2014; DeNysschen 2011; Dolan 2016; Duijits
2012; Ergun 2013; Loh 2014; Martin 2013; Musanti 2012;
Naumann 2012; Portela 2008; Short 2014; Vallance 2007). One
study consisted of two comparison arms (usual care and exer-
cise-placebo control in the form of stretching) (Daley 2007), and
Duijits 2012 included a non-exercise cognitive-behaviour therapy
group, while Naumann 2012 included a non-exercise counselling
group. In all, investigators allocated 5761 participants (mean 91,
range 14 to 573) to a physical activity intervention group (n of
participants = 3239, mean 51, range 7 to 302) or a control group
(n = 2524, mean 40, range 8 to 271).
Study participants
Forty trials (63%) reported numbers of participants at each can-
cer stage (Baruth 2013; Basen-Enquist 2006; Cadmus 2009;
Cantarero-Villanueva 2013; Carson 2009; Cerulli 2014; Cormie
2014; Courneya 2003; DeNysschen 2011; Do 2015; Dolan 2016;
Fillion 2008; Guinan 2013; Hatchett 2013; Herrero 2006; Irwin
2015; Kiecolt-Glaser 2014; Ligibel 2008; Littman 2012; Loh
2014; Loudon 2014; Matthews 2007; Mehnert 2011; Milne 2008;
Murtezani 2014; Musanti 2012; Peppone 2015; Pinto 2003; Pinto
2005; Pinto 2015; Portela 2008; Rogers 2009; Rogers 2013;
Rogers 2014; Rogers 2015; Schmitz 2005; Schmitz 2009; Short
2014; Vallance 2007; Winters-Stone 2011). Of these 40, 18 re-
ported numbers of participants with stage 0 breast cancer (total
n = 173, mean 6, range 1 to 28) (Baruth 2013; Basen-Enquist
2006; Cadmus 2009; Dolan 2016; Fillion 2008; Irwin 2015;
Kiecolt-Glaser 2014; Littman 2012; Loudon 2014; Pinto 2003;
Pinto 2005; Pinto 2015; Rogers 2014; Rogers 2015; Schmitz
2005; Schmitz 2009; Short 2014; Winters-Stone 2011), all 40
trials reported numbers of participants with stage I-II breast can-
cer (n = 1334, mean 33, range 5 to 194, and n = 753, mean
32, range 3 to 161, respectively), and 34 trials reported num-
bers of patients with stage III breast cancer (n = 413, mean
12, range 1 to 69) (Baruth 2013; Basen-Enquist 2006; Cadmus
2009; Cantarero-Villanueva 2013; Cerulli 2014; Cormie 2014;
Courneya 2003; DeNysschen 2011; Do 2015; Dolan 2016; Fillion
2008; Guinan 2013; Hatchett 2013; Irwin 2015; Kiecolt-Glaser
2014; Ligibel 2008; Littman 2012; Loudon 2014; Matthews
2007; Mehnert 2011; Milne 2008; Murtezani 2014; Musanti
2012; Peppone 2015; Pinto 2015; Portela 2008; Rogers 2009;
Rogers 2013; Rogers 2015; Schmitz 2005; Schmitz 2009; Short
2014; Vallance 2007; Winters-Stone 2011). Kim 2015 reported
the numbers of participants with stage 0-I (n = 19) and stage II-III
(n = 28) breast cancer. Five trials included a small number of pa-
tients with metastatic breast cancer (Banasik 2011; Basen-Enquist
2006; Hatchett 2013; Portela 2008; Short 2014).
Twenty-four (38%) trials reported participants’ average time since
cancer diagnosis (range 3.5 to 62.5 months) (Basen-Enquist
2006; Cadmus 2009; Carson 2009; Dolan 2016; Ergun 2013;
Fillion 2008; Guinan 2013; Irwin 2015; Kiecolt-Glaser 2014; Kim
2015; Ligibel 2008; Littman 2012; Matthews 2007; Pinto 2003;
Pinto 2005; Pinto 2015; Rogers 2013; Rogers 2015; Schmitz
2005; Schmitz 2009; Segar 1998; Vallance 2007; Waltman 2010;
Winters-Stone 2011). In Hatchett 2013, 60% and 40% of par-
ticipants were less than 30 months and 30 to 70 months post di-
agnosis, respectively, and Loh 2014 reported that 14 and 71 par-
ticipants were within one year and two to five years post diagno-
sis, respectively. Eighteen (29%) trials reported average time be-
yond active treatment (range 3 months to 7.1 years) (Baruth 2013;
Bower 2011; Cerulli 2014; Cormie 2014; Courneya 2003; Guinan
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2013; Herrero 2006; Kaltsatou 2011; Kiecolt-Glaser 2014; Milne
2008; Naumann 2012; Nieman 1995; Peppone 2015; Pinto 2003;
Rogers 2009; Schmitz 2005; Short 2014; Waltman 2010). Other
studies reported that all participants were between two weeks and
30 months (Mustian 2004), two months and five years (Portela
2008), six months and four years (Irwin 2015), and 12 and 36
months (Daley 2007) post treatment; within four weeks (post
surgery, Rogers 2015), six months (Cuesta-Vargas 2014; Martin
2013; Nikander 2007), one year (Cadmus 2009; Matthews 2007;
Mehnert 2011), 1.5 years (Heim 2007), and two years post treat-
ment (Musanti 2012); or at least four weeks (Saarto 2012), eight
weeks (Banasik 2011; Blank 2005; Rogers 2015), three months
(Kim 2015; Ligibel 2008; Littman 2012), six months (McKenzie
2003), one year (Winters-Stone 2011), and two years post treat-
ment (Fillion 2008). Cantarero-Villanueva 2013 and Duijits 2012
reported that 48.3% and 80% of participants were 12 months and
less post treatment, respectively.
Forty-eight (76%) trials reported the numbers of participants who
had received chemotherapy (mean 68%, range 20% to 100%)
(Baruth 2013; Basen-Enquist 2006; Bower 2011; Cadmus 2009;
Cantarero-Villanueva 2013; Carson 2009; Cerulli 2014; Cormie
2014; Courneya 2003; Daley 2007; DeNysschen 2011; Do 2015;
Dolan 2016; Duijits 2012; Ergun 2013; Fillion 2008; Guinan
2013; Hatchett 2013; Heim 2007; Herrero 2006; Irwin 2015;
Kiecolt-Glaser 2014; Kim 2015; Ligibel 2008; Loh 2014; Loudon
2014; Malicka 2011; Matthews 2007; Milne 2008; Murtezani
2014; Musanti 2012; Mustian 2004; Naumann 2012; Nikander
2007; Peppone 2015; Pinto 2003; Pinto 2005; Pinto 2015;
Rahnama 2010; Rogers 2009; Rogers 2015; Saarto 2012; Schmitz
2005; Schmitz 2009; Short 2014; Vallance 2007; Waltman 2010;
Winters-Stone 2011). Five trials consisted entirely of participants
who had received chemotherapy (Cerulli 2014; Ergun 2013;
Guinan 2013; Herrero 2006; Rahnama 2010).
Forty-six (73%) of the 63 trials reported participants’ hormone
therapy details (Baruth 2013; Blank 2005; Bower 2011; Cadmus
2009; Cantarero-Villanueva 2013; Carson 2009; Cerulli 2014;
Cormie 2014; Courneya 2003; Daley 2007; Do 2015; Dolan
2016; Duijits 2012; Fillion 2008; Guinan 2013; Hatchett 2013;
Heim 2007; Irwin 2015; Kiecolt-Glaser 2014; Kim 2015; Ligibel
2008; Malicka 2011; Matthews 2007; Milne 2008; Murtezani
2014; Musanti 2012; Mustian 2004; Naumann 2012; Nikander
2007; Payne 2008; Peppone 2015; Pinto 2003; Pinto 2005; Pinto
2015; Rahnama 2010; Rogers 2009; Rogers 2013; Rogers 2014;
Rogers 2015; Saarto 2012; Schmitz 2005; Schmitz 2009; Short
2014; Vallance 2007; Waltman 2010; Winters-Stone 2011). The
total number of participants who had received hormone therapy in
these 46 trials was 3161 (mean n per study 69, range 9 to 442). Sev-
enteen trials reported use of both selective oestrogen receptor mod-
ulators (SORMs) and aromatase inhibitors (AIs) (Cadmus 2009;
Cantarero-Villanueva 2013; Carson 2009; Dolan 2016; Guinan
2013; Kim 2015; Ligibel 2008; Naumann 2012; Rogers 2009;
Rogers 2013; Rogers 2014; Rogers 2015; Schmitz 2005; Schmitz
2009; Vallance 2007; Waltman 2010; Winters-Stone 2011). One
study specifically investigated only women receiving AIs (Irwin
2015), and another reported only the number of participants re-
ceiving SORMs (Matthews 2007). A total of 690 participants
(mean 38, range 5 to 182) had taken SORMs, and a total of 456
had taken AIs (mean 25, range 2 to 121).
The mean average age of participants in the 58 (92%) trials that
reported this characteristic was 54 (mean age range 46 to 63) years.
Heim 2007 reported the number of participants 30 to 50 years
(n = 32) and 51 to 70 years (n = 31), and Blank 2005 reported
the age range of participants (range 48 to 69 years). Two studies
reported no age data (Hatchett 2013; Taleghani 2012). Twenty-
seven trials (43%) reported the percentage of postmenopausal
participants (Cadmus 2009; Cantarero-Villanueva 2013; Carson
2009; Courneya 2003; DeNysschen 2011; Dolan 2016; Ergun
2013; Fillion 2008; Guinan 2013; Irwin 2015; Kiecolt-Glaser
2014; Kim 2015; Ligibel 2008; Loh 2014; Matthews 2007; Milne
2008; Payne 2008; Pinto 2003; Rogers 2009; Rogers 2013; Rogers
2014; Rogers 2015; Saarto 2012; Schmitz 2005; Vallance 2007;
Waltman 2010; Winters-Stone 2011). The mean percentage of
postmenopausal participants in these trials was 78% (range 0 to
100%). Eleven (18%) trials included exclusively postmenopausal
participants (Cadmus 2009; Courneya 2003; Dolan 2016; Ergun
2013; Irwin 2015; Kim 2015; Matthews 2007; Payne 2008;
Rogers 2014; Waltman 2010; Winters-Stone 2011); Bower 2011
consisted of only premenopausal and perimenopausal participants,
and Heim 2007 stated the percentage of participants who reported
symptoms of menopause (n = 64%), rather than menopausal sta-
tus.
Thirty trials (48%) reported the ethnicity of participants (Banasik
2011; Baruth 2013; Basen-Enquist 2006; Bower 2011; Cadmus
2009; Carson 2009; Daley 2007; DeNysschen 2011; Dolan
2016; Guinan 2013; Hatchett 2013; Irwin 2015; Kiecolt-Glaser
2014; Littman 2012; Loh 2014; Matthews 2007; Musanti 2012;
Mustian 2004; Payne 2008; Peppone 2015; Pinto 2005; Pinto
2015; Rogers 2009; Rogers 2013; Rogers 2014; Rogers 2015;
Schmitz 2005; Schmitz 2009; Segar 1998; Waltman 2010). Most
participants were white (mean % participants = 83%). Black par-
ticipants were the next largest ethnic group (n studies = 18; mean
% participants = 11%). Loh 2014 consisted of Chinese (64%),
Malay (25%), and Indian (11%) participants.
Thirty-two (51%) trials reported the education level of partici-
pants (Baruth 2013; Basen-Enquist 2006; Bower 2011; Cadmus
2009; Cantarero-Villanueva 2013; Carson 2009; Courneya 2003;
Cuesta-Vargas 2014; Daley 2007; DeNysschen 2011; Do 2015;
Duijits 2012; Ergun 2013; Fillion 2008; Hatchett 2013; Irwin
2015; Kiecolt-Glaser 2014; Kim 2015; Littman 2012; Loh 2014;
Mehnert 2011; Murtezani 2014; Mustian 2004; Payne 2008;
Pinto 2003; Pinto 2005; Pinto 2015; Schmitz 2005; Schmitz
2009; Segar 1998; Short 2014; Vallance 2007), with an aver-
age of 47% (range 22% to 70%) of participants reporting ed-
ucational attainment of a university degree or higher. In addi-
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tion, six trials reported the number of years in education (mean
15 years, mean range 14 to 16 years) (Matthews 2007; Rogers
2009; Rogers 2013; Rogers 2014; Rogers 2015; Saarto 2012).
Twenty trials (37%) reported the sociodemographic status (i.e.
earnings per week, month, or year) of participants (Banasik 2011;
Bower 2011; Courneya 2003; DeNysschen 2011; Do 2015; Fillion
2008; Kiecolt-Glaser 2014; Kim 2015; Littman 2012; Loh 2014;
Mustian 2004; Payne 2008; Pinto 2003; Pinto 2005; Rogers 2009;
Rogers 2013; Rogers 2014; Rogers 2015; Short 2014; Vallance
2007). Three studies reported the percentage of participants earn-
ing > USD 40K (mean 61%, range 50% to 70%) (Mustian 2004;
Payne 2008; Pinto 2005), eight studies reported the percentage
earning > USD 50K (mean 61%, range 39% to 76%) (Banasik
2011; Kiecolt-Glaser 2014; Pinto 2003; Pinto 2005; Rogers 2009;
Rogers 2013; Rogers 2014; Rogers 2015), three studies reported
the percentage earning > USD 60K (mean 46%, range 30% to
65%) (Courneya 2003; Littman 2012; Payne 2008), one study re-
ported that 56% of participants earned > USD 70K (DeNysschen
2011), three studies reported the percentage earning > USD 75K
(mean 42%, range 17% to 55%) (Banasik 2011; Bower 2011;
Kiecolt-Glaser 2014), and two studies reported participants earn-
ing > USD 80K (mean 28%, range 26% to 29%) (Littman 2012;
Vallance 2007). Short 2014 reported that 39% of participants
earned > USD 1K per week, and Kim 2015 noted that 42% of
participants earned ≥ USD 2K per month. One study reported
the percentage of participants at low (8%), medium (81%), and
high (11%) income status (no definition of income categories were
given) (Do 2015).
Fourteen (22%) trials reported comorbidity data for participants
(Cadmus 2009; Daley 2007; Do 2015; Irwin 2015; Kim 2015;
Peppone 2015; Rogers 2013; Rogers 2014; Rogers 2015; Saarto
2012; Short 2014; Vallance 2007; Waltman 2010; Winters-Stone
2011). Five of these 14 studies reported a comorbidity index
score (mean 2.2, range 1.8 to 2.7) (Rogers 2009; Rogers 2013;
Rogers 2014; Rogers 2015; Winters-Stone 2011). In three studies
all participants had lymphoedema (Cormie 2014; Loudon 2014;
McKenzie 2003), and another study included an arm of partic-
ipants with lymphoedema and an arm at risk of lymphoedema
(Schmitz 2009). Kim 2015 consisted entirely of participants with
a diagnosis of osteopenia, and Irwin 2015 included participants
reporting arthralgia.
Twenty (32%) studies included physical activity-specific eligibil-
ity criteria to recruit only ‘sedentary’, ‘inactive’, or those per-
forming ‘no activity’ or ‘not meeting recommended physical ac-
tivity guidelines’ (i.e. > 75 minutes of vigorous physical activ-
ity and > 150 minutes of moderate physical activity per week)
(Baruth 2013; Basen-Enquist 2006; Cadmus 2009; Cerulli 2014;
Ergun 2013; Herrero 2006; Ligibel 2008; Matthews 2007; Milne
2008; Mustian 2004; Naumann 2012; Pinto 2003; Pinto 2005;
Pinto 2015; Rahnama 2010; Rogers 2009; Rogers 2013; Schmitz
2005; Segar 1998; Taleghani 2012). Twelve studies reported the
mean baseline minutes of total, walking, moderate, or moder-
ate-to-vigorous physical activity per week (mean ± SD min/week
108 ± 109 minutes, range 13 to 378 minutes) (Cadmus 2009;
Cantarero-Villanueva 2013; Courneya 2003; Guinan 2013; Irwin
2015; Kiecolt-Glaser 2014; Pinto 2005; Pinto 2015; Rogers 2009;
Rogers 2014; Rogers 2015; Vallance 2007). Six studies expressed
baseline physical activity in Met-h/week−1 (mean ± SD 19.5 ±
14.1 metabolic equivalent (MET)-h/week−1, range 4 to 40 MET-
h/week−1) (Baruth 2013; Littman 2012; Matthews 2007; Musanti
2012; Saarto 2012; Schmitz 2009). Eleven studies categorised
baseline physical activity to report the proportion of participants
engaged in given amounts of physical activity (Daley 2007; Do
2015; Dolan 2016; Duijits 2012; Fillion 2008; Hatchett 2013;
Heim 2007; Loh 2014; Mehnert 2011; Saarto 2012; Waltman
2010). A single study noted each of the following: participants’
baseline walking steps/d (Nikander 20077), energy expenditure
(Winters-Stone 2011), leisure score and sport physical activity
score (Schmitz 2005), and self-selected levels of fitness (Loudon
2014). Four trials excluded participants who engaged in any/reg-
ular prior resistance exercise at the time of enrolment (Kim 2015;
Schmitz 2005; Schmitz 2009; Winters-Stone 2011), two studies
excluded participants performing regular yoga practice (Carson
2009; Peppone 2015), and one study recruited only participants
with no prior practice or experience in traditional Greek dances
(Kaltsatou 2011).
Twenty-eight trials (44%) reported the mean body mass of par-
ticipants (Cadmus 2009; Cerulli 2014; Cormie 2014; Courneya
2003; Daley 2007; DeNysschen 2011; Dolan 2016; Duijits
2012; Heim 2007; Herrero 2006; Irwin 2015; Ligibel 2008;
Littman 2012; Malicka 2011; Martin 2013; Matthews 2007;
McKenzie 2003; Murtezani 2014; Musanti 2012; Naumann
2012; Nieman 1995; Nikander 2007; Pinto 2003; Rahnama 2010;
Saarto 2012; Schmitz 2009; Vallance 2007; Winters-Stone 2011),
and 38 (60%) trials reported mean BMI scores of participants
(Baruth 2013; Basen-Enquist 2006; Bower 2011; Cadmus 2009;
Cerulli 2014; Cormie 2014; Courneya 2003; Daley 2007; Dolan
2016; Duijits 2012; Ergun 2013; Herrero 2006; Irwin 2015;
Kiecolt-Glaser 2014; Kim 2015; Ligibel 2008; Littman 2012;
Loudon 2014; Matthews 2007; McKenzie 2003; Milne 2008;
Murtezani 2014; Mustian 2004; Naumann 2012; Nikander 2007;
Pinto 2003; Pinto 2005; Portela 2008; Rahnama 2010; Rogers
2009; Rogers 2013; Rogers 2014; Saarto 2012; Schmitz 2009;
Short 2014; Vallance 2007; Waltman 2010; Winters-Stone 2011).
Average mean body mass in these trials was 74 kg (SD 4.4 kg, range
65.5 to 84.7 kg), and average mean BMI was 28 kg/m2 (SD 2.1
kg/m2, range 23.4 to 32.1 kg/m2). Two additional trials reported
the numbers of participants who fell into particular BMI ranges
(Do 2015; Heim 2007).
Intervention characteristics
Intervention length ranged from four weeks to 24 months.
Most studies provided interventions lasting eight (Banasik 2011;
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Blank 2005; Cantarero-Villanueva 2013; Carson 2009; Cuesta-
Vargas 2014; Daley 2007; Guinan 2013; Herrero 2006; Loh
2014; Loudon 2014; Malicka 2011; Martin 2013; McKenzie
2003; Naumann 2012; Nieman 1995; Taleghani 2012) or 12
weeks (three months) (Baruth 2013; Bower 2011; Cormie 2014;
Duijits 2012; Ergun 2013; Hatchett 2013; Kiecolt-Glaser 2014;
Matthews 2007; Milne 2008; Musanti 2012; Mustian 2004;
Nikander 2007; Pinto 2003; Pinto 2005; Pinto 2015; Rogers
2009; Rogers 2013; Rogers 2014; Rogers 2015; Short 2014;
Vallance 2007). Four (6%) studies conducted year-long interven-
tions (Irwin 2015; Saarto 2012; Schmitz 2009; Winters-Stone
2011). Seventeen (27%) trials had a follow-up period that ex-
tended beyond completion of the intervention (Bower 2011;
Cantarero-Villanueva 2013; Carson 2009; Daley 2007; Duijits
2012; Fillion 2008; Guinan 2013; Kiecolt-Glaser 2014; Loudon
2014; Pinto 2005; Pinto 2015; Rogers 2009; Rogers 2015; Segar
1998; Short 2014; Vallance 2007; Waltman 2010). Follow-up du-
ration ranged from two weeks in Carson 2009 and Segar 1998 to
12 months in Waltman 2010; the most common follow-up dura-
tion was three months (n = 8; Bower 2011; Duijits 2012; Fillion
2008; Guinan 2013; Kiecolt-Glaser 2014; Pinto 2015; Rogers
2009; Rogers 2015). Two trials provided follow-up only to inter-
vention groups (Do 2015; Dolan 2016).
Physical activity modes differed across trials. Only seven (11%)
trials included a separate resistance training condition with no
form of aerobic activity (i.e. any activity that uses large muscle
groups, can be maintained continuously, and is rhythmical in na-
ture) (Cormie 2014; Martin 2013; Musanti 2012; Schmitz 2005;
Schmitz 2009; Waltman 2010; Winters-Stone 2011). Twenty-one
(33%) trials involved an intervention arm that combined aero-
bic activity and resistance training (Cantarero-Villanueva 2013;
Cuesta-Vargas 2014; Do 2015; Ergun 2013; Heim 2007; Herrero
2006; Irwin 2015; Kaltsatou 2011; Ligibel 2008; McKenzie 2003;
Milne 2008; Musanti 2012; Naumann 2012; Nieman 1995; Pinto
2003; Portela 2008; Rahnama 2010; Rogers 2013; Rogers 2014;
Short 2014; Taleghani 2012). Twenty-eight (44%) trials consisted
of an aerobic activity-only condition (Baruth 2013; Basen-Enquist
2006; Cadmus 2009; Cerulli 2014; Courneya 2003; Daley 2007;
DeNysschen 2011; Dolan 2016; Duijits 2012; Ergun 2013; Fillion
2008; Guinan 2013; Hatchett 2013; Loh 2014; Malicka 2011;
Matthews 2007; Mehnert 2011; Murtezani 2014; Musanti 2012;
Nikander 2007; Payne 2008; Pinto 2005; Pinto 2015; Rogers
2009; Rogers 2015; Saarto 2012; Segar 1998; Vallance 2007).
Eight studies (13%) included a yoga-only arm (Banasik 2011;
Blank 2005; Bower 2011; Carson 2009; Kiecolt-Glaser 2014;
Littman 2012; Loudon 2014; Peppone 2015), and one study pro-
vided each of the following intervention arms: pilates only (Martin
2013), tai chi only (Mustian 2004), and qigong (similar to tai chi)
only (Loh 2014).
Frequency (number of days per week) of physical activity ranged
from two days to seven days per week, with most studies pro-
viding physical activity at least three days per week (n = 44;
Baruth 2013; Blank 2005; Cadmus 2009; Cantarero-Villanueva
2013; Carson 2009; Courneya 2003; Cuesta-Vargas 2014; Daley
2007; DeNysschen 2011; Do 2015; Dolan 2016; Ergun 2013;
Fillion 2008; Guinan 2013; Heim 2007; Herrero 2006; Kaltsatou
2011; Littman 2012; Loh 2014; Loudon 2014; Martin 2013;
Matthews 2007; McKenzie 2003; Milne 2008; Murtezani 2014;
Musanti 2012; Mustian 2004; Naumann 2012; Nieman 1995;
Nikander 2007; Payne 2008; Pinto 2003; Pinto 2005; Pinto 2015;
Portela 2008; Rahnama 2010; Rogers 2014; Rogers 2015; Saarto
2012; Segar 1998; Short 2014; Taleghani 2012; Vallance 2007;
Winters-Stone 2011). Duration of sessions ranged from 15 min-
utes to longer than 95 minutes, with a modal duration of 60 min-
utes (n = 16; Cantarero-Villanueva 2013; Cerulli 2014; Cormie
2014; Cuesta-Vargas 2014; Fillion 2008; Kaltsatou 2011; Malicka
2011; Milne 2008; Mustian 2004; Naumann 2012; Nieman 1995;
Nikander 2007; Saarto 2012; Schmitz 2005; Taleghani 2012;
Winters-Stone 2011). Five studies gave participants a goal to-
tal number of minutes of physical activity to achieve each week
(90 minutes/week, Ligibel 2008; 150 minutes/week, Irwin 2015;
Rogers 2009; Rogers 2015; 150 to 180 minutes/week, Duijits
2012). The total number of sessions for physical activity interven-
tions ranged between 12 and 260.
Among 48 (76%) trials that consisted of aerobic physical activ-
ity, 13 provided walking only (Baruth 2013; Ergun 2013; Fillion
2008; Heim 2007; Matthews 2007; Musanti 2012; Nieman
1995; Payne 2008; Portela 2008; Rahnama 2010; Rogers 2009;
Rogers 2014; Rogers 2015), four involved primarily walking
(Basen-Enquist 2006; Cadmus 2009; Irwin 2015; Vallance 2007),
one involved Nordic walking (Malicka 2011), and one pro-
vided walking with gymnastics (Mehnert 2011). Other aerobic
intervention modes involved arm ergometer exercise (McKenzie
2003), cycling only (Courneya 2003; Herrero 2006), deep wa-
ter running (Cuesta-Vargas 2014), deep water aquatic exercise
(Cantarero-Villanueva 2013), Greek dance (Kaltsatou 2011),
horse riding (Cerulli 2014), line dancing and qigong (Loh 2014),
and step aerobics and circuit training (involving steps, hops, and
jumps) (Nikander 2007; Saarto 2012). In all other trials, partici-
pants performed the prescribed physical activity using a range of
modes (e.g. treadmill, rowing ergometer, stair climbing).
Of the 45 studies providing an aerobic activity intervention, 39
reported frequency of aerobic activity ranging from two to seven
days per week. In 33 (53%) studies, the number of aerobic ac-
tivity sessions per week ranged between three and five (Baruth
2013; Cadmus 2009; Cantarero-Villanueva 2013; Cerulli 2014;
Courneya 2003; Cuesta-Vargas 2014; Daley 2007; DeNysschen
2011; Do 2015; Dolan 2016; Ergun 2013; Fillion 2008; Herrero
2006; Kaltsatou 2011; Kim 2015; Littman 2012; Loh 2014;
Matthews 2007; McKenzie 2003; Milne 2008; Murtezani 2014;
Musanti 2012; Nieman 1995; Nikander 2007; Payne 2008; Pinto
2003; Pinto 2015; Portela 2008; Rogers 2014; Saarto 2012; Segar
1998; Taleghani 2012; Vallance 2007). Duration of aerobic activ-
ity ranged between 10 and 90 minutes. Twenty-four (38%) trials
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included aerobic activity sessions with duration of 30 minutes or
greater (Baruth 2013; Cadmus 2009; Cantarero-Villanueva 2013;
Cerulli 2014; Daley 2007; DeNysschen 2011; Do 2015; Ergun
2013; Fillion 2008; Heim 2007; Herrero 2006; Ligibel 2008; Loh
2014; Malicka 2011; Mehnert 2011; Nieman 1995; Nikander
2007; Pinto 2003; Pinto 2015; Portela 2008; Rogers 2014; Saarto
2012; Segar 1998; Vallance 2007).
Intensity of aerobic activity varied substantially between trials, as
did methods used to measure and monitor intensity. Seventeen
(27%) trials set intensity according to percentage of maximum
heart rate (%HRmax range 40% to 80%) (Cadmus 2009; Cerulli
2014; Daley 2007; Herrero 2006; Irwin 2015; Kaltsatou 2011;
Ligibel 2008; Malicka 2011; Milne 2008; Musanti 2012; Nieman
1995; Pinto 2003; Pinto 2005; Portela 2008; Rahnama 2010;
Segar 1998; Taleghani 2012), four (6%) set percentage of target
heart rate using the Karvonen method (Karvonen target heart rate
range 35% to 80%) (Duijits 2012; Guinan 2013; Murtezani 2014;
Rogers 2014), one (2%) study set intensity as heart rate at the
intensity of activity that elicits a blood lactate concentration of 2
to 3 mmol, three (5%) studies used percentage of directly mea-
sured maximal oxygen uptake (% VO max range 45% to 75%)
(Courneya 2003; Do 2015; Mehnert 2011), seven (11%) stud-
ies used rate of perceived exertion (RPE; range 10 to 16) (Baruth
2013; Daley 2007; DeNysschen 2011; Kim 2015; Matthews
2007; Nikander 2007; Saarto 2012), and 12 (19%) trials reported
subjective intensity of the intervention (low to moderate, mod-
erate, or moderate-to-vigorous intensity) (Basen-Enquist 2006;
Cantarero-Villanueva 2013; Dolan 2016; Ergun 2013; Naumann
2012; Payne 2008; Pinto 2015; Rogers 2009; Rogers 2013; Rogers
2015; Short 2014; Vallance 2007). Two (3%) trials did not pro-
vide the intensity at which aerobic activity was performed (Fillion
2008; Heim 2007).
Frequency of interventions with resistance training ranged be-
tween two and five days, with a modal frequency of three days (n =
14; Ergun 2013; Heim 2007; Herrero 2006; Kaltsatou 2011; Kim
2015; Martin 2013; McKenzie 2003; Milne 2008; Musanti 2012;
Naumann 2012; Nieman 1995; Pinto 2003; Taleghani 2012;
Winters-Stone 2011). Cuesta-Vargas 2014 did not report resis-
tance training frequency. Duration of resistance training sessions
ranged between 15 and 90 minutes, with 11 studies reporting du-
ration of 30 to 60 minutes (Cormie 2014; Ergun 2013; Herrero
2006; Ligibel 2008; Martin 2013; Milne 2008; Nieman 1995;
Rahnama 2010; Schmitz 2005; Waltman 2010; Winters-Stone
2011). Eleven (17%) studies did not report the duration of sessions
(Heim 2007; Irwin 2015; Kim 2015; McKenzie 2003; Musanti
2012; Pinto 2003; Portela 2008; Rogers 2013; Rogers 2014; Short
2014; Taleghani 2012). The number of resistance exercises ranged
between four and 12, with a modal exercise number of nine (n = 6;
Do 2015; Heim 2007; Kim 2015; Rahnama 2010; Schmitz 2005;
Schmitz 2009). Seventeen (27%) trials provided resistance training
exercises for both upper and lower body (Cormie 2014; Do 2015;
Ergun 2013; Herrero 2006; Irwin 2015; Kim 2015; Martin 2013;
Milne 2008; Musanti 2012; Portela 2008; Rahnama 2010; Rogers
2013; Rogers 2014; Schmitz 2005; Schmitz 2009; Waltman 2010;
Winters-Stone 2011), one targeted the lower body and abdomi-
nals (Ligibel 2008), one targeted the upper body and abdominals
(Pinto 2003), one described the programme as general strength-
ening (Cuesta-Vargas 2014), and four targeted the upper body
only (Kaltsatou 2011; McKenzie 2003; Naumann 2012; Taleghani
2012). Remaining studies did not report areas of the body targeted
by exercise (Heim 2007; Nieman 1995; Short 2014). One study
combined resistance training with jump exercises with added re-
sistance up to 10% of body weight (Winters-Stone 2011).
Ten (16%) trials used resistance machines (Irwin 2015; Kaltsatou
2011; Ligibel 2008; Portela 2008; Rahnama 2010; Schmitz 2005;
Schmitz 2009; Segar 1998; Taleghani 2012; Waltman 2010),
eight (13%) used free weights (i.e. dumbbells and barbells)
(Cormie 2014; Pinto 2003; Portela 2008; Rahnama 2010; Schmitz
2005; Schmitz 2009; Waltman 2010; Winters-Stone 2011), and
seven (11%) used resistance (Thera) bands (Ergun 2013; Kim
2015; Musanti 2012; Portela 2008; Rogers 2013; Rogers 2014;
Winters-Stone 2011). The number of sets per resistance exercise
ranged from one to four (mode 2 sets; Cuesta-Vargas 2014; Kim
2015; Milne 2008; Nieman 1995; Portela 2008; Rogers 2014;
Taleghani 2012; Waltman 2010), and the number of repetitions
per set ranged from 6 to 20, with the modal repetition range
of 8 to 12 (n = 4; Irwin 2015; Taleghani 2012; Waltman 2010;
Winters-Stone 2011). Intensity of resistance exercises was set ac-
cording to the percentage of maximum weight a participant could
lift in one repetition (%1RM range 65% to 85%) in four (6%) tri-
als (Cormie 2014; Do 2015; Ligibel 2008; Winters-Stone 2011),
with 12 to 15 repetition maximum in one trial (Herrero 2006), and
with RPE in three (5%) trials (Martin 2013; Musanti 2012; Portela
2008); participants lifted “as much as they could” in Rahnama
2010, and as much as they could achieve “with good form” in
Milne 2008.
Most of the eight yoga studies employed a form of Hatha yoga
(n = 6; Hatha: Kiecolt-Glaser 2014; Peppone 2015; Iyengar:
Banasik 2011; Blank 2005; Bower 2011; Viniyoga: Littman
2012); Loudon 2014 included a Satyananda yoga intervention
arm, and Carson 2009 a Yoga of Awareness intervention arm. Yoga
studies ranged between 4 and 24 weeks in duration, with four stud-
ies lasting eight weeks (Banasik 2011; Blank 2005; Carson 2009;
Loudon 2014). Frequency of yoga practice ranged between two
and seven sessions per week (mode 2 sessions/week; Banasik 2011;
Bower 2011; Kiecolt-Glaser 2014; Peppone 2015), and yoga ses-
sion duration ranged between 20 and 90 minutes (mode 90 min-
utes; Banasik 2011; Bower 2011; Kiecolt-Glaser 2014; Loudon
2014). Investigators in these studies described the intensity of all
yoga interventions as moderate, apart from Carson 2009, which
referred to gentle intensity, and Peppone 2015, which described
light intensity. Light-to-moderate-intensity qigong and tai chi in-
terventions in Loh 2014 and Mustian 2004, respectively, had a
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duration of 8 weeks and 12 weeks, a frequency of three sessions
per week, and session duration of 30 minutes (twice a week at
home) or 90 minutes (once a week supervised) and 60 minutes,
respectively. Martin 2013 provided the only pilates intervention,
which consisted of three 50-minute sessions per week performed
within an RPE intensity range of 9 to 14 for eight weeks.
In 24 (38%) trials, the intervention arm involved a psychobe-
havioural component designed to promote physical activity be-
haviour change (Baruth 2013; Basen-Enquist 2006; Carson 2009;
Courneya 2003; Cuesta-Vargas 2014; Daley 2007; DeNysschen
2011; Duijits 2012; Ergun 2013; Fillion 2008; Hatchett 2013;
Matthews 2007; Musanti 2012; Pinto 2005; Pinto 2015; Portela
2008; Rogers 2009; Rogers 2013; Rogers 2014; Rogers 2015;
Segar 1998; Short 2014; Vallance 2007; Waltman 2010). Seven
studies delivered the psychobehavioural component via group dis-
cussions (Basen-Enquist 2006; Carson 2009; Fillion 2008; Rogers
2009; Rogers 2013; Rogers 2014; Rogers 2015); some trials em-
ployed face-to-face counselling in a single session at the begin-
ning of the intervention (Baruth 2013; Matthews 2007); oth-
ers scheduled multiple sessions during the intervention period
(Rogers 2009; Rogers 2013; Rogers 2015), mailed or emailed sup-
port (Hatchett 2013; Pinto 2005; Short 2014), or provided in-
formation booklets promoting physical activity behaviour change
(Musanti 2012; Short 2014; Vallance 2007). Two studies applied
cognitive-behavioural theories (Cuesta-Vargas 2014; Daley 2007),
and one study utilised self-efficacy theory during supervised ex-
ercise sessions with participants (Waltman 2010). Segar 1998 in-
cluded a study arm that applied self-awarded rewards to serve
as reinforcements to induce physical activity behaviour change.
Courneya 2003 incorporated into the intervention individual
or small group meetings designed to outline goals and provide
feedback on participants’ progress. Eleven studies (17%) imple-
mented weekly or fortnightly telephone counselling or monitoring
throughout the intervention period (Baruth 2013; DeNysschen
2011; Duijits 2012; Ergun 2013; Fillion 2008; Matthews 2007;
Musanti 2012; Pinto 2005; Pinto 2015; Portela 2008; Waltman
2010). The number of telephone counselling sessions ranged be-
tween 4 and 26, and their duration ranged from 5 to 15 minutes.
Topics covered in the psychobehavioural component included goal
setting, barriers to and benefits of physical activity, physical activity
adherence monitoring and safety, behaviour reinforcement, and
symptom management. Several studies included an educational
component at baseline that was deemed not to promote physi-
cal activity behaviour change (Heim 2007; Irwin 2015; Mehnert
2011; Schmitz 2009). Two of these studies provided participants
with education related to lymphoedema and other cancer-related
topics (Irwin 2015; Schmitz 2009), one study provided education
on how to perform specific exercises (Mehnert 2011), and another
trial provided an educational programme, physical therapy, group
exercise, and psycho-oncological interventions for both interven-
tion and control groups (Heim 2007).
Interventions in 32 (51%) trials involved a supervised compo-
nent (Banasik 2011; Bower 2011; Cantarero-Villanueva 2013;
Cerulli 2014; Cormie 2014; Courneya 2003; Cuesta-Vargas 2014;
Daley 2007; Do 2015; Dolan 2016; Ergun 2013; Herrero 2006;
Kaltsatou 2011; Kiecolt-Glaser 2014; Littman 2012; Loudon
2014; Malicka 2011; Martin 2013; McKenzie 2003; Mehnert
2011; Milne 2008; Murtezani 2014; Mustian 2004; Naumann
2012; Nieman 1995; Peppone 2015; Portela 2008; Rahnama
2010; Schmitz 2005; Schmitz 2009; Segar 1998; Taleghani 2012);
16 (25%) trials included a home-based physical activity com-
ponent (Baruth 2013; Basen-Enquist 2006; DeNysschen 2011;
Duijits 2012; Ergun 2013; Hatchett 2013; Heim 2007; Kim 2015;
Matthews 2007; Musanti 2012; Payne 2008; Pinto 2005; Pinto
2015; Portela 2008; Short 2014; Vallance 2007), and 17 (27%)
studies provided an intervention that included both supervised and
home-based physical activity (Blank 2005; Cadmus 2009; Carson
2009; Fillion 2008; Guinan 2013; Irwin 2015; Ligibel 2008;
Loh 2014; Nikander 2007; Pinto 2003; Rogers 2009; Rogers
2013; Rogers 2014; Rogers 2015; Saarto 2012; Waltman 2010;
Winters-Stone 2011). With regards to the format of physical ac-
tivity interventions, 27 (43%) studies consisted of an individ-
ual physical activity format (Baruth 2013; Basen-Enquist 2006;
Cerulli 2014; Courneya 2003; Daley 2007; DeNysschen 2011;
Duijits 2012; Ergun 2013; Hatchett 2013; Heim 2007; Kim 2015;
Matthews 2007; McKenzie 2003; Musanti 2012; Naumann 2012;
Payne 2008; Pinto 2003; Pinto 2005; Pinto 2015; Portela 2008;
Rogers 2013; Rogers 2014; Schmitz 2005; Short 2014; Taleghani
2012; Vallance 2007; Waltman 2010), 15 (24%) studies incor-
porated a group physical activity format (Banasik 2011; Bower
2011; Cantarero-Villanueva 2013; Cormie 2014; Cuesta-Vargas
2014; Fillion 2008; Herrero 2006; Kaltsatou 2011; Malicka 2011;
Mehnert 2011; Milne 2008; Murtezani 2014; Mustian 2004;
Peppone 2015; Schmitz 2009), and 14 (25%) studies used a com-
bination of group and individual physical activity interventions
(Blank 2005; Cadmus 2009; Carson 2009; Guinan 2013; Irwin
2015; Kiecolt-Glaser 2014; Ligibel 2008; Littman 2012; Loh
2014; Loudon 2014; Nikander 2007; Rogers 2009; Saarto 2012;
Winters-Stone 2011). The format employed in the intervention
was unclear in seven studies (Do 2015; Dolan 2016; Martin 2013;
Nieman 1995; Rahnama 2010; Rogers 2015; Segar 1998).
Most trials enlisted the services of doctorate students, exercise
physiologists, exercise/sports trainers/specialists, fitness/exercise
instructors, health counsellors, kinesiologists, physical and sports
therapists, physiotherapists, nurses, yoga instructors, or other pro-
fessionals to lead the exercise programme (n = 46, 73%; Banasik
2011; Blank 2005; Bower 2011; Cadmus 2009; Cantarero-
Villanueva 2013; Carson 2009; Cerulli 2014; Cormie 2014;
Courneya 2003; Cuesta-Vargas 2014; Daley 2007; DeNysschen
2011; Do 2015; Duijits 2012; Ergun 2013; Fillion 2008; Hatchett
2013; Heim 2007; Herrero 2006; Irwin 2015; Kaltsatou 2011;
Kiecolt-Glaser 2014; Kim 2015; Ligibel 2008; Littman 2012;
Loh 2014; Loudon 2014; Matthews 2007; Mehnert 2011; Milne
2008; Mustian 2004; Naumann 2012; Peppone 2015; Pinto 2003;
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Portela 2008; Rogers 2009; Rogers 2013; Rogers 2014; Rogers
2015; Saarto 2012; Schmitz 2005; Schmitz 2009; Short 2014;
Taleghani 2012; Waltman 2010; Winters-Stone 2011). Pinto
2015 trained breast cancer survivors to deliver the physical activ-
ity intervention; Baruth 2013 utilised doctorate students, Martin
2013 used sport and exercise science students, and Musanti 2012,
Payne 2008, and Segar 1998 used research staff.
Most trials (n = 30; 48%) described the comparison arm as “usual”
or “standard” care, “no intervention”, “sedentary control”, or “con-
trol”, and 24 (38%) studies included a comparison arm that was
a “waiting list” or “delayed exercise” control, wherein partici-
pants were offered a portion of or the full exercise programme
at completion of the trial (Blank 2005; Cadmus 2009; Carson
2009; Cormie 2014; Courneya 2003; Cuesta-Vargas 2014; Do
2015; Dolan 2016; Duijits 2012; Hatchett 2013; Kiecolt-Glaser
2014; Ligibel 2008; Littman 2012; Loh 2014; Loudon 2014;
Matthews 2007; Milne 2008; Peppone 2015; Pinto 2003; Pinto
2005; Rogers 2009; Rogers 2013; Schmitz 2005; Schmitz 2009).
Baruth 2013 offered counselling to the usual care group at the
end of the intervention period. In eight (13%) trials, the com-
parison group received an intervention that included health ed-
ucation (Bower 2011); phone calls (DeNysschen 2011); an edu-
cational programme, physical therapy, group discussion exercises,
and psycho-oncological interventions (Heim 2007); psychosocial
support therapy (Mustian 2004); light-intensity body condition-
ing/stretching exercises (e.g. flexibility, passive stretching) (Daley
2007; Musanti 2012; Winters-Stone 2011); and an attention con-
trol (Milne 2008; Pinto 2005).
Trial attrition and adherence
Fifty-five (87%) of the included trials reported attrition data. Nine
trials (16%) reported no dropouts at postintervention follow-up
in both intervention and control groups (Cerulli 2014; Cuesta-
Vargas 2014; DeNysschen 2011; Ergun 2013; Malicka 2011;
Martin 2013; Milne 2008; Nikander 2007; Segar 1998), and four
additional trials (7%) reported no dropouts in the control group
only (Baruth 2013; Mehnert 2011; Pinto 2005; Portela 2008).
Twelve trials (22%) - Basen-Enquist 2006; Carson 2009; Do 2015;
Herrero 2006; Ligibel 2008; Loh 2014; Loudon 2014; Mustian
2004; Nieman 1995; Pinto 2003; Portela 2008; Rogers 2013 - and
eight trials (15%) - Do 2015; Guinan 2013; Herrero 2006; Loh
2014; Mustian 2004; Nieman 1995; Pinto 2003; Rogers 2013 -
reported attrition of at least 20% in the intervention and control
groups, respectively. Most trials that included a postintervention
follow-up period reported greater attrition at least three months
post intervention than immediately post intervention.
Fifty-two trials (83%) reported adherence data in several different
ways, including average, median, range, number, or percentage of
participants completing all or a certain percentage or number of
sessions, numbers meeting physical activity guidelines, and min-
utes of physical activity achieved per week. Furthermore, some
trials provided adherence data for completers only. Among trials
that reported the percentage of completed aerobic exercise and re-
sistance training sessions, average adherence was 79% (range 36%
to 163% of targeted session) and 75% (range 26% to 98%), re-
spectively. Most trials that included postintervention follow-up
adherence data showed considerable reductions, for example, one
trial reported that only 50% of intervention participants met the
recommended physical activity guideline of 150 minutes of mod-
erate-to-vigorous physical activity per week (Vallance 2007), and
another trial observed a decrease in moderate-to-vigorous physical
activity from 130 minutes per week at the end of intervention to
98 minutes three months later (Pinto 2015).
Outcome measures
Health-related quality of life outcomes
Investigators performed HRQoL assessment using the Cancer Re-
habilitation Evaluation System Short Form (CARES-SF) (Schmitz
2005), the European Organization for Research and Treatment
of Cancer (EORTC) Quality of Life Questionnaire-C30 (QLQ-
C30) (Do 2015; Duijits 2012; Ergun 2013; Herrero 2006;
Mehnert 2011; Saarto 2012), Functional Assessment of Can-
cer Therapy (FACT) - Fatigue (FACT-F) (Mustian 2004), Eu-
roQol-five dimensions (EQ-5D) and EQ Visual Analogue Scale
(Cuesta-Vargas 2014), Functional Assessment of Cancer Ther-
apy - General (FACT-G) (Cadmus 2009; Cerulli 2014; Courneya
2003; Daley 2007; Heim 2007; Littman 2012; Loh 2014; Milne
2008; Murtezani 2014; Rogers 2009; Rogers 2015; Vallance
2007), Functional Assessment of Cancer Therapy-Breast (FACT-
B) (Courneya 2003; Daley 2007; Heim 2007; Littman 2012; Loh
2014; Milne 2008; Murtezani 2014; Naumann 2012; Pinto 2015;
Portela 2008; Rogers 2009; Rogers 2015; Short 2014; Vallance
2007), International Breast Cancer Study Group (IBCSG) Quality
of Life Core Questionnaire (Baruth 2013), Lymphoedema Qual-
ity of Life Tool (LYMQOL) (Loudon 2014), Medical Outcomes
Study Short Form-12 (MOS SF-12) (Cuesta-Vargas 2014; Fillion
2008), Medical Outcomes Study Short Form-36 (MOS SF-36)
(Baruth 2013; Basen-Enquist 2006; Cadmus 2009; Cormie 2014;
Duijits 2012; Kiecolt-Glaser 2014; McKenzie 2003; Mehnert
2011; Mustian 2004; Pinto 2015; Schmitz 2009; Winters-Stone
2011), National Medical Center and Beckman Research Institute
Standard Instrument of Quality of Life Breast Cancer Survivors
(Taleghani 2012), and Perceived General Health (Rogers 2009).
We have provided in Table 1 details of HRQoL subscales (cogni-
tive function, emotional function/metal health, general health per-
spective, perceived physical function, role function, sexual func-
tion, sleep, social function) and other psychological outcomes
(anxiety, depression, fatigue and vitality, pain/disability, and self-
esteem/body image) as provided in eligible studies.
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Cardiorespiratory fitness outcomes
Investigators assessed cardiorespiratory fitness using maximal or
submaximal tests for direct or indirect measurement of VO max/
peak or by assessing the distance walked for a given time period. Six
(10%) trials directly measured VO max/peak using a maximal
exercise test (Courneya 2003; DeNysschen 2011; Dolan 2016;
Herrero 2006; Irwin 2015; Mehnert 2011). Twelve (19%) studies
assessed VO max indirectly either maximally or submaximally
(Cerulli 2014; Daley 2007; Do 2015; Fillion 2008; Milne 2008;
Musanti 2012; Naumann 2012; Rahnama 2010; Rogers 2009;
Rogers 2013; Rogers 2014; Rogers 2015). Eleven (17%) studies
assessed cardiorespiratory fitness using a field test (Basen-Enquist
2006; Heim 2007; Kaltsatou 2011; Kim 2015; Murtezani 2014;
Mustian 2004; Nieman 1995; Nikander 2007; Pinto 2005; Portela
2008; Saarto 2012). Details of these cardiorespiratory outcomes
are provided in Table 2. One trial assessed only the intervention
group via a peak graded exercise stress test on a cycle ergometer
(Pinto 2003). Other cardiovascular measures assessed in studies in-
cluded resting heart rate (Courneya 2003; Dolan 2016; Rahnama
2010), resting systolic blood pressure (Cadmus 2009; Courneya
2003; Guinan 2013; Kaltsatou 2011; Rahnama 2010), resting di-
astolic blood pressure (Cadmus 2009; Courneya 2003; Guinan
2013; Rahnama 2010), and heart rate reserve (Courneya 2003).
Physical activity outcomes
In all, 23 (37%) studies measured physical activity via self-report
and 12 (19%) studies performed objective measurements. Twenty
(32%) studies reported both preintervention and postintervention
physical activity (Baruth 2013; Basen-Enquist 2006; Cadmus
2009; Courneya 2003; Guinan 2013; Hatchett 2013; Irwin 2015;
Kiecolt-Glaser 2014; Kim 2015; Littman 2012; Matthews 2007;
Pinto 2005; Pinto 2015; Rogers 2009; Rogers 2015; Saarto 2012;
Schmitz 2009; Short 2014; Vallance 2007; Winters-Stone 2011).
Ten (16%) studies assessed preintervention to postintervention
physical activity objectively via accelerometers (Guinan 2013;
Matthews 2007; Pinto 2005; Pinto 2015; Rogers 2009; Rogers
2014; Rogers 2015); Cadmus 2009, Short 2014, and Vallance
2007 used pedometers. We have provided details of these physical
activity outcomes in Table 2.
Anthropometric outcomes
Anthropometric outcomes included in eligible studies consisted of
body mass (n = 22; 35%), BMI (n = 19; 30%), hip circumference
(n = 7; 11%), waist circumference (n = 9; 14%), and waist-to-hip
ratio (n = 5; 8%). Nineteen (30%) studies included some body
composition measure (Cadmus 2009; Cerulli 2014; Courneya
2003; Daley 2007; DeNysschen 2011; Guinan 2013; Herrero
2006; Ligibel 2008; Matthews 2007; Musanti 2012; Mustian
2004; Naumann 2012; Rogers 2009; Rogers 2013; Rogers 2014;
Saarto 2012; Schmitz 2005; Schmitz 2009; Winters-Stone 2011).
We have provided details of anthropometric and body composition
outcomes in Table 2.
Muscular strength outcomes
Seventeen (27%) studies assessed lower body muscular strength
(Cerulli 2014; Cormie 2014; Do 2015; Dolan 2016; Heim
2007; Milne 2008; Musanti 2012; Naumann 2012; Nieman
1995; Nikander 2007; Rogers 2009; Rogers 2013; Saarto 2012;
Schmitz 2005; Schmitz 2009; Waltman 2010; Winters-Stone
2011), whereas 20 (32%) studies included a measure of upper body
muscular strength (Cerulli 2014; Cormie 2014; Do 2015; Heim
2007; Irwin 2015; Kaltsatou 2011; Kim 2015; Malicka 2011;
Milne 2008; Musanti 2012; Mustian 2004; Naumann 2012;
Nikander 2007; Portela 2008; Rogers 2009; Saarto 2012; Schmitz
2005; Schmitz 2009; Waltman 2010; Winters-Stone 2011). We
have provided details of muscular strength outcomes in Table 2.
One study reported the “maximal weight lifted for each exercise
during strength training sessions” only for the intervention group
(Ligibel 2008).
Bone-related outcomes
Two (3%) studies measured total bone mineral content (BMC)
using dual-energy X-ray absorptiometry (DEXA) (Cadmus 2009;
Saarto 2012); Saarto 2012 assessed BMC of the distal tibia, tib-
ial midshaft, and femoral neck. Six trials assessed bone mineral
density (BMD) via DEXA (Cadmus 2009; Kim 2015; Rogers
2009; Saarto 2012; Waltman 2010; Winters-Stone 2011). Saarto
2012 assessed BMC, total cross-sectional area, cortical density, and
density-weighted polar section modulus via peripheral quantita-
tive computed tomography (pQCT) scans of the left distal tibia
and tibial midshaft. Four (6%) studies provided data for biomark-
ers of bone turnover (Kim 2015; Mustian 2004; Waltman 2010;
Winters-Stone 2011). We have provided details of bone-related
outcomes in Table 2.
Excluded studies
We retrieved a total of 86 studies, then excluded them after review
as they did not meet the inclusion criteria. We excluded 13 (15%)
studies as they used a non-randomised controlled trial design
and included no comparison group (Fernandez-Lao 2013; Fong
2014; Galantino 2013; Hojan 2013; Hunt-Shanks 2006; Hutnick
2005; Johnsson 2013; Lee 2010; Naumann 2012a; Sherman 2010;
Speed-Andrews 2010; Sprod 2010; Ulger 2010). We excluded 13
(15%) studies as they did not analyse populations with breast can-
cer separately (Buffart 2012; Burnham 2002; Culos-Reed 2006;
Demark 2006; Ibfelt 2011; LaStayo 2011; Ligibel 2012; May
2008; Oh 2010; Stevinson 2007; Tang 2010; Thorsen 2005;
Van Weert 2005). We excluded two (2%) studies as they in-
volved only patients with stage IV breast disease (Cunningham
21Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
1998; Headley 2004). We excluded one (1%) study as it involved
only pretreatment patients with breast cancer (Cohen 2010), and
13 (15%) as they included patients receiving concurrent adju-
vant chemotherapy and radiotherapy (Anderson 2012; Danhauer
2009; Hsiao-Fang 2013; Hsieh 2008; Husebo 2014; Isabell 2010;
Kilbreath 2012; Moadel 2007; Naraphong 2015; Sandel 2005;
Segal 2001; Taso 2014; Yuen 2007). We excluded 29 (34%) studies
as they did not compare a physical activity intervention versus no
physical activity, another intervention, or usual care (Benton 2014;
Cadmus-Bertram 2011; Carter 2012; Cheema 2006; D’Atillio
2007; Damush 2006; De Backer 2007; Dimeo 2008; Eyigor
2010; Hanna 2008; Johansson 2005; Kovacic 2011; Noble 2012;
Oldervoll 2011; Pinto 2008; Pinto 2013; Rabin 2006; Rabin
2009; Schmidt 2012; Schneider 2007; Schwartz 1999; Sprod
2005; Stan 2012; Stan 2013; Szczwpanska-Gieracha 2010; Turner
2004; Van Puymbroeck 2011; Wong 2012; Wu 2008). We ex-
cluded 10 (12%) studies in which the effect of physical activity
could not be isolated because the intervention included dietary
modification (Casla 2015; Djuric 2002; Kim Soo 2011; Mefferd
2007), lifestyle interventions and/or patient education (Bloom
2008; Cho 2006), or manual therapy (Cantarero-Villanueva
2012a; Cantarero-Villanueva 2012; Cantarero-Villanueva 2013a;
Fernandez-Lao 2012). We excluded seven (8%) studies as the phys-
ical activity intervention was limited to shoulder and arm training
(Gordon 2005; Hayes 2013; Jeff 2012; Kilbreath 2006; Kilgour
2008; McClure 2010; Tidhar 2010). For detailed information on
reasons for exclusion of retrieved studies, see the Characteristics
of excluded studies table.
Risk of bias in included studies
For each trial, we have detailed risk of bias in the ’Risk of bias’
tables included under Characteristics of included studies and in
the ’Risk of bias’ summary provided in Figure 2. In addition, we
have presented an overall assessment of risk of bias in Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Allocation
Thirty-two (51%) trials were at a low risk of selection bias owing to
adequate generation of the randomised sequence because these tri-
als used a random component to generate the sequence (Cadmus
2009; Cantarero-Villanueva 2013; Carson 2009; Cormie 2014;
Courneya 2003; Daley 2007; Do 2015; Duijits 2012; Ergun
2013; Fillion 2008; Guinan 2013; Irwin 2015; Kiecolt-Glaser
2014; Kim 2015; Loh 2014; Loudon 2014; Martin 2013; Milne
2008; Murtezani 2014; Musanti 2012; Mustian 2004; Peppone
2015; Portela 2008; Rogers 2009; Rogers 2013; Rogers 2014;
Rogers 2015; Saarto 2012; Schmitz 2005; Schmitz 2009; Short
2014; Vallance 2007). Four (6%) trials had high risk of selec-
tion bias as they used a non-random component to generate se-
quences (Cuesta-Vargas 2014; Heim 2007; Naumann 2012; Segar
1998). We considered 26 (41%) trials to have unclear risk of se-
lection bias, mainly because study authors did not describe gener-
ation of the random sequence (Banasik 2011; Baruth 2013; Blank
2005; Bower 2011; Cerulli 2014; DeNysschen 2011; Dolan 2016;
Hatchett 2013; Herrero 2006; Kaltsatou 2011; Ligibel 2008;
Littman 2012; Malicka 2011; Matthews 2007; McKenzie 2003;
Mehnert 2011; Nieman 1995; Nikander 2007; Payne 2008; Pinto
2003; Pinto 2005; Pinto 2015; Rahnama 2010; Taleghani 2012;
Waltman 2010; Winters-Stone 2011).
Twenty-one (33%) studies were at low risk of selection bias
owing to adequate concealment of allocation to the interven-
tion because participants and investigators could not foresee as-
signment to study groups (Cadmus 2009; Cantarero-Villanueva
2013; Cormie 2014; Courneya 2003; Daley 2007; Herrero 2006;
Kiecolt-Glaser 2014; Loh 2014; Loudon 2014; Mehnert 2011;
Milne 2008; Murtezani 2014; Musanti 2012; Rogers 2009; Rogers
2014; Rogers 2015; Saarto 2012; Schmitz 2005; Schmitz 2009;
Short 2014; Vallance 2007). Six (10%) trials were at high risk
of selection bias because it was possible that participants and/or
investigators could foresee assignment to study groups (Carson
2009; Cuesta-Vargas 2014; Heim 2007; Mustian 2004; Naumann
2012; Winters-Stone 2011). Although participant allocation was
placed in sealed, sequentially numbered envelopes, trial authors
in Winters-Stone 2011 did not report whether the envelopes were
opaque. We determined that 36 (57%) studies had unclear risk
of selection bias owing to allocation concealment, predominantly
because investigators did not describe allocation concealment or
did not describe allocation concealment in adequate detail for a
decision to be made (Banasik 2011; Baruth 2013; Basen-Enquist
2006; Blank 2005; Bower 2011; Cerulli 2014; DeNysschen 2011;
Do 2015; Dolan 2016; Duijits 2012; Ergun 2013; Fillion 2008;
Guinan 2013; Hatchett 2013; Irwin 2015; Kaltsatou 2011; Kim
2015; Ligibel 2008; Littman 2012; Malicka 2011; Martin 2013;
Matthews 2007; McKenzie 2003; Nieman 1995; Nikander 2007;
Payne 2008; Peppone 2015; Pinto 2003; Pinto 2005; Pinto 2015;
Portela 2008; Rahnama 2010; Rogers 2013; Segar 1998; Taleghani
2012; Waltman 2010).
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Blinding
All trials included in this review were at high risk for performance
bias because the nature of the intervention (i.e. physical activity)
made it impossible to blind trial personnel and participants. We
considered 24 (38%) studies to be at low risk of detection bias be-
cause outcome assessors were blinded to allocation of participants
to study groups (Basen-Enquist 2006; Bower 2011; Cadmus 2009;
Cantarero-Villanueva 2013; Carson 2009; Cuesta-Vargas 2014;
DeNysschen 2011; Ergun 2013; Guinan 2013; Herrero 2006;
Kiecolt-Glaser 2014; Loudon 2014; Murtezani 2014; Musanti
2012; Pinto 2015; Portela 2008; Rahnama 2010; Rogers 2014;
Rogers 2015; Saarto 2012; Schmitz 2005; Schmitz 2009; Short
2014; Winters-Stone 2011). However, this was typically done for
outcome assessors measuring physical fitness outcomes rather than
in cases of self-report outcomes, such as HRQoL and psycholog-
ical outcomes. Eleven (17%) studies were at high risk of detec-
tion bias owing to lack of blinding of outcome assessment (Daley
2007; Fillion 2008; Heim 2007; Littman 2012; Mehnert 2011;
Milne 2008; Mustian 2004; Payne 2008; Pinto 2003; Pinto 2005;
Segar 1998). Twenty-eight (44%) studies had unclear risk of detec-
tion bias (Banasik 2011; Baruth 2013; Bower 2011; Cerulli 2014;
Cormie 2014; Courneya 2003; Do 2015; Dolan 2016; Duijits
2012; Hatchett 2013; Irwin 2015; Kaltsatou 2011; Kim 2015;
Ligibel 2008; Loh 2014; Malicka 2011; Martin 2013; Matthews
2007; McKenzie 2003; Naumann 2012; Nieman 1995; Nikander
2007; Peppone 2015; Rogers 2009; Rogers 2013; Taleghani 2012;
Vallance 2007; Waltman 2010).
Incomplete outcome data
Eighteen (29%) studies were at low risk of attrition bias owing
to the quantity, nature, or handling of incomplete outcome data
(i.e. no missing data or used an acceptable method for handling
missing data, such as multiple imputation) (Basen-Enquist 2006;
Bower 2011; Cerulli 2014; Courneya 2003; Cuesta-Vargas 2014;
DeNysschen 2011; Irwin 2015; Malicka 2011; Martin 2013;
McKenzie 2003; Milne 2008; Musanti 2012; Naumann 2012;
Peppone 2015; Pinto 2015; Rogers 2009; Rogers 2015; Waltman
2010). Thirty-five (56%) trials had high risk of attrition bias ow-
ing to exclusion of participants with missing data, lack of descrip-
tion of how missing data were handled, or inappropriate meth-
ods of handling missing data, such as use of the last observation
carried forward (LOCF) method (Banasik 2011; Baruth 2013;
Cadmus 2009; Cantarero-Villanueva 2013; Carson 2009; Cormie
2014; Do 2015; Dolan 2016; Duijits 2012; Fillion 2008; Guinan
2013; Hatchett 2013; Heim 2007; Kiecolt-Glaser 2014; Kim
2015; Littman 2012; Loh 2014; Loudon 2014; Matthews 2007;
Murtezani 2014; Mustian 2004; Nieman 1995; Pinto 2003; Pinto
2005; Portela 2008; Rahnama 2010; Rogers 2013; Rogers 2014;
Saarto 2012; Schmitz 2005; Schmitz 2009; Segar 1998; Short
2014; Vallance 2007; Winters-Stone 2011). Ten (16%) studies had
unclear risk of bias (Blank 2005; Daley 2007; Ergun 2013; Herrero
2006; Kaltsatou 2011; Ligibel 2008; Mehnert 2011; Nikander
2007; Payne 2008; Taleghani 2012).
Selective reporting
Most trials (n = 55; 87%) were at low risk of reporting bias, and,
based on information provided by trial authors, we had no rea-
son to believe that selective reporting of primary and secondary
outcomes occurred. Owing to incomplete reporting of outcome
variables, we considered six (10%) studies to be at high risk for
reporting bias (Banasik 2011; Baruth 2013; DeNysschen 2011;
Guinan 2013; Martin 2013; Musanti 2012), and only two (3%)
studies to have unclear risk (Basen-Enquist 2006; Littman 2012).
Other potential sources of bias
Forty-five (71%) studies were at low risk of other biases, and
we considered 16 (25%) trials to be at high risk of other biases
(Basen-Enquist 2006; Blank 2005; DeNysschen 2011; Do 2015;
Heim 2007; Irwin 2015; Ligibel 2008; Loh 2014; Mehnert 2011;
Milne 2008; Murtezani 2014; Musanti 2012; Nieman 1995;
Peppone 2015; Pinto 2003; Pinto 2005) owing to potential con-
tamination (i.e. increased physical activity in usual care groups),
possible occurrence of ‘null bias’ due to insufficiently delivered
interventions (e.g. low adherence to intervention, high dropout
rates), and imbalance between groups at baseline. Two (3%) stud-
ies were at unclear risk of other biases (Matthews 2007; Payne
2008).
Effects of interventions
See: Summary of findings for the main comparison Physical
activity versus control for women with breast cancer after
adjuvant therapy (immediate postintervention values); Summary
of findings 2 Physical activity versus control for women with
breast cancer after adjuvant therapy (change from baseline to end
of intervention values)
See Summary of findings for the main comparison and Summary
of findings 2. For detailed information on each of the outcomes,
as well as on numbers of trials reporting the outcomes, numbers of
participants for whom outcomes were reported, statistical methods
used for analysis, and effect estimates, see Data and analyses.
Breast cancer-related mortality
No randomised or quasi-randomised controlled trials reported
breast cancer-related mortality.
Quality of life
Health-related quality of life
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Immediately after physical activity interventions, follow-up values
showed significant small improvement in overall HRQoL com-
pared with control interventions (standardised mean difference
(SMD) 0.39, 95% confidence interval (CI) 0.21 to 0.57, I² = 68%,
22 studies, 1996 participants; low-quality evidence; Analysis 1.1;
Summary of findings for the main comparison). This improve-
ment did not persist at three months or longer post intervention
(Analysis 1.1; Figure 4). For analysis of immediately postinter-
vention values, exclusion of the two most extreme trials lowered
heterogeneity to a level where it might not be important (I² =
18%) while maintaining the significant effect of physical activity
(Cerulli 2014; Milne 2008).
Figure 4. Forest plot of comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control,
outcome: 1.1 Overall HRQoL (follow-up values).
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Change in overall HRQoL from baseline to end of intervention
revealed significant moderate improvement with physical activity
compared with control (SMD 0.78, 95% CI 0.39 to 1.17, I² =
90%, 14 studies, 1459 participants; low-quality evidence; Analysis
1.2; Figure 5; Summary of findings 2). This change in overall
HRQoL persisted from baseline to three months or longer post
intervention (SMD 0.52, 95% CI 0.15 to 0.88, I² = 0%, 2 studies,
132 participants; Analysis 1.2; Figure 5). Exclusion of extreme
values did not reduce heterogeneity to acceptable levels for the
change from baseline to end of intervention analysis.
Figure 5. Forest plot of comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control,
outcome: 1.2 Overall HRQoL (change values).
Low versus unclear/high risk of bias studies
Data show significant small effects of physical activity on HRQoL
compared with control for postintervention follow-up values in
trials with both low and unclear/high risk of bias (SMD 0.43,
95% CI 0.19 to 0.66, I² = 76%, 15 studies, 1521 participants;
and SMD 0.30, 95% CI 0.06 to 0.55, I² = 32%, 7 studies, 475
participants, respectively; Analysis 18.1). A significant moderate
effect on change from baseline to end of intervention scores (SMD
0.70, 95% CI 0.28 to 1.12, I² = 91%, 11 studies, 1360 partic-
ipants; Analysis 18.2) with physical activity was observed com-
pared among controls only in trials with low risk of bias.
Postmenopausal only versus not postmenopausal only (i.e.
premenopausal or varied menopausal statuses)
A significant small effect of physical activity versus control on
immediately postintervention HRQoL values was observed only
when ‘not postmenopausal only’ studies were analysed (SMD 0.42,
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95% CI 0.22 to 0.63, I² = 73%, 19 studies, 1810 participants,
Analysis 12.1). Significant small changes from baseline to end of
intervention were found in postmenopausal only studies (SMD
0.49, 95% CI 0.19 to 0.79, I² = 0%, 3 studies, 186 participants;
Analysis 12.2).
Measurement type
Analysis was possible only for EORTC QLQ-C30 and FACT-G
and -B questionnaires, as only these questionnaires were included
in at least two trials. Significant improvement in immediately
postintervention values was noted in physical activity groups com-
pared with control groups for FACT-G (mean difference (MD)
7.06, 95% CI 2.82 to 11.30, I² = 86%, 10 studies, 1094 partici-
pants) and FACT-B (MD 6.31, 95% CI 1.15 to 11.47, I² = 87%,
11 studies, 1395 participants) and for QLQ-C30 global health
(MD 7.85, 95% CI 2.16 to 13.55, I² = 21%, 4 studies, 195 partic-
ipants; Analysis 1.3; Analysis 1.5; Analysis 1.10). Between-group
differences immediately post intervention represented a meaning-
ful clinically important difference (MCID) for FACT-G (MCID
5 to 6 points) but not for FACT-B (MCID 7 to 8 points) (Eton
2004).
Significant changes from baseline to end of intervention scores
in physical activity groups compared with control groups were
found for FACT-G (MD 5.04, 95% CI 1.32 to 8.75, I² = 91%,
6 studies, 663 participants) and FACT-B (MD 8.16, 95% CI
2.56 to 13.76, I² = 89%, 6 studies, 605 participants), but changes
in QLQ-C30 were not significant (Analysis 1.4; Analysis 1.6;
Analysis 1.11). These changes from baseline scores represented an
MCID in FACT-G and FACT-B. The FACT-breast cancer sub-
scale indicated significant improvement in breast cancer symptoms
in immediately postintervention follow-up values only (MD 1.98,
95% CI 0.92 to 3.04, I² = 48%, 11 studies, 1043 participants),
but these improvements were below the MCID for this subscale
(MCID 2 to 3 points) (Eton 2004). FACT-trial outcome index
subscale analysis was possible only for immediately postinterven-
tion values and revealed no significant effect of physical activity
compared with control.
Intervention mode
Compared with control, data show improvement in overall
HRQoL immediately post intervention for aerobic exercise (SMD
0.41, 95% CI 0.19 to 0.63, I² = 55%, 12 studies, 971 participants)
and combined aerobic and resistance exercise (SMD 0.63, 95% CI
0.08 to 1.19, I² = 87%, 7 studies, 589 participants; Analysis 13.1).
No differences were found for yoga, tai chi, qigong, and pilates
interventions when compared with control. Trials on resistance
training were too few for subgroup analysis of immediately postin-
tervention values. We found a significant change from baseline to
end of intervention in HRQoL for aerobic exercise interventions
(SMD 0.68, 95% CI 0.22 to 1.15, I² = 92%, 12 studies, 971
participants; Analysis 13.2) compared with controls, but not for
combined aerobic and resistance exercise interventions. Subgroup
analyses of change from baseline scores were not possible for yoga,
tai chi, qigong, and pilates or resistance training interventions.
Intervention intensity
Compared with control, light-to-moderate physical activity im-
proved HRQoL (SMD 0.51, 95% CI 0.25 to 0.77, I² = 72%,
16 studies, 983 participants; Analysis 14.1). A similar result was
observed at change from baseline to end of intervention (SMD
0.99, 95% CI 0.39 to 1.60, I² = 90%, 10 studies, 534 participants;
Analysis 14.2).
Intervention duration ≤ 12 weeks versus > 12 weeks
Immediately post intervention, interventions of duration ≤ 12
weeks and > 12 weeks led to significant small improvement com-
pared with controls (≤ 12 weeks: SMD 0.45, 95% CI 0.19 to
0.70, I² = 77%, 16 studies, 1404 participants; and > 12 weeks:
SMD 0.38, 95% CI 0.10 to 0.65, I² = 35%, 6 studies, 399 par-
ticipants; Analysis 15.1). However, interventions of ≤ 12 weeks
but not > 12 weeks in duration led to significant large changes
from baseline to end of intervention in HRQoL compared with
controls (SMD 0.99, 95% CI 0.49 to 1.52, I² = 90%, 11 studies,
828 participants; Analysis 15.2).
Intervention format
All intervention settings led to significant improvement in imme-
diate postintervention follow-up values compared with controls,
with large effects evident for group format interventions (SMD
0.99, 95% CI 0.22 to 1.75, I² = 84%, 5 studies, 214 participants)
compared with small effects for both individual and combined
individual and group format interventions (SMD 0.21, 95% CI
0.03 to 0.38, I² = 39%, 10 studies, 1137 participants; and SMD
0.33, 95% CI 0.04 to 0.62, I² = 36%, 6 studies, 390 participants,
respectively; Analysis 16.1). Both group and individual format in-
terventions significantly improved change from baseline to end of
intervention HRQoL scores (SMD 1.88, 95% CI 0.19 to 3.56,
I² = 95%, 5 studies, 198 participants; and SMD 0.43, 95% CI
0.25 to 0.61, I² = 6%, 6 studies, 649 participants, respectively)
compared with controls; combined group and individual format
interventions led to no improvement (Analysis 16.2).
Intervention setting
Facility-based interventions resulted in moderate improvement in
immediately postintervention follow-up values (SMD 0.55, 95%
CI 0.27 to 0.83, I² = 71%, 15 studies, 833 participants) and large
effects on change from baseline to end of intervention scores of
HRQoL (SMD 1.18, 95% CI 0.53 to 1.82, I² = 90%, 10 studies,
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492 participants; Analysis 17.1). Compared with controls, signifi-
cant small effects on immediately postintervention HRQoL values
were found for combined home and facility-based interventions
(SMD 0.48, 95% CI 0.04 to 0.92, I² = 55%, 4 studies, 227 partic-
ipants), and small effects were observed on change from baseline
to end of intervention HRQoL scores for home-based interven-
tions (SMD 0.27, 95% CI 0.04 to 0.50, I² = 0%, 2 studies, 375
participants; Analysis 17.2).
Studies from which data could not be extracted
Data could not be extracted from five trials that reported on
HRQoL (Baruth 2013; Duijits 2012; Heim 2007; Herrero 2006;
McKenzie 2003). Baruth 2013 reported their findings in Cohen d
units (d < 2 indicates a trivial effect, 0.2 a small effect, 0.5 a medium
effect, and ≥ 0.8 a large effect), and found that participants given a
walking intervention showed improvement in indicators of QoL,
such as current health (d = 0.27), as measured by the IBCSG QoL
Core Questionnaire, and general health perspective (d = 0.66), as
measured via MOS SF-36, compared with those in the control
group. Duijits 2012 found no significant overall group differences
over time in general health perspective measured via MOS SF-
36. Heim 2007 reported that physical activity resulted in a sig-
nificant group-by-time increase in HRQoL (P = 0.0015), mea-
sured via FACT-G, in favour of the intervention group. Herrero
2006 reported a significant mean change on the global scale (P =
0.002) after a training programme, as measured by the EORTC
QLQ-C30, compared with a control. McKenzie 2003 found no
significant group-by-time increases in general health (P > 0.05)
measured via MOS SF-36 in the exercise group compared with
the control group.
Quality of life subscales
Emotional function
For emotional function, immediately postintervention (moderate-
quality evidence) and three months or longer postintervention
follow-up values and change from baseline to end of intervention
scores (low-quality evidence) showed small but significant effects
of physical activity compared with controls, but not for change
from baseline to three months or longer postintervention values
(Summary of findings for the main comparison; Summary of
findings 2; Table 3). Heterogeneity (I² = 72%) observed in the
change from baseline to end of intervention analysis was reduced
to a level that might not be important (I² = 23%) by removal of the
most extreme trial value (Murtezani 2014); this could be further
explained by the wide range of measurement instruments used,
participants’ menopausal status, and variations in study duration.
Sensitivity analysis revealed that significant effects on immediately
postintervention follow-up values and on changes from baseline
to end of intervention scores for emotional function were retained
when only trials with low risk of bias were analysed (Analysis
18.3; Analysis 18.4). Significant improvement in emotional func-
tion was noted in immediately postintervention follow-up val-
ues for QLQ-C30 emotional function (Analysis 1.10), Profile of
Mood States (POMS) total mood disturbance (Analysis 1.24), and
POMS anger (Analysis 1.26), but not among postmenopausal only
women; these effects were also observed for aerobic exercise and
combined aerobic and resistance exercise interventions (interven-
tions of low-to-moderate intensity, ≤ 12 weeks’ duration, facil-
ity-based, group and individual format physical activity interven-
tions) compared with controls. Significant changes from baseline
to end of intervention were found for the FACT emotional well-
being subscale (Analysis 1.15) and the MOS SF mental health scale
(Analysis 1.19) among postmenopausal women (aerobic exercise
only, light-to-moderate intensity, ≤ 12 weeks’ duration, facility-
based, individual format interventions) compared with controls.
Improvement in FACT emotional well-being was below the min-
imum important difference of two points (Cella 2002a).
Perceived physical function
Analysis of immediately (moderate-quality evidence) and three
months or longer postintervention follow-up values and changes
from baseline to end of intervention scores (moderate-quality evi-
dence) was possible for perceived physical function; all analyses re-
vealed significant effects for physical activity compared with con-
trols (Analysis 1.29; Analysis 1.30; Summary of findings for the
main comparison; Summary of findings 2; Table 3). Removal of
the most extreme immediately postintervention follow-up value
- from Milne 2008 - reduced heterogeneity to a level that might
not be considered important (I² from 61% to 18%), but removal
of the most extreme change from baseline to end of intervention
score - from Murtezani 2014 -, did not substantially lower hetero-
geneity. However, heterogeneity could be explained by the wide
range of measurement instruments used, physical activity modes,
participants’ menopausal status, and variations in study duration.
Effects on immediately postintervention follow-up values and
changes from baseline to end of intervention scores were main-
tained in a sensitivity analysis of studies with low risk of bias
(Analysis 18.5; Analysis 18.6). Subgroup analyses showed signif-
icant effects of physical activity on immediately postintervention
follow-up physical function values for FACT physical well-being
and for MOS SF physical function composite and subscale in-
struments (Analysis 1.31; Analysis 1.33; Analysis 1.35), but not
for postmenopausal women only; these effects were also observed
for interventions consisting of aerobic exercise only (low-to-mod-
erate intensity, ≤ 12 and > 12 weeks’ duration, combined home
and facility-based settings, group and individual formats) com-
pared with controls. Improvement in FACT physical well-being
was below the minimum important difference of two points (Cella
2002a). Change from baseline to end of intervention scores was
significantly improved for the MOS SF physical function instru-
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ment (Analysis 1.36) and for interventions consisting of aerobic
exercise only (low-to-moderate intensity, ≤ 12 weeks’ duration,
facility-based, group format) compared with controls.
Role function
Low-quality evidence suggests that immediately postintervention
follow-up values, but not three months or longer postintervention
follow-up values, or change from baseline to end of intervention
scores (analysis of change from baseline to three months or longer
postintervention scores was not possible), for role function showed
a small statistically significant improvement with physical activity
compared with control (Analysis 1.40; Analysis 1.41; Table 3).
Heterogeneity was reduced to a level that might not be considered
important (I² = 10%) by removal of the most extreme immedi-
ately postintervention follow-up values - from Milne 2008 - and
could be explained by the wide range of measurement instruments
used, intervention mode intensity, duration, setting, format, and
menopausal status.
Sensitivity analyses revealed significant improvement in immedi-
ately postintervention role function values, but not in change from
baseline to end of intervention scores, for physical activity inter-
ventions with low risk of bias compared with controls (Analysis
18.7; Analysis 18.8). Subgroup analyses revealed that the signifi-
cant effect on immediately postintervention follow-up role func-
tion values was maintained for the FACT functional well-being
measurement instrument (Analysis 1.42) and for interventions
consisting of aerobic exercise only (light-to-moderate intensity, ≤
12 and > 12 weeks’ duration, individual format) compared with
controls. Significant improvement in change from baseline to end
of intervention role function scores was found in analysis of FACT
functional well-being measurement data (Analysis 1.43), but not
in other subgroup analyses.
Social function
For social function, analysis of both immediately postintervention
follow-up values and change from baseline to end of intervention
scores (both moderate-quality evidence) showed significant im-
provement with physical activity compared with control (Analysis
1.48; Analysis 1.49; Table 3). Data were insufficient for analyses
of three months or longer postintervention follow-up values or
change scores. Heterogeneity observed in the change from baseline
to end of intervention scores analysis (I² = 87%) was accounted
for by removal of the three most extreme values (Murtezani 2014;
Saarto 2012; Vallance 2007), without altering the significant im-
provement in social function. Heterogeneity in the change from
baseline to end of intervention analyses was also explained by the
wide range of instruments used and by menopausal status and in-
tervention mode.
Sensitivity analysis revealed significant improvement in postinter-
vention follow-up values and in change from baseline to end of in-
tervention scores of social function for physical activity trials with
low risk of bias compared with controls (Analysis 18.9; Analysis
18.10). Significant effects on immediately postintervention social
function values were maintained in analysis of the FACT social
well-being subscale measurement instrument (Analysis 1.50), and
with interventions consisting of aerobic exercise (light-to-moder-
ate intensity, ≤ 12 weeks’ duration, facility-based and combined
home and facility-based settings, combined group and individ-
ual format) compared with controls. Significant improvement in
change from baseline to end of intervention social function scores
was found for the FACT social well-being subscale (Analysis 1.51),
among postmenopausal women only, and for interventions con-
sisting of aerobic exercise and combined aerobic and resistance ex-
ercise (light-to-moderate intensity, ≤ 12 weeks’ duration, facility-
based, individual format) compared with controls.
Cognitive function
We observed a significant but small effect, with no evidence of
heterogeneity, of physical activity on cognitive function at imme-
diately postintervention follow-up (low-quality evidence), but not
at three months or longer postintervention follow-up, or change
from baseline to end of intervention or change from baseline to
three months or longer postintervention scores, compared with
control (Analysis 1.56; Analysis 1.57; Table 3).
A sensitivity analysis revealed small significant improvement in
postintervention follow-up cognitive function values with physi-
cal activity interventions at low risk of bias compared with con-
trols (Analysis 18.11; Analysis 18.12). Subgroup analysis revealed
significant improvement in postintervention follow-up cognitive
function values with the POMS confusion subscale (Analysis
1.60), not among postmenopausal women only, and for interven-
tions consisting of combined aerobic and resistance exercise (light-
to-moderate intensity, all studies ≤ 12 weeks’ duration). We ob-
served no significant effect on change from baseline to end of in-
tervention score for physical activity in any of the subgroup anal-
yses.
General health perspective
Data show no significant effect of physical activity compared with
control on overall general health perspective, or in analyses in-
volving individual instruments, studies with low risk of bias, or
any other subgroup analysis of follow-up values and change scores
(very low-quality evidence for both) (Analysis 1.61; Analysis 1.62;
Table 3).
Sexual function
Trialists noted no significant effects of physical activity interven-
tions compared with controls on sexual function for follow-up
values or change scores in main or subgroup analyses, or for any
reported measure (very low-quality evidence for both) (Analysis
1.65; Analysis 1.66; Table 3).
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Sleep
We observed no significant effects of physical activity on postin-
tervention follow-up values and on change from baseline scores
for overall sleep, any measure of sleep, sensitivity analysis by risk
of bias, or subgroup analyses (low-quality evidence for both) com-
pared with control (Analysis 1.68; Analysis 1.69; Table 3).
Studies from which HRQoL subscale data could not be
extracted
Data could not be extracted from four trials that reported
emotional function (Baruth 2013; Carson 2009; Duijits 2012;
McKenzie 2003), five trials that reported perceived physical func-
tion (Baruth 2013; Duijits 2012; Heim 2007; Herrero 2006;
McKenzie 2003), four trials reporting role function (Baruth 2013;
Duijits 2012; Heim 2007; McKenzie 2003), three trials that re-
ported social functioning (Baruth 2013; Duijits 2012; McKenzie
2003), and two trials that reported general health perspective
(Duijits 2012; McKenzie 2003). Baruth 2013 observed significant
effects on mood (d = 0.30), role-emotional (d = 0.14), mental
health (d = 0.28), physical well-being (d = 0.38), physical func-
tioning (d = 0.69), and role-physical function (d = 0.60), but not
on social functioning (d = 0.04), as measured via MOS SF-36,
with a walking intervention compared with a control. Duijits 2012
observed a significant effect on physical functioning (d = 0.41)
but not on mental health, role-physical function, social function-
ing, or general health perspective, as measured via MOS SF-36,
with physical exercise compared with cognitive-behavioural ther-
apy (CBT), CBT and physical exercise combined, and control.
McKenzie 2003 found no significant changes in role-emotional
and mental health, physical functioning, role-physical function,
social functioning, or general health perspective (via MOS SF-36)
in an exercise group compared with a control group. Carson 2009
found no significant postintervention differences in negative mood
between yoga and control groups. Heim 2007 reported that in-
creases in physical and functional well-being (measured via FACT-
G) from baseline to post intervention in both physical activity
and control groups were sustained in the only exercise group at
three months or longer postintervention follow-up. Herrero 2006
reported a significant mean change in physical function scale, as
assessed via EORTC QLQ-C30 (P = .04), after an exercise pro-
gramme compared with a control.
In one trial from which data could not be extracted, Kiecolt-Glaser
2014 found that cognitive complaints did not differ significantly
between a yoga group and a wait-list group immediately following
the intervention (P = 0.25), but participants in the yoga group
reported 23% fewer cognitive problems than wait-list participants
at three-month postintervention follow-up (P = 0.003). Mehnert
2011 did not report findings from analysis of sexual attractiveness,
and Do 2015 did not report sexual functioning and sexual enjoy-
ment outcomes.
Sleep data could not be extracted from two trials (Carson 2009;
Payne 2008). Carson 2009 found a significant reduction in sleep
disturbance (measured on a 0 to 9 scale) after a yoga interven-
tion compared with control (P = 0.007), but this effect was not
sustained after three months’ follow-up (P = 0.17). Payne 2008
found a significant improvement in sleep quality assessed via the
Pittsburgh Sleep Quality Index (PSQI) with a 12-week exercise
intervention compared with a control (P =0.007). Payne 2008 also
assessed sleep using Actigraph, and observed significant reductions
in actual wake time (P = 0.02), actual sleep time (P = 0.05), and
movement during sleep (P = 0.002), but no statistically signifi-




Data show a significant reduction in anxiety with physical activ-
ity interventions, compared with controls, for both immediately
postintervention follow-up values (very low-quality evidence) and
change from baseline to end of intervention scores (low-quality
evidence) (Analysis 2.1; Analysis 2.2; Summary of findings for the
main comparison; Summary of findings 2; Table 3). Available data
were insufficient for analysis of three months or longer follow-up
values or change scores.
Heterogeneity observed in immediately postintervention follow-
up anxiety analysis was lowered to a level that might not be consid-
ered important (I² from 60% to 38%) by removal of the most ex-
treme value (Segar 1998), with maintenance of the significant ef-
fect of physical activity. Heterogeneity was explained by the range
of assessment instruments used, participants’ menopausal status,
physical activity mode, and intervention setting and format.
Sensitivity analysis, which was possible only for immediately
postintervention follow-up values, revealed a significant but small
effect in physical activity trials with low risk of bias. Subgroup anal-
ysis revealed significantly improved immediately postintervention
anxiety follow-up values for the POMS anxiety-tension subscale
(Analysis 2.3), not for postmenopausal women only, with aerobic
exercise only (light-to-moderate intensity, ≤ 12 weeks’ duration,
facility-based, group format interventions). Significant changes
from baseline to end of intervention anxiety scores were noted for
interventions including combined aerobic and resistance exercise
(light-to-moderate intensity, ≤ 12 weeks’ duration, facility-based,
group format interventions). When the overall effect of physical
activity on anxiety was expressed via the 0 to 9 PROMIS (Patient
Reported Outcomes Measurement Information System) scale, ef-
fects on change from baseline to end of intervention scores, but
not on immediately postintervention follow-up values, for anxi-
ety revealed a minimum important difference improvement above
the minimum important difference of 3 to 4.5 units (Summary of
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findings for the main comparison; Summary of findings 2) (Yost
2011).
Depression (i.e. depressive symptoms)
Immediate and three months or longer post-physical activity inter-
vention follow-up values (very low-quality evidence) and change
from baseline to end of intervention (low-quality evidence) showed
small significant improvement in depressive symptoms compared
with controls (Analysis 3.1; Analysis 3.2; Summary of findings for
the main comparison; Summary of findings 2; Table 3). Available
data were insufficient for change from baseline to three months or
longer postintervention analysis.
Heterogeneity observed in analysis of immediately postinterven-
tion follow-up values and change from baseline to end of interven-
tion scores could be explained by the wide range of measurement
instruments used, participants’ menopausal status, physical activ-
ity mode and intensity, and variations in intervention duration,
setting, and format.
Sensitivity analyses of trials with low risk of bias did not reveal sig-
nificant effects of physical activity on depression, compared with
controls, for immediately postintervention values or change from
baseline to end of intervention scores (Analysis 18.23; Analysis
18.24). Subgroup analyses revealed significant effects on immedi-
ately postintervention follow-up depression values for Beck De-
pression Inventory and Profile of Mood States (POMS) depression
and tension measurement instruments (Analysis 3.3; Analysis 3.6;
Analysis 3.7), not for postmenopausal women only, with physical
activity interventions (≤ 12 weeks’ duration, facility-based, group
format) compared with controls. However, improvement on the
Beck Depression Inventory was below the minimum important
difference of 18% (Button 2015). For change from baseline to end
of intervention depression scores, significant effects were found for
interventions that consisted of combined aerobic and resistance
exercise (light-to-moderate intensity, ≤ 12 weeks’ duration, facil-
ity-based, group format) compared with controls.
Fatigue
Both immediate (moderate-quality evidence) and three months
or longer post-physical activity intervention follow-up values re-
vealed significant but small beneficial effects on fatigue compared
with controls (Analysis 4.1; Summary of findings for the main
comparison; Table 3). Change from baseline to three months or
longer postintervention values, but not change from baseline to
end of intervention scores, demonstrated significant but small im-
provement in fatigue with physical activity compared with control
(Analysis 4.2; Summary of findings 2; Table 3).
Removal of the most extreme studies for immediately postinter-
vention follow-up fatigue values - Cantarero-Villanueva 2013;
Milne 2008 - resulted in heterogeneity that might not have been
important (I² = 9%). Heterogeneity was further explained by par-
ticipants’ menopausal status, physical activity mode, intensity, du-
ration, setting, and format.
For immediately postintervention values only, sensitivity analysis
revealed significant effects of physical activity on overall fatigue
compared with control for studies with low risk of bias (Analysis
18.25; Analysis 18.26). Subgroup analyses of fatigue revealed sig-
nificant improvement in immediately postintervention follow-up
values as maintained for EORTC QLQ-30 fatigue scale, MOS
SF vitality, POMS fatigue and vigour scales, and revised Piper
Fatigue Scale (PFS) affective/meaning measurement instruments
(Analysis 4.5; Analysis 4.12; Analysis 4.16; Analysis 4.20; Analysis
4.22), not for postmenopausal women only, with interventions
consisting of aerobic exercise only, combined aerobic and resis-
tance training, yoga, tai chi, qigong, and pilates (light-to-moderate
intensity, ≤ 12 weeks’ duration, facility-based, group or individual
format). For change from baseline to end of intervention fatigue
scores, significant effects of physical activity were maintained for
combined aerobic and resistance training and for interventions ≤
12 weeks’ duration compared with control. Significant effects for
revised PFS total fatigue scores were maintained at three months
or longer postintervention follow-up, whereas significant changes
from baseline to three months or longer postintervention values
were observed with revised PFS total fatigue scores (Analysis 4.9;
Analysis 4.10). When we expressed the overall effect of physical
activity on fatigue using the FACT-F instrument, effects on fa-
tigue immediately post intervention follow-up values and changes
from baseline to end of intervention scores were below the mini-
mum important difference of three units (Cella 2002; Summary
of findings for the main comparison; Summary of findings 2).
Pooled analysis of only vigour/vitality measures revealed small but
significant improvement with physical activity interventions com-
pared with controls, for immediately postintervention and three
months or longer postintervention follow-up values, but not for
change from baseline scores (Analysis 4.18; Analysis 4.19; Table
3).
Pain/disability
Low-quality evidence suggests no significant effect of physical
activity compared with control on pain/disability (immediately
postintervention follow-up and change from baseline to end of
intervention analyses) both overall and in sensitivity analyses in-
volving studies with low risk of bias (Analysis 5.1; Analysis 5.2;
Analysis 18.27; Analysis 18.28; Table 3). No pain/disability data
were available for three months or longer postintervention analy-
sis.
Compared with controls, physical activity led to significant effects
only for change from baseline to end of intervention scores for brief
pain inventory severity score and disabilities of the arm, shoulder,
and hand (DASH) (combined follow-up and change data) mea-
surement instruments. Subgroup analyses did not reveal signifi-
cant differences between groups in effects of physical activity on
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pain/disability for any of the analyses conducted.
Self-esteem
A small significant effect of physical activity versus control was
observed on self-esteem scores for immediately postintervention
follow-up values (moderate-quality evidence) but not for changes
from baseline to end of intervention scores (low-quality evidence)
or sensitivity analyses of trials with low risk of bias (Analysis 6.1;
Analysis 6.2; Analysis 18.21; Analysis 18.22; Table 3). Owing
to insufficient data, three months or longer follow-up or change
analyses could not be performed.
Heterogeneity was reduced to 13% by removal of the most extreme
immediately postintervention follow-up value (Musanti 2012);
this was explained by the wide range of measurement instruments
used, participants’ menopausal status, physical activity modes and
intensity, and variations in intervention duration, setting, and for-
mat.
For immediately postintervention values, significant effects of
physical activity on self-esteem, compared with control, were
maintained in analyses by the Physical Self-Perception Profile-at-
tractiveness of body subscale (Analysis 6.4) (with interventions of
light-to-moderate intensity, ≤ 12 weeks’ duration, facility-based).
A significant effect of physical activity versus control was found for
change from baseline to end of intervention scores on the Rosen-
berg Self-Esteem (RSE) scale (Analysis 6.7).
Studies from which HRQoL-related outcomes data could not
be extracted
Five trials assessed both anxiety and depression (Duijits 2012;
Fillion 2008; Heim 2007; Loh 2014; Musanti 2012), whereas one
additional study measured only depression (Schmitz 2005). No
significant differences were found between physical activity and
control groups for anxiety assessed via the Depression, Anxiety
and Stress Scale (DASS)-21 (Loh 2014) or the Hospital Anxiety
and Depression Scale (HADS) (Heim 2007), for depression as-
sessed via HADS (Duijits 2012; Heim 2007; Loh 2014) or the
Center for Epidemiologic Studies (CES) Depression Scale, or for
frequency of depression (Schmitz 2005), psychological distress (as-
sessed via HADS) (Duijits 2012), and combined anxiety and de-
pression assessed by POM subscale scores (Fillion 2008). Musanti
2012 used combined anxiety and depression scores from HADS
and observed a significant decrease over time only among partic-
ipants who scored above the threshold of clinical significance on
the HADS (score ≥ 11) at baseline (P = .001).
Data could not be extracted from six trials that assessed fatigue
(Baruth 2013; Carson 2009; Heim 2007; Musanti 2012; Payne
2008; Peppone 2015). Baruth 2013 found significant small-to-
moderate improvement in fatigue (d = -0.36) and moderate in-
creases in vigour (d = 0.57) when comparing the walking interven-
tion versus control. Musanti 2012 observed a significant reduction
in clinically significant fatigue post physical activity versus control
(both P < 0.000), whereas Heim 2007 found that at three months
postintervention follow-up, but not immediately post interven-
tion, fatigue was significantly reduced with physical activity com-
pared with control (P = 0.003). However, Payne 2008 reported no
group-by-time differences in fatigue. Of two trials that compared
yoga interventions versus control, Carson 2009 found significant
improvement in fatigue and vigour assessed via 0 to 9 scales (both
P < 0.01) with yoga, whereas Peppone 2015 reported significantly
greater improvement in fatigue and significantly greater reduction
in levels of ‘needing help finishing activities’, time spent in bed,
and feelings of heaviness in the body post yoga (all P < 0.05).
We could not extract pain/disability data from three trials (Baruth
2013; Peppone 2015; Carson 2009). Baruth 2013 found no effect
on pain (d = -0.04) with a walking intervention compared with
control. Compared with control, yoga was found to significantly
reduce musculoskeletal symptoms, such as general pain, muscle
aches, and total physical discomfort (all P < 0.05) in Peppone 2015,
and joint pain in Carson 2009. In the only study from which self-
esteem data could not be extracted (Mustian 2004), a significant
improvement in self-esteem was observed from baseline to post tai
chi intervention compared with control (P = 0.04).
All-cause mortality
No randomised or quasi-randomised controlled trials reported all-
cause mortality.
Breast cancer recurrences
No randomised or quasi-randomised controlled trials reported
breast cancer recurrence as an outcome. Seven studies reported
breast cancer recurrence data as a reason for dropout or as an
adverse event, with similar numbers in intervention and control
groups (n = 15 and 14, respectively) (Basen-Enquist 2006; Fillion
2008; Ligibel 2008; Loudon 2014; Nieman 1995; Saarto 2012;
Schmitz 2005).
Cardiorespiratory fitness
Data show significant small and large increases in cardiorespiratory
fitness when all measurement methods were considered with phys-
ical activity interventions compared with controls for immediately
postintervention follow-up values and for change from baseline to
end of intervention scores, respectively (SMD 0.44, 95% CI 0.30
to 0.58, I² = 30%, 23 studies, 1265 participants; moderate-qual-
ity evidence; and SMD 0.83, 95% CI 0.40 to 1.27, I² = 82%, 9
studies, 863 participants; very low-quality evidence, respectively)
(Analysis 7.1; Analysis 7.2; Summary of findings for the main
comparison; Summary of findings 2). This effect was still evident
three months or longer post intervention for both follow-up values
and change from baseline scores (Table 3).
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Removal of the most extreme value did not reduce heterogene-
ity in the change from baseline to end of intervention analysis
(Nieman 1995). Heterogeneity in change from baseline to end
of intervention scores was explained by risk of bias, menopausal
status, intervention mode, and duration.
Sensitivity analysis revealed that a significant effect of physical ac-
tivity versus control was evident across trials with low risk of bias
for immediately postintervention follow-up values, but not for
change from baseline to end of intervention scores (Analysis 18.29;
Analysis 18.30). When separate measurement methods were con-
sidered, significant effects for physical activity, compared with con-
trol, were evident for directly assessed VO max/peak (mL/kg/
min) for both immediate postintervention values and change from
baseline to end of intervention scores, estimated VO max via a
modified Bruce treadmill test (combined follow-up and change
from baseline data), and 6-minute walk test performance (com-
bined follow-up and change from baseline data) (Table 3). The
mean difference for directly measured VO max/peak (1.89 mL/
kg/min) was below the improvement of 3.5 mL/kg/min associated
with a 13% decrease in risk of all-cause mortality in the general
population (Kodama 2009). However, average improvement in
walk distance (MD 54.74 m) exceeded the MCID of 32 to 34 m
reported for this test in various clinical populations (Shoemaker
2013).
Significant improvement in postintervention follow-up cardiores-
piratory fitness values was maintained for physical activity com-
pared with control in subgroup analysis for postmenopausal
women only, for both aerobic exercise and combined aerobic and
resistance exercise interventions, regardless of intervention inten-
sity, duration, setting, or format. Significant changes from base-
line to end of intervention for cardiorespiratory fitness with physi-
cal activity interventions compared with controls were maintained
for postmenopausal women only, with both aerobic exercise and
combined aerobic and resistance exercise (physical activity modes,
interventions of light-to-moderate intensity, facility-based, indi-
vidual format, regardless of duration).
Studies from which data could not be extracted
Two trials from which we were unable to extract data also reported
on cardiorespiratory fitness (DeNysschen 2011; Heim 2007).
DeNysschen 2011 (via maximal exercise testing) and Heim 2007
(via the Harvard Step Test) reported no significant improvement
in cardiorespiratory fitness with physical activity compared with
control.
Other outcomes-related to cardiorespiratory fitness
In a pooled analysis of just two studies, a significant increase in im-
mediately postintervention follow-up peak power output during
cycle ergometer testing was found for physical activity compared
with control (Analysis 7.7). Furthermore, significant reductions
were found in immediately postintervention follow-up values, but
not in change from baseline to end of intervention scores, for rest-
ing heart rate observed with physical activity interventions com-
pared with controls (Analysis 7.18; Analysis 7.19). Data show no
significant effects for physical activity compared with control on
peak heart rate and respiratory exchange ratio or resting systolic
and diastolic blood pressure (Analysis 7.8; Analysis 7.9; Analysis
7.20; Analysis 7.21; Analysis 7.22; Analysis 7.23).
Physical activity assessed as an outcome measure
For overall self-reported physical activity, immediately postinter-
vention follow-up values and change from baseline to end of inter-
vention scores showed significant moderate improvement in inter-
vention groups (SMD 0.52, 95% CI 0.33 to 0.71, I² = 72%, 17
studies, 2012 participants; low-quality evidence; and SMD 0.57,
95% CI 0.25 to 0.90, I² = 82%, 8 studies, 1274 participants;
low-quality evidence, respectively) compared with control groups
(Analysis 8.1; Analysis 8.2; Table 3). These significant effects per-
sisted for both three months or longer postintervention follow-up
values and change from baseline to three months or longer postin-
tervention scores (Table 3).
Heterogeneity in self-reported physical activity analysis was ex-
plained by the intervention mode and setting for follow-up val-
ues, participants’ menopausal status, and intervention setting and
format for change scores.
For objectively measured physical activity, we found significant
small and moderate effects of physical activity interventions com-
pared with controls on both immediately postintervention follow-
up values and change from baseline to end of intervention scores,
respectively (SMD 0.43, 95% CI 0.19 to 0.66, I² = 67%, 10 stud-
ies, 1248 participants; moderate-quality evidence; and SMD 0.71,
95% CI 0.14 to 1.29, I² = 83%, 5 studies, 508 participants; low-
quality evidence, respectively) (Analysis 8.17; Analysis 8.18; Table
3). No significant effect was observed for three months or longer
postintervention follow-up values or change from baseline to three
months or longer postintervention scores for objectively measured
physical activity (Table 3).
For analysis of change from baseline to end of intervention ob-
jective physical activity scores, removal of the most extreme value
reduced heterogeneity to levels that might not be important (I² =
0%) (Vallance 2007), while maintaining a significant effect. Het-
erogeneity was explained in analysis of both immediately postin-
tervention follow-up and change from baseline to end of inter-
vention by participants’ menopausal status and by intervention
intensity, setting, and format.
Sensitivity analyses of trials with low risk of bias maintained sig-
nificant improvement in both self-reported and objective phys-
ical activity for immediately postintervention follow-up values,
but not for change from baseline to end of intervention scores,
compared with controls (Analysis 18.31; Analysis 18.32; Analysis
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18.33; Analysis 18.34).
Analysis of trials that assessed moderate and moderate-to-vigor-
ous physical activity immediately postintervention follow-up val-
ues via the self-report, a seven-day physical activity recall instru-
ment revealed significant effects of interventions versus controls
(Analysis 8.14). Analysis of immediately postintervention follow-
up accelerometer-derived counts per minute also revealed signifi-
cant increases with physical activity compared with control inter-
ventions (Analysis 8.22).
In subgroup analyses, we found significant effects of physical ac-
tivity compared with controls on immediately postintervention
follow-up self-reported physical activity values with aerobic ex-
ercise and yoga, tai chi, qigong, and pilates intervention modes,
with individual and group and individual intervention formats,
in addition to any intervention intensity, duration, or setting. For
change from baseline to end of intervention, self-reported phys-
ical activity scores maintained significance regardless of intensity
for interventions consisting of aerobic exercise only and combined
aerobic and resistance exercise (≤ 12 weeks’ duration, home-based
and combined home and facility-based, individual and combined
group and individual formats).
For objective physical activity, significant improvement in imme-
diately postintervention follow-up values was found for physical
activity interventions consisting of aerobic exercise only (light-to-
moderate intensity, ≤ 12 weeks’ duration, home-based and com-
bined home and facility-based settings, individual and combined
group and individual formats) compared with controls. Compared
with controls, interventions of light-to-moderate intensity with
combined home and facility-based setting and combined group
and individual format maintained a significant effect on objec-
tively measured physical activity change from baseline to end of
intervention scores.
With regards to other physical activity outcomes, significant ef-
fects of interventions versus controls were found in change from
baseline to end of intervention self-reported walking scores, and
in both immediate postintervention follow-up values and change
from baseline to end of intervention scores for self-reported total
and moderate-intensity physical activity, and for objectively mea-
sured moderate-to-vigorous physical activity (Table 3). The odds
of participants given physical activity interventions meeting rec-
ommended physical activity guidelines were significantly greater
than for control participants immediately post intervention and at
three months or longer post intervention (Table 3). No significant
reductions in overall or objectively measured sedentary behaviour
were found for physical activity interventions compared with con-
trols (Analysis 8.25; Analysis 8.26; Analysis 8.27).
Studies from which data could not be extracted
Among trials from which no data on physical activity could be
extracted, one trial measured the number of walking steps during
one week before and in the middle of the 12-week intervention
with a pedometer, but not post intervention (Nikander 2007),
and another reported accelerometry data from baseline to post
intervention in the intervention group only (Rogers 2013).
Body mass, BMI, body composition, and other
anthropometric measurements
Body mass change from baseline to end of intervention, but not
immediately postintervention follow-up body mass values, showed
a significant effect of physical activity compared with control (MD
-0.05 kg, 95% CI -0.98 to -0.01, I² = 59%, 11 studies, 1047 par-
ticipants; low-quality evidence; Analysis 9.1; Analysis 9.2). How-
ever, no significant effect of physical activity was found for either
follow-up or change from baseline BMI when compared with con-
trol (Analysis 9.3; Analysis 9.4).
Physical activity also resulted in a small but statistically signifi-
cant reduction in postintervention follow-up values and in change
from baseline to end of intervention body fat levels (SMD -0.18,
95% CI -0.34 to -0.03, I² = 35%, 18 studies, 1162 participants;
moderate-quality evidence; and SMD -0.62, 95% CI -1.19 to -
0.06, I² = 88%, 9 studies, 499 participants; low-quality evidence,
respectively) compared with controls (Analysis 9.5; Analysis 9.6).
Owing to insufficient data, three months or longer data analysis
could not be performed for follow-up values nor for change scores
in body mass, BMI, or body fat.
Removal of the most extreme values reduced heterogeneity to 0%
in both body mass - Irwin 2015; Murtezani 2014 - and body fat -
Schmitz 2005 - analyses. Heterogeneity in analysis of body mass
was explained by participants’ menopausal status and interven-
tion mode and format, whereas heterogeneity observed in body fat
analyses was explained by diversity in measurement type, partic-
ipants’ menopausal status, and intervention mode, intensity, du-
ration, setting, and format.
Sensitivity analysis of physical activity trials at low risk of bias
revealed no significant effects on follow-up nor change in body
mass, BMI, and body fat when compared with controls (Analysis
18.35; Analysis 18.36; Analysis 18.37; Analysis 18.38; Analysis
18.39; Analysis 18.40). Analysis by body composition measure-
ment type revealed significant reductions only in change in body
fat %, fat mass, and lean mass from baseline to end of interven-
tion as assessed via DEXA and immediately at postintervention
follow-up, as well as change from baseline to end of intervention
body fat as measured by bioelectrical impedance analysis (BIA)
(Analysis 9.7; Analysis 9.8; Analysis 9.9; Analysis 9.10). Subgroup
analyses revealed no significant effects of physical activity on body
mass but significant changes in BMI from baseline to end of inter-
vention with aerobic exercise compared with control. Subgroup
analyses also showed significant reduction in immediately postin-
tervention follow-up body fat values with interventions consist-
ing of aerobic exercise (light-to-moderate intensity, facility-based,
individual format) and significant reduction in changes in body
fat from baseline to end of intervention for aerobic exercise inter-
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ventions (moderate-to-high intensity, ≤ 12 weeks’ duration) com-
pared with control.
Among other anthropometric measurements, significant effects
of physical activity versus control were found for change in both
waist and hip circumferences from baseline to end of intervention
(MD -1.71 cm, 95% CI -2.56 to -0.86, I² = 48%, 5 studies, 285
participants; and MD -2.37 cm, 95% CI -3.31 to -1.44, I² = 5%,
2 studies, 115 participants, respectively) but not for waist-to-hip
ratio (WHR) (Analysis 9.20; Analysis 9.21; Analysis 9.22; Analysis
9.23; Analysis 9.24; Analysis 9.25; Table 3).
Studies from which data could not be extracted
Of four trials from which data could not be extracted, one found
no changes in body mass (P = 0.53), BMI (P = 0.43), percentage
body fat (P = 0.25), or muscle mass (P = 0.46) (Guinan 2013); one
observed no significant differences in BMI and body fat percentage
at post intervention between supervised exercise and usual care and
between supervised exercise and exercise-placebo (Daley 2007).
One trial reported no significant differences between intervention
and control conditions at post intervention in BMI and in hip or
waist circumference (Basen-Enquist 2006). Another trial reported
postintervention body mass values for the intervention group only
(Pinto 2003).
Muscular strength
For immediate postintervention follow-up values and change from
baseline to end of intervention scores, physical activity showed
significant increases in lower body (SMD 0.44, 95% CI 0.09 to
0.78, I² = 74%, 10 studies, 637 participants; low quality-evidence;
and SMD 0.72, 95% CI 0.38 to 1.07, I² = 73%, 8 studies, 720
participants; low quality-evidence, respectively) and upper body
(SMD 0.42, 95% CI 0.08 to 0.76, I² = 79%, 13 studies, 768
participants; very low quality-evidence; and SMD 0.72, 95% CI
0.30 to 1.14, I² = 86%, 8 studies, 832 participants; moderate-
quality evidence, respectively) muscular strength compared with
controls (Analysis 10.1; Analysis 10.2; Analysis 10.11; Analysis
10.12). We found insufficient three months or longer data for
analysis.
Removal of the most extreme values did not reduce heterogeneity
in any analyses. Heterogeneity was explained by intervention mode
(follow-up values and change scores), intensity (follow-up values
and change scores), setting (follow-up values), and format (change
scores) in lower body strength analysis, rather than by participants’
menopausal status (follow-up values), intervention mode (follow-
up values), setting (follow-up values and change scores), and for-
mat (follow-up values).
Sensitivity analyses of studies with low risk of bias revealed sig-
nificant effects for immediately postintervention follow-up values
and change from baseline to end of intervention scores on lower
body and upper body strength (Analysis 18.41; Analysis 18.42;
Analysis 18.43; Analysis 18.44). In subgroup analyses, we found
that physical activity significantly increased immediately postin-
tervention follow-up lower body strength when measured via leg
press (Analysis 10.3) for interventions involving resistance exercise
(light-to-moderate intensity, > 12 weeks’ duration, facility-based,
group and individual formats). Changes in lower body strength
from baseline to end of intervention significantly improved when
assessed via leg press and leg extension (Analysis 10.4; Analysis
10.7), and for interventions that included a resistance exercise
mode (facility-based, group and individual formats), regardless of
intervention intensity and duration.
For immediately postintervention follow-up upper body strength,
subgroup analyses revealed significant effects of physical activity on
grip strength values (Analysis 10.15), with interventions involving
aerobic exercise or resistance exercise (> 12 weeks’ duration, home-
based and home and facility-based combined settings, combined
group and individual format). Significant effects of physical ac-
tivity on change from baseline to end of intervention values were
found via chest press (Analysis 10.14) for interventions consisting
of resistance exercise (light-to-moderate intensity, > 12 weeks’ du-
ration, facility-based and combined home and facility-based set-
tings, group format).
Studies from which data could not be extracted
Data could not be extracted from three trials (Heim 2007; Ligibel
2008; Musanti 2012). Ligibel 2008 reported only postintervention
strength outcomes (measured by recording the maximal weight
lifted for each exercise during strength training sessions) for the
intervention group only. Heim 2007 reported no time-by-group
interaction effects for leg extensor and arm flexor strength values,
and Musanti 2012 did not report results of analysis of leg press
data.
Bone health-related outcomes
No significant effect of physical activity, compared with control,
was found for immediately postintervention follow-up values and
change from baseline to end of intervention scores for BMC,
femoral neck, lumbar spine, and total hip BMD values, and alka-
line phosphate and serum N-telopeptides of type I collagen (NTx)
concentrations, in the main analysis or in sensitivity analysis of
low risk of bias trials (Analysis 11.1; Analysis 11.2; Analysis 11.3;
Analysis 11.4; Analysis 11.5; Analysis 11.6).
No significant effects on total or hip BMD were found in any
subgroup analyses, whereas analysis of combined follow-up and
change from baseline to end of intervention lumbar spine BMD
values revealed significant improvement only for resistance exercise
interventions.
One trial from which data could be extracted found no difference
for femoral neck and lumbar (L2-L4) bone mineral density (i.e.
-0.01 change for each measure in both intervention and control
groups) (Rogers 2009).
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Adverse events
Of the 34 trials that provided data on adverse events, 10 tri-
als reported no adverse events during the trial (Basen-Enquist
2006; Dolan 2016; Ergun 2013; Herrero 2006; Kim 2015;
Loudon 2014; Naumann 2012; Rogers 2009; Waltman 2010;
Winters-Stone 2011). Adverse events reported in intervention
groups of the remaining studies included two instances of plantar
fasciitis (Cadmus 2009), three reports of discomfort and low-in-
tensity stiffness (Cantarero-Villanueva 2013), two recurrences of
chronic back and shoulder problems (Irwin 2015), low back pain
in one participant (Murtezani 2014), two instances of tendonitis
in the shoulder and foot (Musanti 2012), one pelvis stress fracture
and 14 further reports of back or lower extremity pain or injury
(Rogers 2015), one instance each of chest pain and high blood
pressure during a treadmill stress test (Rogers 2014), one report
of intervention discontinuation due to chest pain developed dur-
ing exercise (Pinto 2005), one report each of an asthma episode
and a hypoglycaemia episode (Portela 2008), and an unspecified
number of self-resolving musculoskeletal issues (Schmitz 2005).
One trial reported a broken hip in one participant, which was not
attributed to the yoga or control intervention (Loudon 2014). Ten
participants in another trial developed musculoskeletal injuries,
but it was not clear how many occurred in each group (Schmitz
2009). Of four trials that reported an impact on lymphoedema as
an adverse event, one trial reported that three participants in the
intervention group developed lymphoedema (Murtezani 2014),
and three trials reported no lymphoedema exacerbations (Cormie
2014; Schmitz 2005; Schmitz 2009). Indeed in Schmitz 2009, the
intervention group experienced reduced risk.
With regards to medical complications and poor health, one study
reported medical complications as an adverse event in two control
participants (Daley 2007). Payne 2008 reported worsening health
condition as a reason for dropping out of the trial in both interven-
tion and control groups (no numbers per group were provided);
one participant each in the intervention and control groups re-
ported health issues during Pinto 2015, four participants in the
intervention group developed poor health leading to missing data
in Short 2014, one participant in the intervention group and four
in the control group discontinued the study because of poor health
in Winters-Stone 2011, and in another study (Waltman 2010),
continuation of health problems was a cause of missing data for
two participants in the control group. Finally, one trial reported
cognitive deficit leading to study discontinuation for 10 partici-
pants (Mustian 2004).
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Physical activity versus control for women with breast cancer after adjuvant therapy
Patient or population: women with breast cancer af ter adjuvant therapy
Settings: home-based, facility-based, and combined home and facility-based
Intervention: physical act ivity
Comparison: control
Outcomes Illustrative comparative risks* (95% CI) No. of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control Physical activity
HRQoL change from base-
line to end of intervention
Follow-up: median 12
weeks
Mean HRQoL change f rom
baseline to end of interven-
t ion ranged across control
groups f rom
- 2.40 to 1.25 standard de-
viation units
Mean HRQoL change f rom
baseline to end of inter-









SMD 0.78 (0.39 to 1.17) re-
expressed using FACT-G (0
to 104 scale); the interven-
t ion mean change was 5.
0 (2.5 to 7.5) points higher
than control (MID 5 to 6
points)
Emotional function/mental
health change from base-
line to end of intervention
Follow-up: median 12
weeks
Mean emotional funct ion/
mental health change f rom
baseline to end of interven-
t ion ranged across control
groups f rom
- 0.39 to 3.47 standard de-
viation units
Mean emotional funct ion/
mental health change f rom
baseline to end of inter-









SMD 0.31 (0.09 to 0.53) re-
expressed using FACT-EBW
(0 to 24 scale); the interven-
t ion mean change was 0.
8 (0.2 to 1.3) points higher
than control (MID 2 points)
Perceived physical func-
tion change from baseline
to end of intervention
Follow-up: median 12
weeks
Mean physical funct ion
change f rom baseline to
end of intervent ion ranged
across control groups f rom
- 1.34 to 1.66 standard de-
Mean physical funct ion
change f rom baseline to
end of intervent ion in the in-






SMD 0.60 (0.23 to 0.97) re-
expressed using FACT-PBW
(0 to 28 scale); the interven-











































































































(0.23 to 0.97 higher)a
3 (0.5 to 2.1) points higher
than control (MID 2 points)
Anxiety change from base-
line to end of intervention
Follow-up: median 11
weeks
Mean anxiety change f rom
baseline to end of interven-
t ion ranged across control
groups f rom
- 1.47 to 0.73 standard de-
viation units
Mean anxiety change f rom
baseline to end of inter-









SMD -0.37 (-0.63 to -0.12)
re-expressed using PROMIS
(0 to 9 scale); the interven-
t ion mean change was 4.
6 (7.6 to 1.5) points lower
than control (MID 3 to 4.5
points)
Depression change from





f rom baseline to end of
intervent ion ranged across
control groups f rom
- 1.51 to 1.83 standard de-
viation units
Mean depression change
f rom baseline to end of in-
tervent ion in the interven-
t ion groups was
0.34 standard deviations
lower





SMD -0.34 (-0.63 to -0.05)
re-expressed using BDI-II (0
to 63 scale); the interven-
t ion mean change was 2.5
(4.6 to 0.4) % lower than
control (MID 18%)
Fatigue change from base-
line to end of intervention
Follow-up: median 12
weeks
Mean fat igue change f rom
baseline to end of interven-
t ion ranged across control
groups f rom
- 1.81 to 1.83 standard de-
viation units
Mean fat igue change f rom
baseline to end of inter-









SMD -0.3 (-0.61 to 0) re-ex-
pressed using FACT-F (0 to
52 scale); the intervent ion
mean change was 2.6 (5.2
to 0) points lower than con-
trol (MID 3 units)
Cardiorespiratory fitness




Mean cardiorespiratory f it -
ness change f rom base-
line to end of interven-
t ion ranged across control
groups f rom
- 1.45 to 2.38 standard de-
viation units
Mean cardiorespiratory f it -
ness change f rom baseline
to end of intervent ion in the
intervent ion groups was
0.83 standard deviations
higher





SMD 0.83 (0.4 to 1.27) re-
expressed using VO max
(mL/ kg/ m in); the interven-
t ion mean change was 2.
3 (1.1 to 3.4) mL/ kg/ m in
higher than control (MID 3.










































































































* The basis for the assumed risk (e.g. median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is based on
the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
BDI: Beck Depression Inventory; CI: conf idence interval; FACT-EBW: FACT-EBW: Funct ional Assessment of Cancer Therapy Emotional Wellbeing; FACT-F: Funct ional Assessment
of Cancer Therapy - Fat igue; FACT-G: Funct ional Assessment of Cancer Therapy - General; FACT-PBW: Funct ional Assessment of Cancer Therapy Physical Wellbeing; HRQoL:
health-related quality of lif e; MID: minimal important dif f erence; PROMIS: Pat ient Reported Outcomes Measurement Information System; SMD: standardised mean dif ference; VO
max: maximal oxygen uptake
GRADE Working Group grades of evidence.
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
Moderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
aAs a rule of thumb, 0.2 SD represents a small ef fect, 0.5 SD a moderate ef fect, and 0.8 SD a large ef fect.
bWe downgraded by two levels due to evidence of inconsistency supported by presence of considerable heterogeneity (I² =
75% to 100%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01), and
suspected publicat ion bias (Egger’s test, P < 0.05).
cAll t rials lacked blinding of part icipants (performance bias), and most trials lacked blinding of outcome assessors (detect ion
bias) and had incomplete outcome report ing and/ or high attrit ion (attrit ion bias), but most were at a low risk of select ion bias,
report ing bias, and other bias, and therefore, we did not downgraded based on risk of bias.
dWe downgraded by two levels due to evidence of inconsistency supported by presence of substant ial heterogeneity (I² =
50% to 90%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01), and
imprecision because the 95% conf idence intervals included negligible ef fects as well as an appreciable benef it (>0.5).
eWe downgraded by one level due to evidence of inconsistency supported by presence of considerable heterogeneity (I² =
75% to 100%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01).
fWe downgraded by two levels due to suspected publicat ion bias (Egger’s test, P < 0.05), and imprecision because the 95%
conf idence intervals included negligible ef fects as well as an appreciable benef it (>0.5) and the sample size does not meet
the ‘‘rule of thumb’’ of approximately 400 (200 per group) part icipants. The majority of trials were at a low risk of select ion
bias, attrit ion bias, report ing bias, and other bias, and therefore, we did not downgraded based on risk of bias.
gWe downgraded by three levels due to evidence of inconsistency supported by presence of substant ial heterogeneity (I²
= 50% to 90%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01),
suspected publicat ion bias (Egger’s test, P < 0.05), and imprecision because the 95% conf idence intervals included negligible
ef fects as well as an appreciable benef it (>0.5).
hWe downgraded by two levels due to evidence of inconsistency supported by presence of considerable heterogeneity (I² =
75% to 100%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01), and










































































































iWe downgraded by three levels due to evidence of inconsistency supported of considerable heterogeneity (I² = 75% to
100%) and point est imates widely dif f ered and 95% conf idence intervals that did not overlap (P value Chi² < 0.01), suspected
publicat ion bias (included studies were small and the funnel plot shows asymmetry), and all t rials lacked blinding of
part icipants (performance bias) and most trials lacked blinding of outcome assessors (detect ion bias), had incomplete












































































































D I S C U S S I O N
Summary of main results
We included 63 trials with a total of 5761 women with breast
cancer post adjuvant therapy randomised to physical activity in-
tervention (n = 3239) or comparison (n = 2524) groups. Modes of
physical activity interventions differed across trials and included
aerobic exercise such as walking, cycling, and water-based exercise;
resistance training; and yoga, pilates, qigong, or tai chi. Investiga-
tors examined a wide and diverse range of outcomes and measures
across trials, including health-related quality of life (HRQoL),
HRQoL-related and psychological outcomes, cardiorespiratory
fitness, physical activity as an outcome, anthropometric outcomes,
muscular strength, and bone health outcomes. Attrition was a
problem across trials, with one-fifth of trials reporting that at least
20% of participants dropped out of the intervention group. Sim-
ilarly, few trials reported that participants had complied with the
amount of physical activity prescribed, and approximately one-
quarter of the targeted number of sessions were missed on average
across trials reporting such data.
Physical activity interventions of a median of 12 weeks’ dura-
tion resulted in significant small-to-moderate improvements in
HRQoL, emotional function, perceived physical function, social
function, anxiety, cardiorespiratory fitness, physical activity (both
self-reported and objectively measured), body fat, and lower and
upper body strength in analysis of both immediately postinterven-
tion follow-up values and change from baseline to end of inter-
vention scores. Role function, cognitive function, depression, fa-
tigue, vigour, and self-esteem improved only with physical activity
interventions in analysis of immediately postintervention follow-
up values, and only body mass and waist and hip circumferences
were significantly reduced in the change from baseline to end of in-
tervention scores analysis only. No significant improvements were
noted in immediately postintervention follow-up values or change
from baseline to end of intervention scores for general health, sex-
ual function, sleep, pain, body mass index (BMI), waist-to-hip ra-
tio (WHR), bone mineral content (BMC), BMD of the femoral
neck, lumbar spine, or hip, and measures of bone formation (alka-
line phosphatase) and bone resorption (serum biomarker N-ter-
minal telopeptide (NTx)). Unfortunately, we could not find any
evidence on effects of physical activity on breast cancer-related
mortality, breast cancer recurrence, or all-cause mortality. Also,
relatively few adverse events were reported across the included tri-
als, suggesting that physical activity is safe for patients with breast
cancer after they have received adjuvant therapy. Only HRQoL,
perceived physical function, anxiety, cardiorespiratory fitness, and
both self-reported and objective physical activity were considered
precise effect estimates (i.e. 95% confidence intervals (CIs) do not
include a harmful effect, or show no effect or negligible effects, and
effects exceed a minimal important difference) for both immedi-
ately postintervention follow-up values and change from baseline
to end of intervention score analyses, although effects on cognitive
function, fatigue, and vigour were precise for immediately postin-
tervention values alone, and social function and lower and upper
body strength effects were precise for change from baseline to end
of intervention scores only. When effects were re-expressed using
the most commonly employed measure, physical activity inter-
ventions led to meaningful important differences (using change
from baseline scores) in only HRQoL and anxiety (Summary of
findings 2).
Available evidence regarding sustainability of the benefits of phys-
ical activity was limited because only 14 studies included a fol-
low-up period of three months or longer beyond the end of the
intervention for all conditions. Physical activity intervention im-
provements were sustained three months or longer post interven-
tion for fatigue, cardiorespiratory fitness, and self-reported phys-
ical activity for both follow-up values and change from baseline
scores. Beneficial effects on emotional health, physical function,
depression, and vigour were still apparent in analysis of imme-
diately postintervention follow-up values, and improvements in
HRQoL remained significant in analysis of change from baseline
to three months or longer post intervention. However, no signifi-
cant improvements were found for physical activity interventions
after three months or longer post intervention in analysis of follow-
up values or change from baseline scores for cognitive function
and objectively measured physical activity; or of follow-up values
for HRQoL, role function, sit-to-stand performance, or change
from baseline scores for emotional function values. No analysis
was possible for general health perspective, sexual function, sleep,
anxiety, pain, self-esteem, body mass, BMI, body fat %, WHR,
waist and hip circumferences, upper and lower body strength, or
bone health outcomes of three months or longer postintervention
follow-up values or change from baseline to three months or longer
postintervention scores.
We performed subgroup analysis by intervention mode, intensity,
duration, setting, and format, wherever possible. Caution is re-
quired when interpreting these analyses owing to small sample
sizes and high heterogeneity. Regarding mode of physical activity,
both aerobic exercise and combined aerobic and resistance exer-
cise interventions improved HRQoL and cardiorespiratory fitness,
and aerobic exercise interventions resulted in greater increases in
HRQoL-related outcomes, such as emotional, perceived physical,
and social function, and in self-reported physical activity. Resis-
tance exercise interventions were superior for improving upper and
lower body strength, and combined aerobic and resistance exercise
interventions led to reduced fatigue. Interventions of light or light-
to-moderate intensity appeared to be more effective than those de-
scribed as moderate or moderate-to-high intensity for improving
HRQoL, emotional function, perceived physical function, social
function, anxiety, cardiorespiratory fitness, objectively measured
physical activity levels, and lower body muscular strength. Phys-
ical activity interventions longer than 12 weeks in duration were
more effective than interventions of 12 weeks or less for improv-
ing only upper and lower body muscular strength, but interven-
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tions of 12 weeks or less were superior in improving HRQoL,
emotional function, perceived physical function, social function,
anxiety, depression, and fatigue. It appears that interventions that
were facility-based were more effective than home-based interven-
tions and those utilising combined home and facility-based phys-
ical activity in improving HRQoL, emotional function, perceived
physical function, social function, anxiety, depression, and lower
body strength. However, both home-based and combined home
and facility-based interventions were superior in improving self-
reported physical activity, although greater increases in objectively
measured physical activity and upper body strength were observed
in combined home and facility-based interventions. Group-based
and individual-based interventions appear to be effective in im-
proving HRQoL and lower body strength among breast cancer
survivors compared with combined (both group- and individual-
based) interventions, whereas individual-based and combined in-
terventions were more effective than group-based interventions for
improving self-reported physical activity. Group-based interven-
tions were more effective in improving emotional function, per-
ceived physical function, anxiety, and depression, whereas individ-
ual-based interventions were superior for cardiorespiratory fitness,
and combined interventions were better for improving objective
physical activity.
Overall completeness and applicability of
evidence
The current review draws upon trials from across the world, al-
though most trials were based in North America. This review in-
cludes 63 trials, of which 60 were randomised controlled trials
(RCTs) and three were quasi-RCTs (we excluded non-randomised
controlled trials) consisting of a total of 5761 participants. All
trials included only participants with a diagnosis of breast can-
cer who had completed adjuvant cancer treatment (except for en-
docrine therapy). We excluded trials in which all participants had
received a diagnosis of metastatic breast cancer (two trials), but
five of the eligible trials included a small number of patients with
metastatic breast cancer. Eligible trials used a wide range of inter-
vention modes; however, most trials provided aerobic-based ac-
tivity (e.g. walking, cycling, Nordic walking, dance, water-based
exercise, horse-riding), and only seven trials included a resistance
training-only study arm. Similarly, only one trial was available for
each of pilates, qigong, and tai chi. We included trials only when
it was possible to isolate effects of physical activity; therefore, we
excluded interventions that combined physical activity with calo-
rie restriction, manual therapy, or cognitive-behavioural therapy
components if studies included a no physical activity control group
that did not receive the additional component. The Characteristics
of included studies table provides detailed information on trial
attributes.
We obtained information from several electronic databases
through a comprehensive search strategy (Cochrane Breast Cancer
Group Specialised Register, MEDLINE PubMed, Embase, Cen-
tral Register of Controlled Trials (CENTRAL) in the Cochrane Li-
brary, Cumulative Index to Nursing and Allied Health Literature
(CINAHL), Physiotherapy Evidence Database (PEDro), SPORT-
Discus, PsycINFO, OpenGrey, and Health Management Infor-
mation Consortium (HMIC)) and via review of reference lists
of other reviews on the topic (i.e. physical activity/exercise and
cancer) and reference lists of all included trials. We identified fu-
ture potentially eligible trials via the World Health Organization
(WHO) International Clinical Trials Registry Platform (ICTRP)
and clinicaltrials.gov. We applied no language or date restrictions
in our search strategy. We included all outcomes apart from those
related to specific impairments in the shoulder, the arm, or both
(e.g. range of motion, arm volume, arm circumference), as well
as blood biomarkers, which we excluded because they were be-
yond the scope of the current review. See Search methods for
identification of studies for details.
Regarding applicability of evidence, owing to underreporting of
sociodemographic characteristics of participants (cancer stage,
cancer treatment received, race/ethnicity, menopausal status, ed-
ucation level, annual income, and baseline physical activity lev-
els and body mass/BMI), a thorough comparison between trials
with assessment of the generalisability of findings was not possible.
However, based on the characteristics reported, most patients with
breast cancer who were enrolled in eligible trials had stage I-III
cancer, received chemotherapy, and were undergoing endocrine
therapy. Most participants were postmenopausal and Caucasian,
earned over USD 40,000, received at least a high school education
(47% attained at least a University degree), and were overweight
(BMI ≥ 25 kg/m²). These characteristics would potentially limit
the applicability of evidence to a broader population of patients
with breast cancer.
Interventions tested in eligible trials were diverse in terms of mode,
frequency, intensity, and duration, as well as sessions, setting, and
format. As evidenced in our subgroup analysis, a paucity of data is
available regarding the efficacy of activity modes, such as yoga (n
= 8), resistance training (n = 7), pilates (n = 1), qigong (n = 1), and
tai chi (n = 1); settings (facility-based vs home-based vs facility and
home-based combined); and formats (individual-based vs group-
based vs combined individual and group-based) across many of
the outcomes examined in the current review. Variation in these
important elements required to make physical activity recommen-
dations limits the precision of evidence-informed decision mak-
ing and applicability of findings. Furthermore, most trials were
short-term (≤ 12 weeks’ duration), and only a minority of trials
included postintervention follow-up to assess the sustainability of
intervention effects. Only one trial included a follow-up assess-
ment 12 months post intervention. Most of the remaining studies
included follow-up only at three months or less post intervention.
Thus it is unclear how sustainable the beneficial effects of physical
activity interventions would be.
Unfortunately, we could not provide an analysis of effects of phys-
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ical activity interventions on one of our primary outcomes - breast
cancer-related mortality - because currently no randomised or
quasi-randomised controlled trials have reported this outcome.
Similarly, physical activity interventions for breast cancer recur-
rence and all-cause mortality could not be investigated owing to
lack of available data. We assessed outcomes for which sufficient
data were available using a wide range of instruments with vary-
ing psychometric properties (i.e. level of measurement, reliability,
validity, responsiveness) (see analysis). Although analysis of out-
comes by different instrument types used revealed varying inter-
vention effects, sample size was small in many analyses. Further-
more, HRQoL and subscales and HRQoL-related psychological
outcomes were reliant on self-report and therefore were at risk of
biases such as recall and social desirability. We included analyses of
both follow-up values and change from baseline values; however,
owing to underreporting, change from baseline analyses included
smaller sample sizes than were included in analyses of follow-up
values. Similarly, small samples for analyses of sleep, anxiety, waist-
to-hip ratio, and waist and hip circumferences precluded firm con-
clusions.
Quality of the evidence
The GRADE system revealed moderate-quality evidence by end of
intervention follow-up for change from baseline to end of interven-
tion values analyses of HRQoL, physical function, and social func-
tion; for follow-up values analyses of BMI, body fat %, cardiores-
piratory fitness, emotional function, fatigue, self-esteem, and ob-
jective physical activity; and for change from baseline values anal-
ysis of upper body strength (Guyatt 2008). Low-quality evidence
was provided by the end of intervention follow-up for change from
baseline to end of intervention values analyses of cognition, sleep,
pain, role function, self-reported physical activity, and lower body
strength; for follow-up values analyses of depression and mass; and
for change from baseline values analyses of anxiety, BMI, body
fat %, emotional function, fatigue, objective physical activity, and
self-esteem. Although very low-quality evidence was provided by
end of intervention follow-up for change from baseline to end of
intervention values analyses of femoral neck, lumbar spine, and
hip BMD, general health, and sexual function, follow-up values
analyses included anxiety and upper body strength and change
from baseline values analyses of depression, cardiorespiratory fit-
ness, and upper body strength. Specifically, all trials were at risk of
performance bias owing to inability to blind study participants to
administration of physical activity. Most trials were at risk of selec-
tion bias owing to inadequate or unclear allocation concealment,
detection bias, lack of blinding of outcome assessors, and attrition
bias due to incomplete outcome data reporting (most often as a
result of high attrition and inadequate handling of missing data).
However, a large number of trials were at unclear risk of selection
and detection bias, which may reflect poor quality of reporting
rather than poor methodological practices. When we performed
sensitivity analyses of both immediately postintervention values
and change from baseline to end of intervention by including only
trials at lower risk of bias, we found that effects of physical activity
interventions on HRQoL, emotional function, physical function,
social function, anxiety, and lower body and upper body muscular
strength remained significant and were of similar or higher mag-
nitude than when all studies were included.
When considering both end of intervention follow-up and change
from baseline to end of intervention values, we found precise es-
timates of effects of physical activity interventions on HRQoL,
self-reported physical function, cardiorespiratory fitness, and both
self-reported and objective physical activity. In addition, precise
effect estimates were provided from change values analyses of so-
cial function, lower and upper body strength, and end of interven-
tion follow-up fatigue. Heterogeneity was evident in all outcomes,
except for sleep, cognition, pain, and self-esteem, for both end of
intervention follow-up and baseline to end of intervention change
values analyses; for BMI, body fat %, emotional function, mass,
sexual function, and social function immediately postintervention
values analyses; and for anxiety change from baseline to end of
intervention change values analyses.
Evidence of heterogeneity might be explained by several factors in-
cluding variation in participant characteristics (e.g. disease sever-
ity, treatment regimen, menopausal status, baseline levels of out-
comes), components of the physical activity intervention (e.g. fre-
quency, intensity, duration, mode of activity), and types of com-
parison groups used (e.g. attention control, usual care, delayed in-
tervention), including potential variations in usual care. Both our
exploration of heterogeneity and subgroup analyses were limited
owing to the large number of potential heterogeneity factors, small
sample sizes, and underreporting of key components (e.g. ~ 50%
of trials reported an assessment of activity intensity). For instance,
variation in intervention components within each mode of inter-
vention (i.e. aerobic, resistance, combined aerobic and resistance
exercise, and interventions such as yoga, tai chi, qigong, and pi-
lates) impacts consistency and limits confidence in our analyses by
intervention mode.
Potential biases in the review process
Strengths of this review include the comprehensive search strategy,
which comprised a search of 12 databases, review of reference lists
of relevant reviews in the field and reference lists of all included tri-
als, systematic appraisal of study quality through GRADE and risk
of bias through the Cochrane ’Risk of bias’ tool, and systematic
and well-defined data synthesis. In addition, we applied a broad
definition of physical activity, which included lower intensity in-
terventions such as tai chi, qigong, pilates, yoga, horse-riding, and
line-dancing, as well as higher-intensity activities such as resistance
exercise and interval training. Inclusion of lighter-intensity activ-
ities might be contentious, but application of the World Health
Organization (WHO) definition of physical activity (i.e. any bod-
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ily movement produced by contraction of skeletal muscle that in-
creases energy expenditure above a basal level) meant that inter-
ventions including these types of activities were eligible (Caspersen
1985). It is important to note that we attempted to isolate effects
of physical activity as much as possible; therefore, we excluded tri-
als that combined physical activity with another component (e.g.
dietary modification), in which a potential synergistic or additive
effect could not be ruled out. In particular, this criterion led to
exclusion of several studies that would potentially have been eligi-
ble, including trials that combined physical activity with dietary
modification (Casla 2015; Djuric 2002; Kim Soo 2011; Mefferd
2007), educational counselling (Bloom 2008; Cho 2006), or man-
ual therapy (Cantarero-Villanueva 2012; Cantarero-Villanueva
2012a; Cantarero-Villanueva 2013a; Fernandez-Lao 2012). Al-
though the contributions of these additional components to the
overall effect of physical activity may be small, an effect could not
be isolated and accounted for; therefore, the review authors believe
that a more robust approach would be to exclude them from the
review. We analysed effects of physical activity interventions on a
broad range of outcomes, including both patient-important out-
comes, such as HRQoL, and objective outcomes related to future
health, such as cardiorespiratory fitness.
The search strategy was designed and applied to ensure that re-
view authors identified and retrieved the maximal number of eli-
gible published and grey literature trials. We applied no language
restrictions, so that all trials published in non-English language
were translated and screened for eligibility. However, although
we screened several non-English language trials for eligibility, we
found none to be eligible. Similarly, we found no additional eli-
gible trials through our searches of grey literature. In spite of our
comprehensive search strategy, it is still possible that this review
may have a publication bias. We have presented funnel plots for
end of intervention follow-up (Figure 6) and change from base-
line to end of intervention values (no shown) from analyses of our
primary outcome of overall HRQoL. Visual inspection of both
figures revealed asymmetry, indicating that some publication bias
for HRQoL may characterise this field of research; this was sup-
ported by Egger’s test for these analyses (P = 0.06 and 0.07, re-
spectively). To investigate publication bias in the remaining out-
comes for which we identified a sufficient number of studies (n >
10), we also performed Egger’s test (Egger 1997) analyses of body
mass (both end of intervention follow-up and change from base-
line to end of intervention values) and BMI (immediately postin-
tervention values), which suggested publication bias (P < 0.10).
Whereas we included fewer than 10 studies in analyses of both
follow-up and change values for anxiety, BMD of femoral neck,
lumbar spine, and hip, cognitive function, general health, pain,
sexual function, and sleep, and in analyses of change values for de-
pression, self-esteem, and self-reported and objectively measured
physical activity, inspection of funnel plots revealed asymmetry,
suggesting the presence of publication bias. In all cases, observed
asymmetry was evident particularly because trials were lacking on
the side of the plot that would suggest a negative effect of physi-
cal activity. A potential rationale for apparent publication bias in
the change from baseline to postintervention values analysis may
be underreporting of change values in the included trials, rather
than lack of unpublished trials with negative findings. Across most
analyses, fewer trials were available for analysis of these change
values than were available for analysis of follow-up values. We may
have missed potentially eligible trials in our grey literature search,
although it is unclear whether additional trials found only in the
grey literature would meaningfully impact the results of this re-
view, given that these types of trials typically include small samples
and produce inclusive results (McAuley 2000).
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Figure 6. Funnel plot of comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control,
outcome: 1.1 Overall HRQoL (follow-up values).
Deviations from our proposed protocol were few. However, we
did not perform planned analysis of effects of physical activity on
blood biomarkers because we considered these outcomes to be be-
yond the scope of the current review, and because uncertainty per-
sists regarding the prognostic value of blood biomarkers in breast
cancer populations (Ballard-Barbash 2012). Therefore, future re-
views are required to explore both the prognostic value and effects
of physical activity on biomarkers that might be relevant to pa-
tients with a diagnosis of breast cancer, such as glucose, insulin, in-
flammatory cytokines, and growth factors. We originally planned
to conduct subgroup analyses by participants’ menopausal status
(premenopausal vs postmenopausal) and treatment regimen (che-
motherapy vs no chemotherapy). However, we identified insuffi-
cient numbers of trials that included premenopausal patients with
breast cancer and those who had not undergone chemotherapy to
perform these analyses.
We corresponded with and requested additional data from nine
trial authors (Baruth 2013; Carson 2009; Daley 2007; Heim
2007; Loh 2014; McKenzie 2003; Payne 2008; Peppone 2015;
Vallance 2007), four of whom (Daley 2007; Loh 2014; Payne
2008; Vallance 2007) replied to our requests. Of these four trial au-
thors, only the authors of Vallance 2007 were able to provide data
on all outcomes requested. The addition of data obtained from
these trial authors allowed us to increase sample sizes in quantita-
tive meta-analyses and to perform more complete analyses, leading
to more robust conclusions. Conversely, our inability to obtain
complete data may have contributed to observed publication bias.
Agreements and disagreements with other
studies or reviews
Several relatively recent systematic reviews have investigated ef-
fects of physical activity/exercise on health outcomes among
patients with cancer; however, some included all cancer types
(Bourke 2013; Bourke 2014; Bradt 2011; Brown 2011; Brown
2012; Buffart 2012a; Chiu 2015; Craft 2012; Cramp 2012;
Ferrer 2011; Fong 2012; Knols 2010; Mishra 2012a; Speck 2010;
Winters-Stone 2010; Zimmer 2016), instead of focusing on breast
cancer only (Battaglini 2014; Bluethmann 2015; Bluethmann
2016; Bourke 2013; Bourke 2014; Cheema 2014; Chung 2013;
Duijts 2011; Keilani 2016; Meneses-Echavez 2015; Nelson 2016;
Pan 2015; Paramanandam 2014; Yang 2016; Zeng 2014; Zhu
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2016). Most of these systematic reviews included a meta-analy-
sis (Bluethmann 2015; Bluethmann 2016; Bourke 2013; Bourke
2014; Bradt 2011; Brown 2011; Brown 2012; Buffart 2012a;
Candy 2016; Cheema 2014; Chiu 2015; Craft 2012; Cramp 2012;
Duijts 2011; Ferrer 2011; Fong 2012; Knols 2010; Lee 2010a;
Meneses-Echavez 2015; Mishra 2012a; Pan 2015; Paramanandam
2014; Speck 2010; Yang 2016; Zeng 2014; Zhu 2016). Some
of the listed systematic reviews focused on specific outcomes,
such as aromatase inhibitor-associated arthralgia (Yang 2016),
breast cancer-related lymphoedema (Keilani 2016; Nelson 2016;
Paramanandam 2014), bone health (Winters-Stone 2010), can-
cer-related fatigue (Brown 2011; Cramp 2010; Meneses-Echavez
2015), cognitive impairments (Chan 2015; Zimmer 2016), de-
pressive symptoms (Brown 2012; Craft 2012), physical activity/
exercise behaviour (Bluethmann 2015; Bluethmann 2016; Bourke
2013; Bourke 2014; Knols 2010), outcome maintenance (Spark
2013), sexual function (Candy 2016), sleep (Chiu 2015), and
quality of life (Ferrer 2011; Mishra 2012a; Zeng 2014). Some
investigated effects of particular types of physical activity such
as dance/movement therapy (Bradt 2011), physical activity inter-
ventions based on behaviour change theory (Bluethmann 2015;
Bluethmann 2016), physical activity and/or dietary interven-
tions (Spark 2013), resistance exercise (Cheema 2014; Keilani
2016; Nelson 2016; Paramanandam 2014), supervised exercise
(Meneses-Echavez 2015), tai chi (Lee 2010a; Pan 2015), walking
(Chiu 2015; Knols 2010), and yoga (Buffart 2012a), and others
included trials in which participants were still undergoing breast
cancer treatment (Battaglini 2014; Bradt 2011; Brown 2011;
Brown 2012; Buffart 2012a; Cheema 2014; Chung 2013; Cramp
2012; Duijts 2011; Fong 2012; Lee 2010a; Meneses-Echavez
2015; Mishra 2012a; Spark 2013; Zeng 2014; Zhu 2016; Zimmer
2016).
Similar to meta-analyses included in the current review, previous
meta-analyses investigating effects of physical activity found im-
provements in HRQoL in analyses that included only trials in-
volving solely breast cancer survivors (Duijts 2011; Fong 2012;
Mishra 2012a; Zeng 2014; Zhu 2016), trials including mostly
(83%) breast cancer survivors (Speck 2010), and trials with female
cancer survivors (Ferrer 2011). Similarly, two previous systematic
reviews concluded that physical activity improves HRQoL among
breast cancer survivors (Battaglini 2014; Chung 2013). Likewise,
our findings of improvement in breast cancer-specific HRQoL
were similar to those of previous meta-analyses (Mishra 2012a;
Speck 2010). Although previous meta-analyses of resistance exer-
cise interventions found improvements in HRQoL among breast
cancer survivors in Cheema 2014 and among patients with breast
cancer-related lymphoedema in Paramanandam 2014, owing to
differences in review methods (both reviews included trials com-
prising patients with breast cancer who were undergoing adju-
vant therapy, and Cheema 2014 combined overall HRQoL and
physical function values in analysis), we did not identify a suffi-
cient number of trials for investigation of this particular analysis.
Similarly, in conflict with Buffart 2012a, we found no effects of
yoga interventions on HRQoL among patients with breast cancer.
However, Buffart 2012a included trials in which participants were
undergoing breast cancer treatment. Unlike previous meta-analy-
ses (Lee 2010a; Pan 2015), we could not perform a meta-analy-
sis of only tai chi interventions owing to lack of available eligible
trials. However, we found evidence of double-counting of trials
within these analyses, for instance, the six publications produced
from the single trial of Mustian 2004, were included separately in
analyses of Pan 2015.
Among HRQoL-related outcomes, we observed improvement in
emotional function similar to those reported in three meta-anal-
yses (Mishra 2012a; Zeng 2014; Zhu 2016), perceived physi-
cal function increases similar to those reported by Speck 2010,
and enhanced social function similar to that described by Zhu
2016. However, Mishra 2012a found no improvements in per-
ceived physical or social function, and Speck 2010 reported no in-
crease in mental health or social, emotional, and role function with
physical activity interventions. Unlike one previous meta-analysis
(Paramanandam 2014), we found no improvements in perceived
physical function, specifically with resistance exercise. Similarly,
we found no change in emotional, social, or role function with
yoga, unlike Buffart 2012a, although, similar to this meta-analy-
sis, we found no effect on physical function among breast cancer
survivors. Consistent with findings of the Mishra 2012a meta-
analysis and the Zimmer 2016 systematic review, we did not find
an effect of physical activity on cognitive function among breast
cancer survivors. One previous systematic review - Chan 2015 -
concluded, based on two trials, that physical activity interventions
were effective in improving executive function and self-reported
concentration among patients with breast cancer after chemother-
apy. However, our findings of no effect of physical activity on
sexual function of breast cancer survivors differed from those of
Mishra 2012a, which reported a small effect at six months, but
was in agreement with the findings of three other meta-analyses
(Candy 2016; Speck 2010; Zhu 2016). Our finding of no effect of
physical activity on the general health perspectives of breast cancer
survivors was consistent with that of Mishra 2012a. In agreement
with two meta-analyses (Buffart 2012a; Zhu 2016), we found no
effects of physical activity interventions on sleep outcomes. How-
ever, one previous meta-analysis found improvement in sleep dis-
turbance with physical activity when comparing follow-up val-
ues with those of the comparison group at 12 weeks’ follow-up
(Mishra 2012a), and another meta-analysis revealed that moder-
ate-intensity walking exercise improved sleep among patients with
breast cancer (Chiu 2015).
Regarding other psychological outcomes, we found significant re-
ductions in anxiety with physical activity interventions; this was
consistent with the findings of two previous meta-analyses among
breast cancer survivors (Mishra 2012a; Zhu 2016), as well as one
examining effects of yoga among cancer survivors (Buffart 2012a),
but not with the findings of two other meta-analyses (Duijts 2011;
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Speck 2010). Although we found a small decrease in depression
with physical activity interventions, we failed to find a significant
reduction in the change from baseline to end of intervention values
analysis. Two previous meta-analyses found no effect of physical
activity on depression (Mishra 2012a; Speck 2010), and another
six found a significant reduction in depression among cancer and
breast cancer survivors (Brown 2012; Buffart 2012a; Craft 2012;
Duijts 2011; Fong 2012; Zhu 2016). We found a significant but
small decrease in fatigue in favour of physical activity interventions
when we analysed immediately postintervention values; however
we noted a significant reduction in fatigue in the change from
baseline to at least three months follow-up analysis, and we found
that the change from baseline to end of intervention values analysis
was not significant (P = 0.05). Several other meta-analyses showed
significant reduction in fatigue with physical activity among can-
cer survivors (Brown 2011; Buffart 2012a; Cramp 2012; Speck
2010), as well as breast cancer survivors (Duijts 2011; Fong 2012;
Meneses-Echavez 2015; Mishra 2012a); however, similar to the
current review, one review did not find significant reductions in
fatigue (Zhu 2016).
Our finding of no effect of physical activity on pain among breast
cancer survivors is consistent with that of previous meta-analyses
(Mishra 2012a; Pan 2015; Speck 2010; Yang 2016), although
Mishra 2012a observed significant effects when using follow-up
values at 12 weeks only. Similar to Mishra 2012a and Duijts
2011, we found improvements in self-esteem/body image among
breast cancer survivors, although two previous meta-analyses could
analyse only body image and reported improvement with physical
activity interventions (Speck 2010; Zeng 2014).
We found improved cardiorespiratory fitness when comparing
physical activity versus control groups, which was consistent with
the findings of previous meta-analyses in mixed cancer popula-
tion trials (Bourke 2013; Bourke 2014; Fong 2012; Speck 2010),
as well as one systematic review involving only trials of physical
activity among breast cancer survivors over the previous 25 years
(Battaglini 2014). However, Fong 2012 did not report significant
improvement in a separate subanalysis involving only trials con-
sisting solely of breast cancer survivors. Previous meta-analyses
of Bluethmann 2015, Bluethmann 2016, and Speck 2010 were
consistent with our finding of increased physical activity (both
self-reported and objectively measured physical activity) among
breast cancer survivors given physical activity interventions. Fur-
thermore, we found that increases in self-reported, but not objec-
tively measured, physical activity were maintained at least three
months post intervention, which is somewhat supported by a pre-
vious meta-analysis (Spark 2013). Spark 2013 investigated the
number of trials consisting of breast cancer survivors that achieved
successful postintervention maintenance of physical activity and/
or dietary outcomes. The authors of Spark 2013 found that four
out of nine studies that targeted physical activity improvement
among primarily breast cancer survivors achieved successful main-
tenance of physical activity at least three months post intervention,
although another four trials involving only breast cancer survivors
did not achieve successful maintenance.
Our finding of significant but small decreases in body mass (change
from baseline to end of intervention values only) was consistent
with the findings of two previous meta-analyses (Fong 2012;
Speck 2010); however, Fong 2012 found no decreases in a separate
analysis of breast cancer survivors only. In agreement with the
findings of Fong 2012, we found no significant reduction in BMI
among breast cancer survivors. However, Speck 2010 did note
reductions in BMI in physical activity trials consisting mostly of
breast cancer survivors. We also found significant small reductions
in body fat (both follow-up and change values) similar to those
reported by Speck 2010 but in disagreement with the findings of
Fong 2012.
In agreement with previous meta-analyses of mostly breast can-
cer survivors in Speck 2010 and only breast cancer survivors in
Fong 2012, we found that physical activity interventions improved
both upper and lower body strength and lower body strength.
This finding was also supported by a previous systematic review
(Battaglini 2014). Similarly, in subgroup analyses by intervention
mode, we observed the greatest effect with resistance exercise. Pre-
vious meta-analyses - Cheema 2014; Paramanandam 2014 - and
systematic reviews - Chung 2013; Keilani 2016; Nelson 2016 -
have concluded that resistance exercise interventions improve up-
per and lower body strength among breast cancer survivors, while
adding that these strength gains are achieved safely without trig-
gering changes in lymphoedema status, worsening symptoms, or
increasing arm volume. Our findings of a lack of effect of physical
activity on BMD is consistent with a previous systematic review
of exercise interventions to improve bone health in adult cancer
survivors (Winters-Stone 2010). Winters-Stone 2010 found that
only two of eight included trials reported significant effects of aer-
obic exercise on preservation of BMD at the spine or in the whole
body, and none reported exercise benefits at the hip.
Differences between the current review and previous reviews are
likely due to variations in time and design of search strategies,
as well as in eligibility criteria and their application. Specifically,
previous reviews focused on certain types of interventions or out-
comes and/or included mixed cancer populations at various stages
of treatment.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Physical activity may have small to moderate beneficial effects
on overall health-related quality of life (HRQoL), some HRQoL
domains (such as emotional, perceived physical, and social func-
tion), anxiety, cardiorespiratory fitness, self-reported and objec-
tively measured physical activity, body fat, and lower and upper
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body muscular strength among women with breast cancer after ad-
juvant therapy. Furthermore, at the end of the study period, partic-
ipants in physical activity interventions achieved more favourable
values for role and cognitive function, depressive symptoms, fa-
tigue, vigour, and self-esteem compared with survivors in control
groups. In addition, physical activity may lead to greater albeit
modest decreases in body mass and waist and hip circumferences
from the beginning to the end of the intervention. We found a
small number of minor adverse events and no evidence of nega-
tive/harmful effects of physical activity interventions. Therefore,
physical activity could be considered relatively safe and effective
in improving HRQoL along with psychological, behavioural, and
physical outcomes in breast cancer survivors.
Positive results must be interpreted cautiously owing to the het-
erogeneity and imprecision of observed effects, the risk of bias in
many trials (primarily performance, attrition, detection, and se-
lection bias), and very low-to-moderate quality of evidence. Vari-
ations in design of physical activity interventions (i.e. modes of
physical activity, frequency and intensity of sessions, duration of
both sessions and intervention, and level of behavioural support
given), risks of bias, and diversity among instruments used to assess
outcomes likely explain most of the heterogeneity observed. In ad-
dition, most statistically significant effects were small to moderate
and lacked precision (i.e. 95% confidence intervals (CIs) included
a harmful effect, no effect, or a negligible effect). When effects
were re-expressed via the most commonly employed measurement
tool or test, physical activity interventions led to meaningful clin-
ically important differences in overall HRQoL and anxiety only.
Furthermore, intervention adherence and attrition varied greatly
across trials. All of these factors limit the degree to which results
are attributable to physical activity interventions, and as a result
the practical application of findings.
We found limited evidence related to maintenance of outcomes
beyond the period of active intervention. Only a minority of tri-
als included data regarding outcome maintenance at least three
months post intervention. Therefore, although we observed sus-
tained favourable effects of physical activity interventions on fa-
tigue, cardiorespiratory fitness, and self-reported physical activity
at least three months post intervention, these analyses were based
on small sample sizes. Furthermore, assessments of follow-up be-
yond intervention completion were affected by poorer adherence
and greater attrition than were seen in assessments performed im-
mediately post intervention. Owing to these limitations, it is diffi-
cult to draw firm conclusions regarding how sustainable effects of
physical activity interventions are beyond the intervention period.
Owing to insufficient available data, we could make no conclu-
sions regarding maintenance of general health perspective, sexual
function, sleep, anxiety, pain, self-esteem, mass, body mass index
(BMI), body fat, waist-to-hip ratio (WHR), waist and hip circum-
ferences, upper and lower body strength, or bone health outcomes.
From a practice perspective, we need a greater understanding of
which components of physical activity interventions can lead to
more optimal effects on outcomes important to breast cancer sur-
vivors. Our findings appear to suggest that effects of physical ac-
tivity are not transferable across all modes, and that the mode of
physical activity chosen may influence potential benefits received.
Therefore, practitioners would benefit from knowledge of which
mode or combination of modes of physical activity (e.g. contin-
uous aerobic exercise, high-intensity intermittent exercise, resis-
tance training, yoga, tai chi, pilates) coupled with physical activ-
ity prescription components (frequency, intensity and duration of
sessions and programme) is optimal for improving a particular
outcome. In addition, understanding which behavioural change
techniques facilitate the greatest physical activity adherence would
promote the sustainability of physical activity-induced benefits.
Implications for research
This systematic review and meta-analysis of 63 trials investigated
effects of physical activity interventions among women with breast
cancer after adjuvant therapy and found that after physical activity
interventions, breast cancer survivors had more favourable postin-
tervention values and experienced greater changes during the inter-
vention period in overall health-related quality of life (HRQoL); in
emotional, perceived physical, and social function; and in anxiety,
cardiorespiratory fitness, self-reported and objectively measured
physical activity, body fat, and lower and upper body strength.
Furthermore, despite a non-significant change from baseline to
end of intervention, breast cancer survivors given physical activ-
ity interventions had more favourable values post intervention for
role and cognitive function, depression, fatigue, vigour, and self-
esteem compared with survivors given control interventions. Con-
versely, although end of intervention values in the intervention
group were not different from those in the control group, breast
cancer survivors experienced greater decreases in body mass and
in waist and hip circumferences during the intervention period.
We found no data on effects of physical activity on breast cancer-
related mortality, breast cancer recurrence, or all-cause mortality.
Therefore, future research is required to investigate effects of phys-
ical activity interventions on these as primary outcomes. Similarly,
limited data are available regarding the cost-effectiveness of phys-
ical activity interventions for women with breast cancer after ad-
juvant therapy. Further research is needed to determine whether
physical activity interventions offer equivalent or superior health
outcomes for a similar level of expenditure compared with other
available interventions.
Although available data were scarce, three months or longer postin-
tervention follow-up values for emotional and perceived physi-
cal function, depression, fatigue, vigour, cardiorespiratory fitness,
and self-reported physical activity were more favourable among
intervention groups, and intervention groups maintained greater
change from baseline to three months or longer postintervention
values in HRQoL, fatigue, cardiorespiratory fitness, and self-re-
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ported physical activity, compared with control groups. There-
fore, additional trials that include long-term follow-up assess-
ments beyond completion of interventions are required to estab-
lish whether effects of a physical activity intervention are main-
tained beyond the active intervention period. In addition, future
research is needed to determine the optimal duration after inter-
vention completion at which breast cancer survivors should receive
follow-up assessments.
Future trials could help to enhance precision around effect esti-
mates for presented outcomes by adopting more rigorous meth-
ods. A large proportion of trials included relatively small sample
sizes, with 28 of the 63 trials consisting of intervention and control
groups including fewer than 30 breast cancer survivors. More ad-
equately powered trials are required for each particular outcome.
Most of the outcomes included in this current meta-analysis were
secondary outcomes in the included trials. For some outcomes,
such as fatigue, we found little evidence from trials that specifi-
cally targeted improvement for this outcome. Trials could ensure
that appropriate randomisation and allocation concealment are
performed by using computer sequence generation coupled with
either telephone- or Internet-based central randomisation, or at
least sealed opaque envelopes. Although blinding of participants
to the allocation of physical activity is not possible (even though
physical activity placebo interventions may be an option), when
possible, such as in non-patient-reported outcomes, assessments
could be conducted by an independent clinician blinded to allo-
cation. In addition, trials could limit loss to follow-up rates by
better monitoring participants during the intervention period and
by using attention and delayed intervention control groups. How-
ever, when loss to follow-up occurs, incomplete missing data could
be analysed appropriately via intention-to-treat analysis based on
a multiple imputation method. Establishing risk of bias across
trials was made difficult by inadequate reporting; adherence to
CONSORT reporting guidelines for randomised controlled trials
(RCTs) would increase transparency in future trials and would aid
their critical appraisal and interpretation (Moher 2010).
Further research is necessary to establish the optimal physical ac-
tivity prescription needed to improve a particular desired outcome.
Trials manipulate different modes, frequencies, intensities, and
durations of both sessions and interventions to determine their
effects on specific outcomes important to women with breast can-
cer post adjuvant therapy, and to provide more refined physical
activity guidelines for breast cancer survivors. In addition, because
compliance with physical activity interventions during and after
the intervention period is an issue, future research is required to
gain a better understanding of the most effective physical activ-
ity behaviour change techniques among breast cancer survivors.
Comparisons of findings between trials were challenging owing
to the heterogeneous range of measures used to assess outcomes
included in the current review. Consensus on the most valid and
reliable measures for assessment of each outcome would help re-
searchers to address this issue. Similarly, when possible, researchers
could utilise more objective measures to assess outcomes of inter-
est (e.g. use of accelerometers to measure physical activity, use of
functional tests to measure physical function).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Banasik 2011
Methods Study design: single-centre RCT
Number randomised: 18; 9 to yoga intervention, 9 to wait-list control
Study start: not reported; stop date: not reported
Length of intervention: 8 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 63.3 (6.9)
• Control: 62.4 (7.3)
Stage, n (%):
• All women had a diagnosis of stage II-IV breast cancer.
Inclusion criteria:
• Women with stage II-IV breast cancer who were at least 2 months post treatment
Exclusion criteria:
• Receiving Herceptin therapy (an immune modifier).
• Pregnant or lactating
• Past or current history of another neoplasm
• Active serious infection, or immune deficiency
• History of psychiatric disorders requiring use of psychoactive medications or of docu-
mented alcohol or drug abuse
• Taking current steroid therapy or other known immunomodulating medications
• Physical condition preventing participation in yoga
Interventions 9 participants assigned to exercise intervention:
• Active yoga practice used in this study was primarily physical in nature and
included poses traditionally found in beginning Iyengar classes. Sessions were more
physically demanding than those of restorative or gentle yoga, with progressing
difficulty of poses, including increased duration of weight-bearing on the arms as
individual abilities improved. Two 90-minute group yoga sessions per week were
performed over 8 weeks.
Adherence:
Seven participants in the yoga group who completed the study attended an average of
14 of 16 possible yoga sessions (87.5%) with a range of 12 to 15 sessions
9 participants assigned to control:
• Control group participants were instructed to continue their regular routines and
were offered an opportunity for yoga programme participation at the end of the study
period.
Contamination of control group: not reported
Outcomes Outcomes:
• Quality of life via Functional Assessment of Cancer Therapy Form B (FACT-B)
• Fatigue by a fatigue score determined by averaging Likert scale responses to
fatigue-related items using the same scoring range
• Salivary cortisol via collected salivary samples using salivette collection vials
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Banasik 2011 (Continued)
(Starsedt Inc., Newton, NC) 4 times during the day for 2 consecutive days at baseline
and again 8 weeks later. The supernatant was assayed for cortisol via enzyme-linked
immunoassay kits (R&D Systems, Minneapolis, MN).
Numbers of participants assessed:
• Intervention: baseline, 9; at 8 weeks, 7
• Control: baseline, 9; at 8 weeks, 7
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: in part by University of Washington Center for Women’s Health and Gender
Research, Washington State University Cancer Prevention and Research Center, and in
part by Washington State University College of Nursing
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”; method of randomi-
sation was not reported
Allocation concealment (selection bias) Unclear risk Whether allocation was concealed was not
reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
High risk Analyses included only 14 participants - 7
in each group - who completed the study
Selective reporting (reporting bias) High risk Summary outcomes of FACT-B were not
provided (FACT-B, FACT-G, and TOI)
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
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Baruth 2013
Methods Study design: single-centre RCT
Number randomised: 32; 20 to intervention, 12 to control
Study start: not reported; stop date: not reported
Length of intervention: 12 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 57.4 (6.1)
• Control: 54.9 (6.5)
Stage, n (%):
• Intervention: stage 0, 1 (7.1%); stage I, 5 (35.7%); stage II, 7 (50.0%); stage III,
1 (7.1%); missing, 6
• Control: stage 0, 0 (0.0%); stage I, 5 (41.7%); stage II, 5 (41.7%); stage III, 0 (0.
0%); missing, 2
Inclusion criteria:
• Given a diagnosis of stage I-III cancer, had completed adjuvant treatment within the
previous 12 months, and were postmenopausal
• Free of cardiovascular disease and major orthopaedic limitations
• Not regularly active (< 5 days/week)
Interventions 20 participants assigned to exercise intervention:
• 12-Week home-based walking programme (3 to 5 days per week of 20 to 30 to 40
minutes at RPE 10 to 11 to 12 to 15 by week 8) using the Active Choices model
developed and refined by King and colleagues. Primary purpose of the intervention was
to increase walking. Participants received a brief (~30 minutes) in-person counselling
session, followed by 5 short (10 to 15 minutes each) telephone counselling calls during
weeks 1, 2, 4, 7, and 10.
• Initial one-on-one counselling session focussed on goal setting and exercise safety.
Subsequent counselling calls applied key constructs of the social cognitive theory,
whereby the counsellor and participants discussed a specific behaviour change principle
(e.g. social support, rewards) that participants could use to increase their walking.
Adherence:
• On average, participants completed 86.2 ± 11.9% (range 62.1% to 100%) of
prescribed walking sessions each week (missing logs were assigned zeros for the number
of walking sessions completed during those particular weeks; data not shown).
12 participants assigned to control:
• Usual care control group asked to maintain usual physical activity levels
throughout the 12-week study period. Study staff had contact with this group only at
follow-up appointments. Upon completion of the study, women in the usual care
control group received baseline intervention counselling session, materials, and
pedometer.
Contamination of control group: not reported
Outcomes Outcomes:
• QoL assessed via 2 measures:
◦ Medical Outcomes 36-Item Short Form Health Survey (MOS SF-36)
◦ International Breast Cancer Study Group (IBCSG) QoL Core
Questionnaire, breast cancer-specific questionnaire, developed to measure the impact
of adjuvant therapy on QoL. Questionnaire consists of 10 single-item visual analogue
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Baruth 2013 (Continued)
scales, anchored at both ends with words describing highest and lowest extremes of
item content.
• 13-Item subscale of the Functional Assessment of Cancer Therapy: Fatigue
(FACT-Fatigue) questionnaire used to assess fatigue
• Completed 41-item validated Community Health Activities Model Program for
Seniors (CHAMPS) questionnaire
Numbers of participants assessed:
• Intervention: baseline, 20; at 12 weeks, 18
• Control: baseline, 12; at 12 weeks, 12
Adverse events: none reported
Notes Trial registration link: none available
Trial authors contacted: yes, for additional data (means and SDs for outcomes), but trial
authors did not reply
Intention-to-treat analysis: no
Funding: supported by the US Army, Grant # DAMD17-01-1-0628
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Participants were randomized 2:1 (inter-
vention: control)”.
It is unclear how the allocation sequence
was generated.
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
High risk Post-test data at 12 weeks were collected on
94% of participants; only completers were
analysed
Selective reporting (reporting bias) High risk Physical activity data post intervention
were not reported.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
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Basen-Enquist 2006
Methods Study design: single-centre RCT
Number randomised: 60; 30 to intervention, 25 to standard care
Study start: April 2003; stop date: April 2004
Length of intervention: 6 months
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 55.7 (11.1)
• Control: 54.4 (11.7)
Stage, n (%):
• Intervention: DCIS, 9 (27); stage I, 9 (27); stage II, 7 (21); stage III, 8 (24); stage
IV, 1 (3); missing, 1
• Control: DCIS, 4 (17); stage I, 8 (33); stage II, 8 (33); stage III, 3 (13); stage IV,
1 (4); missing, 1
Inclusion criteria:
• Within 7 years of a breast cancer diagnosis
• No longer receiving treatment for breast cancer (except hormone therapy)
• Not engaging in focussed moderate physical activity for 30 minutes or longer a day
most days of the week
Exclusion criteria:
• Clearance received from physician to ensure that they had no medical conditions
contraindicating moderately intensive exercise
Interventions 35 participants assigned to exercise intervention:
• Participants in the lifestyle programme attended 90-minute group meetings each
week for 16 weeks, and every other week for 8 weeks (21 sessions total). Behaviour
change methods were based on the transtheoretical model. Participants were taught to
assess their motivational readiness for physical activity, which they did every 4 to 5
weeks, and received booklets about increasing physical activity matched to their stage
of readiness.
• Intervention sessions emphasised information and skills such as benefits of
physical activity, making small changes, overcoming barriers, goal setting, rewarding
yourself, and self-monitoring. Several methods of self-monitoring were used, including
recording minutes of activity and recording steps using a pedometer. Information and
skills were sequenced so that cognitive methods (e.g. recognising benefits of physical
activity) were presented in earlier sessions and behavioural methods (e.g. monitoring
steps, rewarding yourself ) were presented in later sessions.
Adherence:
Among those who started the intervention, the mean number of sessions attended was
14.6 out of 21 (SD 5.1), with a range of 2 to 21 sessions
25 participants assigned to control:
• During 6-month intervention period, standard care participants received 2
mailings of the same written material as the intervention group, which included topics
related to breast cancer survivorship but did not address physical activity, and standard
care participants did not meet as a group.
Outcomes Outcomes:
• Physical activity during the past week assessed via a 7-day physical activity recall
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Basen-Enquist 2006 (Continued)
questionnaire (7- DPAR), an interviewer-administered measure
• Physical performance assessed via a 6-minute endurance walk test; a 50-foot walk
test; a timed sit-to-stand test; a timed reach-up test; and a forward-reach test
• Anthropometric measures such as BMI, hip and waist circumferences
• Quality of life assessed via Medical Outcomes 36-Item Short Form Health Survey
• Patient satisfaction measured via a brief questionnaire administered to
participants in the lifestyle programme during the last session of the programme
• Lymphoedema assessed by a physical therapist who measured arm girth
circumferentially at predetermined bilateral points. Jobst measuring tapes were used to
take circumferential measurements every inch and a half, starting at the elbow and
moving toward the shoulder and toward the wrist.
Numbers of participants assessed:
• Intervention: baseline, 35; at 6 months, 28
• Control: baseline, 25; at 6 months, 23
Adverse events: The intervention group did not show a significantly larger number of
increases in arm circumference compared with the standard care group
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes
Funding: grants R21 CA89519 and R25 CA57730 from the National Cancer Institute
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Participants were assigned to study arms
using a form of adaptive randomization
called minimization”
Allocation concealment (selection bias) Unclear risk Whether the allocation was concealed is
unclear.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Staff conducting assessments were blind to
participants’ study condition
Incomplete outcome data (attrition bias)
All outcomes
Low risk All participants who were randomised were
included in the analysis, regardless of their
attendance at intervention sessions. Data
for participants who did not complete the
6-month assessment were imputed based
on regression models predicting outcomes
in the remaining sample, using covariates
and design variables
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Basen-Enquist 2006 (Continued)
Selective reporting (reporting bias) Unclear risk No selective reporting of outcomes is ap-
parent.
Other bias High risk Imbalance between numbers allocated to
intervention and control groups could po-
tentially lead to additional bias
Blank 2005
Methods Study design: single-centre RCT
Number randomised: 18; 9 to intervention, 9 to control
Study start, not reported; stop date, not reported
Length of intervention: 8 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age:
• Ages 48 to 69 years
Stage:
• Stage I-III breast cancer
Inclusion criteria:
• Minimum of 8 weeks post chemotherapy
• Oestrogen receptor positive status
• Surgery for lumpectomy, modified mastectomy, or full mastectomy (with/without
reconstruction)
• Life expectancy greater than 6 months
• Adequate blood cell counts and kidney, liver, and cardiac function
• Physical and mental ability to attend all yoga training sessions
Exclusion criteria:
• Receiving Herceptin therapy, current steroid therapy, or other known immunomodu-
lating medications
• Pregnancy or current lactation
• Past or current history of another neoplasm, active serious infection, or immune defi-
ciency
• Documented alcohol or drug abuse
• History of psychiatric disorders requiring use of psychotropic medications
Interventions 9 participants assigned to exercise intervention:
• Beginning level Iyengar yoga class 3 times per week (2 supervised and 1 home-
based). Attention to alignment and symmetry, use of props, and careful sequencing all
improve stamina, strength, flexibility, and confidence, while decreasing stress and side
effects.
Adherence: not reported
9 participants assigned to control:
• Wait-list control
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Blank 2005 (Continued)
Outcomes Outcomes:
• 31-Question self-report survey about reasons for participation, feelings of stress,
level of physical and mental effort during class sessions, and perceptions about how
yoga practice influenced awareness
Numbers of participants assessed:
• Intervention: at 6 weeks, 9
• Control: at 6 weeks, 9
Adverse events: not reported
Notes Trial registration link: none available




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Women were randomized”, but it was un-
clear how the allocation sequence was gen-
erated
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear how many participants were
included in each outcome assessment
Selective reporting (reporting bias) High risk Outcome measures were poorly described
and reported. Scores for each question were
not reported
Other bias High risk Outcomes were not assessed at baseline, so
it was not possible to assess whether out-
comes changed as a result of intervention
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Bower 2011
Methods Study design: single-centre RCT
Number randomised: 31; 16 to intervention, 15 to control
Study start: March 2007; stop date: July 2010
Length of intervention: 12 weeks
Length of follow-up: to end of intervention, at 3 months post intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 54.4 (5.7)




• Original diagnosis of stage 0-II breast cancer
• Completed local and/or adjuvant cancer therapy (with the exception of hormone
therapy) at least 6 months previously
• Ages 40 to 65 years
• Postmenopausal
• No other cancer in the past 5 years
• Experiencing persistent cancer-related fatigue
Exclusion criteria:
• Chronic medical conditions or regular use of medications associated with fatigue (e.g.
untreated hypothyroidism, diabetes, autoimmune disease, anaemia (defined as haemat-
ocrit < 24), chronic fatigue syndrome)
• Evidence that fatigue was driven primarily by a medical or psychiatric disorder other
than cancer (e.g. current major depression, insomnia, sleep apnoea)
• Evidence that fatigue was driven primarily by other non-cancer-related factors (e.g.
shift work, recent change in activity or schedule)
• Physical problems or conditions that could make yoga unsafe (e.g. serious neck injury,
unstable joints)
• Body mass index (BMI) > 31 kg/m²
Interventions 16 participants assigned to exercise intervention:
• Iyengar yoga, a traditional form of Hatha yoga, performed in groups of 4 to 6 women
for 90 minutes twice a week for 12 weeks
Adherence:
Over 80% of participants attending at least 20 of the 24 yoga classes offered. Mean
number of classes attended was 18.9 of 24 classes (78%), and median number was 22 of
24 classes (92%). At 3-month follow-up, 9 of 14 women who attended the yoga classes
(64%) were continuing to use techniques learned in class
Control group: 15 assigned to control:
• Health education classes conducted for 120 minutes once a week for 12 weeks (24
hours) in groups of 4 to 7 women. Classes were led by a PhD-level psychologist with
clinical experience
Adherence:
In the education group, the mean number of classes attended was 9.2 of 12 classes (77%)
, and the median number was 11 of 12 classes (92%)
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Bower 2011 (Continued)
Outcomes Primary outcome:
• Subjective fatigue severity assessed with the Fatigue Symptom Inventory (FSI)
Secondary outcomes:
• Vigour assessed by the vigour subscale of the Multi-dimensional Fatigue
Symptom Inventory (MFSI)
• Depressive symptoms assessed via the Beck Depression Inventory-II (BDI-II)
• Subjective sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI)
• Feelings of stress assessed on the Perceived Stress Scale
• Timed chair-stands used to assess lower extremity strength and endurance
• Functional reach test used to assess strength, flexibility, and balance
• Self-efficacy for managing fatigue assessed via the fatigue subscale of the Human
Immunodeficiency Virus Self-Efficacy Questionnaire adapted for breast cancer
• Fatigue interference with activities, mood, and enjoyment of life assessed with the
interference subscale of the FSI
Numbers of participants assessed:
• Intervention: n = 16 at baseline, n = 14 post intervention, n = 13 months after
intervention
• Control: n = 15 at baseline, n = 13 post intervention, n = 13 months after
intervention
.Adverse events: none reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes
Funding: National Center for Complementary and Alternative Medicine/National In-
stitutes of Health (NCCAM/NIH U01-AT003682; Iyengar Yoga for Breast Cancer Sur-
vivors with Persistent Fatigue)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Allocation sequence was generated inde-
pendently by the study statistician”, but it
is unclear how the allocation sequence was
generated
Allocation concealment (selection bias) Unclear risk “Allocation was concealed in opaque en-
velopes” but whether “sequential” is not
mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to blind participants;
however, it is unclear whether the outcome
was influenced by lack of masking
Blinding of outcome assessment (detection
bias)
Low risk “Outcomes assessors for the performance
tasks were blinded to group assignment,
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All outcomes and all were trained in standardized testing
procedures”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All statistical analyses were performed
on an intent-to-treat basis”. Mixed model
analysis was used to account for missing
data
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Cadmus 2009
Methods Study design: single-centre RCT
Number randomised for 6-month study: 75; to intervention; 37, to control, 38
Number randomised for 12-month study: 50; to intervention, 25; to control, 25
Study start: March 2004; stop date: July 2006
Length of intervention: 6 months; subsample study: 12 months
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 56.5 (9.5)
• Control: 55.1 (7.7)
Stage, n (%):
• Intervention: in situ, 4 (11); stage I, 20 (54); stage II, 10 (27), stage IIIA, 3 (8)
• Control: in situ, 4 (11); stage I, 10 (27); stage II, 18 (46), stage IIIA, 6 (16)
Inclusion criteria:
• Postmenopausal women
• Ages 40 to 75 years
• Stage 0-IIIA breast cancer
• 1 to 10 years post diagnosis
• ≥ 12 months post completion of adjuvant treatment
• Physically able to exercise and physician consent to begin an exercise programme
• Sedentary activity pattern (< 60 minutes/week)
Exclusion criteria:
• Diagnosis of recurrent or other primary cancer event
• Current smoker
• Diabetes mellitus
• Current or planned enrolment in a structured weight loss programme
Interventions 37 participants assigned to exercise intervention:
• Exercise intervention consisted of a combined supervised training programme at a
local health club and a home aerobic training programme. Participants exercised at the
health club during designated sessions 3 times per week and were instructed to exercise
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2 days/week on their own, either at the health club or at home.
• Intervention consisted primarily of walking, although participants could choose
to meet the exercise goal through other forms of aerobic activity. Participants were
asked to perform three 15-minute sessions during week 1, building to five 30-minute
moderate-intensity sessions by week 5. Exercise started at 50% of predicted maximal
heart rate (220-age) and was gradually increased to approximately 60% to 80% of
predicted maximal heart rate.
Adherence:
• Exercise group participants averaged 123 minutes/week (SD 52) of moderate-to-
vigorous-intensity sports/recreational activity (range 0 to 637)
• 34% of exercisers met the study goal of 150 minutes/week
• 56% completed at least 120 minutes/week (80% of the study goal)
• 67% attended supervised exercise sessions
• 96% reported exercising at least twice per week at home
38 participants assigned to control:
• Control groups were told that they could exercise on their own if they chose, but
that the study’s physical activity programme would not be available to them. They
received all exercise programme materials at 6-month follow-up. Participants in both
groups were also asked not to make significant changes in their dietary habits.
Outcomes Outcomes:
• Happiness assessed by the 2-item Fordyce Happiness Measure
• Self-esteem assessed on the Rosenberg Self-Esteem (RSE) Scale
• Depression assessed via the Centers for Epidemiological Studies-Depression Scale
(CES-D)
• Anxiety assessed by the State-Trait Anxiety Index (STAI)
• Stress assessed on Cohen’s 10-Item Perceived Stress Scale
• Quality of life (QoL) assessed by FACT-B and Medical Outcomes 36-Item Short
Form Health Survey (MOS SF-36)
• Physical activity assessed via a 7-day physical activity log (PAL) and daily steps
recorded on a 7-day pedometer log
• Anthropometric measurements including body weight, body mass index (BMI),
total percent body fat, and lean mass obtained with whole-body dual-energy X-ray
absorptiometry (DEXA)
• Bone mineral density and bone mineral content via DEXA
• Waist and hip circumferences
• Insulin and plasma concentrations of total insulin-like growth factor-1 (IGF-1)
and insulin-like growth factor binding protein-3 (IGFBP-3) measured in serum with
an enzyme-linked immunosorbent assay (ELISA) kit
• Systolic and diastolic blood pressure (available for 65 participants)
• Metabolic variable assays, fasting high-density lipoprotein (HDL-C),
triglycerides, blood glucose (all enzymatically measured via Alfa Wassermann ACE
Alera Chemistry Analyzer with reagents supplied by the company), and metabolic
syndrome z-score (all outcomes available for 65 participants)
Numbers of participants assessed:
• Intervention: baseline, 37 (35 for metabolic variable assays); at 6 months, 37 (35
for metabolic variable assays)
• Control: baseline, 38 (30 for metabolic variable assays); at 6 months, 37 (30 for
metabolic variable assays)
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Adverse events: none reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes but last observation carried forward (LOCF)
Funding: Lance Armstrong Foundation, American Cancer Society, Susan G. Komen. In
part by the National Center of Research Resources (NIH)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number generator was used.
Allocation concealment (selection bias) Low risk “The randomization code for each partic-
ipant was obtained by the principal inves-
tigator (who was not involved in recruit-
ment or data collection) only after baseline
measures for that individual had been com-
pleted and staff conducting clinic visits did
not have access to the randomization pro-
gram”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study personnel and outcome assessors
were not masked or blinded to study inter-
ventions
Incomplete outcome data (attrition bias)
All outcomes
High risk Last observation carried forward (LOCF)
approach was used; “baseline QoL values
were carried forward”
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
78Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cantarero-Villanueva 2013
Methods Study design: single-centre RCT
Numbers allocated, 68; 34 to exercise intervention; 34 to usual care
Study start: March 2009; stop date: June 2010
Length of intervention: 8 weeks
Length of follow-up: at 6 months after discharge
Country: Spain
Participants Age, years (mean SD):
• Intervention: 48.4 (10.8)
• Control: 46.2 (7.4)
Stage, n (%):
• Intervention: stage I, 4 (12.4); stage II, 23 (72.0); stage IIIA, 5 (15.5)
• Control: stage I, 10 (34.4); stage II, 14 (48.3); stage IIIA, 5 (17.3)
Inclusion criteria:
• Between 25 and 65 years old with a diagnosis of breast cancer (stage I-IIIA)
• Finished oncology treatment except hormone therapy in the previous 18 months
• Exhibit clinically significant fatigue (> 3 in total score on the Piper Fatigue Scale)
Exclusion criteria:
• Receiving oncology treatment at the time of the study
• Physical limitations associated with orthopaedic conditions
Interventions 34 participants assigned to exercise intervention:
• 8-Week water-based intervention was carried out 3 times per week for a duration
of 60 minutes (10 minutes of warm-up, 40 minutes of aerobic and endurance exercises,
and 10 minutes of cool-down exercises) in an indoor heated swimming pool sized 25 ×
12.5 m, with 140 to 200 cm water depth, 28°C of water temperature, and 30°C of
room temperature.
• Aerobic exercises consisted of different horizontal movements: forward and
backward jogging with arms moving, pulling, and pressing; leaps, leg cross-overs, and
hopping movements focussing on movement in multiple directions. Endurance
exercises were considered moderate as the parameters set for each exercise included 2 to
3 sets of 8 to 12 repetitions.
Adherence:
• 34 participants finished the aquatic exercise programme and completed 84% of
the 24 physical therapy sessions (mean ± SD, 20 ± 4 sessions).
34 participants assigned to control:
• Participants allocated to the usual care group followed oncologist
recommendations for maintaining a healthy lifestyle based on adequate nutrition,
energy balance, and maintaining usual activities.
Outcomes Primary outcomes:
• Piper Fatigue Scale (PFS) score
Secondary outcomes:
• Mood state assessed via the Spanish version of the Profile of Mood States (POMS)
containing 63 adjectives rated by participants on a 5-point scale
• Lower body muscular strength assessed via the “multiple sit-to-stand test” involves
counting the time in seconds needed by participants to rise until they reach full knee
extension and sit back, 10 times, as fast as possible
• Muscular endurance of abdominal muscles tested via the trunk curl static
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endurance test
Numbers of participants assessed:
• Intervention: baseline, 34; at 8 weeks, 34; at 6 months, 32
• Control: baseline, 34; at 8 weeks, not stated; at 6 months, 29
Adverse events: Adverse effects reported during the study included discomfort or low-
intensity pain/stiffness after an exercise session in 3 participants; nevertheless, they con-
tinued the programme
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: Health Institute Carlos III and PN I+D+I 2008-2011, Madrid, Spanish gov-
ernment (grant no. FIS PI10/02749); Research Office of the University of Granada,
Spain
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated numbers produced a
sequence that was entered into opaque en-
velopes
Allocation concealment (selection bias) Low risk “Computer-generated number sequence
was entered into opaque envelopes. These
envelopes were opened by a blinded re-
searcher after the first outcome measure-
ment”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Assessors were blinded to treatment alloca-
tion.
Incomplete outcome data (attrition bias)
All outcomes
High risk Only those who completed postinterven-
tion and 6-month assessments were in-
cluded in analysis
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
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Methods Study design: single-centre RCT
Number randomised: 37; 17 to intervention, 20 to control
Study start: June 2005; stop date: October 2006
Length of intervention: 8 weeks
Length of follow-up: at 8 weeks, at 3 months
Country: USA
Participants Age, years (mean SD):
• Intervention: 53.9 (9.0)
• Control: 54.9 (6.2)
Stage, n (%):
• Intervention: stage IA, 7 (41.2); stage IIA, 5 (29.4); stage IIB, 5 (29.4)
• Control: stage IA, 8 (40.0); stage IIA, 6 (30.0); stage IIB, 6 (30.0)
Inclusion criteria:
• At least 1 hot flash per day on 4 or more days per week
• No signs of active breast cancer
• No current cytotoxic chemotherapy
• Diagnosis of breast cancer at stage IA-IIB ≥ 2 years before
• No hormone replacement therapy currently or within prior 3 months
• Stabilised on a constant regimen of menopausal symptom medications and supplements
for at least 3 weeks
• Taking antidepressants, stabilised at a fixed dose for at least 3 months
Exclusion criteria:
• Resided > 70 miles from the research site and thus were less likely to attend intervention
sessions
• Unavailable to attend the intervention on the day and at the time offered (most yoga
groups were scheduled so as to be accessible to women holding full-time day jobs)
• Currently engaged in intensive yoga practice (> 3 days/week)
• Received treatment for serious psychiatric disorders (e.g. schizophrenia) in the previous
6 months
• Not English speaking
Interventions 17 participants assigned to exercise intervention:
• Yoga of Awareness including yoga postures, breathing techniques, meditation,
study of pertinent topics, group discussion. Once per week (participants were
encouraged to spend time practicing yoga strategies daily at home, but actual
adherence to this was not reported) for a duration of 40 minutes over 8 weeks
Adherence:
On average, participants attended 6 of the 8 classes (range 0 to 8). Only 3 women
attended < 4 classes. Adherence to daily yoga practice, average 30 minutes/d at post and
16 minutes at 3 months
Control group: 20 assigned to control:
• Wait-list
Outcomes Treatment outcomes. assessed via a brief daily diary measurement strategy
• Daily menopausal symptoms on 0 to 9 scales in which higher scores reflected
greater amounts, common menopausal symptoms across the preceding 24 hours: hot
flash frequency, hot flash severity, joint pain, fatigue, negative mood, sleep disturbance,
night sweats, and bother (menopausal symptom-related distress). Primary outcome of
hot flash total scores was computed as frequency × severity.
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• With 0 to 9 scales in which higher scores reflected greater amounts, 3 therapeutic
processes targeted by the Yoga of Awareness programme-relaxation, vigour, and
acceptance-were assessed by telephone voice system diaries.
• Minutes spent in daily yoga practice (post and follow-up assessments only)
Numbers of participants assessed:
• Intervention: n = 17 at baseline, n = 13 at 8 weeks, n = 13 at 3 months
• Control: n = 20 at baseline, n = 17 at 8 weeks, n = 17 at 3 months
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: yes, for means and SDs for outcomes. However, trial authors
did not provide these data
Intention-to-treat analysis: no
Funding: Susan G. Komen Breast Cancer Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random number table was used.
Allocation concealment (selection bias) High risk “Concealed in envelopes”; sequential se-
quencing or opaque envelopes were not
mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to blind participants;
however, it is unclear whether the outcome
was influenced by lack of masking
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Research assistant collecting assessment
data was kept blind with regard to partici-
pant condition assignments
Incomplete outcome data (attrition bias)
All outcomes
High risk No ITT, and no mention of how missing
data were handled. 8 participants did not
complete the intervention
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
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Methods Study design: single-centre RCT
Number randomised: 20; 10 to exercise, 10 to control
Study start and stop dates: not reported
Length of intervention: 16 weeks
Length of follow-up: to end of intervention
Country: Italy
Participants Age, years (mean SD):
• Intervention: 45.3 (4.3)
• Control: 46.0 (2.8)
Stage, n (%):
• Intervention: stage I, 3 (30); stage II, 5 (50); stage III, 2 (20)
• Control: stage I, 1 (10); stage II, 5 (50); stage III, 4 (40)
Inclusion criteria:
• Age 40 to 50 years
• Conclusion of all cancer-related treatments at least 6 months previously
• Mastectomy
• No external physical activity for at least the preceding 12 months
• Medical eligibility for non-competitive athletic activity
Interventions 10 participants assigned to exercise intervention:
• All intervention group participants received two 1-hour therapeutic horse-riding
treatments at an intensity of 65% to 70% of HR maximum (220-age) per week, for 16
weeks. Each riding session consisted of 3 phases: (1) warm-up, horse-caring, and
grooming; (2) riding; and (3) unsaddling and grooming activities.
Adherence: not reported
10 assigned to control:
• Participants randomly assigned to control group were instructed not to begin any
new formal physical exercise programme
Outcomes Outcomes:
• Maximal oxygen consumption (VO
max) obtained via the Astrand-Rhyming cycle ergometer test
• Maximal strength of principal muscle groups assessed by an inertial measurement
system (Free-Power; Sensorize, Rome, Italy). Maximal strength evaluated for each of 5
weight lifting machines (Technogym SpA, Cesena, Italy): leg press, leg extension, leg
curl, shoulder press, and vertical traction. Participants were asked to perform at least 2
repetitions at 30%, 50%, and 70% of presumed 1RM.
• Body composition (fat mass % and total body water %) assessed via a portable
multi-frequency digital bioelectrical impedance device (Handy 3000; DS Medica,
Milano, Italy)
• Quality of life assessed via FACT-G
• Fatigue assessed by FACT-F
Numbers of participants assessed:
• Intervention: baseline, 10; at 16 weeks, 10
• Control: baseline, 10; at 16 weeks, 10
Adverse events: none reported
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Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no dropouts reported
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Patients were randomly divided into two
groups”. It is unclear how the allocation
sequence was generated
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention, it
was not possible to blind participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Whether study personnel and outcome as-
sessors were masked or blinded to study in-
terventions was not reported
Incomplete outcome data (attrition bias)
All outcomes
Low risk No dropouts were reported.
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Cormie 2014
Methods Study design: RCT
Number randomised: 62; 22 to high-load resistance exercise, 21 to low-load resistance
exercise, 19 to control
Study start: June 2010; stop date: not stated
Length of intervention: 3 months
Length of follow-up: to end of intervention
Country: Australia
Participants Age, years (mean SD):
• High-load resistance exercise (HLRE): 56.1 (8.1)
• Low-load resistance exercise (LLRE): 57.0 (10.0)
• Control: 58.6 (6.7)
84Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cormie 2014 (Continued)
Stage, n (%):
• HLRE: stage I, 2 (9.1); stage II, 18 (81.8); stage III, 2 (9.1)
• LLRE: stage I, 5 (23.8); stage II, 10 (47.6); stage III, 6 (28.6)
• Control: stage I, 6 (31.6); stage II, 9 (47.3); stage III, 4 (21.1)
Time since cancer diagnosis, mean (SD) years:
• HLRE: 5.9 (6.1)
• LLRE: 6.1 (5.2)
• Control: 9.5 (9.8)
Inclusion criteria:
• Histological diagnosis of breast cancer at least 1 year before the study
• Clinical diagnosis of breast cancer-related lymphoedema and medical clearance from
general practitioner
• Clinical diagnosis of lymphoedema defined as having at least a 5% inter-limb discrep-
ancy in volume or circumference at the point of greatest visible difference
Exclusion criteria:
• Unstable lymphoedema defined as receiving intensive therapy (i.e. decongestive therapy
or antibiotics for infection) within the previous 3 months
• Musculoskeletal, cardiovascular, and/or neurological disorder that could inhibit exercise
Interventions 43 participants assigned to 1 of 2 resistance exercise interventions
• Two 60-minute exercise sessions were performed per week for 3 months. Intensity
varied across conditions (moderate-high (12 to 16 RPE); high-load, 75% to 85% of
1RM using 10-6 RM, 1 to 4 sets per exercise; low-load, 55% to 65% of 1RM using
20-15 RM, 1 to 4 sets per exercise)
• Exercise sessions were conducted in groups of up to 8 to 10 participants. The
resistance exercise regimen included 6 exercises that targeted major upper body muscle
groups including chest, back, shoulders, upper arms, and forearms (chest press, seated
row/lat pulldown, shoulder press/lateral raise, biceps curl, triceps extension, and wrist
curl). Additionally, 2 exercises targeting major muscle groups of the lower body were
performed (leg press/leg extension, squat/lunge).
Adherence:
Exercise attendance was high for both resistance training groups, with an average of 23.
2 ± 1.9 out of a possible 24 sessions attended (HLRE 23.4 ± 1.1; LLRE 22.9 ± 2.4)
19 participants assigned to control:
• Participants randomised to the control group were offered the exercise
programme after completion of the intervention period. All participants were
instructed to maintain their usual lymphoedema self-care management regimen,
physical activity levels, and diet throughout the intervention period.
Outcomes Primary outcome:
• Severity of swelling associated with breast cancer-related lymphoedema assessed
via standard objective measures:
◦ Bioimpedance spectroscopy (BIS) impedance ratio
◦ DEXA
◦ Arm circumference measurements
Secondary outcomes:
• Severity of symptoms assessed via:
◦ Disability of the Arm, Shoulder, and Hand questionnaire (DASH)
◦ Brief pain inventory questionnaire (BPI)
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◦ Arm morbidity subscale of the Functional Assessment of Chronic Illness
Therapy breast cancer questionnaire for patients with lymphoedema (FACT-B+4)
◦ Arm symptoms subscale of the European Organization for Research and
Treatment of Cancer breast cancer module (QLQ-BR23)
• Maximal grip strength tested with an isometric hand dynamometer (Model
78011; Lafayette Instruments, Lafayette, IN, USA). Affected and non-affected limbs
were assessed individually, and the best of 3 trials was reported.
• Maximal strength of major muscle groups assessed by the 1RM method in chest
press, seated row, and leg press exercises
• Muscle endurance assessed by a repetition maximum test, which involved
participants performing the maximal number of repetitions possible with 70% of
current 1RM in the chest press, seated row, and leg press
• Range of motion about the wrist, elbow, and shoulder assessed by standard
goniometric techniques
• Health-related QoL assessed with MOS SF-36
Numbers of participants assessed:
• HLRE: baseline, 22; at 3 months, 22
• LLRE: baseline, 21; at 3 months, 21
• Control: baseline, 19; at 3 months, 19
Adverse events: No lymphoedema exacerbations or any other adverse events were reported
Notes Trial registration link: ACTRN12610000788077 (http://www.anzctr.org.au/
ACTRN12610000788077.aspx)
Trial authors contacted: no
Intention-to-treat analysis: yes, but using LOCF
Funding: Edith Cowan University and University of Canberra
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were randomised in an alloca-
tion ratio of 1:1:1 by a random assignment
computer programme
Allocation concealment (selection bias) Low risk Exercise physiologists involved in assigning
participants to groups were blinded to the
allocation sequence
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data were addressed by imputing
change across time as zero
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Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Courneya 2003
Methods Study design: single-centre RCT
Number randomised: 53; intervention, 25; control, 28
Study start: May 2001; stop date: June 2001
Length of intervention: 15 weeks
Length of follow-up: to end of intervention
Country: Canada
Participants Age, years (mean SD):
• Intervention: 59 (5)
• Control: 58 (6)
Stage, n (%):
• Intervention: stage I, 10 (42); stage IIA, 6 (25); stage IIB, 6 (25); stage IIIA, 2 (8)
• Control: stage I, 11 (39); stage II A, 11 (39); stage IIB, 5 (18); stage IIIA, 1 (4)
Inclusion criteria:
• Histologically confirmed stage I-IIIB breast cancer
• Diagnosis between January 1999 and June 2000
• Completed surgery, radiotherapy, and/or chemotherapy (≥ 6 months before randomi-
sation) with or without current tamoxifen or arimidex therapy
• Postmenopausal (not experiencing menstrual periods for previous 12 months)
• Non-smokers (not smoking for previous 12 months)
• Between 50 and 69 years of age
• English-speaking
• Willing to travel to the exercise facility
Exclusion criteria:
• Known cardiac disease
• Uncontrolled hypertension




• Immune or endocrine abnormality
• Body weight reduction ≥ 10% in the past 6 months
• Positive exercise stress test
Interventions 25 participants assigned to exercise intervention:
• Participants trained 3 times per week for 15 weeks on recumbent or upright cycle
ergometers. Exercise intensity was set at the power output that elicited the ventilatory
equivalent for carbon dioxide to ensure optimal training adaptations. This training
intensity corresponds to approximately 70% to 75% of VO
max in untrained participants. Exercise duration began at 15 minutes for weeks 1
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through 3, then systematically increased by 5 minutes every 3 weeks thereafter to 35
minutes for weeks 13 through 15.
Adherence:
Exercise group completed 98.4% (44.3 of 45) of prescribed exercise sessions
28 participants assigned to control:
• Control group did not train and were asked not to begin a structured exercise





• Overall QoL assessed by FACT-B scale and FACT-General (FACT-G) scale
• Natural killer (NK) cell cytotoxic activity in isolated peripheral blood
mononuclear cells
• C-reactive protein (CRP) assessed in serum by enzyme-linked immunosorbent
assay kit
Other outcomes:
• Peak power output, oxygen consumption, and power output at the ventilatory
equivalent for oxygen, and oxygen consumption and power output at the ventilatory
equivalent for carbon dioxide
• QoL outcomes such as happiness assessed by the Happiness Measure, self-esteem
assessed on the RSE scale, and fatigue assessed via FACT-F
• Body composition outcomes were body weight, BMI, and sum of skinfolds
(biceps, triceps, subscapular, suprailiac, and medial calf )
• Exercise outside of the exercise intervention monitored via the Leisure Score
Index (LSI) of the Godin Leisure-Time Exercise Questionnaire
• Fasting insulin, glucose, insulin resistance, IGF-I, IGF-II, IGFBP-1, IGFBP-3,
and IGF-I:IGFBP-3 molar ratio
• Whole blood neutrophil function, phenotypes of isolated mononuclear cells,
estimations of unstimulated and phytohemagglutinin (PHA)-stimulated mononuclear
cell function {rate of [3H] thymidine uptake, production of proinflammatory
[interleukin (IL)-1alpha, tumour necrosis factor, TNF-alpha, IL-6] and anti-
inflammatory cytokines (IL-4, IL-10, transforming growth factor-beta 1)}
• Blood pressure measurements obtained by trained, certified individuals who used
a random zero sphygmomanometer
• Total cholesterol, high-density lipoprotein cholesterol (HDL-C), triglycerides
(TGs), and low-density lipoprotein cholesterol (LDL-C) calculated via the Friedewald
formula. TC:HDL-C ratio calculated as total cholesterol divided by HDL-C
Numbers of participants assessed:
• Intervention: baseline, 25; at 15 weeks, 24
• Control: baseline, 28; at 15 weeks, 26
Adverse events:
• Intervention: lymphoedema (n = 3), gynaecological complication (n = 1),
influenza (n = 1)
• Control: foot fracture (n = 1), bronchitis (n = 1)
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
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Funding: NCIC, CCS, Canadian Institutes of Health Research, Izaak Walton Killiam
Memorial Scholarship, Alberta Heritage Foundation for Medical Research studentship
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random numbers table. Block permuta-
tion procedure was used.
Allocation concealment (selection bias) Low risk “The allocation sequence and group as-
signments were generated by a research as-
sistant and then enclosed in sequentially
numbered and sealed envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Participants were not blinded for self-re-
port measures. Participants were blinded
to their exercise test results until after the
trial. Exercise physiologists were blinded
for physical outcome measures. Laboratory
staff and those who assessed study end-
points were blinded to treatment assign-
ment
Incomplete outcome data (attrition bias)
All outcomes
Low risk One study participant withdrew from the
intervention group. Two participants with-
drew from the control group and were
not included in cardiopulmonary outcome
analyses. Only 1 participant who had with-
drawn from the exercise group was missing
from QoL analyses
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
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Methods Study design: single-centre quasi-RCT
Number randomised: 42; 22 to intervention, 20 to control
Study start: September 2010; stop date: July 2012
Length of intervention: 8 weeks
Length of follow-up: to end of intervention
Country: Spain
Participants Age, years (mean SD):
• Intervention: 47.3 (6.6)




• History of primary breast cancer
• Within 1 year of cancer diagnosis
• Aged 25 to 65 years
• Post cancer treatment in the past 6 months (eligible if receiving hormone therapy)
• Cancer-free at the time of study enrolment
Exclusion criteria:
• Fear of aquatic exercise that would prevent participation in deep water running pro-
gramme
Interventions 22 participants assigned to 8-week exercise intervention:
• Land-based exercise and deep water running (DWR) combined with education
based on cognitive-behavioural principles
• Each session was performed in groups of 8 to 10 participants and comprised 30
minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10
minutes of warm-up and cool-down time. Land-based exercise included 15 minutes of
full-body mobility and 15 minutes of general strengthening exercises. Deep water
running (cross-country style) simulates running by using a flotation device in water
levels over head height.
• From weeks 1 to 4, DWR workload corresponded to heart rate at 2 mmol of
lactic acid. For weeks 5 to 8, workload was set at 3 mmol of lactic acid, based on pretest
lactic acid values.
Adherence:
42 participants attended more than 80% of the 24 treatment sessions. Although 2
intervention participants reported ‘wake up tired in the morning’ after 1 session, this
event did not impact programme completion and was not repeated
22 participants assigned to control:
• Wait-list control group
Outcomes Primary outcome:
• Fatigue assessed by the PFS-R
Other outcomes:
• Physical and mental general health via MOS SF-12
• QoL via European Quality of Life 5 dimensions (EuroQoL-5D) and European
Visual Analogue Scale (EuroQoL-VAS)
Numbers of participants assessed:
• Intervention: baseline, 22; post intervention, 22
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• Control: baseline, 20; post intervention, 20
Adverse events: No further adverse events were associated with participation in the
intervention
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: No missing data were reported.
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Participants were allocated in order of ar-
rival to complete each group
Allocation concealment (selection bias) High risk Allocation was not concealed from re-
searchers.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Assessor, who was blinded to participant
group allocation”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data were reported.
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Daley 2007
Methods Study design: single-centre RCT
Number randomised: 108; 34 to exercise therapy, 36 to exercise placebo, 38 to control
Study start: January 2003; stop date: July 2005
Length of intervention: 8 weeks
Length of follow-up: at 24 weeks
Country: UK
Participants Age, years (mean SD):
• Exercise therapy group: 51.6 (8.8)
• Exercise placebo group: 50.6 (8.7)
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• Control: 51.1 (8.6)
Stage:
• Exercise therapy: not reported
• Exercise placebo: not reported
• Control: not reported
Inclusion criteria:
• Women who were not regularly active
• Treated for localised breast cancer 12 to 36 months
• Aged 18 to 65 years
• Willing to attend supervised exercise sessions 3 times per week for 8 weeks
• Exercise pre-contemplator, contemplator, or preparer as defined by the TTM
Exclusion criteria:
• Women with metastases
• Inoperable or active locoregional disease determined ineligible by clinician
• Physical or psychiatric impairment that would seriously influence physical mobility
• Nausea, anorexia, or other diseases affecting health
• High activity level
• Contraindication to exercise, assessed by Physical Activity Readiness
Interventions 34 participants assigned to 8-week exercise intervention:
• Supervised one-to-one aerobic exercise performed 3 times per week for 50
minutes at moderate intensity (65% to 85% of age-adjusted HR maximum and RPE
of 12 to 13)
• In addition to exercise therapy, a variety of cognitive-behavioural techniques for
promoting exercise behaviour change were explored with participants during sessions.
36 participants assigned to exercise placebo:
• Exercise placebo group also attended 24 one-to-one 50-minute sessions during 8
weeks; performed light-intensity body conditioning/stretching (e.g. flexibility, passive
stretching) exercises during which HR was maintained below 40% heart rate reserve
(HR typically was kept below 100 beats per minute). No exercise counselling or
behavioural change advice was provided; instead, conversations were centred on topics
of everyday life (i.e. weather, news items, and families). Participants assigned to exercise
placebo were otherwise asked to continue with their lifestyle as normal.
Adherence:
Attended at least 70% (at least 17 of 24 sessions) of sessions; exercise therapy group,
77%; exercise placebo group, 88.9%
38 participants assigned to control:






• Fatigue assessed with Revised PFS
• Satisfaction with life
• Depression assessed by BDI-II
• Physical Self-Perception Profile, including five 6-item subscales: perceived sports
competence, attractiveness of body, physical conditioning competence, physical
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strength competence, and physical self-worth
• Physical activity and exercise behaviour assessed by asking participants how often
they had participated in 1 or more physical activities for 20 to 30 minutes per session
in the past 5 months and by completing the stage of change for exercise ladder (SOC)
• Aerobic fitness assessed via submaximal 8-minute single-stage walking test
performed on a treadmill
• Weight and BMI
• Body fat assessed by bioelectrical impedance analysis
• Muscle function assessed by a Bioidex isokinetic machine
Numbers of participants assessed:
• Intervention: baseline, 34; at week 8, 33; at week 24, 31
• Exercise placebo: baseline, 36; at week 8, 36; at week 24, 34
• Control: baseline, 38; at week 8, 33; at week 24, 31
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: yes, trial authors provided additional outcome data
Intention-to-treat analysis: unclear
Funding: Cancer Research UK (grant number: CE8304)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “performed using stratified random per-
muted blocks”
Allocation concealment (selection bias) Low risk Telephone randomisations service was pro-
vided by an independent trials unit
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “Outcome assessors were not blinded to
participants’ group allocation”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk “Data were analysed on an ITT basis”
It is unclear how this was done.
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
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Methods Study design: single-centre RCT
Number randomised: 100; 36 to exercise begun during treatment (EE), 30 to exercise
begun after treatment (CE), 34 to control
Study start and stop dates: 1999 to 2006
Length of intervention: 4 to 6 months
Length of follow-up: at 1 year from baseline
Country: USA
Participants Age, years (mean SD):
• Intervention (EE): 48.7 (8.4)
• Intervention (CE): 49.5 (9.5)
• Control: 51.6 (10.9)
Stage, n (%):
• Intervention (EE): stage I, 13 (39.4); stage II, 14 (42.4); stage III, 6 (48.2)
• Intervention (CE): stage I, 11 (39.3); stage II, 15 (53.6); stage III, 2 (7.1)
• Control: stage I, 14 (42.4); stage II, 13 (39.4); stage III, 6 (18.2)
Inclusion criteria:
• Women aged 18 years or older
• Confirmed diagnosis of breast cancer
• Beginning second cycle of chemotherapy
• Ability to read, write, and understand English
• Mentally able to understand and able to provide written informed consent
• Karnofsky Performance Scale (KPS) score > 60
Exclusion criteria:
• Receiving concurrent radiotherapy for another disease
• Had bone marrow transplantation
• Uncontrolled hypertension or diabetes mellitus
• Pain intensity rating ≥ 3 on a 0 to 10 numerical scale
• Lytic bone lesion or other orthopaedic limitations
• History of major depression or sleep disorders
• Chemotherapy in the past year
• Diagnosis of AIDS-related malignancies or leukaemia
• Absolute contradictions to exercise testing as established by American College of Sports
Medicine (1995)
Interventions 66 participants assigned to exercise intervention (36 to EE, 30 to CE):
• Individualised programme adjusted to participant’s fitness level and adjusted
weekly to maintain the exercise prescription. Programme consisted of cardiovascular/
aerobic exercise of participants’ choice (e.g. walking, jogging, cycling) performed 3 to 5
times per week for 30 minutes at 2- to 14-point intensity level (Borg scale, moderate
exertion) over 4 to 6 months
30 participants assigned to control:
• Usual care; telephoned weekly by research nurse to enquire about their health
Adherence:
EE group reported adherence rate of 74% by end of intervention and 78% by end of
follow-up; CE group reported 86% adherence at end of intervention
Outcomes No primary outcome stated:
• Physical activity questionnaire recorded self-reported exercise activities, frequency,
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intensity, and duration
• Physical performance measured on Karnofsky Performance Status (KPS) scale
• Symptom checklist: list of 25 symptoms commonly experienced by individuals
receiving chemotherapy. Format is a Likert-type rating scale with descriptive anchors
from 0 = none to 10 = terrible/awful
• Body composition via DEXA (fat mass, percent fat, lean body mass)
• Cardiorespiratory fitness assessed by maximal exercise testing
Outcomes measured:
• EE group: n = 36 at baseline, n = 36 at 4 to 6 months (end of intervention)
• CE group: n = 30 at baseline, n = 30 at 4 to 6 months (end of intervention)
• Control group: n = 34 at baseline, n = 34 at 4 to 6 months (end of intervention)
Adverse events: none reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no missing data evident in this study
Funding: National Cancer Institute; Clinical & Translational Science Institute, Clinical
Research Center
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of random sequence was not
described.
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Measurements of study variables were
taken by research nurses who were blinded
to the participants’ group assignment”
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data were reported.
Selective reporting (reporting bias) High risk Data on cardiorespiratory fitness and on
physical activity were not reported
Other bias High risk Control group and intervention groups
were reported as having similar activity lev-
els as intervention groups post interven-
tion, possible contamination. Low adher-
ence rate of 74% by end of intervention
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and 78% at end of follow-up in the inter-
vention group
Do 2015
Methods Study design: single-centre RCT
Number randomised: 212; 106 to early exercise group (EEG), 106 to delayed exercise
group (DEG)
Study start: not reported; stop date, not reported
Length of intervention: 4 weeks.
Length of follow-up: at 6 to 8 weeks only in early exercise group
Country: South Korea
Participants Baseline demographic and medical history variables for 32 in EEG and for 30 in DEG
Age, years (mean SD):
• EEG: 47.1 (8.5)
• DEG: 48.3 (8.2)
Stage, n (%):
• EEG: stage I, 3 (9.3); stage IIA, 13 (40.6); stage IIB, 12 (37.5); stage III, 4 (12.5)




• Evidence of recurrent disease or other musculoskeletal involvement such as low back
pain, disc problems, osteoarthritis, rheumatoid arthritis, shoulder problems
Interventions 106 participants assigned to early exercise intervention:
• 40 minutes of aerobic exercise (40% to 75% of VO
max) and 20 minutes of resistance exercise (9 different exercises of 2 sets of 8 to 12
repetitions at 60% to 80% of 1 repetition maximum for exercises of the extremities, or
5 to 10 repetitions for exercises of the axial muscles) 5 times a week over 4 weeks
Adherence: not reported
106 participants assigned to control:
• Delayed exercise group (DEG; n = 30) completed exercise programme from 4 to 8
weeks.
Outcomes Outcomes:
• QoL evaluated based on European Organization for Research and Treatment of
Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) (version 3) and
EORTC QLQ-BR23
• Cardiorespiratory function measured on the cycle test. Patients commenced
cycling at 20 W and workload was increased by 25 W every minute. Test was completed
when patients reached 85% of estimated maximal heart rate. Cardiorespiratory test
score was assessed as power output that coincided with 85% maximal heart rate.
• Fatigue Severity Scale (FSS) consists of 9 questions responded to via a Likert scale
ranging from 1 to 7, with lower scores meaning “disagreement” (greater disagreement
with lower scores) and higher scores meaning “agreement” in the same fashion.
• Maximal isometric strength was assessed in 4 muscle groups bilaterally with a
hand-held digital dynamometer. Muscles assessed included elbow flexors, hip flexors,
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hip abductors, hip extensors, knee extensors, and knee flexors. Muscular groups were
tested in the middle of the joint range.
Numbers of participants assessed:
• EEG: baseline, 32; at 2 weeks, 32; at 4 weeks, 32; at 6 weeks, 32; at 8 weeks, 32
• DEG: baseline, 30; at 2 weeks, 30; at 4 weeks, 30; at 6 weeks, 30; at 8 weeks, 30
Adverse events: not reported
Notes Trial registration link: none available




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”1:1 ratio using a computer-generated al-
location sequence”
Allocation concealment (selection bias) Unclear risk Whether allocation was concealed was not
reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned whether study personnel
and outcome assessors were masked or
blinded to study interventions
Incomplete outcome data (attrition bias)
All outcomes
High risk Analysis performed only on “completers”;
withdrawals not included in analysis
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk Dropout rate was high (71%).
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Methods Study design: single-centre RCT
Number randomised: 36, 12 to aerobic interval training (AIT), 12 to continuous mod-
erate training (CMT), 12 to control
Study start: February 2013; stop date: December 2014
Length of intervention: 6 weeks
Length of follow-up: at 3 months for physical activity
Country: Canada
Participants Age, years (mean SD):
• AIT: 56.2 (9)
• CMT: 56.3 (9)
• Control: 59.4 (9)
Stage, n (%):
• AIT: stage 0, 0 (0); stage I, 1 (3); stage II, 5 (15); stage III, 3 (9); other, 1 (3)
• CMT: stage 0, 1 (3); stage I, 2 (6); stage II, 2 (6); stage III, 5 (15); other, 1 (3)
• Control: stage 0, 1 (3); stage I, 4 (12); stage II, 2 (6); stage III, 3 (9); other, 0 (0)





• Completed different combinations of surgery, chemotherapy, radiation, and hormonal
therapy for early-stage breast cancer (stage I-IIIA)
• Postmenopausal status was a set condition to minimise possible confounding factors
associated with oestrogen status, treatment, and exercise response
Exclusion criteria:
• Received diagnosis of metastatic disease, uncontrolled hypertension, history of cardiac
disease, or pulmonary disease
• Did not receive approval from physician to participate
• Age > 75 years
• BMI> 40 kg/m²
• Could not commit to 18 exercise sessions in 6 weeks
• Any other contraindications to exercise
Interventions 23 participants assigned to 1 of 2 exercise interventions:
• AIT group was prescribed an interval programme that started with 2 weeks of
introductory intervals at a maximal intensity of 80% VO
peak, followed by progressively higher intensity interval bouts of 3 supervised sessions
per week for 4 weeks, eventually requiring 2-minute efforts that would elicit close to
maximal effort.
• CMT was prescribed a continuous, moderate-intensity aerobic protocol.
Depending on baseline fitness and experience, individuals completed 3.22 km (2
miles) at initial intensity of 55% to 60% VO
peak for 3 supervised sessions per week. By end of week 5, individuals progressed to
4.02 km (2.5 miles) at 70% VO
peak (6-week intervention).
• Exercise sessions were matched by ensuring a set distance was covered at each
session, starting with a minimum of 3.22 km and progressing to 4.02 km by week 5 (2
to 2.5 miles).
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Adherence:
CMT group (n = 11) completed 17.8 sessions that took an average of 40 minutes to
complete and covered a total distance of 65.34 km. AIT group (n = 12) completed 17.8
high-intensity interval sessions in average time of 36 minutes and covered a total distance
of 64.86 km. At 3 months, 92% of women in the AIT group reported achieving or
superseding the recommended weekly exercise dose according to guidelines. Only 42%
of individuals in the CMT group reported meeting the recommended dose
10 participants assigned to control:
• Control group was offered a delayed exercise intervention. Exercise volume in the
control group was not officially tracked. All participants were asked to maintain their
current normal dietary habits and daily activities for the 6-week duration. If individuals
deviated from their current habits, they were asked to report changes at endpoint.
Outcomes Primary outcomes:
• VO
max via maximal incremental cardiopulmonary exercise protocol and expired gases
analysed via the TrueOne 2400 metabolic cart (Parvo Medics Inc., Sandy, UT)
Secondary outcomes:
• Weight (kg)
• Hip circumference (cm)
• Resting heart rate (RHR) noted after 5 minutes of seated silence
• Muscle strength 1RM assessed on the leg press. Maximum weight and number of
repetitions used to estimate 1 repetition
• Insulin measured by the Siemens Immulite 2500 (Siemens Healthcare
Diagnostics, Newark, DE, USA)
• Glucose measured via Siemens ADIVA 1800 (Siemens Healthcare Diagnostics,
Newark, DE, USA)
• CRP measured on Siemens BNII (Siemens Healthcare Diagnostics, Newark, DE,
USA)
• Homeostatic Model Assessment (HOMA)-insulin resistance
Numbers of participants assessed:
• AIT: baseline, 12, at 6 weeks, 12
• CMT: baseline, 12; at 6 weeks, 11
• Control: baseline, 12; at 6 weeks, 10
Adverse events: No adverse events occurred during supervised exercise sessions or were
self-reported by participants
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: BC Sports Medicine Research Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”; method of randomi-
sation not reported
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Allocation concealment (selection bias) Unclear risk Whether allocation was concealed was not
reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not mentioned whether study personnel
and outcome assessors were masked or
blinded to study interventions
Incomplete outcome data (attrition bias)
All outcomes
High risk Analysis performed only on “completers”;
withdrawals not included in analysis
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Duijits 2012
Methods Study design: multi-centre RCT
Number randomised: 422; 109 to cognitive-behavioural therapy (CBT); 104 to physical
exercise; 106 to CBT and physical exercise combined; 103 to control group
Study start: January 2008; recruitment stop date: December 2009
Length of intervention: 12 weeks
Length of follow-up: at 6 months (at 3 months post intervention)
Country: Netherlands
Participants Age, years (mean SD):
• CBT: 48.2 (5.7)
• Exercise: 47.7 (5.6)
• CBT + Exercise: 49.0 (4.9)
• Control: 47.8 (6.0)
Stage:
• Stages: T1-4, N0-1, and M0 (i.e. stage I-IIIC)
Inclusion criteria:
• Primary breast cancer (stages T1-4, N0-1, and M0)
• Younger than 50 years and premenopausal at diagnosis
• Had received adjuvant chemotherapy and/or hormonal therapy
• Disease-free at study entry
• Reported at least a minimal level of menopausal symptoms
• Chemotherapy had to be completed at least 4 months before but not more than 5 years
before study entry (hormonal therapy could still be ongoing)
Exclusion criteria:
• Lack of basic proficiency in Dutch
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• Serious cognitive or psychiatric problems
• Serious physical comorbidity
• Obesity (body mass index > 35), because exercise may be contraindicated as a treatment
for hot flashes in obese women
• Participating in concurrent studies targeted at menopausal symptoms or involving
similar interventions
Interventions 109, 104, and 106 participants were assigned to CBT, exercise and CBT, and exercise
12-week intervention, respectively:
• CBT consisted of 6 weekly group sessions of 90 minutes each and 1 booster
session 6 weeks post completion, including relaxation exercises. The primary focus of
CBT was on hot flashes and night sweats, but other symptoms (e.g. vaginal dryness)
and problem areas (such as body image, sexuality, and mood disturbance) were also
addressed.
• The aerobic exercise programme was an individually tailored, home-based, self-
directed exercise programme of 2.5 to 3 hours per week. During the intake session, the
physiotherapist assisted each woman in selecting an appropriate form of exercise (e.g.
swimming, running, cycling). Each woman was provided with a heart rate monitor and
was instructed in its use to achieve a target heart rate (60% to 80% Karvonen). During
weeks 4 and 8, women had telephone interviews with the physiotherapist to discuss
their experiences and possible need to adjust the programme. During the last week,
women visited the clinic for a final session, during which they received advice on how
best to maintain their desired level of physical activity.
• Women in the combined intervention group underwent CBT and exercise
programmes concurrently.
Adherence:
• Fifty-eight per cent of the CBT group, 64% of the PE group, and 70% of the
CBT and exercise group did not meet criteria for compliance (i.e. at least 4 of 6 CBT
sessions and/or minimum of 24 PE training sessions, with an average of 3 kCals/kg or
6.45 METs per session).
103 participants assigned to control:
• Wait-list control: On completion of the study, control group participants could
choose to undergo the CBT or PE programme.
Outcomes Primary outcomes:
• Endocrine symptoms assessed by the 18-item endocrine subscale of the
Functional Assessment of Cancer Therapy questionnaire (FACT-ES)
• Hot flashes and night sweats (HF/NS) assessed by the Hot Flush Rating Scale.
The Hot Flush Rating Scale comprised 2 items measuring frequency of hot flashes and
night sweats (HF/NS frequency rating) and 3 items measuring the extent to which
these symptoms were perceived to be problematic and interfered with daily life (HF/
NS-problem rating).
Secondary outcomes:
• Sexual functioning assessed by the Sexual Activity Questionnaire (SAQ)
• Urinary symptoms assessed by the 5-item incontinence scale of the Bristol Female
Lower Urinary Tract Symptoms Questionnaire (BFLUTS)
• Body image assessed by the 4-item QLQ-BR23 subscale
• Psychological distress assessed by the 14-item Hospital Anxiety and Depression
Scale (HADS)
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• Generic HRQoL assessed by the MOS SF-36, which includes 8 subscales as well
as physical and mental component scores
• Program compliance assessed via session attendance records for CBT participants
and number and intensity of training sessions, as recorded by the heart rate monitor,
for PE participants. Participants were considered to be compliant if they attended at
least 4 of 6 CBT sessions and/or had a minimum of 24 PE training sessions, with an
average of 3 kCals/kg per session (or 6.45 METs).
Numbers of participants assessed:
• CBT: baseline, 109; at 12 weeks, 86; at 6 months, 88
• Exercise: baseline, 104; at 12 weeks, 87; at 6 months, 79
• CBT + Exercise: baseline, 106; at 12 weeks, 90; at 6 months, 89
• Control: baseline, 103; at 12 weeks, 89; at 6 months, 84
Adverse events: not reported
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00582244
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: supported by grant No. NKI 2006-3470 from the Dutch Cancer Society; the
Integral Cancer Center, Amsterdam; the Pink Ribbon Foundation; and Polar Electro
Nederland
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Computerized block randomization”
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described. Centralised ran-
domisation was not mentioned
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of whether study personnel
and outcome assessors were masked or
blinded to study interventions
Incomplete outcome data (attrition bias)
All outcomes
High risk “Missing values were replaced by the av-
erage score of the completed items in the
same scale for each individual, provided
that at least 50% of the items in that scale
had been completed”
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
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Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Ergun 2013
Methods Study design: single-centre RCT
Number randomised: 60; 20 to supervised exercise, 20 to home exercise, 20 to control
Study start: not reported; stop date: not reported
Length of intervention: 12 weeks
Length of follow-up: to end of intervention
Country: Turkey
Participants Age, years (mean SD):
• Supervised exercise: 49.7 (8.3)
• Home exercise: 55.1 (6.9)
• Control: 50.3 (10.4)
Stage, n (%):
• Not stated but recurrent or progressing breast cancer excluded
Inclusion criteria:
• Completion of surgical therapy, radiation therapy, and chemotherapy
• Postmenopausal
• Not smoking in the past year
• Agreeing to participate in the study
• Absence of any physical condition that would prevent exercising
• Having the cognitive capacity to answer the questions
Exclusion criteria:
• Recurrent or progressing breast cancer, lymphoedema, serious cardiac disease or unreg-
ulated hypertension, acute or chronic respiratory disease, mental disease, any infection,
any immune or endocrinological disorder that would alter immune indicators, rheumatic
disease, serious musculoskeletal disease (that would hinder exercising)
• Loss of more than 10% of body weight in the past 6 months
• Attended a regular exercise programme in the past 6 months
Interventions 40 participants assigned to two 12-week exercise interventions:
• Supervised exercise group performed aerobic exercise + resistive exercise for 45
minutes/d for 3 days/week and brisk walking for 30 minutes/d for 3 days/week.
Exercise programme comprised 10 minutes of warming, breathing exercise, upper and
lower limb resistive exercises with Theraband set at moderate resistance, and semi-
squatting periods. Warming exercise comprised brisk walking, rhythmical range-of-
motion exercises, repeated 10 times, for upper and lower limb joints; cool-down
exercises comprised breathing, stretching (shoulder and pectoral muscles,
gastrocnemius-soleus, flexors and rotators of the hip, back muscles) and relaxation
exercises.
• Home exercise group performed brisk walking for 30 minutes/d for 3 days/week.
Participants in groups 1 and 2 were taught how to measure their heart rate and
maximal heart rate for age calculated to establish pace of walking.
• All participants were given a 30-minute education regarding adverse effects of
breast cancer, prevention of lymphoedema, and related activities, and were given a
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patient information booklet that included lymphoedema-specific exercises.
Adherence: No data on adherence were reported.
20 participants assigned to control:
• Participants received only the education programme mentioned above.
Outcomes Primary outcomes:
• Angiogenesis and apoptosis-related molecules including interleukin-6,
interleukin-8, tumour necrosis factor alpha, epithelial neutrophil activating protein-78,
platelet-derived growth factor, vascular endothelial growth factor, growth-related
oncogene alpha, regulated upon activation, normal T cell, thrombopoietin,
angiogenin, oncostatin M, and monocyte chemotactic proteins 1, 2, and 3
Secondary outcomes:
• HRQoL via EORTC QLQ-C30
• Fatigue assessed via the Brief Fatigue Inventory (BFI)
• Depression via the BDI
Numbers of participants assessed:
• Supervised exercise: baseline, 20; at 12 weeks, 20
• Home exercise: baseline, 20; at 12 weeks, 18
• Control: baseline, 20; at 12 weeks, 20
Adverse events: No participants experienced any side effects or developed lymphoedema
(although 1 participant developed metastasis)
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: unclear
Funding: supported by Ege University Medical Faculty BAP project (Project Number:
2010-TIP-069)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Using random numbers table
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Molecular biologists that performed the
measurements and the oncology specialist
who made the assessment were blind to the
exercise groups of the patients”
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Missing data handling methods were not
reported.
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Fillion 2008
Methods Study design: single-centre RCT
Number randomised: 94; 48 to intervention group, 46 to control group
Study start: not reported; stop date: not reported
Length of intervention: 4 weeks
Length of follow-up: at 3 months
Country: Canada
Participants Age, years (mean SD):
• Intervention: 53.09 (9.65)
• Control: 51.84 (10.25)
Stage, n (%):
• Intervention: stage 0, 2 (4.5); stage I, 21 (47.7); stage II, 18 (40.9); stage III, 3 (6.
8)
• Control: stage 0, 4 (9.3); stage I, 17 (39.5); stage II, 12 (27.9); stage III, 10 (23.3)
Inclusion criteria:
• Diagnosis of initial non-metastatic breast cancer
• Completion of initial breast cancer treatment no longer than 2 years before enrolment
• Receipt of 1 series of adjuvant treatments of radiation therapy, or had received radiation
therapy in combination with other adjuvant treatments (e.g. chemotherapy, hormonal
therapy)
• Ability to understand and speak French
• Residence near the cancer centre
• Availability to take part in a series of 4 weekly sessions
• Acceptance of randomisation procedure pass revised Physical Activity Readiness Med-
ical Examination
• Authorisation of supervising physician before performing fitness assessment
Exclusion criteria:
• Clinical levels of depression symptoms, as measured by HADS (score > 10)
• Insomnia, as defined by the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition
• Any symptom of cancer recurrence
• Known severe health problems other than cancer
Interventions 48 participants assigned to exercise intervention:
• 4 weekly group meetings of 2.5 hours and 1 short telephone booster session (5 to
15 minutes)
• 1 hour devoted to supervision of walking training by a kinesiologist or a trained
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research nurse
• 1.5 hours devoted to psychoeducational fatigue management sessions
Adherence:
• 45 of 48 participants completed the full treatment
Co-intervention: psychoeducational fatigue management
46 participants assigned to control:
• Normal activity
Outcomes Primary outcome:
• Fatigue measured by General/Physical Fatigue subscale of the MFSI
Other outcomes:
• Cardiorespiratory fitness measured as submaximal oxygen consumption,
estimated from single-stage treadmill walking test
• QoL measured with MOS SF-12
• Energy level measured via the vigour subscale of the shortened POMS
• Anxiety and depression measured on the POMS
Numbers of participants assessed:
• Intervention: baseline, 48; at 4 weeks, 45; at 3 months, 45
• Control: baseline, 46; at 4 weeks, 43; at 3 months, 43
Adverse events: cancer recurrence: 2 in exercise group, 1 in control group
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: Fonds de Recherche en Sante du Quebec, Investigator Award
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Sequence of randomisation was “computer
generated”.
Allocation concealment (selection bias) Unclear risk “Sealed envelopes, which were concealed to
both kinesiologist and patient”; no men-
tion of whether they were sequential or
opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study personnel and outcome assessors
were not masked or blinded to study inter-
ventions
Incomplete outcome data (attrition bias)
All outcomes
High risk Four participants from the exercise group
were not included in the analyses (with-
drew, n = 1; cancer recurrence, n = 2;
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metastatic breast cancer diagnosis, n = 1);
3 participants from the control group were
not included in the analyses (withdrew, n =
2; cancer recurrence, n = 1)
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Guinan 2013
Methods Study design: RCT
Number randomised: 26 total; 16 to an exercise intervention, 10 to a control
Study start: March 2010; stop date: January 2011
Length of intervention: 8 weeks
Length of follow-up: at 3 months post intervention
Country: Ireland
Participants Age, years (mean SD):
• Intervention: 50.05 (8.27)
• Control: 45.05 (9.04)
Stage, n (%):
• Intervention: stage I, 3 (18.8); stage II, 10 (62.6); stage III, 3 (18.8)
• Control: stage I, 4 (40.0); stage II, 3 (30); stage III, 3 (30)
Inclusion criteria:
• Breast cancer survivors who had consented to the PEACH trial
• Completion of adjuvant chemotherapy or radiotherapy with curative intent within the
preceding 2 to 6 months
• Receipt of neoadjuvant chemotherapy or chemoradiotherapy followed by surgery
• Continuing onto adjuvant hormone therapy and anti-Her2 directed therapy
• Ability to understand English
• Willingness to be randomised
• Medical clearance to exercise
• Aged 21 to 69
Exclusion criteria:
• Evidence of active cancer
• Chronic medical and orthopaedic conditions that would preclude exercise (e.g. un-
controlled congestive heart failure or angina, recent MI, breathing difficulties requiring
oxygen use, hospitalisation)
• Taking beta-blocker medication
• Prior history of another cancer in previous 5 years (exceptions: non-melanoma skin
cancer, non-invasive cancer of the cervix)
• Confirmed pregnancy
• Dementia or psychiatric illness that would preclude ability to participate in study
• Incomplete haematological recovery after chemotherapy (WCC < 3, Hb < 10, or
platelets < 100)
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• BMI > 35
• LVEF post chemotherapy < 50% or > 20% deterioration of baseline compared with
LVEF before systemic treatment
Interventions 16 participants assigned to exercise intervention:
• Twice-weekly supervised aerobic intervention and a home exercise programme for
8 weeks. Participants rotated between 3 aerobic exercise stations during the class
(stationary bike, treadmill, rowing ergometer). Participants with “poor” fitness started
the intervention at an intensity range of 35% to 55% heart rate reserve (HRR),
participants with “fair” fitness started at 40% to 60% HRR, and those classified as
“average” commenced at 45% to 65%HRR. Aerobic intensity zones were progressed by
5% HRR every 2 weeks. Duration of individual sessions was 21 minutes in week 1,
progressed to 42 minutes in week 8 (3-minute increase every 2 weeks alternate with
intensity increase).
Adherence: 6/16 (37.5%) adhered to < 90% of the exercise class but completed follow-
up assessments
10 participants assigned to control:
• Did not engage in a structured exercise programme but were offered an exercise
advice session following final assessment
Outcomes Outcomes:
• Body composition including body weight estimated by a bioimpedance analyser
(Tanita MC 180 MA Multi-Frequency Body Composition Analyzer; Tanita Corp.,
Tokyo, Japan)
• Waist circumference measured at midpoint between top of the iliac crest and last
rib
• Resting blood pressure measured by the auscultatory method following a 5-
minute rest period. Blood pressure measurements were taken on the non-surgical side,
in duplicate, and averaged for data entry.
• Venous blood samples taken to measure glucose, insulin, lipid profile (TC),
HDL-C, LDL-C and triglycerides, glycosylated haemoglobin levels (HBA1c), and
CRP. Insulin resistance was calculated via HOMA: [(fasting glucose (mmol/L) × fasting
insulin (mU/L))/22.5]
• Metabolic syndrome diagnosed in the presence of any 3 of the following: elevated
waist circumference (≥ 80 cm); elevated triglycerides (≥ 1.7 mmol/L) or drug therapy
for lipid abnormalities; reduced HDL-C (< 1.3 mmol/L) or drug therapy for lipid
abnormalities; elevated blood pressure (systolic ≥ 130 mmHg and/or diastolic ≥ 85
mmHg) or antihypertensive medication; elevated fasting glucose (≥ 100 mg/dL) or
glucose-lowering medication
• Physical activity measured objectively with the triaxial RT3 activity monitor
(Stayhealthy Inc., Montrovia, CA, USA). Participants wore the monitor for 7 days,
during waking hours, following each assessment.
• Physical activity measured subjectively with the Godin Leisure Time Exercise
Questionnaire, which records the frequency of strenuous, moderate, and mild exercise
bouts of at least 15 minutes’ duration
• Estimated dietary record (Medical Research Council, UK) prepared by
participants. Diaries were analysed via WISP (Tinuveil Software, Llanfechell, Anglesey,
UK) nutrition analysis programme.
Numbers of participants assessed:
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• Intervention: baseline, 8 weeks, and 3 months post intervention, 16 (except total
and HDL-C, TC:HDL ratio, triglycerides, glucose, and HBA1c); 15 (LDL-C, insulin);
HOMA, 14
• Control: baseline, 8 weeks, and 3 months post intervention, 10 (except LDL-C,
insulin, HOMA, HBA1c, sedentary activity, light-, moderate-, and vigorous-intensity
activity); 9
Adverse events: not reported
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT01030887
Trial authors contacted: no
Intention-to-treat analysis: yes, but LOCF used
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers list
Allocation concealment (selection bias) Unclear risk Whether allocation was concealed was not
reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Assessments were completed by the same
researcher at every visit who was blinded to
the participants’ group assignment”
Incomplete outcome data (attrition bias)
All outcomes
High risk LOCF procedure was used for missing vari-
ables.
Selective reporting (reporting bias) High risk Unlike all other outcomes, no baseline data
were reported for C-reactive protein; only
change values with 95% CIs were provided.
Cardiorespiratory fitness and quality of life
were mentioned as outcomes in parent trial;
no reasons given for omission of these data
here. Only P values for body composition
variables were provided
Other bias High risk Small sample size and imbalance between
numbers allocated to the intervention and
control group could give rise to additional
biases
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Methods Study design: single-centre RCT
Number randomised: 87; 43 to intervention, 42 to control
Study start: not stated; stop date: not stated
Length of intervention: 12 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Data available only for those who completed the study
Age, years (mean SD):
• Intervention: not reported
• Control: not reported
Stage, n (%):
• Intervention: stage I, 10 (36); stage II, 17 (47); stage III, 6 (17); stage IV, 3 (8)
• Control: stage I, 14 (37); stage II, 17 (45); stage III, 5 (13); stage IV, 2 (5)
Inclusion criteria:
• Female breast cancer survivors
• Completion of cancer treatment
• 18 years of age or older
• Ability to access and navigate the Internet
• Ability to communicate through email
• Ability to complete online questionnaires
• No current physical activity reported at the outset of the intervention
• Ability to engage in physical activity safely
Interventions 43 participants assigned to exercise intervention:
• Participants assigned to the 12-week intervention group received a weekly email
message for the first 5 weeks of the intervention followed by email messages every other
week for the next 6 weeks of the intervention. These messages were designed to
influence social cognitive theory (SCT) variables of interest to enhance participants’
physical activity.
• Participants were offered access to an e-counsellor, who offered advice regarding
exercise and physical activity.
• General exercise recommendations for cancer rehabilitation established by the
Rocky Mountain Cancer Rehabilitation Institute were used to craft exercise
prescriptions. Components of the exercise prescription for patients with cancer are the
same as those recommended by the American College of Sports Medicine.
Adherence:
For the treatment group, investigators reported 2.81 (SD 2.11) days of exercise per week
at 6 weeks and 3.47 (SD 2.19) days of exercise per week at 12 weeks
42 participants assigned to control:
• Control group did not receive email messages, nor did they have access to an e-
counsellor. At the end of 12 weeks, those assigned to the control group were offered the
opportunity to participate in the intervention.
Outcomes Outcomes:
• 7-DPAR used as the physical activity measure
• Self-regulation measured on a 20-item, 5-point Likert-type instrument (1 = never;
5 =most frequent). Self-regulation instrument contains 5 subscales: (1) self-
monitoring, (2) cognitive goal setting, (3) social support, (4) reinforcements, and (5)
relapse prevention.
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• Exercise self-efficacy measured via a 14-item questionnaire. Responses to items are
summed and divided by 14 for a mean self-efficacy score. The higher the score on the
self-efficacy instrument, the greater is one’s confidence to overcome barriers to exercise.
• Exercise role identity measured by a 9-item, 5-point Likert-type instrument
developed by Anderson and Cychosz. Possible minimum and maximum values of
scores are 0to 45. Higher score indicates strong self-identity as an exerciser.
• Outcome expectancy value assessed with a 19-item self-report questionnaire
developed by Steinhardt and Dishman
Numbers of participants assessed:
• Intervention: baseline, 43; at 6 and 8 weeks, 36
• Control: baseline, 42; at 6 and 8 weeks, 38
Adverse events: not reported
Notes Trial registration link: none available




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Randomly assigned”; method of randomi-
sation not reported
Allocation concealment (selection bias) Unclear risk Whether allocation was concealed was not
reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
High risk “The final sample included 74 participants
(control group n = 38, intervention group
n = 36)”
Participants who dropped out were not in-
cluded in analysis.
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
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Methods Study design: single-centre quasi-RCT
Number randomised: 63; 32 to intervention, 31 to control
Study start: not reported; stop date: not reported
Length of intervention: not reported
Length of follow-up: at 3 months post intervention
Country: Germany
Participants Age, years; n (%):
• Intervention: 31 to 50 years, 14 (44); 51 to 70 years, 18 (56)
• Control: 31 to 50 years, 18 (58); 51 to 70 years, 13 (42)
Stage:
• Intervention: not reported
• Control: not reported
Inclusion criteria:
• Score ≥ 4 on a linear analogue scale evaluating fatigue, ranging in value from 0 to 10
Exclusion criteria:
• Psychiatric condition
• < 6 weeks since surgery or chemotherapy
Interventions 32 participants assigned to exercise intervention:
• Educational programme, physical therapy, group exercises (non-physical activity),
and psycho-oncological interventions
• Resistance exercises performed for 30 minutes 3 times per week, and aerobic
exercises performed 2 times per week for 30 minutes
• Brochure with instructions for 9 muscle strength and 9 stretching exercises for all
large muscle groups, demonstrated by instructor
• Instructions for aerobic exercises (walking programme), co-ordination, and
relaxation
Adherence:
• Adherence to muscle strength was 26% at end of rehabilitation and 37% at 3
months after rehabilitation.
• Adherence to stretching was 30% at end of rehabilitation and 42% at 3 months
after rehabilitation.
• Adherence to aerobic exercises was 163% at end of rehabilitation and 192% at 3
months after rehabilitation.
31 participants assigned to control:
• Educational programme, physical therapy, group exercises (non-physical activity),
and psycho-oncological interventions
Outcomes Outcomes:
• Quality of life assessed via FACT-G
• Fatigue assessed via FACT-F
• Depression and anxiety assessed via HADS
• MFI
• Questionnaire on physical activity and motivation to perform exercises and sport
(self-developed)
• Cardiopulmonary fitness via Harvard step test
• Muscular strength with Digimax Multifunktionstest
• Maximal isometric muscle strength via dynamometer for arm flexors and leg
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extensors
Numbers of participants assessed:
• Intervention: baseline, not reported; end of rehabilitation, 32
• Control: baseline, not reported; end of rehabilitation, 31
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: yes, contacted for means and s for outcomes. However, trial
authors did not provide these data
Intention-to-treat analysis: no
Funding: German Fatigue Society
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “According to their admission to hospital;
depending on the alternating weeks they
were allocated to the intervention group or
the control group”
Allocation concealment (selection bias) High risk Owing to use of alternating weeks in the
randomisation process, allocation was not
concealed from investigators
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study personnel and outcome assessors
were not masked or blinded to study inter-
ventions
Incomplete outcome data (attrition bias)
All outcomes
High risk Complete data were available for 59 partic-
ipants, but no information on missing par-
ticipants was provided. “More patients in
the control group (15) than in the training
group (12) did not continue the study”
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk Study was poorly described, and adherence
to resistance exercises was low (42%)
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Methods Study design: single-centre RCT
Number randomised: 20; 10 to intervention, 10 to control
Study start: recruitment started November 2003; stop date: April 2004
Length of intervention: 8 weeks
Length of follow-up: to end of intervention
Country: Spain
Participants Age, years (mean SD):
• Intervention: 50 (5)
• Control: 51 (10)
Stage, n (%):
• Intervention: stage I, 3 (37.5); stage II, 5 (62.5); not provided, 2
• Control: stage I, 4 (50); stage II, 4 (50); not provided, 2
Inclusion criteria:
• Postmenopausal women surviving breast cancer
• 2 to 5 years post treatment
• 40 to 60 years old
• Previous anticancer treatment consisting of surgery with axillary lymphadenectomy
and both postsurgery radiation therapy and chemotherapy
• Walking less than a total of 30 to 60 minutes 3 days per week
• Performing no strenuous exercise such as running, cycling, swimming, or resistance
training
Exclusion criteria:
• Cardiac disease (NYHA II or greater)
• Uncontrolled hypertension (blood pressure > 160/90 mmHg)
• Uncontrolled pain, or any other condition that contraindicated exercise training
• Patients with cancer or cancer survivors, for example, increased risk of bone fracture
• Severe anaemia (< 8 g/dL)
• Platelet count lower than 50 × 109/µL, 7; lymphoedema
Interventions 10 participants assigned to exercise intervention:
• 10-Minute warm-up and cool-down periods, consisting of cycle-ergometer
pedaling at very light workloads and stretching exercises for all major muscle groups
• 70-Minute core portion of the training session divided into resistance and aerobic
training
• Resistance training with 11 exercises engaging the major muscle groups (chest
press, shoulder press, leg extension, leg curl, leg press, leg calf rise, abdominal crunch,
low back extension, arm curl, arm extension, and lateral pull-down), each for 12 to 15
repetitions at 12 to 15 repetitions maximum
• Aerobic training consisting of pedaling on a cycle-ergometer for 20 minutes at
70% maximal heart rate (HRmax) observed during pretraining cardiorespiratory test.
Duration and intensity of sessions were gradually increased during the 8-week period,
so that participants completed 30 minutes of continuous pedaling at 80% HRmax by
end of training programme.
• Stretching of muscles involved in an exercise performed at the end of each set of
resistance exercises
Adherence:
• Mean (SD) percentage adherence was 91.1% (6.9%).
10 participants assigned to control:
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• During the 8-week period, participants in the control group followed their usual
sedentary lifestyle (physical activity level < walking for a total of 30 to 60/min 3 days
per week and performing no strenuous exercise such as running, cycling, swimming, or
resistance training).
Outcomes Primary outcomes:
• Cardiorespiratory test to measure peak oxygen uptake (VO
peak)
• Dynamic strength endurance test, maximum number of repetitions for chest and
leg press exercises at 30% to 35% and 100% to 110% of body mass
• Sit-stand test, frequency count per time
• EORTC QLQ-C30 questionnaire used to assess quality of life
• Haematocrit and haemoglobin levels
• Circulating cytokine levels by human cytokine immunoassay, including beta
nerve growth factor (beta-NGF), cutaneous T cell-attracting chemokine (CTACK),
exotoxin, fibroblast growth factor (FGF) basic, granulocyte colony-stimulating factor
(G-CSF), granulocyte-macrophage colony-stimulating factor (gmCSF), growth-related
oncogene (GRO)α , hepatocyte growth factor (HGF), intercellular adhesion molecule
(ICAM)1, interferon (IFN)α2, IFNγ , interleukin (IL)1α, IL1β, IL1ra, IL2, IL2ra,
IL3, IL4, IL6, IL7, IL8, IL9, IL10, IL12, IL13, IL15, IL16, IL17, IL18, interferon-
inducible protein (IP)10, leukaemia inhibitory factor (LIF), macrophage colony-
stimulating factor (MCS-F), macrophage inflammatory protein (MIP)1α, MIP1β,
macrophage migration inhibitory factor (MIF), monocyte chemotactic protein (MCP)
1, MCP3, monokine induced by IFNγ (MIG), platelet-derived growth factor (PDGF)
bb, stem cell factor (SCF), stem cell growth factor (SCGF)β, stromal cell-derived
factor (SDF)1α, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL),
TNFα, TNFβ, vascular cell adhesion molecule (VCAM)1, and vascular endothelial
growth factor (VEGF). IL10/TNFα ratio was calculated.
Other outcomes:
• Peak power output (PPO) and PPO/body mass, ventilation peak (VEpeak); heart
rate max, peak values of ventilatory equivalent for oxygen (VE/VO
), carbon dioxide (VE/VCO
), and respiratory exchange ratio (RER)
• Body composition assessed indirectly through changes in body mass and
subcutaneous skinfolds
• Skinfold measurements made at 3 sites (triceps, abdominal, and suprailiac) to
allow estimation of percentage of body fat
• Total muscle mass (kg) estimated from anthropometrical data following the
prediction equation with use of multi-slice magnetic resonance imaging
Numbers of participants assessed:
• Intervention: baseline, 10; at 8 weeks, 8
• Control: baseline, 10; at 8 weeks, 8
Adverse events: No major adverse effects and no major health problems were noted
among participants in both groups over the 8-week period
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: Universidad Europea de Madrid
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described.
Allocation concealment (selection bias) Low risk “The treatment allocation system was set
up so that the researcher who was in charge
of enrolling participants did not know in
advance which treatment the next person
would get”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Research assistants (exercise physiologists)
with no knowledge of group assignments
were designated to measure the outcome
variables”
Incomplete outcome data (attrition bias)
All outcomes
High risk 2 participants in each group withdrew, but
no information was provided on reasons
for withdrawal, and their data were not in-
cluded in analysis
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Irwin 2015
Methods Study design: single-centre RCT
Number randomised: 121; 61 to intervention, 60 to control
Study start: June 2009; stop date: June 2013
Length of intervention: 12 months
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 62.0 (7.0)
• Control: 60.5 (7.0)
Stage, %:
• Intervention: stage 0, 1 (1); stage I, 36 (59); stage II, 18 (30); stage III, 6 (10)
• Control: stage 0, 0 (0); stage I, 37 (62); stage II, 19 (32); stage III, 4 (7)
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Inclusion criteria:
• Physically inactive (i.e. < 90 minutes per week of physical activity in the past 6 months
and no strength training in the past year)
• Postmenopausal women given diagnosis 0.5 to 4.0 years before enrolment with hor-
mone receptor-positive stage I to III breast cancer
• Receiving an aromatase inhibitor for at least 6 months
• Experiencing arthralgia at least mild in severity for at least 2 months (i.e. score of ≥ 3
of 10 for worst pain item of Brief Pain Inventory)
• Arthralgia started after initiation of aromatase inhibitor therapy or when pre-existing
joint pain was exacerbated by the use of aromatase inhibitors
Exclusion criteria:
• None reported
Interventions 61 participants assigned to the following intervention:
• Combination of a twice-per-week supervised resistance training programme
(under supervision of American College of Sports Medicine-certified cancer exercise
trainer) at a local health club, and a home-based aerobic exercise programme of 150
minutes per week, in accordance with current exercise recommendations for cancer
survivors
• Aerobic exercise intervention consisted of 150 minutes per week of primarily
brisk walking (treadmill or outside), although participants could choose other aerobic
exercise, such as stationary bicycling. Intensity of aerobic exercise started at 50% of
maximal heart rate (determined from VO
max testing) and increased over the first month to 60% to 80% of maximal heart rate
for the study duration.
• Twice-weekly strength training protocol consisted of 6 exercises (i.e. bench press,
latissimus pull-down, seated row, leg press, leg extension, and leg curl) performed at 8
to 12 repetitions for 3 sets.
• Intensity of resistance exercise: Participants progressed up to 3 sets per exercise
over the first month. After 2 sessions during which a participant lifted the same weight
12 times during each set, weight was increased by the smallest possible increment.
Adherence to the intervention:
• Aerobic, mean (SD) daily activity log aerobic exercise minutes/week: 119 (78)
• Resistance, twice per week attendance % (SD): 70 (28)
60 participants assigned to control:
• Women were instructed to continue with their usual activities. Participants were
not discouraged from exercising on their own but were not given any exercise
instruction until the end of the study. Women were telephoned monthly by research
staff to determine aromatase inhibitor adherence. Both exercise and usual-care groups
were provided with an educational booklet prepared for the this study, which addressed
breast cancer topics such as lymphoedema and fatigue. Topics were discussed monthly
over the telephone.
Outcomes Primary outcomes:
• Arthralgia via 3 different questionnaires: (1) BPI; (2) Western Ontario and
McMaster Universities Osteoarthritis (WOMAC) index, which measures lower
extremity joint symptoms in the past 7 days in 3 domains: pain, stiffness, and physical
function; and (3) DASH questionnaire, which measures physical function and
symptoms in patients with musculoskeletal disorders of the upper limbs
117Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Irwin 2015 (Continued)
• Grip strength via bulb dynamometer (squeezing a rubber ball with the dominant
hand with pressure in psi averaged over 3 trials)
Secondary outcomes:
• Pain medication via medicine supplement questionnaire
• Aromatase inhibitor adherence via a log reviewed monthly by telephone
• Weight taken twice and averaged.
• Physical activity via questionnaire (Kriska et al, 1990) assessing the past 6 months
of activity, including type, frequency, and duration of 20 activities
• Cardiorespiratory fitness measured with a standard VO
max treadmill test
Numbers of participants assessed:
• Intervention: 61; completed 3 and 6 months, 58 (95%); completed 9 and 12
months, 45 (94%)
• Control: 60; completed 3 and 6 months, 49 (82%); completed 9 and 12 months,
38 (80%)
Adverse events: No adverse effects occurred as a result of the exercise programme
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT02056067
Trial authors contacted: no
Intention-to-treat analysis: yes
Funding: supported by National Cancer Institute Grant No. R01 CA132931 and in part
by a grant from the Breast Cancer Research Foundation (M.L.I.), Yale Cancer Center
Support Grant No. P30 CA016359, and Clinical and Translational Science Award Grant
No. UL1 TR000142, from the National Center for Advancing Translational Science
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Permuted block randomisation (at 1:1 ra-
tio) with random block size was performed,
stratified by joint pain before AI therapy
and current bisphosphonate use”
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Mixed-model repeated measures analysis
was employed. This approach is robust be-
cause it includes all available data and ac-
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counts for correlations between repeated
measures
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk “Given funding cuts, the last 25 of the 121
women recruited were enrolled into a 6-
month rather than 12-month trial”
Therefore, participants received interven-
tions of different durations
Kaltsatou 2011
Methods Study design: single-centre RCT
Number randomised: 27; 14 to intervention, 13 to control
Study start: not reported; stop date: not reported
Length of intervention: 24 weeks
Length of follow-up: to end of intervention
Country: Greece
Participants Age, years (mean SD):
• Intervention: 56.6 (4.2)




• Participating only in the dancing exercising programme in which none of the partici-
pants had prior physical practice or experience in traditional Greek dances
• All participants had been given a diagnosis and surgically treated for breast cancer
• Completed cancer therapies, including surgery, radiotherapy, and chemotherapy and
stopped all medical treatments at least 3 months before beginning of the study
Exclusion criteria:
• Poorly controlled hypertension
• Any health condition that would deter patient from performing the exercises
Interventions 14 participants assigned to exercise intervention:
• 60-Minute sessions were performed 3 times per week for 24 weeks, and included
warm-up, aerobic training with Greek traditional dances, upper body training, and
cool-down.
• Warm-up period lasted 10 minutes and included range of motion exercises and
stretching. Aerobic training phase lasted 25 minutes and included learning and
practising traditional Greek dances (intensity between 65% and 80% of maximum
heart rate). Dance phase consisted of basic, low-impact steps, performed in a single
group while holding hands in a semi-circle. Duration of each dance was 3 to 4 minutes,
and breaks between dances lasted 15 seconds.
• Upper body exercise training and cool-down lasted 25 minutes and emphasised
stretching and resistance training with the use of variable resistance machines.
Adherence:
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• Not reported
13 participants assigned to control:
• Participants in the control group continued their usual daily schedule.
Outcomes Outcome measures:
• Physical function assessed via a 6-minute walking test. Participants instructed to
walk as comfortably as possible in 6 minutes
• Handgrip strength assessed on both sides with a baseline handheld dynamometer.
Participants were seated with the forearm in neutral position and the elbow at 90
degrees. They squeezed the handgrip as hard as they could. The mean of 3
measurements was used for further analysis.
• Arm volume measured with a measuring tape to estimate arm volume
• BDI used to evaluate severity of depression
• In addition, participants completed Life Satisfaction Inventory (LSI). The LSI is a
13-item multi-dimensional inventory that validates the satisfaction that the participant
receives from her lifestyle.
• Resting blood pressure and heart rate measured after the individual had been
sitting calmly for 5 minutes. HR was estimated by palpation for four 15-second
periods, and blood pressure was measured by a sphygmomanometer.
Numbers of participants assessed:
• Intervention: baseline, 14; at 24 weeks, not reported
• Control: baseline, 13; at 24 weeks, not reported
Adverse events: none reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no missing data reported
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described.
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
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Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear whether any data were missing,
as this was not reported
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Kiecolt-Glaser 2014
Methods Study design: RCT
Number randomised: 200; 100 to the Hatha yoga intervention, 100 to wait-list control
Study start: not stated; stop date: not stated
Length of intervention: 12 weeks
Length of follow-up: at 3 months
Country: USA
Participants Age, years (mean SD):
• Intervention: 51.8 (9.8)
• Control: 51.3 (8.7)
Stage, n (%):
• Intervention: stage 0, 9 (9%); stage I, 46 (46%); stage IIA, 27 (27%); stage IIB,
10 (10%); stage IIIA, 8 (8%)
• Control: stage 0, 9 (9%); stage I, 43 (%); stage IIA, 25 (25%); stage IIB, 13
(13%); stage IIIA, 10 (10%)
Inclusion criteria:
• Completed breast cancer treatment (except for tamoxifen/aromatase inhibitors) be-
tween 2 months and 3 years previously
Exclusion criteria:
• Engaged in over 5 hours of vigorous physical activity per week
• Prior history of any other cancer (except basal or squamous cell skin cancer)
• Major medical conditions such as anaemia, diabetes, multiple sclerosis, chronic ob-
structive pulmonary disease, symptomatic ischaemic heart disease, uncontrolled hyper-
tension, or liver or kidney failure
• Severe cognitive impairment (e.g. dementia, Alzheimer’s disease) or abuse of alcohol
or drugs
• Current yoga practice or prior yoga practice exceeding 3 months
Interventions 100 participants assigned to exercise intervention:
• Twice-weekly 90-minute Hatha Yoga classes for 12 weeks
• Home practice strongly encouraged, and women recorded total home plus class
practice time in weekly logs. Women were also given a commercial yoga video for
cancer survivors as a home practice aid.
Adherence:
In the yoga group, participants attended a mean of 18.1 (75.4%) of 24 classes with a
median of 19 (79.1%) of 24 classes and reported an average of 24.69 minutes per day
of total home plus class practice across 12 weeks
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100 participants assigned to control:
• Participants assigned to wait-list control were told to continue performing their
usual activities, and to refrain from beginning any yoga practice. After final assessment,
they were offered the yoga classes.
Outcomes Outcomes:
• Fatigue via total score on the MFSI-SF
• Vitality in the past month via the MOS SF-36 Energy Scale. Higher scores
indicate greater vitality and thus lower fatigue.
• CES-D assessing depressive symptoms in the past week
• Cognitive complaints assessed on the Breast Cancer Prevention Trial (BCPT)
Cognitive Problems Scale
• Sleep quality and disturbances rated by participants using the Pittsburgh Sleep
Quality Index
• Perceived support assessed by the Interpersonal Support Evaluation List
• Lipopolysaccharide (LPS)-stimulated production of IL-6, IL-1β, and TNF-alpha.
LPS-stimulated cytokines measured from isolated peripheral blood mononuclear cells
according to Meso Scale Discovery kit instructions
• Physical activity via CHAMPS questionnaire
• Mass and BMI
• Data on foods and beverages consumed in the past 90 days provided through the
Women’s Health Initiative Food Frequency Questionnaire (FFQ)
.Numbers of participants assessed:
• Intervention: baseline, 100; post intervention, 96; at 3-month follow-up, 94
• Control: baseline, 100; post intervention, 90; at 3-month follow-up, 87
Adverse events: Two events appeared potentially attributable to the yoga intervention:
Two women reported recurrence of chronic back and/or shoulder problems
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00486525
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: grants No. R01 CA126857, R01 CA131029, K05 CA172296,
UL1RR025755, and CA016058 from the National Institutes of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “online randomization program to obtain
the block randomization sequence”
Allocation concealment (selection bias) Low risk “The data manager had no participant con-
tact”.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Participants were told not to mention
their group assignment to study personnel
during their post-treatment assessments;
questionnaires were administered via com-
puter. The technicians who analysed blood
samples were blind to all other data”
Incomplete outcome data (attrition bias)
All outcomes
High risk No ITT analysis. Participants were ex-
cluded from analysis if they did not com-
plete either of the post-treatment assess-
ments
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Kim 2015
Methods Study design: single-centre RCT
Number randomised: 43; 23 to the home-based exercise + supplement intervention, 20
to a supplement-only control
Study start: January 2012; stop date: August 2013
Length of intervention: 6 months
Length of follow-up: to end of intervention
Country: South Korea
Participants Age, years (mean SD):
• Intervention: 55.7 (5.3)
• Control: 56.3 (6.7)
Stage, n (%):
• Intervention: stage 0-I, 7 (31.8); stage II-III, 15 (68.2)
• Control: stage 0-I, 12 (60.0); stage II-III, 8 (40.0)
Inclusion criteria:
• Women aged 20 to 70 years
• Diagnosis of stage 0 to III breast cancer
• Completed primary treatment at least 3 months earlier and were postmenopausal
• Osteopenia diagnosed by a bone mineral density screening test
Exclusion criteria:
• Having other cancer(s)
• Bone metastasis
• Disease that could influence bone metabolism
• Under treatment for osteoporosis
• Condition that precluded unsupervised exercise
• Participating regularly in resistance exercise (2 or more 30-minute sessions per week)
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Interventions 23 participants assigned to exercise intervention:
• For women in the exercise group, supplements (500 mg calcium and 1000 IU
vitamin D) were combined with a 6-month home-based exercise intervention.
• Participants were instructed to walk on 3 non-consecutive days for a total of at
least 150 minutes per week (RPE 11 to 13). Walking was combined with elastic band
resistance exercises performed 2 to 3 days per week. Participants used resistance bands
colour-coded for resistance levels to perform 2 sets of 8 to 10 repetitions of 5 upper
body and 4 lower body exercises targeting major muscle groups at light-to-moderate
intensity.
• Intervention was based on self-efficacy theory and consisted of telephone
counselling, exercise logs to review progress, exercise goal setting, and a DVD showing
someone accomplishing exercise goals. Two 30-minute education sessions with a 28-
page workbook were provided before women initiated exercise. Telephone counselling
was provided through 18 15-minute sessions (weekly for 3 months and at 2-week
intervals thereafter) by 2 nurses trained in exercise prescription.
Adherence:
Mean adherence rate was 69.5% for walking and 48.5% for resistance exercise
20 participants assigned to control:
• Women in the control group were a supplement-only group (500 mg calcium and
1000 IU vitamin D) and were instructed to record their supplement intake in logs.
They were not instructed to avoid exercise but were not included in the exercise
intervention.
Outcomes Primary outcomes:
• Bone mineral density (g/cm²) of the lumbar spine (L1-4), femur neck, and total
hip with DEXA
Other outcomes:
• Serum calcium by Arsenazo III dye method
• Serum 25-hydroxyvitamin D by radioimmunoassay
• Physical activity assessed via the Godin Leisure-time exercise questionnaire
• Aerobic capacity measured by the 6-minute walk test
• Forearm grip strength (kg) assessed via handgrip dynamometer
• Lower-extremity muscular strength measured by the chair-stand test (as many
stands from sitting position in 30 seconds as possible)
• Lower body muscular endurance assessed by the wall-squat test (hold squat
position for as long as possible with back against a wall)
Numbers of participants assessed:
• Intervention: baseline, 23; at 6 months, 20
• Control: baseline, 20; at 6 months, 19
Adverse events: “No injuries or adverse events and no symptoms of lymphedema were
reported in either group”
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes, but LOCF
Funding: Basic Science Research Program through the National Research Foundation
of Korea funded by the Ministry of Education, Science, and Technology
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated randomisation was
used.
Allocation concealment (selection bias) Unclear risk Sealed, sequentially numbered envelops
were used, but trial authors did not report
whether they were opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Primary outcome (bone mineral density)
was assessed by technicians blinded to
group allocation, but trial authors did not
report whether assessors of the remaining
were also blinded to group allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk Missing data were imputed by the LOCF
method.
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Ligibel 2008
Methods Study design: single-centre RCT
Number randomised: 101; 51 to intervention, 50 to control
Study start: May 2004; stop date: October 2006
Length of intervention: 16 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 52 (9)
• Control: 53 (9)
Stage, n (%):
• Intervention: stage I, 22 (43); stage II, 22 (6); stage III, 6 (12); missing, 0 (0)
• Control: stage I, 21 (43); stage II, 22 (44); stage III, 4 (8), missing, 2 (4)
Inclusion criteria:
• Histological evidence of stage I-III invasive breast cancer
• Completion of any chemotherapy and/or radiation therapy at least 3 months before
enrolment
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• Absence of diabetes
• No use of corticosteroids
• BMI > 25 and/or body fat percentage > 30%
• Baseline participation in less than 40 minutes of physical activity per week
• Hormonal therapy allowed as long as participants continued therapy for duration of
the study
Exclusion criteria:
• Evidence of persistent or recurrent breast cancer
• Other malignancy
• Uncontrolled heart disease
• Other contraindications to exercise
Interventions 51 participants assigned to 16-week exercise intervention:
• Resistance training programme (2 sessions of 50 minutes per week) focussed
largely on lower body and core muscle strength, given limited data regarding the
impact of upper body exercise on risk of lymphoedema. Exercises included leg press,
quad extension, hamstring curl, hip adductor, hip abductor, abdominal crunches, calf
press, and leg lifts. Intensity of resistance training started at 80% of maximum weight
from baseline strength testing, increased by 10% each week.
• Participants were asked to perform 90 minutes of cardiovascular exercise on their
own each week. Each participant was given a pedometer and a heart rate monitor on
enrolment. Participants were allowed to choose their own form of exercise, as long as it
produced a heart rate in the target zone (55% to 80% maximum heart rate).
• Staff worked with a personal trainer during each of these sessions, monitored by
exercise physiologists
Adherence:
• Although 11 participants ultimately did not complete the intervention, at least
partial exercise data were available for 49 participants. According to intent-to-treat
analyses, participants attended a mean of 73% of scheduled strength training sessions
and performed 114 minutes of aerobic exercise per week.
50 participants assigned to control:
• Control group received routine care for 16 weeks and then was offered
consultation with an exercise trainer at the end of the control period. All participants
were asked to avoid changes in dietary habits undertaken to lose weight for the
duration of the study.
Contamination of control group: not reported
Outcomes Outcomes:
• Anthropometric measurements; BMI, waist circumference measured at the
bending line, and hip measurement recorded at point of maximum girth; waist-to-hip
ratio
• Body composition measured by a bioelectric impedance analyser
• Glucose measured with a hexokinase ultraviolet assay
• Insulin measured via immunochemiluminometric assay and measured in µU/mL
(1 µU/mL = 6.954 pmol/L)
• Insulin resistance calculated by HOMA, with the following formula: HOMA =
[insulin (µU/ mL) × glucose (mg/dL)]/405
• Serum leptin and adiponectin determined by radioimmunoassay
• Serum high-molecular-weight adiponectin (HMWA) measured by ELISA
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Time points of assessment: baseline, completion of the 16-week study period
Numbers of participants assessed:
• Intervention: baseline, 51; at 16 weeks post intervention, 40
• Control: baseline, 50; at 16 weeks post intervention, 42
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: unclear; ITT approach was not described
Funding: supported by the American Society of Clinical Oncology and the Lance Arm-
strong Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described: “participants were randomly
assigned 1:1 to an exercise intervention
group or control group”
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “although hormonal assays were performed
by technicians blinded to group assign-
ment, anthropometric measures were col-
lected by unblinded study staff ”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk ITT approach mentioned but not de-
scribed
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk High dropout numbers in intervention
group (11/51; 22%) and in control group
(8/50; 16%)
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Methods Study design: single-centre RCT
Number randomised: 63; 32 to intervention, 31 to control
Study start: May 2007; stop date: April 2008
Length of intervention: 6 months
Length of follow-up: to end of 6-month intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 60.6 (7.1)
• Control: 58.2 (8.8)
Stage, n (%):
• Intervention: stage 0, 14 (43.8); stage I, 7 (21.9); stage II, 10 (31.3); stage III, 1
(3.1)
• Control: stage 0, 14 (45.2); stage I, 10 (32.3); stage II, 5 (16.1); stage III, 2 (6.5)
Inclusion criteria:
• Age between 21 and 75 years
• Completion of breast cancer treatment (stage 0-III) at least 3 months before (with
the possible exception of ongoing hormonal therapies such as tamoxifen or aromatase
inhibitors)
• BMI ≥ 24 kg/m² (or ≥ 23 kg/m², if of Asian descent)
Exclusion criteria:
• Myocardial infarction or stroke in the previous 6 months
• Diabetes
• Current yoga practice
• Pregnancy or plans to become pregnant
• Other factors that might lead to poor retention and yoga practice, which included
plans to leave the study area during the follow-up period or any contraindications to
practising yoga
Interventions 32 participants assigned to exercise intervention:
• Yoga intervention was based on viniyoga, a Hatha therapeutic style of yoga that
involves physical stretches and poses, breath control, and meditation. Each yoga
practice opened with 5 to 10 minutes of centring exercises to promote relaxation and
internal focus, followed by 50 to 60 minutes of seated and standing poses, and closed
with 10 to 15 minutes of guided relaxation, breathing exercises, and meditation.
• Participants were given the goal of practising 5 times per week, including at least
one 75-minute facility-based class. Women were permitted and encouraged to attend 2
or 3 facility-based classes if they desired; the remainder of their weekly practice sessions
(i.e. 2 (if they attended 3 classes) to 4 (if they attended 1 class)) were to be completed at
home (20 to 30 minutes in duration).
Adherence:
• Women attended an average of 19.6 facility-based classes (range, 1 to 61; median,
20.5) and practised at home an average of 55.8 times (range, 2 to 102; median, 62)
during the 6-month intervention.
14 participants assigned to control:
• Participants in the wait-list control group were asked to not begin yoga and were
not contacted again until it was time to schedule their 6-month follow-up assessment.
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Outcomes Primary outcome measures:
• QoL assessed by FACT-G and the breast cancer module (FACT-B) consisting of
13 additional items
• Fatigue assessed by the 13-item Fatigue Scale (FACT-F) developed specifically for
the cancer population
• Body weight (kg) measured in a dressing gown with undergarments
Secondary outcomes:
• Waist and hip circumferences measured in a dressing gown with undergarments
• Physical activity collected through a self-administered version of the Modifiable
Activity Questionnaire, which includes usual frequency, duration, and number of
months of recreational activities performed during previous 12 (baseline) or 6 (6-month
follow-up questionnaire) months. Physical activity converted to MET-h per week
Numbers of participants assessed:
• Intervention: baseline, 32; at 6 months, 30 complete QoL and fatigue; weight and
blood collection, 28
• Control: baseline, 31; at 6 months, 27 QoL and fatigue, weight and blood
collection
Adverse events: not reported
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00476203
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: supported in part by the Office of Research and Development Cooperative
Studies Program, Department of Veterans Affairs and the Transdisciplinary Research in
Energetics in Cancer (NCI 1U54 CA116847)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described,
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk “we were unable to blind assessors to group
assignment”
Incomplete outcome data (attrition bias)
All outcomes
High risk “We used an intent-to-treat approach”.
However, “those who did not provide fol-
low-up values were not included in analy-
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ses”
Selective reporting (reporting bias) Unclear risk Blood was collected, but no outcome mea-
sures were specified or reported
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Loh 2014
Methods Study design: single-centre RCT
Number randomised: 197; 66 to Qigong, 65 to group line-dancing, 66 to control
Study start: not reported; stop date: not reported
Length of intervention: 8 weeks
Length of follow-up: to end of intervention (at 12 months post intervention for inter-
vention-only groups)
Country: Malaysia
Participants Baseline data available for 95 participants (32, Qigong; 31, line-dancing; 32, usual care)
:
Age, years (mean SD):
• Qigong: not reported
• Line-dancing: not reported
• Control: not reported
Stage, n (%):
• Qigong: stage I, 11 (34.4); stage II, 21 (65.6)
• Line-dancing: stage I, 10 (32.3); stage II, 21 (67.7)
• Control: stage I, 12 (37.5); stage II, 20 (62.5)
Inclusion criteria:
• Medical contraindication to exercise
• Major medical condition such as epilepsy, uncontrolled hypertension, major or-
thopaedic problem or acute cardiovascular disease (patients given diagnosis in the past
6 months and still medically unstable)
• Completed primary cancer treatment with no evidence of metastasis
• At least 1 year post diagnosis
Exclusion criteria:
• Medical contraindication to exercise
• Major medical condition such as epilepsy, uncontrolled hypertension, major or-
thopaedic problem or acute cardiovascular disease (patients given diagnosis in the past
6 months and still medically unstable)
• Currently practising Qigong or line-dancing
• Engaging in more than 4 hours of vigorous physical activity
Interventions 131 participants assigned to one of two 8-week exercise interventions:
• Qigong group: Low- to moderate-intensity internal Qigong (Zhi Neng Qigong)
programme (group activity) was employed. Participants were encouraged to practise a
30-minute routine at home, twice a week (using the supplementary recording provided
on a compact disc) during the 8-week intervention.
• Line-dancing group: Group line-dancing programme with moderate-intensity
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movements. This intervention consisted of 4 sets of aerobic movements that were
taught face-to-face once a week. Each session began with a 10-minute warm-up period;
60-minute dancing sequences; and a 10-minute cool down. Two rest intervals of 5
minutes were provided during the session. Participants were encouraged to practice a
30-minute routine at home, twice a week (aided by a compact disc recording of music
used during the face-to-face session).
Adherence:
Adherence rates were 63% for Qigong and 65% for line-dancing
66 participants were assigned to control.
No change was made to usual management of participants assigned to this group, but
they were offered the Qigong or line-dancing programme at the end of the 8-week
intervention period
Outcomes Primary outcomes:
• Quality of life measured with FACT-B
Other outcomes:
• Fatigue in the previous 7 days measured by the 13-item FACIT-F
• Experience of negative emotional states measured on the Depression and Anxiety
Stress Scale-21 (DASS-21)
Numbers of participants assessed:
• Qigong: baseline, 66; at 8 weeks, 32 (at post 12 months, 14)
• Line-dancing: baseline, 65; at 8 weeks, 31 (at post 12 months, 9)
• Control: baseline, 66; at 8 weeks, 32 (at post 12 months, 0)
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: yes, trial authors provided additional means and SDs for some
outcomes
Intention-to-treat analysis: no, “Outliers more than 1.5SD, were removed, and missing
data were replaced with mean-substitution”
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Block randomisation (block size=six) was
performed by one of the researchers”
Allocation concealment (selection bias) Low risk “Masking of treatment allocation were con-
ducted, with ‘matching’ active, placebo and
control, using a free online Random Allo-
cation Software”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
High risk Inappropriate handling of missing data:
“Outliers more than 1.5SD, were removed,
and missing data were replaced with mean-
substitution”
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk Very high attrition. Only 48% of par-
ticipants randomised at baseline com-
pleted postintervention assessments; there-
fore, less than half of participants received
only part of the intervention
Loudon 2014
Methods Study design: multi-centre RCT
Numbers allocated, 28; 15 to exercise intervention, 13 to control
Study start: February 2011; stop date: May 2011
Length of intervention: 8 weeks
Length of follow-up: at 12 weeks
Country: Tasmania, Australia
Participants Baseline data available for 12 in intervention and 11 in control:
Age, years (mean SD):
• Intervention: 55.1 (2.5)
• Control: 60.5 (3.6)
Stage, n (%):
• Intervention: stage 0, 0 (0); stage I, 3 (25); stage II, 6 (50); stage III, 3 (25)
• Control: stage 0, 1 (9); stage I, 4 (3); stage II, 5 (45); stage III, 1 (9)
Inclusion criteria:
• Stage I unilateral secondary lymphoedema of the arm, as defined by the International
Society of Lymphology and confirmed by a professional lymphoedema therapist
• Completed treatment for breast cancer (surgery, radiotherapy, and chemotherapy) at
least 6 months previously
• Over 18 years of age




• Receiving complex lymphoedema therapy
• Pregnancy
• Wore a pacemaker, which would affect bioimpedance spectroscopy (BIS) readings
• Severe psychological illness
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Interventions 15 participants assigned to exercise intervention:
• 8-Week Yoga intervention consisted of 1 supervised sessions per week (90
minutes) and 6 home-based sessions per week (45 minutes).
• Yoga session consisted of documented breathing practices, physical postures,
meditation, and relaxation techniques according to the Satyananda Yoga tradition.
• Participants were given a DVD with a 45-minute yoga session and were instructed
to perform it daily. The DVD followed the same sequence of practices as the class, with
fewer postures and shorter relaxation. Participants received a log book in which they
recorded their daily practice along with any relevant comments.
Adherence:
Attendance at group yoga sessions was high (97%), as was self-reported compliance with
the home practice DVD (86%)
13 participants assigned to control:
• Participants randomised to the control group maintained their usual self-care as
advised by their lymphoedema therapist. Self-care included wearing of compression
sleeves, self-massage, skin protection, and continued usual lymphatic treatment.
Control group was offered yoga classes at completion of the final measurement.
Outcomes Primary outcome:
• Arm volume of lymphoedema measured by circumference; extracellular fluid
measured by bioimpedance spectroscopy
Secondary outcomes:
• Tissue induration measured by tonometry
• Severity of sensations, pain, and fatigue, and degree to which sensations, pain, and
fatigue limited activity on the day of measurement on a 10-cm visual analogue scale
(VAS). A score of 0 cm indicated “no discomfort”, and a score of 10 cm indicated “the
worst imaginable”.
• Quality of life based on the Lymphoedema Quality of Life Tool (LYMQOL).
Total QoL was self-recorded with scores from 0 to 10, 10 being the best and 0 the
worst rating on the day of testing. Subscales, each consisting of several questions, for
function, symptoms, appearance, and emotions were also self-recorded. Each question
was scaled from 1 to 4, with 4 being the worst. The score for each subscale was based
on the mean of ratings for subscale-related questions. A higher score indicates a lower
QoL rating for that subscale.
Numbers of participants assessed:
• Intervention: baseline, 15; at 8 weeks, 12; at 12 weeks, 9
• Control: baseline, 13; at 8 weeks, 11; at 12 weeks, 10
Adverse events: No adverse events were attributable to the yoga or to the control inter-
vention
Notes Trial registration link: none available




Funding: Swan Research Institute (SRI) and Faculty of Health Sciences Seed Funding,
UTAS. Equipment was provided by Flinders University and University of Tasmania
Risk of bias
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomisation based on a computer-gen-
erated random number system”
Allocation concealment (selection bias) Low risk “An individual not associated with the trial
will perform the randomisation”
“Group notification will be in a sealed en-
velope given to women after completion of
the baseline measurement”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Measurements, based on validated instru-
ments and protocols, were taken by trained
researchers blinded to the group allocation
and previous results”
Incomplete outcome data (attrition bias)
All outcomes
High risk Only those who completed post-interven-
tion and 1-month-after-cessation assess-
ments were included in analysis
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Malicka 2011
Methods Study design: single-centre RCT
Number randomised: 38; 23 to a Nordic walking intervention, 15 to control
Study start: not reported; stop date: not reported
Length of intervention: 8 weeks
Length of follow-up: to end of intervention
Country: Poland
Participants Age, years, mean:
• Overall: 62.8
Stage, n (%):
• Intervention: not reported
• Control: not reported
Inclusion criteria:
• Women after treatment for breast cancer
Exclusion criteria:
• None reported
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Interventions 23 participants assigned to exercise intervention:
• Warm-up (10-minute): exercise of upper extremities with the use of poles, not
only to prepare the body for the subsequent effort but also as part of lymphoedema
prophylaxis
• Nordic walking (40-minute) aimed at learning and improving walking technique
with the use of special poles (load applied was 85% of HRmax (220-age), with pulse
monitored by Polar testers throughout the activity
• Concluding part (10-minute) involving application of muscle stretching,
respiratory, and relaxation exercises, taking into account lymphoedema prophylaxis
Adherence:
Not reported
15 participants assigned to control:
• Control group comprised 15 women not participating in any rehabilitation
programme (no physical activity for the same duration).
Outcomes Outcomes:
• Biodex Multi-Joint 3 isokinetic dynamometer used to assess muscle strength
bilaterally with the upper limb push-pull attachment of the Biodex (pushing motion
consisting of shoulder flexion and elbow extension, and pulling motion consisting of
shoulder extension and elbow flexion)
• Upper extremities circumference (volume of lymphoedema)
Time points of assessment: baseline, at 8 weeks
Numbers of participants assessed:
• Intervention: baseline, 23; at 8 weeks, 23
• Control: baseline, 15; at 8 weeks, 15
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes, no missing data were reported
Funding: none reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “The participants were randomly assigned
to one of two groups”
No method stated
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data (no dropouts) are appar-
ent.
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Martin 2013
Methods Study design: single-centre RCT
Number randomised: 26; 8 to MVe Fitness Chair, 8 to traditional resistance training,
10 to control (no exercise)
Study start: not reported but participants enrolled from January to December 2009; stop
date: not reported
Length of intervention: 8 weeks
Length of follow-up: to end of intervention
Country: Australia
Participants Age, years (mean SD):
• MVe Fitness Chair: 44.6 (8.0)
• Resistance training: 47.8 (11.5)
• Control: 49.5 (14.5)
Stage, n (%):
• All 26 participants given diagnosis of stage I, II, or III breast cancer
Inclusion criteria:
• Female
• Age 29 to 69 years
• Diagnosis of stage I, II, or III breast cancer and completion of all treatments within 6
months
• Consent from oncologist to participate
• Underwent strict health screening
Exclusion criteria:
• Cardiorespiratory disease; bone, joint, or muscle pain or abnormalities that would
compromise the participant’s ability to complete the exercise training protocol
• Already enrolled in a formal exercise programme
Interventions 16 participants assigned to 1 of 2 exercise interventions:
• Target of 3 days of 50-minute sessions consisted of MVe Fitness Chair (n = 8) or
traditional resistance training (n = 8).
• Both interventions are described as resistance training: MVe Fitness Chair (single
leg pump, mermaid, front leg pump, calf raises, 2-arm pump, and pelvic lift),
traditional resistance training (crunches, oblique crunches, ball squats, calf raises, chest
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press, bridge).
• The 2 protocols matched in volume of work and sequence of muscles exercised.
For both interventions, exercise sessions started with 15 minutes of aerobic exercise at
65% to 75% heart rate reserve, using a treadmill, elliptical, or stationary cycle, followed
by 5 minutes of total body stretching, then 25 minutes of resistance training. After
performing resistance exercises, participants cooled down and stretched for 5 minutes.
• Intensity of resistance exercise was quantified on the RPE scale from 6 to 20.
Week 1: RPE 9 to 10; weeks 2 to 3, RPE 10 to 11; weeks 4 to 6, RPE 12 to 13; weeks
7 to 8, RPE 13 to 14.
Adherence:
MVe Fitness Chair group had a mean adherence rate of 83.3%.
Resistance training group had an average adherence rate of 81.2%
10 participants assigned to control:
• Control group was asked to not exercise.
Outcomes Outcomes:
• Muscular endurance evaluated by combined repetitions on a standardised push-
up test, a partial curl-up test, and the Dynamic Muscular Endurance Test Battery for
Cancer Patients of Various Ages. This protocol provides a table, divided into age
groups, which shows what percentage of body weight participants should lift for each
exercise. Exercises consisted of single-arm dumbbell biceps curls on each arm, lateral
pull-downs on a cable machine, seated machine leg extensions, and prone machine
hamstring curls via resistance training machines (Magnum Fitness Retro Series
Machine, South Milwaukee, WI). Participants performed repetitions at 60 beats per
minute to a metronome until they could not keep up with the rhythm, could not
perform any more repetitions, or chose to stop. Summed total repetitions performed
on push-ups, partial curl-ups, both biceps curls, lateral pull-downs, leg extension, and
hamstring curls created a composite score used in analysis of muscular endurance.
Other outcomes:
• Narrative feedback
Numbers of participants assessed:
• Intervention: baseline, 8; post intervention, 8
• Control: baseline, 10; post intervention, 10
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes, no missing data were reported
Funding: Peak Pilates donated the MVe Fitness Chairs used in this study to the Get
REAL & HEEL Breast Cancer Rehabilitation Program. No other financial support was
received for this project
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Simple randomization with replacement”
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Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk No data were missing.
Selective reporting (reporting bias) High risk Oxygen saturation was not reported. Com-
posite score for all tests was reported. Data
for individual tests were not provided
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Matthews 2007
Methods Study design: single-centre RCT
Number randomised: 36; 23 to intervention, 13 to wait-list control
Study start: not reported; stop date: not reported
Length of intervention: 12 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 51.3 (9)
• Control: 56.9 (12.3)
Stage, n (%):
• Intervention: stage I, 13 (59); stage II/III, 4 (18); not available, 5 (23)
• Control: stage I, 9 (64); stage II/III, 3 (21); not available, 2 (14)
Inclusion criteria:
• Diagnosis of stage I-III cancer
• Completed adjuvant treatment in the past 12 months
• Postmenopausal
• Free of cardiovascular disease and major orthopaedic limitations
• Not currently exercising on a regular basis (≥ 5 days/week)
Exclusion criteria:
• None reported
Interventions 22 participants assigned to exercise intervention:
• Brief home-based intervention consisted of a single in-person counselling visit (30
minutes) followed by up to 5 short telephone counselling calls during weeks 1, 2, 4, 7,
and 10 calls after randomisation (10 to 15 minutes/call).
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• Home-based intervention primarily sought to increase walking, consisting of
walking at a moderate-intensity (RPE 11 to 13) from 3 to 5 sessions per week (weeks 1
to 4, 3/week; weeks 5 to 7, 4/week; weeks 8 to 12, 5/week) of 20 to 40 minutes (weeks
1 to 4, 20 to 30 minutes/session; weeks 5 to 12, 30 to 40 minutes/session6) over 12
weeks.
Adherence:
• Average adherence over 12 weeks to walking goals of the intervention as reported
in monthly walking logs was 94% (SD 0.48); average walking time reported in the
walking logs was 147 minutes/week.
14 participants assigned to control:
• Control participants were asked to maintain their current (baseline) activity levels
over the course of the study. They were provided no materials or advice about exercise.
No efforts were made after randomisation to stop women in this condition from
initiating or increasing their activity levels on their own.
• Women in the control condition received baseline intervention counselling and
materials (e.g. pedometer) upon completion of the study and were offered the
opportunity to receive as much telephone counselling as they wanted after this.
Outcomes Outcomes:
• Physical activity assessed by both CHAMPS and, in a subsample (n = 23), the
Manufacturing Technology Actigraph
• Body weight and BMI
• Body composition measured for descriptive purposes by 2 methods: bioelectrical
impedance analysis in 13 participants, and DEXA in the other 23 participants
Time points of assessment: baseline, 6 weeks, and 12 weeks. For body composition-
dependent variables: baseline and 12 weeks
Numbers of participants assessed:
• Intervention: baseline, 22; at 6 weeks, not reported; at 12 weeks, not reported
• Control: baseline, 14; at 6 weeks, not reported; at 12 weeks, not reported
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes, but LOCF used
Funding: Vanderbilt-Ingram Cancer Center, South Carolina Cancer Center, and Van-
derbilt General Clinical Research Center
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described; “participants were randomly
assigned 2:1 to an exercise intervention
group or control group”
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
High risk ITT analyses based on the last observation
carried forward method; missing data not
reported
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Unclear risk Some participants were contacted via a list
of participants from a breast cancer case-
control study. Therefore, these women may
have been particularly motivated to adopt
the walking programme
McKenzie 2003
Methods Study design: single-centre RCT
Number randomised: 14; 7 to exercise intervention, 7 to control
Study start: not reported; stop date: not reported
Length of intervention: 8 weeks
Length of follow-up: to end of intervention
Country: Canada
Participants Age, years (mean SD):
• Intervention: 56.4 (10.4)




• Underwent breast cancer treatment for stage I or II breast cancer that had been com-
pleted more than 6 months before enrolling in the study
• Subsequently developed unilateral lymphoedema > 2 cm and < 8 cm for at least 1
measurement point
Exclusion criteria:
• Stage III lymphoedema, bilateral disease
• Required medication that might affect upper extremity swelling
Interventions 7 participants assigned to exercise intervention:
• Three days per week of resistance training included specific exercises, beginning
with a light weight and progressing as tolerated by each participant. Strength exercises
prescribed were seated row, bench press, latissimus dorsi pull-down, 1 arm bent-over
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rowing, triceps extension, and biceps curl. Two sets of 10 repetitions for each exercise
were done for the first week; 3 sets of 10 were done thereafter. Training sessions
consisted of a 5- to 7-minute period of aerobic warm-up such as cycling or walking, 5
minutes of stretching, the strength training programme, and a cool-down period.
• After 2 weeks, upper body aerobic exercise with an arm cycle ergometer was added
to the programme. Participants exercised under supervision. After a programme that
began with five 1-minute bouts of cycling at resistance of 8.3 W, the programme
progressed to 20 minutes of continuous cycling with resistance up to 25 W.
Adherence:
Not reported
7 participants assigned to control:
• Control participants were given no specific exercise instruction until after they
completed the study, at which time they had the option of being taught the exercise
programme.
Outcomes Outcomes:
• Arm circumference and volume measurements
• HRQoL via the MOS SF-36
Numbers of participants assessed:
• Intervention: baseline, 7; at week 8, 7
• Control: baseline, 7, 7; at week 8, 7
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: Trial authors were contacted for means and SDs for outcomes.
However, they did not provide these data
Intention-to-treat analysis: yes, no missing data were reported
Funding: not reported
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly assigned”, but method not men-
tioned
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No mention of whether study personnel
and outcome assessors were masked or
blinded to study interventions
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Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Mehnert 2011
Methods Study design: single-centre RCT
Number randomised: 63; 35 to intervention, 28 to control
Study start: not reported; stop date: not reported
Length of intervention: 10 weeks
Length of follow-up: to end of intervention
Country: Germany
Participants Age, years (mean SD):
• Intervention: 53.03 (7.40)
• Control: 50.64 (9.44)
Stage, n (%):
• Intervention: stage I, 17 (56.7); stage IIA, 8 (26.7); stage IIB, 3 (10.0); stage IIIA,
1 (3.3); stage IIIB, 1 (3.3)
• Control: stage I, 13 (46.4); stage IIA, 7 (25.0); stage IIB, 5 (17.9); stage IIIA, 3
(10.7); stage IIIB, 0 (0)
Inclusion criteria:
• 18 to 65 years old
• Primary non-metastatic breast cancer
• Minimum 4 weeks after completion of chemotherapy, radiation therapy, or both
• Any disorder that could interfere with ability to perform the physical exercise pro-
gramme
Exclusion criteria:
• Severe acute or chronic illness other than cancer (e.g. disorders of the musculoskeletal
system)
Interventions 35 participants assigned to exercise intervention:
• Gymnastics, movement games, and relaxation
• Moderate walking and jogging conducted outside
• Exercise performed twice weekly for 90-minute duration at an intensity of 60%
VO
max, over 10 weeks
• Although 35 women were assigned to the exercise intervention, 5 women refused
to participate before baseline assessment.
Adherence:
Not reported
28 participants assigned to control:
• Usual care
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Outcomes Outcomes:
• Anxiety and depression measured with HADS
• Cancer-specific QoL measured by EORTC-QLQ-C30
• Generic QoL measured via MOS SF-36
• Psychological symptoms measured with SCL-90R
• Body image assessed via a German version of the Body Image Questionnaire
(BIQ)
Numbers of participants assessed, anxiety and depression:
• Intervention: anxiety and depression: baseline, 30; at 10 weeks, 30. Individual
body image: baseline, 27; at 10 weeks, 27. Social body image: baseline, 30; at 10 weeks,
27
• Control: anxiety and depression: baseline, 28; at 10 weeks, 28. Individual body
image: baseline, 27; at 10 weeks, 27. Social body image: baseline, 27; at 10 weeks, 27
Numbers of individuals with data for cancer-specific HRQoL, generic HRQoL, and
psychological symptoms were not reported
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: unclear how missing data were handled
Funding: Friedrich and Louise Homann Foundation, Hamburg, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk It is unclear how the allocation sequence
was generated.
Allocation concealment (selection bias) Low risk Randomisation was adequately concealed
through external randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study personnel and outcome assessors
were not masked or blinded to study inter-
ventions
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk It is unclear how missing data were han-
dled. Five randomised participants were re-
ported to have “cancelled” participation in
the exercise group
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
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Other bias High risk Participation in physical exercise by women
(91%) in study groups before the inter-
vention was commenced could have con-
tributed to bias
Milne 2008
Methods Study design: single-centre RCT (12-week study included here)
Number randomised: 58; 29 to immediate exercise intervention, 29 to delayed exercise
intervention
Study start: January 2005; stop date: recruitment ended March 2005
Length of intervention: 12 weeks
Length of follow-up: to end of intervention
Country: Australia
Participants Age, years (mean SD):
• Intervention: 55.2 (8.4)
• Control: 55.1 (8.0)
Stage, n (%):
• Intervention: stage I, 6 (20.7); stage IIA, 14 (48.3); stage IIB, 9 (31.0); stage IIA,
0 (0.0)
• Control: stage I, 9 (31.0); stage IIA, 11 (37.9); stage IIB, 7 (24.1); stage IIIA, 2
(6.9)
Inclusion criteria:
• Women with stage I-II breast cancer
• ≥ 18 years old
• English speaking
• Within 24 months of cancer diagnosis
• Completed all treatments except hormone therapy
Exclusion criteria:
• Evidence of recurrent disease
• Previously engaged in any formal exercise programme for 6 months before participation
in this study
• Failed the revised Physical Activity Readiness Questionnaire
• Evidence of recurrent disease
Interventions 29 participants assigned to exercise intervention:
• Aerobic training (cycle and rowing ergometers, mini-trampoline, and step-up
blocks) and resistance training (12 different exercises, including chest press, chest
extension, biceps curls, triceps extension, leg extension, leg curls, hip abduction and
adduction, back extension, abdominal crunches, standing flies, and leg press) 3 times
per week for 1 hour per session over 12 weeks
• Cardiovascular component was conducted for 20 minutes and ended with a 5-
minute cool-down period, whereas for the resistance exercise component, participants
performed 2 sets of 10 to 15 repetitions of light weights and progressed to a heavier
weight once current weight and repetitions could be achieved and with good form.
Participants performed 5 minutes of stretching at the beginning and end of each
session.
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Adherence:
• Average intervention attendance was 60.4% (21.7 of 36 sessions) with a median
of 23 (63.9%) and a range of 11 to 36.
29 participants assigned to control:
• Control group was asked not to participate in exercise during weeks 1 to 12 and
received telephone calls at weeks 3, 6, 9, and 12.
Outcomes Primary outcome:
• QoL outcomes based on FACT-B scale
Other outcomes:
• Fatigue measured on the Schwartz Cancer Fatigue Scale
• Social physique anxiety measured by the Social Physique Anxiety Scale-7 (SPAS-7)
• Physical fitness assessed by submaximal fitness tests performed before and after
exercise training. Aerobic fitness was measured by the Aerobic Power Index (API) cycle
test.
• Strength was measured by recording the weight used during performance of
specific exercises (i.e. biceps curls, leg presses, and chest extensions).
• The Behavioral Regulation for Exercise Questionnaire-2 (BREQ-2) was
developed to provide a measure that assessed the self-determination continuum in
exercise. BREQ-2 subscale items were as follows: amotivation, intrinsic motivation,
identified regulation, introjected regulation, and extrinsic motivation. Responses to
each question were scored on a 5-point Likert scale (0 to 4) indicating how true each
item was for the individual, from not at all to very true. BREQ-2 total score was
established by calculating the sum of each subscale score.
• Basic Psychological Needs Satisfaction Scale (BPNS) was used to measure
autonomy, competence, and relatedness. The BPNS is a revised version of the 21-item
Basic Need Satisfaction at Work Scale, which was used to assess the extent to which
employees experienced satisfaction of their 3 basic needs-autonomy (7 items),
competence (6 items), and relatedness (8 items)-at their job.
Numbers of participants assessed:
• Intervention: baseline, 29; at 6 weeks, 29; at 12 weeks, 28
• Control: baseline, 29; at 6 weeks, 29; at 12 weeks, 28
Adverse events: none reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes, but LOCF was used
Funding: CCS and NCIC/CCS Sociobehavioral Cancer Research Network
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by computer-generated
programme
Allocation concealment (selection bias) Low risk “Group assignments were concealed from
the project director who recruited partici-
pants to the trial”
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Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study personnel and outcome assessors
were not masked or blinded to study inter-
ventions
Incomplete outcome data (attrition bias)
All outcomes
Low risk Minimal loss to follow-up
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk Intervention adherence rate was low (61.
3%).
Murtezani 2014
Methods Study design: single-centre RCT
Number randomised: 73; 37 to intervention, 36 to control
Study start: not reported; stop date: not reported
Length of intervention: 10 weeks
Length of follow-up: to end of intervention
Country: Kosovo
Participants Characteristics data based on 62 participants (30 in exercise group, 32 in control group)
Age, years (mean SD):
• Intervention: 53 (11)
• Control: 51 (11)
Stage, n (%):
• Intervention: stage I, 10 (33); stage IIa, 11 (37); stage IIb, 6 (20); stage IIIa, 3 (10)
• Control: stage I, 15 (47); stage IIa, 8 (25); stage IIb, 7 (22); stage IIIa, 2 (6)
Inclusion criteria:
• Histologically confirmed early-stage breast cancer with no evidence of recurrent or
progressive disease
• Completed surgery, radiotherapy, and/or chemotherapy with or without current hor-
mone therapy
Exclusion criteria:
• Known cardiac disease
• Uncontrolled hypertension
• Thyroid disease, respiratory disease, diabetes, mental illness, infection, immune or
endocrine abnormality
Interventions 37 participants assigned to exercise intervention:
• Women assigned to the intervention group attended a supervised group exercise
programme, 3 times per week for 10 weeks. The exercise programme was divided into
a warm-up period, followed by moderate-intensity aerobic exercises (50% to 75% age
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predicted HRmax), finishing with a cool-down period.
• Warm-up period consisted of 5 minutes of cycling. Core portion consisted of
aerobic exercise programme performed on treadmills, stationary bicycles, and stair-
climbing machines. Duration of aerobic exercise was initially 15 minutes, and session
was divided equally among the 3 exercise modalities (treadmills, stationary bicycles,
and stair-climbing machines). Sessions ended with 5 minutes of cool-down exercises
consisting of slow walking. Aerobic exercise period was increased by 2 minutes a week,
such that this period lasted 35 minutes during week 10.
Adherence:
Exercise adherence was 84.9%.
36 participants assigned to control:
• Control group was told to maintain sedentary lifestyle for 10 weeks.
Outcomes Primary outcome:
• Cardiorespiratory fitness via a 12-minute walk test
Other outcomes:
• Mass and BMI
• QoL via FACT-B
Numbers of participants assessed:
• Intervention: baseline, 37; at 10 weeks, 30
• Control: baseline, 36; at 10 weeks, 32
Adverse events: Three participants developed lymphoedema.
Notes Trial registration link: none available




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated random allocation
sequences”
Allocation concealment (selection bias) Low risk “sequences that were prepared centrally by
the trial statistician”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk The assessor was blinded with regard to al-
location of participants to treatment groups
Incomplete outcome data (attrition bias)
All outcomes
High risk “The data analyses included only those par-
ticipants who had completed the 10 week
interventional period”
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Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk Inappropriate statistical analysis was per-
formed (independent t-tests done on
change values)
Musanti 2012
Methods Study design: single-centre RCT
Number randomised: 55; 12 to aerobic exercise intervention, 17 to resistance exercise
intervention, 13 to combined aerobic and resistance exercise intervention, 13 to flexibility
control
Study start: October 2004; stop date: March 2006
Length of intervention: 12 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Aerobic intervention: 51 (5.5)
• Resistance intervention: 52 (8.9)
• Aerobic and resistance intervention: 48 (6.7)
• Flexibility control: 52 (7.9)
Stage, n (%):
• Aerobic intervention: stage I, 5 (42); stage II, 5 (42); stage III, 2 (16)
• Resistance intervention: stage I, 5 (29); stage II, 10 (59); stage III, 2 (12)
• Aerobic and resistance intervention: stage I, 7 (54); stage II, 6 (46); stage III, 0 (0)
• Flexibility control: stage I, 8 (62); stage II, 3 (23); stage III, 2 (15)
Inclusion criteria:
• English-speaking women
• Stage I-IIIB breast cancer after completion of adjuvant chemotherapy at least 3 months
or radiation therapy at least 6 weeks before entry
• No more than 24 months beyond their last treatment
• Hormonal therapy could be ongoing.
Exclusion criteria:
• Medical history or physical examination revealed evidence of anaemia (haemoglobin
<10 mg/dL), uncontrolled hypertension, congestive heart failure, pulmonary disease,
diabetes, and thyroid or musculoskeletal disease
• Current enrolment in a weight loss or exercise programme
• Positive response to any question on the Physical Activity Readiness Questionnaire,
thus indicating the need for medical clearance before starting an exercise programme
Interventions 42 participants assigned to aerobic, resistance, or aerobic plus resistance exercise inter-
ventions:
• Aerobic exercise: walking at 40% to 65% HRmax, progressing to 85% HRmax
for 15 minutes, progressing to 30 minutes
• Resistance exercise performed at an intensity of RPE (0 to 10) 3 to 5 progressing
to 7 to 8
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• Aerobic exercise was performed 3 times per week; resistance exercise was
performed 3 times per week; in resistance plus aerobic group, aerobic exercise was
performed 4 to 5 times per week and resistance was performed 2 times per week.
• All participants in intervention groups were prescribed flexibility exercise as part
of the warm-up routine.
• In-person verbal instruction plus demonstration was used to teach participants
how to do their assigned exercises.
• Each participant received a written guidebook that included general information
about exercise participation, such as clothing and safety tips, as well as an
individualised exercise prescription, exercise instructions, and an exercise log sheet.
Adherence:
• Aerobic intervention: mean compliance percentage, 107%
• Resistance intervention: mean compliance percentage, 91%
• Aerobic and resistance intervention: mean compliance percentage, 101%
• Flexibility control: mean compliance percentage, 82%
13 participants assigned to flexibility control:
• Flexibility control group consisted of a minimum of 60 sessions in total.
Outcomes Outcomes:
• Cardiorespiratory fitness via Bruce protocol
• Muscular strength assessed by 6-repetition maximum chest press, seated row, and
leg press
• Muscular endurance assessed by YMCA bench press and curl-up test
• Flexibility measures of hip flexion, hip backward extension, shoulder flexion,
shoulder posterior elevation, and shoulder abduction made with a goniometer
• Mass, arm and waist circumferences, and body composition via BIA
• Physical Self-Perception Profile and RSE Scale used as esteem measures
• Anxiety and depression assessed via HADS
• Physical activity via Godin Leisure Time Questionnaire at baseline only
• Resting heart rate and blood pressure
Numbers of participants assessed:
• Aerobic intervention: baseline, 12; at 12 weeks, 10
• Resistance intervention: baseline, 17; at 12 weeks, 9
• Aerobic and resistance intervention: baseline, 13; at 12 weeks, 11
• Control: baseline, 13; at 12 weeks, 12
Five women returned the survey data form but refused final fitness testing because of
time constraints related to work and family obligations; therefore, fitness test participant
number was 37
Adverse events: tendinitis (n = 2): 1 in the shoulder, the other in the foot
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes
Funding: award from the Greater NYC Affiliate of the Susan G. Komen Breast Cancer
Foundation, Inc., New York, NY
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “computer-generated randomization table
generated”
Allocation concealment (selection bias) Low risk “Allocation to study group was made….by
the statistical department of the cancer cen-
tre and maintained by office staff in the
clinical research office”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physical fitness tests: “The same research
assistant, blinded to participant group al-
location, preformed these measurements at
the pre-intervention and post-intervention
measurement time points”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Missing data were random and were han-
dled using multiple imputations”. Reasons
for withdrawal were given
Selective reporting (reporting bias) High risk Not all physical fitness test outcomes were
reported.
Other bias High risk Small sample size was further impacted by
high rate of withdrawal (24%)
Mustian 2004
Methods Study design: single-centre RCT
Number randomised: 31; 17 to Tai Chi Chuan intervention, 14 to control
Study start: not reported; stop date: not reported
Length of intervention: 12 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• 52 (9); range 33 to 78
Stage:
• Stage 0-IIIB (stage data not reported)
Inclusion criteria:
• Female
• Histological diagnosis of primary breast cancer stage 0-IIIB
• Between 1 week and 30 months after treatment
• No drainage tubes or catheters
• Not engaging in moderate-to-vigorous physical activity more than once a week
• Physician’s clearance for fitness testing and exercise
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• No physical limitations prohibiting exercise




Interventions 17 participants assigned to exercise intervention, including Tai Chi Chuan (TCC):
• 10 minutes of warm-up stretching and basic Chi Kung (stationary TCC
fundamentals)
• TCC 3 times per week. Each session consisted of approximately 40 minutes of
TCC, and participants learned a 15-move short form of Yang style TCC.
• During the last 10 minutes of each session, participants were instructed in
regulatory breathing, imagery, and meditation to enhance TCC skills and provide an
exercise cool-down.
• Participants were instructed not to begin any other physical exercise programmes
and not to change their normal daily physical activity during the course of the study.
Adherence:
• Intervention: 72% exercise rate with 100% compliance
• Control: 67% attendance rate with 100% compliance
14 participants assigned to psychosocial support:
• Supportive-expressive group therapy model conducted in an open-ended format
that placed strong emphasis on teaching behavioural coping strategies and providing
peer support and group cohesion
• Participants instructed not to begin any physical exercise programmes and not to
change their normal daily physical activity in any way for the duration of the study
Outcomes Primary outcomes:
• FACT-F, 28-question survey: scale from 0 to 4
• Self-esteem assessed by RSE Scale: scoring: 1 = strongly agree, 5 = strongly disagree
• Aerobic capacity, estimated by a 6-minute walk test protocol
Secondary outcomes:
• Muscular strength evaluated with a handgrip dynamometer to assess maximal
voluntary grip strength
• Flexibility assessed via goniometer measurements
• Body composition calculated by bioelectrical impedance analysis
• Blood markers:
◦ Serum concentrations of insulin measured by radioimmunoassay assay
◦ IGF-I, IGFBP-1, and IGFBP-3 measured by immunoradiometric assay
◦ Serum cytokines (IL-2, IL-6, and IFN-γ ) measured by OPTEIA ELISA kits
◦ Serum NTx levels determined with an enzyme-linked immunosorbent assay
and a specific monoclonal antibody for NTx (osteomark serum NTx)
◦ Serum BSAP levels determined by a chemiluminescent immunoassay
◦ To measure the balance between bone formation and bone resorption, trial
authors used the formula proposed by Eastell et al to calculate a bone remodelling
index (BRI). A positive number for the BRI indicates a net bone gain; a negative
number indicates a net bone loss.
Numbers of participants assessed:
• Intervention: baseline, 17; at 6 weeks, 11; at 12 weeks, 11
• Control: baseline, 14; at 6 weeks, 10; at 12 weeks, 10
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16 participants had evaluable blood samples before and after the intervention for bone-
biomarker tests. 19 participants gave evaluable blood samples for IGF-1, IGFBP-1,
IGFBP-3, and IL-6; 18 and 16 blood samples were evaluable for IL-2 and 16 for IFN-
γ , respectively
Adverse events: no cancer recurrence reported; cognitive deficits reported as reason for
treatment termination
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: Susan Stout Exercise Science Research Fund, Sally Schindel Cone Women’s
and Gender Studies Research Fund
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was achieved by flipping
a coin”.
Allocation concealment (selection bias) High risk Allocation was not concealed from study
personnel.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study personnel and outcome assessors
were not masked or blinded to study inter-
ventions
Incomplete outcome data (attrition bias)
All outcomes
High risk Withdrawals were not included in analyses
(intervention, n = 6; control, n = 4)
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
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Methods Study design: quasi-RCT
Number randomised: 46; 11 to psychological counselling only, 12 to exercise only, 12
to combined exercise and psychological counselling, 11 to usual care
Study start: not stated; stop date: not stated
Length of intervention: 8 weeks
Length of follow-up: to end of intervention
Country: Australia
Participants Age, years (mean SD):
• Counselling: 55.1 (7.5)
• Exercise: 49.0 (10.0)
• Exercise and counselling: 49.0 (8.2)
• Control: 51.8 (11.5)
Stage, n (%):
• Stage I-III invasive breast cancer
Inclusion criteria:
• Female with confirmed stage I-III invasive breast cancer within 12 months of treatment
completion (except hormone therapy)
• Aged 35 to 70 years
• Sufficiently fluent in English
• Either not participating in structured regular exercise or nutrition programmes in the
past 6 months or currently not meeting American College of Sports Medicine guidelines
for adequate physical activity (> 150 minutes/week)
Exclusion criteria:
• Acute or chronic bone, joint, or muscular abnormalities that would compromise ability
to participate in exercise
• Immune deficiency that would compromise ability to participate in exercise
• Failure of Physical Activity Readiness Questionnaire
• Presence of metastatic disease
Interventions 24 participants assigned to 1 of 2 exercise interventions:
• Participants in the exercise group received 8 weeks of individualised exercise
training, 3 times per week, for 45 to 60 minutes. The target goal for each participant
was 150 minutes per week of moderate-intensity physical activity, which met American
College of Sports Medicine guidelines. Each exercise programme was individualised
according to baseline health and fitness levels and personal goals. Each session included
cardiovascular training, strength training, patient-specific rehabilitation, core training,
and flexibility.
• Participants in counselling-only and combined exercise and counselling groups
underwent psychological counselling by meeting with an accredited counsellor for a 1-
hour session once a week for 8 weeks. Counsellors employed a client-centred therapy
approach based on the individual needs of each participant, whereby they facilitated
disclosure of feelings and anxieties, clarified issues, and provided reassurance and
support for the women as required.
Adherence:
Participants completed an average of 84% of all scheduled exercise sessions and 87% of
all scheduled counselling sessions, with no significant differences among groups
11 participants assigned to control:
• Usual care
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Outcomes Outcomes:
• Quality of life via FACT-B
• Fatigue via PFS
• Depression via BDI
• Mass and BMI
• Body composition via a 7-site skinfold measurement (triceps, chest, subscapular,
midaxilla, abdomen, suprailiac, and thigh)
• Cardiorespiratory endurance assessed by the Modified Bruce Treadmill Protocol
• YMCA bench press test utilised to estimate upper body muscular strength
• 1RM leg press test utilised to assess lower body dynamic strength, with a seated
leg press set at a 45-degree angle
Numbers of participants assessed:
• Counselling: baseline, 11; at 8 weeks, 10
• Exercise: baseline, 12, at 8 weeks, 11
• Exercise and counselling: baseline, 12; at 8 weeks, 12
• Control: baseline, 11; at 8 weeks, 10
Adverse events: No adverse reactions to participation in exercise or counselling interven-
tion were reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes
Funding: Foggarty grant and Health Benefits Funds, through the University of Notre
Dame Australia
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “randomized to each group on a rolling en-
rolment basis”
Allocation concealment (selection bias) High risk Rolling enrolment was used; therefore, al-
location was not concealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Baseline data for the 3 women who
dropped out after randomisation were in-
cluded in the intention-to-treat analysis
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Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Nieman 1995
Methods Study design: single-centre RCT
Number randomised: 16; 8 to exercise intervention, 8 to control
Study start: not reported; stop date: not reported
Length of intervention: 8 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SE):
• Intervention: 60.8 (4.0)




• All patients had been diagnosed with breast cancer
• Had undergone surgery, adjuvant chemotherapy, and/or radiotherapy
• Not currently receiving chemotherapy or radiation treatment
Exclusion criteria:
• None reported
Interventions 8 participants assigned to exercise intervention:
• 3 sessions per week for 60 minutes consisting of weight training and walking, over
8 weeks
• Weight training consisting of 7 different resistance exercises for 2 sets of 12
repetitions (30 minutes)
• Walking on an indoor track for 30 minutes at a heart rate of 138 ± 13 bpm (about
75% heart rate max)
Adherence:
• Average attendance 87% (range, 72% to 100%)
8 participants assigned to control:
• Sedentary control
Outcomes Outcomes:
• Symptom-limited exercise testing on a treadmill
• Leg extension strength testing on a Kin Com computerised testing station
• Cardiorespiratory fitness assessed by a 6-minute walking test
• Venous blood collection for assessment of natural killer cell cytotoxic activity by
chromium release assay and concentration of circulating immune cells, including per
cent total natural killer and T-cell subsets
Numbers of participants assessed:
• Intervention: baseline, 8; at 8 weeks, 6
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• Control: baseline, 8; at 8 weeks, 6
Adverse events: 2 recurrences of disease
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: supported in part by a grant from the National Institute of Aging
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described.
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
High risk Analysis was performed only on partici-
pants who completed the intervention
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk Potential imbalances at baseline; “larger
than expected baseline differences in these
variables and others including NKCA”
Nikander 2007
Methods Study design: RCT
Number randomised: 29; 15 to intervention, 14 to control
Study start: not reported; stop date: not reported
Length of intervention: 12 weeks
Length of follow-up: to end of 12-week intervention
Country: Finland
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Participants Age, years (mean SD):
• Intervention: 52.5 (6.4)
• Control: 51.3 (7.3)
Stage:
• Intervention: not reported
• Control: not reported
Inclusion criteria:
• Histologically proven invasive breast cancer
• Adjuvant chemotherapy within 6 months
• Duration of endocrine therapy no longer than 6 months
• Aged from 35 to 65
Exclusion criteria:
• Haematogenous metastases
• No systemic adjuvant therapy
• Pregnancy or lactation
• Severe cardiac disease (NYHA class III or higher)
• Myocardial infarction within 12 months
• Uncontrolled hypertension
• Verified osteoporosis
• Other serious illness or medical condition that could be a contraindication for exercise
• Not capable of training (severe knee arthrosis, ligament or cartilage injury at lower
extremity)
• Residence more than 1 hour from the exercise centre
• Competitive athlete
Interventions 15 participants assigned to exercise intervention:
• During alternate weeks, the effective part of guided training was based on step
aerobics or circuit training. In total, the 12-week planned 3-weekly exercise programme
was intended to consist of 1 weekly guided training session and at least 2 home training
sessions (intensity of exercise: first 2 weeks, intensity of training was moderate (RPE =
11); intensity was increased gradually from moderate to somewhat hard or hard levels
(RPE = 14 to 16) during 12-week exercise period).
• Step aerobics consisted of several typical step movements resulting in a total of
150 to 180 jumps and leaps to diverging directions during each session.
• Circuit training consisted of 3 rounds of 8 to 10 different vigorous movements
such as rope-jumping and skate-jumping, resulting in a total of 100 to 150 jumps and
leaps during each session.
• The home training session consisted of about 100 leaps and jumps similar to
those employed in the circuit training programme. In addition, endurance training
(walking, cycling, swimming, etc.) performed at the same RPE was recommended to
complement the home training session in terms of total duration.
• Each session was performed for 50 to 60 minutes (10-minute warm-up, 30- to
40-minute main session, 10-minute cool-down).
Adherence:
• “Ignoring three participants (2 withdrawals and 1 participant who attended only
three guided sessions), the adherence to the weekly-supervised training sessions was
78%”. The most common reasons for not attending the session included a holiday trip
or flu. Home training was performed 2.1 times per week on average. The mean
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duration of home training sessions was 21 minutes.
14 participants assigned to control:
• Control group was advised to continue normal daily routines and activities during
the 12-week follow-up period.
Outcomes Outcomes:
• Figure-8 running (a measure of dynamic agility)
• Counter movement jump (a measure of dynamic muscle performance) measured
with a force-plate
• Maximal isometric muscle force of leg extension and elbow flexion tests assessed
by an isometric leg press and an arm dynamometer
• Cardiorespiratory fitness assessed via a 2-km walking test
• Weight and BMI
Numbers of participants assessed:
• Intervention: baseline, 14; at 12 weeks, 14
• Control: baseline, 14; at 12 weeks, 14
“One participant withdrew from the study before randomization due to family reasons”
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no, but minimal loss to follow-up
Funding: Support from The Finnish Cancer Foundation, Pirkanmaa Cancer Society
Finland, and AstraZeneca Finland is greatly appreciated
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described.
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up was minimal. An ITT ap-
proach was stated but not described. One
participant withdrew from each group after
baseline assessments were taken, but these
participants were not included in ITT anal-
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ysis
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Payne 2008
Methods Study design: single-centre RCT
Number randomised: 20; 10 to intervention, 10 to control
Study start and stop dates: 9-month period but dates not reported
Length of intervention: 14 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• 64.7 (6.3)
Stage:
• Intervention: not reported
• Control: not reported
Inclusion criteria:
• Postmenopausal women with diagnosis of breast cancer who were receiving hormonal
therapy with tamoxifen, anastrozole, or letrozole (the 3 most frequently prescribed hor-
monal medications during the period of recruitment and study enrolment)
• Aged 55 years and older and with complaints of fatigue
• Karnofsky Performance Scale score ≥ 80
• English speaking
• No documented history of neurological deficits or mental illness such as psychotic
depression in the past year
• No neuromuscular deficits that would contraindicate a walking exercise intervention
Exclusion criteria:
• None reported
Interventions 10 participants assigned to exercise intervention:
• Four weekly 20-minute home-based walking sessions with pedometers over 14
weeks
Adherence:
• 9 out of 10 women completed the study; adherence data on numbers of sessions
completed were not specified: “the authors were unable to verify actual adherence to
study parameters, such as the number of times per week that subjects actually
completed the 20-minute walk”.
10 participants assigned to control:
• Usual care
Outcomes Outcomes:
• Fatigue measured using Revised PFS
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• Sleep disturbance measured by PSQI
• depressive symptoms measured via CES-D
• Blood biomarkers including cortisol, serotonin, IL-6, bilirubin markers
Numbers of participants assessed:
• Intervention: baseline, 10; at 12 weeks and at 14 weeks, 9
• Control: baseline, 10; at 12 weeks, 9; at 14 weeks, 9
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: Trial authors were contacted for means and SDs for outcomes.
Trial authors did provide some additional data, but not for all requested outcomes
Intention-to-treat analysis: unclear, no description of how missing data were handled
Funding: NIH/National Institute of Nursing Research
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of allocation sequence was not
described.
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study personnel and outcome assessors
were not masked or blinded to study inter-
ventions
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Trial authors did not describe how miss-
ing data were handled. Participants in each
group withdrew from the study
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Unclear risk Characteristics of participants in each
group were not well described; therefore, it
was difficult to assess whether groups were
similar at baseline
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Methods Study design: multi-centre RCT
Number randomised: 167; 75 to Yoga intervention, 92 to control
Study start: 2007; stop date: 2012
Length of intervention: 4 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SE):
• Intervention: 55.1 (1.24)
• Control: 53.2 (0.86)
Stage, n (%):
• Intervention: stage 0-I, 32 (44.4); stage II, 30 (41.7); stage III, 10 (13.9)
• Control: stage I, 48 (53.9); stage II 31 (34.8); stage III, 10 (11.2)
Inclusion criteria:
• Enrolled between 2 and 24 months post surgery, chemotherapy, and/or radiation
therapy
For the original study, eligible survivors were required to:
• Have a confirmed diagnosis of cancer
• Have undergone and completed standard treatment for cancer
• Have sleep disturbance (indicated by a response ≥ 3 on a clinical symptom inventory
using an 11-point scale anchored by “0” = no sleep disturbance and “10” = worst possible
sleep disturbance)
• Be able to read English
• Be 21 years of age or older
• Be able to give written informed consent
• Not have maintained a regular personal practice of yoga within the 3 months before
enrolling in the study, or be planning to start yoga on their own during the time they
are enrolled in the study
• Not have a confirmed diagnosis of sleep apnoea
• Not be receiving any form of treatment for cancer, with the exception of hormonal or
monoclonal antibody therapy
• Not have metastatic cancer
Exclusion criteria:
• Not reported
Interventions 75 participants assigned to exercise intervention:
• YOCAS (Yoga intervention based on gentle Hatha and restorative yoga) twice a




92 participants assigned to control:
• Wait-list standard care control; participants were offered YOCAS training after
completing study requirements. During the control period, they received the same
attention (as the intervention group) from staff, apart from YOCAS training.
Participants were asked not to start a new yoga or exercise regimen on their own during
this 4-week period to avoid exercise contamination.
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Outcomes Outcomes:
Musculoskeletal symptoms assessed via selected extracted questions from the following
validated questionnaires:
• University of Rochester Cancer Center Symptom Inventory (URCC SI)
• FACIT-F
• MFSI-Short Form
Numbers of participants assessed:
• Intervention: baseline, 72; at 4 weeks, 72
• Control: baseline, 92; at 4 weeks, 92
Adverse events: not reported
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00397930
Trial authors contacted: Trial authors were contacted for means and SDs for outcomes.
However, they did not provide these data
Intention-to-treat analysis: yes, no missing data were reported
Funding: NCI and the Office of Cancer Complementary and Alternative Medicine
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Group assignment was determined by a
computer-generated random numbers ta-
ble in blocks of two and an allocation ratio
of 1:1”
Allocation concealment (selection bias) Unclear risk Whether allocation was concealed was not
reported.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not mentioned whether study per-
sonnel and outcome assessors were masked
or blinded to study interventions
Incomplete outcome data (attrition bias)
All outcomes
Low risk No missing data were reported; “all data
were analysed using the intent-to-treat
principle”
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk This study consisted of a secondary analysis
from the original study; “the original RCT
was designed to test the effect of yoga on
sleep quality in all cancer survivors. There
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was no a priori aim in the study to exam-
ine the effect of yoga on musculoskeletal
symptoms in breast cancer survivors on en-
docrine therapy”
Pinto 2003
Methods Study design: single-centre RCT
Number randomised: 24; 12 to intervention, 12 to control
Study start: not reported; stop date: not reported
Length of intervention: 12 weeks
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• 52.5 (6.8)
Stage, n (%):
• Stage 0, 2 (9); stage I, 18 (78); stage II, 3 (13)
Inclusion criteria:
• Sedentary women (exercised < 3 times per week for 20 minutes per session)
• Received diagnosis of breast cancer (stage 0, I, or II) over the past 3 years
• Postsurgery patients who had completed chemotherapy or radiation treatment
Exclusion criteria:
• Medical or current psychiatric illness that would make compliance with the study
protocol difficult or dangerous (e.g. coronary artery disease, hypertension, diabetes)
• Orthopaedic problems or neuropathies that would limit exercise training
• Medications that would alter training responses (e.g. beta-blockers) or affect distress
outcomes (e.g. antidepressants)
Interventions 12 participants assigned to exercise intervention:
• Following exercise tolerance test, the supervised exercise intervention group was
taught basic exercise principles and techniques (e.g. stretching techniques, warm-up/
cool-down).
• Exercise session developed into 10 minutes of warm-up (cardiovascular and
flexibility), 10 minutes of cool-down (cardiovascular and flexibility), and 30 minutes of
cardiovascular activity in one’s target heart rate zone (60% to 70% of peak heart rate by
the end of the 12-week intervention).
• Cardiovascular activities included treadmill walking, arm and leg ergometers, arm
cycling, stationary cycling, and rowing. Participants used at least 3 modes of physical
activity per session that would ensure at least 1 cardiovascular arm activity.
• During the last month, participants performed strength training with light
weights (1- to 5-lb handheld weights) for the triceps, biceps, pectoral muscles,
shoulders, and upper back, and stomach crunches; these muscle endurance exercises
were offered to improve upper body endurance. The total duration of sessions was 50
minutes. Also, participants were given instructions for exercising at home and were
encouraged to start to exercise on their own at least once a week.
Adherence:
• Three participants withdrew; the remaining 9 participants completed 88% of the
163Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Pinto 2003 (Continued)
36 sessions.
12 participants assigned to control:
• Wait-list control group
• Asked not to change current level of physical activity for 12 weeks
• On completion of assessments, participants were offered the exercise programme
free of charge
Outcomes Outcomes:
• Peak workload, exercise time, blood pressure, heart rate, and rate pressure product
were assessed during a peak graded exercise stress test on a cycle ergometer (post-test
included only exercise group participants).
• POMS, a 65-item questionnaire, measures a variety of mood states including
anger, tension/anxiety, depression, vigour, fatigue, confusion, and total mood
disturbance; vigour and total mood score were used as primary outcomes in this study.
Response options are presented on a scale of 0 to 4 (0 = not at all, 4 = extremely).
• BES, a 35-item scale, assesses a participant’s evaluation of sexual attractiveness,
weight concerns, and physical condition with 3 subscales, on which higher scores
indicate higher esteem.
• Positive and Negative Affect Scale (PANAS) was used to assess the participant’s
positive and negative affect. Each of the 20 items on the PANAS required a response to
“how you are feeling at the moment?” on a 1 to 5 Likert scale (1 = very slightly, 5 =
extremely).
Numbers of participants assessed:
• Intervention: baseline, 12; after intervention, 9
• Control: baseline, 12; after intervention, 6
Nine participants in the intervention group completed exercise stress tests post interven-
tion; 3 participants in this group withdrew but provided postintervention questionnaire
data
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: National Institute of Mental Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described.
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study personnel and outcome assessors
were not masked or blinded to study inter-
ventions
Incomplete outcome data (attrition bias)
All outcomes
High risk Postintervention exercise stress test and
weight data were unavailable for the con-
trol group, and postintervention mood and
self-esteem data were available for only half
of the control group. Six (50%) control par-
ticipants were not included in the analyses
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk Small sample size was further hampered by
a high dropout rate, particularly in the con-
trol group (50%)
Pinto 2005
Methods Study design: RCT
Number randomised: 86; 43 to intervention, 43 to control
Study start: not reported; stop date: not reported
Length of intervention: 12 weeks
Length of follow-up: at 12 weeks, and at 6 months and 9 months post baseline
Country: USA
Participants Age, years (mean SD):
• Intervention: 53.4 (9.1)
• Control: 52.9 (10.4)
Stage, n (%):
• Intervention: stage 0, 8 (18.6); stage I, 17 (39.5); stage II, 18 (41.9)
• Control: stage 0, 6 (14.0%); stage I, 15 (34.9); stage II, 22 (51.2)
Inclusion criteria:
• Age ≥ 18 years
• Currently sedentary (exercised < 1 time per week for 20 minutes at vigorous intensity
or < 2 times per week for 30 minutes at moderate intensity for the past 6 months)
• Received diagnosis of stage 0 to II breast cancer over the last 5 years and completed
surgery, chemotherapy, and/or radiation
• Ambulatory (able to walk a mile without assistive devices)
• Willing to be randomised
Exclusion criteria:
• Prior history of cancer (exception: non-melanoma skin cancer)
• Medical or current psychiatric illness that could make compliance with the study pro-
tocol difficult or dangerous (e.g. cardiovascular disease, diabetes, orthopaedic problems
that limit exercise training)
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Interventions 43 participants assigned to exercise intervention:
• Instructions were provided on how to exercise at a moderate intensity level
(activities at 55% to 65% HRmax), how to monitor heart rate, and how to warm up
before exercise and cool down after exercise.
• The programme promoted activities such as brisk walking, biking, swimming,
and use of home exercise equipment. For the first few weeks, participants exercised at
least 2 days per week; this increased over the 12 weeks to at least 5 days per week. The
duration of individual sessions for the first few weeks was at least 10 minutes; this
increased over the 12 weeks to at least 30 minutes.
• Participants received weekly physical activity counselling via telephone. This
group also received mailed weekly tip sheets on physical activity and cancer
survivorship.
• After completing end-of-intervention assessments, participants received monthly
calls for 3 months to prompt and reinforce regular physical activity. These monthly
calls stopped after 3 months; at that time, participants were asked to try to maintain
regular physical activity.
Adherence:
• Participants wore a pedometer at week 1, and participants reported an average of
43.12 (SD 44.32) minutes of exercise per week; at week 12, they reported a mean of
128.53 (SD 76.82) minutes/week of exercise.
• Average percentage adhering to target physical activity in intervention group over
the course of 12-week intervention was 40.7%.
43 participants assigned to control:
• No change in current level of physical activity for 12 weeks
• Phone calls from research staff
• Cancer survivor tip worksheet
Outcomes Outcomes:
• Objective physical activity monitored by a Caltrac accelerometer
• Self-reported physical activity assessed by 7-DPAR via a standardised self-report
interview
• Rockport 1-mile walk test with measurement of time taken to walk 1 mile
• Mood states including anger, tension/anxiety, depression, vigour, fatigue,
confusion, and total mood disturbance; vigour and total mood score - primary
outcomes in this study - assessed by POMS, a 65-item questionnaire
• Level of fatigue assessed by asking participants to place a vertical mark on a 10-cm
linear analogue scale. This scale was scored by measuring the distance in millimetres
from the left anchor (i.e. “0”) to the vertical mark. Higher scores represent greater
fatigue.
• Participant’s evaluation of sexual attractiveness, weight concerns, and physical
condition assessed by BES, a 35-item scale with 3 subscales, on which higher scores
indicate higher esteem.
• Individual’s motivational readiness for physical activity assessed by Stage of
Motivational Readiness for physical activity.
• Exercise self-efficacy assessed on a 5-item measure that determines confidence in
one’s ability to engage in regular exercise in specific situations.
• Decisional balance for exercise assessed by a 16-item questionnaire that comprised
items reflecting positive (Pro) and negative (Con) aspects of exercise adoption.
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Numbers of participants assessed:
• Intervention: baseline, 43; after intervention, 39
• Control: baseline, 43; after intervention, 43
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes, but used LOCF
Funding: National Cancer Institute grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described.
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study personnel and outcome assessors
were not masked or blinded to study inter-
ventions
Incomplete outcome data (attrition bias)
All outcomes
High risk LOCF approach was used. Four partici-
pants withdrew from the exercise group be-
fore the end of the 12-week intervention.
Two participants withdrew from the con-
trol group before the 6-month assessment,
and another 2 participants withdrew from
the control group before the 9-month as-
sessment. Reasons for control group with-
drawals were not given
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias High risk Adherence to physical activity was low (40.
7%).
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Methods Study design: multi-centre RCT
Number randomised: 76; 39 to intervention, 37 to control
Study start: January 2010; stop date: April 2012
Length of intervention: 12 weeks
Length of follow-up: at 24 weeks
Country: USA
Participants Age, years (mean SD):
• Intervention: 55.64 (8.59)
• Control: 55.59 (10.59)
Stage, n (%):
• Intervention: stage 0, 3 (7.69); stage I, 16 (41.03); stage II, 16 (41.03); stage III,
4 (10.26)
• Control: stage 0, 2 (5.41); stage I, 13 (35.14); stage II, 18 (48.65); stage III, 4
(10.81)
Inclusion criteria:
• Aged ≥ 21 years with diagnosis of stage 0-III breast cancer in the past 5 years
• Completed surgery (patients receiving ongoing chemotherapy (most had completed),
radiation, or hormone treatment were eligible)
• Ability to read and speak English
• Ability to walk a half-mile without stopping
• Sedentary: < 30 minutes/week of vigorous physical activity or < 90 minutes/week of
moderate-intensity physical activity for the past 6 months
• Access to a telephone and willingness to receive calls
Exclusion criteria:
• Medical or psychiatric problems (e.g. myocardial infarction, orthopaedic problems)
that might interfere with protocol adherence
Interventions 39 participants assigned to physical activity intervention:
• Intervention consisted of telephone-delivered counselling tailored to participants’
motivational readiness. Participants also received a pedometer (Digiwalker) and a heart
rate monitor with instructions to use these during physical activity. Participants were
instructed on maintaining physical activity logs (type of moderate-vigorous physical
activity, duration, heart rate, rate of perceived exertion, and pedometer steps) to
facilitate self-monitoring.
• During weekly calls, coaches were asked to build a supportive relationship with
participants while assessing their motivational readiness, monitoring activity,
identifying and solving problem barriers to activity, and identifying health concerns.
• Overall goal was to encourage participants to gradually increase the amount of
moderate-vigorous physical activity (e.g. brisk walking) over 12 weeks to recommended
goal of ≥ 30 minutes of moderate-intensity physical activity on most days of the week.
• Participants also received the reach-to-recovery (RTR) programme, whereby
coaches responded to questions that participants asked about breast cancer and its
treatment and provided informational and emotional support.
Adherence:
At 12 weeks, weekly moderate-vigorous physical activity participation in the intervention
group averaged 130 minutes, and at week 24, 98 minutes
37 participants assigned to control:
• Control group was provided Reach-to-Recovery informational booklets, and
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coaches provided information and support for participants’ questions and concerns
about breast cancer. During weekly calls, coaches also administered a Weekly Symptom
Questionnaire that assessed problems such as headaches. Participants were asked not to
join a structured programme of MVPA during the 12-week intervention phase. After
completing assessments at 24 weeks, they were provided the same physical activity tip
sheets as were sent to the physical activity Plus RTR group.
Outcomes Primary outcome:
• Moderate-vigorous physical activity assessed via the 7-DPAR, which was
interviewer-administered
Other outcomes:
• HRQoL via the MOS SF-36, which assesses 8 health concepts (e.g. physical
functioning, bodily pain)
• HRQoL also assessed via FACT-B
• Physical and functional effects of fatigue assessed via FACIT-F. In this 13-item
scale, scores range from 6 (high fatigue) to 52 (low fatigue).
Numbers of participants assessed:
• Intervention: baseline, 39; at 12 weeks, 36; at 24 weeks, 36
• Control: baseline, 37; at 12 weeks, 32; at 24 weeks, 31
Adverse events: not reported
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00948701
Trial authors contacted: no
Intention-to-treat analysis: yes
Funding: grant from the National Cancer Institute (R01CA132854) to the first trial
author
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Seventy six breast cancer survivors were
randomized to PA Plus RTR or RTR Con-
trol”
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “A research assistant (blind to the partic-
ipant’s group assignment) was responsible
for collecting all data by mail or by tele-
phone”
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Incomplete outcome data (attrition bias)
All outcomes
Low risk “Generalized linear models take a likeli-
hood-based approach to estimation and
thus make use of all available data without
directly imputing missing values”
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Portela 2008
Methods Study design: single-centre RCT
Number randomised: 44; 16 to gym-exercise, 19 to home-exercise, 9 to no-exercise
control
Study start: recruitment began 2004; stop date: recruitment ended 2007
Length of intervention: 26 weeks
Length of follow-up: to end of intervention
Country: Puerto Rico
Participants Data available on the 34 participants who completed postintervention testing:
Age, years (mean SD):
• Gym-based exercise: 49.8 (6.9)
• Home-based exercise: 51.2 (7.3)
• Control: 59.6 (16.7)
Stage, n (%):
• Gym-based exercise: stage I, 0 (0); stage II, 3 (25); stage III, 6 (50); stage IV, 0 (0);
missing, 3 (25)
• Home-based exercise: stage I, 3 (23); stage II, 5 (38); stage III, 2 (15); stage IV, 0
(0); missing, 3 (23)
• Control: stage I, 2 (22); stage II, 2 (22); stage III, 1 (11); stage IV, 1 (11); missing,
3 (33)
Inclusion criteria:
• Women with new diagnosis of unilateral breast cancer who had received surgical treat-
ment for breast cancer in the past 5 years, with or without adjuvant therapy
Exclusion criteria:
• Unstable cardiac disease
• Coagulopathies
• Active psychiatric conditions
• Metastasis
• Haemoglobin level < 8.0 g/dL
• Absolute neutrophil count < 0.5 × 1000/mL
• Platelet count < 50 × 1000/mL
• Ataxia, dizziness, or peripheral sensory neuropathy
• Loss of more than 35% of premorbid weight
• Dyspnoea
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• Bone pain
• Severe nausea, extreme fatigue, and extreme muscle weakness
Exclusion criteria are considered contraindications to moderate-intensity exercise pro-
gramme following cancer diagnosis
Interventions 35 participants assigned to 1 of 2 exercise interventions:
• Gym-exercise group, in which staff met with participants once a week for exercise
supervision and progression. The gym had qualified personnel who were present to
assist participants during their exercise routine.
• Home-exercise group, in which participants met with staff once a week, for the
first 3 weeks. Thereafter, they met once a month to monitor and progress the exercise
programme, in terms of walking and resistance intensity. A weekly telephone call was
made by the program co-ordinator.
• Both groups performed 2 resistance training sessions and 3 aerobic training
sessions per week. The aerobic exercise mode was walking (30 minutes per session) for
both groups. For the gym-exercise group, resistance exercises targeted muscle groups of
the chest, back, upper extremities, abdomen, and lower extremities. Weight training
exercises were performed mainly with weight training machines, and when participants
experienced difficulty with the machines, free weights were used. The resistance
exercise component for the home group was provided via elastic bands (Theraband)
and consisted of exercises targeting the chest, back, upper extremities, abdomen, and
lower extremities muscle groups.
• Intensity of exercise: Gym-exercise group, aerobic: walking at 60% to 80%
HRmax (220-age); resistance, 2 to 3 sets of 10 to 15 reps at 13 to 15 RPE (on 6 to 20
scale). Home-exercise group, aerobic: walking at 12 to 16 RPE (6 to 20 scale);
resistance, 2 to 3 sets of 10 to 15 reps at 13 to 15 RPE (on 6 to 20 scale).
Adherence:
• Gym-based exercise: Participation in aerobic sessions ranged from 19 to 54 (a
mean of 37 sessions), for a percentage of participation ranging from 24% to 69%.
Participation in strengthening sessions ranged from 12 to 46 (a mean of 33 sessions),
for a percentage of participation ranging from 23% to 88%.
• Home-based exercise: Endurance participation ranged from 27 to 69 sessions
completed (a mean of 55 sessions); percentage of participation ranged from 35% to
88%.
• Participation in strengthening sessions ranged from 18 to 57 (a mean of 45
sessions); percentage of participation ranged from 35% to over 100%.
9 participants assigned to control:
• The control group continued receiving usual care provided by their physicians. At
the end of their participation in the study, control group participants were offered an
orientation session on the benefits of participating in an exercise programme, along
with exercise brochures for home exercises and elastic bands.
Outcomes Outcome:
• 12-Minute walk test used to assess cardiorespiratory fitness
• Handgrip strength examined with a handheld dynamometer. Participants were
evaluated in a seated position, with the arm resting at the side and the elbow flexed at
90° and the forearm in mid-position between pronation and supination.
• BMI measured as an outcome
• Spanish version of FACT-B also administered to assess quality of life
171Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Portela 2008 (Continued)
• Function measured via the DASH questionnaire
• Shoulder flexion, abduction, and external rotation examined through goniometry
• Volumetric measurements collected to monitor the development of lymphoedema
with a volumetric oedema gauge; water displacement volumetry included to provide an
estimate of volume of the upper extremity; volumetric measurements of the entire arm
collected with the participant in a seated position
Numbers of participants assessed:
• Gym-based exercise: baseline, 16; at 13 weeks and post intervention, 12
• Home-based exercise: baseline, 19; at 13 weeks and post intervention, 13
• Control: baseline, 9; at 13 weeks and post intervention, 9
Adverse events:
• None of the women had lymphoedema before enrolment in the study, and no
participant developed it during the course of the study. One participant developed an
asthma episode during the 12-minute walk test at baseline evaluation.
• Another participant had an episode of hypoglycaemia while at the gym during an
exercise session in the morning - the result of skipping breakfast.
• Three participants presented high blood pressure (above 140/90 mmHg) during
their participation in the exercise programmes.
• One participant from the gym-exercise group complained of severe headache at
the second evaluation session, after 3 months of participating in the programme
without any symptoms.
• One participant from the gym-exercise group complained of severe headache at
the second evaluation session, after 3 months of participating in the programme
without any symptoms.
• A participant in the gym-exercise group complained of foot pain before beginning
participation in the exercise programme. After the first exercise session, she commented
on increased pain, underwent foot surgery recommended by her podiatrist, and
decided not to continue in the study.
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: grant number 5P20RR011126 from the National Center for Research Re-
sources, a component of the National Institutes of Health
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation of participants was per-
formed by a computer-generated scheme
developed with the Statistical Analysis Sys-
tem
Allocation concealment (selection bias) Unclear risk Whether allocation was concealed is un-
clear.
Blinding of participants and personnel
(performance bias)
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
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All outcomes the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “One physical therapist, blinded to group
assignment, evaluated the participants in
this study. Participants were instructed not
to discuss their exercise programs or group
assignment with the evaluator”
Incomplete outcome data (attrition bias)
All outcomes
High risk Pre-post-test analysis was performed only
on those who completed all assessments.
No information regarding handling of
missing data was provided
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Rahnama 2010
Methods Study design: single-centre RCT
Number randomised: 32; intervention, not specified; control, not specified
Study start: not reported; stop date: not reported
Length of intervention: 15 weeks
Length of follow-up: to end of intervention
Country: Iran
Participants Age, years:
• 50 to 65
Stage: stage I-IIIB
Inclusion criteria:
• 50 to 65 years old
• Women who received surgery, chemotherapy, and radiotherapy and currently were
taking hormone therapy
• Stage I-IIIB
• No specific illness in the past 6 months
• No experience of a menstrual cycle
• No participation in exercise training or physical activity in the past 6 months




Interventions The number of participants assigned to the exercise intervention was not specified:
• Participants took part in supervised walking programme 2 times per week at 45%
maximum heart rate during weeks 1 to 5, 55% maximum heart rate during weeks 6 to
10, and 65% maximum heart rate during weeks 11 to 15. The duration of walking
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progressed from 25 minutes during weeks 1 to 5 to 35 minutes during weeks 6 to 10.
• Resistance training (60 minutes per session) was performed on different days from
walking and included 9 resistance training exercises performed on Cybex strength
training equipment (Smith press squats, leg press, leg extension, seated leg curl, lat
pull-downs) and with free weights (bench press, overhead press, biceps curls, and
triceps kickbacks).
Adherence: not reported
Number of participants assigned to control not specified:
• Control group participated in measurements only and were asked not to
participate in any physical activity or exercise training. All participants were asked to
avoid changes in dietary habits for weight loss purposes for the duration of the study.
Outcomes Outcomes:
• Weight, BMI, waist and hip circumferences
• Blood pressure measured with a Japanese sphygmomanometer model ALPK2 in
seated position
• Resting heart rate measured each morning with the heart rate monitor belt
• VO
max assessed by modified Bruce protocol
• Insulin measured by electrochemiluminescent immunoassay; glucose measured
with a hexokinase ultraviolet assay; insulin resistance calculated by the HOMA; LDL-
C and triglycerides measured enzymatically
Numbers of participants assessed:
• Intervention: baseline, not specified; at 15 weeks, 14
• Control: baseline, not specified; at 15 weeks, 15
Adverse events: not reported
Notes Trial registration link: none available




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described.
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All the measurements were obtained twice
and recorded by one staff that was blinded
to subjects in pre- and post-tests”
Incomplete outcome data (attrition bias)
All outcomes
High risk Three participants withdrew during the
study period; reasons for withdrawals were
not reported. No intention-to-treat analy-
sis was performed
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Rogers 2009
Methods Study design: single-centre RCT
Number randomised: 41; 21 to intervention, 20 to control
Study start: April 2006; stop date: July 2007
Length of intervention: 12 weeks
Length of follow-up: immediately post intervention and at 3 months post intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 52 (15)
• Control: 52 (8)
Stage, n (%):
• Intervention: stage I, 6 (29); stage II, 11 (52); stage III, 4 (19)
• Control: stage I, 6 (30); stage II, 10 (50); stage III, 4 (20)
Inclusion criteria:
• English-speaking female breast cancer survivors between the ages of 18 and 70 years
with a diagnosis of stage I, II, or IIIA disease
• Currently taking aromatase inhibitors or selective estrogenic receptor modulators and
expected to remain on hormonal therapy for the duration of the study (i.e. ≥ 8 months)
Exclusion criteria:
• Diagnosis of dementia or organic brain syndrome
• Medical, psychological, or social characteristic that would interfere with ability to fully
participate in programme activities and assessments (e.g. psychosis, schizophrenia)
• Contraindication to participation in a regular physical activity programme (e.g. unstable
angina, debilitating arthritis pain)
• Breast cancer recurrence or metastatic disease; inability to ambulate; planning to relocate
out of the study area during the 8-month study period
• Engaged in > 60 minutes of vigorous physical activity or > 150 minutes of moderate
plus vigorous activity per week during the past month (based on self-report)
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Interventions 21 participants assigned to exercise intervention:
• Behaviour change intervention with goal of gradually increasing all participants to
150 minutes of moderate walking per week
• 6 discussion group sessions with a clinical psychologist who encouraged social
support, provided breast cancer survivor exercise role models, and covered the
following topics: journaling, time management, stress management, dealing with
exercise barriers, and behaviour modification
• 12 individual supervised exercise sessions
• 3 individual “face-to-face” update counselling sessions with an exercise specialist
that tapered to a home-based programme by the end of the intervention
Adherence:
• Intervention participants completed 100% (252/252) of individual exercise
sessions, 95% (60/63) of individual update sessions, and 98% (123/126) of group
sessions, for an overall 99% adherence to all possible intervention sessions (435/441).
• Of 63 individual update sessions with exercise specialists, 4 (6%) were
administered by telephone rather than face-to-face owing to logistical reasons and
participant preference.
20 participants assigned to control:
• Control group was provided written materials related to physical activity obtained
from the American Cancer Society. These materials were considered “usual care”
because of their availability to the general public. No specific instructions were given to
the control group concerning physical activity behaviour change. Participants
randomised to the control group were given the opportunity to receive the intervention
at no charge once postintervention assessments were complete
Outcomes Outcomes:
• Physical activity assessed by GT1M accelerometer for 7 consecutive days.
Outcomes included total activity counts, total steps, and minutes of light, moderate,
hard, and very hard activity.
• Leisure time activity assessed via the Godin Leisure-Time Exercise Questionnaire.
Outcomes included were average weekly duration and frequency of light, moderate,
and vigorous leisure time activity for the past month. Reported duration was
multiplied by frequency to determine the minutes per week spent at each of the 3
intensity levels (light, moderate, and vigorous).
• Physical activity stage of readiness (i.e. stage of change) before learning about the
study and post intervention assessed on a previously validated scale
• Submaximal treadmill test based on the Naughton protocol with the endpoint of
85% of predicted maximal heart rate used to determine fitness on the basis of a
published regression equation estimating total oxygen cost of walking at the treadmill
grade and speed achieved
• Muscle strength assessed with a back/leg extensor dynamometer and handgrip
dynamometer. The maximum reading (best of 3 efforts) provided the absolute strength
measure in kilograms.
• Anthropometric measures including BMI and waist and hip circumferences
measured on a non-stretching tape measure, with the participant standing with
abdomen relaxed and arms at sides. At each testing, 3 measurements were obtained and
results averaged before calculation of the waist-to-hip ratio.
• DEXA performed using a Lunar Prodig to determine percentage body fat and
176Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rogers 2009 (Continued)
bone mineral density
• Perceived health assessed by asking participants to rate their general health on a 5-
point Likert scale from 1 = poor to 5 = excellent. Participants were asked to report the
number of sick days missed from work in the past month by completing a single fill-in-
the-blank question.
• Based on the sum of 5-point Likert scales, quality of life measured with the 37-
item FACT-B
• 13-Item FACT-F, 19-item FACT - Endocrine Symptoms (FACT-ES), and 42-
item FACT - Cognitive (FACT-Cog) used to assess fatigue, endocrine symptoms, and
cognitive function, respectively
• Sleep dysfunction assessed via the PSQI with scoring according to the published
protocol so that a higher score indicates greater sleep dysfunction (i.e. habitual sleep
efficiency, sleep latency, sleep duration, subjective sleep quality, use of sleeping
medication, daytime dysfunction, and global score). Owing to limited survey space, the
sleep disturbances subscale was not included, requiring that the global score be
obtained by obtaining the sum of 6 rather than the usual 7 domains.
• Joint pain, stiffness, and physical function assessed by the 5-point Likert scale
version (i.e. 1 = none to 5 = extreme) of the 24-item WOMAC, a measure of lower
extremity pain and function
Numbers of participants assessed:
• Intervention: baseline, 21; at 12 weeks, 20; at 6 months, 19
• Control: baseline, 20; at 12 weeks, 18 (19, DEXA); at 6 months, 17
Adverse events: No adverse events related to the intervention nor to other study proce-
dures occurred. The following non-serious, non-related events were recorded: wheezing
requiring physician valuation for asthma, cholinergic urticaria, herpes zoster, sinusitis,
back pain related to falling, and elective cosmetic reconstructive surgery
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no, but minimal loss to follow-up (n = 2)
Funding: Southern Illinois University School of Medicine Excellence in Academic
Medicine Award, Brooks Medical Research Fund, and Memorial Medical Center Foun-
dation Regional Cancer Center
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation was computer generated.
Allocation concealment (selection bias) Low risk “Randomization was kept in sealed en-
velopes until randomization to prevent bias
in group allocation by study personnel”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not mentioned whether study per-
sonnel and outcome assessors were masked
or blinded to study interventions
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up was minimal. Reasons for
exclusions were presented
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Rogers 2013
Methods Study design: single-centre RCT
Number randomised, 28; 15 to intervention, 13 to control
Study recruitment start: June 2008; recruitment stop date: April 2009
Length of intervention: 3 months
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 58.0 (6.1)
• Control: 53.7 (13.9)
Stage, n (%):
• Intervention: stage I, 10 (67); stage II, 4 (27); stage III, 1 (7)
• Control: stage I, 5 (39); stage II, 5 (39); stage III, 3 (23)
Inclusion criteria:
• Female
• Stage I, II, IIIA breast cancer survivors between the ages of 18 and 70 years
• Not currently receiving (and not planning to receive during the study duration) che-
motherapy or radiation therapy
• ≥ 8 weeks post surgery
• English speaking
• Medical clearance for participation provided by physician
Exclusion criteria:
• Dementia or organic brain syndrome
• Medical, psychological, or social characteristics that would interfere with ability to fully
participate in study activities (e.g. psychosis)
• Contraindication to participate in a regular physical activity programme
• Metastatic or recurrent disease
• Inability to ambulate
• Engaging in ≥ 60 weekly minutes of vigorous physical activity or ≥ 150 weekly minutes
of moderate plus vigorous activity during the past month (based on self-report)
• Anticipated elective surgery during the intervention that would interfere with partici-
pation (e.g. breast reconstructive surgery)
• Did not live or work within 50 miles of study site
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Interventions 15 participants assigned to exercise intervention:
• Behavioural change intervention towards increasing physical activity (150
minutes weekly) and resistance training (20 repetitions of 8 different exercises using
major muscle groups) over 6 months. Participants were tapered from supervised
sessions with an exercise specialist to non-supervised home-based exercise sessions
within the first 6 weeks of the intervention.
• Participants attended 6 group discussion sessions with a clinical psychologist
during the first 9 weeks. They also met with exercise specialists for face-to-face updates
of their physical activities every 2 weeks during the final 6 weeks of the intervention.
Adherence:
• The 14 participants completing the intervention attended 100% supervised
exercise with exercise specialist (168/168), 100% of update sessions with exercise
specialist (42/42), 73% of group sessions (61/84), and 87.5% of resistance exercise
sessions (21/24).
• Adherence to aerobic physical activity (based on accelerometer): Improvement was
noted in weekly minutes of moderate-intensity physical activity for the intervention
group vs the usual care group (i.e. 45.4 vs 37.7; mean between-group difference = 83.1;
effect size (d) =.76; P = .097). At M3, the mean for moderate-intensity physical activity
in the intervention group was 198.4 ± 111.7 minutes per week.
• With regard to resistance training, the 12 participants in the intervention group
providing M3 data completed 21 of 24 possible resistance exercise sessions over the 12-
week period (87.5%) and reported a weekly average of 1.8 sessions per week. During
the final 4 weeks of the intervention, intervention participants completed 5 of the 8
sessions (63%; weekly average = 1.3 sessions).
13 participants assigned to control:
• Control group received written materials from the American Cancer Society,
which included general information about physical activity and diet after cancer
diagnosis but no specific recommendations regarding exercise behaviour. Participants
were told that they could receive the intervention free of charge at completion of the
study.
Outcomes Outcomes:
• Adherence to intervention physical activity recommendations measured with 7-
day MTI/ActiGraph accelerometer monitoring (aerobic) and exercise log (resistance)
• Submaximal treadmill test based on the Naughton protocol for estimated fitness
• Muscle strength measured with a back/leg dynamometer
• Body composition (BMI, waist-to-hip ratio, body fat percentage via bioelectric
impedance (i.e. Quantum X by RJL Systems), in a standardised fashion (i.e. same time
of day for each measurement after a 4-hour fast)
• Pro-inflammatory and anti-inflammatory cytokines: 5 cytokines - IL-1 beta, IL-6,
IL-8, IL-10, and TNF-alpha - measured by the MILLIPLEX MAP human high-
sensitivity cytokine assay. Total adiponectin measured via adipokine MILLIPLEX panel
A, leptin via MILLIPLEX adipokine panel B (HADK2-61K), and high-molecular-
weight adiponectin via an ELISA kit
• Fatigue via FSI
• Self-reported sleep dysfunction measured on the PSQI, which was scored
according to the published protocol (i.e. higher score indicates greater sleep
dysfunction)
• Sleep latency and efficiency measured objectively with the same accelerometer
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used in measuring physical activity by transferring to the wrist when in bed.
Participants recorded time in and out of bed on a record sheet.
Numbers of participants assessed:
• Intervention: baseline, 15; at 3 months, 14
• Control: baseline, 13; at 3 months, 12
Adverse events: Three adverse events were identified - 2 related and non-serious in the
intervention group, and 1 non-related and serious in the control group
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00640666
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: Simmons Cancer Institute at Southern Illinois University School of Medicine
Translational Research Award. Drs. Rogers, Hopkins-Price, Vicari, Rao, and Verhulst re-
ceive salary support from National Cancer Institute Grant 1R21CA135017. Drs. Rogers,
Hopkins-Price, Vicari, and Verhulst also receive salary support from National Cancer
Institute Grant 5R01CA136859. Dr. Courneya is supported by the Canada Research
Chairs Program and National Cancer Institute Grant 5R01CA136859
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomization was based on computer
generated numbers, performed in blocks of
4, and revealed in the order in which par-
ticipants completed baseline testing”
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk “All assays were performed by an inves-
tigator blinded to the experimental treat-
ment”. Other outcome assessment blind-
ing was not described
Incomplete outcome data (attrition bias)
All outcomes
High risk Data analysis was based only on study par-
ticipants completing both baseline and 3-
month follow-up. 8 participants were ex-
cluded
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
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Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Rogers 2014
Methods Study design: single-centre RCT
Number randomised: 46; 22 to intervention, 24 to control group
Study start: not reported; stop date: not reported
Length of intervention: 3 months
Length of follow-up: to end of intervention
Country: USA
Participants Baseline data available for 20 intervention and 24 control participants:
Age, years (mean SD):
• Intervention: 57.2 (5.5)
• Control: 55.2 (9.1)
Stage, n (%):
• Intervention: DCIS, 3 (15.0); stage I, 10 (50.0); stage II, 7 (35.0)
• Control: DCIS, 5 (20.8); stage I, 11 (45.8); stage II, 8 (33.3)
Inclusion criteria:
• Female
• 30 to 70 years of age, ductal carcinoma in situ (DCIS), stage I or II breast cancer
• At least 4 weeks status post final primary treatment administration (longer-term ther-
apies such as aromatase inhibitors, oestrogen receptor modulators allowed)
• ≥ 8 weeks post surgical procedure
• English speaking
• Medical clearance for participation provided by physician
• Postmenopausal
• Average fatigue over the past week rated as ≥ 3 on a 1 to 10 Likert scale, or sleep
dysfunction ≥ 1 on a 0 to 3 Likert scale
• Willingness to abstain from “as needed” medications for 7 days before each blood draw
Exclusion criteria:
• Metastatic or recurrent breast cancer
• Inability to ambulate without assistance
• Unstable angina
• New York Heart Association Class II, III, or IV congestive heart failure
• Uncontrolled asthma
• Interstitial lung disease
• Current use of steroids
• Having been told by a physician to do only exercise prescribed by a physician
• Dementia or organic brain syndrome
• Schizophrenia or active psychosis
• Connective tissue or rheumatological disease (i.e. systemic lupus erythematosus,
rheumatoid arthritis, amyloidosis, Reiter’s syndrome, psoriatic arthritis, mixed connec-
tive tissue disease, Sjögren’s syndrome, progressive systemic sclerosis, CREST syndrome,
polymyositis, dermatomyositis, vasculitis, polymyalgia rheumatic, temporal arteritis)
• Participating, on average, in more than 20 minutes of physical activity on 2 or more
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days per week during the past 6 months
• Elective surgery planned to occur during the time of the intervention that would
interfere with intervention participation (e.g. breast reconstructive surgery)
• Living or working > 50 miles from study site
• Lack of transportation to study site
• Changes in usual medications expected during the study time period
• Planning to move residence out of the local area during the 5 months of study partici-
pation
• Planning to travel out of the local area for vacation during the first 4 weeks of the
intervention, or planning to travel out of the local area for longer than a week during
the last 8 weeks of the intervention
• Contraindication to participation in exercise (i.e. moderate-intensity walking and
strength training with resistance bands)
Interventions 22 participants allocated to exercise intervention:
• Aerobic component: Participants were gradually advanced by week 9 to 40-minute
bouts of moderate-intensity (i.e. 48% to 52% of heart rate reserve) walking 4 times per
week with no more than 1 day between bouts (e.g. exercise on Monday, Wednesday,
Thursday, Saturday each week, exercise on Tuesday, Wednesday, Friday, Sunday each
week), resulting in a total weekly goal of 160 aerobic minutes. Participants attended 26
individual supervised exercise sessions with an exercise specialist (3 per week for first 2
weeks and 2 per week for last 10 weeks). Participants were also instructed to exercise at
home (2 walking sessions per week in last 10 weeks of the intervention).
• Resistance component: Resistance training occurred twice weekly during the same
sessions as supervised aerobic walking (e.g. Monday/Thursday, Tuesday/Friday). The
strength of resistance bands was advanced as tolerated at intervals ≥ 2 weeks. Eight
different resistance exercises focussed on the major muscle groups were included, with
up to 2 sets of 15 repetitions per exercise.
• Behavioural component: To improve adherence, behavioural support was
provided at 6 group meetings with a clinical psychologist or psychology intern under
the supervision of a clinical psychologist (every other week) based on a prior successful
behaviour change intervention. Intervention participation occurred in cohorts or
“waves” to enhance social support provided by group meetings.
Adherence (based on session record sheets):
• Aerobic component: 91%
• Resistance component: 93%
24 participants assigned to control:
• Control group was instructed not to change exercise behaviour beyond what they
were doing at the time of study enrolment.
Outcomes Primary outcome:
• Physical activity assessed by MTI/Actigraph accelerometer
Other outcomes:
• Cancer-related fatigue (intensity) and interference assessed with the FSI
• General fatigue assessed by the Patient Reported Outcomes Measurement
Information System (PROMIS)
• Diet via 3-day diet record
• Cardiorespiratory fitness measured by submaximal treadmill testing based on a
modified Naughton protocol
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• Body composition assessed by bioelectrical impedance, BMI, and waist-to-hip
ratio
• Extensor leg strength measured by back and leg dynamometer
• IL-6, IL-8, IL-10 and TNF-alpha cytokines measured by high sensitivity human
cytokine assay
• Depression and anxiety assessed via PROMIS
• Self-reported sleep disturbance assessed by the PSQI
• Self-reported sleep assessed with PROMIS
• Sleep latency measured via accelerometers (Actigraph)
Numbers of participants assessed:
• Intervention: baseline, 22; at 3 months, 19
• Control: baseline, 24; at 3 months, 23
Adverse events:
• No serious adverse effects occurred.
• Of the non-serious adverse effects:
◦ 2 participants in the intervention group had a modification of their
resistance training programme due to ongoing pre-existing lymphoedema.
◦ 2 participants in the intervention group broke their wrist as the result of a
motor vehicle accident and had a new breast lump with negative mammography.
◦ 2 participants in the control group experienced high blood pressure during
treadmill fitness testing.
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT01147367
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: supported by National Cancer Institute R21CA135017
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “randomization in blocks of four based on
computer generated numbers”
Allocation concealment (selection bias) Low risk “Participants were randomized in the or-
der in which they completed baseline test-
ing. Randomization numbers were kept in
sealed, opaque envelopes so that study staff
and participants were unaware of group al-
location until all baseline testing was com-
plete”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physical measures were obtained by indi-
viduals who were blinded to participants’
study group allocation
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Incomplete outcome data (attrition bias)
All outcomes
High risk “Intent-to-treat analysis was performed (i.
e. differences between the study groups
were assessed with all data regardless of the
participant’s adherence to the exercise in
the intervention group or self-initiation of
exercise in the control group)”
However, only participants with follow-up
data were included in analysis (4 partici-
pants were excluded)
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Rogers 2015
Methods Study design: multi-centre RCT
Number randomised: 222; 110 to intervention, 112 to control
Study start: January 2010; stop date: September 2013
Length of intervention: 3 months
Length of follow-up: at 3 months
Country: USA
Participants Age, years (mean SD):
• Intervention: 54.9 (9.3)
• Control: 53.9 (7.7)
Stage, n (%):
• Intervention: stage DCIS, 13 (11.8); stage I, 47 (42.7); stage II, 37 (33.6); stage
III, 13 (11.8)
• Control: stage DCIS, 12 (10.7); stage I, 46 (41.1); stage II, 41 (36.6); stage III,
13 (11.6)
Inclusion criteria:
• Women aged 18 to 70 years with history of ductal carcinoma in situ (DCIS) or stage I-
IIIA breast cancer who were not currently receiving or planning to receive chemotherapy
or radiation therapy
• C8 weeks post surgical procedure
• English speaking
• Medical clearance for participation provided by physician
• Participating, on average, in 30 minutes of vigorous physical activity or 60 minutes of
moderate activity per week during the past 6 months
Exclusion criteria:
• Dementia or organic brain syndrome
• Disorders that would interfere with ability to fully participate in assessments and BEAT
Cancer activities (e.g. psychosis, schizophrenia)
• Contraindication to participation in regular physical activity
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• Metastatic or recurrent breast cancer
• Inability to ambulate
• Elective surgery anticipated during the intervention that would interfere with partici-
pation (e.g. breast reconstructive surgery)
• Travel plans interfering with scheduled study sessions
• Participating in another exercise study
Interventions 110 participants assigned to exercise intervention:
• 3-Month BEAT Cancer intervention included 12 supervised exercise sessions
(aerobic walking on the treadmill) with a trained exercise specialist, which were tapered
over the first 6 weeks to an exclusively home exercise programme.
• Duration of individual sessions starting at 15 to 25 minutes during week 1, to 30
to 50 minutes by week 7 (intensity: week 1, 40% to 59% of heart rate reserve, 10-point
RPE = 1.5 to 3; week 7, 40% to 59% of heart rate reserve, 10-point RPE = 3.5 to 5.5).
• Frequency starting with 3 weekly exercise sessions during week 1, to 150 minutes
weekly of moderate-intensity physical activity by week 7 (i.e. ≥ 3 weekly sessions)
• During the second 6 weeks of the intervention, participants attended a face-to-
face update counselling session with the exercise specialist every 2 weeks.
• Participants also attended 6 discussion group sessions led by trained facilitators
during the first 9 weeks of the intervention.
Adherence:
Adherence to planned BEAT Cancer components was 98% for supervised exercise ses-
sions, 96% for update sessions, and 91% for discussion group sessions. Only 5 BEAT
Cancer participants did not receive the allocated intervention (i.e. did not complete 75%
of all intervention components combined)
112 participants assigned to control:
• Usual care participants received printed American Cancer Society materials
describing physical activity recommendations for cancer survivors (e.g. Living Smart:
The American Cancer Society’s Guide to Eating Healthy and Being Active). No additional
instructions regarding physical activity were provided with the materials.
Outcomes Primary outcome:
• Weekly minutes of ≥ moderate-intensity physical activity assessed by the MTI/
Acti-Graph accelerometer (models GT1M and GT3X)
Other outcomes:
• Godin Leisure-Time Exercise Questionnaire, which assesses volitional, leisure
time physical activity (minutes of ≥ moderate-intensity physical activity)
• Aerobic fitness measured by a submaximal treadmill test and modified Naughton
protocol
• Quality of life measured via FACT-B
Numbers of participants assessed:
• Intervention: baseline, 110; at 3 months, 106; at 6 months, 105
• Control: baseline, 112; at 3 months, 110; at 6 months, 108
Adverse events: Only 1 related serious adverse event occurred (intervention group; pelvic
stress fracture). Related expected adverse events in the BEAT Cancer group included
back or lower extremity musculoskeletal pain or injury (n = 14), heart rate monitor rash
(n = 1), fall while walking (n = 1), breast reconstruction (n = 3), and chest pain during
treadmill fitness testing (n = 1). Related adverse events in the UC group included arm
tingling (n = 1) during the treadmill test and knee tendonitis (n = 1)
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Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: yes
Funding: supported by National Cancer Institute R01CA136859
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation, based on computer-gener-
ated numbers, is performed in blocks of 4
within each site to facilitate equal distribu-
tion between the 2 study groups at each site
Allocation concealment (selection bias) Low risk Computer generated numbers for each site;
numbers were placed in sealed, opaque en-
velopes and were delivered to the collabo-
rating site with a written protocol for use
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Assessment tools are administered … by
an exercise specialist (blinded to the partic-
ipant’s study group allocation) in the exer-
cise laboratory”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “All analyses were intention-to-treat with
all data available being used”
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Saarto 2012
Methods Study design: single-centre RCT
Number randomised: 573; 302 to intervention, 271 to control
Study start and stop dates: enrolment between September 2005 and September 2007
Length of intervention: 12 months
Length of follow-up: at 6 and 12 months (end of intervention) after baseline
Country: Finland
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Participants Age, years, at baseline, mean (range):
• Intervention: 52 (36-68)
• Control: 52 (35-68)
Stage:
• All stage T1-4, N0-3, M0 (i.e. stage I to IIIC)
Inclusion criteria:
• Histologically confirmed newly diagnosed invasive breast cancer (T1-4 N0-3 M0)
• Pre- and postmenopausal women treated with adjuvant chemotherapy or radiation
therapy within last 4 months
• Started endocrine therapy (anti-oestrogens, aromatase inhibitors, luteinising hormone-
releasing hormone agonists, or a combination) no more than 4 months earlier
• 35 to 68 years old
• Signed informed consent before the start of protocol-specific procedures
Exclusion criteria:
• Male gender
• Prior malignancy except basal cell carcinoma or in situ carcinoma
• Hematogenous metastases (M1)
• Systemic adjuvant therapy
• Postmenopausal women with anti-oestrogens as the only adjuvant treatment (with or
without radiation therapy)
• Pregnancy or recent lactation (< 1 year)
• Severe cardiac disease (NYHA Class III or greater)
• Myocardial infarction within 12 months
• Uncontrolled hypertension
• Verified osteoporosis (proximal femur or lumbar spine T-score < -2.5 or fracture without
trauma)
• Concomitant medications affecting calcium and bone metabolism such as bispho-
sphonates, calcitonin, parathyroid hormone, selective oestrogen receptor modulators,
oral corticosteroids (over 6 months), anticonvulsants (phenytoin, carbamatsebin), and
prolonged heparin therapy
• Other diseases affecting calcium and bone metabolism such as hyperthyroidism, newly
diagnosed hypothyroidism, primary hyperparathyroidism, renal failure, chronic hepatic
diseases, organ transplant
• Residency more than 1 hour from the exercise centre
• Competitive athlete
• Treated only with radiation therapy
• Incapable of training (e.g. severe cardiac disease, osteoporosis, severe knee arthrosis,
ligament or cartilage injuries at lower extremities)
• Other serious illness or medical condition, which could be a contraindication to exercise
Interventions 302 participants assigned to a 2-component supervised 12-month exercise training in-
tervention, with each component performed in alternate weeks. Components included:
• On alternate weeks, the effective part of guided training was based on step aerobics
or circuit training. In total, the planned 60-minute weekly exercise programme was
intended to consist of supervised training sessions and 2 to 3 home training sessions.
• Step aerobics consisted of 150 to 180 jumps and leaps in diverging directions,
progressing from 10-cm high benches to 15-cm benches after 4 months, and to 20-cm
benches after 8 months. Music was set at 118 beats per minute.
• Circuit training started with 100 steps and hops per session and progressed to 150
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to 180 steps and hops per session, with more demanding jumps in the later phase. The
session started with a 20-second training period followed by a 60-second rest, and
progressed to a 40:60 second training/rest ratio, then a 30:60 second ratio with more
demanding jumps such as heel drops, star jumps, and skate jumps.
• The home training session consisted of about 100 leaps and jumps similar to
those employed in the circuit training programme. In addition, endurance training
(walking, cycling, swimming, etc.) performed at the same RPE was recommended to
complement the home trainiIng session in terms of total duration.
• Mostly aerobic with some anaerobic activity. Intensity of exercise for first 2 weeks
was moderate (RPE = 11), and intensity was increased gradually from moderate to
somewhat hard or hard levels (RPE = 14 to 16) during the 12-week exercise period.
Adherence:
Premenopausal trainees attended a median of 30/52 (58%) supervised training sessions:
• 6/124 (5%) did not attend any training; 23/124 (18%) attended < once a month;
78/124 (63%) attended at least every second week (i.e. > 25 times). Based on 109
returned training diaries, premenopausal participants completed home training on
average 2.8 times weekly for a total time of 2.9 hours. The median total number of
training sessions (supervised and home training sessions together) was 3.3 times per
week (interquartile range 2.4 to 4.6).
Postmenopausal trainees attended a median of 33/52 (63%) training sessions:
• 2/138 (< 2%) did not attend any session; 27/138 (20%) attended sessions < once
a month; 96/138 (70%) attended at least every second week. Based on 122 returned
training diaries, postmenopausal participants completed home training on average 3.2
times (107%) weekly for a total time of 3.5 hours. The median total number of
training sessions was 4.3 times per week (interquartile range 2.3 to 5.4).
271 participants assigned to control:
• Usual care
Outcomes No primary outcome was identified.
Physical outcomes:
• Cardiorespiratory fitness assessed via 2-km walk (minutes)
• Dynamic neuromuscular performance assessed by figure-8 running test (seconds)
• Physical activity collected via a recalled questionnaire (MET-h per week)
• Body composition assessed via DEXA (fat mass, lean mass)
• Bone density assessed via DEXA (total bone mineral content, lumbar spine and
femoral neck bone mineral density)
In subsample study of 86 participants (37 intervention and 40 control):
• Countermovement jump force assessed via force plate
• Maximal isometric muscle force of leg extension via isometric leg press
• Maximal isometric grip strength via isometric hand dynamometer
• Body composition via DEXA (fat percentage)
• Left distal tibia and tibial midshaft bone mineral content via pQCT scan
QoL outcomes:
• QoL measured by EORTC QLQ-C30
• Fatigue measured with FACIT-F scale
• Depression measured via BDI
Numbers of participants assessed:
• Intervention: at baseline, 302; at 12 months, 262
• Control: at baseline, 271; at 12 months, 236
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Numbers of participants assessed in subsample study:
• Intervention: at baseline, 37; at 12 months, 30
• Control: at baseline, 40; at 12 months, 37
Adverse events: none reported
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00639210
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: Finnish Cancer Institute; Finnish Cancer Foundation; Academy of Fin-
land; Social Insurance Institution of Finland; Finnish Ministry of Education; Finska
Läkaresällskapet; Special government grant for health science research; Helander Foun-
dation; Gyllenberg Foundation; Paulo Foundation; Kurt and Doris Palander Founda-
tion; Finnish Cultural Foundation and Medical Fund of the Pirkanmaa Hospital Dis-
trict; Finnish AstraZeneca-sponsored step benches for the study; Finnish Breast Cancer
Group
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A computer-generated randomisation
schedule was used to allocate patients”
Allocation concealment (selection bias) Low risk “Study nurse performed randomisation af-
ter baseline visit”.
“randomisation was centralised”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “examiner blinded”
Incomplete outcome data (attrition bias)
All outcomes
High risk Incorrect ITT; “Analyses were performed
on an intention-to-treat basis for all partic-
ipants who completed the baseline and at
least one follow-up measurement”
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
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Methods Study design: single-centre RCT
Number randomised: 86; 43 to intervention, 43 to delayed exercise control
Study start: October 2001; stop date: June 2002
Length of intervention: 6 months
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 53.3 (8.7)
• Control: 52.8 (7.6)
Stage, n (%):
• Intervention: stage 0, 7 (18); stage I, 6 (26.1); stage II, 13 (56.5); stage III, 3 (13)
• Control: stage 0, 1 (4.4); stage I, 7 (30.4); stage II, 13 (56.5); stage III, 2 (8.7)
Inclusion criteria:
• Completed all treatment except hormonal therapy for breast cancer
• Body weight stable within 10% over the past year
• Non-smoker for at least the past 2 years
• Sedentary to moderately physically active (no more than 3 sessions per week of no
more than moderate-intensity activity; no weight training history)
Exclusion criteria:
• Medical condition prohibiting participation in a weight training programme
• Morbidly obese (BMI > 40 kg/m²)
• Hypertensive (systolic blood pressure > 160 mmHg, diastolic blood pressure > 99
mmHg, or both)
• Currently on a weight loss plan or planning to start a weight loss plan during the period
of the study
• Planning to move away from the area or to be away from the area for > 3 weeks during
study
• Not pregnant or lactating, and not planning to become pregnant during the study
period
Interventions 43 participants assigned to exercise intervention:
• Resistance training was performed twice weekly for 6 months. Each 60-minute
session consisted of 9 common weight training exercises with variable resistance
machines and free weights (for muscles of the chest, back, shoulders, arms, buttocks,
hips, and thighs).
• Stretching exercises were performed before and after each weight training session.
• Participants were asked to make no changes in other elements of their exercise
programme (e.g. walking, bicycling, swimming) while incorporating weight training.
Adherence:
• From baseline to 6 months: 1 participant attended < 80% of sessions.
• From months 7 to 12: 14 exercise group participants attended < 70% of sessions.
43 participants assigned to control:
• Wait-list
Outcomes Primary outcomes:
• Baecke Questionnaire given to assess participant physical activity outside of the
weight training protocol
• Cancer Rehabilitation Evaluation System - Short-Form (CARES-SF), which
includes 59 items and 5 subscales for physical, psychosocial, medical interaction,
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marital, sexual, and other miscellaneous subscales. Items assessed on a 5-point Likert
scale (0 = “not at all”, 1 = “a little”, 2 = “a fair amount”, 3 = “much”, 4 = “very much”)
that queries the applicability of the problem/statement to the participant within the
last month. Items of CARES-SF are combined into a global summary score. Both
global summary score and individual subscale scores range from 0 to 100; lower scores
indicate fewer problems.
• Anthropometric measurements including waist circumference, body weight, and
height
• DEXA (used to measure body composition), in addition to a skin pinch meter/
scale
• Upper (bench press) and lower body strength (leg press) assessed by 1-repetition
maximum (1RM)
• Depressive symptoms measured with the CES-D, a 20-item questionnaire scored
on a standard 4-point scale (0 to 3) for each item, with a potential range of 0 to 60
• Fasting blood glucose and plasma insulin levels assessed by colourimetric
reflectance spectrophotometry and chemiluminescent immunoassay, respectively
• Insulin resistance measure used in this study: the HOMA index
• ELISAs to assess IGF-I, IGF-II, IGFBP-1, IGFBP-2, and IGFBP-3
• Lymphoedema measured 3 ways: arm circumference measurements, self-report of
diagnosis, self-report of symptoms
Numbers of participants assessed:
• Intervention: baseline, 43; at 6 months, 38
• Control: baseline, 43; at 6 months, 40
Adverse events: cancer recurrence: 4 in total - 2 each in intervention and control groups;
some limited musculoskeletal issues that were self-resolving
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: Susan G. Komen Foundation, grants to the UMN GCRC from the NIH
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Random number table”
Allocation concealment (selection bias) Low risk “The randomization procedure used pre-
vented investigators from influencing treat-
ment allocation”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Physiological measures were taken by
trained staff blinded to participant status,
with the exception of strength measures
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Incomplete outcome data (attrition bias)
All outcomes
High risk 4 participants were lost to follow-up in the
intervention group - 2 for recurrences and 2
as the result of withdrawals; 3 participants
were lost to follow-up in the control group
- 2 for recurrences and 1 as the result of
withdrawal; none of these were included in
analyses
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Schmitz 2009
Methods Study design: single-centre RCT
Number randomised: 295; 148 (71 with lymphoedema and 77 without lymphoedema)
to the intervention, 147 (70 with lymphoedema and 77 without lymphoedema) to
control
Study start: October 2005; stop date: August 2008
Length of intervention: 12 months
Length of follow-up: to end of intervention
Country: USA
Participants Age, for women with lymphoedema, years (mean SD):
• Intervention: 56 (9)
• Control: 58 (10)
Age, for women without lymphoedema, years (mean SD):
• Intervention: 54 (8)
• Control: 56 (8)
Stage, for women with lymphoedema, n (%):
• Intervention: DCIS, 0 (0); stage I, 33 (46); stage II, 1 (1); stage III, 22 (31);
unknown, 15 (31)
• Control: DCIS 0 (0); stage I, 24 (14); stage II, 0 (0); stage III, 22 (31); unknown,
24 (34)
Stage, for women without lymphoedema, n (%):
• Intervention: DCIS 1 (1); stage I, 43 (56); stage II, 8 (10); stage III, 25 (33)
• Control: DCIS 0 (0); stage I, 43 (56); stage II, 6 (8); stage III, 28 (3)
Inclusion criteria:
• Female
• History of unilateral non-metastatic breast cancer
• Body mass index (calculated as weight in kilograms divided by height in meters squared)
≤ 50
• Currently cancer free
• No medical condition that would limit participation in exercise
• No weight lifting during the year before study entry
• No plans for surgery or to be away for at least 1 month during the study
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• Currently weight stable and not actively trying to lose weight
Additional inclusion criteria, for women with lymphoedema:
• 1 to 15 years post diagnosis
• At least 1 lymph node removed
• Presence of lymphoedema
Additional inclusion criteria, for women without lymphoedema:
• 1 to 5 years post diagnosis
• At least 2 lymph nodes removed
• No prior lymphoedema diagnosis
• No evidence of current lymphoedema
Exclusion criteria for women with lymphoedema:
• Intensive therapy in the past 3 months
• Recorded 10% change in volume or circumference of affected arm in the past 3 months
for ≥ 7 days
• More than 1 lymphoedema-related infection requiring antibiotics (cellulitis) in the past
3 months
Interventions 148 participants (71 with lymphoedema and 77 without lymphoedema) assigned to the
exercise intervention, consisting of progressive strength (weight) training:
• Weight lifting intervention group received a 1-year membership to a community
fitness centre (YMCA). Resistance training was performed twice weekly (13 weeks
supervised and 13 weeks unsupervised).
• Each 90-minute session consisted of upper body exercises (seated row, supine
dumbbell press, lateral or front raise, biceps curl, and triceps push-down), which were
performed with dumbbells or variable resistance machines, and lower body exercises
(leg press, back extension, leg extension, and leg curl), which were performed with
variable resistance machines.
• Weight was increased for each exercise by the smallest possible increment after 2
sessions of 3 sets of 10 repetitions with no change in arm symptoms.
Adherence:
• For women with lymphoedema: Median attendance at weight lifting sessions was
88%.
• For women without lymphoedema: Median attendance at weight lifting sessions
was 79%.
147 participants (70 with lymphoedema and 77 without lymphoedema) assigned to
control:
• Wait-list control
• Requested not to change current level of exercise
Outcomes Outcomes:
• Physical activity outside intervention assessed with the IPAQ
• Muscular strength assessed by bench press and leg press
• Anthropometric measures, weight, BMI, and body fat %; fat mass and lean mass
via DEXA scan
• Body image measured on the Body Image and Relationship Scale
• QoL assessed with the MOS SF-36 version 2
• Diet assessed via the Diet History Questionnaire
• Lymphoedema-related outcomes (not included in this review): Primary outcome
was lymphoedema onset defined as a 5% or greater increase in arm swelling, which was
193Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Schmitz 2009 (Continued)
defined by interlimb water volume difference [(affected arm volume − unaffected arm
volume)/unaffected arm volume]. Water volume displacement was used to measure
arm volumes at baseline and at 12 months.
For women with lymphoedema, outcomes were measured as follows:
• Intervention: baseline, 71; at 1 year, 65
• Control: baseline, 70; at 1 year, 65
For women without lymphoedema, outcomes were measured as follows:
• Intervention: baseline, 77; at 1 year, 66
• Control: baseline, 77; at 1 year, 68
Adverse events among participants with lymphoedema:
• Eight musculoskeletal injuries reported. Cumulative incidence of musculoskeletal
injury in the weight lifting group was 10.2 (95% CI 9.4 to 11.1) per 100 breast cancer
survivors.
Adverse events among participants without lymphoedema:
• Two musculoskeletal injuries reported. Cumulative incidence of musculoskeletal
injury in the weight lifting group was 3.4 (95% CI 2.9 to 3.9) per 100 breast cancer
survivors.
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00194363
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: NIH/National Cancer Institute and the Public Health Services Research Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation sequence was a computer-gen-
erated minimisation scheme
Allocation concealment (selection bias) Low risk “...de-identified data for ... variables were
entered after completion of all baseline
measures, the study coordinator then called
participants to reveal the outcome of ran-
domization and to schedule groups for the
supervised groups”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Measurements obtained by “trained staff
who were unaware of the study-group as-
signments”
“Measurement staff (including CLTs) were
blinded to treatment allocation”
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Incomplete outcome data (attrition bias)
All outcomes
High risk No evidence suggests that missing data
were adequately and appropriate addressed
Large numbers of study participants with-
drew; 11 women without lymphoedema
withdrew from the intervention group and
9 women without lymphoedema withdrew
from the control group
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Segar 1998
Methods Study design: single-centre quasi-randomised partial cross-over controlled trial. Only
first treatment period included here
Number randomised: 30; 10 to exercise intervention, 10 to exercise and behavioural
intervention, 10 to control
Study start: not reported; stop date: not reported
Length of intervention: 10 weeks
Length of follow-up: at 12 weeks
Country: USA
Participants Age, years (mean SD):
• Intervention groups: 47.5 (7.1)
• Control group: 51.8 (8.1)
Stage, n (%):
• Intervention groups: not reported
• Control group: not reported
Inclusion criteria:
• Any type of breast cancer surgery
• 30 to 65 years old
• Not currently participating in exercise
• No contraindications to exercise
• Written release from the physician
Exclusion criteria:
• Cardiovascular or pulmonary disease
• Known physical disabilities
Interventions 10 participants assigned to exercise intervention:
• Request to exercise a minimum of 30 minutes at an intensity ≥ 60% of age-
predicted maximum heart rate on 4 days per week over 10 weeks, with type of exercise
(stationary bike, stair climbers, and hydraulic resistance exercise equipment) as chosen
by participant
10 participants assigned to exercise and behavioural modification intervention:
• Exercise as described for the exercise behavioural modification group by self-
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awarded rewards (activity, food, treats, or movies) to serve as reinforcements
Adherence:
• Overall compliance assessed from self-reported exercise logs averaged 1363 (SD
577) minutes over 10 weeks, where 100% compliance was equivalent to 1200 minutes.
• Compliance for participants reaching at least 89% averaged 1532 (SD 103)
minutes (mean compliance of 130%) with a range from 89% to 250%.
10 participants assigned to control:
• Instructions to maintain sedentary lifestyle
Outcomes Primary outcomes:
• Change in depressive symptoms measured by the 21-item BDI questionnaire,
with scale score ranging between 0 and 63. Higher score indicates greater depressive
symptoms.
• Change in anxiety symptoms measured with the STAI (20 items; 1 = not at all, 4
= very much so)
• Change in self-esteem measured by the RSE Inventory - a unidimensional 64-
item questionnaire with 10 scales that reflect self-evaluation of self-esteem
Time points of assessments: baseline, at 10 weeks
Numbers of participants assessed:
• Intervention: baseline, 16; at 10 weeks, 16
• Control: baseline, 8; at 10 weeks, 8
Reasons for missing data:
• Intervention: no missing data reported
• Control: no missing data reported
Adverse events: none reported
Subgroup analysis: none reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: no
Funding: Michigan Initiative for Women’s Health Grant
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk “Subjects were rotated sequentially into
two treatment conditions and one control
group”
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
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Blinding of outcome assessment (detection
bias)
All outcomes
High risk Study personnel and outcome assessors
were not masked or blinded to study inter-
ventions
Incomplete outcome data (attrition bias)
All outcomes
High risk 4 participants were excluded from the ex-
ercise group and 2 from the control group.
Exclusion from analyses occurred because
of attrition or non-compliance with the
study protocol
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Short 2014
Methods Study design: single-centre RCT
Number randomised: 330; 109 to intervention tailored-print, 110 to intervention tar-
geted-print, 111 to control
Study start: October 2010; stop date: October 2013
Length of intervention: 3 months
Length of follow-up: at 4 and 10 months post intervention
Country: Australia
Participants Age, years, mean (range):
• Intervention tailored-print: 56 (34-74)
• Intervention targeted-print: 55 (36-82)
• Control: 55 (33-75)
Stage, n (%):
• Intervention tailored-print: stage 0, 3 (2,9); stage I, 27 (26.5); stage II, 32 (31.4);
stage III, 23 (22.6); stage IV, 2 (1.9); stage unknown, 15 (14.7)
• Intervention targeted-print: stage 0, 3 (2,8); stage I, 22 (20.8); stage II, 45 (42.5);
stage III, 20 (18.8); stage IV, 1 (0.9); stage unknown, 15 (14.5)
• Control: stage 0, 1 (0.9); stage I, 25 (23.4); stage II, 36 (33.6); stage III, 26 (24.3)
; stage IV, 3 (2.8); stage unknown, 16 (14.9)
Inclusion criteria:
• Female breast cancer survivors over the age of 18
• Finished “active” cancer treatment (defined as surgery, chemotherapy, and/or radio-
therapy)
• Could read and write in English
Exclusion criteria:
• Not reported
Interventions 330 participants assigned to 2 different physical activity behavioural change interven-
tions:
• Intervention tailored-print: Participants received 3 social cognitive theory-based
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computer-tailored A4 4-page newsletters over a 12-week period (6 weeks apart).
Newsletters were iteratively tailored via personal physical activity and demographic,
psychosocial, and health-related information derived from individual assessments at
baseline; and physical activity and goal-setting information derived from “update
cards”, which were sent to participants via mail at 4 weeks and 8 weeks post baseline. If
participants’ update cards were not returned within 2 weeks, newsletters were printed
without iterative physical activity and goal-setting feedback. A recommendation was
provided to engage in aerobic PA of at least moderate intensity for 30 minutes or
longer most days of the week. Participants were also encouraged to perform resistance
training exercises 1 to 3 times per week. However, no specific instructions for resistance
training exercises were provided.
• IBntervention targeted-print: Participants received a copy of the 54-page (A5)
theory of planned behavior-based booklet Exercise for Health: An Exercise Guide for
Breast Cancer Survivors, which has been evaluated in a previous study. We made minor
changes to the guidebook to adapt it for an Australian audience (e.g. substituting
photos and text related to snow). A recommendation was provided to engage in aerobic
PA of at least moderate intensity for 30 minutes or longer most days of the week.
Participants were also encouraged to perform resistance training exercises (at least 6
exercises) 1 to 3 times per week. However, no specific instructions for resistance
training exercises were provided.
Adherence:
• Intervention tailored-print: change in % meeting aerobic guidelines (150
minutes/week) at 4 months vs baseline, +23.9%; mean (SD) resistance exercise score
(sessions*exercise) at 4 months: 13.5 (27.0)
• Intervention targeted-print: change in % meeting aerobic guidelines (150
minutes/week) at 4 months vs baseline, +12.5%; mean (SD) resistance exercise score at
4 months: 10.9 (27.4)
111 participants assigned to control:
• Received the brochure An Active Way to Better Health, describing national PA
guidelines for Australian adults
Outcomes Primary outcome:
• Self-reported minutes of physical activity (aerobic and resistance exercise)
measured by the adapted version of the LSI of the Godin Leisure-Time Exercise
Questionnaire
Other outcomes:
• Adherence to meeting PA guidelines for aerobic (150 minutes of aerobic activity
over at least 5 days of the week) and resistance-based (1 session per week containing at
least 6 exercises, based on the lower suggested threshold) activity, calculated on the
basis of participants’ self-reported PA
• Mean daily steps assessed via at least 3 days of pedometry and a step count diary
• Self-reported sitting time measured with a validated 5-item scale assessing sitting
time across 5 different domains on a weekday and on a weekend day
• Health-related quality of life measured by FACT-B version 4
• Fatigue measured via the FACIT-Fatigue scale
Numbers of participants assessed:
• Intervention tailored-print: baseline, 109; at 4 months, 98
• Intervention targeted-print: baseline, 110; at 4 months, 97
• Control: baseline, 111; at 4 months, 104
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Adverse events: not reported
Notes Trial registration link: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?
ACTRN=12611001061921
Trial authors contacted: no
Intention-to-treat analysis: yes, but LOCF
Funding: funded by the Cancer Institute New South Wales Research Scholar Award (10/
RSA/1-27 - Trial ID in Australian New Zealand)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated block randomisation
sequence”
Allocation concealment (selection bias) Low risk Sequence “implemented in a blinded fash-
ion by an administrative assistant not in-
volved in the project”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “All project team members were blinded to
this process until allocation was complete”
Incomplete outcome data (attrition bias)
All outcomes
High risk Inappropriate handling of missing data in
the analyses; “primary analysis was con-
ducted using all observed data, and sensitiv-
ity analyses using the baseline observations
carried forward approach were conducted
to explore the impact of missing data”
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
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Methods Study design: single-centre RCT
Number randomised: 80; 40 to intervention, 40 to control
Study start: September 2009; stop date: February 2010
Length of intervention: 8 weeks
Length of follow-up: to end of intervention
Country: Iran
Participants Age, years:
• Overall: Women aged 15 to 55 were eligible.
Stage, n (%):
• Overall: stage I-III
Inclusion criteria:
• Women with breast cancer stages I-III
• Aged 15 to 55 years
• Two years since completion of breast cancer-related treatment (except for hormone
therapy)
• Performance status 0 to 4 (as determined by ECOG scale of WHO)
Exclusion criteria:
• Evidence of disease recurrence
• Treatment with anticoagulants, signs of cardiac disease
• Underwent arrhythmia or MI
• Dementia or other psychotic condition
• Regular exercise 2 to 3 sessions per week in the past 6 months
Interventions 40 participants assigned to exercise intervention:
• Protocol included 3 phases of warm-up (containing warm-up and ballistic
exercises), heavy resistance training, and cooling down (containing cooling down and
ballistic exercises). Exercise sessions were conducted under the supervision and
guidance of a coach for each individual participant in this study.
• In the first 5 minutes, ballistic and stretching exercises were done to warm up. In
the next phase, participants slowly jogged on an electronic treadmill, which showed
their heart rate and calories consumed, for 7 minutes. They then pedaled a magnetic
stationary bike, equipped with an LCD to show heart rate and consumed calories, for
another 7 minutes. The intensity of participants’ exercise was controlled by the
maximum heart rate index. Therefore, participants exercised at 55% of intensity rate
for the first 2 weeks, 65% of intensity from weeks 3 to 6, and 75% of intensity from
weeks 7 to 8.
• After doing aerobic exercises and taking a rest, participants performed heavy
resistance training with a chest press machine, in 2 sets of 8 to 12 repetitions.
Adherence:
Not reported
40 participants assigned to control:
• No information provided
Outcomes Primary outcome:
• Standard instrument of quality of life for breast cancer survivors (National
Medical Center and Beckman Research Institute)
Numbers of participants assessed:
• Intervention: baseline, 40; at 8 weeks, not reported
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• Control: baseline, 40; at 8 weeks, not reported
Adverse events: not reported
Notes Trial registration link: none available
Trial authors contacted: no
Intention-to-treat analysis: unclear
Funding: Isfahan University of Medical Sciences
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “randomly divided into two groups of study
and control”; method not stated
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Numbers of participants included in
postintervention analyses were not pro-
vided
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Unclear risk Trial appears to be free of other problems
that could put it at high risk of bias
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Methods Study design: single-centre RCT
Number randomised: 337; 94 to print material intervention (PM), 94 to pedometer
intervention (PED), 93 to combination of print material and pedometers intervention
(COM), 96 to control
Study start: July 2005; stop date: April 2006
Length of intervention: 12 weeks
Length of follow-up: to end of intervention, at 6 months post intervention
Country: Canada
Participants Age, years, mean (range):
• PM: 57 (31-88)
• PED: 58 (34-75)
• COM: 58 (38-86)
• Control: 57 (37-90)
Stage, n (%):
• PM group: stage I, 53 (56.4); stage IIA, 26 (27.7); stage IIB, 11 (11.8); stage IIIA,
4 (4.3)
• PED group: stage I, 38 (40.4); stage IIA, 35 (37.2); stage IIB, 15 (16.0); stage
IIIA, 6 (6.4)
• COM group: stage I, 55 (59.1); stage IIA, 23 (24.7); stage IIB, 11 (11.8); stage
IIIA, 4 (4.3)
• Control: stage I, 48 (50); stage IIA, 27 (28.1); stage IIB, 13 (13.5); stage IIIA, 8
(12.0)
Inclusion criteria:
• Histologically confirmed stage I-IIIA breast cancer
• Physician approval
• Freedom from chronic medical and orthopaedic conditions that would preclude phys-
ical activity (e.g. congestive heart failure, recent knee or hip replacement)
• English as spoken language
• Completion of adjuvant therapy except hormone therapy
• Current absence of breast cancer
Exclusion criteria:
• None reported
Interventions 281 (PM, 94; PED, 94; COM, 94) participants assigned to three 12-week interventions:
• PM group received a copy of Exercise for Health: An Exercise Guide for Breast
Cancer Survivors.
• PED group received a Digi-Walker SW-200 pedometer and a 12-week step
calendar.
• COM group received both interventions (i.e. PM and PED).
• All groups received a standard recommendation to perform 30 minutes of
moderate-vigorous PA 5 days a week.
• Survivors meeting PA guidelines at baseline were encouraged to increase their PA
minutes per day and/or days per week.
Adherence to intervention materials immediately post intervention:
• Survivors in 2 groups that received PED as an intervention (i.e. COM and PED;
n = 187) recorded their pedometer steps on 83.3% (70 of 84) of study days. Survivors
in 2 groups that received PM (i.e. COM and PM; n = 163) reported reading the entire
PM an average of 2.1 times for an average of 113 minutes.
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• Retention for this study was 89.7% (338 of 377) and did not differ among groups.
Adherence to intervention materials at 6-month follow-up:
• Among survivors in the 2 groups that received a PED (COM and PED; N = 136),
38.5% (N = 52) reported that they continued to wear their PED during the 6-month
follow-up period. Survivors in the 2 groups that received PM (COM and PM; N =
127) reported reading the entire PM an average of 1.3 times for an average of 42
minutes during the 6-month follow-up period. 60% of survivors reported reading the
PM at least once, and 34% reported reading the PM for at least 30 minutes.
• Overall retention was 71% (266/377) at the 6-month follow-up time point and
did not statistically differ among groups.
96 participants assigned to control:
• Control group was given the standard recommendation to perform 30 minutes of
moderate-vigorous physical activity 5 days a week. Participants in this group wore a
pedometer only for baseline and postintervention assessments.
Outcomes Primary outcome:
• Self-reported moderate-vigorous physical activity between baseline and post
intervention (i.e. 12 weeks), assessed by the LSI of the Godin Leisure-Time Exercise
Questionnaire
Other outcomes:
• Self-reported QoL assessed by FACT-B
• Fatigue assessed on the Fatigue Scale from the FACT measurement system. On
QoL and fatigue scales, higher scores represent better QoL/fatigue or less severe
symptoms.
• Brisk walking assessed by the LSI of the Godin Leisure-Time Exercise
Questionnaire
• Objective step counts assessed via a 7-day step test with the Digi-Walker
pedometer
Numbers of participants assessed:
PM: baseline, 94; post intervention, 81; 6 months post intervention, 62
PED: baseline, 94; post intervention, 88; 6 months post intervention, 69
COM: baseline, 93; post intervention, 84; 6 months post intervention, 67
Control: baseline, 96; post intervention, 85; 6 months post intervention, 68
Adverse events: none reported
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00221221
Trial authors contacted: yes, additional data were received from trial authors
Intention-to-treat analysis: no
Funding: National Cancer Institute of Canada (NCIC) with funds from the Canadian
Cancer Society (CCS) and the CCS/NCIC Sociobehavioral Cancer Research Network
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated random numbers list
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Allocation concealment (selection bias) Low risk “A research assistant generated the group
assignments in sequentially numbered and
sealed opaque envelopes”
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk It was not mentioned whether study per-
sonnel and outcome assessors were masked
or blinded to study interventions
Incomplete outcome data (attrition bias)
All outcomes
High risk For all analyses, an intention-to-treat ap-
proach was employed with LOCF
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Waltman 2010
Methods Study design: multi-centre RCT
Number randomised: 249; 124 to intervention, 125 to control
Study start: not reported; stop date: not reported
Length of intervention: 24 months.
Length of follow-up: at 36 months
Country: USA
Participants Only baseline characteristics of sample completing the 24-month study period were
reported:
Age, years (mean SD):
• Overall: 58.7 (7.5)
• Intervention: age ≤ 60 y - n (%), 60 (55); age > 60 y - 50 (45)
• Control: age ≤ 60 y - n (%), 69 (61); age > 60 y - 44 (39)
Stage, n (%):
• Intervention: stage 0, 17 (14.2); stage I, 57 (47.5); stage II, 46 (38.3)
• Control: stage 0-III (proportions not reported)
Inclusion criteria:
• 35 to 75 years of age
• History of stage 0 (in situ), I, or II breast cancer
• BMD T-score of -1.0 or less at any of 3 sites (hip, spine, forearm)
• At least 6 months post breast cancer treatment and 12 months postmenopausal
• Residing within 100 miles of 1 of 4 research sites (Omaha, Lincoln, Kearney, and
Scottsbluff, NE)
• Physician’s permission to participate
204Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Waltman 2010 (Continued)
Exclusion criteria:
• Recurrence of breast cancer
• Currently taking hormone therapy, bisphosphonates, glucocorticosteroids, or other
drugs affecting bone
• Currently engaging in strength training exercises
• Body mass index ≥ 35
• Serum calcium, creatinine, or thyroid-stimulating hormone (if on thyroid therapy)
outside normal limits
• Active gastrointestinal problems or other conditions that prohibited strength training
exercises; risedronate, calcium, or vitamin D intake
Interventions 124 participants allocated to strength and weight training exercise interventions:
• Resistance component: Strength and weight training exercises for hip, spine, and
forearm were modified with permission from exercises in Nelson and Wernick’s (1997)
book entitled Strong Women Stay Young. For the first 32 weeks, participants exercised
twice weekly for 30 to 45 minutes in their homes; they were not to lift beyond 20-
pound hand or ankle weights because of safety concerns. After 32 weeks, participants
exercised using weight machines at a nearby fitness centre. Facilitative strategies, such
as education, feedback, and coaching-based on Bandura’s (1997) self-efficacy theory-
were used by both exercise trainers and research nurses during phone contacts and
home or fitness centre visits to promote adherence to exercises.
• Certified exercise trainers demonstrated exercises to participants and safety
precautions in performing exercises, monitored performance during exercises,
instructed participants how to progressively increase weights lifted, and assisted
participants in the transition from home-based to fitness centre exercise. Exercise
trainers made 45-minute home or fitness centre visits to participants every 2 weeks at
the beginning of home-based and fitness-centre exercises and every 2 months for the
remainder of the 24-month study. At orientation and 6-month booster sessions, an
exercise physiologist demonstrated the correct performance of each exercise in the
study, safety precautions in performing exercises, and use of weight machines.
Adherence % (self-reported but also validated by research nurses during monthly inter-
views):
• Average (SD) 24-month adherence to resistance exercise for the 110 women was
69.4% (24.0).
125 participants assigned to control:
• Participants in the comparison group received calcium and vitamin D
supplementation and risedronate but performed no resistance exercises.
Outcomes Outcomes:
• BMD at total hip, femoral neck, L1-L4 spine, total radius, and 33% radius
measured by DEXA
• Bone resorption (nmol/L BCE) assessed via serum NTx assay
• Bone formation (U/L) assessed via bone-specific alkaline phosphatase (Alkphase
B) serum assay
• Muscle strength (peak torque body weight at 60 degrees) assessed via Biodex
System 3 Pro Velocity Spectrum Evaluation. Knee, hip, and wrist flexion and extension
were measured on the non-dominant, non-operative arm and on 1 leg by physical
therapists using this system.
• Dynamic balance assessed by the timed backward tandem walk
205Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Waltman 2010 (Continued)
• Adherence was operationally defined as the ratio of reported to desired exercise
sessions attended and was further validated by research nurses during a monthly
interview via the Adherence and Risk Factor Documentation Interview technique.
• Incidence of falls
• Physical activity via 7-day physical activity record-adapted
Numbers of participants assessed:
• Intervention: baseline, 124; at 12 months, not reported; at 24 months, 110
• Control: baseline, 125; at 12 months, not reported; at 24 months, 113
Adverse events: No long-term adverse effects from exercises were noted for any of the
110 women exercising, including women with a history of lymphoedema
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00567606
Trial authors contacted: no
Intention-to-treat analysis: yes
Funding: National Institute of Nursing Research (1 R01NR07743-01A1)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Participants “were randomised to exercise
plus medication (n = 110) or medication
only (n = 113) treatment groups, and ran-
domisation was stratified by years of post
menopause”. Randomisation method was
not stated
Allocation concealment (selection bias) Unclear risk Whether treatment assignment was con-
cealed from study personnel and partici-
pants was not described
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of outcome assessments was not
described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “intent to treat paradigm was used where
data from all participants were analysed ac-
cording to randomised assignment regard-
less of protocol adherence”
“The generalized estimating equation
(GEE) method with an exchangeable struc-
ture for repeated measures data was used
to fit a generalized linear model to exam-
ine factors associated with muscle strength,
balance, BMD, and bone turnover includ-
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ing time of testing (baseline, 12 and 24
months) and group assignment (exercise or
medication only)”
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent..
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
Winters-Stone 2011
Methods Study design: single-centre RCT
Number randomised: 106; 52 to intervention, 54 to control
Study start: October 2006; stop date: January 2009
Length of intervention: 12 months
Length of follow-up: to end of intervention
Country: USA
Participants Age, years (mean SD):
• Intervention: 63.3 (6.7)
• Control: 62.2 (6.7)
Stage, n (%):
• Intervention: stage 0, 4 (7.7); stage I, 20 (38.5); stage II, 25 (48.1); stage IIIA, 1
(1.9); not reported, 2 (3.8)
• Control: stage 0, 2 (3.7); stage I, 22 (40.7); stage II, 19 (35.2); stage IIIA, 5 (9.3);
not reported, 6 (11.1)
Inclusion criteria:
• Diagnosis of stage 0-IIIA breast cancer at or after age 50
• Postmenopausal
• ≥ 1 year post chemotherapy or radiotherapy
• Non-osteoporotic
• No bone-altering medication other than adjuvant hormone therapy
• Physician clearance to exercise
• No regular participation in resistance and/or impact exercise (fewer than two 30-minute
sessions per week) in the past month
• Physical and cognitive ability to complete study testing
Exclusion criteria:
• None reported
Interventions 52 participants assigned to 1-year exercise intervention:
• Resistance plus impact intervention (POWIR: Prevent Osteoporosis With Impact
+ Resistance) used in this study complied with American College of Sports Medicine
(ACSM) recommendations for preserving bone health in postmenopausal women by
using resistance and/or impact exercise at moderate-to-high bone-loading forces.
• Resistance training at loads corresponding to 60% to 70% of 1RM for 1 to 3 sets
of 8 to 12 repetitions to build lean mass and strength in novice weight lifters and older
adults. Free weights were used to apply resistance-dumbbells for upper body, weighted
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vests for lower body, and a barbell for 1 combined upper + lower body exercise.
• Impact exercise consisted of 2-footed jumps from the ground to a target height 1
from the floor with a bent-knee landing, performed with weighted vests on and in sets
of 10. During a single exercise session, participants warmed up, performed 1 to 6 jump
sets, 1 to 2 sets of 3 to 4 upper body exercises, and 3 to 4 lower body exercises, then
cooled down.
• Home exercises were similar to those performed in the supervised class, except
that resistance bands replaced free weights for upper body exercises, and lower body
exercises were performed without weighted vests.
Adherence:
• Total average attendance: intervention, 57%; control, 62%
• Supervised-only average attendance: intervention, 76%; control, 72%
• Home-only average attendance: intervention, 23%; control, 44%
54 participants assigned to control:
• Progressive low-intensity stretching, 3 times per week for 1 year
• Participants performed a series of whole body stretching and relaxation exercises
in a seated or lying position.
• Selected exercises were chosen to minimise weight-bearing forces, so that little
stimulus to the musculoskeletal system was applied and energy expenditure was
minimal.
Outcomes Primary outcomes:
• Bone mineral density of hip and spine via DEXA
• Biomarkers of blood turnover; serum osteocalcin (ng/mL) and urinary
deoxypyridinoline cross-links (nmol/mmolCr) by ELISA
Other outcomes:
• Body weight and body composition assessed via DEXA
• Habitual physical activity measured with the CHAMPS physical activity
questionnaire for older adults (kcal/day in all activities)
• Habitual calcium (dietary + supplemental)
• Total energy intake assessed with the 2005 Block Food Frequency Questionnaire
Numbers of participants assessed:
• Intervention: baseline, 52; at 6 months, 33; at 12 months, 36
• Control: baseline, 54; at 6 months, 32; at 12 months, 31
Adverse events: No adverse effects were associated with participation in either group
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT00591747
Trial authors contacted: no
Intention-to-treat analysis: yes, but data were available only for per-protocol analyses
Funding: Susan G. Komen Race for the Cure and the National Cancer Institute; partial
support from the Oregon Clinical and Translational Research Institute (OCTRI), Na-
tional Center for Research Resources (NCRR) - a component of the National Institutes
of Health (NIH) - and NIH Roadmap for Medical Research
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Generation of the random sequence was
not described
Allocation concealment (selection bias) High risk “Group assignments were placed in sealed,
sequentially numbered envelopes and
opened by the participant following the
completion of baseline testing”. Envelopes
were not opaque
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Owing to the nature of the intervention,
it was not possible to conceal allocation to
the intervention from participants
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “Trained technicians blinded to group as-
signment” carried out testing
Incomplete outcome data (attrition bias)
All outcomes
High risk The intent-to-treat (ITT) analysis was per-
formed via hierarchical linear modelling.
However, although inferences were based
on ITT analyses, data were available only
for per-protocol analyses (in table format).
High attrition rate was reported in the in-
tervention group
Selective reporting (reporting bias) Low risk No selective reporting of outcomes is ap-
parent.
Other bias Low risk Trial appears to be free of other problems
that could put it at high risk of bias
1RM: 1-repetition maximum.
7-DPAR: 7-day physical activity recall questionnaire.
ACSM: American College of Sports Medicine.
AIDS: acquired immunodeficiency syndrome.
AIT: aerobic interval training.
API: Aerobic Power Index.
BCE: Bone Collagen Equivalents.
BCPT: Breast Cancer Prevention Trial.
BDI: Beck Depression Inventory.
BES: Body Esteem Scale.
BFLUTS: Bristol Female Lower Urinary Tract Symptoms Questionnaire.
BIQ: Body Image Questionnaire.
BIS: bioimpedance spectroscopy.
BMI: body mass index.
BPI: Brief Pain Inventory.
BPNS: Basic Psychological Needs Satisfaction Scale.
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BREQ-2: Behavioral Regulation for Exercise Questionnaire-2.
BRI: bone remodelling index.
BSAP: bone-specific alkaline phosphatase.
CARES-SF: Cancer Rehabilitation Evaluation System Short Form.
CBT: cognitive-behavioural therapy.
CCS: Canadian Cancer Society.
CE: exercise begun after treatment.
CES-D: Centers for Epidemiological Studies-Depression Scale.
CHAMPS: Community Health Activities Model Program for Seniors.
CI: confidence interval.
CMT: continuous moderate training.
COM: combination of print material and pedometers intervention.
CP: chemotactic protein.
CRP: C-reactive protein.
CTACK: cutaneous T cell-attracting chemokine.
DASH: Disability of the Arm, Shoulder, and Hand questionnaire.
DASS-21: Depression and Anxiety Stress Scale-21.
DCIS: ductal carcinoma in situ.
DEG: delayed exercise group.
DEXA: dual-energy X-ray absorptiometry.
DWR: deep water running.
ECOG: Eastern Cooperative Oncology Group.
EE: exercise begun during treatment.
EEG: early exercise group.
ELISA: enzyme-linked immunosorbent assay.
EORTC QLQ-BR23: European Organization for Research and Treatment of Cancer core quality of life questionnaire.
EORTC QLQ-C30: European Organization for Research and Treatment of Cancer core quality of life questionnaire: breast cancer-
specific module.
EuroQoL-5D: European Quality of Life 5 dimensions.
EuroQoL-VAS: European Quality of Life visual analogue scale.
FACIT-F: Functional Assessment of Chronic Illness Therapy - Fatigue.
FACT: Functional Assessment of Cancer Therapy.
FACT-B: Functional Assessment of Cancer Therapy - Breast.
FACT-Cog: Functional Assessment of Cancer Therapy - Cognitive.
FACT-ES: Functional Assessment of Cancer Therapy - Endocrine Subscale.
FACT-F: Functional Assessment of Cancer Therapy - Fatigue.
FACT-G: Functional Assessment of Cancer Therapy - General.
FFQ: Food Frequency Questionnaire.
FGF: fibroblast growth factor.
FSI: Fatigue Symptom Inventory.
FSS: Fatigue Severity Scale.
G-CSF: granulocyte colony-stimulating factor.
gmCSF: granulocyte-macrophage colony-stimulating factor.
GRO: growth-related oncogene.
HADS: Hospital Anxiety and Depression Scale.
HbA1c: glycosylated haemoglobin.
HDL-C: high-density lipoprotein cholesterol.
HF/NS: hot flashes and night sweats.
HGF: hepatocyte growth factor.
HLRE: high-load resistance exercise.
HMWA: high-molecular-weight adiponectin.
HOMA: homeostatic model assessment.
HR: heart rate.
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HRmax: maximum heart rate.
HRR: heart rate reserve.
IBCSG: International Breast Cancer Study Group.
ICAM: intercellular adhesion molecule.
IFN: interferon.
IGF: insulin-like growth factor.
IGFBP: insulin-like growth factor binding protein.
IL: interleukin.
IP: inducible protein.
IPAQ: International Physical Activity Questionnaire.
ITT: intention-to-treat.
KPS: Karnofsky Performance Status.
LDL-C: low-density lipoprotein cholesterol.
LIF: leukaemia inhibitory factor.
LLRE: low-load resistance exercise.
LOCF: last observation carried forward.
LPS: lipopolysaccharide.
LSI: Leisure Score Index; Life Satisfaction Inventory.
LVEF: left ventricular ejection fraction.
MCS-F: macrophage colony-stimulating factor.
MET-h: metabolic equivalent hours.
METs: metabolic equivalents.
MFI: Multi-dimensional Fatigue Inventory.
MFSI: Multi-dimensional Fatigue Symptom Inventory.
MFSI-SF: Multi-dimensional Fatigue Symptom Inventory Short Form.
MI: myocardial infarction.
MIG: monokine induced by IFNγ .
MIP: macrophage inflammatory protein.
MOS SF-36: Medical Outcomes Study Short Form-36.
MVPA: moderate-vigorous physical activity.
NCI: National Cancer Institute.
NCIC: National Cancer Institute of Canada.
NGF: nerve growth factor.
NK: natural killer.
NKCA: natural killer cell activity.
NTx: N-terminal telopeptide.
NYHA: New York Heart Association.
PA: physical activity.
PAL: physical activity log.
PANAS: Positive and Negative Affect Scale.
PDGF: platelet-derived growth factor.
PE: physical education.
PED: pedometer intervention.
PFS: Piper Fatigue Scale.
PFS-R: Revised Piper Fatigue Scale.
PHA: phytohemagglutinin.
PM: print material.
POMS: Profile of Mood States.
PPO: peak power output.
pQCT: peripheral quantitative computed tomography.
PROMIS: Patient Reported Outcomes Measurement Information System.
PSQI: Pittsburgh Sleep Quality Index.
QLQ-BR23: quality of life questionnaire: breast cancer-specific module.
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QoL: quality of life.
RCT: randomised controlled trial.
RER: respiratory exchange ratio.
RM: repetition maximum.
RPE: rate of perceived exertion.
RSE: Rosenberg Self-Esteem Scale.
RTR: reach-to-recovery.
SAQ: Sexual Activity Questionnaire.
SCF: stem cell factor.
SCGF: stem cell growth factor.
SCL-90R: Symptom Checklist-90 Revised.
SCT: social cognitive theory.
SD: standard deviation.
SDF: stromal cell-derived factor.
SOC: stage of change.
SPAS-7: Social Physique Anxiety Scale-7.
STAI: State-Trait Anxiety Index.
TC: total cholesterol.
TCC: Tai Chi Chuan.
TG: triglyceride.
TNF: tumour necrosis factor.
TOI: Trial Outcome Index.
TRAIL: tumour necrosis factor-related apoptosis-inducing ligand.
TTM: Transtheoretical model.
URCC SI: University of Rochester Cancer Center Symptom Inventory.
VCAM: vascular cell adhesion molecule.
VE/VCO : minute ventilation carbon dioxide production relationship.
VE/VO : minute ventilation oxygen production relationship.
VEGF: vascular endothelial growth factor.
VEpeak : peak ventilation.
VO max: maximal oxygen uptake.
VO peak: peak oxygen uptake.
WCC: white cell count.
WHO: World Health Organization.
WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index.
YMCA: Young Men’s Christian Association.
YOCAS: yoga intervention based on gentle Hatha and restorative yoga.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anderson 2012 This study was excluded because it included patients undergoing adjuvant cancer therapy
Benton 2014 This study was excluded as it did not compare physical activity vs no physical activity or usual care
212Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Bloom 2008 This study was excluded because the effects of physical activity could not be isolated
Buffart 2012 This study was excluded because the breast cancer population was not analysed separately
Burnham 2002 This study was excluded because the breast cancer population was not analysed separately
Cadmus-Bertram 2011 This study was excluded as it did not compare physical activity vs no physical activity, another
intervention, or usual care
Cantarero-Villanueva 2012 This study was excluded because the effects of physical activity could not be isolated (physical activity
+ manual therapy)
Cantarero-Villanueva 2012a This study was excluded because the effects of physical activity could not be isolated (physical activity
+ manual therapy)
Cantarero-Villanueva 2013a This study was excluded because the effects of physical activity could not be isolated (physical activity
+ manual therapy)
Carter 2012 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Casla 2015 This study was excluded because the effects of physical activity could not be isolated (physical activity
+ diet modification)
Cheema 2006 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Cho 2006 This study was excluded because the effects of physical activity could not be isolated (physical activity
+ education intervention)
Cohen 2010 This study was excluded because all patients were at pretreatment stage
Culos-Reed 2006 This study was excluded because the breast cancer population was not analysed separately
Cunningham 1998 This study was excluded because groups included all participants with metastatic disease
D’Atillio 2007 This study was excluded because it lacked a non-physical activity comparison group
Damush 2006 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Danhauer 2009 This study was excluded because some participants were receiving treatment during the study
De Backer 2007 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Demark 2006 This study was excluded because it did not include a separate analysis of participants with breast cancer
Dimeo 2008 This study was excluded as it did not compare physical activity vs no physical activity or usual care
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Djuric 2002 This study was excluded because the effects of physical activity could not be isolated (physical activity
+ diet modification)
Eyigor 2010 This study was excluded because it lacked a non-physical activity comparison group
Fernandez-Lao 2012 This study was excluded because the effects of physical activity could not be isolated (physical activity
+ manual therapy)
Fernandez-Lao 2013 This study was excluded because it was a non-randomised controlled trial
Fong 2014 This study was excluded because it was a non-randomised controlled trial
Galantino 2013 This study was excluded because it did not include a comparison group
Gordon 2005 This study was excluded because it included exercises restricted to stretching and local muscular
endurance (i.e. training of shoulders)
Hanna 2008 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Hayes 2013 This study was excluded because it included participants undergoing adjuvant cancer therapy
Headley 2004 This study was excluded because all included participants had metastatic disease initiating chemo-
therapy
Hojan 2013 This study was excluded because it did not include a comparison group
Hsiao-Fang 2013 This study was excluded because it included participants undergoing chemotherapy
Hsieh 2008 This study was excluded because it included participants undergoing chemotherapy and radiotherapy
Hunt-Shanks 2006 This study was excluded because it did not include a comparison group
Husebo 2014 This study was excluded because it included participants undergoing chemotherapy
Hutnick 2005 This study was excluded because it was a non-randomised controlled trial
Ibfelt 2011 This study was excluded because the breast cancer population was not analysed separately
Isabell 2010 This study was excluded because it included participants undergoing chemotherapy and radiotherapy
Jeff 2012 This study was excluded because it included exercises restricted to stretching and local muscular
endurance (i.e. training of shoulders)
Johansson 2005 This study was excluded as it did not compare physical activity vs no physical activity, another
intervention, or usual care
Johnsson 2013 This study was excluded because it did not include a comparison group
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Kilbreath 2006 This study was excluded because it included exercises restricted to stretching and local muscular
endurance (i.e. training of shoulders)
Kilbreath 2012 This study was excluded because it included participants undergoing chemotherapy and radiotherapy
Kilgour 2008 This study was excluded because it included exercises restricted to stretching and local muscular
endurance (i.e. training of shoulders)
Kim Soo 2011 This study was excluded because the effects of physical activity could not be isolated (physical activity
+ diet modification)
Kovacic 2011 This study did not include a physical activity intervention but used a relaxation intervention instead
LaStayo 2011 This study was excluded because the breast cancer population was not analysed separately
Lee 2010 This study was excluded because it compared exercise vs historical control (non-randomised controlled
trial)
Ligibel 2012 This study was excluded because the breast cancer population was not analysed separately
May 2008 This study was excluded because the breast cancer population was not analysed separately
McClure 2010 This study was excluded because it included exercises restricted to stretching and local muscular
endurance (i.e. training of shoulders)
Mefferd 2007 This study was excluded because the effects of physical activity could not be isolated (physical activity
+ diet modification)
Moadel 2007 This study was excluded because it included participants undergoing chemotherapy and radiotherapy,
as well as participants with metastatic disease
Naraphong 2015 This study was excluded because it included participants undergoing chemotherapy
Naumann 2012a This study was excluded because it was a non-randomised controlled trial
Noble 2012 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Oh 2010 This study was excluded because the breast cancer population was not analysed separately
Oldervoll 2011 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Pinto 2008 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Pinto 2013 This study was excluded as it did not compare physical activity vs no physical activity or usual care
(healthcare professional gave PA advice to both intervention groups)
Rabin 2006 This study was excluded because it lacked a non-physical activity comparison group
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Rabin 2009 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Sandel 2005 This study was excluded because it included participants undergoing adjuvant cancer therapy
Schmidt 2012 This study was excluded because it lacked a non-physical activity comparison group
Schneider 2007 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Schwartz 1999 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Segal 2001 This study was excluded because it included participants undergoing adjuvant cancer therapy
Sherman 2010 This study was excluded because it was a controlled clinical trial (participants allocated according to
patient preference and intervention availability)
Speed-Andrews 2010 This study was excluded because it did not include a comparison group
Sprod 2005 This study was excluded because it lacked a non-physical activity comparison group
Sprod 2010 This study was excluded because it was a non-randomised controlled trial
Stan 2012 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Stan 2013 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Stevinson 2007 This study was excluded because the breast cancer population was not analysed separately
Szczwpanska-Gieracha 2010 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Tang 2010 This study was excluded because the breast cancer population was not analysed separately
Taso 2014 This study was excluded because it included participants undergoing adjuvant cancer therapy
Thorsen 2005 This study was excluded because the breast cancer population was not analysed separately
Tidhar 2010 This study was excluded because it involved therapeutic exercise regimens addressing only specific
impairments related to shoulder, arm, or both
Turner 2004 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Ulger 2010 This study was excluded because it did not include a comparison group
Van Puymbroeck 2011 This study was excluded because it lacked a non-physical activity comparison group
Van Weert 2005 This study was excluded because the breast cancer population was not analysed separately
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Wong 2012 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Wu 2008 This study was excluded as it did not compare physical activity vs no physical activity or usual care
Yuen 2007 This study was excluded because it included participants undergoing adjuvant cancer therapy
Characteristics of studies awaiting assessment [ordered by study ID]
Lahart 2016
Methods Study design: RCT
Number expected to be randomised: 80; 40 to exercise intervention, 40 to control
Study start: January 2010; stop date: March 2013
Length of intervention: 6 months
Participants Age, years (mean SD):
• Intervention: 52.4 (10.3)
• Control: 54.7 (8.3)
Stage: stage I-III
Inclusion criteria:
• Females aged 18 to 72 years
• Diagnosis of invasive breast cancer (stage I-III) within 2 years of enrolment
• Post surgery and no surgery planned for at least the next 6 months
• Fully completed adjuvant therapy (radiotherapy and/or chemotherapy) not including hormonal therapy
• No previous malignancy
• Willing to be randomised
• Willing to maintain contact with investigators over 6 months
Exclusion criteria:
• Inability to participate in PA because of severe disability (e.g. severe arthritic conditions)
• Psychiatric illness
• Vulnerable individuals, such as pregnant women or any other patients for whom PA was not approved by their
oncologist owing to the presence of 1 or more contraindications to exercise for patients with cancer
Interventions • Intervention:
◦ Participants received a face-to-face consultation, followed by a support telephone call at the end of
months 1, 2, and 3 (i.e. a total of 3 telephone calls). During each of the last 2 months (4 and 5), participants
received mailed PA reminder leaflets encouraging their participation in home-based physical activity. Face-to-face
consultations were conducted by the primary researcher immediately after initial baseline measurements and were
based on 4 core motivational interviewing principles: expressing empathy, developing discrepancy, rolling with
resistance, and supporting self-efficacy. The goal of follow-up phone calls (end of months 1 to 3) was to prevent
relapse back to inactivity and/or improve maintenance of physical activity (accumulating 30 minutes of moderate-
intensity PA 3 to 5 days/week); researchers covered topics similar to those discussed in the face-to-face consultation.
• Usual care:
◦ Participants randomised to the usual care arm received standard information regarding PA (i.e. current
recommended PA guidelines), as provided to all participants with breast cancer treated at the site. Usual care group
participants were instructed to maintain their current lifestyle.
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Outcomes Primary outcome:
• Total physical activity levels via IPAQ
Secondary outcomes:
• Weight maintenance and BMI
• Body composition (body fat %) via bioelectrical impedence analysis
• HRQoL assessed via FACT-B
• Blood biomarkers: The Vitros 5 IFS Chemistry System (Ortho Clinical Diagnostics Inc., Rochester, NY,
USA) was used to measure all lipid components; however, total cholesterol, HDL-C, and triglycerides were
measured on multi-layered slides, whereas measurement of LDL-C required a dual-chamber package. Plasma
glucose was measured with the VITROS 5.1 FS Chemistry System (Johnson and Johnson Inc., Langhorne, PA,
USA); insulin was estimated via solid-phase 2-site chemiluminescence immunometric assay (Immulite 2000
Analyser, Siemens Healthcare Diagnostics, Deerfield, IL, USA); HOMA-insulin resistance was evaluated from
fasting glucose and insulin.
Notes Country of trial: UK
https://clinicaltrials.gov/ct2/show/NCT02408107
Dr. Ian Lahart; I.Lahart@wlv.ac.uk
Lohrisch 2011
Methods Study design: RCT
Number randomised: 22; 11 to exercise intervention, 11 to control
Study start: not reported; study completion: not reported
Length of intervention: 48 weeks
Participants Eligible women with postmenopausal early breast cancer had arthralgias/myalgias (A/M) related to adjuvant anastro-
zole
Among 20 evaluated participants:
• Baseline median age was 62.
• BMI was 26 kg/m² in Exercise and Control arms.
• Median number of arthralgia/myalgia sites was 5, with a median worst score of 2 (CTC version 2 criteria)
Interventions Exercise participants exercised 3 times weekly for 48 weeks: for the first 12 weeks in a supervised setting; for the
second 12 weeks, supervised once weekly and independently twice weekly; for the last 24 weeks, independently via
aerobic and resistance programmes tailored to their fitness
Outcomes Primary outcome:
• Change in SF-36 bodily pain domain scores at week 12 (W12)
Secondary outcomes:
• Change in bone mineral density (BMD)
• Change in body mass index (BMI)
• Strength (bench press and leg strength)
• Hot flash index
Notes Study closed owing to poor accrual after 3 years, with 22 (11 exercise and 11 exercise) of the planned 72 participants
enrolled at 2 sites among 98 screened
Only conference abstract is available.
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Luu 2014
Methods Study design: RCT
Number randomised: 38; 24 to a yoga intervention, 14 to control
Study start: not reported; study completion: not reported
Length of intervention: 12 weeks
Participants “Urban underserved breast cancer survivors”
Interventions Participants were randomised to the treatment group (1-hour Hatha yoga classes) or the wait-list control group
Frequency of yoga classes per week is unclear.
Outcomes Outcomes:
• Quality of life via FACT-B
• Spiritual well-being via functional assessment of chronic illness therapy - spiritual well-being
Notes Only conference abstract is available.
A/M: arthralgia/myalgia.
BMD: bone mineral density.
BMI: body mass index.
CTC: common toxicity criteria.
FACT-B: Functional Assessment of Cancer Therapy - Breast.
HDL-C: high-density lipoprotein cholesterol.
HOMA: homeostatic model assessment.
HRQoL: health-related quality of life.
IPAQ: International Physical Activity Questionnaire.
LDL-C: low-density lipoprotein cholesterol.
PA: physical activity.
RCT: randomised controlled trial.
SD: standard deviation.
SF-36: Short Form-36.
Characteristics of ongoing studies [ordered by study ID]
Deli-Conwright 2014
Trial name or title Exercise Program for Early Breast Cancer Survivors
Methods Accrual: not reported
Accrual target: 100 breast cancer survivors
Multi-centre/single-centre: single centre, but participants will be encouraged in a home-based exercise session
over 30 to 45 minutes once weekly
Phase of trial: not reported
Country where trial is being conducted: USA (Los Angeles, CA)
Any intended follow-up details: 12 weeks
Stated study design: RCT, efficacy study
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Participants Inclusion criteria:
• Newly diagnosed (I-III) first primary invasive breast cancer
• Underwent lumpectomy or mastectomy
• Completed neoadjuvant/adjuvant chemotherapy and able to initiate Exercise programme (if randomised to
that arm) within 12 weeks of therapy completion
• Body mass index (BMI) > 25 kg/m² or body fat > 30% (as determined by Dr. Dieli-Conwright at baseline
visit)
• Currently participate in less than 60 minutes of physical activity per week
• May use adjuvant endocrine therapy if use will be continued for duration of study period
• Non-smoker (i.e. not smoking during previous 12 months)
• Willing to travel to the exercise facility and USC
• Able to provide physician clearance to participate in exercise programme
• Women of all racial and ethnic backgrounds to be included in the study enrolment process
Exclusion criteria:
• History of chronic disease including diabetes, uncontrolled hypertension, or thyroid disease
• Weight reduction ≥ 10% in the past 6 months
• Diagnosis of human epidermal growth factor receptor 2 (HER2)-positive tumour (exclusion due to patient
use of Herceptin medication for 1 year following chemotherapy)
• Metastatic disease
• Planned reconstructive surgery with flap repair during trial and follow-up period
• Cardiovascular, respiratory, or musculoskeletal disease or joint problems that preclude moderate physical
activity
Interventions ARM 1:
• Intervention details: Participants complete supervised exercise sessions over 60 minutes thrice weekly
and are encouraged to participate in a home-based exercise session over 30 to 45 minutes once weekly for 16
weeks.
ARM 2:
• Comparator details: Participants refrain from increasing physical activity levels for 16 weeks.
Outcomes Primary outcome:
• Change in components of metabolic syndrome (i.e. hypertension, high waist circumference,
hyperglycaemia, low/high-density lipoproteins, elevated triglycerides)
Secondary outcomes:
• Cardiorespiratory fitness (4-minute walk test)
• Muscle strength (10-RM leg extension, leg flexion, chest press, seated row)
• Body composition (DEXA, weight, height, lean mass, % body fat, hip circumference)
• Quality of life (SF-36, FACT-B, CES-D)
• Shoulder strength (muscle force for scapular plane elevation and external rotation)
• Shoulder function (measured with goniometer at 90° external rotation, forward flexion)
• Upper limb musculoskeletal disorder assessment (Disabilities of the Arm, Shoulder, and Hand -
DASH - and Penn Shoulder Scale - PSS)
• Biomarkers - inflammation and endocrine function (analysed in peripheral blood)
Starting date Start date: May 2012
Estimated completion date: May 2017
Contact information Christina Dieli-Conwright, PhD; 323-442-2905
Email: cdieli@usc.edu
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Deli-Conwright 2014 (Continued)
Notes Trial registration link: https://clinicaltrials.gov/show/NCT01140282
Sponsor of the trial: University of Southern California, National Cancer Institute
This study is still recruiting participants.
Intention-to-treat analysis: not reported
Funding considerations: not funded by Pharma or otherwise
Galiano-Castillo 2013
Trial name or title Telehealth System to Improve Quality of Life in Breast Cancer Survivors
Methods Accrual: 72
Accrual target: 80 breast cancer survivors
Multi-centre/single-centre: not reported but most likely home-based (paper or registry does not explicitly say
this)
Phase of trial: not reported
Country where trial is being conducted: Spain
Any intended follow-up details: 8 weeks
Stated study design: RCT, efficacy study
Participants Inclusion criteria:
• 18 to 65 years of age
• Female
• Diagnosis of stage I, II, or IIIA breast cancer
• Medical clearance for participation
• Without chronic disease or orthopaedic disease that would interfere with ability to participate in a physical
activity programme
• Access to Internet
• Basic ability to use the computer or living with a relative who has this ability
• Completion of adjuvant therapy except for hormone therapy
• No history of cancer recurrence
• Interest in improving lifestyle: fitness/stress level





◦ Behavioral telerehabilitation group: Interventions will be based on providing cardiovascular,
mobility, strength, and stretching exercises through telerehabilitation system.
ARM 2:
• Comparator details: information about usual care
Outcomes Primary outcome:
• Quality of life (European Organization for Research and Treatment of Cancer Core Quality of Life
Questionnaire 30)
Secondary outcomes:
• Algometry (pressure pain thresholds measured through an electronic algometer)
• Pain (visual analogue scale and brief pain inventory)
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Galiano-Castillo 2013 (Continued)
• Body composition (weight, body mass index, skeletal muscle mass, and percentage of body fat
obtained through bioelectrical impedance analysis)
• Physical measurements (abdominal McQuade test, handgrip strength and back muscle strength via
digital dynamometers, and multiple sit-to-stand test used to assess general lower extremity endurance)
• Cardiorespiratory fitness (International Fitness Scale and 6-minute walk test)
• Fatigue via PFS-Revised
• Anxiety and depression via HADS
• Cognitive function (Trail Making Test and Auditory Consonant Trigram)
• Accelerometry (Actigraph tri-axial accelerometer)
Starting date Start date: March 2012
Estimated completion date: July 2014
Contact information Manuel Arroyo-Morales
Email: marroyo@ugr.es
Notes Trial registration link: https://clinicaltrials.gov/ct2/show/NCT01801527
Sponsor of the trial: Universidad de Granada and Carlos III Health Institute
Intention-to-treat analysis: not reported
Funding considerations: not funded by Pharma or otherwise
IRCT2014042117379N1
Trial name or title Comparing Self-Efficacy, Outcome Expectations for Promoting the Physical Activity of Women With Breast
Cancer in Two Groups With and Without Educational Program
Methods Study design: RCT
Number expected to be randomised: 70
Study start: September 2014; estimated stop date: November 2015
Length of intervention: 8 weeks
Participants 50 malignant neoplasms of breast cancer
Inclusion criteria:
• Final diagnosis of breast cancer by a physician
• Individual consent and spousal consent if married
• Physician’s written consent to participation in the educational programme
• Ability to read and write
Exclusion criteria:
• Therapist’s prescription for a ban on attending sessions
• Lack of desire to participate in the study
• Absence for more than 1 session during educational sessions
• Cognitive disorder diagnosed during the educational intervention
Age: not reported
Interventions Intervention 1:
• The first session is devoted to identifying need for patient education in the experimental group. Participants
then receive education during at least 4 90-minute sessions with respect to the barriers to self-efficacy in physical
activity, energy management, stress management, lymphoedema prevention, and other topics mentioned in
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IRCT2014042117379N1 (Continued)
the group. Training sessions are presented in PowerPoint by relevant experts on each topic
• Educational activities are intended for promotion of self-efficacy, brainstorming strategies, verbal persuasion,
successor experience, and framing questions in the group
Usual care:
• No special arrangement is made for the control group, except for normal medical care
Outcomes Primary outcomes:
• Self-efficacy for physical activity (measured before and 1 month after the intervention via the standard
self-efficacy questionnaire for physical activity by Bandura)
• Outcome expectation for physical activity (measured before and 1 month after the intervention via the
“questionnaire”)
Seconday outcome:
• Physical activity (measured before and 3 months after the intervention by “standard physical activity
measurement questionnaire”)
Starting date 20 March 2014
Contact information Rahele Solymani
Rahelesolymani@hlth.mui.ac.ir; raheel s59@yahoo.com
Notes Country of trial: Iran, Islamic Republic of
http://apps.who.int/trialsearch/Trial2.aspx?TrialID=IRCT2014042117379N1
KIlbreath 2011
Trial name or title Exercise to Prevent Osteoporosis as a Consequence of Hormone Treatment in Post Menopausal Women
Treated for Breast Cancer
Methods Accrual: not reported
Accrual target: 60
Multi-centre/single-centre: multi-centre
Phase of trial: not reported
Country where trial is being conducted: Australia
Any intended follow-up details: no follow-up
Stated study design: RCT, blinded
Participants Inclusion criteria
• Postmenopausal
• Above 18 years of age
• Mmenses history and/or surgery
• Stage I-III breast cancer
• Oestrogen receptor and/or progesterone receptor positive breast cancer
• Commenced taking aromatase inhibitor within 10 weeks
• Eastern Collaborative Oncology Group performance status ≤ 2 (Oken et al, 1982)
• Sedentary.
Exclusion criteria
• Any clinical or radiological evidence of distant spread of disease
• Any HRT in the past 12 months
223Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
KIlbreath 2011 (Continued)
• Taken bisphosphonates in the past 6 months
• Prior treatment with continuous systemic glucocorticoids in the past 6 months
• Current treatment with any drugs known to affect the skeleton (e.g. calcitonin, calcitriol, mithramycin,
gallium nitrate)
• History of diseases that influence bone metabolism, such as Paget’s disease or ongoing thyroid toxicosis
• Previous or concomitant malignancy (apart from breast cancer) in the past 5 years except adequately treated
basal or squamous cell carcinoma of the skin or in situ carcinoma of the cervix
Interventions ARM 1:
• Intervention details: exercise programme - exercise training will run for 12 months, 3 times per week
for approximately 1 hour each session. A trainer will meet women at their local community gym 3 times per
week for the first 4 weeks, then once a month for the rest of the year. The programme will consist of a 5-
minute warm-up, 25 minutes of high-impact exercise using steps (jumping, running, hopping), 25 minutes
of resistance exercise in the limbs and trunk with free weights and resistance equipment, and a 5-minute
cool-down. Daily calcium carbonate (1200 mg) and vitamin D (1000 IU) supplements
ARM 2:
• Comparator details: daily calcium carbonate (1200 mg) and vitamin D (1000 IU) supplements. No
exercise prescription
Outcomes Primary outcome:
• Bone mineral density (DEXA scans of spine and hip)
Secondary outcomes:
• Biochemical markers of bone remodelling (bone formation and resorption)
• Self-report outcomes (quality of life questionnaire and medical outcomes survey short forms)
• Lymphoedema status
• Bone mineral density (DEXA scans of trochanteric, femoral neck, and spinal bone mineral density)
Starting date Start date: May 2008
Estimated completion date: not reported
Contact information Prof Sharon Kilbreath
Email: sharon.kilbreath@sydney.edu.au
Notes Trial registration link: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=82762
Sponsor of the trial: Cancer Australia
Trial authors were contacted and we were informed by the authors that the study had been completed and
they were preparing for publication.
Intention-to-treat analysis: not reported
Funding considerations: not funded by Pharma or otherwise
NCT02057536
Trial name or title The Effect of an Exercise Program in Breast Cancer Patients With Joint Pain While Taking Aromatase
Inhibitors
Methods Study design: RCT
Number expected to be randomised: 30
Study start: January 2014; estimated stop date: January 2015
224Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT02057536 (Continued)
Length of intervention: 8 weeks
Participants Stage: I-III
Time since cancer diagnosis: not specified
Inclusion criteria:
• Women over age 40 with histological evidence of hormone receptor positive breast cancer
• Postmenopausal
• Adjuvant AI therapy
• Significant joint discomfort/stiffness when attempting activities of daily living, which began or significantly
increased after initiation of AI therapy
• Currently not in an active directed exercise programme (> 60 minutes 2×/week)
• Age: 40 years or older
Ethnicity: not reported
Interventions 8-Week directed exercise programme
Outcomes Primary objective:
• Change in Pain Disability Index from baseline to 8 weeks
Starting date January 2014
Contact information Christiana Care/Helen F. Graham Cancer Center, Newark, DE, USA 19713
Notes Country of trial: USA
https://ClinicalTrials.gov/show/NCT02057536
NCT02235051
Trial name or title Exercise Intervention in Preventing Breast Cancer Recurrence in Postmenopausal Breast Cancer Survivors
Methods Study design: RCT
Number expected to be randomised: 50
Study start: May 2015; estimated stop date: November 2016
Length of intervention: 16 weeks
Participants Stage: I-IIIA
Time since cancer diagnosis: within first 3 years post treatment
Inclusion criteria:
• Women with diagnosis of first primary invasive oestrogen receptor (ER) positive (+) breast cancer (stage I-
IIIA) within first 3 years post treatment
• Postmenopausal women
• Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier
method of birth control or abstinence) before study entry and for 6 months following duration of study
participation; should a woman become pregnant or suspect that she is pregnant while participating in the
trial, she should inform her treating physician immediately
• Any body mass index (BMI)
• Sedentary (has not participated in a regular exercise programme in the past 12 months)
• Non-smoker (not smoking during previous 12 months)
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• Willing and able to travel to the exercise facility
• Diagnosis of first primary invasive ER+ breast cancer (stage I-IIIA)
• Has undergone a lumpectomy or mastectomy
• Completed adjuvant chemotherapy and/or radiation within 3 years before study enrolment (when cytokine
levels are predicted to be high) and able to initiate an exercise programme
• May use adjuvant endocrine therapy if use will be continued for duration of study period
• Must have the ability to understand and the willingness to sign a written informed consent
Age: 56 years and older
Ethnicity: not reported
Interventions Patients participate in a supervised Curves exercise programme 3 days a week for 16 weeks. The circuit-style
workout consists of 14 exercises constructed with pneumatic or hydraulic resistance that target opposing
muscle groups in a concentric-only fashion. Each session at a Curves facility will include 2 complete circuits,
which corresponds to exercising for approximately 30 minutes, followed by a standardised stretching routine
Outcomes Primary objectives:
• To test the hypothesis that regular exercise increases DNA repair capacity
• To test the hypothesis that regular exercise reduces inflammatory response
• To test the hypothesis that regular exercise modulates telomerase activity
Secondary objectives:
• To assess adherence to the study protocol
• To examine differences in body composition before and after the exercise intervention
• To examine differences in fitness before and after the exercise intervention
• To test the hypothesis that regular exercise improves quality of life in breast cancer survivors
• To examine the safety of the exercise intervention
Starting date May 2015
Contact information Principal Investigator: Jessica Clague DeHart
Contact: Jessica Clague DeHart; 800-826-4673; jclague@coh.org
Notes Country of trial: USA
https://ClinicalTrials.gov/show/NCT02235051
NCT02332876
Trial name or title Physical Activity and Neuropsychological Outcomes in a Cancer Population
Methods Study design: RCT
Number expected to be randomised: 87
Study start: August 2014; estimated stop date: August 2017
Length of intervention: 12 weeks
Participants Stage: I-III
Time since cancer diagnosis: less than 5 years
Inclusion criteria:
• Breast cancer survivors; diagnosis at stage I, II, or III less than 5 years ago
• Not scheduled for or currently undergoing chemotherapy; sedentary, defined as engaging in less than 60
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minutes of moderate-to-vigorous physical activity each week
• Accessible geographically and by telephone
• Access to the Internet
• Endorse experience difficulties with thinking abilities
• Participants on adjuvant therapy (e.g. tamoxifen, aromatase inhibitors) must be able and willing to remain
on that treatment for the 3-month intervention period to prevent confounding of biomarker concentrations
by treatment
Age: 21 to 85 years
Ethnicity: not reported
Interventions 12-Week individually tailored phone and email-based exercise programme
Outcomes Primary objective:
• Change in score on the NIH Toolbox Cognition measure from baseline to 12 weeks
Starting date August 2014
Contact information Sheri Hartman, Assistant Professor, University of California, San Diego
Notes Country of trial: USA
https://ClinicalTrials.gov/show/NCT02332876
NCT02420249
Trial name or title Qigong for Breast Cancer Survivors
Methods Study design: RCT
Number expected to be randomised: 60
Study start: March 2015; estimated stop date: May 2017
Length of intervention: 3 months
Participants Stage: not reported
Time since cancer diagnosis: not reported
Inclusion criteria:
• History of a breast malignancy at any stage
• History of mastectomy or lumpectomy with or without adjuvant chemotherapy or radiotherapy
• Completed conventional cancer treatment and medically stable
• No known neurological deficits resulting from breast cancer treatment or other neurological disorders
• Persistent lymphoedema defined as a circumference difference > 2 cm at any point between the surgical
upper limb and the contralateral upper limb
• Female aged 18 or above
Age: 18 years or above
Ethnicity: Chinese
Interventions Participants assigned to the Qigong group will receive Qigong training
The Qigong training programme will be run for 3 months with 2 supervised 1-hour sessions per week
Participants will learn the 18 Forms of Tai Chi Internal Qigong
Training sessions will be conducted by a qualified Qigong instructor from the Natural Health Qigong Asso-
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• Change in upper limb circumference
• Change in arterial resistance and blood flow velocities
• Change in shoulder flexibility
• Change in shoulder muscular strength
• Change in body balance
Secondary objective:
• Change in quality of life
Starting date March 2015
Contact information Shirley SM Fong, PT, PhD; 852-970-90337; smfong@hku.hk
Notes Country of trial: Hong Kong
https://ClinicalTrials.gov/show/NCT02420249
NCT02433067
Trial name or title Physical Activity Intervention on Myocardial Function in Patients With HER2 + Breast Cancer (CARDAPAC)
Methods Study design: RCT
Number expected to be randomised: 117
Study start: April 2015; estimated stop date: April 2017
Length of intervention: 12 weeks
Participants Stage: not specified
Time since cancer diagnosis: receiving adjuvant trastuzumab after undergoing surgery for breast cancer
Inclusion criteria:
• First breast cancer HER2 + histologically confirmed
• WHO grade performance index ≤ 1
• Normal renal function (creatinine clearance ≥ 60 mL/min−1)
• Normal heart function with LVEF ≥ 50%
• Normal liver function (AST and ALT normal)
• Physical activity certificate issued by a cardiologist or an oncologist
• Active contraception or postmenopausal
• Age: 18 to 65 years
Ethnicity: not reported
Interventions Participants will participate in a physical activity intervention 3 times per week for 3 months and an interval
training programme on a cycle-ergometer
Outcomes Primary objective:
• To evaluate any change in the left ventricular ejection fraction (LVEF), as evaluated by
echocardiography, from baseline to 6 months
Secondary objectives:
To measure any changes in the following from baseline to 3 months and 6 months:
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• Weight and volume of left and right ventricular by echocardiography
• Body composition evaluated by impedance and with tape measure and pliers of Harpenden
• Metabolic responses evaluated with enzyme-linked immunosorbent assay (ELISA)
• Maximal voluntary quadriceps evaluated with chair quadriceps with strain gauge
• Quality of life evaluated with questionnaire
• Pain evaluated with questionnaire
• Fatigue evaluated with questionnaire
• Level of physical activity evaluated with questionnaire
• Pulmonary function evaluated with respiratory functional test and maximal exercise test
• Hormonal responses evaluated with ELISA
• inflammatory responses evaluated with ELISA
Starting date April 2015
Contact information Contact: Fabienne Mougin-Guillaume, PhD; fabienne.mougin-guillaume@univ-fcomte.fr
Principal Investigator: Nathalie Meneveau
Notes Country of trial: France
https://clinicaltrials.gov/show/NCT02433067
NCT02527889
Trial name or title The Effect of Resistive Exercise on Forearm Blood Flow and Tissue Oxygenation Among Breast Cancer
Survivors With or at Risk for Breast Cancer-Related Lymphoedema (BCRL)
Methods Study design: RCT
Number expected to be randomised: 150
Study start: July 2015; estimated stop date: December 2016
Length of intervention: 8 weeks
Participants Stage: not reported
Time since cancer diagnosis: not reported
Inclusion criteria:
• Female breast cancer survivors
• Remained disease free, as defined by unremarkable clinical examination within recent 6 months, with a
clinical diagnosis of stable lymphoedema and without lymphoedema
Age: 18 to 70 years
Ethnicity: Chinese
Interventions Participants assigned to the exercise group will receive a supervised resistive exercise programme, which
includes 1-hour physiotherapist-supervised small group-based exercise sessions twice a week for 8 weeks.
Before resistive exercises, participants will perform warm-up with movements of large joints and shoulder
girdle for 15 minutes. Resistive exercises will focus on the major muscle groups in the upper body. Loading
of resistive exercises will be prescribed and progressed according to individual capacity and will reach a level
of moderate-to-high loading (6 to 12 repetition maximum); these will be followed by stretching exercises
specific to the muscle groups trained after the session
Control group: no intervention; all 30 participants recruited
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Outcomes Primary objectives:
• Changes in brachial artery blood flow as measured by a Doppler ultrasonic device with a linear probe
• Changes in tissue oxygenation as measured by near-infrared spectroscopy
Secondary objectives:
To measure changes at 20 weeks in:
• Arm circumference as measured by a tape measure at 10-cm interval from the ulnar styloid process
• Extent of lymphoedema as measured by bioelectrical impedance spectroscopy
• Self-reported lymphoedema symptoms
• Hand grip strength as measured by hand grip dynamometer
• Upper limb range of motion measurement
• Shoulder range of motion measured with a standard goniometer
• Quality of life measured by FACT-Breast Cancer Subscale Questionnaire
Starting date July 2015
Contact information Rufina Lau; (852)27666718; Rufina.Lau@polyu.edu.hk




BMI: body mass index.
CES-D: Centers for Epidemiological Studies-Depression Scale.
DASH: Disability of the Arm, Shoulder, and Hand questionnaire.
DEXA: dual-energy X-ray absorptiometry.
ELISA: enzyme-linked immunosorbent assay.
FACT-B: Functional Assessment of Cancer Therapy - Breast.
HADS: Hospital Anxiety and Depression Scale.
HER2: human epidermal growth factor receptor 2.
LVEF: left ventricular ejection fraction.
PFS: Piper Fatigue Scale.
PSS: Penn Shoulder Scale.
RCT: randomised controlled trial.
RM: repetition maximum.
USC: University of Southern California.
WHO: World Health Organization.
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D A T A A N D A N A L Y S E S
Comparison 1. Comparison: HRQoL outcomes, all physical activity vs control




participants Statistical method Effect size
1 Overall HRQoL (follow-up
values)
22 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 End of intervention 22 1996 Std. Mean Difference (IV, Random, 95% CI) 0.39 [0.21, 0.57]
1.2 Follow-up 4 418 Std. Mean Difference (IV, Random, 95% CI) 0.20 [0.00, 0.39]
2 Overall HRQoL (change values) 14 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 End of intervention 14 1459 Std. Mean Difference (IV, Random, 95% CI) 0.78 [0.39, 1.17]
2.2 Follow-up 2 132 Std. Mean Difference (IV, Random, 95% CI) 0.52 [0.15, 0.88]
3 FACT-G (follow-up values) 10 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 End of intervention 10 1094 Mean Difference (IV, Random, 95% CI) 7.06 [2.82, 11.30]
3.2 Follow-up 3 342 Mean Difference (IV, Random, 95% CI) 2.81 [-0.46, 6.08]
4 FACT-G (change values) 6 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 End of intervention 6 663 Mean Difference (IV, Random, 95% CI) 5.04 [1.32, 8.75]
4.2 Follow-up 2 132 Mean Difference (IV, Random, 95% CI) 6.16 [1.63, 10.69]
5 FACT-B (follow-up values) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 End of intervention 11 1395 Mean Difference (IV, Random, 95% CI) 6.31 [1.15, 11.47]
5.2 Follow-up 4 421 Mean Difference (IV, Random, 95% CI) 3.77 [0.11, 7.43]
6 FACT-B (change values) 6 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 End of intervention 6 605 Mean Difference (IV, Random, 95% CI) 8.16 [2.56, 13.76]
6.2 Follow-up 2 132 Mean Difference (IV, Random, 95% CI) 6.95 [1.34, 12.56]
7 FACT Breast Cancer Subscale
(follow-up values)
11 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 End of intervention 11 1043 Mean Difference (IV, Random, 95% CI) 1.98 [0.92, 3.04]
7.2 Follow-up 4 386 Mean Difference (IV, Random, 95% CI) 3.20 [-0.65, 7.05]
8 FACT Breast Cancer Subscale
(change values)
7 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 End of intervention 7 646 Mean Difference (IV, Random, 95% CI) 1.78 [-0.14, 3.70]
8.2 Follow-up 1 36 Mean Difference (IV, Random, 95% CI) 1.30 [-1.56, 4.16]
9 FACT Trial Outcome Index
(follow-up values)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 End of intervention 4 658 Mean Difference (IV, Random, 95% CI) 7.90 [-1.24, 17.04]
9.2 Follow-up 1 213 Mean Difference (IV, Random, 95% CI) 3.60 [0.01, 7.19]
10 EORTC QLQ-C30 Global
Health (follow-up values)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 End of intervention 4 195 Mean Difference (IV, Random, 95% CI) 7.85 [2.16, 13.55]
10.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 EORTC QLQ-C30 Global
Health (change values)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 End of intervention 4 633 Mean Difference (IV, Random, 95% CI) 9.53 [-2.43, 21.49]




26 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 End of intervention 26 2102 Std. Mean Difference (IV, Random, 95% CI) 0.21 [0.10, 0.32]
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15 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 End of intervention 15 1579 Std. Mean Difference (IV, Random, 95% CI) 0.31 [0.09, 0.53]
13.2 Follow-up 3 179 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.29, 0.41]
14 FACT Emotional well-being
(follow-up values)
11 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 End of intervention 11 1064 Mean Difference (IV, Random, 95% CI) 0.47 [0.01, 0.94]
14.2 Follow-up 3 311 Mean Difference (IV, Random, 95% CI) 0.14 [-0.85, 1.14]
15 FACT Emotional well-being
(change values)
6 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 End of intervention 6 582 Mean Difference (IV, Random, 95% CI) 0.96 [0.34, 1.57]
15.2 Follow-up 1 36 Mean Difference (IV, Random, 95% CI) 0.79 [-0.67, 2.25]
16 MOS SF Mental composite
(follow-up values)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 End of intervention 5 563 Mean Difference (IV, Random, 95% CI) 0.49 [-1.09, 2.06]
16.2 Follow-up 3 281 Mean Difference (IV, Random, 95% CI) 2.27 [0.05, 4.50]
17 MOS SF Mental composite
(change values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 End of intervention 2 294 Mean Difference (IV, Fixed, 95% CI) 2.22 [-0.95, 5.40]
17.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 MOS SF Mental health
(follow-up values)
7 Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 End of intervention 7 524 Mean Difference (IV, Random, 95% CI) 1.67 [-0.65, 3.99]
18.2 Follow-up 2 196 Mean Difference (IV, Random, 95% CI) 3.49 [-0.97, 7.95]
19 MOS SF Mental health (change
values)
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
19.1 End of intervention 5 333 Mean Difference (IV, Fixed, 95% CI) 2.22 [0.70, 3.74]
19.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20 MOS SF Emotional role
(follow-up values)
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
20.1 End of intervention 5 330 Mean Difference (IV, Fixed, 95% CI) -0.00 [-1.09, 1.09]
20.2 Follow-up 1 120 Mean Difference (IV, Fixed, 95% CI) 3.06 [-11.55, 17.67]
21 MOS SF Emotional role
(change values)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
21.1 End of intervention 4 213 Mean Difference (IV, Fixed, 95% CI) 0.23 [-0.79, 1.24]
21.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 EORTC QLQ-C30 Emotional
function (follow-up values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 End of intervention 3 135 Mean Difference (IV, Random, 95% CI) 11.53 [3.96, 19.11]
22.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
23 EORTC QLQ-C30 Emotional
function (change values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 End of intervention 3 573 Mean Difference (IV, Random, 95% CI) 0.90 [-5.12, 6.92]
23.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
24 POMS total mood disturbance
(follow-up values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 End of intervention 3 161 Std. Mean Difference (IV, Random, 95% CI) -0.93 [-1.55, -0.32]
24.2 Follow-up 1 61 Std. Mean Difference (IV, Random, 95% CI) -0.54 [-1.06, -0.03]
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25 POMS total mood disturbance
(change values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 End of intervention 2 143 Std. Mean Difference (IV, Random, 95% CI) 0.07 [-0.65, 0.79]
25.2 Follow-up 2 143 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.23, 0.42]
26 POMS anger subscale
(follow-up values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 End of intervention 2 79 Std. Mean Difference (IV, Random, 95% CI) -0.78 [-1.25, -0.31]
26.2 Follow-up 1 61 Std. Mean Difference (IV, Random, 95% CI) -0.44 [-0.94, 0.07]
27 Happiness/satisfaction with life
(follow-up values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 End of intervention 4 209 Std. Mean Difference (IV, Random, 95% CI) 0.61 [-0.16, 1.37]
27.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
28 Happiness/satisfaction with life
(change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
28.1 End of intervention 3 182 Std. Mean Difference (IV, Random, 95% CI) 0.28 [-0.05, 0.62]
28.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
29 Overall physical function
(follow-up values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 End of intervention 25 2129 Std. Mean Difference (IV, Random, 95% CI) 0.33 [0.18, 0.49]
29.2 Follow-up 6 637 Std. Mean Difference (IV, Random, 95% CI) 0.21 [0.06, 0.37]
30 Overall physical function
(change values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
30.1 End of intervention 13 1433 Std. Mean Difference (IV, Random, 95% CI) 0.60 [0.23, 0.97]
30.2 Follow-up 1 36 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.48, 0.83]
31 FACT Physical well-being
(follow-up values)
11 Mean Difference (IV, Random, 95% CI) Subtotals only
31.1 End of intervention 11 1064 Mean Difference (IV, Random, 95% CI) 1.44 [0.31, 2.56]
31.2 Follow-up 3 311 Mean Difference (IV, Random, 95% CI) 1.17 [0.22, 2.12]
32 FACT Physical well-being
(change values)
6 Mean Difference (IV, Random, 95% CI) Subtotals only
32.1 End of intervention 6 579 Mean Difference (IV, Random, 95% CI) 1.60 [-0.85, 4.05]
32.2 Follow-up 1 36 Mean Difference (IV, Random, 95% CI) 0.9 [-2.37, 4.17]
33 MOS SF Physical composite
(follow-up values)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
33.1 End of intervention 4 437 Mean Difference (IV, Fixed, 95% CI) 1.78 [0.12, 3.43]
33.2 Follow-up 2 163 Mean Difference (IV, Fixed, 95% CI) 1.30 [-1.23, 3.82]
34 MOS SF Physical composite
(change values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
34.1 End of intervention 2 294 Mean Difference (IV, Fixed, 95% CI) 2.56 [-0.13, 5.25]
34.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
35 MOS SF Physical function
(follow-up values)
7 Mean Difference (IV, Random, 95% CI) Subtotals only
35.1 End of intervention 7 515 Mean Difference (IV, Random, 95% CI) 2.09 [0.03, 4.15]
35.2 Follow-up 2 239 Mean Difference (IV, Random, 95% CI) 2.71 [-1.58, 6.99]
36 MOS SF Physical function
(change values)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
36.1 End of intervention 5 333 Mean Difference (IV, Random, 95% CI) 2.08 [0.21, 3.94]
36.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
37 EORTC QLQ-C30 Physical
function (follow-up values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
37.1 End of intervention 3 135 Mean Difference (IV, Random, 95% CI) 2.99 [-1.64, 7.63]
37.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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38 EORTC QLQ-C30 Physical
function (change values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
38.1 End of intrevention 3 573 Mean Difference (IV, Random, 95% CI) 3.12 [-3.24, 9.49]
38.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
39 Body Esteem Scale - Physical
condition (follow-up values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
39.1 End of intervention 2 106 Mean Difference (IV, Random, 95% CI) 4.41 [0.57, 8.25]
39.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
40 Overall role function
(follow-up values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
40.1 End of intervention 18 1370 Std. Mean Difference (IV, Random, 95% CI) 0.29 [0.07, 0.51]
40.2 Follow-up 2 249 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.12, 0.38]
41 Overall role function (change
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 End of intervention 12 1315 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.05, 0.33]
41.2 Follow-up 1 36 Std. Mean Difference (IV, Random, 95% CI) 0.37 [-0.29, 1.03]
42 FACT Functional well-being
(follow-up values)
11 Mean Difference (IV, Random, 95% CI) Subtotals only
42.1 End of intervention 11 1064 Mean Difference (IV, Random, 95% CI) 1.67 [0.29, 3.06]
42.2 Follow-up 2 249 Mean Difference (IV, Random, 95% CI) 0.68 [-0.65, 2.01]
43 FACT Functional well-being
(change values)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
43.1 End of intervention 6 582 Mean Difference (IV, Fixed, 95% CI) 0.72 [0.42, 1.01]
43.2 Follow-up 1 36 Mean Difference (IV, Fixed, 95% CI) 1.31 [-1.02, 3.64]
44 MOS SF Physical role
(follow-up values)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
44.1 End of intervention 3 143 Mean Difference (IV, Fixed, 95% CI) -0.16 [-1.47, 1.15]
44.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
45 MOS SF Physical role (change
values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
45.1 End of intervention 3 155 Mean Difference (IV, Random, 95% CI) 0.46 [-1.52, 2.43]
45.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
46 EORTC QLQ-C30 Role
function (follow-up values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
46.1 End of intervention 3 135 Mean Difference (IV, Random, 95% CI) 0.44 [-5.78, 6.66]
46.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
47 EORTC QLQ-C30 Role
function (change values)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
47.1 End of intervention 3 573 Mean Difference (IV, Fixed, 95% CI) -1.08 [-4.52, 2.36]




18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
48.1 End of intervention 18 1557 Std. Mean Difference (IV, Random, 95% CI) 0.19 [0.08, 0.30]




12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
49.1 End of intervention 12 1384 Std. Mean Difference (IV, Random, 95% CI) 0.52 [0.16, 0.87]
49.2 Follow-up 1 36 Std. Mean Difference (IV, Random, 95% CI) 0.69 [0.01, 1.36]
50 FACT Social well-being
(follow-up values)
11 Mean Difference (IV, Random, 95% CI) Subtotals only
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50.1 End of intervention 11 1064 Mean Difference (IV, Random, 95% CI) 0.77 [0.11, 1.43]
50.2 Follow-up 1 213 Mean Difference (IV, Random, 95% CI) 0.5 [-1.02, 2.02]
51 FACT Social well-being
(change values)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
51.1 End of intervention 6 582 Mean Difference (IV, Fixed, 95% CI) 1.93 [1.58, 2.28]
51.2 Follow-up 1 36 Mean Difference (IV, Fixed, 95% CI) 3.86 [0.17, 7.55]
52 MOS SF Social functioning
(follow-up values)
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
52.1 End of intervention 5 234 Mean Difference (IV, Fixed, 95% CI) -0.32 [-1.87, 1.23]
52.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
53 MOS SF Social functioning
(change values)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
53.1 End of intervention 4 213 Mean Difference (IV, Fixed, 95% CI) 1.05 [-0.08, 2.18]
53.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
54 EORTC QLQ-C30 Social
function (follow-up values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
54.1 End of intervention 2 73 Mean Difference (IV, Random, 95% CI) 7.55 [-11.77, 26.86]
54.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
55 EORTC QLQ-C30 Social
function (change values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
55.1 End of intervention 3 573 Mean Difference (IV, Random, 95% CI) 2.14 [-8.02, 12.30]
55.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
56 Overall cognitive function
(follow-up values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
56.1 End of intervention 5 189 Std. Mean Difference (IV, Random, 95% CI) 0.40 [0.11, 0.69]
56.2 Follow-up 2 97 Std. Mean Difference (IV, Random, 95% CI) 0.31 [-0.09, 0.71]
57 Overall cognitive function
(change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
57.1 End of intervention 5 672 Std. Mean Difference (IV, Random, 95% CI) -0.00 [-0.27, 0.26]
57.2 Follow-up 2 97 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.20, 0.60]
58 EORTC QLQ-C30 Cognitive
function (follow-up values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
58.1 End of intervention 2 73 Mean Difference (IV, Fixed, 95% CI) 2.43 [-5.75, 10.61]
58.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
59 EORTC QLQ-C30 Cognitive
function (change values)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
59.1 End of intervention 3 573 Mean Difference (IV, Fixed, 95% CI) -3.25 [-6.31, -0.18]
59.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
60 POMS confusion subscale
(follow-up values)
2 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
60.1 End of intervention 2 79 Std. Mean Difference (IV, Fixed, 95% CI) -0.66 [-1.12, -0.19]
60.2 Follow-up 1 61 Std. Mean Difference (IV, Fixed, 95% CI) -0.45 [-0.96, 0.06]
61 Overall general health
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
61.1 End of intervention 9 456 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.08, 0.45]
61.2 Follow-up 1 36 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.87, 0.44]
62 Overall general health (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
62.1 End of intervention 9 906 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.07, 0.40]
62.2 Follow-up 1 36 Std. Mean Difference (IV, Random, 95% CI) 0.07 [-0.59, 0.72]
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63 MOS SF General health
(follow-up values)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
63.1 End of intervention 5 233 Mean Difference (IV, Random, 95% CI) 2.14 [-2.61, 6.88]
63.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
64 MOS SF General health
(change values)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
64.1 End of intervention 4 213 Mean Difference (IV, Fixed, 95% CI) 0.10 [-1.26, 1.45]
64.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
65 Overall sexual function
(follow-up values)
5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
65.1 End of intervention 5 411 Std. Mean Difference (IV, Fixed, 95% CI) 0.16 [-0.04, 0.35]
65.2 Follow-up 1 102 Std. Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.20, 0.58]
66 Overall sexual function (change
values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
66.1 End of intervention 3 693 Std. Mean Difference (IV, Random, 95% CI) 0.22 [-0.08, 0.52]
66.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
67 Body Esteem Scale - sexual
attractiveness (follow-up
values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
67.1 End of intervention 2 100 Mean Difference (IV, Fixed, 95% CI) 1.71 [-1.41, 4.82]
67.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
68 Overall sleep (follow-up values) 5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
68.1 End of intervention 5 188 Std. Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.37, 0.20]
68.2 Follow-up 1 31 Std. Mean Difference (IV, Fixed, 95% CI) -0.49 [-1.20, 0.23]
69 Overall sleep (change values) 3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
69.1 End of intervention 3 136 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.20, 0.48]
69.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
70 PSQI Global sleep score
(follow-up values)
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
70.1 End of intervention 5 317 Mean Difference (IV, Fixed, 95% CI) -0.47 [-1.01, 0.08]
70.2 Follow-up 1 31 Mean Difference (IV, Fixed, 95% CI) -1.5 [-3.63, 0.63]
71 PSQI Global sleep score
(change values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
71.1 End of intervention 2 80 Mean Difference (IV, Fixed, 95% CI) 0.54 [-1.11, 2.19]
71.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
72 PSQI sleep quality (follow-up
values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
72.1 End of intervention 2 80 Mean Difference (IV, Random, 95% CI) -0.24 [-0.81, 0.32]
72.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
73 PSQI sleep efficiency
(follow-up values)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
73.1 End of intervention 3 100 Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.24, 0.53]
73.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
74 PSQI sleep latency (follow-up
values)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
74.1 End of intervention 3 100 Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.16, 0.55]
74.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
75 PSQI sleep duration (follow-up
values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
75.1 End of intervention 2 80 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.28, 0.41]
75.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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76 PSQI daytime dysfunction
(follow-up values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
76.1 End of intervention 3 100 Mean Difference (IV, Random, 95% CI) -0.08 [-0.51, 0.35]
76.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
77 PSQI medication use
(follow-up values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
77.1 End of intervention 2 80 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.50, 0.38]
77.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
78 Accelerator-derived sleep
efficiency (follow-up values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
78.1 End of intervention 2 62 Mean Difference (IV, Fixed, 95% CI) -2.25 [-5.52, 1.01]
78.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
79 Accelerator-derived sleep
latency (follow-up values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
79.1 End of intervention 2 62 Mean Difference (IV, Fixed, 95% CI) -2.04 [-4.78, 0.69]
79.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Comparison: anxiety, all physical activity vs control




participants Statistical method Effect size
1 Overall anxiety (follow-up
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 End of intervention 7 326 Std. Mean Difference (IV, Random, 95% CI) -0.57 [-0.95, -0.19]
1.2 Follow-up 1 61 Std. Mean Difference (IV, Random, 95% CI) -0.47 [-0.98, 0.04]
2 Overall anxiety (change values) 4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 End of intervention 4 235 Std. Mean Difference (IV, Fixed, 95% CI) -0.37 [-0.63, -0.12]
2.2 Follow-up 1 61 Std. Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.81, 0.20]
3 POMS tension - anxiety
(follow-up values)
2 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 End of intervention 2 79 Std. Mean Difference (IV, Fixed, 95% CI) -0.66 [-1.12, -0.20]
3.2 Follow-up 1 61 Std. Mean Difference (IV, Fixed, 95% CI) -0.47 [-0.98, 0.04]
4 State Trait Anxiety Inventory
(follow-up values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 End of intervention 2 89 Std. Mean Difference (IV, Random, 95% CI) -1.20 [-3.49, 1.09]
4.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Cohen’s Perceived Stress Scale 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 End of intervention 2 105 Mean Difference (IV, Fixed, 95% CI) -1.25 [-3.99, 1.50]
5.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Comparison 3. Comparison: depression, all physical activity vs control




participants Statistical method Effect size
1 Overall depression (follow-up
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 End of intervention 12 657 Std. Mean Difference (IV, Random, 95% CI) -0.34 [-0.62, -0.05]
1.2 Follow-up 4 340 Std. Mean Difference (IV, Random, 95% CI) -0.28 [-0.51, -0.05]
2 Overall depression (change
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 End of intervention 7 816 Std. Mean Difference (IV, Random, 95% CI) -0.34 [-0.63, -0.05]
2.2 Follow-up 1 61 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-0.97, 0.05]
3 Beck Depression Inventory-II
(follow-up values)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 End of intervention 5 198 Mean Difference (IV, Random, 95% CI) -3.25 [-5.94, -0.56]
3.2 Follow-up 2 93 Mean Difference (IV, Random, 95% CI) -2.35 [-5.31, 0.60]
4 Beck Depression Inventory-II
(change values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 End of intervention 3 581 Mean Difference (IV, Random, 95% CI) -1.84 [-5.33, 1.65]
4.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 CES-Depression scale (follow-up
values)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 End of intervention 3 280 Mean Difference (IV, Fixed, 95% CI) -1.36 [-3.39, 0.67]
5.2 Follow-up 1 186 Mean Difference (IV, Fixed, 95% CI) -1.90 [-4.32, 0.52]
6 POMS depression subscale
(follow-up values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 End of intervention 2 79 Mean Difference (IV, Random, 95% CI) -6.39 [-10.66, -2.12]
6.2 Follow-up 1 61 Mean Difference (IV, Random, 95% CI) -6.65 [-11.97, -1.33]
7 POMS tension subscale
(follow-up values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 End of intervention 2 79 Mean Difference (IV, Random, 95% CI) -5.14 [-9.55, -0.73]
7.2 Follow-up 1 61 Mean Difference (IV, Random, 95% CI) -4.87 [-10.09, 0.35]
Comparison 4. Comparison: fatigue and vigour, all physical activity vs control




participants Statistical method Effect size
1 Overall fatigue (follow-up
values)
26 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 End of intervention 26 2020 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.47, -0.18]
1.2 Follow-up 7 536 Std. Mean Difference (IV, Random, 95% CI) -0.43 [-0.60, -0.26]
2 Overall fatigue (change values) 13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 End of intervention 13 1289 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.61, 0.00]
2.2 Follow-up 4 178 Std. Mean Difference (IV, Random, 95% CI) -0.47 [-0.84, -0.11]
3 FACT-Fatigue (follow-up values) 7 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 End of intervention 7 952 Mean Difference (IV, Fixed, 95% CI) 1.14 [-0.06, 2.35]
3.2 Follow-up 2 112 Mean Difference (IV, Fixed, 95% CI) 1.49 [-1.95, 4.93]
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4 FACT-Fatigue (change values) 4 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 End of intervention 4 925 Mean Difference (IV, Random, 95% CI) -0.54 [-3.23, 2.14]
4.2 Follow-up 1 36 Mean Difference (IV, Random, 95% CI) 1.28 [-4.11, 6.67]
5 EORTC QLQ-C30 Fatigue
scale (follow-up values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 End of intervention 2 119 Mean Difference (IV, Fixed, 95% CI) -6.83 [-13.08, -0.58]
5.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 EORTC QLQ-C30 Fatigue
scale (change values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 End of intervention 2 73 Mean Difference (IV, Random, 95% CI) -2.81 [-14.98, 9.36]




5 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 End of intervention 5 366 Mean Difference (IV, Random, 95% CI) -0.53 [-1.35, 0.29]




2 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 End of intervention 2 62 Mean Difference (IV, Random, 95% CI) -0.37 [-1.34, 0.60]
8.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Revised Piper Fatigue Scale total
fatigue (follow-up values)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 End of intervention 4 187 Mean Difference (IV, Random, 95% CI) -1.18 [-2.38, 0.02]
9.2 Follow-up 2 120 Mean Difference (IV, Random, 95% CI) -1.15 [-1.86, -0.43]
10 Revised Piper Fatigue Scale
total fatigue (change values)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 End of intervention 4 166 Mean Difference (IV, Random, 95% CI) -1.96 [-2.93, 1.00]
10.2 Follow-up 2 120 Mean Difference (IV, Random, 95% CI) -1.14 [-1.78, -0.49]
11 Revised Piper Fatigue Scale
behavioural/severity (follow-up
values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 End of intervention 3 121 Mean Difference (IV, Random, 95% CI) -1.24 [-2.49, 0.01]
11.2 Follow-up 1 61 Mean Difference (IV, Random, 95% CI) -1.41 [-2.57, -0.25]
12 Revised Piper Fatigue Scale
affective/meaning (follow-up
values)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 End of intervention 3 121 Mean Difference (IV, Fixed, 95% CI) -2.11 [-3.03, -1.20]
12.2 Follow-up 1 61 Mean Difference (IV, Fixed, 95% CI) -2.05 [-3.21, -0.89]
13 Revised Piper Fatigue Scale
sensory (follow-up values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 End of intervention 3 121 Mean Difference (IV, Random, 95% CI) -0.44 [-3.11, 2.22]
13.2 Follow-up 1 61 Mean Difference (IV, Random, 95% CI) -1.60 [-2.65, -0.55]
14 Revised Piper Fatigue Scale
cognitive/mood (follow-up
values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 End of intervention 3 121 Mean Difference (IV, Random, 95% CI) -0.72 [-2.31, 0.87]
14.2 Follow-up 1 61 Mean Difference (IV, Random, 95% CI) -1.40 [-2.50, -0.30]
15 Schwartz Cancer Fatigue Scale
(follow-up values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 End of intervention 2 125 Mean Difference (IV, Random, 95% CI) -2.01 [-9.25, 5.23]
15.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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16 POMS fatigue scale (follow-up
values)
2 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
16.1 End of intervention 2 79 Std. Mean Difference (IV, Fixed, 95% CI) -0.54 [1.00, -0.08]
16.2 Follow-up 1 61 Std. Mean Difference (IV, Fixed, 95% CI) -0.57 [-1.08, -0.05]
17 Visual analogue scale fatigue
(follow-up and change values)
4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 End of intervention 4 148 Std. Mean Difference (IV, Fixed, 95% CI) -0.51 [-0.88, -0.14]
17.2 Follow-up 1 22 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Overall vigour/vitality
(follow-up values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 End of intervention 10 762 Std. Mean Difference (IV, Random, 95% CI) 0.36 [0.21, 0.50]
18.2 Follow-up 4 454 Std. Mean Difference (IV, Random, 95% CI) 0.26 [0.04, 0.48]
19 Overall vigour/vitality (change
values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 End of intervention 6 359 Std. Mean Difference (IV, Random, 95% CI) 0.23 [0.00, 0.45]
19.2 Follow-up 2 233 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.06, 0.46]
20 MOS SF vitality (follow-up
values)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
20.1 End of intervention 6 514 Mean Difference (IV, Fixed, 95% CI) 3.08 [0.84, 5.31]
20.2 Follow-up 2 306 Mean Difference (IV, Fixed, 95% CI) 5.09 [0.99, 9.19]
21 MOS SF vitality (change
values)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
21.1 End of intervention 4 212 Mean Difference (IV, Fixed, 95% CI) 1.36 [-0.52, 3.25]
21.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
22 POMS vigour scale (follow-up
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 End of intervention 4 248 Std. Mean Difference (IV, Random, 95% CI) 0.46 [0.13, 0.79]
22.2 Follow-up 2 148 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.34, 0.77]
23 POMS vigour scale (change
values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 End of intervention 2 147 Std. Mean Difference (IV, Random, 95% CI) 0.25 [-0.45, 0.95]
23.2 Follow-up 2 233 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.06, 0.46]
Comparison 5. Comparison: pain/disability, all physical activity vs control




participants Statistical method Effect size
1 Overall pain/disability
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 End of intervention 9 535 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.09, 0.25]
1.2 Follow-up 1 162 Std. Mean Difference (IV, Random, 95% CI) 0.19 [-0.12, 0.50]
2 Overall pain/disability (change
values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 End of intervention 5 296 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.33, 0.16]
2.2 Follow-up 1 36 Std. Mean Difference (IV, Random, 95% CI) 0.22 [-0.43, 0.88]
3 Brief Pain Inventory severity
score (change values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 End of intervention 2 145 Mean Difference (IV, Random, 95% CI) -0.84 [-1.92, 0.23]
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3.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Brief Pain Inventory interference
score (change values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 End of intervention 2 145 Mean Difference (IV, Random, 95% CI) -1.08 [-1.91, -0.24]
4.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 DASH (follow-up and change
values)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 End of intervention 3 179 Mean Difference (IV, Fixed, 95% CI) -4.00 [-9.08, -2.91]
5.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 EORTC QLQ-C30 Pain scale
(follow-up and change values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
6.1 End of intervention 2 119 Mean Difference (IV, Fixed, 95% CI) -1.04 [-9.83, 7.75]
6.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 MOS SF Pain (follow-up values) 5 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 End of intervention 5 378 Mean Difference (IV, Random, 95% CI) 1.25 [-1.40, 3.90]
7.2 Follow-up 1 162 Mean Difference (IV, Random, 95% CI) 4.45 [-2.80, 11.70]
8 MOS SF Pain (change values) 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 End of intervention 4 213 Mean Difference (IV, Fixed, 95% CI) 0.07 [-1.04, 1.17]
8.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 WOMAC joint pain (follow-up
and change values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 End of intervention 2 121 Mean Difference (IV, Random, 95% CI) -2.36 [-7.55, 2.82]
9.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 WOMAC physical dysfunction
(follow-up and change values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 End of intervention 2 121 Mean Difference (IV, Random, 95% CI) -6.15 [-16.21, 3.92]
10.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 WOMAC total score
(follow-up and change values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 End of intervention 2 121 Mean Difference (IV, Random, 95% CI) -6.49 [-13.57, 0.58]
11.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 6. Comparison: self-esteem, all physical activity vs control




participants Statistical method Effect size
1 Overall self-esteem/body image
(follow-up values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 End of intervention 12 667 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.05, 0.48]
1.2 Follow-up 1 61 Std. Mean Difference (IV, Random, 95% CI) 0.57 [0.05, 1.08]
2 Overall self-esteem/body image
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 End of intervention 9 992 Std. Mean Difference (IV, Random, 95% CI) 0.23 [-0.11, 0.58]
2.2 Follow-up 1 62 Std. Mean Difference (IV, Random, 95% CI) 0.46 [-0.05, 0.96]
3 Body Esteem Scale - weight
concern (follow-up values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 End of intervention 2 100 Mean Difference (IV, Random, 95% CI) 4.22 [-1.01, 9.45]
3.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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4 Physical self-perception profile
- attractiveness of body
(follow-up values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 End of intervention 2 107 Mean Difference (IV, Fixed, 95% CI) 0.46 [0.13, 0.79]
4.2 Follow-up 1 61 Mean Difference (IV, Fixed, 95% CI) 0.29 [0.04, 0.54]
5 Physical self-perception profile -
attractiveness of body (change
values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 End of intervention 2 108 Mean Difference (IV, Fixed, 95% CI) 0.26 [-0.07, 0.59]
5.2 Follow-up 1 62 Mean Difference (IV, Fixed, 95% CI) 0.26 [-0.02, 0.54]
6 Rosenberg Self-Esteem Scale
(follow-up values)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 End of intervention 4 183 Mean Difference (IV, Random, 95% CI) 0.24 [-1.79, 2.26]
6.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Rosenberg Self-Esteem Scale
(change values)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 End of intervention 4 189 Mean Difference (IV, Fixed, 95% CI) 2.78 [1.98, 3.58]
7.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 EORTC QLQ-C30 Body image
(follow-up and change values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 End of intervention 2 562 Mean Difference (IV, Fixed, 95% CI) -0.85 [-4.38, 2.68]
8.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 7. Comparison: cardiorespiratory fitness, all physical activity vs control




participants Statistical method Effect size
1 Overall cardiorespiratory fitness
(follow-up values)
23 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 End of intervention 23 1265 Std. Mean Difference (IV, Random, 95% CI) 0.44 [0.30, 0.58]
1.2 Follow-up 3 362 Std. Mean Difference (IV, Random, 95% CI) 0.36 [0.03, 0.69]
2 Overall cardiorespiratory fitness
(change values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 End of intervention 9 863 Std. Mean Difference (IV, Random, 95% CI) 0.83 [0.40, 1.27]
2.2 Follow-up 2 115 Std. Mean Difference (IV, Random, 95% CI) 0.42 [0.05, 0.79]
3 Directly assessed VO max/peak
(follow-up values)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 End of intervention 4 199 Mean Difference (IV, Fixed, 95% CI) 1.89 [0.65, 3.13]
3.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Directly assessed VO max/peak
(change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 End of intervention 3 166 Std. Mean Difference (IV, Random, 95% CI) 1.31 [0.66, 1.96]
4.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Directly assessed VO max/peak
- treadmill (follow-up and
change values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 End of intervention 2 116 Std. Mean Difference (IV, Random, 95% CI) 1.04 [-0.49, 2.58]
5.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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6 Directly assessed VO max/peak
- cycle ergometer (follow-up
values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 End of intervention 3 116 Mean Difference (IV, Random, 95% CI) 1.99 [0.39, 3.59]
6.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Peak Power Output - cycle
ergometer test (follow-up
values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
7.1 End of intervention 2 66 Mean Difference (IV, Fixed, 95% CI) 18.92 [9.64, 28.20]
7.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Peak Respiratory Exchange
Ratio - cycle ergometer test
(follow-up values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 End of intervention 2 66 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.04, 0.03]
8.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Peak Heart Rate - cycle
ergometer test (follow-up
values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 End of intervention 2 66 Mean Difference (IV, Fixed, 95% CI) 2.02 [-5.65, 9.68]
9.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Ebbeling single-stage treadmill
test (follow-up and change
values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 End of intervention 2 189 Mean Difference (IV, Random, 95% CI) 1.30 [-0.16, 2.75]
10.2 Follow-up 2 149 Mean Difference (IV, Random, 95% CI) 1.77 [-1.23, 4.77]
11 Modified Bruce treadmill test
(follow-up and change values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 End of intervention 3 92 Mean Difference (IV, Random, 95% CI) 3.57 [0.95, 6.19]
11.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Naughton submaximal
treadmill test (follow-up and
change values)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 End of intervention 4 315 Mean Difference (IV, Random, 95% CI) 2.02 [-0.33, 4.37]
12.2 Follow-up 2 249 Mean Difference (IV, Random, 95% CI) 1.91 [0.57, 3.26]
13 Cardiorespiratory fitness walk
tests (follow-up values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 End of intervention 7 314 Std. Mean Difference (IV, Random, 95% CI) 0.62 [0.33, 0.91]
13.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Cardiorespiratory fitness walk
tests (change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 End of intervention 3 592 Std. Mean Difference (IV, Random, 95% CI) 0.72 [-0.05, 1.49]
14.2 Follow-up 1 79 Std. Mean Difference (IV, Random, 95% CI) 0.54 [0.09, 0.99]
15 6-Minute walk test (follow-up
and change values)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 End of intervention 5 159 Mean Difference (IV, Random, 95% CI) 54.74 [33.25, 76.22]
15.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 12-Minute walk test (follow-up
values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 End of intervention 2 96 Mean Difference (IV, Random, 95% CI) 94.56 [-24.25, 213.
37]
16.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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17 2-Kilometer walk test
(follow-up and change values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 End of intervention 2 526 Mean Difference (IV, Random, 95% CI) -0.11 [-0.46, 0.25]
17.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Resting Heart Rate (follow-up
values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 End of intervention 2 82 Mean Difference (IV, Fixed, 95% CI) -4.47 [-7.94, -1.00]
18.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
19 Resting Heart Rate (change
values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 End of intervention 2 86 Std. Mean Difference (IV, Random, 95% CI) -1.05 [-2.22, 0.11]
19.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Resting Systolic Blood Pressure
(follow-up values)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 End of intervention 4 134 Mean Difference (IV, Random, 95% CI) -0.83 [-3.72, 2.05]
20.2 Follow-up 1 26 Mean Difference (IV, Random, 95% CI) 5.20 [-5.35, 15.75]
21 Resting Systolic Blood Pressure
(change values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 End of intervention 3 143 Mean Difference (IV, Random, 95% CI) -1.12 [-7.74, 5.50]
21.2 Follow-up 1 26 Mean Difference (IV, Random, 95% CI) -2.70 [-5.94, 0.54]
22 Resting Diastolic Blood
Pressure (follow-up values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 End of intervention 3 106 Mean Difference (IV, Random, 95% CI) 0.66 [-2.89, 4.21]
22.2 Follow-up 1 26 Mean Difference (IV, Random, 95% CI) 2.10 [-3.78, 7.98]
23 Resting Diastolic Blood
Pressure (change values)
3 170 Mean Difference (IV, Random, 95% CI) -0.04 [-1.82, 1.73]
23.1 End of intervention 3 144 Mean Difference (IV, Random, 95% CI) 0.53 [-1.61, 2.68]
23.2 Follow-up 1 26 Mean Difference (IV, Random, 95% CI) -1.30 [-3.85, 1.25]
Comparison 8. Comparison: physical activity, all physical activity vs control




participants Statistical method Effect size
1 Overall self-reported physical
activity (follow-up values)
17 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 End of intervention 17 2012 Std. Mean Difference (IV, Random, 95% CI) 0.52 [0.33, 0.71]
1.2 Follow-up 4 683 Std. Mean Difference (IV, Random, 95% CI) 0.44 [0.17, 0.72]
2 Overall self-reported physical
activity (change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 End of intervention 8 1274 Std. Mean Difference (IV, Random, 95% CI) 0.57 [0.25, 0.90]
2.2 Follow-up 4 521 Std. Mean Difference (IV, Random, 95% CI) 0.51 [0.08, 0.93]
3 Self-reported total physical
activity (follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 End of intervention 9 881 Std. Mean Difference (IV, Random, 95% CI) 0.57 [0.28, 0.86]
3.2 Follow-up 1 26 Std. Mean Difference (IV, Random, 95% CI) 0.37 [-0.43, 1.16]
4 Self-reported total physical
activity (change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 End of intervention 5 332 Std. Mean Difference (IV, Random, 95% CI) 0.80 [0.30, 1.31]
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4.2 Follow-up 2 108 Std. Mean Difference (IV, Random, 95% CI) 0.73 [-0.36, 1.83]
5 Self-reported moderate physical
activity (follow-up values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 End of intervention 4 249 Std. Mean Difference (IV, Random, 95% CI) 0.77 [0.47, 1.07]
5.2 Follow-up 1 26 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.69, 0.89]
6 Self-reported moderate physical
activity (change values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 End of intervention 2 93 Std. Mean Difference (IV, Random, 95% CI) 1.19 [0.27, 2.11]




6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 End of intervention 6 1025 Std. Mean Difference (IV, Random, 95% CI) 0.42 [0.12, 0.72]
7.2 Follow-up 3 657 Std. Mean Difference (IV, Random, 95% CI) 0.46 [0.13, 0.78]
8 Self-reported moderate-vigorous
physical activity (change values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 End of intervention 2 875 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.14, 0.44]
8.2 Follow-up 3 495 Std. Mean Difference (IV, Random, 95% CI) 0.30 [0.00, 0.59]
9 Self-reported vigorous physical
activity (follow-up values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 End of intervention 3 182 Std. Mean Difference (IV, Random, 95% CI) 0.74 [0.43, 1.04]
9.2 Follow-up 1 26 Std. Mean Difference (IV, Random, 95% CI) 0.19 [-0.61, 0.98]
10 Self-reported vigorous physical
activity (change values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 End of intervention 2 108 Std. Mean Difference (IV, Random, 95% CI) 1.72 [0.78, 2.66]
10.2 Follow-up 2 108 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.92, 0.66]
11 Self-reported walking
(follow-up values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 End of intervention 2 374 Std. Mean Difference (IV, Random, 95% CI) 0.40 [-0.06, 0.86]
11.2 Follow-up 1 338 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.15, 0.34]
12 Self-reported walking (change
values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 End of intervention 2 374 Std. Mean Difference (IV, Random, 95% CI) 0.50 [0.23, 0.77]
12.2 Follow-up 1 338 Std. Mean Difference (IV, Random, 95% CI) 0.23 [-0.02, 0.47]
13 7-Day PAR self-reported
moderate physical activity
(follow-up values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
13.1 End of intervention 2 149 Mean Difference (IV, Fixed, 95% CI) 110.44 [72.50, 148.
38]
13.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 7-day PAR self-reported
moderate-vigorous physical
activity (follow-up values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 End of intervention 2 128 Mean Difference (IV, Random, 95% CI) 52.86 [29.04, 76.67]
14.2 Follow-up 1 67 Mean Difference (IV, Random, 95% CI) 41.2 [11.81, 70.59]
15 Godin LSI self-reported
moderate-vigorous physical
activity (follow-up values)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 End of intervention 5 936 Mean Difference (IV, Random, 95% CI) 39.42 [-1.51, 80.34]
15.2 Follow-up 2 590 Mean Difference (IV, Random, 95% CI) 55.07 [17.16, 92.99]
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6 Odds Ratio (M-H, Random, 95% CI) Subtotals only
16.1 End of intervention 6 819 Odds Ratio (M-H, Random, 95% CI) 8.44 [2.41, 29.56]
16.2 Follow-up 2 280 Odds Ratio (M-H, Random, 95% CI) 3.11 [1.50, 6.46]
17 Overall objective physical
activity (follow-up values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 End of intervention 10 1248 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.19, 0.66]
17.2 Follow-up 3 305 Std. Mean Difference (IV, Random, 95% CI) 0.22 [-0.21, 0.66]
18 Overall objective physical
activity (change values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 End of intervention 5 508 Std. Mean Difference (IV, Random, 95% CI) 0.71 [0.14, 1.29]




5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 End of intervention 5 390 Std. Mean Difference (IV, Random, 95% CI) 1.49 [0.47, 2.51]
19.2 Follow-up 2 280 Std. Mean Difference (IV, Random, 95% CI) 0.36 [-0.08, 0.79]
20 Objective moderate-vigorous
physical activity (change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 End of intervention 2 78 Std. Mean Difference (IV, Random, 95% CI) 0.92 [0.45, 1.40]
20.2 Follow-up 1 36 Std. Mean Difference (IV, Random, 95% CI) 0.84 [0.15, 1.52]
21 Objective vigorous physical
activity (follow-up values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 End of intervention 2 63 Std. Mean Difference (IV, Random, 95% CI) 0.46 [-0.05, 0.97]
21.2 Follow-up 1 25 Std. Mean Difference (IV, Random, 95% CI) -0.16 [-0.97, 0.66]
22 Accelerometer counts
(follow-up values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 End of intervention 2 74 Std. Mean Difference (IV, Random, 95% CI) 0.90 [0.08, 1.72]
22.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
23 Pedometer/accelerometer
steps/d (follow-up values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 End of intervention 5 809 Std. Mean Difference (IV, Random, 95% CI) 0.22 [-0.08, 0.53]
23.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
24 Pedometer/accelerometer
steps/d (change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 End of intervention 3 441 Std. Mean Difference (IV, Random, 95% CI) 0.45 [-0.18, 1.09]
24.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
25 Overall sedentary behaviour
(follow-up values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 End of intervention 4 402 Std. Mean Difference (IV, Random, 95% CI) -1.01 [-2.28, 0.26]
25.2 Follow-up 1 25 Std. Mean Difference (IV, Random, 95% CI) 0.58 [-0.26, 1.41]
26 Objective sedentary behaviour
(follow-up values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 End of intervention 3 103 Std. Mean Difference (IV, Random, 95% CI) -1.45 [-3.68, 0.78]
26.2 Follow-up 1 25 Std. Mean Difference (IV, Random, 95% CI) 0.58 [-0.26, 1.41]
27 Objective sedentary behaviour
(change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 End of intervention 3 103 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.63, 0.60]
27.2 Follow-up 1 25 Std. Mean Difference (IV, Random, 95% CI) 0.88 [0.02, 1.74]
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Comparison 9. Comparison: anthropometric outcomes, all physical activity vs control




participants Statistical method Effect size
1 Mass (follow-up values) 16 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 End of intervention 16 1210 Mean Difference (IV, Fixed, 95% CI) 0.00 [-0.57, 0.58]
1.2 Follow-up 1 49 Mean Difference (IV, Fixed, 95% CI) 5.02 [-5.17, 15.21]
2 Mass (change values) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 End of intervention 11 1047 Mean Difference (IV, Random, 95% CI) -0.50 [-0.98, -0.01]
2.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 BMI (follow-up values) 17 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 End of intervention 17 1481 Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.19, 0.22]
3.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 BMI (change values) 8 Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 End of intervention 8 485 Mean Difference (IV, Random, 95% CI) -0.22 [-0.45, 0.01]
4.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Overall body fat (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 End of intervention 18 1162 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.34, -0.03]
5.2 Follow-up 1 49 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.48, 0.64]
6 Overall body fat (change values) 9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 End of intervention 9 499 Std. Mean Difference (IV, Random, 95% CI) -0.62 [-1.19, -0.06]
6.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Percentage body fat - DEXA
(follow-up values)
6 Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 End of intervention 6 580 Mean Difference (IV, Random, 95% CI) -0.66 [-1.70, 0.37]
7.2 Follow-up 1 49 Mean Difference (IV, Random, 95% CI) 0.52 [-3.18, 4.22]
8 Percentage body fat - DEXA
(change values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 End of intervention 3 228 Mean Difference (IV, Random, 95% CI) -1.32 [-1.66, -0.99]
8.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Percentage body fat - BIA
(follow-up values)
7 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 End of intervention 7 331 Mean Difference (IV, Fixed, 95% CI) -1.47 [-2.84, -0.10]
9.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
10 Percentage body fat - BIA
(change values)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
10.1 End of intervention 4 185 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.26, -0.13]
10.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
11 Percentage body fat - SKF
(follow-up values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 End of intervention 3 165 Mean Difference (IV, Random, 95% CI) -0.73 [-2.41, 0.96]
11.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Fat mass (follow-up values) 5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 End of intervention 5 460 Mean Difference (IV, Fixed, 95% CI) -0.70 [-1.40, -0.00]
12.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13 Fat mass (change values) 4 Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 End of intervention 4 768 Mean Difference (IV, Random, 95% CI) -0.46 [-1.08, 0.15]
13.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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14 Fat mass - DEXA (follow-up
values)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 End of intervention 3 408 Mean Difference (IV, Fixed, 95% CI) -0.68 [-1.39, 0.03]
14.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Fat mass - DEXA (change
values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 End of intervention 2 207 Mean Difference (IV, Random, 95% CI) -0.74 [-0.93, -0.56]
15.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Lean mass (follow-up values) 8 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
16.1 End of intervention 8 612 Std. Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.11, 0.21]
16.2 Follow-up 1 49 Std. Mean Difference (IV, Fixed, 95% CI) 0.33 [-0.24, 0.89]
17 Lean mass (change values) 5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 End of intervention 5 760 Std. Mean Difference (IV, Random, 95% CI) 0.80 [-0.13, 1.72]
17.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Lean mass - DEXA (follow-up
values)
5 Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 End of intervention 5 541 Mean Difference (IV, Fixed, 95% CI) 0.43 [-0.54, 1.40]
18.2 Follow-up 1 49 Mean Difference (IV, Fixed, 95% CI) 2.41 [-1.62, 6.44]
19 Lean mass - DEXA (change
values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 End of intervention 2 207 Mean Difference (IV, Random, 95% CI) 0.73 [0.17, 1.29]
19.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Waist-to-hip ratio (follow-up
values)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 End of intervention 5 213 Mean Difference (IV, Random, 95% CI) -0.03 [-0.06, 0.01]
20.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
21 Waist-to-hip ratio (change
values)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
21.1 End of intervention 2 124 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.01, 0.01]
21.2 Follow-up 1 36 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.14, 0.22]
22 Waist circumference (follow-up
values)
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
22.1 End of intervention 6 330 Mean Difference (IV, Fixed, 95% CI) -0.50 [-3.18, 2.18]
22.2 Follow-up 1 26 Mean Difference (IV, Fixed, 95% CI) 1.40 [-8.29, 11.09]
23 Waist circumference (change
values)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 End of intervention 5 285 Mean Difference (IV, Random, 95% CI) -1.71 [-2.56, -0.86]
23.2 Follow-up 1 26 Mean Difference (IV, Random, 95% CI) -0.90 [-2.61, 0.81]
24 Hip circumference (follow-up
values)
4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
24.1 End of intervention 4 249 Mean Difference (IV, Fixed, 95% CI) -0.97 [-3.96, 2.01]
24.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
25 Hip circumference (change
values)
2 Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 End of intervention 2 115 Mean Difference (IV, Random, 95% CI) -2.37 [-3.31, -1.44]
25.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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Comparison 10. Comparison: muscular strength, all physical activity vs control




participants Statistical method Effect size
1 Lower body strength (follow-up
values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 End of intervention 10 637 Std. Mean Difference (IV, Random, 95% CI) 0.44 [0.09, 0.78]
1.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Lower body strength (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 End of intervention 8 720 Std. Mean Difference (IV, Random, 95% CI) 0.72 [0.38, 1.07]
2.2 Follow-up 1 36 Std. Mean Difference (IV, Random, 95% CI) 0.78 [0.10, 1.46]
3 Leg press (follow-up values) 5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 End of intervention 5 422 Std. Mean Difference (IV, Random, 95% CI) 0.79 [0.35, 1.22]
3.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Leg press (change values) 5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 End of intervention 5 393 Std. Mean Difference (IV, Random, 95% CI) 0.94 [0.68, 1.20]
4.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Back & leg strength (follow-up
values)
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 End of intervention 2 58 Mean Difference (IV, Fixed, 95% CI) 7.90 [-2.31, 18.11]
5.2 Follow-up 0 0 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Leg extension (follow-up values) 4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 End of intervention 4 177 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.34, 0.32]
6.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
7 Leg extension (change values) 4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 End of intervention 4 389 Std. Mean Difference (IV, Random, 95% CI) 0.57 [0.03, 1.12]
7.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
8 Hip extension (follow-up values) 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 End of intervention 2 285 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.45, 0.72]
8.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
9 Hip flexion (follow-up values) 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 End of intervention 2 285 Std. Mean Difference (IV, Random, 95% CI) 0.04 [-0.76, 0.83]
9.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
10 Leg flexion (follow-up values) 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 End of intervention 2 243 Std. Mean Difference (IV, Random, 95% CI) 0.86 [-0.05, 1.76]
10.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11 Upper body strength (follow-up
values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 End of intervention 13 768 Std. Mean Difference (IV, Random, 95% CI) 0.42 [0.08, 0.76]
11.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Upper body strength (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 End of intervention 8 832 Std. Mean Difference (IV, Random, 95% CI) 0.72 [0.30, 1.14]
12.2 Follow-up 1 36 Std. Mean Difference (IV, Random, 95% CI) 0.76 [0.08, 1.44]
13 Chest press (follow-up values) 5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 End of intervention 5 444 Std. Mean Difference (IV, Random, 95% CI) 0.51 [-0.15, 1.17]
13.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
14 Chest press (change values) 4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 End of intervention 4 381 Std. Mean Difference (IV, Random, 95% CI) 1.13 [0.46, 1.80]
14.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
249Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
15 Grip strength (follow-up) 7 Mean Difference (IV, Random, 95% CI) Subtotals only
15.1 End of intervention 7 320 Mean Difference (IV, Random, 95% CI) 2.37 [0.20, 4.55]
15.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16 Grip strength (change values) 3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 End of intervention 2 145 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.09, 0.58]
16.2 Follow-up 1 36 Std. Mean Difference (IV, Random, 95% CI) 0.76 [0.08, 1.44]
17 Grip strength right hand
(follow-up)
5 Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 End of intervention 5 232 Mean Difference (IV, Random, 95% CI) 2.30 [-0.56, 5.16]
17.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18 Grip strength left hand
(follow-up)
4 Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 End of intervention 4 198 Mean Difference (IV, Random, 95% CI) 2.12 [-1.05, 5.30]
18.2 Follow-up 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Elbow flexion (follow-up
values)
3 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
19.1 End of intervention 3 148 Std. Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.41, 0.24]
19.2 Follow-up 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 11. Comparison: bone health, all physical activity vs control




participants Statistical method Effect size
1 Bone mineral content (follow-up
and change values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 End of intervention 2 525 Std. Mean Difference (IV, Random, 95% CI) 0.04 [-0.20, 0.27]
1.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
2 Bone mineral density - femoral
neck (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 End of intervention 4 786 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.13, 0.55]
2.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
3 Bone mineral density - lumbar
spine (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 End of intervention 4 786 Std. Mean Difference (IV, Random, 95% CI) 0.22 [-0.09, 0.53]
3.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
4 Bone mineral density - total hip
(follow-up and change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 End of intervention 3 329 Std. Mean Difference (IV, Random, 95% CI) 0.58 [-0.02, 1.18]
4.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
5 Bone formation - alkaline
phosphatase (follow-up and
change values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 End of intervention 2 239 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-1.81, 1.31]
5.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
6 Bone resorption - serum NTx
(follow-up and change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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6.1 End of intervention 3 278 Std. Mean Difference (IV, Random, 95% CI) 0.38 [-1.58, 2.34]
6.2 Follow-up 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 12. Subanalysis: outcomes by menopausal status




participants Statistical method Effect size
1 Overall HRQoL (follow-up
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Postmenopausal only 3 186 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.05, 0.54]
1.2 Not postmenopausal only 6 818 Std. Mean Difference (IV, Random, 95% CI) 0.55 [0.11, 0.98]
2 Overall HRQoL (change values) 7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Postmenopausal only 3 186 Std. Mean Difference (IV, Random, 95% CI) 0.49 [0.19, 0.79]




11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Postmenopausal only 2 126 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.14, 0.56]




7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Postmenopausal only 2 126 Std. Mean Difference (IV, Random, 95% CI) 0.37 [0.01, 0.72]
4.2 Not postmenopausal only 5 1013 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.17, 0.33]
5 Overall physical function
(follow-up values)
11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Postmenopausal only 3 187 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.20, 0.38]
5.2 Not postmenopausal only 8 929 Std. Mean Difference (IV, Random, 95% CI) 0.50 [0.10, 0.90]
6 Overall physical function
(change values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Postmenopausal only 2 126 Std. Mean Difference (IV, Random, 95% CI) 0.52 [-0.36, 1.39]
6.2 Not postmenopausal only 4 949 Std. Mean Difference (IV, Random, 95% CI) 0.03 [-0.20, 0.25]
7 Overall role function (follow-up
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Postmenopausal only 2 126 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.08, 0.62]
7.2 Not postmenopausal only 6 818 Std. Mean Difference (IV, Random, 95% CI) 0.42 [-0.07, 0.90]
8 Overall role function (change
values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Postmenopausal only 2 126 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.24, 0.46]




8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Postmenopausal only 3 168 Std. Mean Difference (IV, Random, 95% CI) 0.43 [-0.06, 0.91]




6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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10.1 Postmenopausal only 3 168 Std. Mean Difference (IV, Random, 95% CI) 0.50 [0.19, 0.80]
10.2 Not postmenopausal
only
3 873 Std. Mean Difference (IV, Random, 95% CI) 0.50 [-0.39, 1.40]
11 Overall cognitive function
(follow-up values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 Postmenopausal only 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Not postmenopausal
only
3 116 Std. Mean Difference (IV, Random, 95% CI) 0.58 [0.20, 0.95]
12 Overall cognitive function
(change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 Postmenopausal only 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Not postmenopausal
only
3 599 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.31, 0.55]
13 Overall general health
(follow-up values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 Postmenopausal only 2 134 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.41, 0.35]
13.2 Not postmenopausal
only
2 117 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.57, 0.39]
14 Overall general health (change
values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Postmenopausal only 2 134 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.18, 0.71]
14.2 Not postmenopausal
only
3 617 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.22, 0.21]
15 Overall sexual function
(follow-up values)
2 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 Postmenopausal only 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
15.2 Not postmenopausal
only
2 161 Std. Mean Difference (IV, Fixed, 95% CI) 0.31 [-0.00, 0.62]
16 Overall sexual function (change
values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 Postmenopausal only 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Not postmenopausal
only
2 579 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.14, 0.30]
17 Overall sleep (follow-up values) 4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 Postmenopausal only 1 42 Std. Mean Difference (IV, Fixed, 95% CI) -0.11 [-0.72, 0.49]
17.2 Not postmenopausal
only
3 89 Std. Mean Difference (IV, Fixed, 95% CI) 0.18 [-0.24, 0.60]
18 Overall sleep (change values) 2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 Postmenopausal only 1 42 Std. Mean Difference (IV, Random, 95% CI) 0.23 [-0.38, 0.84]
18.2 Not postmenopausal
only
1 38 Std. Mean Difference (IV, Random, 95% CI) 0.05 [-0.59, 0.68]
19 Overall anxiety (follow-up
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 Postmenopausal only 2 116 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.46, 0.27]
19.2 Not postmenopausal
only
2 79 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-1.12, -0.20]
20 Overall anxiety (change values) 3 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
20.1 Postmenopausal only 2 116 Std. Mean Difference (IV, Fixed, 95% CI) -0.23 [-0.60, 0.13]
20.2 Not postmenopausal
only
1 61 Std. Mean Difference (IV, Fixed, 95% CI) -0.61 [-1.12, -0.09]
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21 Overall self-esteem/body image
(follow-up values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 Postmenopausal only 2 126 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.25, 0.45]
21.2 Not postmenopausal
only
2 76 Std. Mean Difference (IV, Random, 95% CI) 0.60 [-0.15, 1.35]
22 Overall self-esteem/body image
(change values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 Postmenopausal only 2 126 Std. Mean Difference (IV, Random, 95% CI) 0.38 [-0.30, 1.05]
22.2 Not postmenopausal
only
2 558 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.31, 0.47]
23 Overall depression (follow-up
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 Postmenopausal only 4 196 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.13, 0.48]
23.2 Not postmenopausal
only
4 296 Std. Mean Difference (IV, Random, 95% CI) -0.42 [-0.77, -0.06]
24 Overall depression (change
values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 Postmenopausal only 3 176 Std. Mean Difference (IV, Random, 95% CI) -0.27 [-0.57, 0.04]
24.2 Not postmenopausal
only
2 561 Std. Mean Difference (IV, Random, 95% CI) -0.21 [-0.82, 0.40]
25 Overall fatigue (follow-up
values)
15 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 Postmenopausal only 6 313 Std. Mean Difference (IV, Random, 95% CI) 0.04 [-0.19, 0.26]
25.2 Not postmenopausal
only
9 834 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.87, -0.18]
26 Overall fatigue (change values) 7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 Postmenopausal only 2 70 Std. Mean Difference (IV, Random, 95% CI) 0.05 [-1.55, 1.64]
26.2 Not postmenopausal
only
5 954 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.69, 0.20]
27 Overall pain/disability
(follow-up values)
2 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 Postmenopausal only 1 74 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.51, 0.40]
27.2 Not postmenopausal
only
1 38 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.89, 0.38]
28 Overall pain/disability (change
values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
28.1 Postmenopausal only 2 157 Std. Mean Difference (IV, Random, 95% CI) -0.29 [-0.61, 0.02]
28.2 Not postmenopausal
only
1 36 Std. Mean Difference (IV, Random, 95% CI) 0.22 [-0.43, 0.88]
29 Overall cardiorespiratory fitness
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 Postmenopausal only 4 214 Std. Mean Difference (IV, Random, 95% CI) 0.61 [0.30, 0.92]
29.2 Not postmenopausal
only
5 418 Std. Mean Difference (IV, Random, 95% CI) 0.19 [-0.01, 0.38]
30 Overall cardiorespiratory fitness
(change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
30.1 Postmenopausal only 4 208 Std. Mean Difference (IV, Random, 95% CI) 1.07 [0.48, 1.67]
30.2 Not postmenopausal
only
1 498 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.02, 0.33]
31 Overall self-reported physical
activity (follow-up values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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31.1 Postmenopausal only 5 292 Std. Mean Difference (IV, Random, 95% CI) 0.63 [0.17, 1.10]
31.2 Not postmenopausal
only
5 810 Std. Mean Difference (IV, Random, 95% CI) 0.45 [0.16, 0.75]
32 Overall self-reported physical
activity (change values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
32.1 Postmenopausal only 3 186 Std. Mean Difference (IV, Random, 95% CI) 0.83 [0.53, 1.13]
32.2 Not postmenopausal
only
3 901 Std. Mean Difference (IV, Random, 95% CI) 0.57 [-0.02, 1.16]
33 Overall objective physical
activity (follow-up values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
33.1 Postmenopausal only 3 145 Std. Mean Difference (IV, Random, 95% CI) 0.87 [0.27, 1.46]
33.2 Not postmenopausal
only
5 645 Std. Mean Difference (IV, Random, 95% CI) 0.19 [-0.03, 0.42]
34 Overall objective physical
activity (change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
34.1 Postmenopausal only 3 145 Std. Mean Difference (IV, Random, 95% CI) 0.89 [0.54, 1.24]
34.2 Not postmenopausal
only
2 363 Std. Mean Difference (IV, Random, 95% CI) 0.45 [-0.67, 1.58]
35 Mass (follow-up values) 8 Mean Difference (IV, Fixed, 95% CI) Subtotals only
35.1 Postmenopausal only 4 222 Mean Difference (IV, Fixed, 95% CI) 0.69 [-3.74, 5.13]
35.2 Not postmenopausal
only
4 411 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.52, 0.68]
36 Mass (change values) 7 Mean Difference (IV, Random, 95% CI) Subtotals only
36.1 Postmenopausal only 4 202 Mean Difference (IV, Random, 95% CI) -0.99 [-1.96, -0.02]
36.2 Not postmenopausal
only
3 613 Mean Difference (IV, Random, 95% CI) 0.11 [-0.07, 0.29]
37 BMI (follow-up values) 9 Mean Difference (IV, Fixed, 95% CI) Subtotals only
37.1 Postmenopausal only 3 161 Mean Difference (IV, Fixed, 95% CI) -0.60 [-2.62, 1.42]
37.2 Not postmenopausal
only
6 745 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.13, 0.29]
38 BMI (change values) 4 Mean Difference (IV, Random, 95% CI) Subtotals only
38.1 Postmenopausal only 2 92 Mean Difference (IV, Random, 95% CI) -0.17 [-0.54, 0.20]
38.2 Not postmenopausal
only
2 161 Mean Difference (IV, Random, 95% CI) -0.02 [-0.09, 0.05]
39 Overall body fat (follow-up
values)
11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
39.1 Postmenopausal only 5 264 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.36, 0.25]
39.2 Not postmenopausal
only
6 353 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.59, 0.15]
40 Overall body fat (change
values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
40.1 Postmenopausal only 3 128 Std. Mean Difference (IV, Random, 95% CI) -0.35 [-0.70, 0.00]
40.2 Not postmenopausal
only
2 161 Std. Mean Difference (IV, Random, 95% CI) -1.67 [-4.39, 1.05]
41 Lower body strength (follow-up
values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 Postmenopausal only 1 67 Std. Mean Difference (IV, Random, 95% CI) 0.19 [-0.30, 0.67]
41.2 Not postmenopausal
only
5 228 Std. Mean Difference (IV, Random, 95% CI) 0.46 [0.04, 0.88]
42 Lower body strength (change
values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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42.1 Postmenopausal only 2 256 Std. Mean Difference (IV, Random, 95% CI) 0.70 [-0.01, 1.41]
42.2 Not postmenopausal
only
1 45 Std. Mean Difference (IV, Random, 95% CI) 1.27 [0.63, 1.92]
43 Upper body strength (follow-up
values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
43.1 Postmenopausal only 1 67 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.34, 0.62]
43.2 Not postmenopausal
only
4 208 Std. Mean Difference (IV, Random, 95% CI) 0.44 [-0.40, 1.28]
44 Upper body strength (change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
44.1 Postmenopausal only 2 306 Std. Mean Difference (IV, Random, 95% CI) 0.25 [0.03, 0.48]
44.2 Not postmenopausal
only
2 81 Std. Mean Difference (IV, Random, 95% CI) 1.49 [0.04, 2.93]
45 Bone mineral density - femoral
neck (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
45.1 Postmenopausal only 3 329 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.39, 0.75]
45.2 Not postmenopausal
only
1 457 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.00, 0.37]
46 Bone mineral density - lumbar
spine (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
46.1 Postmenopausal only 3 329 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.16, 0.70]
46.2 Not postmenopausal
only
1 457 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.09, 0.27]
Comparison 13. Subanalysis: outcomes by mode of physical activity intervention




participants Statistical method Effect size
1 Overall HRQoL (follow-up
values)
22 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Aerobic exercise
interventions
12 971 Std. Mean Difference (IV, Random, 95% CI) 0.41 [0.19, 0.63]
1.2 Resistance exercise
interventions
1 79 Std. Mean Difference (IV, Random, 95% CI) 0.35 [-0.09, 0.79]
1.3 Combined aerobic and
resistance exercise
7 589 Std. Mean Difference (IV, Random, 95% CI) 0.63 [0.08, 1.19]
1.4 Yoga, Tai Chi, and Pilates
interventions
3 184 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.22, 0.45]
2 Overall HRQoL (change values) 14 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Aerobic exercise
interventions
9 1280 Std. Mean Difference (IV, Random, 95% CI) 0.68 [0.22, 1.15]
2.2 Resistance exercise
interventions
1 79 Std. Mean Difference (IV, Random, 95% CI) 0.40 [-0.05, 0.84]
2.3 Combined aerobic and
resistance exercise
4 139 Std. Mean Difference (IV, Random, 95% CI) 0.69 [0.01, 1.38]
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2.4 Yoga, Tai Chi, and Pilates
interventions




26 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Aerobic exercise
interventions
14 1415 Std. Mean Difference (IV, Random, 95% CI) 0.15 [0.04, 0.25]
3.2 Resistance exercise
interventions
2 311 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.28, 0.44]
3.3 Combined aerobic and
resistance exercise
6 263 Std. Mean Difference (IV, Random, 95% CI) 0.72 [0.47, 0.97]
3.4 Yoga, Tai Chi, and Pilates
interventions




15 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Aerobic exercise 7 701 Std. Mean Difference (IV, Random, 95% CI) 0.44 [0.06, 0.82]
4.2 Resistance exercise 3 261 Std. Mean Difference (IV, Random, 95% CI) 0.22 [-0.09, 0.54]
4.3 Combined aerobic and
resistance exercise
4 598 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.38, 0.36]
4.4 Yoga, Tai Chi, and Pilates 1 19 Std. Mean Difference (IV, Random, 95% CI) 1.06 [0.08, 2.03]
5 Overall physical function
(follow-up values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Aerobic exercise 14 1465 Std. Mean Difference (IV, Random, 95% CI) 0.28 [0.15, 0.41]
5.2 Resistance exercise 3 372 Std. Mean Difference (IV, Random, 95% CI) 0.23 [-0.11, 0.57]
5.3 Combined aerobic and
resistance exercise
5 202 Std. Mean Difference (IV, Random, 95% CI) 0.80 [-0.04, 1.64]
5.4 Yoga, Tai Chi, and Pilates 3 90 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.26, 0.57]
6 Overall physical function
(change values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Aerobic exercise 7 1116 Std. Mean Difference (IV, Random, 95% CI) 0.72 [0.14, 1.30]
6.2 Resistance exercise 3 261 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.17, 0.65]
6.3 Combined aerobic and
resistance exercise
2 37 Std. Mean Difference (IV, Random, 95% CI) 0.75 [-0.22, 1.73]
6.4 Yoga, Tai Chi, and Pilates 1 19 Std. Mean Difference (IV, Random, 95% CI) 0.93 [-0.03, 1.89]
7 Overall role function (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Aerobic exercise 10 1043 Std. Mean Difference (IV, Random, 95% CI) 0.28 [0.12, 0.44]
7.2 Resistance exercise 1 79 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.32, 0.57]
7.3 Combined aerobic and
resistance exercise
3 136 Std. Mean Difference (IV, Random, 95% CI) 0.61 [-1.15, 2.37]
7.4 Yoga, Tai Chi, and Pilates 4 112 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.26, 0.48]
8 Overall role function (change
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Aerobic exercise 7 1118 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.10, 0.43]
8.2 Resistance exercise 2 141 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.32, 0.65]
8.3 Combined aerobic and
resistance exercise
2 37 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.52, 0.77]
8.4 Yoga, Tai Chi, and Pilates 1 19 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-1.05, 0.76]
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18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Aerobic exercise 10 1044 Std. Mean Difference (IV, Random, 95% CI) 0.18 [0.04, 0.31]
9.2 Resistance exercise 1 121 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.21, 0.50]
9.3 Combined aerobic and
resistance exercise
3 116 Std. Mean Difference (IV, Random, 95% CI) 0.45 [-0.16, 1.05]




12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 Aerobic exercise 7 1119 Std. Mean Difference (IV, Random, 95% CI) 0.60 [0.07, 1.13]
10.2 Resistance exercise 2 183 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.19, 0.41]
10.3 Combined aerobic and
resistance exercise
2 63 Std. Mean Difference (IV, Random, 95% CI) 0.66 [0.15, 1.17]
10.4 Yoga, Tai Chi, and Pilates 1 19 Std. Mean Difference (IV, Random, 95% CI) 0.76 [-0.18, 1.70]
11 Overall cognitive function
(follow-up values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 Aerobic exercise 2 94 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.17, 0.65]
11.2 Resistance exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.3 Combined aerobic and
resistance exercise
3 95 Std. Mean Difference (IV, Random, 95% CI) 0.57 [0.15, 0.98]
11.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Overall cognitive function
(change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 Aerobic exercise 2 95 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.50, 0.65]
12.2 Resistance exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.3 Combined aerobic and
resistance exercise
3 577 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.38, 0.35]
12.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
13 Overall general health
(follow-up values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 Aerobic exercise 6 293 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.29, 0.51]
13.2 Resistance exercise 1 79 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.34, 0.55]
13.3 Combined aerobic and
resistance exercise
3 118 Std. Mean Difference (IV, Random, 95% CI) 0.46 [0.00, 0.91]
13.4 Yoga, Tai Chi, and Pilates 1 18 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-1.11, 0.74]
14 Overall general health (change
values)
9 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
14.1 Aerobic exercise 5 710 Std. Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.17, 0.13]
14.2 Resistance exercise 2 141 Std. Mean Difference (IV, Fixed, 95% CI) 0.23 [-0.12, 0.57]
14.3 Combined aerobic and
resistance exercise
2 76 Std. Mean Difference (IV, Fixed, 95% CI) 0.66 [0.17, 1.16]
14.4 Yoga, Tai Chi, and Pilates 1 19 Std. Mean Difference (IV, Fixed, 95% CI) -0.20 [-1.10, 0.71]
15 Overall sexual function
(follow-up values)
5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 Aerobic exercise 2 136 Std. Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.34, 0.34]
15.2 Resistance exercise 2 193 Std. Mean Difference (IV, Fixed, 95% CI) 0.21 [-0.07, 0.49]
15.3 Combined aerobic and
resistance exercise
1 82 Std. Mean Difference (IV, Fixed, 95% CI) 0.29 [-0.14, 0.73]
15.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
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16 Overall sexual function (change
values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 Aerobic exercise 1 500 Mean Difference (IV, Random, 95% CI) 0.5 [-3.86, 4.86]
16.2 Resistance exercise 2 193 Mean Difference (IV, Random, 95% CI) 3.83 [-1.83, 9.48]
16.3 Combined aerobic and
resistance exercise
0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.4 Yoga, Tai Chi, and Pilates 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Overall sleep (follow-up values) 5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 Aerobic exercise 2 95 Std. Mean Difference (IV, Fixed, 95% CI) -0.18 [-0.59, 0.23]
17.2 Resistance exercise 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.3 Combined aerobic and
resistance exercise
2 62 Std. Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.57, 0.43]
17.4 Yoga, Tai Chi, and Pilates 1 31 Std. Mean Difference (IV, Fixed, 95% CI) 0.15 [-0.55, 0.86]
18 Overall sleep (change values) 3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 Aerobic exercise 2 94 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.30, 0.51]
18.2 Resistance exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.3 Combined aerobic and
resistance exercise
1 42 Std. Mean Difference (IV, Random, 95% CI) 0.23 [-0.38, 0.84]
18.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Overall anxiety (follow-up
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 Aerobic exercise 4 205 Std. Mean Difference (IV, Random, 95% CI) -0.76 [-1.37, -0.14]
19.2 Resistance exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.3 Combined aerobic and
resistance exercise
3 121 Std. Mean Difference (IV, Random, 95% CI) -0.40 [-0.87, 0.07]
19.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
20 Overall anxiety (change values) 4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
20.1 Aerobic exercise 2 132 Std. Mean Difference (IV, Fixed, 95% CI) -0.27 [-0.61, 0.07]
20.2 Resistance exercise 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.3 Combined aerobic and
resistance exercise
2 103 Std. Mean Difference (IV, Fixed, 95% CI) -0.51 [-0.90, -0.12]
20.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
21 Overall depression (follow-up
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 Aerobic exercise 6 273 Std. Mean Difference (IV, Random, 95% CI) -0.32 [-0.78, 0.14]
21.2 Resistance exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
21.3 Combined aerobic and
resistance exercise
5 187 Std. Mean Difference (IV, Random, 95% CI) -0.33 [-0.90, 0.24]
21.4 Yoga, Tai Chi, and Pilates 2 217 Std. Mean Difference (IV, Random, 95% CI) -0.23 [-0.61, 0.14]
22 Overall depression (change
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 Aerobic exercise 4 672 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.48, 0.11]
22.2 Resistance exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
22.3 Combined aerobic and
resistance exercise
4 164 Std. Mean Difference (IV, Random, 95% CI) -0.47 [-0.92, -0.02]
22.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
23 Overall fatigue (follow-up
values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 Aerobic exercise 11 925 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.41, -0.07]
23.2 Resistance exercise 1 67 Std. Mean Difference (IV, Random, 95% CI) 0.23 [-0.25, 0.72]
23.3 Combined aerobic and
resistance exercise
9 642 Std. Mean Difference (IV, Random, 95% CI) -0.48 [-0.83, -0.13]
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23.4 Yoga, Tai Chi, and Pilates 5 311 Std. Mean Difference (IV, Random, 95% CI) -0.36 [-0.58, -0.13]
24 Overall fatigue (change values) 12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 Aerobic exercise 7 1130 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.38, 0.23]
24.2 Resistance exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
24.3 Combined aerobic and
resistance exercise
4 118 Std. Mean Difference (IV, Random, 95% CI) -0.81 [-1.57, -0.05]
24.4 Yoga, Tai Chi, and Pilates 1 23 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.89, 0.75]
25 Overall pain/disability
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 Aerobic exercise 5 397 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.15, 0.37]
25.2 Resistance exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
25.3 Combined aerobic and
resistance exercise
2 96 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.29, 0.54]
25.4 Yoga, Tai Chi, and Pilates 2 42 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.78, 0.43]
26 Overall pain/disability (change
values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 Aerobic exercise 2 132 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.44, 0.39]
26.2 Resistance exercise 1 62 Std. Mean Difference (IV, Random, 95% CI) 0.22 [-0.33, 0.76]
26.3 Combined aerobic and
resistance exercise
1 83 Std. Mean Difference (IV, Random, 95% CI) -0.35 [-0.79, 0.08]
26.4 Yoga, Tai Chi, and Pilates 1 19 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-1.06, 0.75]
27 Overall self-esteem/body image
(follow-up values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 Aerobic exercise 7 364 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.07, 0.64]
27.2 Resistance exercise 2 143 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.27, 0.39]
27.3 Combined aerobic and
resistance exercise
4 161 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.46, 0.74]
27.4 Yoga, Tai Chi, and Pilates 1 23 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.62, 1.02]
28 Overall self-esteem/body image
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
28.1 Aerobic exercise 6 771 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.12, 0.39]
28.2 Resistance exercise 2 143 Std. Mean Difference (IV, Random, 95% CI) -0.29 [-0.88, 0.30]
28.3 Combined aerobic and
resistance exercise
2 81 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.54, 0.75]
28.4 Yoga, Tai Chi, and Pilates 1 21 Std. Mean Difference (IV, Random, 95% CI) 3.42 [1.99, 4.86]
29 Overall cardiorespiratory fitness
(follow-up values)
23 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 Aerobic exercise 12 814 Std. Mean Difference (IV, Random, 95% CI) 0.37 [0.21, 0.54]
29.2 Resistance exercise 1 21 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.60, 1.14]
29.3 Combined aerobic and
resistance exercise
11 433 Std. Mean Difference (IV, Random, 95% CI) 0.56 [0.30, 0.81]
29.4 Yoga, Tai Chi, and Pilates 1 21 Std. Mean Difference (IV, Random, 95% CI) 0.39 [-0.48, 1.25]
30 Overall cardiorespiratory fitness
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
30.1 Aerobic exercise 5 685 Std. Mean Difference (IV, Random, 95% CI) 0.79 [0.17, 1.42]
30.2 Resistance exercise 1 21 Std. Mean Difference (IV, Random, 95% CI) -0.04 [-0.91, 0.82]
30.3 Combined aerobic and
resistance exercise
5 181 Std. Mean Difference (IV, Random, 95% CI) 0.75 [0.18, 1.31]
30.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
31 Overall self-reported physical
activity (follow-up values)
17 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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31.1 Aerobic exercise 10 1011 Std. Mean Difference (IV, Random, 95% CI) 0.69 [0.44, 0.94]
31.2 Resistance exercise 2 331 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.13, 0.30]
31.3 Combined aerobic and
resistance exercise
3 421 Std. Mean Difference (IV, Random, 95% CI) 0.53 [-0.05, 1.10]
31.4 Yoga, Tai Chi, and Pilates 2 249 Std. Mean Difference (IV, Random, 95% CI) 0.33 [0.08, 0.58]
32 Overall self-reported physical
activity (change values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
32.1 Aerobic exercise 6 1086 Std. Mean Difference (IV, Random, 95% CI) 0.59 [0.20, 0.97]
32.2 Resistance exercise 1 105 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.17, 0.60]
32.3 Combined aerobic and
resistance exercise
1 83 Std. Mean Difference (IV, Random, 95% CI) 0.94 [0.48, 1.40]
32.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
33 Overall objective physical
activity (follow-up values)
11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
33.1 Aerobic exercise 8 876 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.15, 0.70]
33.2 Resistance exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
33.3 Combined aerobic and
resistance exercise
3 394 Std. Mean Difference (IV, Random, 95% CI) 0.54 [-0.31, 1.40]
33.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
34 Overall objective physical
activity (change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
34.1 Aerobic exercise 4 466 Std. Mean Difference (IV, Random, 95% CI) 0.61 [-0.01, 1.23]
34.2 Resistance exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
34.3 Combined aerobic and
resistance exercise
1 42 Std. Mean Difference (IV, Random, 95% CI) 1.13 [0.47, 1.78]
34.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
35 Mass (follow-up values) 16 Mean Difference (IV, Fixed, 95% CI) Subtotals only
35.1 Aerobic exercise 7 411 Mean Difference (IV, Fixed, 95% CI) -1.29 [-4.06, 1.47]
35.2 Resistance exercise 3 410 Mean Difference (IV, Fixed, 95% CI) 0.26 [-0.67, 1.20]
35.3 Combined aerobic and
resistance exercise
3 127 Mean Difference (IV, Fixed, 95% CI) -2.46 [-7.24, 2.33]
35.4 Yoga, Tai Chi, and Pilates 3 262 Mean Difference (IV, Fixed, 95% CI) -0.01 [-0.78, 0.76]
36 Mass (change values) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
36.1 Aerobic exercise 5 679 Mean Difference (IV, Random, 95% CI) -0.74 [-1.58, 0.09]
36.2 Resistance exercise 2 209 Mean Difference (IV, Random, 95% CI) 0.10 [-0.15, 0.34]
36.3 Combined aerobic and
resistance exercise
3 140 Mean Difference (IV, Random, 95% CI) -0.55 [-1.99, 0.90]
36.4 Yoga, Tai Chi, and Pilates 1 19 Mean Difference (IV, Random, 95% CI) -0.90 [-2.40, 0.60]
37 BMI (follow-up values) 17 Mean Difference (IV, Fixed, 95% CI) Subtotals only
37.1 Aerobic exercise 6 639 Mean Difference (IV, Fixed, 95% CI) -0.41 [-1.26, 0.43]
37.2 Resistance exercise 2 343 Mean Difference (IV, Fixed, 95% CI) 0.17 [-0.15, 0.48]
37.3 Combined aerobic and
resistance exercise
6 237 Mean Difference (IV, Fixed, 95% CI) -1.03 [-2.63, 0.56]
37.4 Yoga, Tai Chi, and Pilates 3 262 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.32, 0.26]
38 BMI (change values) 8 Mean Difference (IV, Random, 95% CI) Subtotals only
38.1 Aerobic exercise 2 112 Mean Difference (IV, Random, 95% CI) -0.48 [-0.84, -0.13]
38.2 Resistance exercise 2 209 Mean Difference (IV, Random, 95% CI) -0.01 [-0.08, 0.06]
38.3 Combined aerobic and
resistance exercise
3 145 Mean Difference (IV, Random, 95% CI) -0.02 [-0.28, 0.24]
38.4 Yoga, Tai Chi, and Pilates 1 19 Mean Difference (IV, Random, 95% CI) -0.71 [-1.33, -0.09]
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39 Overall body fat (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
39.1 Aerobic exercise 10 551 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.28, 0.06]
39.2 Resistance exercise 4 429 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.81, 0.28]
39.3 Combined aerobic and
resistance exercise
5 185 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.42, 0.16]
39.4 Yoga, Tai Chi, and Pilates 1 21 Std. Mean Difference (IV, Random, 95% CI) -0.66 [-1.54, 0.23]
40 Overall body fat (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
40.1 Aerobic exercise 3 108 Std. Mean Difference (IV, Random, 95% CI) -0.43 [-0.82, -0.05]
40.2 Resistance exercise 3 228 Std. Mean Difference (IV, Random, 95% CI) -1.38 [-3.39, 0.63]
40.3 Combined aerobic and
resistance exercise
4 168 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.61, 0.00]
40.4 Yoga, Tai Chi, and Pilates 1 19 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-1.09, 0.72]
41 Lower body strength (follow-up
values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 Aerobic exercise 3 125 Std. Mean Difference (IV, Random, 95% CI) 0.75 [-0.20, 1.69]
41.2 Resistance exercise 3 344 Std. Mean Difference (IV, Random, 95% CI) 0.72 [0.22, 1.23]
41.3 Combined aerobic and
resistance exercise
4 168 Std. Mean Difference (IV, Random, 95% CI) 0.05 [-0.28, 0.38]
41.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
42 Lower body strength (change
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
42.1 Aerobic exercise 1 33 Std. Mean Difference (IV, Random, 95% CI) 1.17 [0.37, 1.97]
42.2 Resistance exercise 4 562 Std. Mean Difference (IV, Random, 95% CI) 0.85 [0.48, 1.22]
42.3 Combined aerobic and
resistance exercise
3 125 Std. Mean Difference (IV, Random, 95% CI) 0.28 [-0.37, 0.93]
42.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
43 Upper body strength (follow-up
values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
43.1 Aerobic exercise 5 175 Std. Mean Difference (IV, Random, 95% CI) 0.35 [0.05, 0.65]
43.2 Resistance exercise 4 365 Std. Mean Difference (IV, Random, 95% CI) 0.80 [0.28, 1.33]
43.3 Combined aerobic and
resistance exercise
5 231 Std. Mean Difference (IV, Random, 95% CI) 0.25 [-0.47, 0.97]
43.4 Yoga, Tai Chi, and Pilates 1 21 Std. Mean Difference (IV, Random, 95% CI) 0.60 [-0.28, 1.49]
44 Upper body strength (change
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
44.1 Aerobic exercise 1 22 Std. Mean Difference (IV, Random, 95% CI) 0.36 [-0.48, 1.21]
44.2 Resistance exercise 5 583 Std. Mean Difference (IV, Random, 95% CI) 0.96 [0.43, 1.49]
44.3 Combined aerobic and
resistance exercise
3 168 Std. Mean Difference (IV, Random, 95% CI) 0.07 [-0.34, 0.48]
44.4 Yoga, Tai Chi, and Pilates 1 83 Std. Mean Difference (IV, Random, 95% CI) 1.30 [0.82, 1.78]
45 Bone mineral density - femoral
neck (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
45.1 Aerobic exercise 1 457 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.00, 0.37]
45.2 Resistance exercise 2 290 Std. Mean Difference (IV, Random, 95% CI) 0.41 [-0.09, 0.91]
45.3 Combined aerobic and
resistance exercise
1 39 Std. Mean Difference (IV, Random, 95% CI) -0.37 [-1.00, 0.27]
45.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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46 Bone mineral density - lumbar
spine (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
46.1 Aerobic exercise 1 457 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.09, 0.27]
46.2 Resistance exercise 2 290 Std. Mean Difference (IV, Random, 95% CI) 0.49 [0.25, 0.72]
46.3 Combined aerobic and
resistance exercise
1 39 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.89, 0.37]
46.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
47 Bone mineral density - total hip
(follow-up and change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
47.1 Aerobic exercise 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
47.2 Resistance exercise 2 290 Std. Mean Difference (IV, Random, 95% CI) 0.64 [-0.20, 1.48]
47.3 Combined aerobic and
resistance exercise
1 39 Std. Mean Difference (IV, Random, 95% CI) 10.34 [7.84, 12.84]
47.4 Yoga, Tai Chi, and Pilates 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
Comparison 14. Subanalysis: outcomes by intensity of physical activity intervention




participants Statistical method Effect size
1 Overall HRQoL (follow-up
values)
22 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Light-to-moderate
intensity
16 983 Std. Mean Difference (IV, Random, 95% CI) 0.51 [0.25, 0.77]
1.2 Moderate-to-high
intensity
6 820 Std. Mean Difference (IV, Random, 95% CI) 0.19 [-0.05, 0.43]
2 Overall HRQoL (change values) 14 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Light-to-moderate
intensity
10 534 Std. Mean Difference (IV, Random, 95% CI) 0.99 [0.39, 1.60]
2.2 Moderate-to-high
intensity




26 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Light-to-moderate
intensity
21 1489 Std. Mean Difference (IV, Random, 95% CI) 0.19 [0.08, 0.30]
3.2 Moderate-to-high
intensity




15 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Light-to-moderate
intensity
10 592 Std. Mean Difference (IV, Random, 95% CI) 0.41 [0.04, 0.77]
4.2 Moderate-to-high
intensity
5 987 Std. Mean Difference (IV, Random, 95% CI) 0.07 [-0.07, 0.21]
5 Overall physical function
(follow-up values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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5.1 Light-to-moderate
intensity
20 1466 Std. Mean Difference (IV, Random, 95% CI) 0.38 [0.19, 0.58]
5.2 Moderate-to-high
intensity
5 663 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.02, 0.30]
6 Overall physical function
(change values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Light-to-moderate
intensity
8 449 Std. Mean Difference (IV, Random, 95% CI) 0.81 [0.11, 1.51]
6.2 Moderate-to-high
intensity
5 984 Std. Mean Difference (IV, Random, 95% CI) 0.28 [-0.06, 0.62]
7 Overall role function (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Light-to-moderate
intensity
14 883 Std. Mean Difference (IV, Random, 95% CI) 0.36 [0.08, 0.64]
7.2 Moderate-to-high
intensity
4 487 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.13, 0.35]
8 Overall role function (change
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Light-to-moderate
intensity
7 328 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.19, 0.56]
8.2 Moderate-to-high
intensity




18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Light-to-moderate
intensity
15 1132 Std. Mean Difference (IV, Random, 95% CI) 0.23 [0.10, 0.36]
9.2 Moderate-to-high
intensity




12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 Light-to-moderate
intensity
8 413 Std. Mean Difference (IV, Random, 95% CI) 0.63 [0.21, 1.04]
10.2 Moderate-to-high
intensity
4 971 Std. Mean Difference (IV, Random, 95% CI) 0.33 [-0.33, 0.98]
11 Overall cognitive function
(follow-up values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 Light-to-moderate
intensity
4 173 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.11, 0.74]
11.2 Moderate-to-high
intensity
1 16 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.82, 1.14]
12 Overall cognitive function
(change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 Light-to-moderate
intensity
3 156 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.21, 0.55]
12.2 Moderate-to-high
intensity
2 516 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.35, 0.00]
13 Overall general health
(follow-up values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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13.1 Light-to-moderate
intensity
6 304 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.14, 0.48]
13.2 Moderate-to-high
intensity
4 184 Std. Mean Difference (IV, Random, 95% CI) 0.30 [-0.35, 0.95]
14 Overall general health (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Light-to-moderate
intensity
5 254 Std. Mean Difference (IV, Random, 95% CI) 0.23 [-0.02, 0.48]
14.2 Moderate-to-high
intensity
4 652 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.24, 0.64]
15 Overall sexual function
(follow-up values)
5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 Light-to-moderate
intensity
4 293 Std. Mean Difference (IV, Fixed, 95% CI) 0.22 [-0.01, 0.45]
15.2 Moderate-to-high
intensity
1 118 Std. Mean Difference (IV, Fixed, 95% CI) 0.01 [-0.35, 0.38]
16 Overall sexual function (change
values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 Light-to-moderate
intensity
2 193 Mean Difference (IV, Random, 95% CI) 3.83 [-1.83, 9.48]
16.2 Moderate-to-high
intensity
1 500 Mean Difference (IV, Random, 95% CI) 0.5 [-3.86, 4.86]
17 Overall anxiety (follow-up
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 Light-to-moderate
intensity
5 237 Std. Mean Difference (IV, Random, 95% CI) -0.56 [-0.88, -0.25]
17.2 Moderate-to-high
intensity
2 89 Std. Mean Difference (IV, Random, 95% CI) -1.20 [-3.49, 1.09]
18 Overall anxiety (change values) 4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 Light-to-moderate
intensity
3 161 Std. Mean Difference (IV, Fixed, 95% CI) -0.48 [-0.79, -0.16]
18.2 Moderate-to-high
intensity
1 74 Std. Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.61, 0.30]
19 Overall depression (follow-up
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 Light-to-moderate
intensity
9 542 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.53, 0.06]
19.2 Moderate-to-high
intensity
3 115 Std. Mean Difference (IV, Random, 95% CI) -0.92 [-1.95, 0.11]
20 Overall depression (change
values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 Light-to-moderate
intensity
4 182 Std. Mean Difference (IV, Random, 95% CI) -0.60 [-0.89, -0.30]
20.2 Moderate-to-high
intensity
2 574 Std. Mean Difference (IV, Random, 95% CI) 0.00 [-0.21, 0.22]
21 Overall fatigue (follow-up
values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 Light-to-moderate
intensity
21 1155 Std. Mean Difference (IV, Random, 95% CI) -0.38 [-0.56, -0.19]
21.2 Moderate-to-high
intensity
4 770 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.28, 0.03]
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22 Overall fatigue (change values) 12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 Light-to-moderate
intensity
9 420 Std. Mean Difference (IV, Random, 95% CI) -0.36 [-0.84, 0.11]
22.2 Moderate-to-high
intensity
3 851 Std. Mean Difference (IV, Random, 95% CI) 0.05 [-0.14, 0.24]
23 Overall pain/disability
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 Light-to-moderate
intensity
5 189 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.25, 0.50]
23.2 Moderate-to-high
intensity
4 346 Std. Mean Difference (IV, Random, 95% CI) 0.03 [-0.18, 0.24]
24 Overall pain/disability (change
values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 Light-to-moderate
intensity
2 77 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.33, 0.56]
24.2 Moderate-to-high
intensity
3 219 Std. Mean Difference (IV, Random, 95% CI) -0.15 [-0.47, 0.16]
25 Overall self-esteem/body image
(follow-up values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 Light-to-moderate
intensity
8 474 Std. Mean Difference (IV, Random, 95% CI) 0.35 [0.14, 0.55]
25.2 Moderate-to-high
intensity
4 193 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.45, 0.56]
26 Overall self-esteem/body image
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 Light-to-moderate
intensity
6 376 Std. Mean Difference (IV, Random, 95% CI) 0.52 [-0.09, 1.13]
26.2 Moderate-to-high
intensity
3 616 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.21, 0.10]
27 Overall cardiorespiratory fitness
(follow-up values)
23 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 Light-to-moderate
intensity
16 975 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.27, 0.59]
27.2 Moderate-to-high
intensity
7 290 Std. Mean Difference (IV, Random, 95% CI) 0.46 [0.13, 0.80]
28 Overall cardiorespiratory fitness
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
28.1 Light-to-moderate
intensity
6 228 Std. Mean Difference (IV, Random, 95% CI) 1.18 [0.60, 1.77]
28.2 Moderate-to-high
intensity
4 645 Std. Mean Difference (IV, Random, 95% CI) 0.57 [0.01, 1.14]
29 Overall self-reported physical
activity (follow-up values)
17 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 Light-to-moderate
intensity
11 1112 Std. Mean Difference (IV, Random, 95% CI) 0.47 [0.23, 0.72]
29.2 Moderate-to-high
intensity
6 893 Std. Mean Difference (IV, Random, 95% CI) 0.65 [0.27, 1.03]
30 Overall self-reported physical
activity (change values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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30.1 Light-to-moderate
intensity
4 249 Std. Mean Difference (IV, Random, 95% CI) 0.79 [0.15, 1.44]
30.2 Moderate-to-high
intensity
4 1025 Std. Mean Difference (IV, Random, 95% CI) 0.46 [0.07, 0.85]
31 Overall objective physical
activity (follow-up values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
31.1 Light-to-moderate
intensity
9 574 Std. Mean Difference (IV, Random, 95% CI) 0.58 [0.29, 0.87]
31.2 Moderate-to-high
intensity
3 735 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.03, 0.28]
32 Overall objective physical
activity (change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
32.1 Light-to-moderate
intensity
3 103 Std. Mean Difference (IV, Random, 95% CI) 1.05 [0.62, 1.47]
32.2 Moderate-to-high
intensity
2 405 Std. Mean Difference (IV, Random, 95% CI) 0.32 [-0.45, 1.09]
33 Mass (follow-up values) 16 Mean Difference (IV, Fixed, 95% CI) Subtotals only
33.1 Light-to-moderate
intensity
12 1015 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.56, 0.61]
33.2 Moderate-to-high
intensity
4 195 Mean Difference (IV, Fixed, 95% CI) -1.34 [-5.66, 2.98]
34 Mass (change values) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
34.1 Light-to-moderate
intensity
8 418 Mean Difference (IV, Random, 95% CI) -0.58 [-1.21, 0.05]
34.2 Moderate-to-high
intensity
4 639 Mean Difference (IV, Random, 95% CI) -0.97 [-2.18, 0.24]
35 BMI (follow-up values) 17 Mean Difference (IV, Fixed, 95% CI) Subtotals only
35.1 Light-to-moderate
intensity
12 930 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.18, 0.24]
35.2 Moderate-to-high
intensity
5 551 Mean Difference (IV, Fixed, 95% CI) -0.35 [-1.40, 0.69]
36 BMI (change values) 8 Mean Difference (IV, Random, 95% CI) Subtotals only
36.1 Light-to-moderate
intensity
7 403 Mean Difference (IV, Random, 95% CI) -0.23 [-0.50, 0.05]
36.2 Moderate-to-high
intensity
1 82 Mean Difference (IV, Random, 95% CI) -0.2 [-0.57, 0.17]
37 Overall body fat (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
37.1 Light-to-moderate
intensity
13 886 Std. Mean Difference (IV, Random, 95% CI) -0.24 [-0.44, -0.04]
37.2 Moderate-to-high
intensity
5 276 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.27, 0.21]
38 Overall body fat (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
38.1 Light-to-moderate
intensity
7 375 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-1.44, 0.09]
38.2 Moderate-to-high
intensity
2 124 Std. Mean Difference (IV, Random, 95% CI) -0.39 [-0.76, -0.02]
39 Lower body strength (follow-up
values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
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39.1 Light-to-moderate
intensity
7 480 Std. Mean Difference (IV, Random, 95% CI) 0.69 [0.34, 1.04]
39.2 Moderate-to-high
intensity
3 157 Std. Mean Difference (IV, Random, 95% CI) -0.10 [-0.42, 0.21]
40 Lower body strength (change
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
40.1 Light-to-moderate
intensity
5 331 Std. Mean Difference (IV, Random, 95% CI) 0.87 [0.64, 1.09]
40.2 Moderate-to-high
intensity
4 399 Std. Mean Difference (IV, Random, 95% CI) 0.62 [0.07, 1.17]
41 Upper body strength (follow-up
values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 Light-to-moderate
intensity
7 481 Std. Mean Difference (IV, Random, 95% CI) 0.43 [-0.11, 0.96]
41.2 Moderate-to-high
intensity
6 287 Std. Mean Difference (IV, Random, 95% CI) 0.41 [-0.05, 0.87]
42 Upper body strength (change
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
42.1 Light-to-moderate
intensity
3 360 Std. Mean Difference (IV, Random, 95% CI) 1.32 [0.47, 2.16]
42.2 Moderate-to-high
intensity
5 472 Std. Mean Difference (IV, Random, 95% CI) 0.37 [-0.05, 0.79]
43 Bone mineral density - femoral
neck (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
43.1 Light-to-moderate
intensity
2 106 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.54, 0.37]
43.2 Moderate-to-high
intensity
2 680 Std. Mean Difference (IV, Random, 95% CI) 0.39 [-0.04, 0.83]
44 Bone mineral density - lumbar
spine (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
44.1 Light-to-moderate
intensity
2 106 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.48, 0.60]
44.2 Moderate-to-high
intensity
2 680 Std. Mean Difference (IV, Random, 95% CI) 0.31 [-0.14, 0.75]
45 Bone mineral density - total hip
(follow-up and change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
45.1 Light-to-moderate
intensity
2 106 Std. Mean Difference (IV, Random, 95% CI) 5.19 [-4.76, 15.14]
45.2 Moderate-to-high
intensity
1 223 Std. Mean Difference (IV, Random, 95% CI) 1.05 [0.77, 1.33]
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Comparison 15. Subanalysis: outcomes by duration of physical activity intervention




participants Statistical method Effect size
1 Overall HRQoL (follow-up
values)
22 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 12 weeks or less 16 1404 Std. Mean Difference (IV, Random, 95% CI) 0.45 [0.19, 0.70]
1.2 More than 12 weeks 6 399 Std. Mean Difference (IV, Random, 95% CI) 0.38 [0.10, 0.65]
2 Overall HRQoL (change values) 14 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 12 weeks or less 11 828 Std. Mean Difference (IV, Random, 95% CI) 0.99 [0.45, 1.52]




26 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 12 weeks or less 20 1557 Std. Mean Difference (IV, Random, 95% CI) 0.26 [0.12, 0.39]




15 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 12 weeks or less 10 754 Std. Mean Difference (IV, Random, 95% CI) 0.39 [0.03, 0.76]
4.2 More than 12 weeks 5 825 Std. Mean Difference (IV, Random, 95% CI) 0.19 [-0.05, 0.43]
5 Overall physical function
(follow-up values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 12 weeks or less 18 1523 Std. Mean Difference (IV, Random, 95% CI) 0.37 [0.17, 0.58]
5.2 More than 12 weeks 7 606 Std. Mean Difference (IV, Random, 95% CI) 0.24 [0.08, 0.40]
6 Overall physical function
(change values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 12 weeks or less 8 608 Std. Mean Difference (IV, Random, 95% CI) 0.97 [0.27, 1.66]
6.2 More than 12 weeks 5 825 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.16, 0.45]
7 Overall role function (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 12 weeks or less 13 1057 Std. Mean Difference (IV, Random, 95% CI) 0.30 [-0.01, 0.60]
7.2 More than 12 weeks 5 313 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.04, 0.49]
8 Overall role function (change
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 12 weeks or less 8 610 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.06, 0.55]




18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 12 weeks or less 13 1202 Std. Mean Difference (IV, Random, 95% CI) 0.23 [0.06, 0.39]




12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 12 weeks or less 8 637 Std. Mean Difference (IV, Random, 95% CI) 0.73 [0.35, 1.11]
10.2 More than 12 weeks 4 747 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.19, 0.42]
11 Overall cognitive function
(follow-up values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 12 weeks or less 5 189 Std. Mean Difference (IV, Random, 95% CI) 0.40 [0.11, 0.69]
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11.2 More than 12 weeks 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12 Overall cognitive function
(change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 12 weeks or less 4 172 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.17, 0.44]
12.2 More than 12 weeks 1 500 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.35, 0.00]
13 Overall general health
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 12 weeks or less 6 252 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.16, 0.50]
13.2 More than 12 weeks 3 204 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.32, 0.75]
14 Overall general health (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 12 weeks or less 6 253 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.09, 0.67]
14.2 More than 12 weeks 3 653 Std. Mean Difference (IV, Random, 95% CI) 0.01 [-0.20, 0.22]
15 Overall sexual function
(follow-up values)
5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 12 weeks or less 3 218 Std. Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.16, 0.38]
15.2 More than 12 weeks 2 193 Std. Mean Difference (IV, Fixed, 95% CI) 0.21 [-0.07, 0.49]
16 Overall sexual function (change
values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 12 weeks or less 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 More than 12 weeks 3 693 Mean Difference (IV, Random, 95% CI) 2.44 [-0.76, 5.64]
17 Overall sleep (follow-up values) 5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 12 weeks or less 5 188 Std. Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.37, 0.20]
17.2 More than 12 weeks 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
18 Overall sleep (change values) 3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 12 weeks or less 3 136 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.20, 0.48]
18.2 More than 12 weeks 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19 Overall anxiety (follow-up
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 12 weeks or less 6 252 Std. Mean Difference (IV, Random, 95% CI) -0.67 [-1.09, -0.25]
19.2 More than 12 weeks 1 74 Std. Mean Difference (IV, Random, 95% CI) -0.14 [-0.60, 0.31]
20 Overall anxiety (change values) 4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
20.1 12 weeks or less 3 161 Std. Mean Difference (IV, Fixed, 95% CI) -0.48 [-0.79, -0.16]
20.2 More than 12 weeks 1 74 Std. Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.61, 0.30]
21 Overall depression (follow-up
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 12 weeks or less 9 537 Std. Mean Difference (IV, Random, 95% CI) -0.36 [-0.70, -0.01]
21.2 More than 12 weeks 3 120 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.90, 0.30]
22 Overall depression (change
values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 12 weeks or less 4 182 Std. Mean Difference (IV, Random, 95% CI) -0.60 [-0.89, -0.30]
22.2 More than 12 weeks 2 574 Std. Mean Difference (IV, Random, 95% CI) 0.00 [-0.21, 0.22]
23 Overall fatigue (follow-up
values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 12 weeks or less 20 1657 Std. Mean Difference (IV, Random, 95% CI) -0.42 [-0.59, -0.25]
23.2 More than 12 weeks 5 268 Std. Mean Difference (IV, Random, 95% CI) 0.02 [-0.22, 0.26]
24 Overall fatigue (change values) 12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 12 weeks or less 10 719 Std. Mean Difference (IV, Random, 95% CI) -0.44 [-0.83, -0.05]
24.2 More than 12 weeks 2 552 Std. Mean Difference (IV, Random, 95% CI) 0.36 [-0.43, 1.15]
25 Overall pain/disability
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 12 weeks or less 6 376 Std. Mean Difference (IV, Random, 95% CI) 0.03 [-0.17, 0.23]
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25.2 More than 12 weeks 3 159 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.27, 0.70]
26 Overall pain/disability (change
values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 12 weeks or less 3 139 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.19, 0.50]
26.2 More than 12 weeks 2 157 Std. Mean Difference (IV, Random, 95% CI) -0.29 [-0.61, 0.02]
27 Overall self-esteem/body image
(follow-up values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 12 weeks or less 9 419 Std. Mean Difference (IV, Random, 95% CI) 0.36 [0.07, 0.66]
27.2 More than 12 weeks 3 248 Std. Mean Difference (IV, Random, 95% CI) 0.08 [-0.17, 0.33]
28 Overall self-esteem/body image
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
28.1 12 weeks or less 5 244 Std. Mean Difference (IV, Random, 95% CI) 0.54 [-0.10, 1.18]
28.2 More than 12 weeks 4 748 Std. Mean Difference (IV, Random, 95% CI) 0.01 [-0.37, 0.39]
29 Overall cardiorespiratory fitness
(follow-up values)
23 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 12 weeks or less 15 923 Std. Mean Difference (IV, Random, 95% CI) 0.35 [0.20, 0.49]
29.2 More than 12 weeks 8 342 Std. Mean Difference (IV, Random, 95% CI) 0.67 [0.40, 0.94]
30 Overall cardiorespiratory fitness
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
30.1 12 weeks or less 6 232 Std. Mean Difference (IV, Random, 95% CI) 0.91 [0.31, 1.52]
30.2 More than 12 weeks 3 631 Std. Mean Difference (IV, Random, 95% CI) 0.76 [0.02, 1.51]
31 Overall self-reported physical
activity (follow-up values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
31.1 12 weeks or less 11 1401 Std. Mean Difference (IV, Random, 95% CI) 0.60 [0.36, 0.84]
31.2 More than 12 weeks 7 643 Std. Mean Difference (IV, Random, 95% CI) 0.41 [0.09, 0.74]
32 Overall self-reported physical
activity (change values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
32.1 12 weeks or less 4 521 Std. Mean Difference (IV, Random, 95% CI) 0.78 [0.20, 1.36]
32.2 More than 12 weeks 4 753 Std. Mean Difference (IV, Random, 95% CI) 0.46 [-0.01, 0.92]
33 Overall objective physical
activity (follow-up values)
11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
33.1 12 weeks or less 10 1203 Std. Mean Difference (IV, Random, 95% CI) 0.44 [0.18, 0.70]
33.2 More than 12 weeks 1 67 Std. Mean Difference (IV, Random, 95% CI) 0.38 [-0.11, 0.86]
34 Overall objective physical
activity (change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
34.1 12 weeks or less 4 441 Std. Mean Difference (IV, Random, 95% CI) 0.72 [-0.02, 1.46]
34.2 More than 12 weeks 1 67 Std. Mean Difference (IV, Random, 95% CI) 0.75 [0.25, 1.24]
35 Mass (follow-up values) 16 Mean Difference (IV, Fixed, 95% CI) Subtotals only
35.1 12 weeks or less 7 451 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.85, 0.65]
35.2 More than 12 weeks 9 759 Mean Difference (IV, Fixed, 95% CI) 0.14 [-0.76, 1.05]
36 Mass (change values) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
36.1 12 weeks or less 5 171 Mean Difference (IV, Random, 95% CI) -0.82 [-1.81, 0.17]
36.2 More than 12 weeks 6 876 Mean Difference (IV, Random, 95% CI) -0.25 [-0.73, 0.24]
37 BMI (follow-up values) 17 Mean Difference (IV, Fixed, 95% CI) Subtotals only
37.1 12 weeks or less 9 819 Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.35, 0.20]
37.2 More than 12 weeks 8 662 Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.18, 0.43]
38 BMI (change values) 8 Mean Difference (IV, Random, 95% CI) Subtotals only
38.1 12 weeks or less 4 144 Mean Difference (IV, Random, 95% CI) -0.27 [-0.76, 0.22]
38.2 More than 12 weeks 4 341 Mean Difference (IV, Random, 95% CI) -0.08 [-0.22, 0.07]
39 Overall body fat (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
39.1 12 weeks or less 9 402 Std. Mean Difference (IV, Random, 95% CI) -0.16 [-0.37, 0.04]
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39.2 More than 12 weeks 9 760 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.45, 0.05]
40 Overall body fat (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
40.1 12 weeks or less 5 160 Std. Mean Difference (IV, Random, 95% CI) -0.36 [-0.68, -0.04]
40.2 More than 12 weeks 4 339 Std. Mean Difference (IV, Random, 95% CI) -0.94 [-2.07, 0.18]
41 Lower body strength (follow-up
values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 12 weeks or less 5 206 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.19, 0.50]
41.2 More than 12 weeks 5 431 Std. Mean Difference (IV, Random, 95% CI) 0.72 [0.20, 1.24]
42 Lower body strength (change
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
42.1 12 weeks or less 5 220 Std. Mean Difference (IV, Random, 95% CI) 0.71 [0.06, 1.37]
42.2 More than 12 weeks 3 500 Std. Mean Difference (IV, Random, 95% CI) 0.76 [0.36, 1.17]
43 Upper body strength (follow-up
values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
43.1 12 weeks or less 6 249 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.32, 0.62]
43.2 More than 12 weeks 7 519 Std. Mean Difference (IV, Random, 95% CI) 0.64 [0.24, 1.04]
44 Upper body strength (change
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
44.1 12 weeks or less 4 249 Std. Mean Difference (IV, Random, 95% CI) 0.72 [-0.06, 1.50]
44.2 More than 12 weeks 4 583 Std. Mean Difference (IV, Random, 95% CI) 0.71 [0.17, 1.25]
Comparison 16. Subanalysis: outcomes by format of intervention




participants Statistical method Effect size
1 Overall HRQoL (follow-up
values)
21 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Group format 5 214 Std. Mean Difference (IV, Random, 95% CI) 0.99 [0.22, 1.75]
1.2 Individual format 10 1137 Std. Mean Difference (IV, Random, 95% CI) 0.21 [0.03, 0.38]
1.3 Both group and individual
formats
6 390 Std. Mean Difference (IV, Random, 95% CI) 0.33 [0.04, 0.62]
2 Overall HRQoL (change values) 14 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Group format 5 198 Std. Mean Difference (IV, Random, 95% CI) 1.88 [0.19, 3.56]
2.2 Individual format 6 649 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.25, 0.61]
2.3 Both group and individual
formats




26 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Group format 10 649 Std. Mean Difference (IV, Random, 95% CI) 0.28 [0.07, 0.49]
3.2 Individual format 10 923 Std. Mean Difference (IV, Random, 95% CI) 0.16 [0.02, 0.30]
3.3 Both group and individual
formats




15 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Group format 7 398 Std. Mean Difference (IV, Random, 95% CI) 0.42 [-0.14, 0.99]
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4.2 Individual format 5 569 Std. Mean Difference (IV, Random, 95% CI) 0.26 [0.08, 0.44]
4.3 Both group and individual
formats
3 612 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.16, 0.34]
5 Overall physical function
(follow-up values)
24 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Group format 9 588 Std. Mean Difference (IV, Random, 95% CI) 0.53 [0.12, 0.94]
5.2 Individual format 9 941 Std. Mean Difference (IV, Random, 95% CI) 0.28 [0.12, 0.45]
5.3 Both group and individual
formats
6 538 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.06, 0.42]
6 Overall physical function
(change values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Group format 6 337 Std. Mean Difference (IV, Random, 95% CI) 1.25 [0.29, 2.21]
6.2 Individual format 3 432 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.01, 0.41]
6.3 Both group and individual
formats
4 664 Std. Mean Difference (IV, Random, 95% CI) 0.19 [-0.25, 0.63]
7 Overall role function (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Group format 6 225 Std. Mean Difference (IV, Random, 95% CI) 0.52 [-0.27, 1.30]
7.2 Individual format 7 689 Std. Mean Difference (IV, Random, 95% CI) 0.23 [0.07, 0.40]
7.3 Both group and individual
formats
5 426 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.15, 0.45]
8 Overall role function (change
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Group format 5 216 Std. Mean Difference (IV, Random, 95% CI) 0.36 [-0.14, 0.85]
8.2 Individual format 4 487 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.07, 0.32]
8.3 Both group and individual
formats




18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Group format 7 348 Std. Mean Difference (IV, Random, 95% CI) 0.22 [0.00, 0.45]
9.2 Individual format 5 546 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.07, 0.61]
9.3 Both group and individual
formats




12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 Group format 5 322 Std. Mean Difference (IV, Random, 95% CI) 0.57 [-0.06, 1.19]
10.2 Individual format 4 450 Std. Mean Difference (IV, Random, 95% CI) 0.72 [0.38, 1.06]
10.3 Both group and
individual formats
3 612 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.31, 0.85]
11 Overall cognitive function
(follow-up values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 Group format 3 134 Std. Mean Difference (IV, Random, 95% CI) 0.32 [-0.02, 0.66]
11.2 Individual format 1 18 Std. Mean Difference (IV, Random, 95% CI) 1.14 [0.07, 2.20]
11.3 Both group and
individual formats
1 37 Std. Mean Difference (IV, Random, 95% CI) 0.42 [-0.24, 1.07]
12 Overall cognitive function
(change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 Group format 3 134 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.31, 0.43]
12.2 Individual format 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
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12.3 Both group and
individual formats
2 538 Std. Mean Difference (IV, Random, 95% CI) 0.03 [-0.51, 0.57]
13 Overall general health
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 Group format 3 92 Std. Mean Difference (IV, Random, 95% CI) 0.38 [-0.31, 1.07]
13.2 Individual format 4 222 Std. Mean Difference (IV, Random, 95% CI) 0.34 [-0.08, 0.76]
13.3 Both group and
individual formats
2 112 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.64, 0.11]
14 Overall general health (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Group format 4 155 Std. Mean Difference (IV, Random, 95% CI) 0.35 [-0.25, 0.95]
14.2 Individual format 2 139 Std. Mean Difference (IV, Random, 95% CI) 0.38 [0.04, 0.73]
14.3 Both group and
individual formats
3 612 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.23, 0.09]
15 Overall sexual function
(follow-up values)
5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 Group format 1 114 Std. Mean Difference (IV, Fixed, 95% CI) 0.14 [-0.23, 0.51]
15.2 Individual format 4 297 Std. Mean Difference (IV, Fixed, 95% CI) 0.17 [-0.06, 0.40]
15.3 Both group and
individual formats
0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
16 Overall sleep (follow-up values) 5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
16.1 Group format 2 88 Std. Mean Difference (IV, Fixed, 95% CI) -0.26 [-0.68, 0.16]
16.2 Individual format 2 62 Std. Mean Difference (IV, Fixed, 95% CI) -0.07 [-0.57, 0.43]
16.3 Both group and
individual formats
1 38 Std. Mean Difference (IV, Fixed, 95% CI) 0.28 [-0.36, 0.92]
17 Overall anxiety (follow-up
values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 Group format 3 177 Std. Mean Difference (IV, Random, 95% CI) -0.73 [-1.03, -0.42]
17.2 Individual format 2 60 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.64, 0.39]
17.3 Both group and
individual formats
1 74 Std. Mean Difference (IV, Random, 95% CI) -0.14 [-0.60, 0.31]
18 Overall anxiety (change values) 4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
18.1 Group format 2 119 Std. Mean Difference (IV, Fixed, 95% CI) -0.52 [-0.88, -0.15]
18.2 Individual format 1 42 Std. Mean Difference (IV, Fixed, 95% CI) -0.37 [-0.99, 0.24]
18.3 Both group and
individual formats
1 74 Std. Mean Difference (IV, Fixed, 95% CI) -0.15 [-0.61, 0.30]
19 Overall depression (change
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 Group format 2 119 Std. Mean Difference (IV, Random, 95% CI) -0.54 [-0.91, -0.18]
19.2 Individual format 3 123 Std. Mean Difference (IV, Random, 95% CI) -0.51 [-1.03, 0.01]
19.3 Both group and
individual formats
2 574 Std. Mean Difference (IV, Random, 95% CI) 0.00 [-0.21, 0.22]
20 Overall depression (follow-up
values)
11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
20.1 Group format 4 176 Std. Mean Difference (IV, Random, 95% CI) -0.68 [-0.98, -0.37]
20.2 Individual format 5 206 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.51, 0.49]
20.3 Both group and
individual formats
2 260 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.37, 0.12]
21 Overall fatigue (follow-up
values)
24 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 Group format 7 350 Std. Mean Difference (IV, Random, 95% CI) -0.77 [-1.15, -0.39]
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21.2 Individual format 11 1068 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.36, -0.02]
21.3 Both group and
individual formats
6 445 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.37, 0.01]
22 Overall fatigue (change values) 12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 Group format 2 73 Std. Mean Difference (IV, Random, 95% CI) -0.10 [-0.70, 0.50]
22.2 Individual format 7 637 Std. Mean Difference (IV, Random, 95% CI) -0.40 [-0.98, 0.17]
22.3 Both group and
individual formats
3 561 Std. Mean Difference (IV, Random, 95% CI) -0.02 [-0.18, 0.15]
23 Overall pain/disability
(follow-up values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 Group format 2 77 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.26, 0.63]
23.2 Individual format 3 261 Std. Mean Difference (IV, Random, 95% CI) 0.22 [-0.22, 0.65]
23.3 Both group and
individual formats
3 135 Std. Mean Difference (IV, Random, 95% CI) -0.16 [-0.50, 0.18]
24 Overall pain/disability (change
values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 Group format 3 139 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.19, 0.50]
24.2 Individual format 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
24.3 Both group and
individual formats
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
25 Overall self-esteem/body image
(follow-up values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 Group format 3 234 Std. Mean Difference (IV, Random, 95% CI) 0.28 [-0.04, 0.60]
25.2 Individual format 5 259 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.21, 0.76]
25.3 Both group and
individual formats
2 97 Std. Mean Difference (IV, Random, 95% CI) 0.15 [-0.25, 0.55]
26 Overall self-esteem/body image
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 Group format 4 258 Std. Mean Difference (IV, Random, 95% CI) 0.59 [-0.33, 1.51]
26.2 Individual format 3 160 Std. Mean Difference (IV, Random, 95% CI) 0.31 [-0.19, 0.81]
26.3 Both group and
individual formats
2 574 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.21, 0.12]
27 Overall cardiorespiratory fitness
(follow-up values)
21 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 Group format 7 321 Std. Mean Difference (IV, Random, 95% CI) 0.29 [0.06, 0.51]
27.2 Individual format 10 493 Std. Mean Difference (IV, Random, 95% CI) 0.59 [0.38, 0.79]
27.3 Both group and
individual formats
4 362 Std. Mean Difference (IV, Random, 95% CI) 0.24 [0.03, 0.44]
28 Overall cardiorespiratory fitness
(change values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
28.1 Group format 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
28.2 Individual format 4 216 Std. Mean Difference (IV, Random, 95% CI) 0.64 [0.08, 1.19]
28.3 Both group and
individual formats
2 581 Std. Mean Difference (IV, Random, 95% CI) 0.44 [-0.18, 1.05]
29 Overall self-reported physical
activity (follow-up values)
17 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 Group format 1 264 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.11, 0.37]
29.2 Individual format 8 989 Std. Mean Difference (IV, Random, 95% CI) 0.59 [0.28, 0.90]
29.3 Both group and
individual formats
8 752 Std. Mean Difference (IV, Random, 95% CI) 0.55 [0.25, 0.84]
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30 Overall self-reported physical
activity (change values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
30.1 Group format 1 105 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.17, 0.60]
30.2 Individual format 3 495 Std. Mean Difference (IV, Random, 95% CI) 0.38 [0.18, 0.57]
30.3 Both group and
individual formats
4 674 Std. Mean Difference (IV, Random, 95% CI) 0.92 [0.14, 1.70]
31 Overall objective physical
activity (follow-up values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
31.1 Group format 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
31.2 Individual format 8 957 Std. Mean Difference (IV, Random, 95% CI) 0.51 [0.18, 0.85]
31.3 Both group and
individual formats
4 352 Std. Mean Difference (IV, Random, 95% CI) 0.34 [0.13, 0.55]
32 Overall objective physical
activity (change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
32.1 Group format 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
32.2 Individual format 3 416 Std. Mean Difference (IV, Random, 95% CI) 0.62 [-0.23, 1.46]
32.3 Both group and
individual formats
2 92 Std. Mean Difference (IV, Random, 95% CI) 0.83 [0.40, 1.27]
33 Mass (follow-up values) 15 Mean Difference (IV, Fixed, 95% CI) Subtotals only
33.1 Group format 4 363 Mean Difference (IV, Fixed, 95% CI) -1.10 [-3.92, 1.72]
33.2 Individual format 5 331 Mean Difference (IV, Fixed, 95% CI) 0.16 [-0.79, 1.10]
33.3 Both group and
individual formats
6 487 Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.76, 0.76]
34 Mass (change values) 10 Mean Difference (IV, Random, 95% CI) Subtotals only
34.1 Group format 3 211 Mean Difference (IV, Random, 95% CI) -1.23 [-2.10, -0.35]
34.2 Individual format 4 186 Mean Difference (IV, Random, 95% CI) 0.10 [-0.08, 0.28]
34.3 Both group and
individual formats
3 617 Mean Difference (IV, Random, 95% CI) -0.58 [-1.80, 0.63]
35 BMI (follow-up values) 16 Mean Difference (IV, Fixed, 95% CI) Subtotals only
35.1 Group format 3 347 Mean Difference (IV, Fixed, 95% CI) -0.71 [-1.74, 0.32]
35.2 Individual format 7 647 Mean Difference (IV, Fixed, 95% CI) 0.13 [-0.18, 0.44]
35.3 Both group and
individual formats
6 458 Mean Difference (IV, Fixed, 95% CI) -0.03 [-0.31, 0.26]
36 BMI (change values) 8 Mean Difference (IV, Random, 95% CI) Subtotals only
36.1 Group format 3 211 Mean Difference (IV, Random, 95% CI) -0.67 [-0.98, -0.36]
36.2 Individual format 3 150 Mean Difference (IV, Random, 95% CI) -0.03 [-0.22, 0.15]
36.3 Both group and
individual formats
2 124 Mean Difference (IV, Random, 95% CI) -0.12 [-0.43, 0.20]
37 Overall body fat (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
37.1 Group format 3 299 Std. Mean Difference (IV, Random, 95% CI) -0.23 [-0.46, -0.00]
37.2 Individual format 10 539 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.54, -0.06]
37.3 Both group and
individual formats
5 324 Std. Mean Difference (IV, Random, 95% CI) 0.05 [-0.17, 0.26]
38 Overall body fat (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
38.1 Group format 2 147 Std. Mean Difference (IV, Random, 95% CI) -0.06 [-0.38, 0.26]
38.2 Individual format 6 270 Std. Mean Difference (IV, Random, 95% CI) -0.86 [-1.74, 0.02]
38.3 Both group and
individual formats
1 82 Std. Mean Difference (IV, Random, 95% CI) -0.29 [-0.73, 0.14]
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39 Lower body strength (follow-up
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
39.1 Group format 2 290 Std. Mean Difference (IV, Random, 95% CI) 0.69 [0.29, 1.10]
39.2 Individual format 3 85 Std. Mean Difference (IV, Random, 95% CI) 1.04 [0.08, 2.00]
39.3 Both group and
individual formats
4 200 Std. Mean Difference (IV, Random, 95% CI) 0.13 [-0.22, 0.47]
40 Lower body strength (change
values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
40.1 Group format 2 294 Std. Mean Difference (IV, Random, 95% CI) 0.92 [0.61, 1.22]
40.2 Individual format 3 289 Std. Mean Difference (IV, Random, 95% CI) 0.65 [0.09, 1.22]
40.3 Both group and
individual formats
0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
41 Upper body strength (follow-up
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 Group format 4 365 Std. Mean Difference (IV, Random, 95% CI) 0.53 [-0.29, 1.35]
41.2 Individual format 4 141 Std. Mean Difference (IV, Random, 95% CI) 0.63 [-0.06, 1.32]
41.3 Both group and
individual formats
4 200 Std. Mean Difference (IV, Random, 95% CI) 0.29 [0.01, 0.57]
42 Upper body strength (change
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
42.1 Group format 3 377 Std. Mean Difference (IV, Random, 95% CI) 1.01 [0.49, 1.53]
42.2 Individual format 3 310 Std. Mean Difference (IV, Random, 95% CI) 1.00 [-0.08, 2.09]
42.3 Both group and
individual formats
1 83 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.27, 0.59]
43 Bone mineral density - femoral
neck (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
43.1 Group format 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
43.2 Individual format 2 262 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.80, 1.14]
43.3 Both group and
individual formats
2 524 Std. Mean Difference (IV, Random, 95% CI) 0.17 [0.00, 0.34]
44 Bone mineral density - lumbar
spine (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
44.1 Group format 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
44.2 Individual format 2 262 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.59, 0.98]
44.3 Both group and
individual formats
2 524 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.06, 0.29]
45 Bone mineral density - total hip
(follow-up and change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
45.1 Group format 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
45.2 Individual format 1 39 Std. Mean Difference (IV, Random, 95% CI) 10.34 [7.84, 12.84]
45.3 Both group and
individual formats
2 290 Std. Mean Difference (IV, Random, 95% CI) 0.64 [-0.20, 1.48]
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Comparison 17. Subanalysis: outcomes by setting of intervention




participants Statistical method Effect size
1 Overall HRQoL (follow-up
values)
22 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Home-based 5 792 Std. Mean Difference (IV, Random, 95% CI) 0.04 [-0.11, 0.19]
1.2 Facility-based 15 833 Std. Mean Difference (IV, Random, 95% CI) 0.55 [0.27, 0.83]
1.3 Both home- and facility-
based
4 227 Std. Mean Difference (IV, Random, 95% CI) 0.48 [0.04, 0.92]
2 Overall HRQoL (change values) 14 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Home-based 2 375 Std. Mean Difference (IV, Random, 95% CI) 0.27 [0.04, 0.50]
2.2 Facility-based 10 492 Std. Mean Difference (IV, Random, 95% CI) 1.18 [0.53, 1.82]
2.3 Both home- and facility-
based




26 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Home-based 5 670 Std. Mean Difference (IV, Random, 95% CI) 0.11 [-0.06, 0.27]
3.2 Facility-based 15 901 Std. Mean Difference (IV, Random, 95% CI) 0.31 [0.12, 0.50]
3.3 Both home- and facility-
based




15 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Home-based 2 417 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.06, 0.37]
4.2 Facility-based 10 550 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.04, 0.82]
4.3 Both home- and facility-
based
3 612 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.16, 0.34]
5 Overall physical function
(follow-up values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Home-based 5 720 Std. Mean Difference (IV, Random, 95% CI) 0.19 [0.03, 0.34]
5.2 Facility-based 13 816 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.14, 0.73]
5.3 Both home- and facility-
based
7 592 Std. Mean Difference (IV, Random, 95% CI) 0.23 [-0.02, 0.48]
6 Overall physical function
(change values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Home-based 1 332 Std. Mean Difference (IV, Random, 95% CI) 0.26 [0.02, 0.51]
6.2 Facility-based 9 489 Std. Mean Difference (IV, Random, 95% CI) 0.95 [0.31, 1.59]
6.3 Both home- and facility-
based
3 612 Std. Mean Difference (IV, Random, 95% CI) -0.08 [-0.24, 0.08]
7 Overall role function (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Home-based 2 386 Std. Mean Difference (IV, Random, 95% CI) 0.26 [-0.14, 0.66]
7.2 Facility-based 12 564 Std. Mean Difference (IV, Random, 95% CI) 0.33 [-0.03, 0.69]
7.3 Both home- and facility-
based
4 420 Std. Mean Difference (IV, Random, 95% CI) 0.20 [-0.14, 0.54]
8 Overall role function (change
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Home-based 1 335 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.08, 0.41]
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8.2 Facility-based 8 368 Std. Mean Difference (IV, Random, 95% CI) 0.26 [-0.06, 0.58]
8.3 Both home- and facility-
based




18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Home-based 2 386 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.23, 0.22]
9.2 Facility-based 11 709 Std. Mean Difference (IV, Random, 95% CI) 0.22 [0.07, 0.37]
9.3 Both home- and facility-
based




12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 Home-based 1 335 Std. Mean Difference (IV, Random, 95% CI) 0.97 [0.71, 1.23]
10.2 Facility-based 7 395 Std. Mean Difference (IV, Random, 95% CI) 0.50 [0.05, 0.95]
10.3 Both home- and facility-
based
4 654 Std. Mean Difference (IV, Random, 95% CI) 0.41 [-0.15, 0.96]
11 Overall cognitive function
(follow-up values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 Home-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
11.2 Facility-based 3 134 Std. Mean Difference (IV, Random, 95% CI) 0.32 [-0.02, 0.66]
11.3 Both home- and facility-
based
2 55 Std. Mean Difference (IV, Random, 95% CI) 0.65 [-0.01, 1.31]
12 Overall cognitive function
(change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 Home-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
12.2 Facility-based 3 134 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.31, 0.43]
12.3 Both home- and facility-
based
2 538 Std. Mean Difference (IV, Random, 95% CI) 0.03 [-0.51, 0.57]
13 Overall general health
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 Home-based 2 111 Std. Mean Difference (IV, Random, 95% CI) 0.43 [-0.32, 1.17]
13.2 Facility-based 6 273 Std. Mean Difference (IV, Random, 95% CI) 0.25 [0.01, 0.49]
13.3 Both home- and facility-
based
2 112 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.64, 0.11]
14 Overall general health (change
values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Home-based 1 40 Std. Mean Difference (IV, Random, 95% CI) 0.42 [-0.21, 1.05]
14.2 Facility-based 2 59 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.49, 1.03]
14.3 Both home- and facility-
based
3 612 Std. Mean Difference (IV, Random, 95% CI) -0.07 [-0.23, 0.09]
15 Overall sexual function
(follow-up values)
5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 Home-based 2 136 Std. Mean Difference (IV, Fixed, 95% CI) -0.00 [-0.34, 0.34]
15.2 Facility-based 2 193 Std. Mean Difference (IV, Fixed, 95% CI) 0.21 [-0.07, 0.49]
15.3 Both home- and facility-
based
1 82 Std. Mean Difference (IV, Fixed, 95% CI) 0.29 [-0.14, 0.73]
16 Overall sexual function (change
values)
3 Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 Home-based 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
16.2 Facility-based 2 193 Mean Difference (IV, Random, 95% CI) 3.83 [-1.83, 9.48]
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16.3 Both home- and facility-
based
1 500 Mean Difference (IV, Random, 95% CI) 0.5 [-3.86, 4.86]
17 Overall sleep (follow-up values) 5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 Home-based 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
17.2 Facility-based 2 88 Std. Mean Difference (IV, Fixed, 95% CI) -0.26 [-0.68, 0.16]
17.3 Both home- and facility-
based
3 100 Std. Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.33, 0.46]
18 Overall sleep (change values) 3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 Home-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
18.2 Facility-based 1 56 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.38, 0.67]
18.3 Both home- and facility-
based
2 80 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.30, 0.58]
19 Overall anxiety (follow-up
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 Home-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
19.2 Facility-based 4 192 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.34, -0.41]
19.3 Both home- and facility-
based
3 134 Std. Mean Difference (IV, Random, 95% CI) -0.14 [-0.48, 0.21]
20 Overall anxiety (change values) 4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
20.1 Home-based 0 0 Std. Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
20.2 Facility-based 2 119 Std. Mean Difference (IV, Fixed, 95% CI) -0.52 [-0.88, -0.15]
20.3 Both home- and facility-
based
2 116 Std. Mean Difference (IV, Fixed, 95% CI) -0.23 [-0.60, 0.13]
21 Overall depression (follow-up
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 Home-based 2 60 Std. Mean Difference (IV, Random, 95% CI) 0.34 [-0.17, 0.85]
21.2 Facility-based 8 483 Std. Mean Difference (IV, Random, 95% CI) -0.55 [-0.85, -0.25]
21.3 Both home- and facility-
based
3 134 Std. Mean Difference (IV, Random, 95% CI) 0.05 [-0.52, 0.61]
22 Overall depression (change
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 Home-based 1 40 Std. Mean Difference (IV, Random, 95% CI) -0.39 [-1.02, 0.23]
22.2 Facility-based 3 140 Std. Mean Difference (IV, Random, 95% CI) -0.63 [-0.97, -0.29]
22.3 Both home- and facility-
based
3 616 Std. Mean Difference (IV, Random, 95% CI) -0.11 [-0.41, 0.19]
23 Overall fatigue (follow-up
values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 Home-based 6 850 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.39, 0.03]
23.2 Facility-based 13 749 Std. Mean Difference (IV, Random, 95% CI) -0.53 [-0.77, -0.29]
23.3 Both home- and facility-
based
7 346 Std. Mean Difference (IV, Random, 95% CI) -0.09 [-0.30, 0.13]
24 Overall fatigue (change values) 12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 Home-based 2 417 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-1.10, 0.61]
24.2 Facility-based 7 296 Std. Mean Difference (IV, Random, 95% CI) -0.43 [-1.06, 0.20]
24.3 Both home- and facility-
based
3 558 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.17, 0.16]
25 Overall pain/disability
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 Home-based 3 249 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.20, 0.68]
25.2 Facility-based 5 183 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.20, 0.38]
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25.3 Both home- and facility-
based
2 112 Std. Mean Difference (IV, Random, 95% CI) -0.12 [-0.49, 0.25]
26 Overall pain/disability (change
values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 Home-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
26.2 Facility-based 3 139 Std. Mean Difference (IV, Random, 95% CI) 0.16 [-0.19, 0.50]
26.3 Both home- and facility-
based
2 157 Std. Mean Difference (IV, Random, 95% CI) -0.29 [-0.61, 0.02]
27 Overall self-esteem/body image
(follow-up values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 Home-based 2 124 Std. Mean Difference (IV, Random, 95% CI) -0.10 [-1.17, 0.97]
27.2 Facility-based 8 451 Std. Mean Difference (IV, Random, 95% CI) 0.29 [0.09, 0.50]
27.3 Both home- and facility-
based
2 92 Std. Mean Difference (IV, Random, 95% CI) 0.52 [-0.44, 1.48]
28 Overall self-esteem/body image
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
28.1 Home-based 1 42 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.89, 0.45]
28.2 Facility-based 6 376 Std. Mean Difference (IV, Random, 95% CI) 0.52 [-0.09, 1.13]
28.3 Both home- and facility-
based
2 574 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.21, 0.12]
29 Overall cardiorespiratory fitness
(follow-up values)
23 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 Home-based 5 245 Std. Mean Difference (IV, Random, 95% CI) 0.66 [0.40, 0.92]
29.2 Facility-based 13 603 Std. Mean Difference (IV, Random, 95% CI) 0.45 [0.25, 0.66]
29.3 Both home- and facility-
based
6 426 Std. Mean Difference (IV, Random, 95% CI) 0.29 [0.03, 0.56]
30 Overall cardiorespiratory fitness
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
30.1 Home-based 2 124 Std. Mean Difference (IV, Random, 95% CI) 0.39 [-0.20, 0.99]
30.2 Facility-based 4 116 Std. Mean Difference (IV, Random, 95% CI) 1.62 [1.03, 2.21]
30.3 Both home- and facility-
based
3 623 Std. Mean Difference (IV, Random, 95% CI) 0.40 [-0.02, 0.82]
31 Overall self-reported physical
activity (follow-up values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
31.1 Home-based 9 1028 Std. Mean Difference (IV, Random, 95% CI) 0.57 [0.29, 0.85]
31.2 Facility-based 3 513 Std. Mean Difference (IV, Random, 95% CI) 0.23 [0.05, 0.40]
31.3 Both home- and facility-
based
6 503 Std. Mean Difference (IV, Random, 95% CI) 0.62 [0.23, 1.00]
32 Overall self-reported physical
activity (change values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
32.1 Home-based 3 495 Std. Mean Difference (IV, Random, 95% CI) 0.38 [0.18, 0.57]
32.2 Facility-based 1 105 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.17, 0.60]
32.3 Both home- and facility-
based
4 674 Std. Mean Difference (IV, Random, 95% CI) 0.92 [0.14, 1.70]
33 Overall objective physical
activity (follow-up values)
11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
33.1 Home-based 5 854 Std. Mean Difference (IV, Random, 95% CI) 0.45 [0.07, 0.82]
33.2 Facility-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
33.3 Both home- and facility-
based
6 416 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.17, 0.68]
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34 Overall objective physical
activity (change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
34.1 Home-based 2 374 Std. Mean Difference (IV, Random, 95% CI) 0.37 [-0.56, 1.30]
34.2 Facility-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
34.3 Both home- and facility-
based
3 134 Std. Mean Difference (IV, Random, 95% CI) 0.92 [0.56, 1.28]
35 Mass (follow-up values) 16 Mean Difference (IV, Fixed, 95% CI) Subtotals only
35.1 Home-based 2 100 Mean Difference (IV, Fixed, 95% CI) -3.38 [-10.29, 3.53]
35.2 Facility-based 10 864 Mean Difference (IV, Fixed, 95% CI) 0.03 [-0.56, 0.61]
35.3 Both home- and facility-
based
4 246 Mean Difference (IV, Fixed, 95% CI) 0.04 [-3.96, 4.04]
36 Mass (change values) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
36.1 Home-based 1 36 Mean Difference (IV, Random, 95% CI) -0.03 [-1.46, 1.40]
36.2 Facility-based 7 394 Mean Difference (IV, Random, 95% CI) -0.61 [-1.31, 0.08]
36.3 Both home- and facility-
based
3 617 Mean Difference (IV, Random, 95% CI) -0.58 [-1.80, 0.63]
37 BMI (follow-up values) 17 Mean Difference (IV, Fixed, 95% CI) Subtotals only
37.1 Home-based 3 442 Mean Difference (IV, Fixed, 95% CI) -0.53 [-1.64, 0.57]
37.2 Facility-based 9 767 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.17, 0.26]
37.3 Both home- and facility-
based
6 281 Mean Difference (IV, Fixed, 95% CI) -0.61 [-2.14, 0.91]
38 BMI (change values) 8 Mean Difference (IV, Random, 95% CI) Subtotals only
38.1 Home-based 0 0 Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
38.2 Facility-based 6 361 Mean Difference (IV, Random, 95% CI) -0.27 [-0.58, 0.04]
38.3 Both home- and facility-
based
2 124 Mean Difference (IV, Random, 95% CI) -0.12 [-0.43, 0.20]
39 Overall body fat (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
39.1 Home-based 4 224 Std. Mean Difference (IV, Random, 95% CI) -0.18 [-0.45, 0.09]
39.2 Facility-based 7 550 Std. Mean Difference (IV, Random, 95% CI) -0.39 [-0.69, -0.08]
39.3 Both home- and facility-
based
7 388 Std. Mean Difference (IV, Random, 95% CI) 0.01 [-0.19, 0.21]
40 Overall body fat (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
40.1 Home-based 2 78 Std. Mean Difference (IV, Random, 95% CI) -0.48 [-0.97, -0.00]
40.2 Facility-based 5 297 Std. Mean Difference (IV, Random, 95% CI) -0.84 [-1.94, 0.26]
40.3 Both home- and facility-
based
2 124 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.62, 0.09]
41 Lower body strength (follow-up
values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 Home-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
41.2 Facility-based 5 417 Std. Mean Difference (IV, Random, 95% CI) 0.75 [0.24, 1.27]
41.3 Both home- and facility-
based
5 220 Std. Mean Difference (IV, Random, 95% CI) 0.12 [-0.16, 0.40]
42 Lower body strength (change
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
42.1 Home-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
42.2 Facility-based 7 497 Std. Mean Difference (IV, Random, 95% CI) 0.80 [0.38, 1.23]
42.3 Both home- and facility-
based
1 223 Std. Mean Difference (IV, Random, 95% CI) 0.42 [0.15, 0.69]
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43 Upper body strength (follow-up
values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
43.1 Home-based 2 64 Std. Mean Difference (IV, Random, 95% CI) 0.58 [0.05, 1.12]
43.2 Facility-based 8 513 Std. Mean Difference (IV, Random, 95% CI) 0.43 [-0.12, 0.98]
43.3 Both home- and facility-
based
4 200 Std. Mean Difference (IV, Random, 95% CI) 0.29 [0.01, 0.57]
44 Upper body strength (change
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
44.1 Home-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
44.2 Facility-based 6 526 Std. Mean Difference (IV, Random, 95% CI) 0.92 [0.34, 1.50]
44.3 Both home- and facility-
based
2 306 Std. Mean Difference (IV, Random, 95% CI) 0.25 [0.03, 0.48]
45 Bone mineral density - femoral
neck (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
45.1 Home-based 1 39 Std. Mean Difference (IV, Random, 95% CI) -0.37 [-1.00, 0.27]
45.2 Facility-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
45.3 Both home- and facility-
based
3 747 Std. Mean Difference (IV, Random, 95% CI) 0.32 [-0.01, 0.65]
46 Bone mineral density - lumbar
spine (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
46.1 Home-based 1 39 Std. Mean Difference (IV, Random, 95% CI) -0.26 [-0.89, 0.37]
46.2 Facility-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
46.3 Both home- and facility-
based
3 747 Std. Mean Difference (IV, Random, 95% CI) 0.30 [-0.02, 0.63]
47 Bone mineral density - total hip
(follow-up and change values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
47.1 Home-based 1 39 Std. Mean Difference (IV, Random, 95% CI) 10.34 [7.84, 12.84]
47.2 Facility-based 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
47.3 Both home- and facility-
based
2 290 Std. Mean Difference (IV, Random, 95% CI) 0.64 [-0.20, 1.48]
Comparison 18. Sensitivity analysis: outcomes by risk of bias




participants Statistical method Effect size
1 Overall HRQoL (follow-up
values)
22 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
1.1 Low risk of bias 15 1521 Std. Mean Difference (IV, Random, 95% CI) 0.43 [0.19, 0.66]
1.2 Unclear/high risk of bias 7 475 Std. Mean Difference (IV, Random, 95% CI) 0.30 [0.06, 0.55]
2 Overall HRQoL (change values) 14 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
2.1 Low risk of bias 11 1360 Std. Mean Difference (IV, Random, 95% CI) 0.70 [0.28, 1.12]




26 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
3.1 Low risk of bias 15 1427 Std. Mean Difference (IV, Random, 95% CI) 0.22 [0.09, 0.34]
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15 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
4.1 Low risk of bias 11 1399 Std. Mean Difference (IV, Random, 95% CI) 0.31 [0.04, 0.58]
4.2 Unclear/high risk of bias 4 180 Std. Mean Difference (IV, Random, 95% CI) 0.28 [-0.08, 0.65]
5 Overall physical function
(follow-up values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
5.1 Low risk of bias 13 1343 Std. Mean Difference (IV, Random, 95% CI) 0.38 [0.13, 0.63]
5.2 Unclear/high risk of bias 12 786 Std. Mean Difference (IV, Random, 95% CI) 0.28 [0.14, 0.42]
6 Overall physical function
(change values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
6.1 Low risk of bias 10 1335 Std. Mean Difference (IV, Random, 95% CI) 0.63 [0.19, 1.07]
6.2 Unclear/high risk of bias 3 98 Std. Mean Difference (IV, Random, 95% CI) 0.50 [0.09, 0.90]
7 Overall role function (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
7.1 Low risk of bias 12 1111 Std. Mean Difference (IV, Random, 95% CI) 0.32 [0.02, 0.61]
7.2 Unclear/high risk of bias 6 259 Std. Mean Difference (IV, Random, 95% CI) 0.24 [-0.01, 0.48]
8 Overall role function (change
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
8.1 Low risk of bias 9 1218 Std. Mean Difference (IV, Random, 95% CI) 0.17 [-0.06, 0.40]




18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Low risk of bias 12 1263 Std. Mean Difference (IV, Random, 95% CI) 0.21 [0.07, 0.36]




12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
10.1 Low risk of bias 9 1286 Std. Mean Difference (IV, Random, 95% CI) 0.56 [0.13, 0.98]
10.2 Unclear/high risk of bias 3 98 Std. Mean Difference (IV, Random, 95% CI) 0.31 [-0.09, 0.71]
11 Overall cognitive function
(follow-up values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
11.1 Low risk of bias 3 114 Std. Mean Difference (IV, Random, 95% CI) 0.45 [0.07, 0.82]
11.2 Unclear/high risk of bias 2 75 Std. Mean Difference (IV, Random, 95% CI) 0.52 [-0.44, 1.48]
12 Overall cognitive function
(change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
12.1 Low risk of bias 4 615 Std. Mean Difference (IV, Random, 95% CI) 0.07 [-0.28, 0.42]
12.2 Unclear/high risk of bias 1 57 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.71, 0.33]
13 Overall general health
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
13.1 Low risk of bias 5 267 Std. Mean Difference (IV, Random, 95% CI) 0.06 [-0.31, 0.43]
13.2 Unclear/high risk of bias 4 189 Std. Mean Difference (IV, Random, 95% CI) 0.36 [0.02, 0.70]
14 Overall general health (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
14.1 Low risk of bias 7 829 Std. Mean Difference (IV, Random, 95% CI) 0.21 [-0.08, 0.49]
14.2 Unclear/high risk of bias 2 77 Std. Mean Difference (IV, Random, 95% CI) 0.10 [-0.35, 0.55]
15 Overall sexual function
(follow-up values)
5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
15.1 Low risk of bias 2 193 Std. Mean Difference (IV, Fixed, 95% CI) 0.21 [-0.07, 0.49]
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15.2 Unclear/high risk of bias 3 218 Std. Mean Difference (IV, Fixed, 95% CI) 0.11 [-0.16, 0.38]
16 Overall sexual function (change
values)
3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
16.1 Low risk of bias 3 693 Std. Mean Difference (IV, Random, 95% CI) 0.22 [-0.08, 0.52]
16.2 Unclear/high risk of bias 0 0 Std. Mean Difference (IV, Random, 95% CI) 0.0 [0.0, 0.0]
17 Overall sleep (follow-up values) 5 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
17.1 Low risk of bias 3 111 Std. Mean Difference (IV, Fixed, 95% CI) 0.09 [-0.28, 0.47]
17.2 Unclear/high risk of bias 2 77 Std. Mean Difference (IV, Fixed, 95% CI) -0.35 [-0.80, 0.10]
18 Overall sleep (change values) 3 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
18.1 Low risk of bias 2 80 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.30, 0.58]
18.2 Unclear/high risk of bias 1 56 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.38, 0.67]
19 Overall anxiety (follow-up
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
19.1 Low risk of bias 4 235 Std. Mean Difference (IV, Random, 95% CI) -0.46 [-0.89, -0.03]
19.2 Unclear/high risk of bias 3 91 Std. Mean Difference (IV, Random, 95% CI) -0.95 [-1.92, 0.02]
20 Overall anxiety (change values) 4 Std. Mean Difference (IV, Fixed, 95% CI) Subtotals only
20.1 Low risk of bias 3 177 Std. Mean Difference (IV, Fixed, 95% CI) -0.36 [-0.66, -0.06]
20.2 Unclear/high risk of bias 1 58 Std. Mean Difference (IV, Fixed, 95% CI) -0.42 [-0.95, 0.10]
21 Overall self-esteem/body image
(follow-up values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
21.1 Low risk of bias 7 436 Std. Mean Difference (IV, Random, 95% CI) 0.14 [-0.12, 0.40]
21.2 Unclear/high risk of bias 5 231 Std. Mean Difference (IV, Random, 95% CI) 0.48 [0.16, 0.80]
22 Overall self-esteem/body image
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
22.1 Low risk of bias 7 914 Std. Mean Difference (IV, Random, 95% CI) 0.07 [-0.21, 0.34]
22.2 Unclear/high risk of bias 2 78 Std. Mean Difference (IV, Random, 95% CI) 1.72 [-1.48, 4.92]
23 Overall depression (follow-up
values)
12 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
23.1 Low risk of bias 7 520 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.52, 0.12]
23.2 Unclear/high risk of bias 5 137 Std. Mean Difference (IV, Random, 95% CI) -0.67 [-1.23, -0.11]
24 Overall depression (change
values)
7 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
24.1 Low risk of bias 5 737 Std. Mean Difference (IV, Random, 95% CI) -0.20 [-0.47, 0.06]
24.2 Unclear/high risk of bias 2 79 Std. Mean Difference (IV, Random, 95% CI) -0.75 [-1.39, -0.10]
25 Overall fatigue (follow-up
values)
25 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
25.1 Low risk of bias 15 1443 Std. Mean Difference (IV, Random, 95% CI) -0.38 [-0.59, -0.18]
25.2 Unclear/high risk of bias 10 482 Std. Mean Difference (IV, Random, 95% CI) -0.25 [-0.45, -0.05]
26 Overall fatigue (change values) 13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
26.1 Low risk of bias 8 1091 Std. Mean Difference (IV, Random, 95% CI) -0.22 [-0.61, 0.16]
26.2 Unclear/high risk of bias 5 198 Std. Mean Difference (IV, Random, 95% CI) -0.45 [-0.95, 0.05]
27 Overall pain/disability
(follow-up values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
27.1 Low risk of bias 4 169 Std. Mean Difference (IV, Random, 95% CI) -0.13 [-0.44, 0.18]
27.2 Unclear/high risk of bias 5 352 Std. Mean Difference (IV, Random, 95% CI) 0.25 [0.04, 0.46]
28 Overall pain/disability (change
values)
6 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
28.1 Low risk of bias 2 136 Std. Mean Difference (IV, Random, 95% CI) -0.03 [-0.45, 0.40]
28.2 Unclear/high risk of bias 4 196 Std. Mean Difference (IV, Random, 95% CI) -0.05 [-0.36, 0.26]
29 Overall cardiorespiratory fitness
(follow-up values)
23 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
29.1 Low risk of bias 10 657 Std. Mean Difference (IV, Random, 95% CI) 0.44 [0.24, 0.65]
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29.2 Unclear/high risk of bias 13 608 Std. Mean Difference (IV, Random, 95% CI) 0.44 [0.23, 0.65]
30 Overall cardiorespiratory fitness
(change values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
30.1 Low risk of bias 4 632 Std. Mean Difference (IV, Random, 95% CI) 0.49 [-0.09, 1.06]
30.2 Unclear/high risk of bias 5 231 Std. Mean Difference (IV, Random, 95% CI) 1.16 [0.60, 1.72]
31 Overall self-reported physical
activity (follow-up values)
17 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
31.1 Low risk of bias 8 1482 Std. Mean Difference (IV, Random, 95% CI) 0.45 [0.21, 0.68]
31.2 Unclear/high risk of bias 9 530 Std. Mean Difference (IV, Random, 95% CI) 0.61 [0.31, 0.91]
32 Overall self-reported physical
activity (change values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
32.1 Low risk of bias 4 1047 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.00, 0.55]
32.2 Unclear/high risk of bias 4 227 Std. Mean Difference (IV, Random, 95% CI) 0.99 [0.40, 1.58]
33 Overall objective physical
activity (follow-up values)
11 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
33.1 Low risk of bias 7 1105 Std. Mean Difference (IV, Random, 95% CI) 0.41 [0.15, 0.66]
33.2 Unclear/high risk of bias 4 165 Std. Mean Difference (IV, Random, 95% CI) 0.50 [-0.24, 1.25]
34 Overall objective physical
activity (change values)
5 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
34.1 Low risk of bias 3 447 Std. Mean Difference (IV, Random, 95% CI) 0.56 [-0.18, 1.30]
34.2 Unclear/high risk of bias 2 61 Std. Mean Difference (IV, Random, 95% CI) 0.99 [0.44, 1.54]
35 Mass (follow-up values) 16 Mean Difference (IV, Fixed, 95% CI) Subtotals only
35.1 Low risk of bias 8 828 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.54, 0.64]
35.2 Unclear/high risk of bias 8 382 Mean Difference (IV, Fixed, 95% CI) -1.28 [-4.26, 1.70]
36 Mass (change values) 11 Mean Difference (IV, Random, 95% CI) Subtotals only
36.1 Low risk of bias 5 819 Mean Difference (IV, Random, 95% CI) -0.43 [-1.05, 0.20]
36.2 Unclear/high risk of bias 6 228 Mean Difference (IV, Random, 95% CI) -0.62 [-1.44, 0.19]
37 BMI (follow-up values) 17 Mean Difference (IV, Fixed, 95% CI) Subtotals only
37.1 Low risk of bias 10 1162 Mean Difference (IV, Fixed, 95% CI) 0.05 [-0.16, 0.26]
37.2 Unclear/high risk of bias 7 319 Mean Difference (IV, Fixed, 95% CI) -1.07 [-2.29, 0.14]
38 BMI (change values) 8 Mean Difference (IV, Random, 95% CI) Subtotals only
38.1 Low risk of bias 5 363 Mean Difference (IV, Random, 95% CI) -0.24 [-0.56, 0.08]
38.2 Unclear/high risk of bias 3 122 Mean Difference (IV, Random, 95% CI) -0.20 [-0.65, 0.25]
39 Overall body fat (follow-up
values)
18 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
39.1 Low risk of bias 10 768 Std. Mean Difference (IV, Random, 95% CI) -0.19 [-0.41, 0.03]
39.2 Unclear/high risk of bias 8 394 Std. Mean Difference (IV, Random, 95% CI) -0.17 [-0.40, 0.07]
40 Overall body fat (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
40.1 Low risk of bias 5 341 Std. Mean Difference (IV, Random, 95% CI) -0.87 [-1.86, 0.12]
40.2 Unclear/high risk of bias 4 158 Std. Mean Difference (IV, Random, 95% CI) -0.30 [-0.62, 0.01]
41 Lower body strength (follow-up
values)
10 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
41.1 Low risk of bias 5 440 Std. Mean Difference (IV, Random, 95% CI) 0.61 [0.22, 1.00]
41.2 Unclear/high risk of bias 5 197 Std. Mean Difference (IV, Random, 95% CI) 0.23 [-0.32, 0.79]
42 Lower body strength (change
values)
8 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
42.1 Low risk of bias 3 339 Std. Mean Difference (IV, Random, 95% CI) 0.97 [0.70, 1.25]
42.2 Unclear/high risk of bias 5 381 Std. Mean Difference (IV, Random, 95% CI) 0.46 [0.04, 0.88]
43 Upper body strength (follow-up
values)
13 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
43.1 Low risk of bias 7 516 Std. Mean Difference (IV, Random, 95% CI) 0.53 [0.04, 1.01]
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43.2 Unclear/high risk of bias 6 252 Std. Mean Difference (IV, Random, 95% CI) 0.29 [-0.21, 0.78]
44 Upper body strength (change
values)
9 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
44.1 Low risk of bias 4 381 Std. Mean Difference (IV, Random, 95% CI) 1.13 [0.46, 1.80]
44.2 Unclear/high risk of bias 5 487 Std. Mean Difference (IV, Random, 95% CI) 0.43 [-0.05, 0.91]
45 Bone mineral density - femoral
neck (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
45.1 Low risk of bias 1 457 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.00, 0.37]
45.2 Unclear/high risk of bias 3 329 Std. Mean Difference (IV, Random, 95% CI) 0.18 [-0.39, 0.75]
46 Bone mineral density - lumbar
spine (follow-up and change
values)
4 Std. Mean Difference (IV, Random, 95% CI) Subtotals only
46.1 Low risk of bias 1 457 Std. Mean Difference (IV, Random, 95% CI) 0.09 [-0.09, 0.27]
46.2 Unclear/high risk of bias 3 329 Std. Mean Difference (IV, Random, 95% CI) 0.27 [-0.16, 0.70]
Analysis 1.1. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 1
Overall HRQoL (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 1 Overall HRQoL (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 2.0 % 1.30 [ 0.19, 2.41 ]
Cerulli 2014 10 85.23 (4.2) 10 65.89 (14.66) 2.1 % 1.72 [ 0.66, 2.78 ]
Mustian 2004 11 121.7 (22.67) 10 124.3 (25.9) 2.8 % -0.10 [ -0.96, 0.75 ]
Loudon 2014 12 -7.42 (1.24) 11 -7.45 (1.44) 3.0 % 0.02 [ -0.80, 0.84 ]
Portela 2008 25 107.2 (28.5) 9 91.6 (28.5) 3.2 % 0.53 [ -0.24, 1.31 ]
Milne 2008 29 86.4 (8.3) 29 64.1 (10.8) 3.7 % 2.28 [ 1.61, 2.96 ]
Rogers 2009 20 92 (11.4) 18 87.4 (13.1) 3.9 % 0.37 [ -0.27, 1.01 ]
Courneya 2003 24 91.3 (11) 28 89.3 (10.9) 4.5 % 0.18 [ -0.37, 0.73 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 4.5 % 0.19 [ -0.35, 0.73 ]
Murtezani 2014 30 86.5 (7.3) 32 79.1 (7.5) 4.6 % 0.99 [ 0.46, 1.52 ]
Mehnert 2011 30 74.72 (21.72) 27 65.43 (16.78) 4.6 % 0.47 [ -0.06, 1.00 ]
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(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 4.8 % 0.28 [ -0.22, 0.79 ]
Cadmus 2009 37 91.2 (12.6) 37 86.2 (17.4) 5.1 % 0.33 [ -0.13, 0.78 ]
Pinto 2015 39 117.79 (12.74) 37 113.98 (18.02) 5.1 % 0.24 [ -0.21, 0.69 ]
Schmitz 2005 39 -44.2 (8.7) 40 -47.4 (9.4) 5.2 % 0.35 [ -0.09, 0.79 ]
Taleghani 2012 40 217.5 (36.3) 40 210.1 (41.5) 5.2 % 0.19 [ -0.25, 0.63 ]
Loh 2014 63 112.4 (14.09) 32 109.29 (13.26) 5.3 % 0.22 [ -0.20, 0.65 ]
Daley 2007 33 90.85 (13.47) 69 86.44 (15.07) 5.4 % 0.30 [ -0.12, 0.72 ]
Littman 2012 30 90.3 (11) 110 87.7 (15) 5.5 % 0.18 [ -0.22, 0.59 ]
Rogers 2015 105 88.1 (12.4) 108 83.2 (15.5) 6.5 % 0.35 [ 0.08, 0.62 ]
Vallance 2007 250 91.54 (11.76) 85 90.55 (12.95) 6.6 % 0.08 [ -0.16, 0.33 ]
Short 2014 195 106.8 (16.7) 104 108.2 (18.2) 6.7 % -0.08 [ -0.32, 0.16 ]
Subtotal (95% CI) 1102 894 100.0 % 0.39 [ 0.21, 0.57 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 65.99, df = 21 (P<0.00001); I2 =68%
Test for overall effect: Z = 4.23 (P = 0.000023)
2 Follow-up
Rogers 2009 19 86.1 (13.6) 17 85.4 (18.4) 8.9 % 0.04 [ -0.61, 0.70 ]
Pinto 2015 39 115.68 (14.97) 37 111.39 (17.74) 18.7 % 0.26 [ -0.19, 0.71 ]
Daley 2007 31 90.25 (14.94) 65 87.86 (14.29) 20.7 % 0.16 [ -0.26, 0.59 ]
Rogers 2015 105 86.9 (14.5) 105 83.6 (15.8) 51.7 % 0.22 [ -0.05, 0.49 ]
Subtotal (95% CI) 194 224 100.0 % 0.20 [ 0.00, 0.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.99 (P = 0.046)
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Analysis 1.2. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 2
Overall HRQoL (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 2 Overall HRQoL (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 11 15 (5) 10 0 (5) 4.5 % 2.88 [ 1.59, 4.17 ]
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 4.7 % 1.92 [ 0.68, 3.17 ]
Murtezani 2014 30 9.16 (2.12) 32 -0.56 (2.01) 5.7 % 4.65 [ 3.67, 5.63 ]
Naumann 2012 11 14.5 (10.6) 10 3.1 (11.4) 6.0 % 1.00 [ 0.08, 1.92 ]
Rogers 2009 20 4.5 (8.4) 18 2.9 (12) 7.2 % 0.15 [ -0.49, 0.79 ]
Cuesta-Vargas 2014 22 0.32 (0.18) 20 0.33 (0.09) 7.4 % -0.07 [ -0.67, 0.54 ]
Courneya 2003 24 5.7 (7.4) 28 0.6 (7.4) 7.6 % 0.68 [ 0.12, 1.24 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 7.6 % 0.52 [ -0.03, 1.06 ]
Mehnert 2011 30 9.72 (21.03) 27 5.55 (16.5) 7.7 % 0.22 [ -0.31, 0.74 ]
Cadmus 2009 37 0.6 (7.5) 37 -2.4 (9.8) 8.0 % 0.34 [ -0.12, 0.80 ]
Schmitz 2005 39 2.3 (4.5) 40 0.6 (4) 8.0 % 0.40 [ -0.05, 0.84 ]
Daley 2007 33 10.22 (11.2) 69 3.2 (11.26) 8.1 % 0.62 [ 0.20, 1.04 ]
Vallance 2007 250 2.3 (11.08) 85 -0.16 (6.4) 8.7 % 0.24 [ 0.00, 0.49 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 8.8 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 818 641 100.0 % 0.78 [ 0.39, 1.17 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 124.60, df = 13 (P<0.00001); I2 =90%
Test for overall effect: Z = 3.93 (P = 0.000086)
2 Follow-up
Rogers 2009 19 3.4 (11) 17 -3.5 (10.8) 29.4 % 0.62 [ -0.05, 1.29 ]
Daley 2007 31 9.69 (15.18) 65 4.03 (9.92) 70.6 % 0.47 [ 0.04, 0.91 ]
Subtotal (95% CI) 50 82 100.0 % 0.52 [ 0.15, 0.88 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0055)
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Analysis 1.3. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 3
FACT-G (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 3 FACT-G (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cerulli 2014 10 85.23 (4.2) 10 65.89 (14.66) 7.6 % 19.34 [ 9.89, 28.79 ]
Rogers 2009 20 92 (11.4) 18 87.4 (13.1) 8.6 % 4.60 [ -3.25, 12.45 ]
Cadmus 2009 37 91.2 (12.6) 37 86.2 (17.4) 9.2 % 5.00 [ -1.92, 11.92 ]
Courneya 2003 24 91.3 (11) 28 89.3 (10.9) 9.8 % 2.00 [ -3.97, 7.97 ]
Daley 2007 33 90.85 (13.47) 69 86.44 (15.07) 9.9 % 4.41 [ -1.40, 10.22 ]
Milne 2008 29 86.4 (8.3) 29 64.1 (10.8) 10.5 % 22.30 [ 17.34, 27.26 ]
Littman 2012 30 90.3 (11) 110 87.7 (15) 10.5 % 2.60 [ -2.23, 7.43 ]
Rogers 2015 105 88.1 (12.4) 108 83.2 (15.5) 11.1 % 4.90 [ 1.14, 8.66 ]
Murtezani 2014 30 86.5 (7.3) 32 79.1 (7.5) 11.2 % 7.40 [ 3.72, 11.08 ]
Vallance 2007 250 91.54 (11.76) 85 90.55 (12.95) 11.5 % 0.99 [ -2.13, 4.11 ]
Subtotal (95% CI) 568 526 100.0 % 7.06 [ 2.82, 11.30 ]
Heterogeneity: Tau2 = 38.26; Chi2 = 64.11, df = 9 (P<0.00001); I2 =86%
Test for overall effect: Z = 3.26 (P = 0.0011)
2 Follow-up
Rogers 2009 19 86.1 (13.6) 17 85.4 (18.4) 9.4 % 0.70 [ -9.97, 11.37 ]
Daley 2007 31 90.25 (14.94) 65 87.86 (14.29) 27.0 % 2.39 [ -3.91, 8.69 ]
Rogers 2015 105 86.9 (14.5) 105 83.6 (15.8) 63.6 % 3.30 [ -0.80, 7.40 ]
Subtotal (95% CI) 155 187 100.0 % 2.81 [ -0.46, 6.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.092)
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Analysis 1.4. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 4
FACT-G (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 4 FACT-G (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 4.5 (8.4) 18 2.9 (12) 12.3 % 1.60 [ -5.05, 8.25 ]
Daley 2007 33 10.22 (11.2) 69 3.2 (11.26) 15.4 % 7.02 [ 2.37, 11.67 ]
Courneya 2003 24 5.7 (7.4) 28 0.6 (7.4) 16.4 % 5.10 [ 1.07, 9.13 ]
Cadmus 2009 37 0.6 (7.5) 37 -2.4 (9.8) 16.5 % 3.00 [ -0.98, 6.98 ]
Vallance 2007 250 2.3 (11.08) 85 -0.16 (6.4) 19.3 % 2.46 [ 0.53, 4.39 ]
Murtezani 2014 30 9.16 (2.12) 32 -0.56 (2.01) 20.0 % 9.72 [ 8.69, 10.75 ]
Subtotal (95% CI) 394 269 100.0 % 5.04 [ 1.32, 8.75 ]
Heterogeneity: Tau2 = 17.63; Chi2 = 53.23, df = 5 (P<0.00001); I2 =91%
Test for overall effect: Z = 2.66 (P = 0.0079)
2 Follow-up
Rogers 2009 19 3.4 (11) 17 -3.5 (10.8) 40.3 % 6.90 [ -0.23, 14.03 ]
Daley 2007 31 9.69 (15.18) 65 4.03 (9.92) 59.7 % 5.66 [ -0.20, 11.52 ]
Subtotal (95% CI) 50 82 100.0 % 6.16 [ 1.63, 10.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.67 (P = 0.0077)
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Analysis 1.5. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 5
FACT-B (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 5 FACT-B (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Portela 2008 25 107.2 (28.5) 9 91.6 (28.5) 3.8 % 15.60 [ -6.11, 37.31 ]
Rogers 2009 20 114.4 (16.2) 18 118.7 (14.4) 8.1 % -4.30 [ -14.03, 5.43 ]
Courneya 2003 24 119.6 (16.9) 28 115.8 (14.9) 8.5 % 3.80 [ -4.93, 12.53 ]
Daley 2007 33 115.09 (17.6) 69 109.18 (19.54) 9.1 % 5.91 [ -1.66, 13.48 ]
Pinto 2015 39 117.79 (12.74) 37 113.98 (18.02) 9.3 % 3.81 [ -3.24, 10.86 ]
Milne 2008 29 110.5 (10.3) 29 82.6 (14.3) 9.6 % 27.90 [ 21.49, 34.31 ]
Loh 2014 63 112.4 (14.09) 32 109.29 (13.26) 9.9 % 3.11 [ -2.65, 8.87 ]
Rogers 2015 105 115.9 (17.2) 108 109.4 (20.4) 10.2 % 6.50 [ 1.44, 11.56 ]
Murtezani 2014 30 113.2 (9.7) 32 101.2 (9.5) 10.3 % 12.00 [ 7.22, 16.78 ]
Vallance 2007 250 120.2 (16.3) 85 119.2 (17.3) 10.5 % 1.00 [ -3.20, 5.20 ]
Short 2014 219 106.8 (16.7) 111 108.2 (18.2) 10.6 % -1.40 [ -5.44, 2.64 ]
Subtotal (95% CI) 837 558 100.0 % 6.31 [ 1.15, 11.47 ]
Heterogeneity: Tau2 = 61.30; Chi2 = 75.46, df = 10 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.40 (P = 0.017)
2 Follow-up
Rogers 2009 19 112.6 (17.6) 17 110.7 (22.3) 7.6 % 1.90 [ -11.33, 15.13 ]
Daley 2007 31 115.39 (20.11) 65 113.39 (18.17) 19.2 % 2.00 [ -6.34, 10.34 ]
Pinto 2015 39 115.68 (14.97) 37 111.39 (17.74) 24.4 % 4.29 [ -3.11, 11.69 ]
Rogers 2015 105 115.1 (18.8) 108 110.6 (20.2) 48.7 % 4.50 [ -0.74, 9.74 ]
Subtotal (95% CI) 194 227 100.0 % 3.77 [ 0.11, 7.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.34, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
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Analysis 1.6. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 6
FACT-B (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 6 FACT-B (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Naumann 2012 11 14.5 (10.6) 10 3.1 (11.4) 13.0 % 11.40 [ 1.96, 20.84 ]
Rogers 2009 20 5.4 (10.8) 18 3.1 (14.1) 14.5 % 2.30 [ -5.75, 10.35 ]
Courneya 2003 24 9.1 (14.1) 28 0.3 (8.5) 16.2 % 8.80 [ 2.34, 15.26 ]
Daley 2007 33 13.5 (14.58) 69 4.43 (15.03) 16.6 % 9.07 [ 2.96, 15.18 ]
Vallance 2007 250 3.84 (12.72) 80 1.2 (13.67) 19.2 % 2.64 [ -0.75, 6.03 ]
Murtezani 2014 30 13.4 (2.74) 32 -0.81 (2.52) 20.4 % 14.21 [ 12.90, 15.52 ]
Subtotal (95% CI) 368 237 100.0 % 8.16 [ 2.56, 13.76 ]
Heterogeneity: Tau2 = 39.49; Chi2 = 47.55, df = 5 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.86 (P = 0.0043)
2 Follow-up
Rogers 2009 19 4.1 (12) 17 -4.1 (13.8) 43.7 % 8.20 [ -0.29, 16.69 ]
Daley 2007 31 13.52 (19.64) 65 7.54 (11.77) 56.3 % 5.98 [ -1.50, 13.46 ]
Subtotal (95% CI) 50 82 100.0 % 6.95 [ 1.34, 12.56 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 2.43 (P = 0.015)
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Analysis 1.7. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 7
FACT Breast Cancer Subscale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 7 FACT Breast Cancer Subscale (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 27 (5.5) 18 26.7 (6.4) 5.6 % 0.30 [ -3.51, 4.11 ]
Banasik 2011 7 8.8 (3.11) 7 8.43 (3.91) 5.8 % 0.37 [ -3.33, 4.07 ]
Courneya 2003 24 28.4 (6.7) 28 26.4 (5.1) 6.9 % 2.00 [ -1.28, 5.28 ]
Murtezani 2014 30 26.6 (5.6) 32 22.1 (5.5) 8.5 % 4.50 [ 1.73, 7.27 ]
Milne 2008 29 24.1 (4.9) 29 18.5 (5.8) 8.5 % 5.60 [ 2.84, 8.36 ]
Daley 2007 32 24.4 (5.73) 32 21.3 (5.21) 8.8 % 3.10 [ 0.42, 5.78 ]
Cadmus 2009 37 26.7 (5.8) 37 24.1 (5.9) 8.9 % 2.60 [ -0.07, 5.27 ]
Littman 2012 30 26.8 (4.2) 27 25.2 (5.5) 9.3 % 1.60 [ -0.96, 4.16 ]
Pinto 2015 39 27.03 (5.4) 37 26.34 (4.95) 10.2 % 0.69 [ -1.64, 3.02 ]
Rogers 2015 105 27.8 (6.2) 108 26.2 (6.3) 13.4 % 1.60 [ -0.08, 3.28 ]
Vallance 2007 250 28.67 (6.48) 85 28.61 (6.23) 14.1 % 0.06 [ -1.49, 1.61 ]
Subtotal (95% CI) 603 440 100.0 % 1.98 [ 0.92, 3.04 ]
Heterogeneity: Tau2 = 1.45; Chi2 = 19.14, df = 10 (P = 0.04); I2 =48%
Test for overall effect: Z = 3.66 (P = 0.00025)
2 Follow-up
Rogers 2009 19 26 (6) 17 25.3 (6.7) 21.6 % 0.70 [ -3.47, 4.87 ]
Daley 2007 30 25.3 (5.88) 31 23.63 (5.58) 24.9 % 1.67 [ -1.21, 4.55 ]
Pinto 2015 39 27.11 (6.08) 37 25.17 (4.79) 25.9 % 1.94 [ -0.51, 4.39 ]
Rogers 2015 105 28.2 (5.7) 108 20.5 (5.4) 27.7 % 7.70 [ 6.21, 9.19 ]
Subtotal (95% CI) 193 193 100.0 % 3.20 [ -0.65, 7.05 ]
Heterogeneity: Tau2 = 13.38; Chi2 = 27.76, df = 3 (P<0.00001); I2 =89%
Test for overall effect: Z = 1.63 (P = 0.10)
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Analysis 1.8. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 8
FACT Breast Cancer Subscale (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 8 FACT Breast Cancer Subscale (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Naumann 2012 11 1.6 (3.8) 10 2.3 (3.9) 11.5 % -0.70 [ -4.00, 2.60 ]
Rogers 2009 20 1 (5.3) 18 0.3 (5) 11.5 % 0.70 [ -2.58, 3.98 ]
Daley 2007 32 24.4 (5.73) 32 21.3 (5.21) 13.0 % 3.10 [ 0.42, 5.78 ]
Courneya 2003 24 3.3 (4) 28 -0.3 (3.2) 14.6 % 3.60 [ 1.61, 5.59 ]
Cadmus 2009 37 1 (3) 37 0.8 (3.4) 15.8 % 0.20 [ -1.26, 1.66 ]
Vallance 2007 250 1.36 (4.79) 85 1.02 (3.9) 16.6 % 0.34 [ -0.68, 1.36 ]
Murtezani 2014 30 4.23 (1.38) 32 -0.25 (1.41) 17.0 % 4.48 [ 3.79, 5.17 ]
Subtotal (95% CI) 404 242 100.0 % 1.78 [ -0.14, 3.70 ]
Heterogeneity: Tau2 = 5.49; Chi2 = 63.43, df = 6 (P<0.00001); I2 =91%
Test for overall effect: Z = 1.82 (P = 0.069)
2 Follow-up
Rogers 2009 19 0.7 (3.7) 17 -0.6 (4.9) 100.0 % 1.30 [ -1.56, 4.16 ]
Subtotal (95% CI) 19 17 100.0 % 1.30 [ -1.56, 4.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
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Analysis 1.9. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 9
FACT Trial Outcome Index (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 9 FACT Trial Outcome Index (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Courneya 2003 24 77 (12) 28 74.8 (10.1) 24.0 % 2.20 [ -3.89, 8.29 ]
Milne 2008 29 70.3 (7.9) 29 46.5 (12.8) 24.5 % 23.80 [ 18.33, 29.27 ]
Vallance 2007 250 91.02 (13.45) 85 90.22 (14.93) 25.8 % 0.80 [ -2.79, 4.39 ]
Rogers 2015 105 74.2 (11.9) 108 69 (14.5) 25.8 % 5.20 [ 1.64, 8.76 ]
Subtotal (95% CI) 408 250 100.0 % 7.90 [ -1.24, 17.04 ]
Heterogeneity: Tau2 = 81.10; Chi2 = 50.37, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.69 (P = 0.090)
2 Follow-up
Rogers 2015 105 73.6 (12.4) 108 70 (14.3) 100.0 % 3.60 [ 0.01, 7.19 ]
Subtotal (95% CI) 105 108 100.0 % 3.60 [ 0.01, 7.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.049)
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Analysis 1.10. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 10
EORTC QLQ-C30 Global Health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 10 EORTC QLQ-C30 Global Health (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 15.6 % 18.80 [ 5.40, 32.20 ]
Mehnert 2011 30 74.72 (21.72) 27 65.43 (16.78) 25.2 % 9.29 [ -0.73, 19.31 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 27.1 % 3.69 [ -5.88, 13.26 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 32.0 % 4.90 [ -3.66, 13.46 ]
Subtotal (95% CI) 110 85 100.0 % 7.85 [ 2.16, 13.55 ]
Heterogeneity: Tau2 = 7.29; Chi2 = 3.82, df = 3 (P = 0.28); I2 =21%
Test for overall effect: Z = 2.70 (P = 0.0069)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.11. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 11
EORTC QLQ-C30 Global Health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 11 EORTC QLQ-C30 Global Health (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 22.0 % 28.10 [ 14.55, 41.65 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 22.4 % 12.10 [ -1.05, 25.25 ]
Mehnert 2011 30 9.72 (21.03) 27 5.55 (16.5) 25.5 % 4.17 [ -5.60, 13.94 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 30.2 % -1.40 [ -4.17, 1.37 ]
Subtotal (95% CI) 341 292 100.0 % 9.53 [ -2.43, 21.49 ]
Heterogeneity: Tau2 = 121.42; Chi2 = 21.28, df = 3 (P = 0.00009); I2 =86%
Test for overall effect: Z = 1.56 (P = 0.12)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.12. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 12
Overall emotional function/mental health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 12 Overall emotional function/mental health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Banasik 2011 7 0.47 (0.36) 7 0.38 (0.31) 1.0 % 0.25 [ -0.80, 1.30 ]
Herrero 2006 8 90.6 (9.3) 8 83.3 (14.8) 1.1 % 0.56 [ -0.45, 1.56 ]
Mustian 2004 9 24.78 (2.04) 10 24.8 (3.19) 1.4 % -0.01 [ -0.91, 0.89 ]
Pinto 2003 12 -10.83 (28.1) 12 -27.17 (19.5) 1.6 % 0.65 [ -0.17, 1.48 ]
Loudon 2014 12 -1.58 (0.7) 11 -1.61 (0.49) 1.6 % 0.05 [ -0.77, 0.87 ]
Rogers 2009 20 20 (3.1) 18 21.1 (2.9) 2.5 % -0.36 [ -1.00, 0.28 ]
Cuesta-Vargas 2014 22 42.9 (19.17) 20 32.3 (33.33) 2.7 % 0.39 [ -0.22, 1.00 ]
Basen-Enquist 2006 28 78.2 (10.58) 23 77.2 (11.99) 3.2 % 0.09 [ -0.46, 0.64 ]
Courneya 2003 24 21.5 (3.4) 28 20.7 (3) 3.2 % 0.25 [ -0.30, 0.79 ]
Milne 2008 29 19.6 (2.4) 29 16.7 (4.1) 3.3 % 0.85 [ 0.31, 1.39 ]
Do 2015 32 87.4 (8.8) 30 70.4 (21.5) 3.3 % 1.03 [ 0.50, 1.57 ]
Littman 2012 30 20.3 (4) 27 20.8 (3.1) 3.5 % -0.14 [ -0.66, 0.38 ]
Mehnert 2011 30 77.01 (35.75) 28 69.05 (40.5) 3.5 % 0.21 [ -0.31, 0.72 ]
Cantarero-Villanueva 2013 32 -17175 (4279) 29 -20390 (6113) 3.5 % 0.61 [ 0.09, 1.12 ]
Murtezani 2014 30 19.5 (3.3) 32 18.3 (3.5) 3.7 % 0.35 [ -0.15, 0.85 ]
Daley 2007 33 19.06 (4.18) 33 18.45 (3.31) 3.9 % 0.16 [ -0.32, 0.64 ]
Cadmus 2009 37 20.5 (3) 37 19.8 (4.2) 4.2 % 0.19 [ -0.27, 0.65 ]
Pinto 2015 39 54.21 (9.28) 37 52.48 (9.62) 4.3 % 0.18 [ -0.27, 0.63 ]
Schmitz 2005 39 -45.6 (8.2) 40 -48.2 (8.2) 4.4 % 0.31 [ -0.13, 0.76 ]
Pinto 2005 39 -8.02 (20.69) 43 -16.51 (28.75) 4.5 % 0.33 [ -0.10, 0.77 ]
Loh 2014 63 19.87 (2.81) 32 19.98 (3.22) 4.7 % -0.04 [ -0.46, 0.39 ]
Fillion 2008 44 48.54 (7.91) 43 47.49 (9.08) 4.7 % 0.12 [ -0.30, 0.54 ]
Duijits 2012 37 73.92 (34.7) 89 77.46 (34.32) 5.4 % -0.10 [ -0.49, 0.28 ]
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(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rogers 2015 105 20.6 (2.9) 108 19.7 (3.2) 8.0 % 0.29 [ 0.02, 0.56 ]
Schmitz 2009 112 53.2 (9.6) 120 53.8 (8.7) 8.4 % -0.07 [ -0.32, 0.19 ]
Vallance 2007 250 20.28 (3.31) 85 19.92 (3.44) 8.7 % 0.11 [ -0.14, 0.35 ]
Subtotal (95% CI) 1123 979 100.0 % 0.21 [ 0.10, 0.32 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 34.19, df = 25 (P = 0.10); I2 =27%
Test for overall effect: Z = 3.71 (P = 0.00021)
2 Follow-up
Rogers 2009 19 19.5 (3.1) 17 20.8 (3) 6.1 % -0.42 [ -1.08, 0.25 ]
Cantarero-Villanueva 2013 32 -17306 (4501) 29 -19915 (4966) 10.0 % 0.54 [ 0.03, 1.06 ]
Daley 2007 31 19.52 (4.47) 31 18.97 (3.26) 10.5 % 0.14 [ -0.36, 0.64 ]
Pinto 2015 39 53.44 (8.57) 37 50.52 (10.9) 12.5 % 0.30 [ -0.16, 0.75 ]
Fillion 2008 44 51.38 (7.57) 43 47.96 (9.3) 14.0 % 0.40 [ -0.02, 0.82 ]
Duijits 2012 36 77.48 (37.52) 84 74.42 (37.21) 16.3 % 0.08 [ -0.31, 0.47 ]
Rogers 2015 105 20.5 (3.5) 108 20 (3.2) 30.6 % 0.15 [ -0.12, 0.42 ]
Subtotal (95% CI) 306 349 100.0 % 0.20 [ 0.03, 0.36 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.64, df = 6 (P = 0.36); I2 =10%
Test for overall effect: Z = 2.28 (P = 0.022)
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Analysis 1.13. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 13
Overall emotional function/mental health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 13 Overall emotional function/mental health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 9.3 (19.6) 8 -2.1 (5.9) 3.3 % 0.74 [ -0.28, 1.77 ]
Mustian 2004 9 2.44 (2.52) 10 0.1 (1.68) 3.5 % 1.06 [ 0.08, 2.03 ]
Naumann 2012 11 1 (2.69) 10 -0.1 (2.72) 4.1 % 0.39 [ -0.48, 1.26 ]
Rogers 2009 20 0.9 (2.5) 18 -0.1 (2.7) 5.7 % 0.38 [ -0.27, 1.02 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 6.1 % 1.80 [ 1.21, 2.40 ]
Courneya 2003 24 2.3 (3.1) 28 0.8 (2.9) 6.5 % 0.49 [ -0.06, 1.05 ]
Cormie 2014 43 4.4 (9) 19 2.7 (8.6) 6.6 % 0.19 [ -0.35, 0.73 ]
Mehnert 2011 30 2.3 (35.5) 28 3.57 (17.6) 6.8 % -0.04 [ -0.56, 0.47 ]
Cantarero-Villanueva 2013 32 -1445 (4452) 29 353 (3323) 6.9 % -0.45 [ -0.96, 0.06 ]
Cadmus 2009 37 0.3 (2.2) 37 -0.5 (3.3) 7.4 % 0.28 [ -0.18, 0.74 ]
Schmitz 2005 39 2.5 (4.4) 40 0.3 (3.9) 7.5 % 0.52 [ 0.08, 0.97 ]
Pinto 2005 39 -3.8 (27.7) 43 -11.47 (25.8) 7.6 % 0.28 [ -0.15, 0.72 ]
Schmitz 2009 58 3.3 (23.2) 62 3.1 (17.2) 8.4 % 0.01 [ -0.35, 0.37 ]
Vallance 2007 250 0.47 (3.54) 85 0.08 (2.49) 9.5 % 0.12 [ -0.13, 0.36 ]
Saarto 2012 263 1.2 (17.79) 237 1.9 (18.46) 10.1 % -0.04 [ -0.21, 0.14 ]
Subtotal (95% CI) 893 686 100.0 % 0.31 [ 0.09, 0.53 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 50.63, df = 14 (P<0.00001); I2 =72%
Test for overall effect: Z = 2.71 (P = 0.0067)
2 Follow-up
Rogers 2009 19 0.5 (2.7) 17 -0.29 (1.7) 22.9 % 0.34 [ -0.32, 1.00 ]
Cantarero-Villanueva 2013 32 -1324 (5711) 29 -121 (1606) 34.6 % -0.28 [ -0.78, 0.23 ]
Pinto 2005 39 3.09 (27.9) 43 -2 (26.2) 42.5 % 0.19 [ -0.25, 0.62 ]
Subtotal (95% CI) 90 89 100.0 % 0.06 [ -0.29, 0.41 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 2.72, df = 2 (P = 0.26); I2 =27%
Test for overall effect: Z = 0.34 (P = 0.73)
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Analysis 1.14. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 14
FACT Emotional well-being (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 14 FACT Emotional well-being (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 20 (3.1) 18 21.1 (2.9) 4.9 % -1.10 [ -3.01, 0.81 ]
Littman 2012 30 20.3 (4) 27 20.8 (3.1) 5.2 % -0.50 [ -2.35, 1.35 ]
Daley 2007 33 19.06 (4.18) 33 18.45 (3.31) 5.3 % 0.61 [ -1.21, 2.43 ]
Courneya 2003 24 21.5 (3.4) 28 20.7 (3) 5.6 % 0.80 [ -0.96, 2.56 ]
Milne 2008 29 19.6 (2.4) 29 16.7 (4.1) 5.7 % 2.90 [ 1.17, 4.63 ]
Murtezani 2014 30 19.5 (3.3) 32 18.3 (3.5) 5.9 % 1.20 [ -0.49, 2.89 ]
Cadmus 2009 37 20.5 (3) 37 19.8 (4.2) 6.1 % 0.70 [ -0.96, 2.36 ]
Loh 2014 63 19.87 (2.81) 32 19.98 (3.22) 8.6 % -0.11 [ -1.42, 1.20 ]
Vallance 2007 250 20.28 (3.31) 85 19.92 (3.44) 14.4 % 0.36 [ -0.48, 1.20 ]
Rogers 2015 105 20.6 (2.9) 108 19.7 (3.2) 14.7 % 0.90 [ 0.08, 1.72 ]
Banasik 2011 7 0.47 (0.36) 7 0.38 (0.31) 23.4 % 0.09 [ -0.26, 0.44 ]
Subtotal (95% CI) 628 436 100.0 % 0.47 [ 0.01, 0.94 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 17.02, df = 10 (P = 0.07); I2 =41%
Test for overall effect: Z = 1.99 (P = 0.047)
2 Follow-up
Rogers 2009 19 19.5 (3.1) 17 20.8 (3) 20.4 % -1.30 [ -3.29, 0.69 ]
Daley 2007 31 19.52 (4.47) 31 18.97 (3.26) 21.2 % 0.55 [ -1.40, 2.50 ]
Rogers 2015 105 20.5 (3.5) 108 20 (3.2) 58.4 % 0.50 [ -0.40, 1.40 ]
Subtotal (95% CI) 155 156 100.0 % 0.14 [ -0.85, 1.14 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 2.71, df = 2 (P = 0.26); I2 =26%
Test for overall effect: Z = 0.28 (P = 0.78)
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Analysis 1.15. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 15
FACT Emotional well-being (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 15 FACT Emotional well-being (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Naumann 2012 11 1 (2.69) 10 -0.1 (2.72) 6.0 % 1.10 [ -1.22, 3.42 ]
Rogers 2009 20 0.9 (2.5) 18 -0.1 (2.7) 10.2 % 1.00 [ -0.66, 2.66 ]
Courneya 2003 24 2.3 (3.1) 28 0.8 (2.9) 10.3 % 1.50 [ -0.14, 3.14 ]
Cadmus 2009 37 -0.3 (2.2) 37 -0.5 (3.3) 14.5 % 0.20 [ -1.08, 1.48 ]
Vallance 2007 250 0.47 (3.54) 85 0.08 (2.49) 26.1 % 0.39 [ -0.30, 1.08 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 32.9 % 1.53 [ 1.11, 1.95 ]
Subtotal (95% CI) 372 210 100.0 % 0.96 [ 0.34, 1.57 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 10.23, df = 5 (P = 0.07); I2 =51%
Test for overall effect: Z = 3.04 (P = 0.0023)
2 Follow-up
Rogers 2009 19 0.5 (2.7) 17 -0.29 (1.7) 100.0 % 0.79 [ -0.67, 2.25 ]
Subtotal (95% CI) 19 17 100.0 % 0.79 [ -0.67, 2.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
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Analysis 1.16. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 16
MOS SF Mental composite (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 16 MOS SF Mental composite (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cuesta-Vargas 2014 22 42.9 (19.17) 20 32.3 (33.33) 0.9 % 10.60 [ -6.06, 27.26 ]
Pinto 2015 39 54.21 (9.28) 37 52.48 (9.62) 13.7 % 1.73 [ -2.52, 5.98 ]
Fillion 2008 44 48.54 (7.91) 43 47.49 (9.08) 19.3 % 1.05 [ -2.53, 4.63 ]
Duijits 2012 37 49.41 (8.88) 89 48.39 (8.72) 21.6 % 1.02 [ -2.37, 4.41 ]
Schmitz 2009 112 53.2 (9.6) 120 53.8 (8.7) 44.4 % -0.60 [ -2.96, 1.76 ]
Subtotal (95% CI) 254 309 100.0 % 0.49 [ -1.09, 2.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.75, df = 4 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Follow-up
Pinto 2015 39 53.44 (8.57) 37 50.52 (10.9) 25.2 % 2.92 [ -1.50, 7.34 ]
Duijits 2012 36 48.69 (9.53) 82 48.11 (9.3) 35.9 % 0.58 [ -3.13, 4.29 ]
Fillion 2008 44 51.38 (7.57) 43 47.96 (9.3) 38.8 % 3.42 [ -0.15, 6.99 ]
Subtotal (95% CI) 119 162 100.0 % 2.27 [ 0.05, 4.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.28, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.045)
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Analysis 1.17. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 17
MOS SF Mental composite (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 17 MOS SF Mental composite (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Cormie 2014 43 4.2 (8.8) 19 2.7 (8.3) 48.4 % 1.50 [ -3.07, 6.07 ]
Schmitz 2009 112 3.3 (18.6) 120 0.4 (15.5) 51.6 % 2.90 [ -1.52, 7.32 ]
Subtotal (95% CI) 155 139 100.0 % 2.22 [ -0.95, 5.40 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.18. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 18
MOS SF Mental health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 18 MOS SF Mental health (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mehnert 2011 30 69.3 (18.3) 28 63.2 (18.6) 5.1 % 6.10 [ -3.41, 15.61 ]
Basen-Enquist 2006 28 78.2 (10.58) 23 77.2 (11.99) 9.8 % 1.00 [ -5.27, 7.27 ]
Duijits 2012 37 73.69 (14.99) 89 70.09 (14.61) 11.2 % 3.60 [ -2.10, 9.30 ]
Cadmus 2009 37 50.6 (10.9) 37 47.4 (12) 12.6 % 3.20 [ -2.02, 8.42 ]
Pinto 2015 39 81.8 (12.7) 37 76.1 (5.75) 15.4 % 5.70 [ 1.30, 10.10 ]
Schmitz 2009 58 52.2 (9.5) 62 54.2 (8.5) 20.7 % -2.00 [ -5.23, 1.23 ]
Mustian 2004 9 24.78 (2.04) 10 24.8 (3.19) 25.3 % -0.02 [ -2.40, 2.36 ]
Subtotal (95% CI) 238 286 100.0 % 1.67 [ -0.65, 3.99 ]
Heterogeneity: Tau2 = 4.06; Chi2 = 10.99, df = 6 (P = 0.09); I2 =45%
Test for overall effect: Z = 1.41 (P = 0.16)
2 Follow-up
Pinto 2015 39 79.72 (13.2) 37 74.5 (15.83) 46.0 % 5.22 [ -1.35, 11.79 ]
Duijits 2012 36 71.84 (15.69) 84 69.83 (15.2) 54.0 % 2.01 [ -4.06, 8.08 ]
Subtotal (95% CI) 75 121 100.0 % 3.49 [ -0.97, 7.95 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.13)
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Analysis 1.19. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 19
MOS SF Mental health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 19 MOS SF Mental health (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mehnert 2011 30 4.8 (17.64) 28 2.54 (19.1) 2.6 % 2.26 [ -7.22, 11.74 ]
Schmitz 2009 58 3.3 (23.2) 62 3.1 (17.2) 4.3 % 0.20 [ -7.15, 7.55 ]
Cormie 2014 43 4.7 (7.84) 19 1.7 (7.56) 13.6 % 3.00 [ -1.13, 7.13 ]
Cadmus 2009 37 0.8 (6.6) 37 -0.9 (8.7) 18.7 % 1.70 [ -1.82, 5.22 ]
Mustian 2004 9 2.44 (2.52) 10 0.1 (1.68) 60.9 % 2.34 [ 0.39, 4.29 ]
Subtotal (95% CI) 177 156 100.0 % 2.22 [ 0.70, 3.74 ]
Heterogeneity: Chi2 = 0.53, df = 4 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.86 (P = 0.0043)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.20. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 20
MOS SF Emotional role (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 20 MOS SF Emotional role (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mehnert 2011 30 77.01 (33.75) 28 69.05 (40.5) 0.3 % 7.96 [ -11.30, 27.22 ]
Basen-Enquist 2006 28 81.2 (26.99) 25 79.4 (28) 0.5 % 1.80 [ -13.05, 16.65 ]
Duijits 2012 37 73.92 (34.7) 89 77.46 (34.32) 0.7 % -3.54 [ -16.80, 9.72 ]
Cadmus 2009 37 50.2 (10.4) 37 47.4 (12) 4.5 % 2.80 [ -2.32, 7.92 ]
Mustian 2004 9 2.25 (1.23) 10 2.4 (1.27) 93.9 % -0.15 [ -1.27, 0.97 ]
Subtotal (95% CI) 141 189 100.0 % 0.00 [ -1.09, 1.09 ]
Heterogeneity: Chi2 = 2.21, df = 4 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
2 Follow-up
Duijits 2012 36 77.48 (37.52) 84 74.42 (37.21) 100.0 % 3.06 [ -11.55, 17.67 ]
Subtotal (95% CI) 36 84 100.0 % 3.06 [ -11.55, 17.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
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Analysis 1.21. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 21
MOS SF Emotional role (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 21 MOS SF Emotional role (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mehnert 2011 30 2.3 (35.5) 28 3.57 (17.6) 0.5 % -1.27 [ -15.55, 13.01 ]
Cormie 2014 43 4.4 (9) 19 2.7 (8.6) 4.6 % 1.70 [ -3.01, 6.41 ]
Cadmus 2009 37 0.9 (12) 37 -0.9 (4.4) 6.1 % 1.80 [ -2.32, 5.92 ]
Mustian 2004 9 0.25 (0.99) 10 0.2 (1.39) 88.8 % 0.05 [ -1.03, 1.13 ]
Subtotal (95% CI) 119 94 100.0 % 0.23 [ -0.79, 1.24 ]
Heterogeneity: Chi2 = 1.08, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.22. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 22
EORTC QLQ-C30 Emotional function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 22 EORTC QLQ-C30 Emotional function (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mehnert 2011 30 67.5 (26.92) 27 62.04 (27.28) 23.0 % 5.46 [ -8.64, 19.56 ]
Herrero 2006 8 90.6 (9.3) 8 83.3 (14.8) 29.0 % 7.30 [ -4.81, 19.41 ]
Do 2015 32 87.4 (8.8) 30 70.4 (21.5) 48.0 % 17.00 [ 8.72, 25.28 ]
Subtotal (95% CI) 70 65 100.0 % 11.53 [ 3.96, 19.11 ]
Heterogeneity: Tau2 = 13.26; Chi2 = 2.80, df = 2 (P = 0.25); I2 =29%
Test for overall effect: Z = 2.99 (P = 0.0028)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.23. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 23
EORTC QLQ-C30 Emotional function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 23 EORTC QLQ-C30 Emotional function (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mehnert 2011 30 3.06 (27.13) 27 5.25 (29.2) 14.1 % -2.19 [ -16.87, 12.49 ]
Herrero 2006 8 9.3 (19.6) 8 -2.1 (5.9) 15.0 % 11.40 [ -2.78, 25.58 ]
Saarto 2012 263 1.2 (17.79) 237 1.9 (18.46) 70.9 % -0.70 [ -3.89, 2.49 ]
Subtotal (95% CI) 301 272 100.0 % 0.90 [ -5.12, 6.92 ]
Heterogeneity: Tau2 = 10.66; Chi2 = 2.73, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 0.29 (P = 0.77)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.24. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 24
POMS total mood disturbance (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 24 POMS total mood disturbance (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Pinto 2003 12 10.83 (28.1) 6 27.17 (19.5) 21.9 % -0.60 [ -1.61, 0.40 ]
Cantarero-Villanueva 2013 32 17175 (4279) 29 20390 (6113) 38.5 % -0.61 [ -1.12, -0.09 ]
Pinto 2005 39 8.02 (20.69) 43 42.28 (26.2) 39.6 % -1.43 [ -1.92, -0.94 ]
Subtotal (95% CI) 83 78 100.0 % -0.93 [ -1.55, -0.32 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 5.81, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 2.97 (P = 0.0030)
2 Follow-up
Cantarero-Villanueva 2013 32 17306 (4501) 29 19915 (4966) 100.0 % -0.54 [ -1.06, -0.03 ]
Subtotal (95% CI) 32 29 100.0 % -0.54 [ -1.06, -0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.08 (P = 0.037)
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Analysis 1.25. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 25
POMS total mood disturbance (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 25 POMS total mood disturbance (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cantarero-Villanueva 2013 32 1445 (4452) 29 -353 (3323) 48.3 % 0.45 [ -0.06, 0.96 ]
Pinto 2005 39 3.8 (27) 43 11.47 (25.8) 51.7 % -0.29 [ -0.72, 0.15 ]
Subtotal (95% CI) 71 72 100.0 % 0.07 [ -0.65, 0.79 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 4.64, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.18 (P = 0.85)
2 Follow-up
Cantarero-Villanueva 2013 32 1324 (5711) 29 121 (1606) 42.4 % 0.28 [ -0.23, 0.78 ]
Pinto 2005 39 -3.09 (27.9) 43 -2 (26.2) 57.6 % -0.04 [ -0.47, 0.39 ]
Subtotal (95% CI) 71 72 100.0 % 0.09 [ -0.23, 0.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
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Analysis 1.26. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 26
POMS anger subscale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 26 POMS anger subscale (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Pinto 2003 12 3.33 (4.1) 6 4.83 (3.6) 22.2 % -0.36 [ -1.35, 0.63 ]
Cantarero-Villanueva 2013 32 48.17 (9.44) 29 58.25 (12.58) 77.8 % -0.90 [ -1.43, -0.37 ]
Subtotal (95% CI) 44 35 100.0 % -0.78 [ -1.25, -0.31 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 3.28 (P = 0.0010)
2 Follow-up
Cantarero-Villanueva 2013 32 50 (10.16) 29 54.9 (12.06) 100.0 % -0.44 [ -0.94, 0.07 ]
Subtotal (95% CI) 32 29 100.0 % -0.44 [ -0.94, 0.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
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Analysis 1.27. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 27
Happiness/satisfaction with life (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 27 Happiness/satisfaction with life (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Kaltsatou 2011 14 45.42 (4.98) 13 33.31 (4.01) 19.3 % 2.59 [ 1.52, 3.65 ]
Courneya 2003 24 65.4 (24.6) 28 58.3 (22) 26.4 % 0.30 [ -0.25, 0.85 ]
Daley 2007 31 12.56 (2.7) 25 12.32 (3.08) 26.7 % 0.08 [ -0.44, 0.61 ]
Cadmus 2009 37 68.6 (22.4) 37 68.1 (22.7) 27.6 % 0.02 [ -0.43, 0.48 ]
Subtotal (95% CI) 106 103 100.0 % 0.61 [ -0.16, 1.37 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 19.90, df = 3 (P = 0.00018); I2 =85%
Test for overall effect: Z = 1.55 (P = 0.12)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.28. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 28
Happiness/satisfaction with life (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 28 Happiness/satisfaction with life (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Courneya 2003 24 17.3 (26.1) 28 0.8 (23) 28.8 % 0.66 [ 0.10, 1.23 ]
Daley 2007 31 12.56 (2.7) 25 12.32 (3.08) 31.8 % 0.08 [ -0.44, 0.61 ]
Cadmus 2009 37 3 (18) 37 -0.1 (19.1) 39.5 % 0.17 [ -0.29, 0.62 ]
Subtotal (95% CI) 92 90 100.0 % 0.28 [ -0.05, 0.62 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.58, df = 2 (P = 0.28); I2 =23%
Test for overall effect: Z = 1.65 (P = 0.099)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.29. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 29
Overall physical function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 29 Overall physical function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Banasik 2011 7 -0.77 (0.94) 7 -0.42 (0.25) 1.6 % -0.48 [ -1.54, 0.59 ]
Herrero 2006 8 94.1 (7.5) 8 92.5 (6.6) 1.8 % 0.21 [ -0.77, 1.20 ]
Mustian 2004 9 26.89 (4.11) 10 26.5 (4.14) 2.1 % 0.09 [ -0.81, 0.99 ]
Pinto 2003 12 32.3 (4.3) 12 25.3 (8.2) 2.2 % 1.03 [ 0.17, 1.89 ]
Milne 2008 29 24 (2.6) 29 15.6 (4.5) 3.0 % 2.26 [ 1.59, 2.92 ]
Rogers 2009 20 23.3 (4.5) 18 25.4 (2.3) 3.1 % -0.57 [ -1.22, 0.08 ]
Cuesta-Vargas 2014 22 42.9 (4.06) 20 32.4 (32.48) 3.3 % 0.46 [ -0.16, 1.07 ]
Basen-Enquist 2006 28 82.5 (12.7) 23 77.4 (11.5) 3.7 % 0.41 [ -0.15, 0.97 ]
Courneya 2003 24 25.3 (2.5) 28 25.3 (2.8) 3.8 % 0.0 [ -0.55, 0.55 ]
Mehnert 2011 30 88.96 (9.13) 28 78.12 (21.22) 3.9 % 0.66 [ 0.13, 1.19 ]
Littman 2012 30 25.4 (1.7) 27 24.3 (4.4) 3.9 % 0.33 [ -0.19, 0.86 ]
Murtezani 2014 30 22.6 (4.4) 32 19.4 (4.4) 4.0 % 0.72 [ 0.20, 1.23 ]
Winters-Stone 2011 36 51.7 (6.2) 25 52.3 (5.9) 4.0 % -0.10 [ -0.61, 0.41 ]
Do 2015 32 89.4 (8.4) 30 89 (8.7) 4.1 % 0.05 [ -0.45, 0.54 ]
Daley 2007 33 25.61 (2.15) 33 23.61 (5.7) 4.2 % 0.46 [ -0.03, 0.95 ]
Cadmus 2009 37 25.1 (2.7) 37 24 (4.1) 4.4 % 0.31 [ -0.15, 0.77 ]
Schmitz 2005 39 -44.2 (5.6) 40 -48.3 (7.7) 4.5 % 0.60 [ 0.15, 1.05 ]
Pinto 2015 39 87.08 (4.4) 37 84.69 (15.91) 4.5 % 0.21 [ -0.25, 0.66 ]
Pinto 2005 39 30.26 (7.88) 43 27.33 (6.76) 4.6 % 0.40 [ -0.04, 0.83 ]
Loh 2014 63 24.92 (2.54) 32 24.17 (2.23) 4.7 % 0.30 [ -0.12, 0.73 ]
Fillion 2008 44 45.1 (10.42) 43 41.76 (9.76) 4.7 % 0.33 [ -0.10, 0.75 ]
Duijits 2012 87 84.03 (16.88) 89 80.18 (17.08) 5.7 % 0.23 [ -0.07, 0.52 ]
Rogers 2015 105 24.1 (3.5) 108 22.5 (5) 6.0 % 0.37 [ 0.10, 0.64 ]
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(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Schmitz 2009 112 50.6 (8.15) 120 49.1 (9.32) 6.1 % 0.17 [ -0.09, 0.43 ]
Vallance 2007 250 25.1 (2.96) 85 24.95 (3.26) 6.2 % 0.05 [ -0.20, 0.30 ]
Subtotal (95% CI) 1165 964 100.0 % 0.33 [ 0.18, 0.49 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 61.95, df = 24 (P = 0.00003); I2 =61%
Test for overall effect: Z = 4.28 (P = 0.000019)
2 Follow-up
Rogers 2009 19 23.2 (4.5) 17 23.5 (5.7) 5.7 % -0.06 [ -0.71, 0.60 ]
Daley 2007 31 25.22 (2.79) 31 23.74 (3.91) 9.6 % 0.43 [ -0.07, 0.93 ]
Pinto 2015 39 86.67 (13.42) 37 84.33 (15.3) 12.0 % 0.16 [ -0.29, 0.61 ]
Fillion 2008 44 46.76 (9.24) 43 44.64 (11.05) 13.7 % 0.21 [ -0.21, 0.63 ]
Duijits 2012 79 83.69 (18.4) 84 80.7 (18.79) 25.7 % 0.16 [ -0.15, 0.47 ]
Rogers 2015 105 23.9 (3.9) 108 22.7 (5.1) 33.4 % 0.26 [ -0.01, 0.53 ]
Subtotal (95% CI) 317 320 100.0 % 0.21 [ 0.06, 0.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.67, df = 5 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.70 (P = 0.0070)
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Analysis 1.30. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 30
Overall physical function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 30 Overall physical function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 6.7 (5) 8 -1.7 (6.9) 5.2 % 1.32 [ 0.21, 2.43 ]
Mustian 2004 9 1.89 (2.61) 10 -0.2 (1.61) 5.9 % 0.93 [ -0.03, 1.89 ]
Murtezani 2014 30 4.43 (1.53) 32 -1.34 (1.15) 6.1 % 4.23 [ 3.31, 5.15 ]
Naumann 2012 11 1.9 (3.3) 10 0.8 (3.4) 6.4 % 0.32 [ -0.55, 1.18 ]
Rogers 2009 20 2.3 (5.1) 18 2.6 (6) 7.6 % -0.05 [ -0.69, 0.58 ]
Courneya 2003 24 1.9 (2) 28 -0.2 (2.2) 7.9 % 0.98 [ 0.40, 1.56 ]
Cormie 2014 43 3.49 (5.15) 19 -0.5 (5.67) 8.0 % 0.74 [ 0.19, 1.30 ]
Mehnert 2011 30 3.96 (10.83) 28 -2.15 (16.7) 8.2 % 0.43 [ -0.09, 0.95 ]
Cadmus 2009 37 0.1 (6.02) 37 -0.5 (7.42) 8.5 % 0.09 [ -0.37, 0.54 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 8.5 % -0.05 [ -0.49, 0.39 ]
Schmitz 2009 58 6.6 (17.1) 62 4.1 (17.3) 8.9 % 0.14 [ -0.21, 0.50 ]
Vallance 2007 247 1 (3.32) 85 0.19 (2.07) 9.3 % 0.26 [ 0.02, 0.51 ]
Saarto 2012 263 1.9 (13.65) 237 3.4 (13.35) 9.5 % -0.11 [ -0.29, 0.06 ]
Subtotal (95% CI) 819 614 100.0 % 0.60 [ 0.23, 0.97 ]
Heterogeneity: Tau2 = 0.37; Chi2 = 106.29, df = 12 (P<0.00001); I2 =89%
Test for overall effect: Z = 3.15 (P = 0.0016)
2 Follow-up
Rogers 2009 19 1.8 (5.4) 17 0.9 (4.6) 100.0 % 0.17 [ -0.48, 0.83 ]
Subtotal (95% CI) 19 17 100.0 % 0.17 [ -0.48, 0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.52 (P = 0.60)
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Analysis 1.31. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 31
FACT Physical well-being (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 31 FACT Physical well-being (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 23.3 (4.5) 18 25.4 (2.3) 7.7 % -2.10 [ -4.34, 0.14 ]
Murtezani 2014 30 22.6 (4.4) 32 19.4 (4.4) 7.8 % 3.20 [ 1.01, 5.39 ]
Daley 2007 33 25.61 (2.15) 33 23.61 (5.7) 8.0 % 2.00 [ -0.08, 4.08 ]
Milne 2008 29 24 (2.6) 29 15.6 (4.5) 8.4 % 8.40 [ 6.51, 10.29 ]
Littman 2012 30 25.4 (1.7) 27 24.3 (4.4) 8.7 % 1.10 [ -0.67, 2.87 ]
Cadmus 2009 37 25.1 (2.7) 37 24 (4.1) 9.1 % 1.10 [ -0.48, 2.68 ]
Courneya 2003 24 25.3 (2.5) 28 25.3 (2.8) 9.3 % 0.0 [ -1.44, 1.44 ]
Rogers 2015 105 24.1 (3.5) 108 22.5 (5) 9.9 % 1.60 [ 0.44, 2.76 ]
Loh 2014 63 24.92 (2.54) 32 24.17 (2.23) 10.2 % 0.75 [ -0.25, 1.75 ]
Vallance 2007 250 25.1 (2.96) 85 24.95 (3.26) 10.5 % 0.15 [ -0.63, 0.93 ]
Banasik 2011 7 0.77 (0.94) 7 0.42 (0.25) 10.6 % 0.35 [ -0.37, 1.07 ]
Subtotal (95% CI) 628 436 100.0 % 1.44 [ 0.31, 2.56 ]
Heterogeneity: Tau2 = 2.97; Chi2 = 81.45, df = 10 (P<0.00001); I2 =88%
Test for overall effect: Z = 2.51 (P = 0.012)
2 Follow-up
Rogers 2009 19 23.2 (4.5) 17 23.5 (5.7) 7.9 % -0.30 [ -3.68, 3.08 ]
Daley 2007 31 25.22 (2.79) 31 23.74 (3.91) 31.4 % 1.48 [ -0.21, 3.17 ]
Rogers 2015 105 23.9 (3.9) 108 22.7 (5.1) 60.7 % 1.20 [ -0.02, 2.42 ]
Subtotal (95% CI) 155 156 100.0 % 1.17 [ 0.22, 2.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.86, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.016)
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Analysis 1.32. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 32
FACT Physical well-being (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 32 FACT Physical well-being (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 2.3 (5.1) 18 2.6 (6) 13.6 % -0.30 [ -3.86, 3.26 ]
Cadmus 2009 37 0.1 (6.02) 37 -0.5 (7.42) 14.6 % 0.60 [ -2.48, 3.68 ]
Naumann 2012 11 1.9 (0.01) 10 2.3 (3.858) 16.1 % -0.40 [ -2.79, 1.99 ]
Courneya 2003 24 1.9 (2) 28 -0.2 (2.2) 18.2 % 2.10 [ 0.96, 3.24 ]
Murtezani 2014 30 4.43 (1.53) 32 -1.34 (1.15) 18.7 % 5.77 [ 5.09, 6.45 ]
Vallance 2007 247 1 (3.32) 85 0.19 (2.07) 18.8 % 0.81 [ 0.21, 1.41 ]
Subtotal (95% CI) 369 210 100.0 % 1.60 [ -0.85, 4.05 ]
Heterogeneity: Tau2 = 8.22; Chi2 = 128.58, df = 5 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Follow-up
Rogers 2009 19 1.8 (5.4) 17 0.9 (4.6) 100.0 % 0.90 [ -2.37, 4.17 ]
Subtotal (95% CI) 19 17 100.0 % 0.90 [ -2.37, 4.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
-20 -10 0 10 20
Favours control Favours physical activity
320Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.33. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 33
MOS SF Physical composite (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 33 MOS SF Physical composite (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Cuesta-Vargas 2014 22 42.9 (4.06) 20 32.4 (32.48) 1.3 % 10.50 [ -3.84, 24.84 ]
Fillion 2008 44 45.1 (10.42) 43 41.76 (9.76) 15.3 % 3.34 [ -0.90, 7.58 ]
Pinto 2015 39 52 (6.71) 37 50.93 (6.94) 29.1 % 1.07 [ -2.00, 4.14 ]
Schmitz 2009 112 50.6 (8.15) 120 49.1 (9.32) 54.3 % 1.50 [ -0.75, 3.75 ]
Subtotal (95% CI) 217 220 100.0 % 1.78 [ 0.12, 3.43 ]
Heterogeneity: Chi2 = 2.21, df = 3 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
2 Follow-up
Fillion 2008 44 46.76 (9.24) 43 44.64 (11.05) 34.7 % 2.12 [ -2.17, 6.41 ]
Pinto 2015 39 51.49 (7.07) 37 50.63 (6.81) 65.3 % 0.86 [ -2.26, 3.98 ]
Subtotal (95% CI) 83 80 100.0 % 1.30 [ -1.23, 3.82 ]
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
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Analysis 1.34. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 34
MOS SF Physical composite (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 34 MOS SF Physical composite (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Schmitz 2009 112 6.1 (17.9) 120 3.4 (19.5) 31.2 % 2.70 [ -2.11, 7.51 ]
Cormie 2014 43 3.2 (6) 19 0.7 (6) 68.8 % 2.50 [ -0.74, 5.74 ]
Subtotal (95% CI) 155 139 100.0 % 2.56 [ -0.13, 5.25 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.35. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 35
MOS SF Physical function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 35 MOS SF Physical function (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mehnert 2011 30 88.96 (9.13) 28 78.12 (21.22) 5.2 % 10.84 [ 2.33, 19.35 ]
Basen-Enquist 2006 28 82.5 (12.7) 23 77.4 (11.5) 8.0 % 5.10 [ -1.55, 11.75 ]
Pinto 2015 39 87.08 (4.4) 37 84.69 (15.91) 11.4 % 2.39 [ -2.92, 7.70 ]
Duijits 2012 87 84.03 (16.88) 89 80.18 (17.08) 12.4 % 3.85 [ -1.17, 8.87 ]
Mustian 2004 9 26.89 (4.11) 10 26.5 (4.14) 18.5 % 0.39 [ -3.32, 4.10 ]
Cadmus 2009 37 50 (6.4) 37 48 (7.6) 21.8 % 2.00 [ -1.20, 5.20 ]
Winters-Stone 2011 36 51.7 (6.2) 25 52.3 (5.9) 22.8 % -0.60 [ -3.67, 2.47 ]
Subtotal (95% CI) 266 249 100.0 % 2.09 [ 0.03, 4.15 ]
Heterogeneity: Tau2 = 2.40; Chi2 = 8.87, df = 6 (P = 0.18); I2 =32%
Test for overall effect: Z = 1.99 (P = 0.047)
2 Follow-up
Pinto 2015 39 86.67 (13.42) 37 84.33 (15.3) 43.7 % 2.34 [ -4.14, 8.82 ]
Duijits 2012 79 83.69 (18.4) 84 80.7 (18.79) 56.3 % 2.99 [ -2.72, 8.70 ]
Subtotal (95% CI) 118 121 100.0 % 2.71 [ -1.58, 6.99 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.24 (P = 0.22)
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Analysis 1.36. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 36
MOS SF Physical function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 36 MOS SF Physical function (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mehnert 2011 30 3.96 (10.83) 28 -2.15 (16.7) 5.8 % 6.11 [ -1.19, 13.41 ]
Schmitz 2009 58 6.6 (17.1) 62 4.1 (17.3) 7.8 % 2.50 [ -3.66, 8.66 ]
Cormie 2014 43 3.49 (5.15) 19 -0.5 (5.67) 22.5 % 3.99 [ 1.01, 6.97 ]
Cadmus 2009 37 -0.2 (5.1) 37 0 (4.4) 30.8 % -0.20 [ -2.37, 1.97 ]
Mustian 2004 9 1.89 (2.61) 10 -0.2 (1.61) 33.1 % 2.09 [ 0.11, 4.07 ]
Subtotal (95% CI) 177 156 100.0 % 2.08 [ 0.21, 3.94 ]
Heterogeneity: Tau2 = 1.71; Chi2 = 6.81, df = 4 (P = 0.15); I2 =41%
Test for overall effect: Z = 2.19 (P = 0.029)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.37. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 37
EORTC QLQ-C30 Physical function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 37 EORTC QLQ-C30 Physical function (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 94.1 (7.5) 8 92.5 (6.6) 27.1 % 1.60 [ -5.32, 8.52 ]
Mehnert 2011 30 94 (9.32) 27 85.95 (14.48) 29.7 % 8.05 [ 1.65, 14.45 ]
Do 2015 32 89.4 (8.4) 30 89 (8.7) 43.3 % 0.40 [ -3.86, 4.66 ]
Subtotal (95% CI) 70 65 100.0 % 2.99 [ -1.64, 7.63 ]
Heterogeneity: Tau2 = 8.21; Chi2 = 3.89, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 1.27 (P = 0.21)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.38. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 38
EORTC QLQ-C30 Physical function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 38 EORTC QLQ-C30 Physical function (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intrevention
Mehnert 2011 30 5.3 (10.92) 27 1.49 (13) 29.7 % 3.81 [ -2.46, 10.08 ]
Herrero 2006 8 6.7 (5) 8 -1.7 (6.9) 30.7 % 8.40 [ 2.50, 14.30 ]
Saarto 2012 263 1.9 (13.65) 237 3.4 (13.35) 39.5 % -1.50 [ -3.87, 0.87 ]
Subtotal (95% CI) 301 272 100.0 % 3.12 [ -3.24, 9.49 ]
Heterogeneity: Tau2 = 25.22; Chi2 = 10.65, df = 2 (P = 0.005); I2 =81%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.39. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 39
Body Esteem Scale - Physical condition (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 39 Body Esteem Scale - Physical condition (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Pinto 2003 12 32.3 (4.3) 12 25.3 (8.2) 36.4 % 7.00 [ 1.76, 12.24 ]
Pinto 2005 39 30.26 (7.88) 43 27.33 (6.76) 63.6 % 2.93 [ -0.26, 6.12 ]
Subtotal (95% CI) 51 55 100.0 % 4.41 [ 0.57, 8.25 ]
Heterogeneity: Tau2 = 3.38; Chi2 = 1.69, df = 1 (P = 0.19); I2 =41%
Test for overall effect: Z = 2.25 (P = 0.024)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.40. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 40
Overall role function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 40 Overall role function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Banasik 2011 7 3.46 (0.64) 7 3.24 (0.56) 2.9 % 0.34 [ -0.72, 1.40 ]
Herrero 2006 8 97.6 (5.9) 8 100 (0.01) 3.1 % -0.54 [ -1.55, 0.46 ]
Mustian 2004 9 2.44 (1.5) 9 2.8 (1.53) 3.4 % -0.23 [ -1.15, 0.70 ]
Loudon 2014 12 -1.3 (0.31) 11 -1.3 (0.36) 4.0 % 0.0 [ -0.82, 0.82 ]
Milne 2008 29 22.2 (3) 29 12.5 (4.8) 4.8 % 2.39 [ 1.71, 3.08 ]
Rogers 2009 20 21.4 (4.8) 18 23.8 (3.2) 5.0 % -0.57 [ -1.22, 0.08 ]
Basen-Enquist 2006 28 86.1 (22.2) 23 73 (24.5) 5.6 % 0.55 [ -0.01, 1.12 ]
Courneya 2003 24 23.4 (4) 28 23.1 (4) 5.7 % 0.07 [ -0.47, 0.62 ]
Mehnert 2011 30 90 (20.34) 27 79.6 (25.04) 5.9 % 0.45 [ -0.07, 0.98 ]
Littman 2012 30 22.6 (3.9) 27 21.7 (4.7) 5.9 % 0.21 [ -0.31, 0.73 ]
Murtezani 2014 30 24.2 (2.8) 32 23 (2.5) 6.0 % 0.45 [ -0.06, 0.95 ]
Do 2015 32 78.1 (19.5) 30 79.2 (14.6) 6.1 % -0.06 [ -0.56, 0.44 ]
Daley 2007 33 22.88 (4.52) 33 20.3 (5.57) 6.2 % 0.50 [ 0.01, 0.99 ]
Cadmus 2009 37 23.1 (4.7) 37 20.6 (7.2) 6.4 % 0.41 [ -0.05, 0.87 ]
Schmitz 2005 39 -49.2 (6.5) 40 -50 (6.2) 6.5 % 0.12 [ -0.32, 0.57 ]
Loh 2014 63 23.37 (4.33) 32 22.22 (4.99) 6.7 % 0.25 [ -0.18, 0.68 ]
Rogers 2015 105 22.3 (4.5) 108 20.3 (5.5) 7.9 % 0.40 [ 0.12, 0.67 ]
Vallance 2007 250 23.22 (3.98) 85 22.72 (4.58) 8.0 % 0.12 [ -0.13, 0.37 ]
Subtotal (95% CI) 786 584 100.0 % 0.29 [ 0.07, 0.51 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 55.40, df = 17 (P<0.00001); I2 =69%
Test for overall effect: Z = 2.61 (P = 0.0090)
2 Follow-up
Rogers 2009 19 21.9 (4.7) 17 22.4 (5.4) 14.4 % -0.10 [ -0.75, 0.56 ]
Rogers 2015 105 21.4 (5.1) 108 20.5 (5.7) 85.6 % 0.17 [ -0.10, 0.43 ]
Subtotal (95% CI) 124 125 100.0 % 0.13 [ -0.12, 0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
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Analysis 1.41. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 41
Overall role function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 41 Overall role function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 2.1 (13.9) 8 2.1 (5.9) 3.2 % 0.0 [ -0.98, 0.98 ]
Mustian 2004 9 0.56 (1.59) 10 0.8 (1.55) 3.7 % -0.15 [ -1.05, 0.76 ]
Naumann 2012 11 1.5 (4.41) 10 0.5 (4.49) 4.0 % 0.22 [ -0.64, 1.08 ]
Rogers 2009 20 0.4 (3.3) 18 1.4 (4.3) 6.2 % -0.26 [ -0.90, 0.38 ]
Courneya 2003 24 0.9 (2.8) 28 0.4 (2.7) 7.7 % 0.18 [ -0.37, 0.73 ]
Cormie 2014 43 4.9 (7.1) 19 1.7 (7.1) 7.7 % 0.45 [ -0.10, 0.99 ]
Murtezani 2014 30 1.66 (0.71) 32 0.87 (0.64) 7.8 % 1.16 [ 0.62, 1.70 ]
Mehnert 2011 30 6.67 (23.84) 27 5.56 (27) 8.1 % 0.04 [ -0.48, 0.56 ]
Cadmus 2009 37 -0.3 (3.7) 37 -0.5 (3.4) 9.4 % 0.06 [ -0.40, 0.51 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 9.8 % -0.05 [ -0.49, 0.39 ]
Vallance 2007 250 0.63 (4.14) 85 -0.01 (2.7) 15.2 % 0.17 [ -0.08, 0.41 ]
Saarto 2012 263 2.4 (21.51) 237 3.8 (21.6) 17.3 % -0.06 [ -0.24, 0.11 ]
Subtotal (95% CI) 764 551 100.0 % 0.14 [ -0.05, 0.33 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 21.96, df = 11 (P = 0.02); I2 =50%
Test for overall effect: Z = 1.46 (P = 0.15)
2 Follow-up
Rogers 2009 19 1.1 (2.99) 17 -0.21 (4) 100.0 % 0.37 [ -0.29, 1.03 ]
Subtotal (95% CI) 19 17 100.0 % 0.37 [ -0.29, 1.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
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Analysis 1.42. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 42
FACT Functional well-being (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 42 FACT Functional well-being (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cadmus 2009 37 23.1 (4.7) 37 20.6 (7.2) 7.7 % 2.50 [ -0.27, 5.27 ]
Rogers 2009 20 21.4 (4.8) 18 23.8 (3.2) 8.0 % -2.40 [ -4.97, 0.17 ]
Daley 2007 33 22.88 (4.52) 33 20.3 (5.57) 8.2 % 2.58 [ 0.13, 5.03 ]
Littman 2012 30 22.6 (3.9) 27 21.7 (4.7) 8.5 % 0.90 [ -1.36, 3.16 ]
Courneya 2003 24 23.4 (4) 28 23.1 (4) 8.7 % 0.30 [ -1.88, 2.48 ]
Milne 2008 29 22.2 (3) 29 12.5 (4.8) 8.9 % 9.70 [ 7.64, 11.76 ]
Loh 2014 63 23.37 (4.33) 32 22.22 (4.99) 8.9 % 1.15 [ -0.88, 3.18 ]
Rogers 2015 105 22.3 (4.5) 108 20.3 (5.5) 10.0 % 2.00 [ 0.65, 3.35 ]
Murtezani 2014 30 24.2 (2.8) 32 23 (2.5) 10.0 % 1.20 [ -0.12, 2.52 ]
Vallance 2007 250 23.22 (3.98) 85 22.72 (4.58) 10.3 % 0.50 [ -0.59, 1.59 ]
Banasik 2011 7 3.46 (0.64) 7 3.24 (0.56) 10.8 % 0.22 [ -0.41, 0.85 ]
Subtotal (95% CI) 628 436 100.0 % 1.67 [ 0.29, 3.06 ]
Heterogeneity: Tau2 = 4.52; Chi2 = 87.26, df = 10 (P<0.00001); I2 =89%
Test for overall effect: Z = 2.37 (P = 0.018)
2 Follow-up
Rogers 2009 19 21.9 (4.7) 17 22.4 (5.4) 16.0 % -0.50 [ -3.82, 2.82 ]
Rogers 2015 105 21.4 (5.1) 108 20.5 (5.7) 84.0 % 0.90 [ -0.55, 2.35 ]
Subtotal (95% CI) 124 125 100.0 % 0.68 [ -0.65, 2.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.00 (P = 0.32)
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Analysis 1.43. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 43
FACT Functional well-being (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 43 FACT Functional well-being (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Naumann 2012 11 1.9 (3.3) 10 0.8 (3.4) 1.0 % 1.10 [ -1.77, 3.97 ]
Rogers 2009 20 0.4 (3.3) 18 1.4 (4.3) 1.4 % -1.00 [ -3.46, 1.46 ]
Cadmus 2009 37 -0.3 (3.7) 37 -0.5 (3.4) 3.3 % 0.20 [ -1.42, 1.82 ]
Courneya 2003 24 0.9 (2.8) 28 0.4 (2.7) 3.8 % 0.50 [ -1.00, 2.00 ]
Vallance 2007 250 0.63 (4.14) 85 -0.01 (2.7) 14.6 % 0.64 [ -0.13, 1.41 ]
Murtezani 2014 30 1.66 (0.71) 32 0.87 (0.64) 75.9 % 0.79 [ 0.45, 1.13 ]
Subtotal (95% CI) 372 210 100.0 % 0.72 [ 0.42, 1.01 ]
Heterogeneity: Chi2 = 2.63, df = 5 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 4.77 (P < 0.00001)
2 Follow-up
Rogers 2009 19 1.1 (2.99) 17 -0.21 (4) 100.0 % 1.31 [ -1.02, 3.64 ]
Subtotal (95% CI) 19 17 100.0 % 1.31 [ -1.02, 3.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
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Analysis 1.44. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 44
MOS SF Physical role (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 44 MOS SF Physical role (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Basen-Enquist 2006 28 86.1 (22.2) 23 73 (24.5) 1.0 % 13.10 [ 0.14, 26.06 ]
Cadmus 2009 37 49.7 (9.3) 37 49.5 (7.8) 11.2 % 0.20 [ -3.71, 4.11 ]
Mustian 2004 9 2.44 (1.5) 9 2.8 (1.53) 87.7 % -0.36 [ -1.76, 1.04 ]
Subtotal (95% CI) 74 69 100.0 % -0.16 [ -1.47, 1.15 ]
Heterogeneity: Chi2 = 4.13, df = 2 (P = 0.13); I2 =52%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.45. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 45
MOS SF Physical role (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 45 MOS SF Physical role (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cadmus 2009 37 1.5 (11.9) 37 1.9 (9.1) 14.3 % -0.40 [ -5.23, 4.43 ]
Cormie 2014 43 4.9 (7.1) 19 1.7 (7.1) 20.9 % 3.20 [ -0.63, 7.03 ]
Mustian 2004 9 0.56 (1.59) 10 0.8 (1.55) 64.8 % -0.24 [ -1.65, 1.17 ]
Subtotal (95% CI) 89 66 100.0 % 0.46 [ -1.52, 2.43 ]
Heterogeneity: Tau2 = 1.05; Chi2 = 2.77, df = 2 (P = 0.25); I2 =28%
Test for overall effect: Z = 0.45 (P = 0.65)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.46. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 46
EORTC QLQ-C30 Role function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 46 EORTC QLQ-C30 Role function (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mehnert 2011 30 90 (20.34) 27 79.63 (25.04) 19.3 % 10.37 [ -1.55, 22.29 ]
Do 2015 32 78.1 (19.5) 30 79.2 (14.6) 29.4 % -1.10 [ -9.64, 7.44 ]
Herrero 2006 8 97.6 (5.9) 8 100 (0.01) 51.4 % -2.40 [ -6.49, 1.69 ]
Subtotal (95% CI) 70 65 100.0 % 0.44 [ -5.78, 6.66 ]
Heterogeneity: Tau2 = 15.23; Chi2 = 3.94, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.47. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 47
EORTC QLQ-C30 Role function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 47 EORTC QLQ-C30 Role function (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mehnert 2011 30 6.67 (23.84) 27 5.56 (27) 6.7 % 1.11 [ -12.18, 14.40 ]
Herrero 2006 8 2.1 (13.9) 8 2.1 (5.9) 10.8 % 0.0 [ -10.46, 10.46 ]
Saarto 2012 263 2.4 (21.51) 237 3.8 (21.6) 82.5 % -1.40 [ -5.18, 2.38 ]
Subtotal (95% CI) 301 272 100.0 % -1.08 [ -4.52, 2.36 ]
Heterogeneity: Chi2 = 0.17, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.48. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 48
Overall social well-being/function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 48 Overall social well-being/function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Banasik 2011 7 2.8 (0.67) 7 3.16 (0.83) 1.1 % -0.45 [ -1.51, 0.62 ]
Herrero 2006 8 87.5 (19.4) 8 91.7 (23.6) 1.3 % -0.18 [ -1.17, 0.80 ]
Mustian 2004 9 8.63 (1.89) 10 9 (1.83) 1.5 % -0.19 [ -1.09, 0.71 ]
Rogers 2014 20 7.3 (4.9) 22 3.1 (3.2) 2.9 % 1.01 [ 0.36, 1.65 ]
Rogers 2009 20 22.6 (4.1) 18 21.8 (5.7) 3.0 % 0.16 [ -0.48, 0.80 ]
Basen-Enquist 2006 28 84.6 (16.93) 23 84.9 (19.18) 3.9 % -0.02 [ -0.57, 0.54 ]
Courneya 2003 24 21.1 (3.5) 28 20.7 (3.6) 4.0 % 0.11 [ -0.43, 0.66 ]
Littman 2012 30 22.1 (5) 27 20.9 (6) 4.3 % 0.22 [ -0.31, 0.74 ]
Milne 2008 29 20.7 (4) 29 19.4 (3.9) 4.3 % 0.32 [ -0.19, 0.84 ]
Mehnert 2011 30 85.35 (20.88) 28 79.91 (22.65) 4.4 % 0.25 [ -0.27, 0.76 ]
Murtezani 2014 30 20.2 (2.8) 32 18.3 (2.7) 4.4 % 0.68 [ 0.17, 1.20 ]
Daley 2007 33 23.3 (4.78) 33 20.4 (6.8) 4.8 % 0.49 [ 0.00, 0.98 ]
Cadmus 2009 37 22.3 (4.9) 37 20.6 (7.2) 5.4 % 0.27 [ -0.18, 0.73 ]
Loh 2014 63 21.48 (4.88) 32 19.61 (4.9) 6.1 % 0.38 [ -0.05, 0.81 ]
Schmitz 2009 59 14.9 (5.2) 62 14.1 (5.8) 8.4 % 0.14 [ -0.21, 0.50 ]
Kiecolt-Glaser 2014 96 95.2 (10.8) 90 93.8 (9.3) 11.9 % 0.14 [ -0.15, 0.43 ]
Rogers 2015 105 21 (5.7) 108 20.7 (5.8) 13.2 % 0.05 [ -0.22, 0.32 ]
Vallance 2007 250 22.94 (4.96) 85 22.96 (5.05) 15.1 % 0.00 [ -0.25, 0.24 ]
Subtotal (95% CI) 878 679 100.0 % 0.19 [ 0.08, 0.30 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 19.03, df = 17 (P = 0.33); I2 =11%
Test for overall effect: Z = 3.27 (P = 0.0011)
2 Follow-up
Rogers 2015 105 21 (5.9) 108 20.5 (5.4) 100.0 % 0.09 [ -0.18, 0.36 ]
Subtotal (95% CI) 105 108 100.0 % 0.09 [ -0.18, 0.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
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Analysis 1.49. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 49
Overall social well-being/function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 49 Overall social well-being/function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 9 1.5 (1.5) 10 0.44 (1.17) 6.0 % 0.76 [ -0.18, 1.70 ]
Naumann 2012 11 0.9 (3.32) 10 -0.2 (3.32) 6.5 % 0.32 [ -0.54, 1.18 ]
Rogers 2009 20 0.9 (2.6) 18 -1.2 (2.7) 7.7 % 0.78 [ 0.11, 1.44 ]
Rogers 2014 20 2.1 (3.2) 22 -0.8 (3.5) 7.8 % 0.85 [ 0.21, 1.48 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 8.1 % 1.80 [ 1.21, 2.40 ]
Courneya 2003 24 0.6 (2.4) 28 -0.5 (3.3) 8.4 % 0.37 [ -0.18, 0.92 ]
Cormie 2014 43 3.5 (8.5) 19 2.5 (8.3) 8.4 % 0.12 [ -0.42, 0.66 ]
Mehnert 2011 30 7.33 (22.33) 28 3.12 (24.3) 8.6 % 0.18 [ -0.34, 0.69 ]
Cadmus 2009 37 0.6 (4.6) 37 -1 (3.2) 8.9 % 0.40 [ -0.06, 0.86 ]
Schmitz 2009 59 4.4 (33.8) 62 0.7 (34) 9.5 % 0.11 [ -0.25, 0.47 ]
Vallance 2007 250 0.21 (4.82) 85 -4.15 (3.34) 9.9 % 0.97 [ 0.71, 1.23 ]
Saarto 2012 263 5 (21.1) 237 8.8 (20.81) 10.2 % -0.18 [ -0.36, -0.01 ]
Subtotal (95% CI) 796 588 100.0 % 0.52 [ 0.16, 0.87 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 86.83, df = 11 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.86 (P = 0.0043)
2 Follow-up
Rogers 2009 19 -0.04 (4.3) 17 -3.9 (6.6) 100.0 % 0.69 [ 0.01, 1.36 ]
Subtotal (95% CI) 19 17 100.0 % 0.69 [ 0.01, 1.36 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.99 (P = 0.047)
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Analysis 1.50. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 50
FACT Social well-being (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 50 FACT Social well-being (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 22.6 (4.1) 18 21.8 (5.7) 3.7 % 0.80 [ -2.39, 3.99 ]
Littman 2012 30 22.1 (5) 27 20.9 (6) 4.4 % 1.20 [ -1.68, 4.08 ]
Daley 2007 33 23.3 (4.78) 33 20.4 (6.8) 4.6 % 2.90 [ 0.06, 5.74 ]
Cadmus 2009 37 22.3 (4.9) 37 20.6 (7.2) 4.6 % 1.70 [ -1.11, 4.51 ]
Loh 2014 63 21.48 (4.88) 32 19.61 (4.9) 7.5 % 1.87 [ -0.21, 3.95 ]
Milne 2008 29 20.7 (4) 29 19.4 (3.9) 7.7 % 1.30 [ -0.73, 3.33 ]
Courneya 2003 24 21.1 (3.5) 28 20.7 (3.6) 8.3 % 0.40 [ -1.53, 2.33 ]
Rogers 2015 105 21 (5.7) 108 20.7 (5.8) 11.2 % 0.30 [ -1.24, 1.84 ]
Murtezani 2014 30 20.2 (2.8) 32 18.3 (2.7) 12.9 % 1.90 [ 0.53, 3.27 ]
Vallance 2007 250 22.94 (4.96) 85 22.96 (5.05) 14.4 % -0.02 [ -1.26, 1.22 ]
Banasik 2011 7 2.8 (0.67) 7 3.16 (0.83) 20.6 % -0.36 [ -1.15, 0.43 ]
Subtotal (95% CI) 628 436 100.0 % 0.77 [ 0.11, 1.43 ]
Heterogeneity: Tau2 = 0.38; Chi2 = 15.28, df = 10 (P = 0.12); I2 =35%
Test for overall effect: Z = 2.29 (P = 0.022)
2 Follow-up
Rogers 2015 105 21 (5.9) 108 20.5 (5.4) 100.0 % 0.50 [ -1.02, 2.02 ]
Subtotal (95% CI) 105 108 100.0 % 0.50 [ -1.02, 2.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
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Analysis 1.51. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 51
FACT Social well-being (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 51 FACT Social well-being (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Naumann 2012 11 0.9 (3.32) 10 -0.2 (3.32) 1.5 % 1.10 [ -1.74, 3.94 ]
Cadmus 2009 37 0.6 (4.6) 37 -1 (3.2) 3.8 % 1.60 [ -0.21, 3.41 ]
Rogers 2009 20 0.9 (2.6) 18 -1.2 (2.7) 4.3 % 2.10 [ 0.41, 3.79 ]
Courneya 2003 24 0.6 (2.4) 28 -0.5 (3.3) 5.1 % 1.10 [ -0.45, 2.65 ]
Vallance 2007 250 0.21 (4.82) 85 -4.15 (3.34) 14.3 % 4.36 [ 3.43, 5.29 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 71.0 % 1.53 [ 1.11, 1.95 ]
Subtotal (95% CI) 372 210 100.0 % 1.93 [ 1.58, 2.28 ]
Heterogeneity: Chi2 = 31.48, df = 5 (P<0.00001); I2 =84%
Test for overall effect: Z = 10.81 (P < 0.00001)
2 Follow-up
Rogers 2009 19 -0.04 (4.3) 17 -3.9 (6.6) 100.0 % 3.86 [ 0.17, 7.55 ]
Subtotal (95% CI) 19 17 100.0 % 3.86 [ 0.17, 7.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.05 (P = 0.040)
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Analysis 1.52. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 52
MOS SF Social functioning (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 52 MOS SF Social functioning (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Baruth 2013 20 87.2 (0) 12 78.4 (0) Not estimable
Mehnert 2011 30 85.35 (20.88) 28 79.91 (22.65) 1.9 % 5.44 [ -5.79, 16.67 ]
Basen-Enquist 2006 28 84.6 (16.93) 23 84.9 (19.18) 2.4 % -0.30 [ -10.34, 9.74 ]
Cadmus 2009 37 49.5 (12) 37 50.5 (9.6) 9.8 % -1.00 [ -5.95, 3.95 ]
Mustian 2004 9 8.63 (1.89) 10 9 (1.83) 85.8 % -0.37 [ -2.05, 1.31 ]
Subtotal (95% CI) 124 110 100.0 % -0.32 [ -1.87, 1.23 ]
Heterogeneity: Chi2 = 1.09, df = 3 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.53. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 53
MOS SF Social functioning (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 53 MOS SF Social functioning (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mehnert 2011 30 7.33 (22.33) 28 3.12 (24.3) 0.9 % 4.21 [ -7.83, 16.25 ]
Cormie 2014 43 3.5 (8.5) 19 2.5 (8.3) 6.2 % 1.00 [ -3.51, 5.51 ]
Cadmus 2009 37 0.7 (11) 37 0.1 (6.8) 7.3 % 0.60 [ -3.57, 4.77 ]
Mustian 2004 9 1.5 (1.5) 10 0.44 (1.17) 85.6 % 1.06 [ -0.16, 2.28 ]
Subtotal (95% CI) 119 94 100.0 % 1.05 [ -0.08, 2.18 ]
Heterogeneity: Chi2 = 0.31, df = 3 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.83 (P = 0.068)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.54. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 54
EORTC QLQ-C30 Social function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 54 EORTC QLQ-C30 Social function (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 87.5 (19.4) 8 91.7 (23.6) 41.3 % -4.20 [ -25.37, 16.97 ]
Mehnert 2011 30 85.56 (23.05) 27 69.75 (28.13) 58.7 % 15.81 [ 2.37, 29.25 ]
Subtotal (95% CI) 38 35 100.0 % 7.55 [ -11.77, 26.86 ]
Heterogeneity: Tau2 = 118.36; Chi2 = 2.45, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 0.77 (P = 0.44)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.55. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 55
EORTC QLQ-C30 Social function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 55 EORTC QLQ-C30 Social function (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 0 (15.4) 8 -4.2 (18.4) 22.1 % 4.20 [ -12.43, 20.83 ]
Mehnert 2011 30 12.78 (24.93) 27 1.23 (27.8) 27.2 % 11.55 [ -2.22, 25.32 ]
Saarto 2012 263 5 (21.1) 237 8.8 (20.81) 50.7 % -3.80 [ -7.48, -0.12 ]
Subtotal (95% CI) 301 272 100.0 % 2.14 [ -8.02, 12.30 ]
Heterogeneity: Tau2 = 49.46; Chi2 = 5.10, df = 2 (P = 0.08); I2 =61%
Test for overall effect: Z = 0.41 (P = 0.68)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.56. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 56
Overall cognitive function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 56 Overall cognitive function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Pinto 2003 12 -4.33 (2.5) 6 -7.17 (2.1) 7.5 % 1.14 [ 0.07, 2.20 ]
Herrero 2006 8 91.7 (12.6) 8 89.6 (12.4) 8.8 % 0.16 [ -0.82, 1.14 ]
Rogers 2009 19 -124.5 (30.8) 18 -135.5 (19.5) 20.0 % 0.42 [ -0.24, 1.07 ]
Mehnert 2011 30 81.1 (16.8) 27 78.4 (24.38) 31.4 % 0.13 [ -0.39, 0.65 ]
Cantarero-Villanueva 2013 32 -37.93 (8.48) 29 -43.03 (10.01) 32.4 % 0.55 [ 0.03, 1.06 ]
Subtotal (95% CI) 101 88 100.0 % 0.40 [ 0.11, 0.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.41, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0074)
2 Follow-up
Rogers 2009 19 -126.4 (31.8) 17 -129.2 (31.5) 37.7 % 0.09 [ -0.57, 0.74 ]
Cantarero-Villanueva 2013 32 -37.75 (7.34) 29 -42.02 (11.31) 62.3 % 0.45 [ -0.06, 0.96 ]
Subtotal (95% CI) 51 46 100.0 % 0.31 [ -0.09, 0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.73, df = 1 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
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Analysis 1.57. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 57
Overall cognitive function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 57 Overall cognitive function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 6.2 (19.8) 8 8.3 (14.8) 6.3 % -0.11 [ -1.09, 0.87 ]
Rogers 2009 20 4.2 (16.8) 18 -4.7 (25.9) 12.7 % 0.40 [ -0.24, 1.05 ]
Mehnert 2011 30 1.67 (22.36) 27 6.18 (24.6) 17.4 % -0.19 [ -0.71, 0.33 ]
Cantarero-Villanueva 2013 32 2.2 (7.63) 29 -0.18 (5.5471) 18.1 % 0.35 [ -0.16, 0.86 ]
Saarto 2012 263 -1 (18.2) 237 2.2 (18.46) 45.5 % -0.17 [ -0.35, 0.00 ]
Subtotal (95% CI) 353 319 100.0 % 0.00 [ -0.27, 0.26 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 6.17, df = 4 (P = 0.19); I2 =35%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Follow-up
Rogers 2009 19 5.4 (16.3) 17 0.68 (23.6) 37.0 % 0.23 [ -0.43, 0.89 ]
Cantarero-Villanueva 2013 32 2.37 (10.2) 29 0.84 (5) 63.0 % 0.19 [ -0.32, 0.69 ]
Subtotal (95% CI) 51 46 100.0 % 0.20 [ -0.20, 0.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
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Analysis 1.58. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 58
EORTC QLQ-C30 Cognitive function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 58 EORTC QLQ-C30 Cognitive function (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Herrero 2006 8 91.7 (12.6) 8 89.6 (12.4) 44.6 % 2.10 [ -10.15, 14.35 ]
Mehnert 2011 30 81.1 (16.8) 27 78.4 (24.38) 55.4 % 2.70 [ -8.29, 13.69 ]
Subtotal (95% CI) 38 35 100.0 % 2.43 [ -5.75, 10.61 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.59. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 59
EORTC QLQ-C30 Cognitive function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 59 EORTC QLQ-C30 Cognitive function (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Herrero 2006 8 6.2 (19.8) 8 8.3 (14.8) 3.2 % -2.10 [ -19.23, 15.03 ]
Mehnert 2011 30 1.67 (22.36) 27 6.18 (24.6) 6.3 % -4.51 [ -16.76, 7.74 ]
Saarto 2012 263 -1 (18.2) 237 2.2 (18.46) 90.6 % -3.20 [ -6.42, 0.02 ]
Subtotal (95% CI) 301 272 100.0 % -3.25 [ -6.31, -0.18 ]
Heterogeneity: Chi2 = 0.06, df = 2 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.60. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 60
POMS confusion subscale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 60 POMS confusion subscale (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Pinto 2003 12 4.33 (2.5) 6 7.17 (2.1) 18.8 % -1.14 [ -2.20, -0.07 ]
Cantarero-Villanueva 2013 32 37.93 (8.48) 29 43.03 (10.01) 81.2 % -0.55 [ -1.06, -0.03 ]
Subtotal (95% CI) 44 35 100.0 % -0.66 [ -1.12, -0.19 ]
Heterogeneity: Chi2 = 0.96, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0054)
2 Follow-up
Cantarero-Villanueva 2013 32 37.75 (7.34) 29 42.02 (11.31) 100.0 % -0.45 [ -0.96, 0.06 ]
Subtotal (95% CI) 32 29 100.0 % -0.45 [ -0.96, 0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.085)
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Analysis 1.61. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 61
Overall general health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 61 Overall general health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 4.7 % 1.30 [ 0.19, 2.41 ]
Mustian 2004 9 18.6 (4.77) 9 19.3 (1.92) 6.2 % -0.18 [ -1.11, 0.74 ]
Rogers 2009 20 3.5 (0.9) 18 3.8 (0.5) 10.1 % -0.40 [ -1.04, 0.25 ]
Basen-Enquist 2006 28 77.4 (11.64) 23 67.1 (13.43) 11.5 % 0.81 [ 0.24, 1.39 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 12.3 % 0.19 [ -0.35, 0.73 ]
Mehnert 2011 30 74.38 (11.84) 28 70.01 (20.81) 12.8 % 0.26 [ -0.26, 0.77 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 13.2 % 0.28 [ -0.22, 0.79 ]
Cadmus 2009 37 50 (8.8) 37 51.7 (8.4) 14.3 % -0.20 [ -0.65, 0.26 ]
Schmitz 2005 39 53.8 (5.3) 40 53.2 (6) 14.7 % 0.10 [ -0.34, 0.55 ]
Subtotal (95% CI) 243 213 100.0 % 0.18 [ -0.08, 0.45 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 15.19, df = 8 (P = 0.06); I2 =47%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Follow-up
Rogers 2009 19 3.5 (0.9) 17 3.7 (0.9) 100.0 % -0.22 [ -0.87, 0.44 ]
Subtotal (95% CI) 19 17 100.0 % -0.22 [ -0.87, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.52)
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Analysis 1.62. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 62
Overall general health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 62 Overall general health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 3.1 % 1.92 [ 0.68, 3.17 ]
Mustian 2004 9 0.22 (1.92) 10 0.68 (2.5) 5.3 % -0.20 [ -1.10, 0.71 ]
Rogers 2009 20 0.15 (0.6) 18 0.17 (0.7) 8.9 % -0.03 [ -0.67, 0.61 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 10.8 % 0.52 [ -0.03, 1.06 ]
Cormie 2014 43 3.7 (7) 19 2.8 (7.1) 10.9 % 0.13 [ -0.41, 0.67 ]
Mehnert 2011 30 6.6 (13.7) 28 3.24 (19.7) 11.5 % 0.20 [ -0.32, 0.71 ]
Cadmus 2009 37 0.2 (4.4) 37 -0.1 (5.1) 13.1 % 0.06 [ -0.39, 0.52 ]
Schmitz 2005 39 0.7 (4.8) 40 -0.6 (3.9) 13.5 % 0.29 [ -0.15, 0.74 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 22.8 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 489 417 100.0 % 0.17 [ -0.07, 0.40 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 15.82, df = 8 (P = 0.05); I2 =49%
Test for overall effect: Z = 1.40 (P = 0.16)
2 Follow-up
Rogers 2009 19 0.16 (0.6) 17 0.12 (0.6) 100.0 % 0.07 [ -0.59, 0.72 ]
Subtotal (95% CI) 19 17 100.0 % 0.07 [ -0.59, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.20 (P = 0.85)
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Analysis 1.63. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 63
MOS SF General health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 63 MOS SF General health (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Baruth 2013 20 68.1 (0) 12 61.6 (0) Not estimable
Mehnert 2011 30 74.38 (11.84) 28 70.01 (20.81) 16.5 % 4.37 [ -4.43, 13.17 ]
Basen-Enquist 2006 28 77.4 (11.64) 23 67.1 (13.43) 20.9 % 10.30 [ 3.32, 17.28 ]
Cadmus 2009 37 50 (8.8) 37 51.7 (8.4) 30.4 % -1.70 [ -5.62, 2.22 ]
Mustian 2004 9 18.6 (4.77) 9 19.3 (1.92) 32.1 % -0.70 [ -4.06, 2.66 ]
Subtotal (95% CI) 124 109 100.0 % 2.14 [ -2.61, 6.88 ]
Heterogeneity: Tau2 = 15.30; Chi2 = 10.02, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.64. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 64
MOS SF General health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 64 MOS SF General health (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mehnert 2011 30 6.6 (13.7) 28 3.24 (19.7) 2.4 % 3.36 [ -5.43, 12.15 ]
Cormie 2014 43 3.7 (7) 19 2.8 (7.1) 12.6 % 0.90 [ -2.92, 4.72 ]
Cadmus 2009 37 0.2 (4.4) 37 -0.1 (5.1) 38.9 % 0.30 [ -1.87, 2.47 ]
Mustian 2004 9 0.22 (1.92) 10 0.68 (2.5) 46.1 % -0.46 [ -2.45, 1.53 ]
Subtotal (95% CI) 119 94 100.0 % 0.10 [ -1.26, 1.45 ]
Heterogeneity: Chi2 = 1.03, df = 3 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
-20 -10 0 10 20
Favours control Favours physical activity
352Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.65. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 65
Overall sexual function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 65 Overall sexual function (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Pinto 2005 12 42.75 (9.2) 6 43.7 (6.1) 3.9 % -0.11 [ -1.09, 0.87 ]
Schmitz 2005 39 -51 (7.5) 40 -53.5 (8) 19.2 % 0.32 [ -0.12, 0.76 ]
Pinto 2003 39 42.45 (9.24) 43 40.12 (6.3) 20.0 % 0.29 [ -0.14, 0.73 ]
Schmitz 2009 57 -27.3 (5.3) 57 -28.1 (6.2) 28.1 % 0.14 [ -0.23, 0.51 ]
Duijits 2012 53 0.6 (0.79) 65 0.59 (0.79) 28.8 % 0.01 [ -0.35, 0.38 ]
Subtotal (95% CI) 200 211 100.0 % 0.16 [ -0.04, 0.35 ]
Heterogeneity: Chi2 = 1.80, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.59 (P = 0.11)
2 Follow-up
Duijits 2012 48 0.55 (0.69) 54 0.42 (0.69) 100.0 % 0.19 [ -0.20, 0.58 ]
Subtotal (95% CI) 48 54 100.0 % 0.19 [ -0.20, 0.58 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.94 (P = 0.35)
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Analysis 1.66. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 66
Overall sexual function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 66 Overall sexual function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Schmitz 2005 39 1.7 (4.8) 40 0.2 (5.2) 24.8 % 0.30 [ -0.15, 0.74 ]
Schmitz 2009 57 7.2 (14.6) 57 -0.2 (16.7) 29.5 % 0.47 [ 0.10, 0.84 ]
Saarto 2012 263 4.3 (25.38) 237 3.8 (24.35) 45.7 % 0.02 [ -0.16, 0.20 ]
Subtotal (95% CI) 359 334 100.0 % 0.22 [ -0.08, 0.52 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 5.22, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.67. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 67
Body Esteem Scale - sexual attractiveness (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 67 Body Esteem Scale - sexual attractiveness (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Pinto 2005 12 42.75 (9.2) 6 43.7 (6.1) 19.0 % -0.95 [ -8.09, 6.19 ]
Pinto 2003 39 42.45 (9.24) 43 40.12 (6.3) 81.0 % 2.33 [ -1.13, 5.79 ]
Subtotal (95% CI) 51 49 100.0 % 1.71 [ -1.41, 4.82 ]
Heterogeneity: Chi2 = 0.66, df = 1 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.68. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 68
Overall sleep (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 68 Overall sleep (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2013 11 6.3 (2.7) 9 6.2 (3.2) 10.7 % 0.03 [ -0.85, 0.91 ]
Bower 2011 16 8.1 (2.5) 15 7.7 (2.6) 16.7 % 0.15 [ -0.55, 0.86 ]
Rogers 2009 20 6.65 (4.17) 18 5.5 (4) 20.3 % 0.28 [ -0.36, 0.92 ]
Rogers 2014 20 6.7 (3.7) 22 7.1 (3.2) 22.6 % -0.11 [ -0.72, 0.49 ]
Mehnert 2011 30 23.75 (27) 27 38.27 (31.63) 29.8 % -0.49 [ -1.02, 0.04 ]
Subtotal (95% CI) 97 91 100.0 % -0.09 [ -0.37, 0.20 ]
Heterogeneity: Chi2 = 3.98, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
2 Follow-up
Bower 2011 16 7.6 (2.7) 15 9.1 (3.3) 100.0 % -0.49 [ -1.20, 0.23 ]
Subtotal (95% CI) 16 15 100.0 % -0.49 [ -1.20, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
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Analysis 1.69. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 69
Overall sleep (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 69 Overall sleep (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 0.45 (2.1) 18 0.28 (4.7) 28.0 % 0.05 [ -0.59, 0.68 ]
Rogers 2014 20 -1.3 (3.2) 22 -2.2 (4.4) 30.8 % 0.23 [ -0.38, 0.84 ]
Mehnert 2011 29 -5.36 (29.88) 27 -9.88 (33.3) 41.2 % 0.14 [ -0.38, 0.67 ]
Subtotal (95% CI) 69 67 100.0 % 0.14 [ -0.20, 0.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.70. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 70
PSQI Global sleep score (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 70 PSQI Global sleep score (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2013 11 6.3 (2.7) 9 6.2 (3.2) 4.3 % 0.10 [ -2.53, 2.73 ]
Rogers 2009 20 6.65 (4.17) 18 5.5 (4) 4.4 % 1.15 [ -1.45, 3.75 ]
Rogers 2014 20 6.7 (3.7) 22 7.1 (3.2) 6.7 % -0.40 [ -2.50, 1.70 ]
Bower 2011 16 8.1 (2.5) 15 7.7 (2.6) 9.1 % 0.40 [ -1.40, 2.20 ]
Kiecolt-Glaser 2014 96 6.3 (2.16) 90 7 (2.18) 75.6 % -0.70 [ -1.32, -0.08 ]
Subtotal (95% CI) 163 154 100.0 % -0.47 [ -1.01, 0.08 ]
Heterogeneity: Chi2 = 3.10, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.68 (P = 0.093)
2 Follow-up
Bower 2011 16 7.6 (2.7) 15 9.1 (3.3) 100.0 % -1.50 [ -3.63, 0.63 ]
Subtotal (95% CI) 16 15 100.0 % -1.50 [ -3.63, 0.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.38 (P = 0.17)
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Analysis 1.71. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 71
PSQI Global sleep score (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 71 PSQI Global sleep score (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2009 20 0.45 (2.1) 18 0.28 (4.7) 49.0 % 0.17 [ -2.19, 2.53 ]
Rogers 2014 20 -1.3 (3.2) 22 -2.2 (4.4) 51.0 % 0.90 [ -1.41, 3.21 ]
Subtotal (95% CI) 40 40 100.0 % 0.54 [ -1.11, 2.19 ]
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.72. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 72
PSQI sleep quality (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 72 PSQI sleep quality (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 1.3 (0.86) 18 1.22 (0.81) 44.2 % 0.08 [ -0.45, 0.61 ]
Rogers 2014 20 0.7 (0.6) 22 1.2 (0.6) 55.8 % -0.50 [ -0.86, -0.14 ]
Subtotal (95% CI) 40 40 100.0 % -0.24 [ -0.81, 0.32 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 3.12, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.85 (P = 0.40)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.73. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 73
PSQI sleep efficiency (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 73 PSQI sleep efficiency (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2013 11 0.8 (1) 9 0.7 (0.9) 21.3 % 0.10 [ -0.73, 0.93 ]
Rogers 2009 20 1.05 (1.36) 18 0.61 (0.85) 29.0 % 0.44 [ -0.27, 1.15 ]
Rogers 2014 20 0.6 (0.8) 22 0.6 (1) 49.7 % 0.0 [ -0.55, 0.55 ]
Subtotal (95% CI) 51 49 100.0 % 0.15 [ -0.24, 0.53 ]
Heterogeneity: Chi2 = 0.94, df = 2 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
-4 -2 0 2 4
Favours Physical activity Favours control
361Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.74. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 74
PSQI sleep latency (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 74 PSQI sleep latency (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2013 11 1.3 (0.6) 9 1.3 (1) 22.5 % 0.0 [ -0.74, 0.74 ]
Rogers 2009 20 1.1 (0.85) 18 0.78 (1.06) 32.8 % 0.32 [ -0.30, 0.94 ]
Rogers 2014 20 1.2 (1) 22 1 (0.7) 44.7 % 0.20 [ -0.33, 0.73 ]
Subtotal (95% CI) 51 49 100.0 % 0.19 [ -0.16, 0.55 ]
Heterogeneity: Chi2 = 0.42, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.75. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 75
PSQI sleep duration (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 75 PSQI sleep duration (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2013 20 1.3 (0.92) 18 1.06 (0.64) 48.4 % 0.24 [ -0.26, 0.74 ]
Rogers 2014 20 1.1 (0.8) 22 1.2 (0.8) 51.6 % -0.10 [ -0.58, 0.38 ]
Subtotal (95% CI) 40 40 100.0 % 0.06 [ -0.28, 0.41 ]
Heterogeneity: Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.76. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 76
PSQI daytime dysfunction (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 76 PSQI daytime dysfunction (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2013 11 0.6 (0.5) 9 0.9 (0.9) 24.8 % -0.30 [ -0.96, 0.36 ]
Rogers 2009 20 1.15 (0.88) 18 0.83 (0.51) 35.7 % 0.32 [ -0.13, 0.77 ]
Rogers 2014 20 0.7 (0.6) 22 1 (0.7) 39.5 % -0.30 [ -0.69, 0.09 ]
Subtotal (95% CI) 51 49 100.0 % -0.08 [ -0.51, 0.35 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 4.64, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.77. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 77
PSQI medication use (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 77 PSQI medication use (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 0.75 (1.16) 18 1 (1.14) 47.4 % -0.21 [ -0.85, 0.43 ]
Rogers 2014 20 0.8 (1.3) 22 0.7 (1.2) 52.6 % 0.08 [ -0.53, 0.68 ]
Subtotal (95% CI) 40 40 100.0 % -0.06 [ -0.50, 0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.78. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 78
Accelerator-derived sleep efficiency (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 78 Accelerator-derived sleep efficiency (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2013 11 79.5 (8.3) 9 83.2 (10.5) 15.0 % -3.70 [ -12.13, 4.73 ]
Rogers 2014 20 82.9 (5.7) 22 84.9 (6) 85.0 % -2.00 [ -5.54, 1.54 ]
Subtotal (95% CI) 31 31 100.0 % -2.25 [ -5.52, 1.01 ]
Heterogeneity: Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 1.79. Comparison 1 Comparison: HRQoL outcomes, all physical activity vs control, Outcome 79
Accelerator-derived sleep latency (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 1 Comparison: HRQoL outcomes, all physical activity vs control
Outcome: 79 Accelerator-derived sleep latency (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2013 11 7.1 (3.8) 9 9.8 (5.2) 45.1 % -2.70 [ -6.77, 1.37 ]
Rogers 2014 20 7.4 (5.6) 22 8.9 (6.6) 54.9 % -1.50 [ -5.19, 2.19 ]
Subtotal (95% CI) 31 31 100.0 % -2.04 [ -4.78, 0.69 ]
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.1. Comparison 2 Comparison: anxiety, all physical activity vs control, Outcome 1 Overall anxiety
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 2 Comparison: anxiety, all physical activity vs control
Outcome: 1 Overall anxiety (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Segar 1998 10 28.5 (3) 5 39.5 (6) 5.1 % -2.49 [ -3.98, -1.00 ]
Pinto 2003 12 7.58 (7.3) 6 10.5 (3.7) 9.3 % -0.43 [ -1.43, 0.56 ]
Rogers 2014 20 45.6 (8.9) 22 45.7 (8) 15.5 % -0.01 [ -0.62, 0.59 ]
Milne 2008 29 15.3 (6.2) 29 21 (5.7) 16.8 % -0.94 [ -1.49, -0.40 ]
Mehnert 2011 30 4.83 (3.46) 28 7.14 (4.97) 17.2 % -0.54 [ -1.06, -0.01 ]
Cantarero-Villanueva 2013 32 42.51 (8.6) 29 49.93 (11.7) 17.3 % -0.72 [ -1.24, -0.20 ]
Cadmus 2009 37 32.1 (12.3) 37 34.1 (15.4) 18.7 % -0.14 [ -0.60, 0.31 ]
Subtotal (95% CI) 170 156 100.0 % -0.57 [ -0.95, -0.19 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 14.94, df = 6 (P = 0.02); I2 =60%
Test for overall effect: Z = 2.97 (P = 0.0030)
2 Follow-up
Cantarero-Villanueva 2013 32 43.97 (9.47) 29 48.84 (11.17) 100.0 % -0.47 [ -0.98, 0.04 ]
Subtotal (95% CI) 32 29 100.0 % -0.47 [ -0.98, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
-4 -2 0 2 4
Favours physical activity Favours control
368Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Comparison: anxiety, all physical activity vs control, Outcome 2 Overall anxiety
(change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 2 Comparison: anxiety, all physical activity vs control
Outcome: 2 Overall anxiety (change values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Cadmus 2009 37 -0.7 (9.2) 37 0.5 (5.8) 32.1 % -0.15 [ -0.61, 0.30 ]
Cantarero-Villanueva 2013 32 -4.2 (9.8) 29 0.75 (5.5) 25.3 % -0.61 [ -1.12, -0.09 ]
Mehnert 2011 30 -1.67 (3.68) 28 0.18 (4.89) 24.7 % -0.42 [ -0.95, 0.10 ]
Rogers 2014 20 -4 (6.5) 22 -1.8 (5) 17.9 % -0.37 [ -0.99, 0.24 ]
Subtotal (95% CI) 119 116 100.0 % -0.37 [ -0.63, -0.12 ]
Heterogeneity: Chi2 = 1.71, df = 3 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
2 Follow-up
Cantarero-Villanueva 2013 32 -3.44 (13.45) 29 -0.34 (3.63) 100.0 % -0.30 [ -0.81, 0.20 ]
Subtotal (95% CI) 32 29 100.0 % -0.30 [ -0.81, 0.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.18 (P = 0.24)
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Analysis 2.3. Comparison 2 Comparison: anxiety, all physical activity vs control, Outcome 3 POMS tension -
anxiety (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 2 Comparison: anxiety, all physical activity vs control
Outcome: 3 POMS tension - anxiety (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Pinto 2003 12 7.58 (7.3) 6 10.5 (3.7) 21.5 % -0.43 [ -1.43, 0.56 ]
Cantarero-Villanueva 2013 32 42.51 (8.6) 29 49.93 (11.7) 78.5 % -0.72 [ -1.24, -0.20 ]
Subtotal (95% CI) 44 35 100.0 % -0.66 [ -1.12, -0.20 ]
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0051)
2 Follow-up
Cantarero-Villanueva 2013 32 43.97 (9.47) 29 48.84 (11.17) 100.0 % -0.47 [ -0.98, 0.04 ]
Subtotal (95% CI) 32 29 100.0 % -0.47 [ -0.98, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.79 (P = 0.073)
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Analysis 2.4. Comparison 2 Comparison: anxiety, all physical activity vs control, Outcome 4 State Trait
Anxiety Inventory (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 2 Comparison: anxiety, all physical activity vs control
Outcome: 4 State Trait Anxiety Inventory (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Segar 1998 10 28.5 (3) 5 39.5 (6) 45.2 % -2.49 [ -3.98, -1.00 ]
Cadmus 2009 37 32.1 (12.3) 37 34.1 (15.4) 54.8 % -0.14 [ -0.60, 0.31 ]
Subtotal (95% CI) 47 42 100.0 % -1.20 [ -3.49, 1.09 ]
Heterogeneity: Tau2 = 2.44; Chi2 = 8.68, df = 1 (P = 0.003); I2 =88%
Test for overall effect: Z = 1.03 (P = 0.30)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 2.5. Comparison 2 Comparison: anxiety, all physical activity vs control, Outcome 5 Cohen’s
Perceived Stress Scale.
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 2 Comparison: anxiety, all physical activity vs control
Outcome: 5 Cohen’s Perceived Stress Scale





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Bower 2011 16 23.5 (7.3) 15 25.4 (5.9) 34.6 % -1.90 [ -6.56, 2.76 ]
Cadmus 2009 37 12.9 (6.2) 37 13.8 (8.5) 65.4 % -0.90 [ -4.29, 2.49 ]
Subtotal (95% CI) 53 52 100.0 % -1.25 [ -3.99, 1.50 ]
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 3.1. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 1 Overall
depression (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 3 Comparison: depression, all physical activity vs control
Outcome: 1 Overall depression (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Segar 1998 10 5.5 (2) 5 10 (2) 3.3 % -2.12 [ -3.51, -0.73 ]
Pinto 2003 12 6.17 (7.2) 6 9.83 (6.8) 5.2 % -0.49 [ -1.49, 0.50 ]
Payne 2008 10 12.7 (8.7) 10 11.4 (7.9) 6.1 % 0.15 [ -0.73, 1.03 ]
Kaltsatou 2011 13 16.54 (1.66) 13 22.33 (7.73) 6.6 % -1.00 [ -1.83, -0.18 ]
Bower 2011 16 7.7 (5.8) 15 11.6 (7.1) 7.5 % -0.59 [ -1.31, 0.13 ]
Rogers 2014 20 44.2 (8.6) 22 25.1 (44.2) 8.6 % 0.58 [ -0.04, 1.19 ]
Ergun 2013 40 6.88 (6.76) 20 5.15 (5.18) 9.6 % 0.27 [ -0.27, 0.81 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 9.8 % -0.51 [ -1.04, 0.01 ]
Cantarero-Villanueva 2013 32 45.58 (9.68) 29 53.71 (11.6) 9.8 % -0.75 [ -1.28, -0.23 ]
Daley 2007 33 6 (6.47) 33 10.33 (7.19) 10.1 % -0.63 [ -1.12, -0.13 ]
Cadmus 2009 37 9.6 (9.3) 37 10.8 (10.1) 10.6 % -0.12 [ -0.58, 0.33 ]
Kiecolt-Glaser 2014 96 8.1 (8.6) 90 9.2 (8.2) 12.7 % -0.13 [ -0.42, 0.16 ]
Subtotal (95% CI) 349 308 100.0 % -0.34 [ -0.62, -0.05 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 30.12, df = 11 (P = 0.002); I2 =63%
Test for overall effect: Z = 2.32 (P = 0.020)
2 Follow-up
Bower 2011 16 9.9 (8) 15 10.5 (7.9) 10.4 % -0.07 [ -0.78, 0.63 ]
Cantarero-Villanueva 2013 32 46.03 (9.01) 29 52.68 (11.84) 18.7 % -0.63 [ -1.14, -0.11 ]
Daley 2007 31 6.52 (6.95) 31 9.55 (7) 19.5 % -0.43 [ -0.93, 0.07 ]
Kiecolt-Glaser 2014 96 8.5 (8.62) 90 9.7 (8.25) 51.3 % -0.14 [ -0.43, 0.15 ]
Subtotal (95% CI) 175 165 100.0 % -0.28 [ -0.51, -0.05 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.30, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 2.38 (P = 0.017)
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Analysis 3.2. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 2 Overall
depression (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 3 Comparison: depression, all physical activity vs control
Outcome: 2 Overall depression (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Naumann 2012 11 -3.6 (4.34) 10 2 (4.55) 6.9 % -1.21 [ -2.16, -0.26 ]
Rogers 2014 20 -1.7 (6.9) 22 1.1 (4.2) 11.9 % -0.49 [ -1.10, 0.13 ]
Ergun 2013 40 1.22 (6.19) 20 2.35 (8.03) 13.7 % -0.16 [ -0.70, 0.37 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 14.0 % -0.51 [ -1.04, 0.01 ]
Cantarero-Villanueva 2013 32 -2.95 (7.82) 29 1.46 (7.36) 14.3 % -0.57 [ -1.09, -0.06 ]
Cadmus 2009 37 0.3 (6.4) 37 1.7 (6.3) 15.7 % -0.22 [ -0.68, 0.24 ]
Saarto 2012 263 -0.3 (3.31) 237 -0.5 (3.38) 23.6 % 0.06 [ -0.12, 0.24 ]
Subtotal (95% CI) 433 383 100.0 % -0.34 [ -0.63, -0.05 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 15.81, df = 6 (P = 0.01); I2 =62%
Test for overall effect: Z = 2.28 (P = 0.023)
2 Follow-up
Cantarero-Villanueva 2013 32 -2.51 (7.79) 29 0.43 (4.1) 100.0 % -0.46 [ -0.97, 0.05 ]
Subtotal (95% CI) 32 29 100.0 % -0.46 [ -0.97, 0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.77 (P = 0.077)
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Analysis 3.3. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 3 Beck
Depression Inventory-II (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 3 Comparison: depression, all physical activity vs control
Outcome: 3 Beck Depression Inventory-II (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Bower 2011 16 7.7 (5.8) 15 11.6 (7.1) 16.0 % -3.90 [ -8.48, 0.68 ]
Kaltsatou 2011 13 16.54 (1.66) 13 22.33 (7.73) 16.9 % -5.79 [ -10.09, -1.49 ]
Daley 2007 33 6 (6.47) 33 10.33 (7.19) 20.6 % -4.33 [ -7.63, -1.03 ]
Ergun 2013 40 6.88 (6.76) 20 5.15 (5.18) 21.4 % 1.73 [ -1.36, 4.82 ]
Segar 1998 10 5.5 (2) 5 10 (2) 25.1 % -4.50 [ -6.65, -2.35 ]
Subtotal (95% CI) 112 86 100.0 % -3.25 [ -5.94, -0.56 ]
Heterogeneity: Tau2 = 6.31; Chi2 = 13.11, df = 4 (P = 0.01); I2 =69%
Test for overall effect: Z = 2.37 (P = 0.018)
2 Follow-up
Bower 2011 16 9.9 (8) 15 10.5 (7.9) 27.8 % -0.60 [ -6.20, 5.00 ]
Daley 2007 31 6.52 (6.95) 31 9.55 (7) 72.2 % -3.03 [ -6.50, 0.44 ]
Subtotal (95% CI) 47 46 100.0 % -2.35 [ -5.31, 0.60 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.52, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 1.56 (P = 0.12)
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Analysis 3.4. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 4 Beck
Depression Inventory-II (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 3 Comparison: depression, all physical activity vs control
Outcome: 4 Beck Depression Inventory-II (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Ergun 2013 40 1.22 (6.19) 20 2.35 (8.03) 27.8 % -1.13 [ -5.14, 2.88 ]
Naumann 2012 11 -3.6 (4.34) 10 2 (4.55) 28.8 % -5.60 [ -9.41, -1.79 ]
Saarto 2012 263 -0.3 (3.31) 237 -0.5 (3.38) 43.4 % 0.20 [ -0.39, 0.79 ]
Subtotal (95% CI) 314 267 100.0 % -1.84 [ -5.33, 1.65 ]
Heterogeneity: Tau2 = 7.21; Chi2 = 9.02, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 1.03 (P = 0.30)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 3.5. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 5 CES-
Depression scale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 3 Comparison: depression, all physical activity vs control
Outcome: 5 CES-Depression scale (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Payne 2008 10 12.7 (8.7) 10 11.4 (7.9) 7.8 % 1.30 [ -5.98, 8.58 ]
Cadmus 2009 37 9.6 (9.3) 37 10.8 (10.1) 21.2 % -1.20 [ -5.62, 3.22 ]
Kiecolt-Glaser 2014 96 8.1 (8.6) 90 9.8 (8.2) 71.0 % -1.70 [ -4.11, 0.71 ]
Subtotal (95% CI) 143 137 100.0 % -1.36 [ -3.39, 0.67 ]
Heterogeneity: Chi2 = 0.59, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.31 (P = 0.19)
2 Follow-up
Kiecolt-Glaser 2014 96 8.5 (8.62) 90 10.4 (8.25) 100.0 % -1.90 [ -4.32, 0.52 ]
Subtotal (95% CI) 96 90 100.0 % -1.90 [ -4.32, 0.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
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Analysis 3.6. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 6 POMS
depression subscale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 3 Comparison: depression, all physical activity vs control
Outcome: 6 POMS depression subscale (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Pinto 2003 12 6.17 (7.2) 6 9.83 (6.8) 38.8 % -3.66 [ -10.46, 3.14 ]
Cantarero-Villanueva 2013 32 45.58 (9.68) 29 53.71 (11.6) 61.2 % -8.13 [ -13.52, -2.74 ]
Subtotal (95% CI) 44 35 100.0 % -6.39 [ -10.66, -2.12 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 2.93 (P = 0.0033)
2 Follow-up
Cantarero-Villanueva 2013 32 46.03 (9.01) 29 52.68 (11.84) 100.0 % -6.65 [ -11.97, -1.33 ]
Subtotal (95% CI) 32 29 100.0 % -6.65 [ -11.97, -1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.45 (P = 0.014)
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Analysis 3.7. Comparison 3 Comparison: depression, all physical activity vs control, Outcome 7 POMS
tension subscale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 3 Comparison: depression, all physical activity vs control
Outcome: 7 POMS tension subscale (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cantarero-Villanueva 2013 32 42.51 (8.6) 29 49.93 (11.66) 49.3 % -7.42 [ -12.61, -2.23 ]
Pinto 2003 12 7.58 (7.3) 6 10.5 (3.7) 50.7 % -2.92 [ -8.00, 2.16 ]
Subtotal (95% CI) 44 35 100.0 % -5.14 [ -9.55, -0.73 ]
Heterogeneity: Tau2 = 3.26; Chi2 = 1.48, df = 1 (P = 0.22); I2 =32%
Test for overall effect: Z = 2.28 (P = 0.022)
2 Follow-up
Cantarero-Villanueva 2013 32 43.97 (9.47) 29 48.84 (11.17) 100.0 % -4.87 [ -10.09, 0.35 ]
Subtotal (95% CI) 32 29 100.0 % -4.87 [ -10.09, 0.35 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
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Analysis 4.1. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 1
Overall fatigue (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 1 Overall fatigue (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Banasik 2011 7 1 (0.89) 7 1.57 (0.98) 1.5 % -0.57 [ -1.65, 0.51 ]
Pinto 2003 12 7.16 (6.4) 6 9 (6.4) 1.7 % -0.27 [ -1.26, 0.71 ]
Payne 2008 9 4.7 (2.6) 9 3.5 (1.7) 1.8 % 0.52 [ -0.42, 1.46 ]
Rogers 2013 11 4.2 (1.8) 9 4.2 (1.6) 2.0 % 0.0 [ -0.88, 0.88 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 2.3 % -0.07 [ -0.89, 0.75 ]
Bower 2011 16 3.4 (1.8) 15 4.9 (1.3) 2.6 % -0.93 [ -1.67, -0.18 ]
Rogers 2009 20 -12.4 (10.4) 18 -10.1 (6.6) 3.2 % -0.26 [ -0.90, 0.38 ]
Cuesta-Vargas 2014 22 4 (1.8) 20 5.2 (3.2) 3.3 % -0.46 [ -1.07, 0.15 ]
Rogers 2014 20 4.1 (2.1) 22 4 (1.8) 3.4 % 0.05 [ -0.56, 0.66 ]
Milne 2008 29 11.9 (3.2) 29 17.4 (4.7) 3.6 % -1.35 [ -1.92, -0.78 ]
Cantarero-Villanueva 2013 32 3.78 (1.78) 29 6.23 (1.72) 3.7 % -1.38 [ -1.94, -0.82 ]
Courneya 2003 24 -8.3 (7.9) 28 -8.8 (8.1) 3.8 % 0.06 [ -0.48, 0.61 ]
Ergun 2013 40 2.94 (2.24) 20 3.3 (1.79) 3.9 % -0.17 [ -0.71, 0.37 ]
Mehnert 2011 30 28.52 (25.58) 27 39.92 (25.09) 3.9 % -0.44 [ -0.97, 0.08 ]
Littman 2012 30 -45 (5.3) 27 -43.1 (10.3) 4.0 % -0.23 [ -0.75, 0.29 ]
Do 2015 32 16.8 (13.3) 30 22.3 (15.1) 4.1 % -0.38 [ -0.89, 0.12 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 4.2 % -0.71 [ -1.21, -0.21 ]
Winters-Stone 2011 36 45 (5.3) 31 43.1 (10.3) 4.3 % 0.23 [ -0.25, 0.72 ]
Cadmus 2009 37 -51.9 (9) 37 -50.6 (10) 4.5 % -0.14 [ -0.59, 0.32 ]
Pinto 2015 39 -43.83 (7.8) 37 -41.22 (8.49) 4.6 % -0.32 [ -0.77, 0.14 ]
Pinto 2005 39 27.08 (21.41) 43 42.28 (26.2) 4.6 % -0.63 [ -1.07, -0.18 ]
Loh 2014 63 -41.94 (6.49) 32 -40.38 (9.08) 4.8 % -0.21 [ -0.63, 0.22 ]
Fillion 2008 44 2.65 (0.72) 43 2.86 (0.83) 4.8 % -0.27 [ -0.69, 0.15 ]
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(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Kiecolt-Glaser 2014 96 6.3 (19.6) 90 12.7 (18.97) 6.2 % -0.33 [ -0.62, -0.04 ]
Vallance 2007 250 -42.7 (8.4) 85 -42.6 (8.7) 6.6 % -0.01 [ -0.26, 0.23 ]
Short 2014 195 -41.5 (9.3) 104 -39.8 (10.4) 6.7 % -0.17 [ -0.41, 0.06 ]
Subtotal (95% CI) 1178 842 100.0 % -0.32 [ -0.47, -0.18 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 53.85, df = 25 (P = 0.00069); I2 =54%
Test for overall effect: Z = 4.34 (P = 0.000014)
2 Follow-up
Bower 2011 16 2.8 (2.3) 15 4.7 (1.5) 5.3 % -0.95 [ -1.69, -0.20 ]
Rogers 2009 19 -13.8 (11.7) 17 -13.5 (11.3) 6.9 % -0.03 [ -0.68, 0.63 ]
Cantarero-Villanueva 2013 32 4.01 (2.08) 29 5.47 (1.82) 10.9 % -0.74 [ -1.26, -0.21 ]
Daley 2007 28 2.42 (1.95) 31 3.2 (2.18) 11.1 % -0.37 [ -0.89, 0.14 ]
Pinto 2015 39 -42.2 (7.77) 37 -40.4 (9.32) 14.5 % -0.21 [ -0.66, 0.24 ]
Fillion 2008 44 2.4 (0.84) 43 2.75 (0.93) 16.4 % -0.39 [ -0.82, 0.03 ]
Kiecolt-Glaser 2014 96 5.8 (19.6) 90 14.7 (18.97) 34.8 % -0.46 [ -0.75, -0.17 ]
Subtotal (95% CI) 274 262 100.0 % -0.43 [ -0.60, -0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.67, df = 6 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 4.88 (P < 0.00001)
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Analysis 4.2. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 2
Overall fatigue (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 2 Overall fatigue (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 -4.2 (19.6) 8 6.4 (14.5) 5.1 % -0.58 [ -1.59, 0.43 ]
Payne 2008 9 -0.93 (1.95) 9 0.52 (1.38) 5.3 % -0.82 [ -1.79, 0.15 ]
Naumann 2012 11 -3.6 (4.35) 10 2 (4.55) 5.4 % -1.21 [ -2.16, -0.26 ]
Rogers 2013 11 4.2 (2) 9 3.9 (1.5) 5.9 % 0.16 [ -0.72, 1.04 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 6.3 % -0.07 [ -0.89, 0.75 ]
Rogers 2009 20 1.9 (9.6) 18 4.2 (12.3) 7.6 % -0.21 [ -0.84, 0.43 ]
Courneya 2003 24 9.3 (10.2) 28 2 (7.5) 8.2 % 0.81 [ 0.24, 1.38 ]
Cantarero-Villanueva 2013 32 -2 (1.75) 29 0.34 (1.39) 8.2 % -1.45 [ -2.02, -0.88 ]
Mehnert 2011 30 -0.74 (20.73) 27 -2.88 (25.3) 8.6 % 0.09 [ -0.43, 0.61 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 8.7 % -0.71 [ -1.21, -0.21 ]
Pinto 2005 39 -14.93 (23.54) 43 1.79 (23.48) 9.2 % -0.70 [ -1.15, -0.26 ]
Vallance 2007 250 2.49 (8.17) 85 1.15 (6.61) 10.6 % 0.17 [ -0.08, 0.42 ]
Saarto 2012 263 -2.4 (9.06) 237 -2.4 (8.6) 11.0 % 0.0 [ -0.18, 0.18 ]
Subtotal (95% CI) 742 547 100.0 % -0.30 [ -0.61, 0.00 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 59.54, df = 12 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.94 (P = 0.052)
2 Follow-up
Pinto 2005 8 3.01 (0) 14 4.58 (0) Not estimable
Rogers 2009 19 -0.08 (7.8) 17 1.2 (8.6) 25.8 % -0.15 [ -0.81, 0.50 ]
Cantarero-Villanueva 2013 32 -1.77 (2) 29 -0.42 (1.16) 36.7 % -0.81 [ -1.33, -0.28 ]
Daley 2007 28 2.42 (1.95) 31 3.2 (2.18) 37.5 % -0.37 [ -0.89, 0.14 ]
Subtotal (95% CI) 87 91 100.0 % -0.47 [ -0.84, -0.11 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.61, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 2.52 (P = 0.012)
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Analysis 4.3. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 3
FACT-Fatigue (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 3 FACT-Fatigue (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2009 20 12.4 (10.4) 18 10.1 (6.6) 4.8 % 2.30 [ -3.18, 7.78 ]
Courneya 2003 24 8.3 (7.9) 28 8.8 (8.1) 7.6 % -0.50 [ -4.86, 3.86 ]
Littman 2012 30 45 (5.3) 27 43.1 (10.3) 7.7 % 1.90 [ -2.42, 6.22 ]
Pinto 2015 39 43.83 (7.8) 37 41.22 (8.49) 10.7 % 2.61 [ -1.06, 6.28 ]
Loh 2014 63 41.94 (6.49) 32 40.38 (9.08) 11.6 % 1.56 [ -1.97, 5.09 ]
Short 2014 195 41.5 (9.3) 104 39.8 (10.4) 25.4 % 1.70 [ -0.69, 4.09 ]
Vallance 2007 250 42.7 (8.4) 85 42.6 (8.7) 32.1 % 0.10 [ -2.02, 2.22 ]
Subtotal (95% CI) 621 331 100.0 % 1.14 [ -0.06, 2.35 ]
Heterogeneity: Chi2 = 2.64, df = 6 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.86 (P = 0.062)
2 Follow-up
Rogers 2009 19 13.8 (11.7) 17 13.5 (11.3) 20.9 % 0.30 [ -7.22, 7.82 ]
Pinto 2015 39 42.2 (7.77) 37 40.4 (9.32) 79.1 % 1.80 [ -2.07, 5.67 ]
Subtotal (95% CI) 58 54 100.0 % 1.49 [ -1.95, 4.93 ]
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
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Analysis 4.4. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 4
FACT-Fatigue (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 4 FACT-Fatigue (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 -1.9 (9.6) 18 -4.2 (12.3) 10.7 % 2.30 [ -4.77, 9.37 ]
Courneya 2003 24 -9.3 (10.2) 28 -2 (7.5) 17.3 % -7.30 [ -12.24, -2.36 ]
Vallance 2007 250 2.49 (8.17) 85 1.15 (6.61) 35.5 % 1.34 [ -0.39, 3.07 ]
Saarto 2012 263 2.4 (9.06) 237 2.4 (8.6) 36.5 % 0.0 [ -1.55, 1.55 ]
Subtotal (95% CI) 557 368 100.0 % -0.54 [ -3.23, 2.14 ]
Heterogeneity: Tau2 = 4.51; Chi2 = 10.93, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 0.39 (P = 0.69)
2 Follow-up
Rogers 2009 19 0.08 (7.8) 17 -1.2 (8.6) 100.0 % 1.28 [ -4.11, 6.67 ]
Subtotal (95% CI) 19 17 100.0 % 1.28 [ -4.11, 6.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
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Analysis 4.5. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 5
EORTC QLQ-C30 Fatigue scale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 5 EORTC QLQ-C30 Fatigue scale (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mehnert 2011 30 28.52 (25.58) 27 39.92 (25.09) 22.5 % -11.40 [ -24.57, 1.77 ]
Do 2015 32 16.8 (13.3) 30 22.3 (15.1) 77.5 % -5.50 [ -12.60, 1.60 ]
Subtotal (95% CI) 62 57 100.0 % -6.83 [ -13.08, -0.58 ]
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.032)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 4.6. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 6
EORTC QLQ-C30 Fatigue scale (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 6 EORTC QLQ-C30 Fatigue scale (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 -4.2 (19.6) 8 6.4 (14.5) 38.8 % -10.60 [ -27.49, 6.29 ]
Mehnert 2011 30 -0.74 (20.73) 27 -2.88 (25.3) 61.2 % 2.14 [ -9.95, 14.23 ]
Subtotal (95% CI) 38 35 100.0 % -2.81 [ -14.98, 9.36 ]
Heterogeneity: Tau2 = 24.99; Chi2 = 1.44, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.45 (P = 0.65)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 4.7. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 7
Multidimensional Fatigue Symptom Inventory (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 7 Multidimensional Fatigue Symptom Inventory (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Kiecolt-Glaser 2014 96 6.3 (19.6) 90 12.7 (18.97) 2.1 % -6.40 [ -11.94, -0.86 ]
Rogers 2013 11 4.2 (1.8) 9 4.2 (1.6) 17.0 % 0.0 [ -1.49, 1.49 ]
Rogers 2014 20 4.1 (2.1) 22 4 (1.8) 21.4 % 0.10 [ -1.09, 1.29 ]
Bower 2011 16 3.4 (1.8) 15 4.9 (1.3) 22.9 % -1.50 [ -2.60, -0.40 ]
Fillion 2008 44 2.65 (0.72) 43 2.86 (0.83) 36.7 % -0.21 [ -0.54, 0.12 ]
Subtotal (95% CI) 187 179 100.0 % -0.53 [ -1.35, 0.29 ]
Heterogeneity: Tau2 = 0.45; Chi2 = 10.10, df = 4 (P = 0.04); I2 =60%
Test for overall effect: Z = 1.27 (P = 0.20)
2 Follow-up
Kiecolt-Glaser 2014 96 5.8 (19.6) 90 14.7 (18.97) 12.4 % -8.90 [ -14.44, -3.36 ]
Bower 2011 16 2.8 (2.3) 15 4.7 (1.5) 40.6 % -1.90 [ -3.26, -0.54 ]
Fillion 2008 44 2.4 (0.84) 43 2.75 (0.93) 47.0 % -0.35 [ -0.72, 0.02 ]
Subtotal (95% CI) 156 148 100.0 % -2.04 [ -4.30, 0.23 ]
Heterogeneity: Tau2 = 2.81; Chi2 = 13.52, df = 2 (P = 0.001); I2 =85%
Test for overall effect: Z = 1.76 (P = 0.078)
-20 -10 0 10 20
Favours physical activity Favours control
387Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.8. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 8
Multidimensional Fatigue Symptom Inventory - interference (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 8 Multidimensional Fatigue Symptom Inventory - interference (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2013 11 2.6 (1.5) 9 2.4 (1.1) 42.9 % 0.20 [ -0.94, 1.34 ]
Rogers 2014 20 1.8 (0.8) 22 2.6 (1.9) 57.1 % -0.80 [ -1.67, 0.07 ]
Subtotal (95% CI) 31 31 100.0 % -0.37 [ -1.34, 0.60 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 1.87, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.75 (P = 0.45)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 4.9. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 9
Revised Piper Fatigue Scale total fatigue (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 9 Revised Piper Fatigue Scale total fatigue (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Payne 2008 9 4.7 (2.6) 9 3.5 (1.7) 17.7 % 1.20 [ -0.83, 3.23 ]
Cuesta-Vargas 2014 22 4 (1.8) 20 5.2 (3.2) 22.0 % -1.20 [ -2.79, 0.39 ]
Cantarero-Villanueva 2013 32 3.78 (1.78) 29 6.23 (1.72) 30.1 % -2.45 [ -3.33, -1.57 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 30.2 % -1.30 [ -2.17, -0.43 ]
Subtotal (95% CI) 96 91 100.0 % -1.18 [ -2.38, 0.02 ]
Heterogeneity: Tau2 = 1.05; Chi2 = 11.59, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 1.93 (P = 0.054)
2 Follow-up
Daley 2007 28 2.42 (1.95) 31 3.2 (2.18) 46.3 % -0.78 [ -1.83, 0.27 ]
Cantarero-Villanueva 2013 32 4.01 (2.08) 29 5.47 (1.82) 53.7 % -1.46 [ -2.44, -0.48 ]
Subtotal (95% CI) 60 60 100.0 % -1.15 [ -1.86, -0.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.86, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 3.13 (P = 0.0018)
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Analysis 4.10. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 10
Revised Piper Fatigue Scale total fatigue (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 10 Revised Piper Fatigue Scale total fatigue (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Naumann 2012 11 -3.6 (4.35) 10 2 (4.55) 5.7 % -5.60 [ -9.42, -1.78 ]
Payne 2008 9 -0.93 (1.95) 9 0.52 (1.38) 21.7 % -1.45 [ -3.01, 0.11 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 35.4 % -1.30 [ -2.17, -0.43 ]
Cantarero-Villanueva 2013 32 -2 (1.75) 29 0.34 (1.39) 37.2 % -2.34 [ -3.13, -1.55 ]
Subtotal (95% CI) 85 81 100.0 % -1.96 [ -2.93, -1.00 ]
Heterogeneity: Tau2 = 0.49; Chi2 = 6.96, df = 3 (P = 0.07); I2 =57%
Test for overall effect: Z = 3.98 (P = 0.000070)
2 Follow-up
Daley 2007 28 2.42 (1.95) 31 3.2 (2.18) 37.2 % -0.78 [ -1.83, 0.27 ]
Cantarero-Villanueva 2013 32 -1.77 (2) 29 -0.42 (1.16) 62.8 % -1.35 [ -2.16, -0.54 ]
Subtotal (95% CI) 60 60 100.0 % -1.14 [ -1.78, -0.49 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 3.47 (P = 0.00052)
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Analysis 4.11. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 11
Revised Piper Fatigue Scale behavioural/severity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 11 Revised Piper Fatigue Scale behavioural/severity (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Payne 2008 9 3.4 (3.2) 9 2.9 (1.8) 17.9 % 0.50 [ -1.90, 2.90 ]
Cantarero-Villanueva 2013 32 3.78 (1.95) 29 6.05 (1.82) 40.0 % -2.27 [ -3.22, -1.32 ]
Cuesta-Vargas 2014 22 3.7 (0.9) 20 4.7 (1.71) 42.1 % -1.00 [ -1.84, -0.16 ]
Subtotal (95% CI) 63 58 100.0 % -1.24 [ -2.49, 0.01 ]
Heterogeneity: Tau2 = 0.79; Chi2 = 6.52, df = 2 (P = 0.04); I2 =69%
Test for overall effect: Z = 1.94 (P = 0.052)
2 Follow-up
Cantarero-Villanueva 2013 32 4.04 (2.22) 29 5.45 (2.38) 100.0 % -1.41 [ -2.57, -0.25 ]
Subtotal (95% CI) 32 29 100.0 % -1.41 [ -2.57, -0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
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Analysis 4.12. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 12
Revised Piper Fatigue Scale affective/meaning (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 12 Revised Piper Fatigue Scale affective/meaning (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Cuesta-Vargas 2014 22 4.2 (6.32) 20 6.1 (2.99) 9.6 % -1.90 [ -4.85, 1.05 ]
Payne 2008 9 5.8 (2.2) 9 4.8 (2.3) 19.4 % 1.00 [ -1.08, 3.08 ]
Cantarero-Villanueva 2013 32 3.82 (2.31) 29 6.81 (2.02) 71.0 % -2.99 [ -4.08, -1.90 ]
Subtotal (95% CI) 63 58 100.0 % -2.11 [ -3.03, -1.20 ]
Heterogeneity: Chi2 = 11.13, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 4.52 (P < 0.00001)
2 Follow-up
Cantarero-Villanueva 2013 32 4.42 (2.42) 29 6.47 (2.2) 100.0 % -2.05 [ -3.21, -0.89 ]
Subtotal (95% CI) 32 29 100.0 % -2.05 [ -3.21, -0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.47 (P = 0.00053)
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Analysis 4.13. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 13
Revised Piper Fatigue Scale sensory (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 13 Revised Piper Fatigue Scale sensory (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cuesta-Vargas 2014 22 4.8 (5.19) 20 5.3 (2.35) 30.0 % -0.50 [ -2.90, 1.90 ]
Payne 2008 9 5.9 (2.3) 9 4.1 (2) 32.5 % 1.80 [ -0.19, 3.79 ]
Cantarero-Villanueva 2013 32 3.92 (1.88) 29 6.25 (2.06) 37.6 % -2.33 [ -3.32, -1.34 ]
Subtotal (95% CI) 63 58 100.0 % -0.44 [ -3.11, 2.22 ]
Heterogeneity: Tau2 = 4.66; Chi2 = 13.83, df = 2 (P = 0.00099); I2 =86%
Test for overall effect: Z = 0.32 (P = 0.75)
2 Follow-up
Cantarero-Villanueva 2013 32 4.08 (2.25) 29 5.68 (1.93) 100.0 % -1.60 [ -2.65, -0.55 ]
Subtotal (95% CI) 32 29 100.0 % -1.60 [ -2.65, -0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.99 (P = 0.0028)
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Analysis 4.14. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 14
Revised Piper Fatigue Scale cognitive/mood (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 14 Revised Piper Fatigue Scale cognitive/mood (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cuesta-Vargas 2014 22 5.1 (4.51) 20 5.3 (2.35) 26.3 % -0.20 [ -2.35, 1.95 ]
Payne 2008 9 2.9 (1.8) 9 2.5 (1.9) 32.0 % 0.40 [ -1.31, 2.11 ]
Cantarero-Villanueva 2013 32 3.75 (1.87) 29 5.66 (2.25) 41.7 % -1.91 [ -2.95, -0.87 ]
Subtotal (95% CI) 63 58 100.0 % -0.72 [ -2.31, 0.87 ]
Heterogeneity: Tau2 = 1.29; Chi2 = 5.94, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 0.89 (P = 0.37)
2 Follow-up
Cantarero-Villanueva 2013 32 3.69 (1.97) 29 5.09 (2.37) 100.0 % -1.40 [ -2.50, -0.30 ]
Subtotal (95% CI) 32 29 100.0 % -1.40 [ -2.50, -0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
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Analysis 4.15. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 15
Schwartz Cancer Fatigue Scale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 15 Schwartz Cancer Fatigue Scale (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Winters-Stone 2011 36 45 (5.3) 31 43.1 (10.3) 47.2 % 1.90 [ -2.12, 5.92 ]
Milne 2008 29 11.9 (3.2) 29 17.4 (4.7) 52.8 % -5.50 [ -7.57, -3.43 ]
Subtotal (95% CI) 65 60 100.0 % -2.01 [ -9.25, 5.23 ]
Heterogeneity: Tau2 = 24.72; Chi2 = 10.30, df = 1 (P = 0.001); I2 =90%
Test for overall effect: Z = 0.54 (P = 0.59)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 4.16. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 16
POMS fatigue scale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 16 POMS fatigue scale (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Pinto 2003 12 7.16 (6.4) 6 9 (6.4) 21.5 % -0.27 [ -1.26, 0.71 ]
Cantarero-Villanueva 2013 32 47.79 (8.11) 29 53.34 (9.82) 78.5 % -0.61 [ -1.13, -0.10 ]
Subtotal (95% CI) 44 35 100.0 % -0.54 [ -1.00, -0.08 ]
Heterogeneity: Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 2.31 (P = 0.021)
2 Follow-up
Cantarero-Villanueva 2013 32 47.41 (10.61) 29 53.31 (9.84) 100.0 % -0.57 [ -1.08, -0.05 ]
Subtotal (95% CI) 32 29 100.0 % -0.57 [ -1.08, -0.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
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Analysis 4.17. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 17
Visual analogue scale fatigue (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 17 Visual analogue scale fatigue (follow-up and change values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Carson 2009 12 2.87 (0) 17 4.34 (0) Not estimable
Banasik 2011 7 1 (0.89) 7 1.57 (0.98) 11.6 % -0.57 [ -1.65, 0.51 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 20.1 % -0.07 [ -0.89, 0.75 ]
Pinto 2005 39 27.08 (21.41) 43 42.28 (26.2) 68.3 % -0.63 [ -1.07, -0.18 ]
Subtotal (95% CI) 70 78 100.0 % -0.51 [ -0.88, -0.14 ]
Heterogeneity: Chi2 = 1.37, df = 2 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.71 (P = 0.0066)
2 Follow-up
Pinto 2005 (1) 8 3.01 (0) 14 4.58 (0) Not estimable
Subtotal (95% CI) 8 14 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 4.18. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 18
Overall vigour/vitality (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 18 Overall vigour/vitality (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Pinto 2003 12 17.75 (6.4) 6 14.17 (7.3) 2.1 % 0.51 [ -0.49, 1.51 ]
Mustian 2004 9 15.22 (5.37) 10 15.2 (4.74) 2.6 % 0.00 [ -0.90, 0.90 ]
Basen-Enquist 2006 28 60.9 (11.64) 23 58.1 (11.99) 6.9 % 0.23 [ -0.32, 0.79 ]
Mehnert 2011 30 64.22 (17.08) 28 56.13 (19.58) 7.8 % 0.44 [ -0.09, 0.96 ]
Cantarero-Villanueva 2013 32 51.62 (7.15) 29 50.46 (7.63) 8.4 % 0.16 [ -0.35, 0.66 ]
Cadmus 2009 37 51.9 (9) 37 50.6 (10) 10.2 % 0.14 [ -0.32, 0.59 ]
Pinto 2005 39 20.58 (5.7) 43 15.81 (5.39) 10.3 % 0.85 [ 0.40, 1.31 ]
Fillion 2008 44 2.41 (0.72) 43 2.14 (0.87) 11.9 % 0.34 [ -0.09, 0.76 ]
Duijits 2012 37 65.22 (16.83) 89 59.74 (16.4) 14.3 % 0.33 [ -0.06, 0.72 ]
Kiecolt-Glaser 2014 96 58.7 (18.62) 90 52.3 (16.13) 25.3 % 0.37 [ 0.08, 0.66 ]
Subtotal (95% CI) 364 398 100.0 % 0.36 [ 0.21, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.11, df = 9 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 4.78 (P < 0.00001)
2 Follow-up
Cantarero-Villanueva 2013 32 50.27 (9.42) 29 51.06 (8.15) 16.4 % -0.09 [ -0.59, 0.41 ]
Fillion 2008 44 2.63 (0.72) 43 2.24 (0.88) 21.5 % 0.48 [ 0.05, 0.91 ]
Duijits 2012 36 61.19 (18.5) 84 59.01 (18.03) 24.6 % 0.12 [ -0.27, 0.51 ]
Kiecolt-Glaser 2014 96 58.1 (18.62) 90 51.6 (16.13) 37.5 % 0.37 [ 0.08, 0.66 ]
Subtotal (95% CI) 208 246 100.0 % 0.26 [ 0.04, 0.48 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.93, df = 3 (P = 0.27); I2 =24%
Test for overall effect: Z = 2.27 (P = 0.023)
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Analysis 4.19. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 19
Overall vigour/vitality (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 19 Overall vigour/vitality (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 9 2 (3.99) 9 0.4 (2.07) 5.5 % 0.48 [ -0.46, 1.42 ]
Cormie 2014 43 3.41 (8.4) 19 1 (8.12) 15.5 % 0.29 [ -0.26, 0.83 ]
Mehnert 2011 30 6.89 (16.68) 28 3.99 (19) 17.0 % 0.16 [ -0.36, 0.68 ]
Cantarero-Villanueva 2013 32 -1.93 (17.25) 29 -0.37 (5.7311) 17.8 % -0.12 [ -0.62, 0.39 ]
Cadmus 2009 37 1.6 (6.6) 37 1.2 (7.1) 21.1 % 0.06 [ -0.40, 0.51 ]
Pinto 2005 43 2.51 (6.75) 43 -1.33 (5.97) 23.2 % 0.60 [ 0.16, 1.03 ]
Subtotal (95% CI) 194 165 100.0 % 0.23 [ 0.00, 0.45 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.53, df = 5 (P = 0.35); I2 =10%
Test for overall effect: Z = 1.99 (P = 0.046)
2 Follow-up
Cantarero-Villanueva 2013 32 0.58 (8.2377) 29 0.22 (3.628) 26.3 % 0.05 [ -0.45, 0.56 ]
Pinto 2005 86 1.05 (6.78) 86 -0.59 (6.3) 73.7 % 0.25 [ -0.05, 0.55 ]
Subtotal (95% CI) 118 115 100.0 % 0.20 [ -0.06, 0.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
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Analysis 4.20. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 20
MOS SF vitality (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 20 MOS SF vitality (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mehnert 2011 30 64.22 (17.08) 28 56.13 (19.58) 5.6 % 8.09 [ -1.39, 17.57 ]
Basen-Enquist 2006 28 60.9 (11.64) 23 58.1 (11.99) 11.7 % 2.80 [ -3.73, 9.33 ]
Duijits 2012 37 65.22 (16.83) 89 59.74 (16.4) 12.2 % 5.48 [ -0.92, 11.88 ]
Kiecolt-Glaser 2014 96 58.7 (18.62) 90 52.3 (16.13) 20.0 % 6.40 [ 1.40, 11.40 ]
Mustian 2004 9 15.22 (5.37) 10 15.2 (4.74) 23.9 % 0.02 [ -4.56, 4.60 ]
Cadmus 2009 37 51.9 (9) 37 50.6 (10) 26.6 % 1.30 [ -3.03, 5.63 ]
Subtotal (95% CI) 237 277 100.0 % 3.08 [ 0.84, 5.31 ]
Heterogeneity: Chi2 = 5.68, df = 5 (P = 0.34); I2 =12%
Test for overall effect: Z = 2.70 (P = 0.0070)
2 Follow-up
Duijits 2012 36 61.19 (18.5) 84 59.01 (18.03) 32.7 % 2.18 [ -4.99, 9.35 ]
Kiecolt-Glaser 2014 96 58.1 (18.62) 90 51.6 (16.13) 67.3 % 6.50 [ 1.50, 11.50 ]
Subtotal (95% CI) 132 174 100.0 % 5.09 [ 0.99, 9.19 ]
Heterogeneity: Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 2.43 (P = 0.015)
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Analysis 4.21. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 21
MOS SF vitality (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 21 MOS SF vitality (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mehnert 2011 30 6.89 (16.68) 28 3.99 (19) 4.2 % 2.90 [ -6.33, 12.13 ]
Cormie 2014 43 3.41 (8.4) 19 1 (8.12) 18.1 % 2.41 [ -2.02, 6.84 ]
Cadmus 2009 37 1.6 (6.6) 37 1.2 (7.1) 36.5 % 0.40 [ -2.72, 3.52 ]
Mustian 2004 9 2 (3.99) 9 0.4 (2.07) 41.2 % 1.60 [ -1.34, 4.54 ]
Subtotal (95% CI) 119 93 100.0 % 1.36 [ -0.52, 3.25 ]
Heterogeneity: Chi2 = 0.71, df = 3 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 4.22. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 22
POMS vigour scale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 22 POMS vigour scale (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Pinto 2003 12 17.75 (6.4) 6 14.17 (7.3) 9.5 % 0.51 [ -0.49, 1.51 ]
Cantarero-Villanueva 2013 32 51.62 (7.15) 29 50.46 (7.63) 27.0 % 0.16 [ -0.35, 0.66 ]
Pinto 2005 39 20.58 (5.7) 43 15.81 (5.39) 30.5 % 0.85 [ 0.40, 1.31 ]
Fillion 2008 44 2.41 (0.72) 43 2.14 (0.87) 33.0 % 0.34 [ -0.09, 0.76 ]
Subtotal (95% CI) 127 121 100.0 % 0.46 [ 0.13, 0.79 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 4.63, df = 3 (P = 0.20); I2 =35%
Test for overall effect: Z = 2.74 (P = 0.0062)
2 Follow-up
Cantarero-Villanueva 2013 32 50.27 (9.42) 29 51.06 (8.15) 47.2 % -0.09 [ -0.59, 0.41 ]
Fillion 2008 44 2.63 (0.72) 43 2.24 (0.88) 52.8 % 0.48 [ 0.05, 0.91 ]
Subtotal (95% CI) 76 72 100.0 % 0.21 [ -0.34, 0.77 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 2.87, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.75 (P = 0.45)
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Analysis 4.23. Comparison 4 Comparison: fatigue and vigour, all physical activity vs control, Outcome 23
POMS vigour scale (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 4 Comparison: fatigue and vigour, all physical activity vs control
Outcome: 23 POMS vigour scale (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cantarero-Villanueva 2013 32 -1.93 (17.25) 29 -0.37 (5.7311) 48.3 % -0.12 [ -0.62, 0.39 ]
Pinto 2005 43 2.51 (6.75) 43 -1.33 (5.97) 51.7 % 0.60 [ 0.16, 1.03 ]
Subtotal (95% CI) 75 72 100.0 % 0.25 [ -0.45, 0.95 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 4.46, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 0.71 (P = 0.48)
2 Follow-up
Cantarero-Villanueva 2013 32 0.58 (8.2377) 29 0.22 (3.628) 26.3 % 0.05 [ -0.45, 0.56 ]
Pinto 2005 86 1.05 (6.78) 86 -0.59 (6.3) 73.7 % 0.25 [ -0.05, 0.55 ]
Subtotal (95% CI) 118 115 100.0 % 0.20 [ -0.06, 0.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.42, df = 1 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.50 (P = 0.13)
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Analysis 5.1. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 1 Overall
pain/disability (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 1 Overall pain/disability (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 9 9.11 (1.35) 10 9.1 (1.74) 3.6 % 0.01 [ -0.89, 0.91 ]
Loudon 2014 12 0.8 (1.48) 11 1.44 (2.24) 4.3 % -0.33 [ -1.15, 0.50 ]
Portela 2008 25 -20.6 (20.2) 9 -20.8 (15.5) 5.1 % 0.01 [ -0.75, 0.77 ]
Rogers 2009 20 -3.03 (2.98) 18 -2.28 (2.76) 7.2 % -0.26 [ -0.89, 0.38 ]
Basen-Enquist 2006 28 79.7 (10.58) 23 72.1 (11.51) 9.1 % 0.68 [ 0.11, 1.25 ]
Mehnert 2011 30 79.4 (23.1) 28 73.5 (24.83) 11.0 % 0.24 [ -0.27, 0.76 ]
Do 2015 32 21.1 (24.6) 30 16.5 (26.7) 11.8 % 0.18 [ -0.32, 0.68 ]
Cadmus 2009 37 50.3 (9.1) 37 50.8 (9) 14.2 % -0.05 [ -0.51, 0.40 ]
Duijits 2012 87 79.27 (23.59) 89 78.79 (23.78) 33.7 % 0.02 [ -0.28, 0.32 ]
Subtotal (95% CI) 280 255 100.0 % 0.08 [ -0.09, 0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.35, df = 8 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Follow-up
Duijits 2012 79 79.07 (23.41) 83 74.62 (23.68) 100.0 % 0.19 [ -0.12, 0.50 ]
Subtotal (95% CI) 79 83 100.0 % 0.19 [ -0.12, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.19 (P = 0.23)
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Analysis 5.2. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 2 Overall
pain/disability (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 2 Overall pain/disability (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 9 -0.22 (1.29) 10 0 (1.42) 7.0 % -0.15 [ -1.06, 0.75 ]
Cormie 2014 43 3.4 (6.5) 19 2 (6.2) 18.7 % 0.22 [ -0.33, 0.76 ]
Mehnert 2011 30 -2.4 (24.95) 28 -7.61 (25.2) 20.5 % 0.21 [ -0.31, 0.72 ]
Cadmus 2009 37 -2.2 (11.3) 37 -0.1 (7) 25.7 % -0.22 [ -0.68, 0.24 ]
Irwin 2015 45 -6 (18.97) 38 0.7 (18.56) 28.2 % -0.35 [ -0.79, 0.08 ]
Subtotal (95% CI) 164 132 100.0 % -0.08 [ -0.33, 0.16 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.22, df = 4 (P = 0.38); I2 =5%
Test for overall effect: Z = 0.69 (P = 0.49)
2 Follow-up
Rogers 2009 19 -0.8 (1.37) 17 -1.8 (6.21) 100.0 % 0.22 [ -0.43, 0.88 ]
Subtotal (95% CI) 19 17 100.0 % 0.22 [ -0.43, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 5.3. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 3 Brief
Pain Inventory severity score (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 3 Brief Pain Inventory severity score (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Irwin 2015 45 -1.1 (1.66) 38 0.3 (1.52) 49.5 % -1.40 [ -2.08, -0.72 ]
Cormie 2014 43 -0.3 (1.1) 19 0 (1.25) 50.5 % -0.30 [ -0.95, 0.35 ]
Subtotal (95% CI) 88 57 100.0 % -0.84 [ -1.92, 0.23 ]
Heterogeneity: Tau2 = 0.49; Chi2 = 5.21, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 1.54 (P = 0.12)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 5.4. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 4 Brief
Pain Inventory interference score (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 4 Brief Pain Inventory interference score (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cormie 2014 43 -0.55 (1.32) 19 0.1 (1.45) 49.9 % -0.65 [ -1.41, 0.11 ]
Irwin 2015 45 -1.1 (1.66) 38 0.4 (1.83) 50.1 % -1.50 [ -2.26, -0.74 ]
Subtotal (95% CI) 88 57 100.0 % -1.08 [ -1.91, -0.24 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 2.40, df = 1 (P = 0.12); I2 =58%
Test for overall effect: Z = 2.53 (P = 0.011)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 5.5. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 5 DASH
(follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 5 DASH (follow-up and change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Portela 2008 (1) 25 20.6 (20.2) 9 20.8 (15.5) 5.7 % -0.20 [ -13.05, 12.65 ]
Irwin 2015 (2) 45 -6.7 (10.98) 38 1.3 (10.95) 42.4 % -8.00 [ -12.73, -3.27 ]
Cormie 2014 (3) 43 -4.4 (7.98) 19 0.6 (7.9) 51.9 % -5.00 [ -9.28, -0.72 ]
Subtotal (95% CI) 113 66 100.0 % -6.00 [ -9.08, -2.91 ]
Heterogeneity: Chi2 = 1.68, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.81 (P = 0.00014)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 5.6. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 6 EORTC
QLQ-C30 Pain scale (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 6 EORTC QLQ-C30 Pain scale (follow-up and change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Do 2015 (1) 32 -21.1 (24.6) 30 -16.5 (26.7) 47.1 % -4.60 [ -17.40, 8.20 ]
Mehnert 2011 (2) 30 -0.74 (20.73) 27 -2.88 (25.3) 52.9 % 2.14 [ -9.95, 14.23 ]
Subtotal (95% CI) 62 57 100.0 % -1.04 [ -9.83, 7.75 ]
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 5.7. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 7 MOS SF
Pain (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 7 MOS SF Pain (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mehnert 2011 30 79.4 (23.1) 28 73.5 (24.83) 4.2 % 5.90 [ -6.47, 18.27 ]
Duijits 2012 87 79.27 (23.59) 89 78.79 (23.78) 11.3 % 0.48 [ -6.52, 7.48 ]
Basen-Enquist 2006 28 79.7 (10.58) 23 72.1 (11.51) 13.9 % 7.60 [ 1.48, 13.72 ]
Cadmus 2009 37 50.3 (9.1) 37 50.8 (9) 23.4 % -0.50 [ -4.62, 3.62 ]
Mustian 2004 9 9.11 (1.35) 10 9.1 (1.74) 47.1 % 0.01 [ -1.38, 1.40 ]
Subtotal (95% CI) 191 187 100.0 % 1.25 [ -1.40, 3.90 ]
Heterogeneity: Tau2 = 3.37; Chi2 = 6.55, df = 4 (P = 0.16); I2 =39%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Follow-up
Duijits 2012 79 79.07 (23.41) 83 74.62 (23.68) 100.0 % 4.45 [ -2.80, 11.70 ]
Subtotal (95% CI) 79 83 100.0 % 4.45 [ -2.80, 11.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
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Analysis 5.8. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 8 MOS SF
Pain (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 8 MOS SF Pain (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mehnert 2011 30 2.4 (24.95) 28 7.61 (25.2) 0.7 % -5.21 [ -18.13, 7.71 ]
Cadmus 2009 37 2.2 (11.3) 37 0.1 (7) 6.6 % 2.10 [ -2.18, 6.38 ]
Cormie 2014 43 3.4 (6.5) 19 2 (6.2) 10.6 % 1.40 [ -2.00, 4.80 ]
Mustian 2004 9 -0.22 (1.29) 10 0 (1.42) 82.1 % -0.22 [ -1.44, 1.00 ]
Subtotal (95% CI) 119 94 100.0 % 0.07 [ -1.04, 1.17 ]
Heterogeneity: Chi2 = 2.31, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.90)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 5.9. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 9 WOMAC
joint pain (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 9 WOMAC joint pain (follow-up and change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Irwin 2015 (1) 45 -6 (18.97) 38 0.7 (18.56) 27.1 % -6.70 [ -14.80, 1.40 ]
Rogers 2009 (2) 20 2.28 (2.76) 18 3.03 (2.98) 72.9 % -0.75 [ -2.58, 1.08 ]
Subtotal (95% CI) 65 56 100.0 % -2.36 [ -7.55, 2.82 ]
Heterogeneity: Tau2 = 8.73; Chi2 = 1.97, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.89 (P = 0.37)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 5.10. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 10
WOMAC physical dysfunction (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 10 WOMAC physical dysfunction (follow-up and change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Irwin 2015 (1) 45 -10.4 (15.31) 38 1.1 (15.21) 47.9 % -11.50 [ -18.09, -4.91 ]
Rogers 2009 (2) 20 6.03 (8.16) 18 7.25 (8.05) 52.1 % -1.22 [ -6.38, 3.94 ]
Subtotal (95% CI) 65 56 100.0 % -6.15 [ -16.21, 3.92 ]
Heterogeneity: Tau2 = 43.73; Chi2 = 5.80, df = 1 (P = 0.02); I2 =83%
Test for overall effect: Z = 1.20 (P = 0.23)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 5.11. Comparison 5 Comparison: pain/disability, all physical activity vs control, Outcome 11
WOMAC total score (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 5 Comparison: pain/disability, all physical activity vs control
Outcome: 11 WOMAC total score (follow-up and change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 (1) 20 10.08 (12.21) 18 12.75 (11.85) 47.1 % -2.67 [ -10.33, 4.99 ]
Irwin 2015 (2) 45 -9.4 (15.98) 38 0.5 (15.82) 52.9 % -9.90 [ -16.76, -3.04 ]
Subtotal (95% CI) 65 56 100.0 % -6.49 [ -13.57, 0.58 ]
Heterogeneity: Tau2 = 12.38; Chi2 = 1.90, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 1.80 (P = 0.072)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 6.1. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 1 Overall
self-esteem/body image (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 6 Comparison: self-esteem, all physical activity vs control
Outcome: 1 Overall self-esteem/body image (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Segar 1998 10 33 (1.8) 5 30.5 (2.7) 2.9 % 1.11 [ -0.06, 2.28 ]
Pinto 2003 12 32.3 (4.3) 6 25.3 (8.2) 3.4 % 1.15 [ 0.08, 2.22 ]
Loudon 2014 12 -1.43 (0.33) 11 -1.56 (0.86) 5.1 % 0.20 [ -0.62, 1.02 ]
Musanti 2012 30 23.83 (3.48) 12 26.33 (3.94) 6.6 % -0.68 [ -1.37, 0.01 ]
Mehnert 2011 27 -5.47 (1.66) 27 -6.82 (2.6) 8.9 % 0.61 [ 0.06, 1.16 ]
Courneya 2003 24 34.8 (4.7) 28 34.6 (4.4) 8.9 % 0.04 [ -0.50, 0.59 ]
Milne 2008 29 -17.9 (6.8) 29 -20.1 (6.3) 9.4 % 0.33 [ -0.19, 0.85 ]
Daley 2007 33 2.03 (0.83) 32 1.57 (0.5) 9.8 % 0.66 [ 0.16, 1.16 ]
Do 2015 (1) 32 37.9 (18.9) 30 36.1 (18.3) 9.8 % 0.10 [ -0.40, 0.59 ]
Cadmus 2009 37 34.2 (5.5) 37 33.4 (5.9) 10.8 % 0.14 [ -0.32, 0.60 ]
Pinto 2005 39 30.26 (7.82) 43 27.23 (6.76) 11.2 % 0.41 [ -0.03, 0.85 ]
Schmitz 2009 59 -70.4 (16.3) 63 -71.5 (18) 13.3 % 0.06 [ -0.29, 0.42 ]
Subtotal (95% CI) 344 323 100.0 % 0.27 [ 0.05, 0.48 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 18.93, df = 11 (P = 0.06); I2 =42%
Test for overall effect: Z = 2.46 (P = 0.014)
2 Follow-up
Daley 2007 30 2.17 (0.53) 31 1.88 (0.48) 100.0 % 0.57 [ 0.05, 1.08 ]
Subtotal (95% CI) 30 31 100.0 % 0.57 [ 0.05, 1.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
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Analysis 6.2. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 2 Overall
self-esteem/body image (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 6 Comparison: self-esteem, all physical activity vs control
Outcome: 2 Overall self-esteem/body image (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 11 3 (1) 10 -1.5 (1.5) 4.2 % 3.42 [ 1.99, 4.86 ]
Musanti 2012 30 -0.4 (4.53) 12 0.58 (3.92) 9.7 % -0.22 [ -0.89, 0.45 ]
Courneya 2003 24 2.6 (3.7) 28 -0.1 (3.5) 10.9 % 0.74 [ 0.18, 1.30 ]
Mehnert 2011 30 0.73 (2.12) 27 0.39 (2.12) 11.4 % 0.16 [ -0.36, 0.68 ]
Milne 2008 29 1.5 (3.7) 29 0.1 (3.9) 11.5 % 0.36 [ -0.16, 0.88 ]
Daley 2007 33 1.79 (0.71) 33 1.56 (0.67) 11.8 % 0.33 [ -0.16, 0.82 ]
Cadmus 2009 37 0.4 (4.4) 37 0.2 (2.9) 12.2 % 0.05 [ -0.40, 0.51 ]
Schmitz 2009 59 -12 (15.5) 63 -4.1 (16.2) 13.3 % -0.49 [ -0.86, -0.13 ]
Saarto 2012 263 10.7 (21.51) 237 12 (21.99) 15.0 % -0.06 [ -0.24, 0.12 ]
Subtotal (95% CI) 516 476 100.0 % 0.23 [ -0.11, 0.58 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 40.55, df = 8 (P<0.00001); I2 =80%
Test for overall effect: Z = 1.33 (P = 0.18)
2 Follow-up
Daley 2007 31 2.02 (0.55) 31 1.76 (0.57) 100.0 % 0.46 [ -0.05, 0.96 ]
Subtotal (95% CI) 31 31 100.0 % 0.46 [ -0.05, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.78 (P = 0.075)
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Analysis 6.3. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 3 Body
Esteem Scale - weight concern (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 6 Comparison: self-esteem, all physical activity vs control
Outcome: 3 Body Esteem Scale - weight concern (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Pinto 2003 12 30.91 (8.2) 6 23.5 (4.2) 41.2 % 7.41 [ 1.68, 13.14 ]
Pinto 2005 39 27.02 (9.02) 43 25.03 (7.42) 58.8 % 1.99 [ -1.61, 5.59 ]
Subtotal (95% CI) 51 49 100.0 % 4.22 [ -1.01, 9.45 ]
Heterogeneity: Tau2 = 8.73; Chi2 = 2.47, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 6.4. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 4 Physical
self-perception profile - attractiveness of body (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 6 Comparison: self-esteem, all physical activity vs control
Outcome: 4 Physical self-perception profile - attractiveness of body (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Musanti 2012 30 14.63 (4.17) 12 14.3 (3.31) 1.9 % 0.33 [ -2.06, 2.72 ]
Daley 2007 33 2.03 (0.83) 32 1.57 (0.5) 98.1 % 0.46 [ 0.13, 0.79 ]
Subtotal (95% CI) 63 44 100.0 % 0.46 [ 0.13, 0.79 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 2.73 (P = 0.0064)
2 Follow-up
Daley 2007 30 2.17 (0.53) 31 1.88 (0.48) 100.0 % 0.29 [ 0.04, 0.54 ]
Subtotal (95% CI) 30 31 100.0 % 0.29 [ 0.04, 0.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.24 (P = 0.025)
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Analysis 6.5. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 5 Physical
self-perception profile - attractiveness of body (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 6 Comparison: self-esteem, all physical activity vs control
Outcome: 5 Physical self-perception profile - attractiveness of body (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Musanti 2012 30 2.11 (3.2) 12 0.83 (2.62) 3.1 % 1.28 [ -0.59, 3.15 ]
Daley 2007 33 1.79 (0.71) 33 1.56 (0.67) 96.9 % 0.23 [ -0.10, 0.56 ]
Subtotal (95% CI) 63 45 100.0 % 0.26 [ -0.07, 0.59 ]
Heterogeneity: Chi2 = 1.17, df = 1 (P = 0.28); I2 =15%
Test for overall effect: Z = 1.57 (P = 0.12)
2 Follow-up
Daley 2007 31 2.02 (0.55) 31 1.76 (0.57) 100.0 % 0.26 [ -0.02, 0.54 ]
Subtotal (95% CI) 31 31 100.0 % 0.26 [ -0.02, 0.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.83 (P = 0.068)
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Analysis 6.6. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 6 Rosenberg
Self-Esteem Scale (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 6 Comparison: self-esteem, all physical activity vs control
Outcome: 6 Rosenberg Self-Esteem Scale (follow-up values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Segar 1998 10 33 (1.8) 5 30.5 (2.7) 24.6 % 2.50 [ -0.12, 5.12 ]
Cadmus 2009 37 34.2 (5.5) 37 33.4 (5.9) 24.7 % 0.80 [ -1.80, 3.40 ]
Musanti 2012 30 23.83 (3.48) 12 26.33 (3.94) 25.1 % -2.50 [ -5.05, 0.05 ]
Courneya 2003 24 34.8 (4.7) 28 34.6 (4.4) 25.6 % 0.20 [ -2.29, 2.69 ]
Subtotal (95% CI) 101 82 100.0 % 0.24 [ -1.79, 2.26 ]
Heterogeneity: Tau2 = 2.55; Chi2 = 7.47, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 0.23 (P = 0.82)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
-20 -10 0 10 20
Favours control Favours physical activity
420Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.7. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 7 Rosenberg
Self-Esteem Scale (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 6 Comparison: self-esteem, all physical activity vs control
Outcome: 7 Rosenberg Self-Esteem Scale (change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Musanti 2012 30 -0.4 (4.53) 12 0.58 (3.92) 8.5 % -0.98 [ -3.73, 1.77 ]
Courneya 2003 24 2.6 (3.7) 28 -0.1 (3.5) 16.5 % 2.70 [ 0.73, 4.67 ]
Cadmus 2009 37 0.4 (4.4) 37 0.2 (2.9) 22.2 % 0.20 [ -1.50, 1.90 ]
Mustian 2004 11 3 (1) 10 -1.5 (1.5) 52.8 % 4.50 [ 3.40, 5.60 ]
Subtotal (95% CI) 102 87 100.0 % 2.78 [ 1.98, 3.58 ]
Heterogeneity: Chi2 = 25.44, df = 3 (P = 0.00001); I2 =88%
Test for overall effect: Z = 6.81 (P < 0.00001)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 6.8. Comparison 6 Comparison: self-esteem, all physical activity vs control, Outcome 8 EORTC
QLQ-C30 Body image (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 6 Comparison: self-esteem, all physical activity vs control
Outcome: 8 EORTC QLQ-C30 Body image (follow-up and change values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Do 2015 (1) 32 37.9 (18.9) 30 36.1 (18.3) 14.5 % 1.80 [ -7.46, 11.06 ]
Saarto 2012 (2) 263 10.7 (21.51) 237 12 (21.99) 85.5 % -1.30 [ -5.12, 2.52 ]
Subtotal (95% CI) 295 267 100.0 % -0.85 [ -4.38, 2.68 ]
Heterogeneity: Chi2 = 0.37, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
-20 -10 0 10 20
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Analysis 7.1. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome
1 Overall cardiorespiratory fitness (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 1 Overall cardiorespiratory fitness (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 25.9 (4.5) 8 25.7 (3.7) 1.9 % 0.05 [ -0.93, 1.03 ]
Cerulli 2014 10 31.29 (4.95) 10 32.26 (10.1) 2.3 % -0.12 [ -0.99, 0.76 ]
Mustian 2004 11 636.1 (50.6) 10 610.3 (75.9) 2.3 % 0.39 [ -0.48, 1.25 ]
Rogers 2013 12 23.9 (6.2) 10 23.9 (3.8) 2.4 % 0.0 [ -0.84, 0.84 ]
Portela 2008 25 3006.96 (410.8) 9 2416.1 (718.6) 2.6 % 1.14 [ 0.33, 1.96 ]
Kaltsatou 2011 14 483.33 (85.95) 13 403.08 (71.92) 2.6 % 0.98 [ 0.17, 1.78 ]
Rahnama 2010 14 20.65 (5.73) 15 13.85 (5.18) 2.6 % 1.21 [ 0.41, 2.01 ]
Nikander 2007 14 -17.6 (1.3) 14 -17.2 (1.4) 3.0 % -0.29 [ -1.03, 0.46 ]
Musanti 2012 30 24.6 (4.93) 12 23 (4.29) 3.5 % 0.33 [ -0.34, 1.00 ]
Rogers 2014 20 30.9 (6.3) 22 25.1 (5) 3.7 % 1.01 [ 0.36, 1.65 ]
Kim 2015 20 424.8 (55.8) 19 394.4 (54) 3.8 % 0.54 [ -0.10, 1.18 ]
Rogers 2009 20 29.5 (6.6) 18 27.6 (6.1) 3.8 % 0.29 [ -0.35, 0.93 ]
Courneya 2003 24 21.3 (3.7) 26 18.2 (3.9) 4.4 % 0.80 [ 0.22, 1.38 ]
Mehnert 2011 27 26.9 (4.4) 23 25.7 (4.7) 4.6 % 0.26 [ -0.30, 0.82 ]
Basen-Enquist 2006 35 1643 (122.5) 25 1546 (127.5) 4.9 % 0.77 [ 0.24, 1.30 ]
Do 2015 30 31.7 (12.4) 30 24.5 (6.6) 5.1 % 0.72 [ 0.19, 1.24 ]
Milne 2008 29 1.49 (0.31) 29 1.48 (0.43) 5.2 % 0.03 [ -0.49, 0.54 ]
Murtezani 2014 30 875.1 (86.7) 32 823.5 (87.1) 5.2 % 0.59 [ 0.08, 1.10 ]
Pinto 2005 39 -16.34 (2.09) 43 -17.85 (2.24) 6.2 % 0.69 [ 0.24, 1.14 ]
Irwin 2015 45 24.6 (5.5) 38 23 (4.7) 6.4 % 0.31 [ -0.13, 0.74 ]
Fillion 2008 44 27.04 (4.39) 43 26.53 (5.81) 6.7 % 0.10 [ -0.32, 0.52 ]
Daley 2007 33 34.99 (4.42) 69 33.05 (5.3) 6.7 % 0.38 [ -0.04, 0.80 ]
Rogers 2015 105 23.6 (4.8) 108 22.7 (0.3) 10.1 % 0.27 [ 0.00, 0.54 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 639 626 100.0 % 0.44 [ 0.30, 0.58 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 31.26, df = 22 (P = 0.09); I2 =30%
Test for overall effect: Z = 6.06 (P < 0.00001)
2 Follow-up
Daley 2007 31 33.8 (4.8) 31 30.5 (4) 24.7 % 0.74 [ 0.22, 1.25 ]
Fillion 2008 44 28.1 (4.74) 43 27.86 (5.65) 31.1 % 0.05 [ -0.37, 0.47 ]
Rogers 2015 105 23.7 (5.2) 108 21.8 (4.9) 44.2 % 0.37 [ 0.10, 0.65 ]
Subtotal (95% CI) 180 182 100.0 % 0.36 [ 0.03, 0.69 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 4.22, df = 2 (P = 0.12); I2 =53%
Test for overall effect: Z = 2.16 (P = 0.031)
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Analysis 7.2. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome
2 Overall cardiorespiratory fitness (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 2 Overall cardiorespiratory fitness (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Nieman 1995 6 60.8 (8.4) 6 12 (17.8) 3.8 % 3.24 [ 1.29, 5.18 ]
Naumann 2012 11 3.1 (2.9) 10 -0.1 (3.1) 9.2 % 1.03 [ 0.10, 1.95 ]
Dolan 2016 23 12.2 (10.2) 10 -5.97 (7.2) 9.5 % 1.88 [ 0.99, 2.77 ]
Musanti 2012 30 1 (3.1) 12 0.9 (3.4) 11.4 % 0.03 [ -0.64, 0.70 ]
Courneya 2003 24 2.7 (2.6) 26 -0.6 (1.7) 11.8 % 1.49 [ 0.86, 2.12 ]
Rogers 2014 20 2.8 (4.9) 22 1.1 (4.2) 12.0 % 0.37 [ -0.24, 0.98 ]
Irwin 2015 45 1.5 (2.1) 38 -0.4 (2.7) 13.5 % 0.79 [ 0.34, 1.24 ]
Pinto 2005 39 1.35 (2.4) 43 -0.25 (2.5) 13.5 % 0.65 [ 0.20, 1.09 ]
Saarto 2012 262 0.89 (1.15) 236 0.72 (1.01) 15.4 % 0.16 [ -0.02, 0.33 ]
Subtotal (95% CI) 460 403 100.0 % 0.83 [ 0.40, 1.27 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 44.63, df = 8 (P<0.00001); I2 =82%
Test for overall effect: Z = 3.79 (P = 0.00015)
2 Follow-up
Rogers 2009 19 3.6 (22.27) 17 0.9 (0.0007) 32.0 % 0.16 [ -0.49, 0.82 ]
Pinto 2005 39 1.7 (2.7) 40 0.3 (2.4) 68.0 % 0.54 [ 0.09, 0.99 ]
Subtotal (95% CI) 58 57 100.0 % 0.42 [ 0.05, 0.79 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.88, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 2.23 (P = 0.026)
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Analysis 7.3. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome
3 Directly assessed VO max/peak (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 3 Directly assessed VO max/peak (follow-up values)





N Mean(SD)[ml/kg/min] N Mean(SD)[ml/kg/min] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Herrero 2006 8 25.9 (4.5) 8 25.7 (3.7) 9.4 % 0.20 [ -3.84, 4.24 ]
Mehnert 2011 27 26.9 (4.4) 23 25.7 (4.7) 23.9 % 1.20 [ -1.34, 3.74 ]
Irwin 2015 45 24.6 (5.5) 38 23 (4.7) 32.0 % 1.60 [ -0.59, 3.79 ]
Courneya 2003 24 21.3 (3.7) 26 18.2 (3.9) 34.7 % 3.10 [ 0.99, 5.21 ]
Subtotal (95% CI) 104 95 100.0 % 1.89 [ 0.65, 3.13 ]
Heterogeneity: Chi2 = 2.29, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.4. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome
4 Directly assessed VO max/peak (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 4 Directly assessed VO max/peak (change values)







N Mean(SD)[ml/kg/min] N Mean(SD)[ml/kg/min] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Dolan 2016 (1) 23 12.2 (10.2) 10 -5.97 (7.2) 25.9 % 1.88 [ 0.99, 2.77 ]
Courneya 2003 24 2.7 (2.6) 26 -0.6 (1.7) 33.8 % 1.49 [ 0.86, 2.12 ]
Irwin 2015 45 1.5 (2.1) 38 -0.4 (2.7) 40.3 % 0.79 [ 0.34, 1.24 ]
Subtotal (95% CI) 92 74 100.0 % 1.31 [ 0.66, 1.96 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 6.24, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 3.95 (P = 0.000079)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.5. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome
5 Directly assessed VO max/peak - treadmill (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 5 Directly assessed VO max/peak - treadmill (follow-up and change values)







N Mean(SD)[ml/kg/min] N Mean(SD)[ml/kg/min] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Dolan 2016 (1) 23 12.2 (10.2) 10 -5.97 (7.2) 46.9 % 1.88 [ 0.99, 2.77 ]
Irwin 2015 (2) 45 24.6 (5.5) 38 23 (4.7) 53.1 % 0.31 [ -0.13, 0.74 ]
Subtotal (95% CI) 68 48 100.0 % 1.04 [ -0.49, 2.58 ]
Heterogeneity: Tau2 = 1.11; Chi2 = 9.76, df = 1 (P = 0.002); I2 =90%
Test for overall effect: Z = 1.33 (P = 0.18)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.6. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome
6 Directly assessed VO max/peak - cycle ergometer (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 6 Directly assessed VO max/peak - cycle ergometer (follow-up values)





N Mean(SD)[ml/kg/min] N Mean(SD)[ml/kg/min] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 25.9 (4.5) 8 25.7 (3.7) 15.0 % 0.20 [ -3.84, 4.24 ]
Mehnert 2011 27 26.9 (4.4) 23 25.7 (4.7) 35.6 % 1.20 [ -1.34, 3.74 ]
Courneya 2003 24 21.3 (3.7) 26 18.2 (3.9) 49.4 % 3.10 [ 0.99, 5.21 ]
Subtotal (95% CI) 59 57 100.0 % 1.99 [ 0.39, 3.59 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 2.19, df = 2 (P = 0.33); I2 =9%
Test for overall effect: Z = 2.44 (P = 0.015)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.7. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome
7 Peak Power Output - cycle ergometer test (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 7 Peak Power Output - cycle ergometer test (follow-up values)





N Mean(SD)[W] N Mean(SD)[W] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Herrero 2006 8 110 (16) 8 94 (12) 44.8 % 16.00 [ 2.14, 29.86 ]
Courneya 2003 24 113.6 (23.6) 26 92.3 (21.3) 55.2 % 21.30 [ 8.80, 33.80 ]
Subtotal (95% CI) 32 34 100.0 % 18.92 [ 9.64, 28.20 ]
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 4.00 (P = 0.000064)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.8. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome
8 Peak Respiratory Exchange Ratio - cycle ergometer test (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 8 Peak Respiratory Exchange Ratio - cycle ergometer test (follow-up values)





N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Herrero 2006 8 1.12 (0.05) 8 1.11 (0.1) 20.1 % 0.01 [ -0.07, 0.09 ]
Courneya 2003 24 1.13 (0.07) 26 1.14 (0.07) 79.9 % -0.01 [ -0.05, 0.03 ]
Subtotal (95% CI) 32 34 100.0 % -0.01 [ -0.04, 0.03 ]
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
-0.2 -0.1 0 0.1 0.2
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Analysis 7.9. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control, Outcome
9 Peak Heart Rate - cycle ergometer test (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 9 Peak Heart Rate - cycle ergometer test (follow-up values)





N Mean(SD)[beats/min] N Mean(SD)[beats/min] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Herrero 2006 8 161 (16) 8 156 (15) 25.4 % 5.00 [ -10.20, 20.20 ]
Courneya 2003 24 157 (16) 26 156 (16) 74.6 % 1.00 [ -7.88, 9.88 ]
Subtotal (95% CI) 32 34 100.0 % 2.02 [ -5.65, 9.68 ]
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.61)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.10. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 10 Ebbeling single-stage treadmill test (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 10 Ebbeling single-stage treadmill test (follow-up and change values)





N Mean(SD)[ml/kg/min] N Mean(SD)[ml/kg/min] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Fillion 2008 44 27.04 (4.39) 43 26.53 (5.81) 45.0 % 0.51 [ -1.66, 2.68 ]
Daley 2007 33 34.99 (4.42) 69 33.05 (5.3) 55.0 % 1.94 [ -0.02, 3.90 ]
Subtotal (95% CI) 77 112 100.0 % 1.30 [ -0.16, 2.75 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.92, df = 1 (P = 0.34); I2 =0.0%
Test for overall effect: Z = 1.75 (P = 0.080)
2 Follow-up
Daley 2007 31 33.8 (4.8) 31 30.5 (4) 50.0 % 3.30 [ 1.10, 5.50 ]
Fillion 2008 44 28.1 (4.74) 43 27.86 (5.65) 50.0 % 0.24 [ -1.95, 2.43 ]
Subtotal (95% CI) 75 74 100.0 % 1.77 [ -1.23, 4.77 ]
Heterogeneity: Tau2 = 3.43; Chi2 = 3.73, df = 1 (P = 0.05); I2 =73%
Test for overall effect: Z = 1.16 (P = 0.25)
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Analysis 7.11. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 11 Modified Bruce treadmill test (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 11 Modified Bruce treadmill test (follow-up and change values)





N Mean(SD)[ml/kg/min] N Mean(SD)[ml/kg/min] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rahnama 2010 14 20.65 (5.73) 15 13.85 (5.18) 25.8 % 6.80 [ 2.81, 10.79 ]
Musanti 2012 30 24.6 (4.93) 12 23 (4.29) 34.7 % 1.60 [ -1.40, 4.60 ]
Naumann 2012 11 3.1 (2.9) 10 -0.1 (3.1) 39.5 % 3.20 [ 0.63, 5.77 ]
Subtotal (95% CI) 55 37 100.0 % 3.57 [ 0.95, 6.19 ]
Heterogeneity: Tau2 = 2.80; Chi2 = 4.20, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 2.67 (P = 0.0075)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.12. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 12 Naughton submaximal treadmill test (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 12 Naughton submaximal treadmill test (follow-up and change values)





N Mean(SD)[ml/kg/min] N Mean(SD)[ml/kg/min] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2013 12 23.9 (6.2) 10 23.9 (3.8) 18.0 % 0.0 [ -4.23, 4.23 ]
Rogers 2009 20 29.5 (6.6) 18 27.6 (6.1) 19.0 % 1.90 [ -2.14, 5.94 ]
Rogers 2014 20 30.9 (6.3) 22 25.1 (5) 22.3 % 5.80 [ 2.34, 9.26 ]
Rogers 2015 105 23.6 (4.8) 108 22.7 (0.3) 40.6 % 0.90 [ -0.02, 1.82 ]
Subtotal (95% CI) 157 158 100.0 % 2.02 [ -0.33, 4.37 ]
Heterogeneity: Tau2 = 3.31; Chi2 = 7.61, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 1.69 (P = 0.092)
2 Follow-up
Rogers 2009 (1) 19 3.6 (22.27) 17 0.9 (0.0007) 1.8 % 2.70 [ -7.31, 12.71 ]
Rogers 2015 105 23.7 (5.2) 108 21.8 (4.9) 98.2 % 1.90 [ 0.54, 3.26 ]
Subtotal (95% CI) 124 125 100.0 % 1.91 [ 0.57, 3.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 2.79 (P = 0.0053)
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Analysis 7.13. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 13 Cardiorespiratory fitness walk tests (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 13 Cardiorespiratory fitness walk tests (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 11 636.1 (50.6) 10 610.3 (75.9) 9.0 % 0.39 [ -0.48, 1.25 ]
Portela 2008 25 3006.96 (410.8) 9 2416.1 (718.6) 10.0 % 1.14 [ 0.33, 1.96 ]
Kaltsatou 2011 14 483.33 (85.95) 13 403.08 (71.92) 10.1 % 0.98 [ 0.17, 1.78 ]
Nikander 2007 14 -17.6 (1.3) 14 -17.2 (1.4) 11.4 % -0.29 [ -1.03, 0.46 ]
Basen-Enquist 2006 35 1643 (122.5) 25 1546 (127.5) 18.1 % 0.77 [ 0.24, 1.30 ]
Murtezani 2014 30 875.1 (86.7) 32 823.5 (87.1) 19.1 % 0.59 [ 0.08, 1.10 ]
Pinto 2005 39 -16.34 (2.09) 43 -17.85 (2.24) 22.2 % 0.69 [ 0.24, 1.14 ]
Subtotal (95% CI) 168 146 100.0 % 0.62 [ 0.33, 0.91 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 8.71, df = 6 (P = 0.19); I2 =31%
Test for overall effect: Z = 4.20 (P = 0.000027)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
-4 -2 0 2 4
Favours control Favours physical activity
436Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 7.14. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 14 Cardiorespiratory fitness walk tests (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 14 Cardiorespiratory fitness walk tests (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Nieman 1995 6 60.8 (8.4) 6 12 (17.8) 11.7 % 3.24 [ 1.29, 5.18 ]
Pinto 2005 39 1.35 (2.4) 43 -0.25 (2.5) 41.4 % 0.65 [ 0.20, 1.09 ]
Saarto 2012 262 0.89 (1.15) 236 0.72 (1.01) 46.9 % 0.16 [ -0.02, 0.33 ]
Subtotal (95% CI) 307 285 100.0 % 0.72 [ -0.05, 1.49 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 13.20, df = 2 (P = 0.001); I2 =85%
Test for overall effect: Z = 1.84 (P = 0.065)
2 Follow-up
Pinto 2005 39 1.7 (2.7) 40 0.3 (2.4) 100.0 % 0.54 [ 0.09, 0.99 ]
Subtotal (95% CI) 39 40 100.0 % 0.54 [ 0.09, 0.99 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
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Analysis 7.15. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 15 6-Minute walk test (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 15 6-Minute walk test (follow-up and change values)





N Mean(SD)[m] N Mean(SD)[m] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Kaltsatou 2011 14 483.33 (85.95) 13 403.08 (71.92) 9.7 % 80.25 [ 20.62, 139.88 ]
Mustian 2004 11 636.1 (50.6) 10 610.3 (75.9) 10.7 % 25.80 [ -29.94, 81.54 ]
Kim 2015 20 424.8 (55.8) 19 394.4 (54) 19.2 % 30.40 [ -4.06, 64.86 ]
Basen-Enquist 2006 (1) 35 500.8 (37.3) 25 421.2 (38.9) 28.9 % 79.60 [ 59.97, 99.23 ]
Nieman 1995 (2) 6 60.8 (8.4) 6 12 (17.8) 31.6 % 48.80 [ 33.05, 64.55 ]
Subtotal (95% CI) 86 73 100.0 % 54.74 [ 33.25, 76.22 ]
Heterogeneity: Tau2 = 316.15; Chi2 = 10.21, df = 4 (P = 0.04); I2 =61%
Test for overall effect: Z = 4.99 (P < 0.00001)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.16. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 16 12-Minute walk test (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 16 12-Minute walk test (follow-up values)





N Mean(SD)[m] N Mean(SD)[m] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Portela 2008 (1) 25 916.52 (125.21) 9 736.43 (219.03) 33.4 % 180.09 [ 28.81, 331.37 ]
Murtezani 2014 30 875.1 (86.7) 32 823.5 (87.1) 66.6 % 51.60 [ 8.32, 94.88 ]
Subtotal (95% CI) 55 41 100.0 % 94.56 [ -24.25, 213.37 ]
Heterogeneity: Tau2 = 5032.24; Chi2 = 2.56, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 1.56 (P = 0.12)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.17. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 17 2-Kilometer walk test (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 17 2-Kilometer walk test (follow-up and change values)





N Mean(SD)[minutes] N Mean(SD)[minutes] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Nikander 2007 14 17.6 (1.3) 14 17.2 (1.4) 11.3 % 0.40 [ -0.60, 1.40 ]
Saarto 2012 (1) 262 -0.89 (1.15) 236 -0.72 (1.01) 88.7 % -0.17 [ -0.36, 0.02 ]
Subtotal (95% CI) 276 250 100.0 % -0.11 [ -0.46, 0.25 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.20, df = 1 (P = 0.27); I2 =17%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.18. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 18 Resting Heart Rate (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 18 Resting Heart Rate (follow-up values)





N Mean(SD)[beats/min] N Mean(SD)[beats/min] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Courneya 2003 25 81.1 (8.2) 28 83.3 (14.1) 32.0 % -2.20 [ -8.33, 3.93 ]
Rahnama 2010 14 83.92 (5.62) 15 89.46 (5.94) 68.0 % -5.54 [ -9.75, -1.33 ]
Subtotal (95% CI) 39 43 100.0 % -4.47 [ -7.94, -1.00 ]
Heterogeneity: Chi2 = 0.77, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.012)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.19. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 19 Resting Heart Rate (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 19 Resting Heart Rate (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Dolan 2016 (1) 23 -9.4 (5.5) 10 4.9 (12.6) 46.0 % -1.70 [ -2.56, -0.84 ]
Courneya 2003 25 -4.4 (11) 28 1.1 (10.4) 54.0 % -0.51 [ -1.06, 0.04 ]
Subtotal (95% CI) 48 38 100.0 % -1.05 [ -2.22, 0.11 ]
Heterogeneity: Tau2 = 0.57; Chi2 = 5.22, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 1.78 (P = 0.076)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 7.20. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 20 Resting Systolic Blood Pressure (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 20 Resting Systolic Blood Pressure (follow-up values)





N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 118.5 (16.5) 10 114.4 (9.5) 8.3 % 4.10 [ -5.90, 14.10 ]
Courneya 2003 24 131.6 (13.1) 28 134.7 (18.2) 11.4 % -3.10 [ -11.64, 5.44 ]
Kaltsatou 2011 14 125 (9.04) 13 126.92 (7.51) 21.3 % -1.92 [ -8.17, 4.33 ]
Rahnama 2010 14 123.6 (3.79) 15 124.3 (6.3) 59.0 % -0.70 [ -4.46, 3.06 ]
Subtotal (95% CI) 68 66 100.0 % -0.83 [ -3.72, 2.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.33, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
2 Follow-up
Guinan 2013 16 117 (14.2) 10 111.8 (12.8) 100.0 % 5.20 [ -5.35, 15.75 ]
Subtotal (95% CI) 16 10 100.0 % 5.20 [ -5.35, 15.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 7.21. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 21 Resting Systolic Blood Pressure (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 21 Resting Systolic Blood Pressure (change values)





N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Courneya 2003 24 -5.4 (15.6) 28 0.1 (16.6) 25.6 % -5.50 [ -14.26, 3.26 ]
Cadmus 2009 35 0.66 (13.3) 30 -5.23 (13.3) 32.1 % 5.89 [ -0.60, 12.38 ]
Guinan 2013 16 -6.1 (4.32) 10 -2.3 (3.63) 42.2 % -3.80 [ -6.89, -0.71 ]
Subtotal (95% CI) 75 68 100.0 % -1.12 [ -7.74, 5.50 ]
Heterogeneity: Tau2 = 24.52; Chi2 = 7.54, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 0.33 (P = 0.74)
2 Follow-up
Guinan 2013 16 -7.6 (3.94) 10 -4.9 (4.19) 100.0 % -2.70 [ -5.94, 0.54 ]
Subtotal (95% CI) 16 10 100.0 % -2.70 [ -5.94, 0.54 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
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Analysis 7.22. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 22 Resting Diastolic Blood Pressure (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 22 Resting Diastolic Blood Pressure (follow-up values)





N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Kaltsatou 2011 14 78.75 (11.1) 13 81.15 (7.11) 22.0 % -2.40 [ -9.38, 4.58 ]
Guinan 2013 16 78.8 (9.7) 10 74.6 (4.4) 32.6 % 4.20 [ -1.28, 9.68 ]
Courneya 2003 25 85 (8.9) 28 85.4 (7.1) 45.5 % -0.40 [ -4.77, 3.97 ]
Subtotal (95% CI) 55 51 100.0 % 0.66 [ -2.89, 4.21 ]
Heterogeneity: Tau2 = 2.24; Chi2 = 2.57, df = 2 (P = 0.28); I2 =22%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Follow-up
Guinan 2013 16 76.1 (7.8) 10 74 (7.2) 100.0 % 2.10 [ -3.78, 7.98 ]
Subtotal (95% CI) 16 10 100.0 % 2.10 [ -3.78, 7.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
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Analysis 7.23. Comparison 7 Comparison: cardiorespiratory fitness, all physical activity vs control,
Outcome 23 Resting Diastolic Blood Pressure (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 7 Comparison: cardiorespiratory fitness, all physical activity vs control
Outcome: 23 Resting Diastolic Blood Pressure (change values)





N Mean(SD)[mmHg] N Mean(SD)[mmHg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Courneya 2003 25 -4.1 (11) 28 -0.5 (10) 8.8 % -3.60 [ -9.28, 2.08 ]
Cadmus 2009 35 0.75 (6.9) 30 -1.02 (6.9) 21.3 % 1.77 [ -1.59, 5.13 ]
Guinan 2013 16 0.4 (2.44) 10 -0.4 (2.94) 38.3 % 0.80 [ -1.38, 2.98 ]
Subtotal (95% CI) 76 68 68.4 % 0.53 [ -1.61, 2.68 ]
Heterogeneity: Tau2 = 0.91; Chi2 = 2.59, df = 2 (P = 0.27); I2 =23%
Test for overall effect: Z = 0.49 (P = 0.63)
2 Follow-up
Guinan 2013 16 -2.3 (3) 10 -1 (3.36) 31.6 % -1.30 [ -3.85, 1.25 ]
Subtotal (95% CI) 16 10 31.6 % -1.30 [ -3.85, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.00 (P = 0.32)
Total (95% CI) 92 78 100.0 % -0.04 [ -1.82, 1.73 ]
Heterogeneity: Tau2 = 0.90; Chi2 = 4.12, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Chi2 = 1.16, df = 1 (P = 0.28), I2 =14%
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Analysis 8.1. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 1 Overall
self-reported physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 1 Overall self-reported physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 38.7 (26.9) 10 19.9 (11.3) 3.3 % 0.81 [ -0.01, 1.64 ]
Matthews 2007 22 54.2 (34.1) 14 27.2 (22.7) 4.0 % 0.87 [ 0.17, 1.58 ]
Rogers 2009 20 121.4 (73.2) 18 114.3 (131.5) 4.5 % 0.07 [ -0.57, 0.70 ]
Kim 2015 20 17.6 (16.03) 19 11.8 (11.6) 4.5 % 0.40 [ -0.23, 1.04 ]
Basen-Enquist 2006 35 428 (254.4) 25 404 (265) 5.4 % 0.09 [ -0.42, 0.61 ]
Cadmus 2009 34 161.7 (114.7) 33 55.6 (101.9) 5.5 % 0.97 [ 0.46, 1.47 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 5.5 % 1.01 [ 0.50, 1.52 ]
Littman 2012 32 19.2 (19.1) 31 12.1 (13.6) 5.5 % 0.42 [ -0.08, 0.92 ]
Hatchett 2013 38 3.47 (2.19) 36 1.42 (1.67) 5.6 % 1.04 [ 0.55, 1.53 ]
Winters-Stone 2011 36 430.8 (281.4) 31 461.7 (346.4) 5.7 % -0.10 [ -0.58, 0.38 ]
Irwin 2015 45 222.1 (118.6) 38 103.6 (104.6) 5.9 % 1.04 [ 0.58, 1.51 ]
Pinto 2005 39 202.43 (161.65) 43 78.36 (86) 5.9 % 0.96 [ 0.50, 1.42 ]
Kiecolt-Glaser 2014 96 11.2 (7.6) 90 9.1 (6.1) 7.5 % 0.30 [ 0.01, 0.59 ]
Rogers 2015 110 169 (119) 112 74 (107) 7.6 % 0.84 [ 0.56, 1.11 ]
Vallance 2007 253 207.6 (169) 85 163 (121) 7.8 % 0.28 [ 0.03, 0.53 ]
Schmitz 2009 131 3348.8 (9019.4) 133 2339.8 (6213.7) 7.9 % 0.13 [ -0.11, 0.37 ]
Short 2014 195 217.9 (222.9) 104 180.3 (206.9) 7.9 % 0.17 [ -0.07, 0.41 ]
Subtotal (95% CI) 1158 854 100.0 % 0.52 [ 0.33, 0.71 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 58.12, df = 16 (P<0.00001); I2 =72%
Test for overall effect: Z = 5.43 (P < 0.00001)
2 Follow-up
Guinan 2013 16 31.2 (21.1) 10 24.3 (11.9) 9.5 % 0.37 [ -0.43, 1.16 ]
Pinto 2015 36 54.6 (81.6) 31 13.4 (35.2) 19.2 % 0.63 [ 0.14, 1.12 ]
Rogers 2015 105 137 (137) 108 63 (95) 33.8 % 0.63 [ 0.35, 0.90 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vallance 2007 281 177.3 (190.8) 96 142 (126) 37.5 % 0.20 [ -0.03, 0.43 ]
Subtotal (95% CI) 438 245 100.0 % 0.44 [ 0.17, 0.72 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.33, df = 3 (P = 0.10); I2 =53%
Test for overall effect: Z = 3.18 (P = 0.0015)
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Analysis 8.2. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 2 Overall
self-reported physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 2 Overall self-reported physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 15.6 (11.4476) 10 -8.3 (4.1937) 5.9 % 2.46 [ 1.39, 3.53 ]
Matthews 2007 22 21.5 (30.6) 14 5 (13.8) 9.7 % 0.63 [ -0.06, 1.32 ]
Cadmus 2009 34 129 (117.9) 33 44.3 (89.4) 12.2 % 0.80 [ 0.30, 1.30 ]
Irwin 2015 45 159 (136) 38 49 (86) 12.9 % 0.94 [ 0.48, 1.40 ]
Pinto 2005 39 84.74 (189.2) 43 -18.27 (200.7) 13.1 % 0.52 [ 0.08, 0.96 ]
Schmitz 2009 (1) 48 2.8 (16.8) 57 -0.8 (16.6) 13.9 % 0.21 [ -0.17, 0.60 ]
Vallance 2007 281 82 (168.7) 96 30 (167.8) 15.9 % 0.31 [ 0.08, 0.54 ]
Saarto 2012 262 3.5 (18.3) 236 3.3 (21.5) 16.5 % 0.01 [ -0.17, 0.19 ]
Subtotal (95% CI) 747 527 100.0 % 0.57 [ 0.25, 0.90 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 39.44, df = 7 (P<0.00001); I2 =82%
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 3.50 (P = 0.00047)
2 Follow-up
Guinan 2013 16 8 (8.8) 10 -3.9 (7.8) 14.9 % 1.37 [ 0.48, 2.25 ]
Rogers 2009 19 78.7 (119.2) 17 -21.4 (113.9) 20.0 % 0.84 [ 0.15, 1.52 ]
Pinto 2005 39 72.4 (208.6) 43 21.9 (203.9) 28.7 % 0.24 [ -0.19, 0.68 ]
Vallance 2007 281 54.7 (254.5) 96 9 (251.7) 36.4 % 0.18 [ -0.05, 0.41 ]
Subtotal (95% CI) 355 166 100.0 % 0.51 [ 0.08, 0.93 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 9.01, df = 3 (P = 0.03); I2 =67%
Test for overall effect: Z = 2.31 (P = 0.021)
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449Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.3. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 3 Self-
reported total physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 3 Self-reported total physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 38.7 (26.9) 10 19.9 (11.3) 7.0 % 0.81 [ -0.01, 1.64 ]
Matthews 2007 22 54.2 (34.1) 14 27.2 (22.7) 8.3 % 0.87 [ 0.17, 1.58 ]
Littman 2012 32 19.2 (19.1) 31 12.1 (13.6) 10.9 % 0.42 [ -0.08, 0.92 ]
Hatchett 2013 38 3.47 (2.19) 36 1.42 (1.67) 11.1 % 1.04 [ 0.55, 1.53 ]
Winters-Stone 2011 36 430.8 (281.4) 31 461.7 (346.4) 11.2 % -0.10 [ -0.58, 0.38 ]
Irwin 2015 45 222.1 (118.6) 38 103.6 (104.6) 11.5 % 1.04 [ 0.58, 1.51 ]
Pinto 2005 39 202.43 (161.65) 43 78.36 (86) 11.5 % 0.96 [ 0.50, 1.42 ]
Kiecolt-Glaser 2014 96 11.2 (7.6) 90 9.1 (6.1) 13.9 % 0.30 [ 0.01, 0.59 ]
Schmitz 2009 131 3348.8 (9019.4) 133 2339.8 (6213.7) 14.5 % 0.13 [ -0.11, 0.37 ]
Subtotal (95% CI) 455 426 100.0 % 0.57 [ 0.28, 0.86 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 31.60, df = 8 (P = 0.00011); I2 =75%
Test for overall effect: Z = 3.84 (P = 0.00012)
2 Follow-up
Guinan 2013 16 31.2 (21.1) 10 24.3 (11.9) 100.0 % 0.37 [ -0.43, 1.16 ]
Subtotal (95% CI) 16 10 100.0 % 0.37 [ -0.43, 1.16 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
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Analysis 8.4. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 4 Self-
reported total physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 4 Self-reported total physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 15.6 (11.4476) 10 -8.3 (4.1937) 12.4 % 2.46 [ 1.39, 3.53 ]
Matthews 2007 22 21.5 (30.6) 14 5 (13.8) 18.3 % 0.63 [ -0.06, 1.32 ]
Irwin 2015 45 159 (136) 38 49 (86) 22.6 % 0.94 [ 0.48, 1.40 ]
Pinto 2005 39 84.74 (189.2) 43 -18.27 (200.7) 22.9 % 0.52 [ 0.08, 0.96 ]
Schmitz 2009 (1) 48 2.8 (16.8) 57 -0.8 (16.6) 23.8 % 0.21 [ -0.17, 0.60 ]
Subtotal (95% CI) 170 162 100.0 % 0.80 [ 0.30, 1.31 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 17.65, df = 4 (P = 0.001); I2 =77%
Test for overall effect: Z = 3.10 (P = 0.0020)
2 Follow-up
Guinan 2013 16 8 (8.8) 10 -3.9 (7.8) 43.8 % 1.37 [ 0.48, 2.25 ]
Pinto 2005 39 72.4 (208.6) 43 21.9 (203.9) 56.2 % 0.24 [ -0.19, 0.68 ]
Subtotal (95% CI) 55 53 100.0 % 0.73 [ -0.36, 1.83 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 4.96, df = 1 (P = 0.03); I2 =80%
Test for overall effect: Z = 1.32 (P = 0.19)
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(1) Change values (% change) for patients with lymphedemia available only
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Analysis 8.5. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 5 Self-
reported moderate physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 5 Self-reported moderate physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 16.1 (19.3) 10 14.8 (10.4) 12.9 % 0.08 [ -0.71, 0.87 ]
Cadmus 2009 34 161.7 (114.7) 33 55.6 (101.9) 26.6 % 0.97 [ 0.46, 1.47 ]
Hatchett 2013 38 1.08 (1.05) 36 0.39 (0.75) 29.6 % 0.74 [ 0.27, 1.22 ]
Pinto 2005 39 192.57 (156.83) 43 77.15 (86.4) 31.0 % 0.92 [ 0.46, 1.37 ]
Subtotal (95% CI) 127 122 100.0 % 0.77 [ 0.47, 1.07 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.92, df = 3 (P = 0.27); I2 =23%
Test for overall effect: Z = 5.00 (P < 0.00001)
2 Follow-up
Guinan 2013 16 16.7 (17.1) 10 15 (13.9) 100.0 % 0.10 [ -0.69, 0.89 ]
Subtotal (95% CI) 16 10 100.0 % 0.10 [ -0.69, 0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.26 (P = 0.80)
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Analysis 8.6. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 6 Self-
reported moderate physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 6 Self-reported moderate physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 1.4 (3.4) 10 -6.5 (5.6) 40.9 % 1.76 [ 0.81, 2.70 ]
Cadmus 2009 34 129 (117.9) 33 44.3 (89.4) 59.1 % 0.80 [ 0.30, 1.30 ]
Subtotal (95% CI) 50 43 100.0 % 1.19 [ 0.27, 2.11 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 3.08, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 2.53 (P = 0.011)
2 Follow-up
Guinan 2013 16 2 (4.1) 10 -6.3 (9.6) 100.0 % 1.20 [ 0.33, 2.06 ]
Subtotal (95% CI) 16 10 100.0 % 1.20 [ 0.33, 2.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.71 (P = 0.0067)
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Analysis 8.7. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 7 Self-
reported moderate-vigorous physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 7 Self-reported moderate-vigorous physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 121.4 (73.2) 18 114.3 (131.5) 11.5 % 0.07 [ -0.57, 0.70 ]
Basen-Enquist 2006 35 428 (254.4) 25 404 (265) 14.0 % 0.09 [ -0.42, 0.61 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 14.1 % 1.01 [ 0.50, 1.52 ]
Rogers 2015 110 169 (119) 112 74 (107) 19.6 % 0.84 [ 0.56, 1.11 ]
Vallance 2007 253 207.6 (169) 85 163 (121) 20.3 % 0.28 [ 0.03, 0.53 ]
Short 2014 195 217.9 (222.9) 104 180.3 (206.9) 20.5 % 0.17 [ -0.07, 0.41 ]
Subtotal (95% CI) 649 376 100.0 % 0.42 [ 0.12, 0.72 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 22.10, df = 5 (P = 0.00050); I2 =77%
Test for overall effect: Z = 2.72 (P = 0.0066)
2 Follow-up
Pinto 2015 36 54.6 (81.6) 31 13.4 (35.2) 23.2 % 0.63 [ 0.14, 1.12 ]
Rogers 2015 105 137 (137) 108 63 (95) 36.9 % 0.63 [ 0.35, 0.90 ]
Vallance 2007 281 177.3 (190.8) 96 142 (126) 40.0 % 0.20 [ -0.03, 0.43 ]
Subtotal (95% CI) 422 235 100.0 % 0.46 [ 0.13, 0.78 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 6.32, df = 2 (P = 0.04); I2 =68%
Test for overall effect: Z = 2.78 (P = 0.0055)
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Analysis 8.8. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 8 Self-
reported moderate-vigorous physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 8 Self-reported moderate-vigorous physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Vallance 2007 281 82 (168.7) 96 30 (167.8) 46.6 % 0.31 [ 0.08, 0.54 ]
Saarto 2012 262 3.5 (18.3) 236 3.3 (21.5) 53.4 % 0.01 [ -0.17, 0.19 ]
Subtotal (95% CI) 543 332 100.0 % 0.15 [ -0.14, 0.44 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 4.01, df = 1 (P = 0.05); I2 =75%
Test for overall effect: Z = 1.00 (P = 0.32)
2 Follow-up
Rogers 2009 19 78.7 (119.2) 17 -21.4 (113.9) 15.1 % 0.84 [ 0.15, 1.52 ]
Pinto 2005 39 72.4 (208.6) 43 21.9 (203.9) 29.6 % 0.24 [ -0.19, 0.68 ]
Vallance 2007 281 54.7 (254.5) 96 9 (251.7) 55.2 % 0.18 [ -0.05, 0.41 ]
Subtotal (95% CI) 339 156 100.0 % 0.30 [ 0.00, 0.59 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.18, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 1.98 (P = 0.047)
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Analysis 8.9. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 9 Self-
reported vigorous physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 9 Self-reported vigorous physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 17.2 (20.9) 10 0.01 (0.001) 12.9 % 1.01 [ 0.16, 1.85 ]
Hatchett 2013 38 2.39 (1.76) 36 1.03 (1.15) 39.9 % 0.90 [ 0.42, 1.38 ]
Pinto 2005 39 9.86 (22.59) 43 1.21 (6.96) 47.2 % 0.52 [ 0.08, 0.96 ]
Subtotal (95% CI) 93 89 100.0 % 0.74 [ 0.43, 1.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.74, df = 2 (P = 0.42); I2 =0.0%
Test for overall effect: Z = 4.76 (P < 0.00001)
2 Follow-up
Guinan 2013 16 7.3 (14.8) 10 4.5 (14.2) 100.0 % 0.19 [ -0.61, 0.98 ]
Subtotal (95% CI) 16 10 100.0 % 0.19 [ -0.61, 0.98 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
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Analysis 8.10. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 10 Self-
reported vigorous physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 10 Self-reported vigorous physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Pinto 2005 39 0 (0) 43 0 (0) Not estimable
Guinan 2013 16 13.2 (9.4) 10 0 (0.0014) 100.0 % 1.72 [ 0.78, 2.66 ]
Subtotal (95% CI) 55 53 100.0 % 1.72 [ 0.78, 2.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.59 (P = 0.00033)
2 Follow-up
Pinto 2005 39 0 (0) 43 0 (0) Not estimable
Guinan 2013 16 3.4 (9) 10 4.5 (6.3) 100.0 % -0.13 [ -0.92, 0.66 ]
Subtotal (95% CI) 55 53 100.0 % -0.13 [ -0.92, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
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Analysis 8.11. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 11 Self-
reported walking (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 11 Self-reported walking (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Matthews 2007 22 16.8 (15.3) 14 6.6 (8.3) 29.3 % 0.76 [ 0.07, 1.46 ]
Vallance 2007 253 145.5 (194.1) 85 102 (105) 70.7 % 0.25 [ 0.00, 0.49 ]
Subtotal (95% CI) 275 99 100.0 % 0.40 [ -0.06, 0.86 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 1.88, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 1.69 (P = 0.091)
2 Follow-up
Vallance 2007 253 105.7 (128.2) 85 94 (124) 100.0 % 0.09 [ -0.15, 0.34 ]
Subtotal (95% CI) 253 85 100.0 % 0.09 [ -0.15, 0.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
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Analysis 8.12. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 12 Self-
reported walking (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 12 Self-reported walking (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Matthews 2007 22 11.9 (14.4) 14 1.7 (5.9) 14.5 % 0.84 [ 0.14, 1.54 ]
Vallance 2007 253 74.7 (169.2) 85 0 (166.9) 85.5 % 0.44 [ 0.19, 0.69 ]
Subtotal (95% CI) 275 99 100.0 % 0.50 [ 0.23, 0.77 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.09, df = 1 (P = 0.30); I2 =9%
Test for overall effect: Z = 3.58 (P = 0.00035)
2 Follow-up
Vallance 2007 253 35.4 (180.8) 85 -6 (180.8) 100.0 % 0.23 [ -0.02, 0.47 ]
Subtotal (95% CI) 253 85 100.0 % 0.23 [ -0.02, 0.47 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.82 (P = 0.069)
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Analysis 8.13. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 13 7-
Day PAR self-reported moderate physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 13 7-Day PAR self-reported moderate physical activity (follow-up values)





N Mean(SD)[min/week]N Mean(SD)[min/week] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Pinto 2005 39 192.57 (156.83) 43 77.15 (86.4) 46.6 % 115.42 [ 59.84, 171.00 ]
Cadmus 2009 34 161.7 (114.7) 33 55.6 (101.9) 53.4 % 106.10 [ 54.19, 158.01 ]
Subtotal (95% CI) 73 76 100.0 % 110.44 [ 72.50, 148.38 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 5.71 (P < 0.00001)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 8.14. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 14 7-
day PAR self-reported moderate-vigorous physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 14 7-day PAR self-reported moderate-vigorous physical activity (follow-up values)





N Mean(SD)[min/week]N Mean(SD)[min/week] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Basen-Enquist 2006 35 428 (254.4) 25 404 (265) 3.2 % 24.00 [ -109.77, 157.77 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 96.8 % 53.80 [ 29.60, 78.00 ]
Subtotal (95% CI) 71 57 100.0 % 52.86 [ 29.04, 76.67 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 4.35 (P = 0.000014)
2 Follow-up
Pinto 2015 36 54.6 (81.6) 31 13.4 (35.2) 100.0 % 41.20 [ 11.81, 70.59 ]
Subtotal (95% CI) 36 31 100.0 % 41.20 [ 11.81, 70.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.75 (P = 0.0060)
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Analysis 8.15. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 15
Godin LSI self-reported moderate-vigorous physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 15 Godin LSI self-reported moderate-vigorous physical activity (follow-up values)





N Mean(SD)[min/week]N Mean(SD)[min/week]IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 121.4 (73.2) 18 114.3 (131.5) 14.6 % 7.10 [ -61.60, 75.80 ]
Short 2014 195 217.9 (222.9) 104 180.3 (206.9) 17.9 % 37.60 [ -13.00, 88.20 ]
Vallance 2007 253 207.6 (169) 85 163 (121) 21.3 % 44.60 [ 11.50, 77.70 ]
Rogers 2015 110 169 (119) 112 74 (107) 21.8 % 95.00 [ 65.21, 124.79 ]
Kim 2015 20 17.6 (16.03) 19 11.8 (11.6) 24.4 % 5.80 [ -2.95, 14.55 ]
Subtotal (95% CI) 598 338 100.0 % 39.42 [ -1.51, 80.34 ]
Heterogeneity: Tau2 = 1765.96; Chi2 = 35.84, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 1.89 (P = 0.059)
2 Follow-up
Vallance 2007 281 177.3 (190.8) 96 142 (126) 48.9 % 35.30 [ 1.64, 68.96 ]
Rogers 2015 105 137 (137) 108 63 (95) 51.1 % 74.00 [ 42.26, 105.74 ]
Subtotal (95% CI) 386 204 100.0 % 55.07 [ 17.16, 92.99 ]
Heterogeneity: Tau2 = 470.22; Chi2 = 2.69, df = 1 (P = 0.10); I2 =63%
Test for overall effect: Z = 2.85 (P = 0.0044)
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Analysis 8.16. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 16
Meeting recommended physical activity guidelines (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 16 Meeting recommended physical activity guidelines (follow-up values)








1 End of intervention
Pinto 2005 15/43 0/41 10.1 % 45.14 [ 2.59, 785.26 ]
Pinto 2015 15/36 2/32 15.9 % 10.71 [ 2.21, 51.88 ]
Irwin 2015 32/45 2/38 16.0 % 44.31 [ 9.28, 211.49 ]
Cadmus 2009 22/36 3/33 17.0 % 15.71 [ 4.02, 61.40 ]
Rogers 2015 58/106 24/110 20.3 % 4.33 [ 2.39, 7.83 ]
Short 2014 61/195 33/104 20.6 % 0.98 [ 0.59, 1.63 ]
Subtotal (95% CI) 461 358 100.0 % 8.44 [ 2.41, 29.56 ]
Total events: 203 (Physical activity), 64 (Control)
Heterogeneity: Tau2 = 1.92; Chi2 = 43.87, df = 5 (P<0.00001); I2 =89%
Test for overall effect: Z = 3.34 (P = 0.00085)
2 Follow-up
Pinto 2015 9/36 5/31 29.0 % 1.73 [ 0.51, 5.86 ]
Rogers 2015 48/105 19/108 71.0 % 3.94 [ 2.11, 7.38 ]
Subtotal (95% CI) 141 139 100.0 % 3.11 [ 1.50, 6.46 ]
Total events: 57 (Physical activity), 24 (Control)
Heterogeneity: Tau2 = 0.09; Chi2 = 1.38, df = 1 (P = 0.24); I2 =28%
Test for overall effect: Z = 3.04 (P = 0.0024)
0.001 0.01 0.1 1 10 100 1000
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463Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.17. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 17
Overall objective physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 17 Overall objective physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 30.7 (15.6) 9 31 (15.6) 5.5 % -0.02 [ -0.84, 0.80 ]
Matthews 2007 22 330.8 (114.7) 14 198.5 (55.4) 6.2 % 1.34 [ 0.60, 2.09 ]
Rogers 2014 20 294 (175) 22 154 (75) 7.4 % 1.04 [ 0.39, 1.69 ]
Rogers 2009 20 252191 (91893) 18 210917 (64078) 7.4 % 0.51 [ -0.14, 1.15 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 9.5 % 1.01 [ 0.50, 1.52 ]
Cadmus 2009 33 6738 (2958) 34 5537 (3352) 9.9 % 0.38 [ -0.11, 0.86 ]
Pinto 2005 39 37.5 (14.25) 43 33.62 (19.43) 10.8 % 0.22 [ -0.21, 0.66 ]
Rogers 2015 110 246 (153) 112 197 (138) 14.1 % 0.34 [ 0.07, 0.60 ]
Vallance 2007 253 8110.5 (4133.9) 85 8028 (3457) 14.4 % 0.02 [ -0.23, 0.27 ]
Short 2014 219 9363.07 (7922.79) 111 8301.2 (3373.4) 14.7 % 0.16 [ -0.07, 0.39 ]
Subtotal (95% CI) 768 480 100.0 % 0.43 [ 0.19, 0.66 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 27.65, df = 9 (P = 0.001); I2 =67%
Test for overall effect: Z = 3.58 (P = 0.00034)
2 Follow-up
Guinan 2013 16 38.4 (25.9) 9 53.4 (53.9) 18.9 % -0.38 [ -1.21, 0.44 ]
Pinto 2015 36 54.6 (81.6) 31 13.4 (35.2) 33.4 % 0.63 [ 0.14, 1.12 ]
Rogers 2015 105 216 (131) 108 192 (136) 47.7 % 0.18 [ -0.09, 0.45 ]
Subtotal (95% CI) 157 148 100.0 % 0.22 [ -0.21, 0.66 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 4.80, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 1.01 (P = 0.31)
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Analysis 8.18. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 18
Overall objective physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 18 Overall objective physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 -1.1 (6.2) 9 -7.9 (5.3) 16.0 % 1.11 [ 0.23, 2.00 ]
Matthews 2007 22 72.2 (114.6) 14 -16.8 (51.5) 18.5 % 0.91 [ 0.20, 1.62 ]
Rogers 2014 20 114 (109) 22 10 (70) 19.3 % 1.13 [ 0.47, 1.78 ]
Cadmus 2009 33 1621 (2108) 34 -60 (2341) 21.6 % 0.75 [ 0.25, 1.24 ]
Vallance 2007 253 -150 (5173.3) 85 91 (5155.4) 24.6 % -0.05 [ -0.29, 0.20 ]
Subtotal (95% CI) 344 164 100.0 % 0.71 [ 0.14, 1.29 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 22.94, df = 4 (P = 0.00013); I2 =83%
Test for overall effect: Z = 2.43 (P = 0.015)
2 Follow-up
Guinan 2013 16 6.75 (11) 9 14.5 (26.2) 48.2 % -0.42 [ -1.25, 0.41 ]
Rogers 2009 19 46082 (95608.9) 17 -15569 (28716.9) 51.8 % 0.83 [ 0.15, 1.52 ]
Subtotal (95% CI) 35 26 100.0 % 0.23 [ -1.00, 1.46 ]
Heterogeneity: Tau2 = 0.64; Chi2 = 5.24, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.37 (P = 0.72)
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Analysis 8.19. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 19
Objective moderate-vigorous physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 19 Objective moderate-vigorous physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2013 12 198.4 (111.7) 10 0 (0) Not estimable
Matthews 2007 22 12.4 (1) 14 8 (1) 20.0 % 4.30 [ 3.05, 5.55 ]
Rogers 2014 20 294 (175) 22 154 (75) 25.5 % 1.04 [ 0.39, 1.69 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 26.6 % 1.01 [ 0.50, 1.52 ]
Rogers 2015 110 246 (153) 112 197 (138) 27.9 % 0.34 [ 0.07, 0.60 ]
Subtotal (95% CI) 200 190 100.0 % 1.49 [ 0.47, 2.51 ]
Heterogeneity: Tau2 = 0.95; Chi2 = 41.60, df = 3 (P<0.00001); I2 =93%
Test for overall effect: Z = 2.85 (P = 0.0043)
2 Follow-up
Pinto 2015 36 54.6 (81.6) 31 13.4 (35.2) 39.2 % 0.63 [ 0.14, 1.12 ]
Rogers 2015 105 216 (131) 108 192 (136) 60.8 % 0.18 [ -0.09, 0.45 ]
Subtotal (95% CI) 141 139 100.0 % 0.36 [ -0.08, 0.79 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 2.50, df = 1 (P = 0.11); I2 =60%
Test for overall effect: Z = 1.61 (P = 0.11)
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Analysis 8.20. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 20
Objective moderate-vigorous physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 20 Objective moderate-vigorous physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Matthews 2007 22 1.8 (4.4) 14 -0.9 (2.5) 47.4 % 0.70 [ 0.01, 1.39 ]
Rogers 2014 20 114 (109) 22 10 (70) 52.6 % 1.13 [ 0.47, 1.78 ]
Subtotal (95% CI) 42 36 100.0 % 0.92 [ 0.45, 1.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 3.80 (P = 0.00015)
2 Follow-up
Rogers 2009 19 78.7 (119.2) 17 -21.4 (113.9) 100.0 % 0.84 [ 0.15, 1.52 ]
Subtotal (95% CI) 19 17 100.0 % 0.84 [ 0.15, 1.52 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.40 (P = 0.017)
-4 -2 0 2 4
Favours control Favours physical activity
467Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.21. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 21
Objective vigorous physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 21 Objective vigorous physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 15.7 (15.7) 9 11.2 (13.5) 38.6 % 0.29 [ -0.53, 1.11 ]
Rogers 2009 20 1.8 (4.3) 18 0 (0.001) 61.4 % 0.56 [ -0.09, 1.21 ]
Subtotal (95% CI) 36 27 100.0 % 0.46 [ -0.05, 0.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.76 (P = 0.078)
2 Follow-up
Guinan 2013 16 15.8 (22.2) 9 19.8 (29.4) 100.0 % -0.16 [ -0.97, 0.66 ]
Subtotal (95% CI) 16 9 100.0 % -0.16 [ -0.97, 0.66 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
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Analysis 8.22. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 22
Accelerometer counts (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 22 Accelerometer counts (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Matthews 2007 22 330.8 (114.7) 14 198.5 (55.4) 47.5 % 1.34 [ 0.60, 2.09 ]
Rogers 2009 20 252191 (91893) 18 210917 (64078) 52.5 % 0.51 [ -0.14, 1.15 ]
Subtotal (95% CI) 42 32 100.0 % 0.90 [ 0.08, 1.72 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 2.75, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 2.16 (P = 0.031)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 8.23. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 23
Pedometer/accelerometer steps/d (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 23 Pedometer/accelerometer steps/d (follow-up values)







N Mean(SD)[steps/day]N Mean(SD)[steps/day]IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Matthews 2007 22 8561.8 (2887.3) 14 5379.9 (1798.1) 11.4 % 1.23 [ 0.50, 1.97 ]
Rogers 2009 20 7301 (2266) 18 8388 (5361) 13.6 % -0.26 [ -0.90, 0.38 ]
Cadmus 2009 33 6738 (2958) 34 5537 (3352) 18.3 % 0.38 [ -0.11, 0.86 ]
Vallance 2007 253 8110.5 (4133.9) 85 8028 (3457) 28.0 % 0.02 [ -0.23, 0.27 ]
Short 2014 219 9363.07 (7922.79) 111 8301.2 (3373.4) 28.7 % 0.16 [ -0.07, 0.39 ]
Subtotal (95% CI) 547 262 100.0 % 0.22 [ -0.08, 0.53 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 11.83, df = 4 (P = 0.02); I2 =66%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 8.24. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 24
Pedometer/accelerometer steps/d (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 24 Pedometer/accelerometer steps/d (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Matthews 2007 22 1152.5 (2408.8) 14 -559.1 (1326.5) 27.7 % 0.81 [ 0.11, 1.51 ]
Cadmus 2009 33 1621 (2108) 34 -60 (2341) 33.2 % 0.75 [ 0.25, 1.24 ]
Vallance 2007 253 -150 (5173.3) 85 91 (5155.4) 39.2 % -0.05 [ -0.29, 0.20 ]
Subtotal (95% CI) 308 133 100.0 % 0.45 [ -0.18, 1.09 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 11.38, df = 2 (P = 0.003); I2 =82%
Test for overall effect: Z = 1.40 (P = 0.16)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 8.25. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 25
Overall sedentary behaviour (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 25 Overall sedentary behaviour (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Matthews 2007 22 72.3 (1.5) 14 79.5 (1.8) 21.8 % -4.34 [ -5.60, -3.09 ]
Guinan 2013 16 446 (127) 9 385.8 (107.9) 24.8 % 0.48 [ -0.35, 1.31 ]
Rogers 2014 20 7141.4 (536.2) 22 7549.2 (628.4) 26.0 % -0.68 [ -1.31, -0.06 ]
Short 2014 (1) 195 481.7 (225.7) 104 486.5 (211.1) 27.5 % -0.02 [ -0.26, 0.22 ]
Subtotal (95% CI) 253 149 100.0 % -1.01 [ -2.28, 0.26 ]
Heterogeneity: Tau2 = 1.50; Chi2 = 48.79, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.56 (P = 0.12)
2 Follow-up
Guinan 2013 16 438 (121.6) 9 359.5 (149.3) 100.0 % 0.58 [ -0.26, 1.41 ]
Subtotal (95% CI) 16 9 100.0 % 0.58 [ -0.26, 1.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
-10 -5 0 5 10
Favours physical activity Favours control
(1) Week day sitting time
472Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 8.26. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 26
Objective sedentary behaviour (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 26 Objective sedentary behaviour (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Matthews 2007 22 72.3 (1.5) 14 79.5 (1.8) 31.8 % -4.34 [ -5.60, -3.09 ]
Guinan 2013 16 446 (127) 9 385.8 (107.9) 33.7 % 0.48 [ -0.35, 1.31 ]
Rogers 2014 20 7141.4 (536.2) 22 7549.2 (628.4) 34.4 % -0.68 [ -1.31, -0.06 ]
Subtotal (95% CI) 58 45 100.0 % -1.45 [ -3.68, 0.78 ]
Heterogeneity: Tau2 = 3.65; Chi2 = 39.84, df = 2 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Follow-up
Guinan 2013 16 438 (121.6) 9 359.5 (149.3) 100.0 % 0.58 [ -0.26, 1.41 ]
Subtotal (95% CI) 16 9 100.0 % 0.58 [ -0.26, 1.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
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Analysis 8.27. Comparison 8 Comparison: physical activity, all physical activity vs control, Outcome 27
Objective sedentary behaviour (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 8 Comparison: physical activity, all physical activity vs control
Outcome: 27 Objective sedentary behaviour (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Guinan 2013 16 18.5 (52.2) 9 -19.8 (62.8) 28.1 % 0.66 [ -0.18, 1.50 ]
Matthews 2007 22 -1.3 (7.3) 14 2.3 (5.6) 34.3 % -0.53 [ -1.21, 0.16 ]
Rogers 2014 20 -84.4 (788.2) 22 -55.2 (435.3) 37.6 % -0.05 [ -0.65, 0.56 ]
Subtotal (95% CI) 58 45 100.0 % -0.01 [ -0.63, 0.60 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 4.60, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 0.04 (P = 0.97)
2 Follow-up
Guinan 2013 16 10.5 (46.7) 9 -46.1 (84.2) 100.0 % 0.88 [ 0.02, 1.74 ]
Subtotal (95% CI) 16 9 100.0 % 0.88 [ 0.02, 1.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.045)
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Analysis 9.1. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 1 Mass (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 1 Mass (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Matthews 2007 22 74.9 (15.2) 14 78.9 (20.3) 0.2 % -4.00 [ -16.39, 8.39 ]
Mustian 2004 11 67.1 (10.42) 10 68.6 (13.84) 0.3 % -1.50 [ -12.06, 9.06 ]
Courneya 2003 24 78.2 (20.5) 26 80.1 (16.2) 0.3 % -1.90 [ -12.20, 8.40 ]
Nikander 2007 14 73.5 (13.3) 14 75.5 (12) 0.4 % -2.00 [ -11.38, 7.38 ]
Cadmus 2009 36 80.73 (16.88) 33 78.51 (20.64) 0.4 % 2.22 [ -6.72, 11.16 ]
Herrero 2006 8 65.6 (8.7) 8 67.3 (8.9) 0.4 % -1.70 [ -10.32, 6.92 ]
Rahnama 2010 14 69.4 (13.5) 15 71.6 (9.2) 0.5 % -2.20 [ -10.67, 6.27 ]
DeNysschen 2011 30 69.3 (14.2) 34 72.4 (19.6) 0.5 % -3.10 [ -11.42, 5.22 ]
Ligibel 2008 40 80 (17.5) 42 83.3 (18.7) 0.5 % -3.30 [ -11.14, 4.54 ]
Littman 2012 28 81.1 (13.6) 27 81.3 (14.3) 0.6 % -0.20 [ -7.58, 7.18 ]
Winters-Stone 2011 36 76.5 (15.6) 31 74.2 (12.3) 0.7 % 2.30 [ -4.39, 8.99 ]
Daley 2007 33 74.26 (12.49) 69 75.6 (12.5) 1.2 % -1.34 [ -6.52, 3.84 ]
Murtezani 2014 30 71.7 (9.5) 32 72.6 (10.75) 1.3 % -0.90 [ -5.94, 4.14 ]
Schmitz 2009 131 76.15 (15.66) 133 77.19 (17.02) 2.1 % -1.04 [ -4.98, 2.90 ]
Schmitz 2005 39 69.5 (2.22) 40 69.2 (2.2) 35.1 % 0.30 [ -0.67, 1.27 ]
Kiecolt-Glaser 2014 96 75.2 (2.8) 90 75.2 (2.6) 55.3 % 0.0 [ -0.78, 0.78 ]
Subtotal (95% CI) 592 618 100.0 % 0.00 [ -0.57, 0.58 ]
Heterogeneity: Chi2 = 4.11, df = 15 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
2 Follow-up
Cadmus 2009 26 81.6 (18.97) 23 76.58 (17.41) 100.0 % 5.02 [ -5.17, 15.21 ]
Subtotal (95% CI) 26 23 100.0 % 5.02 [ -5.17, 15.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 9.2. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 2 Mass (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 2 Mass (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Dolan 2016 23 -0.55 (5.04) 10 1.44 (1.62) 3.7 % -1.99 [ -4.28, 0.30 ]
Irwin 2015 45 -2.1 (4.3) 38 0.1 (3.6) 5.8 % -2.20 [ -3.90, -0.50 ]
Mustian 2004 9 -0.3 (1.86) 10 0.6 (1.43) 6.9 % -0.90 [ -2.40, 0.60 ]
Ligibel 2008 22 0 (2.3) 14 0.04 (2.16) 7.0 % -0.04 [ -1.52, 1.44 ]
Matthews 2007 22 0.01 (2.09) 14 0.04 (2.16) 7.3 % -0.03 [ -1.46, 1.40 ]
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 7.7 % -0.60 [ -1.98, 0.78 ]
Murtezani 2014 30 -2.3 (2.4) 32 -0.3 (2.6) 8.6 % -2.00 [ -3.24, -0.76 ]
Naumann 2012 11 0.45 (1.33) 10 0.12 (1.52) 8.8 % 0.33 [ -0.90, 1.56 ]
Courneya 2003 24 0.1 (2) 26 0.7 (1.8) 10.3 % -0.60 [ -1.66, 0.46 ]
Saarto 2012 262 0.66 (3.68) 236 0.67 (3.84) 14.6 % -0.01 [ -0.67, 0.65 ]
Schmitz 2005 39 0.32 (0.43) 40 0.2 (0.42) 19.4 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 552 495 100.0 % -0.50 [ -0.98, -0.01 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 24.45, df = 10 (P = 0.01); I2 =59%
Test for overall effect: Z = 2.01 (P = 0.045)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.3. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 3 BMI (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 3 BMI (follow-up values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Portela 2008 25 29.1 (5.5) 9 34.7 (15) 0.0 % -5.60 [ -15.63, 4.43 ]
Rogers 2013 12 33.6 (7) 10 30.6 (7.28) 0.1 % 3.00 [ -3.00, 9.00 ]
Rogers 2009 20 30.6 (7.6) 18 30.4 (8.3) 0.2 % 0.20 [ -4.88, 5.28 ]
Mustian 2004 11 23.9 (4.17) 10 26.7 (5.59) 0.2 % -2.80 [ -7.05, 1.45 ]
Nikander 2007 14 26.9 (5.6) 14 27.7 (4.9) 0.3 % -0.80 [ -4.70, 3.10 ]
Courneya 2003 24 29.4 (7.4) 26 29.3 (6) 0.3 % 0.10 [ -3.65, 3.85 ]
Rogers 2014 20 29.6 (5) 22 32.2 (6.7) 0.3 % -2.60 [ -6.16, 0.96 ]
Rahnama 2010 14 27.74 (4.77) 15 28.04 (4.6) 0.4 % -0.30 [ -3.71, 3.11 ]
Cadmus 2009 36 30.45 (6) 33 29.9 (7.59) 0.4 % 0.55 [ -2.70, 3.80 ]
Ligibel 2008 40 30.3 (6.3) 42 31.5 (6.8) 0.5 % -1.20 [ -4.04, 1.64 ]
Littman 2012 28 27.66 (5.01) 27 29.01 (5.62) 0.5 % -1.35 [ -4.17, 1.47 ]
Pinto 2005 39 27.66 (5.01) 43 29.01 (5.62) 0.8 % -1.35 [ -3.65, 0.95 ]
Murtezani 2014 30 25.1 (2.9) 32 25.8 (3.47) 1.7 % -0.70 [ -2.29, 0.89 ]
Schmitz 2009 131 28.46 (5.55) 133 28.94 (6.27) 2.1 % -0.48 [ -1.91, 0.95 ]
Vallance 2007 253 27.01 (5.21) 85 27.2 (5.15) 2.6 % -0.19 [ -1.46, 1.08 ]
Schmitz 2005 39 26 (0.74) 40 25.8 (0.73) 40.1 % 0.20 [ -0.12, 0.52 ]
Kiecolt-Glaser 2014 96 27.8 (1.08) 90 27.8 (0.95) 49.5 % 0.0 [ -0.29, 0.29 ]
Subtotal (95% CI) 832 649 100.0 % 0.01 [ -0.19, 0.22 ]
Heterogeneity: Chi2 = 11.79, df = 16 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.4. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 4 BMI (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 4 BMI (change values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 2.5 % -0.60 [ -1.98, 0.78 ]
Mustian 2004 9 -0.42 (0.75) 10 0.29 (0.61) 8.8 % -0.71 [ -1.33, -0.09 ]
Rogers 2014 20 -0.2 (0.9) 22 -0.3 (1.1) 9.1 % 0.10 [ -0.51, 0.71 ]
Naumann 2012 11 0.1 (0.5) 10 -0.1 (0.57) 12.3 % 0.20 [ -0.26, 0.66 ]
Courneya 2003 24 0 (0.7) 26 0.3 (0.7) 14.3 % -0.30 [ -0.69, 0.09 ]
Murtezani 2014 30 -0.8 (0.7) 32 -0.14 (0.8) 14.7 % -0.66 [ -1.03, -0.29 ]
Ligibel 2008 40 0 (0.9) 42 0.2 (0.8) 14.9 % -0.20 [ -0.57, 0.17 ]
Schmitz 2005 39 0.06 (0.17) 40 0.07 (0.16) 23.4 % -0.01 [ -0.08, 0.06 ]
Subtotal (95% CI) 238 247 100.0 % -0.22 [ -0.45, 0.01 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 19.97, df = 7 (P = 0.01); I2 =65%
Test for overall effect: Z = 1.83 (P = 0.067)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.5. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 5 Overall body fat (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 5 Overall body fat (follow-up values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 22 (5) 8 22 (4) 2.2 % 0.0 [ -0.98, 0.98 ]
Cerulli 2014 10 26.72 (5.34) 10 30.55 (4.4) 2.5 % -0.75 [ -1.66, 0.16 ]
Mustian 2004 11 38.5 (4.47) 10 41.7 (4.89) 2.6 % -0.66 [ -1.54, 0.23 ]
Rogers 2013 10 44.2 (6.7) 12 42.3 (7.7) 2.8 % 0.25 [ -0.59, 1.09 ]
Matthews 2007 22 39.7 (6.3) 14 43.1 (6.9) 4.0 % -0.51 [ -1.19, 0.17 ]
Musanti 2012 30 34.13 (6.64) 12 33.7 (5.7) 4.1 % 0.07 [ -0.60, 0.74 ]
Rogers 2009 20 44.3 (7.4) 19 43.5 (7.5) 4.5 % 0.11 [ -0.52, 0.73 ]
Rogers 2014 20 38.6 (6.4) 22 41.5 (7.4) 4.7 % -0.41 [ -1.02, 0.20 ]
Courneya 2003 24 131.9 (46.4) 26 137.1 (44.4) 5.4 % -0.11 [ -0.67, 0.44 ]
DeNysschen 2011 30 36.9 (8.4) 34 38 (10.2) 6.3 % -0.12 [ -0.61, 0.38 ]
Winters-Stone 2011 36 40.5 (6.2) 31 38.5 (5.8) 6.5 % 0.33 [ -0.16, 0.81 ]
Saarto 2012 37 39.9 (7.5) 30 40.2 (8) 6.5 % -0.04 [ -0.52, 0.44 ]
Cadmus 2009 36 40.54 (6.55) 33 39.6 (5.97) 6.6 % 0.15 [ -0.33, 0.62 ]
Schmitz 2005 39 40.91 (1.31) 40 42.29 (1.3) 6.7 % -1.05 [ -1.52, -0.58 ]
Pinto 2005 39 37.53 (4.79) 43 38.55 (4.83) 7.3 % -0.21 [ -0.64, 0.22 ]
Ligibel 2008 40 42.9 (7.4) 42 44.7 (8) 7.3 % -0.23 [ -0.67, 0.20 ]
Daley 2007 33 39.4 (4.74) 69 40.1 (7.4) 7.7 % -0.10 [ -0.52, 0.31 ]
Schmitz 2009 130 38.47 (5.93) 132 39.74 (5.9) 12.1 % -0.21 [ -0.46, 0.03 ]
Subtotal (95% CI) 575 587 100.0 % -0.18 [ -0.34, -0.03 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 26.29, df = 17 (P = 0.07); I2 =35%
Test for overall effect: Z = 2.29 (P = 0.022)
2 Follow-up
Cadmus 2009 26 40.02 (7.06) 23 39.5 (6.14) 100.0 % 0.08 [ -0.48, 0.64 ]
Subtotal (95% CI) 26 23 100.0 % 0.08 [ -0.48, 0.64 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.27 (P = 0.79)
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Analysis 9.6. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 6 Overall body fat (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 6 Overall body fat (change values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 9 -0.16 (2.91) 10 0.28 (1.57) 9.8 % -0.18 [ -1.09, 0.72 ]
Naumann 2012 11 -0.3 (2.42) 10 0.8 (2.75) 10.0 % -0.41 [ -1.28, 0.46 ]
Musanti 2012 30 -0.24 (2.83) 12 1.4 (1.57) 10.9 % -0.63 [ -1.32, 0.05 ]
Matthews 2007 22 -0.2 (1.62) 14 0.41 (1.94) 11.0 % -0.34 [ -1.02, 0.33 ]
Schmitz 2005 39 -1.15 (0.45) 40 0.23 (0.44) 11.1 % -3.07 [ -3.73, -2.41 ]
Rogers 2014 20 -1.1 (2.2) 22 -0.6 (2.4) 11.3 % -0.21 [ -0.82, 0.39 ]
Courneya 2003 24 -4.9 (15.7) 26 5.1 (24.4) 11.5 % -0.48 [ -1.04, 0.09 ]
Ligibel 2008 40 -0.2 (1.7) 42 0.3 (1.7) 12.1 % -0.29 [ -0.73, 0.14 ]
Schmitz 2009 (1) 65 -0.3 (5.7) 63 -0.1 (3.3) 12.4 % -0.04 [ -0.39, 0.30 ]
Subtotal (95% CI) 260 239 100.0 % -0.62 [ -1.19, -0.06 ]
Heterogeneity: Tau2 = 0.65; Chi2 = 67.55, df = 8 (P<0.00001); I2 =88%
Test for overall effect: Z = 2.15 (P = 0.031)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
-4 -2 0 2 4
Favours physical activity Favours control
(1) with lymphedema
480Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.7. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 7 Percentage body fat - DEXA (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 7 Percentage body fat - DEXA (follow-up values)





N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 44.3 (7.4) 19 43.5 (7.5) 4.4 % 0.80 [ -3.88, 5.48 ]
DeNysschen 2011 30 36.9 (8.4) 34 38 (10.2) 4.7 % -1.10 [ -5.66, 3.46 ]
Cadmus 2009 36 40.54 (6.55) 33 39.6 (5.97) 9.9 % 0.94 [ -2.01, 3.89 ]
Winters-Stone 2011 36 40.5 (6.2) 31 38.5 (5.8) 10.3 % 2.00 [ -0.88, 4.88 ]
Schmitz 2009 130 38.47 (5.93) 132 39.74 (5.9) 26.0 % -1.27 [ -2.70, 0.16 ]
Schmitz 2005 39 40.91 (1.31) 40 42.29 (1.3) 44.8 % -1.38 [ -1.96, -0.80 ]
Subtotal (95% CI) 291 289 100.0 % -0.66 [ -1.70, 0.37 ]
Heterogeneity: Tau2 = 0.53; Chi2 = 7.84, df = 5 (P = 0.17); I2 =36%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Follow-up
Cadmus 2009 26 40.02 (7.06) 23 39.5 (6.14) 100.0 % 0.52 [ -3.18, 4.22 ]
Subtotal (95% CI) 26 23 100.0 % 0.52 [ -3.18, 4.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
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Analysis 9.8. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 8 Percentage body fat - DEXA (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 8 Percentage body fat - DEXA (change values)





N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Naumann 2012 11 -0.3 (2.42) 10 0.8 (2.75) 2.2 % -1.10 [ -3.32, 1.12 ]
Schmitz 2009 (1) 65 -0.3 (5.7) 63 -0.1 (3.3) 4.2 % -0.20 [ -1.81, 1.41 ]
Schmitz 2005 39 -1.15 (0.45) 40 0.23 (0.44) 93.6 % -1.38 [ -1.58, -1.18 ]
Subtotal (95% CI) 115 113 100.0 % -1.32 [ -1.66, -0.99 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.09, df = 2 (P = 0.35); I2 =4%
Test for overall effect: Z = 7.79 (P < 0.00001)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.9. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 9 Percentage body fat - BIA (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 9 Percentage body fat - BIA (follow-up values)





N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2013 10 44.2 (6.7) 12 42.3 (7.7) 5.2 % 1.90 [ -4.12, 7.92 ]
Cerulli 2014 10 26.72 (5.34) 10 30.55 (4.4) 10.3 % -3.83 [ -8.12, 0.46 ]
Rogers 2014 20 38.6 (6.4) 22 41.5 (7.4) 10.8 % -2.90 [ -7.07, 1.27 ]
Mustian 2004 11 38.5 (4.47) 10 41.7 (4.89) 11.7 % -3.20 [ -7.22, 0.82 ]
Musanti 2012 30 34.13 (6.64) 12 33.7 (5.7) 11.8 % 0.43 [ -3.58, 4.44 ]
Ligibel 2008 40 42.9 (7.4) 42 44.7 (8) 17.0 % -1.80 [ -5.13, 1.53 ]
Daley 2007 33 39.4 (4.74) 69 40.1 (7.4) 33.3 % -0.70 [ -3.08, 1.68 ]
Subtotal (95% CI) 154 177 100.0 % -1.47 [ -2.84, -0.10 ]
Heterogeneity: Chi2 = 4.83, df = 6 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.10 (P = 0.036)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.10. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 10 Percentage body fat - BIA (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 10 Percentage body fat - BIA (change values)





N Mean(SD)[%] N Mean(SD)[%] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Mustian 2004 9 -0.16 (2.91) 10 0.28 (1.57) 7.0 % -0.44 [ -2.58, 1.70 ]
Rogers 2014 20 -1.1 (2.2) 22 -0.6 (2.4) 16.5 % -0.50 [ -1.89, 0.89 ]
Musanti 2012 30 -0.24 (2.83) 12 1.4 (1.57) 17.6 % -1.64 [ -2.99, -0.29 ]
Ligibel 2008 40 -0.2 (1.7) 42 0.3 (1.7) 58.9 % -0.50 [ -1.24, 0.24 ]
Subtotal (95% CI) 99 86 100.0 % -0.70 [ -1.26, -0.13 ]
Heterogeneity: Chi2 = 2.29, df = 3 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.42 (P = 0.016)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.11. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 11 Percentage body fat - SKF (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 11 Percentage body fat - SKF (follow-up values)





N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Herrero 2006 8 22 (5) 8 22 (4) 14.4 % 0.0 [ -4.44, 4.44 ]
Saarto 2012 37 39.9 (7.5) 30 40.2 (8) 20.2 % -0.30 [ -4.05, 3.45 ]
Pinto 2005 39 37.53 (4.79) 43 38.55 (4.83) 65.4 % -1.02 [ -3.10, 1.06 ]
Subtotal (95% CI) 84 81 100.0 % -0.73 [ -2.41, 0.96 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.12. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 12 Fat mass (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 12 Fat mass (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Matthews 2007 22 30.2 (9.2) 14 34.9 (14.5) 0.7 % -4.70 [ -13.21, 3.81 ]
Herrero 2006 8 14.7 (4.8) 8 15.3 (4.6) 2.3 % -0.60 [ -5.21, 4.01 ]
Winters-Stone 2011 36 30.9 (9.7) 31 29 (8.1) 2.7 % 1.90 [ -2.36, 6.16 ]
Schmitz 2009 129 29.57 (9.59) 133 31.08 (10.53) 8.2 % -1.51 [ -3.95, 0.93 ]
Schmitz 2005 39 28.29 (1.72) 40 28.97 (1.7) 86.1 % -0.68 [ -1.43, 0.07 ]
Subtotal (95% CI) 234 226 100.0 % -0.70 [ -1.40, 0.00 ]
Heterogeneity: Chi2 = 2.71, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.97 (P = 0.049)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.13. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 13 Fat mass (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 13 Fat mass (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Schmitz 2009 (1) 65 -1.2 (8) 63 0.6 (8.1) 4.4 % -1.80 [ -4.59, 0.99 ]
Matthews 2007 22 -0.13 (1.85) 14 0.35 (2.46) 12.4 % -0.48 [ -1.98, 1.02 ]
Saarto 2012 262 0.7 (2.79) 263 0.65 (2.87) 37.1 % 0.05 [ -0.43, 0.53 ]
Schmitz 2005 39 -0.52 (0.43) 40 0.22 (0.43) 46.1 % -0.74 [ -0.93, -0.55 ]
Subtotal (95% CI) 388 380 100.0 % -0.46 [ -1.08, 0.15 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 9.58, df = 3 (P = 0.02); I2 =69%
Test for overall effect: Z = 1.47 (P = 0.14)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.14. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 14 Fat mass - DEXA (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 14 Fat mass - DEXA (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Winters-Stone 2011 36 30.9 (9.7) 31 29 (8.1) 2.8 % 1.90 [ -2.36, 6.16 ]
Schmitz 2009 129 29.57 (9.59) 133 31.08 (10.53) 8.5 % -1.51 [ -3.95, 0.93 ]
Schmitz 2005 39 28.29 (1.72) 40 28.97 (1.7) 88.7 % -0.68 [ -1.43, 0.07 ]
Subtotal (95% CI) 204 204 100.0 % -0.68 [ -1.39, 0.03 ]
Heterogeneity: Chi2 = 1.85, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.061)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.15. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 15 Fat mass - DEXA (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 15 Fat mass - DEXA (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Schmitz 2009 (1) 65 -1.2 (8) 63 0.6 (8.1) 0.5 % -1.80 [ -4.59, 0.99 ]
Schmitz 2005 39 -0.52 (0.43) 40 0.22 (0.43) 99.5 % -0.74 [ -0.93, -0.55 ]
Subtotal (95% CI) 104 103 100.0 % -0.74 [ -0.93, -0.56 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 7.72 (P < 0.00001)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.16. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 16 Lean mass (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 16 Lean mass (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Herrero 2006 8 28 (2.7) 8 28.3 (2.9) 2.6 % -0.10 [ -1.08, 0.88 ]
Mustian 2004 9 40.2 (7.6) 10 39.1 (5.5) 3.1 % 0.16 [ -0.74, 1.06 ]
Matthews 2007 22 44.8 (7.7) 14 44 (7.6) 5.6 % 0.10 [ -0.57, 0.77 ]
DeNysschen 2011 30 39.5 (5.2) 34 40.7 (6.1) 10.4 % -0.21 [ -0.70, 0.28 ]
Winters-Stone 2011 36 44 (6.7) 31 45.2 (6) 10.9 % -0.19 [ -0.67, 0.30 ]
Cadmus 2009 36 44.35 (6.6) 33 42.68 (7.19) 11.3 % 0.24 [ -0.23, 0.71 ]
Schmitz 2005 39 38.78 (0.77) 40 37.66 (4.9) 12.8 % 0.31 [ -0.13, 0.76 ]
Schmitz 2009 130 47.68 (7.47) 132 47.32 (7.59) 43.2 % 0.05 [ -0.19, 0.29 ]
Subtotal (95% CI) 310 302 100.0 % 0.05 [ -0.11, 0.21 ]
Heterogeneity: Chi2 = 4.12, df = 7 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
2 Follow-up
Cadmus 2009 26 44.62 (7.65) 23 42.21 (6.74) 100.0 % 0.33 [ -0.24, 0.89 ]
Subtotal (95% CI) 26 23 100.0 % 0.33 [ -0.24, 0.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
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Analysis 9.17. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 17 Lean mass (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 17 Lean mass (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 9 -0.03 (3.05) 10 0.36 (1.36) 18.1 % -0.16 [ -1.06, 0.74 ]
Schmitz 2005 39 0.88 (0.23) 40 0.02 (0.23) 19.2 % 3.70 [ 2.96, 4.44 ]
Matthews 2007 22 0.21 (1.44) 14 -0.31 (1.1) 19.6 % 0.39 [ -0.29, 1.06 ]
Schmitz 2009 (1) 65 -1 (3.4) 63 -1.1 (3.6) 21.3 % 0.03 [ -0.32, 0.37 ]
Saarto 2012 262 0.35 (1.8) 236 0.11 (1.6) 21.7 % 0.14 [ -0.04, 0.32 ]
Subtotal (95% CI) 397 363 100.0 % 0.80 [ -0.13, 1.72 ]
Heterogeneity: Tau2 = 1.02; Chi2 = 87.93, df = 4 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.68 (P = 0.093)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.18. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 18 Lean mass - DEXA (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 18 Lean mass - DEXA (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Cadmus 2009 36 44.35 (6.6) 33 42.68 (7.19) 8.9 % 1.67 [ -1.60, 4.94 ]
Winters-Stone 2011 36 44 (6.7) 31 45.2 (6) 10.2 % -1.20 [ -4.24, 1.84 ]
DeNysschen 2011 30 39.5 (5.2) 34 40.7 (6.1) 12.4 % -1.20 [ -3.97, 1.57 ]
Schmitz 2009 130 47.68 (7.47) 132 47.32 (7.59) 28.5 % 0.36 [ -1.46, 2.18 ]
Schmitz 2005 39 38.78 (0.77) 40 37.66 (4.9) 40.1 % 1.12 [ -0.42, 2.66 ]
Subtotal (95% CI) 271 270 100.0 % 0.43 [ -0.54, 1.40 ]
Heterogeneity: Chi2 = 3.77, df = 4 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
2 Follow-up
Cadmus 2009 26 44.62 (7.65) 23 42.21 (6.74) 100.0 % 2.41 [ -1.62, 6.44 ]
Subtotal (95% CI) 26 23 100.0 % 2.41 [ -1.62, 6.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
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Analysis 9.19. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 19 Lean mass - DEXA (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 19 Lean mass - DEXA (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Schmitz 2009 (1) 65 -1 (3.4) 63 -1.1 (3.6) 17.0 % 0.10 [ -1.11, 1.31 ]
Schmitz 2005 39 0.88 (0.23) 40 0.02 (0.23) 83.0 % 0.86 [ 0.76, 0.96 ]
Subtotal (95% CI) 104 103 100.0 % 0.73 [ 0.17, 1.29 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 1.50, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 2.56 (P = 0.011)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.20. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 20 Waist-to-hip ratio (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 20 Waist-to-hip ratio (follow-up values)





N Mean(SD)[cm] N Mean(SD)[cm] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rahnama 2010 14 0.98 (0.7) 15 0.94 (0.7) 0.5 % 0.04 [ -0.47, 0.55 ]
Rogers 2014 20 0.8 (0.1) 22 0.9 (0.1) 19.0 % -0.10 [ -0.16, -0.04 ]
Ligibel 2008 40 0.8 (0.1) 42 0.8 (0.1) 25.8 % 0.0 [ -0.04, 0.04 ]
Rogers 2009 20 0.82 (0.06) 18 0.82 (0.07) 26.6 % 0.0 [ -0.04, 0.04 ]
Rogers 2013 12 0.8 (0.04) 10 0.83 (0.05) 28.1 % -0.03 [ -0.07, 0.01 ]
Subtotal (95% CI) 106 107 100.0 % -0.03 [ -0.06, 0.01 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 8.65, df = 4 (P = 0.07); I2 =54%
Test for overall effect: Z = 1.49 (P = 0.14)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.21. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 21 Waist-to-hip ratio (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 21 Waist-to-hip ratio (change values)





N Mean(SD)[cm] N Mean(SD)[cm] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2014 20 0 (0.00001) 22 0 (0.1) 11.9 % 0.0 [ -0.04, 0.04 ]
Ligibel 2008 40 0 (0.04) 42 0 (0.03) 88.1 % 0.0 [ -0.02, 0.02 ]
Subtotal (95% CI) 60 64 100.0 % 0.0 [ -0.01, 0.01 ]
Heterogeneity: Chi2 = 0.0, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
2 Follow-up
Rogers 2009 19 0.02 (0.36) 17 -0.02 (0.14) 100.0 % 0.04 [ -0.14, 0.22 ]
Subtotal (95% CI) 19 17 100.0 % 0.04 [ -0.14, 0.22 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.65)
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Analysis 9.22. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 22 Waist circumference (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 22 Waist circumference (follow-up values)





N Mean(SD)[cm] N Mean(SD)[cm] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rahnama 2010 14 96.4 (12.9) 15 99.8 (13.5) 7.8 % -3.40 [ -13.01, 6.21 ]
Guinan 2013 16 85.6 (12.5) 10 84.8 (10.8) 8.7 % 0.80 [ -8.27, 9.87 ]
Cadmus 2009 36 89.75 (12.63) 33 88.58 (15.48) 16.0 % 1.17 [ -5.53, 7.87 ]
Ligibel 2008 40 89.2 (14.7) 42 92.5 (13.5) 19.2 % -3.30 [ -9.42, 2.82 ]
Schmitz 2005 33 94.59 (12.6) 36 94.45 (12.6) 20.3 % 0.14 [ -5.81, 6.09 ]
Littman 2012 28 93.1 (8.5) 27 92.7 (10.5) 28.1 % 0.40 [ -4.66, 5.46 ]
Subtotal (95% CI) 167 163 100.0 % -0.50 [ -3.18, 2.18 ]
Heterogeneity: Chi2 = 1.64, df = 5 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
2 Follow-up
Guinan 2013 16 86.2 (12.2) 10 84.8 (12.3) 100.0 % 1.40 [ -8.29, 11.09 ]
Subtotal (95% CI) 16 10 100.0 % 1.40 [ -8.29, 11.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
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Analysis 9.23. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 23 Waist circumference (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 23 Waist circumference (change values)





N Mean(SD)[cm] N Mean(SD)[cm] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cadmus 2009 35 -1.49 (4.5) 30 -0.75 (4.49) 11.3 % -0.74 [ -2.93, 1.45 ]
Dolan 2016 23 -2.3 (2.7) 10 1.95 (2.98) 11.6 % -4.25 [ -6.40, -2.10 ]
Ligibel 2008 40 -1.5 (4.6) 42 0.3 (3.8) 14.6 % -1.80 [ -3.63, 0.03 ]
Guinan 2013 16 -1.8 (1.69) 10 -0.2 (1.54) 22.6 % -1.60 [ -2.86, -0.34 ]
Schmitz 2005 39 0.14 (1.05) 40 1.41 (1.04) 40.0 % -1.27 [ -1.73, -0.81 ]
Subtotal (95% CI) 153 132 100.0 % -1.71 [ -2.56, -0.86 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 7.67, df = 4 (P = 0.10); I2 =48%
Test for overall effect: Z = 3.94 (P = 0.000081)
2 Follow-up
Guinan 2013 16 -1.2 (2.25) 10 -0.3 (2.1) 100.0 % -0.90 [ -2.61, 0.81 ]
Subtotal (95% CI) 16 10 100.0 % -0.90 [ -2.61, 0.81 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
-10 -5 0 5 10
Favours physical activity Favours control
497Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 9.24. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 24 Hip circumference (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 24 Hip circumference (follow-up values)





N Mean(SD)[cm] N Mean(SD)[cm] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rahnama 2010 14 101.7 (9.4) 15 101.4 (10.4) 17.2 % 0.30 [ -6.91, 7.51 ]
Cadmus 2009 37 111.92 (12.56) 38 111.11 (14.97) 22.9 % 0.81 [ -5.44, 7.06 ]
Ligibel 2008 40 109.7 (13.2) 42 113.3 (14.5) 24.8 % -3.60 [ -9.60, 2.40 ]
Littman 2012 32 113 (10.1) 31 113.9 (10.3) 35.1 % -0.90 [ -5.94, 4.14 ]
Subtotal (95% CI) 123 126 100.0 % -0.97 [ -3.96, 2.01 ]
Heterogeneity: Chi2 = 1.17, df = 3 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 9.25. Comparison 9 Comparison: anthropometric outcomes, all physical activity vs control,
Outcome 25 Hip circumference (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 9 Comparison: anthropometric outcomes, all physical activity vs control
Outcome: 25 Hip circumference (change values)





N Mean(SD)[cm] N Mean(SD)[cm] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Ligibel 2008 40 -2.3 (3.3) 42 -0.5 (3.3) 41.1 % -1.80 [ -3.23, -0.37 ]
Dolan 2016 23 -2 (2.2) 10 0.77 (1.24) 58.9 % -2.77 [ -3.95, -1.59 ]
Subtotal (95% CI) 63 52 100.0 % -2.37 [ -3.31, -1.44 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 4.97 (P < 0.00001)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.1. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 1
Lower body strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 1 Lower body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cerulli 2014 10 114.88 (17.09) 10 79.13 (17.78) 5.9 % 1.96 [ 0.85, 3.07 ]
Rogers 2013 11 68.4 (15.5) 9 67.1 (16.2) 7.5 % 0.08 [ -0.80, 0.96 ]
Nikander 2007 14 1305 (177) 14 1393 (275) 8.7 % -0.37 [ -1.12, 0.38 ]
Rogers 2009 20 80.3 (27) 18 64.9 (19.7) 9.6 % 0.63 [ -0.02, 1.29 ]
Schmitz 2005 23 296.6 (48.9) 22 238.9 (46.4) 9.8 % 1.19 [ 0.55, 1.83 ]
Milne 2008 29 66.2 (10.2) 29 61.7 (11) 11.0 % 0.42 [ -0.10, 0.94 ]
Do 2015 32 13 (1.62) 30 13.15 (1.55) 11.2 % -0.09 [ -0.59, 0.41 ]
Saarto 2012 37 136 (23) 30 136 (29) 11.4 % 0.0 [ -0.48, 0.48 ]
Winters-Stone 2011 36 201.3 (57.4) 31 191 (51.7) 11.4 % 0.19 [ -0.30, 0.67 ]
Schmitz 2009 113 223.4 (59.6) 119 175.1 (53.5) 13.4 % 0.85 [ 0.58, 1.12 ]
Subtotal (95% CI) 325 312 100.0 % 0.44 [ 0.09, 0.78 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 35.25, df = 9 (P = 0.00005); I2 =74%
Test for overall effect: Z = 2.47 (P = 0.014)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.2. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 2
Lower body strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 2 Lower body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Nieman 1995 6 28.9 (13.7) 6 3.5 (22.5) 5.3 % 1.26 [ -0.03, 2.55 ]
Naumann 2012 11 7.7 (12.6) 10 3.5 (13.9) 8.9 % 0.30 [ -0.56, 1.17 ]
Dolan 2016 23 11.84 (8.89) 10 0.34 (11.1) 9.6 % 1.17 [ 0.37, 1.97 ]
Schmitz 2005 23 81.8 (48.92) 22 20.3 (45.97) 11.8 % 1.27 [ 0.63, 1.92 ]
Cormie 2014 43 37.6 (25.5) 19 6.7 (25.7) 12.8 % 1.19 [ 0.61, 1.78 ]
Do 2015 32 0.9 (0.7) 60 0.95 (0.61) 15.4 % -0.08 [ -0.51, 0.35 ]
Schmitz 2009 113 33.2 (33.9) 119 7.9 (26.6) 18.0 % 0.83 [ 0.56, 1.10 ]
Waltman 2010 110 4.42 (11.48) 113 0.19 (8.38) 18.1 % 0.42 [ 0.15, 0.69 ]
Subtotal (95% CI) 361 359 100.0 % 0.72 [ 0.38, 1.07 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 25.57, df = 7 (P = 0.00060); I2 =73%
Test for overall effect: Z = 4.13 (P = 0.000037)
2 Follow-up
Rogers 2009 19 11.9 (13.23) 17 0.7 (15.02) 100.0 % 0.78 [ 0.10, 1.46 ]
Subtotal (95% CI) 19 17 100.0 % 0.78 [ 0.10, 1.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.23 (P = 0.025)
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Analysis 10.3. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 3
Leg press (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 3 Leg press (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cerulli 2014 10 114.88 (17.09) 10 79.13 (17.78) 10.3 % 1.96 [ 0.85, 3.07 ]
Schmitz 2005 23 296.6 (48.9) 22 238.9 (46.4) 18.5 % 1.19 [ 0.55, 1.83 ]
Milne 2008 29 66.2 (10.2) 29 61.7 (11) 21.4 % 0.42 [ -0.10, 0.94 ]
Winters-Stone 2011 36 201.3 (57.4) 31 191 (51.7) 22.4 % 0.19 [ -0.30, 0.67 ]
Schmitz 2009 113 223.4 (59.6) 119 175.1 (53.5) 27.5 % 0.85 [ 0.58, 1.12 ]
Subtotal (95% CI) 211 211 100.0 % 0.79 [ 0.35, 1.22 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 13.79, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 3.54 (P = 0.00039)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.4. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 4
Leg press (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 4 Leg press (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Naumann 2012 11 7.7 (12.6) 10 3.5 (13.9) 8.4 % 0.30 [ -0.56, 1.17 ]
Dolan 2016 23 11.84 (8.89) 10 0.34 (11.1) 9.6 % 1.17 [ 0.37, 1.97 ]
Schmitz 2005 23 81.8 (48.92) 22 20.3 (45.97) 14.1 % 1.27 [ 0.63, 1.92 ]
Cormie 2014 43 37.6 (25.5) 19 6.7 (25.7) 16.9 % 1.19 [ 0.61, 1.78 ]
Schmitz 2009 113 33.2 (33.9) 119 7.9 (26.6) 51.1 % 0.83 [ 0.56, 1.10 ]
Subtotal (95% CI) 213 180 100.0 % 0.94 [ 0.68, 1.20 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 4.75, df = 4 (P = 0.31); I2 =16%
Test for overall effect: Z = 7.12 (P < 0.00001)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.5. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 5
Back & leg strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 5 Back % leg strength (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Rogers 2009 20 80.3 (27) 18 64.9 (19.7) 46.8 % 15.40 [ 0.47, 30.33 ]
Rogers 2013 11 68.4 (15.5) 9 67.1 (16.2) 53.2 % 1.30 [ -12.70, 15.30 ]
Subtotal (95% CI) 31 27 100.0 % 7.90 [ -2.31, 18.11 ]
Heterogeneity: Chi2 = 1.82, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 1.52 (P = 0.13)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.6. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 6
Leg extension (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 6 Leg extension (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cerulli 2014 10 51.83 (9.21) 10 44.25 (10.83) 11.9 % 0.72 [ -0.19, 1.63 ]
Nikander 2007 14 1305 (177) 14 1393 (275) 17.2 % -0.37 [ -1.12, 0.38 ]
Do 2015 32 13 (1.62) 30 13.15 (1.55) 34.5 % -0.09 [ -0.59, 0.41 ]
Saarto 2012 37 136 (23) 30 136 (29) 36.4 % 0.0 [ -0.48, 0.48 ]
Subtotal (95% CI) 93 84 100.0 % -0.01 [ -0.34, 0.32 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.47, df = 3 (P = 0.32); I2 =14%
Test for overall effect: Z = 0.06 (P = 0.96)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.7. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 7
Leg extension (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 7 Leg extension (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Nieman 1995 6 28.9 (13.7) 6 3.5 (22.5) 11.9 % 1.26 [ -0.03, 2.55 ]
Cormie 2014 43 37.6 (25.5) 19 6.7 (25.7) 25.5 % 1.19 [ 0.61, 1.78 ]
Do 2015 32 0.9 (0.7) 60 0.95 (0.61) 29.4 % -0.08 [ -0.51, 0.35 ]
Waltman 2010 110 4.42 (11.48) 113 0.19 (8.38) 33.1 % 0.42 [ 0.15, 0.69 ]
Subtotal (95% CI) 191 198 100.0 % 0.57 [ 0.03, 1.12 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 13.57, df = 3 (P = 0.004); I2 =78%
Test for overall effect: Z = 2.06 (P = 0.040)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
-4 -2 0 2 4
Favours control Favours physical activity
506Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.8. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 8
Hip extension (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 8 Hip extension (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Do 2015 32 14.2 (2.39) 30 14.7 (2.49) 43.5 % -0.20 [ -0.70, 0.30 ]
Waltman 2010 110 7.93 (20.59) 113 1.33 (11.21) 56.5 % 0.40 [ 0.13, 0.66 ]
Subtotal (95% CI) 142 143 100.0 % 0.14 [ -0.45, 0.72 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 4.33, df = 1 (P = 0.04); I2 =77%
Test for overall effect: Z = 0.46 (P = 0.65)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.9. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 9
Hip flexion (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 9 Hip flexion (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Do 2015 32 13.05 (2.06) 30 13.9 (2.17) 46.4 % -0.40 [ -0.90, 0.11 ]
Waltman 2010 110 2.93 (7.61) 113 -0.88 (10.39) 53.6 % 0.42 [ 0.15, 0.68 ]
Subtotal (95% CI) 142 143 100.0 % 0.04 [ -0.76, 0.83 ]
Heterogeneity: Tau2 = 0.29; Chi2 = 7.85, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.10 (P = 0.92)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.10. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 10
Leg flexion (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 10 Leg flexion (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cerulli 2014 10 52.56 (11.39) 10 36.76 (9.12) 36.6 % 1.47 [ 0.45, 2.48 ]
Waltman 2010 110 3.9 (10.13) 113 -0.01 (4.23) 63.4 % 0.50 [ 0.24, 0.77 ]
Subtotal (95% CI) 120 123 100.0 % 0.86 [ -0.05, 1.76 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 3.24, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 1.85 (P = 0.065)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.11. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 11
Upper body strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 11 Upper body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 11 29.6 (3.27) 10 26.7 (5.73) 6.1 % 0.60 [ -0.28, 1.49 ]
Cerulli 2014 10 16.08 (5.43) 10 17.2 (8.05) 6.2 % -0.16 [ -1.03, 0.72 ]
Portela 2008 25 39.3 (12.3) 9 35.6 (13.1) 6.8 % 0.29 [ -0.48, 1.05 ]
Nikander 2007 14 131 (20) 14 129 (28) 7.0 % 0.08 [ -0.66, 0.82 ]
Musanti 2012 30 52.13 (20.98) 12 36.75 (20) 7.3 % 0.73 [ 0.04, 1.42 ]
Schmitz 2005 23 83 (13.4) 22 63 (12.7) 7.4 % 1.50 [ 0.84, 2.17 ]
Rogers 2009 20 27.9 (5.04) 18 24.3 (6.18) 7.5 % 0.63 [ -0.03, 1.28 ]
Kaltsatou 2011 28 59.63 (8.49) 26 47.62 (9.83) 7.9 % 1.29 [ 0.70, 1.88 ]
Milne 2008 29 7.6 (2.9) 29 9.4 (2.6) 8.3 % -0.64 [ -1.17, -0.12 ]
Do 2015 32 9.65 (1.67) 30 10.05 (1.68) 8.5 % -0.24 [ -0.74, 0.26 ]
Saarto 2012 37 32.7 (5.3) 30 30.8 (5.7) 8.6 % 0.34 [ -0.14, 0.83 ]
Winters-Stone 2011 36 63.3 (15.3) 31 61.1 (16.8) 8.6 % 0.14 [ -0.34, 0.62 ]
Schmitz 2009 113 52.9 (15.3) 119 40.9 (11.8) 9.7 % 0.88 [ 0.61, 1.15 ]
Subtotal (95% CI) 408 360 100.0 % 0.42 [ 0.08, 0.76 ]
Heterogeneity: Tau2 = 0.29; Chi2 = 56.32, df = 12 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.41 (P = 0.016)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.12. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 12
Upper body strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 12 Upper body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Schmitz 2005 23 32.3 (11.51) 22 6.9 (10.79) 10.2 % 2.24 [ 1.48, 2.99 ]
Musanti 2012 30 7.74 (10.62) 12 0.83 (12.65) 10.8 % 0.60 [ -0.08, 1.29 ]
Cormie 2014 43 5.7 (3.67) 19 1 (3.78) 11.7 % 1.25 [ 0.67, 1.84 ]
Do 2015 32 0.3 (0.5) 30 0.55 (1.2) 12.5 % -0.27 [ -0.77, 0.23 ]
Mustian 2004 45 4.5 (4.71) 38 -0.85 (3.15) 12.7 % 1.30 [ 0.82, 1.78 ]
Irwin 2015 45 0.4 (1.88) 38 0.1 (1.89) 13.1 % 0.16 [ -0.27, 0.59 ]
Waltman 2010 110 1.9 (4.86) 113 0.75 (2.9) 14.4 % 0.29 [ 0.02, 0.55 ]
Schmitz 2009 113 33.2 (40.8) 119 7.6 (43.7) 14.4 % 0.60 [ 0.34, 0.87 ]
Subtotal (95% CI) 441 391 100.0 % 0.72 [ 0.30, 1.14 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 51.53, df = 7 (P<0.00001); I2 =86%
Test for overall effect: Z = 3.39 (P = 0.00070)
2 Follow-up
Rogers 2009 19 1.5 (2.27) 17 -0.3 (2.38) 100.0 % 0.76 [ 0.08, 1.44 ]
Subtotal (95% CI) 19 17 100.0 % 0.76 [ 0.08, 1.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
-4 -2 0 2 4
Favours control Favours physical activity
511Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.13. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 13
Chest press (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 13 Chest press (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Musanti 2012 30 52.13 (20.98) 12 36.75 (20) 18.4 % 0.73 [ 0.04, 1.42 ]
Schmitz 2005 23 83 (13.4) 22 63 (12.7) 18.7 % 1.50 [ 0.84, 2.17 ]
Milne 2008 29 7.6 (2.9) 29 9.4 (2.6) 20.1 % -0.64 [ -1.17, -0.12 ]
Winters-Stone 2011 36 63.3 (15.3) 31 61.1 (16.8) 20.6 % 0.14 [ -0.34, 0.62 ]
Schmitz 2009 113 52.9 (15.3) 119 40.9 (11.8) 22.2 % 0.88 [ 0.61, 1.15 ]
Subtotal (95% CI) 231 213 100.0 % 0.51 [ -0.15, 1.17 ]
Heterogeneity: Tau2 = 0.49; Chi2 = 36.09, df = 4 (P<0.00001); I2 =89%
Test for overall effect: Z = 1.52 (P = 0.13)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.14. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 14
Chest press (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 14 Chest press (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Schmitz 2005 23 32.3 (11.51) 22 6.9 (10.79) 22.1 % 2.24 [ 1.48, 2.99 ]
Musanti 2012 30 7.74 (10.62) 12 0.83 (12.65) 23.4 % 0.60 [ -0.08, 1.29 ]
Cormie 2014 43 5.7 (3.67) 19 1 (3.78) 25.0 % 1.25 [ 0.67, 1.84 ]
Schmitz 2009 113 33.2 (40.8) 119 7.6 (43.7) 29.5 % 0.60 [ 0.34, 0.87 ]
Subtotal (95% CI) 209 172 100.0 % 1.13 [ 0.46, 1.80 ]
Heterogeneity: Tau2 = 0.38; Chi2 = 18.46, df = 3 (P = 0.00035); I2 =84%
Test for overall effect: Z = 3.30 (P = 0.00097)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.15. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 15
Grip strength (follow-up).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 15 Grip strength (follow-up)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Portela 2008 25 39.26 (12.3) 9 35.6 (13.1) 4.0 % 3.66 [ -6.16, 13.48 ]
Mustian 2004 11 29.6 (3.89) 10 26.7 (6.62) 11.1 % 2.90 [ -1.80, 7.60 ]
Rogers 2009 20 29.2 (5.2) 18 25.4 (5.9) 14.3 % 3.80 [ 0.25, 7.35 ]
Saarto 2012 37 32.7 (5.3) 30 30.8 (5.7) 17.1 % 1.90 [ -0.76, 4.56 ]
Winters-Stone 2011 36 25.25 (5.22) 31 24.55 (5.65) 17.3 % 0.70 [ -1.92, 3.32 ]
Kim 2015 20 21.9 (4.23) 19 22.9 (3.67) 17.7 % -1.00 [ -3.48, 1.48 ]
Kaltsatou 2011 28 27.5 (3.85) 26 21.6 (4.5) 18.5 % 5.90 [ 3.66, 8.14 ]
Subtotal (95% CI) 177 143 100.0 % 2.37 [ 0.20, 4.55 ]
Heterogeneity: Tau2 = 5.34; Chi2 = 19.03, df = 6 (P = 0.004); I2 =68%
Test for overall effect: Z = 2.14 (P = 0.032)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.16. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 16
Grip strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 16 Grip strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cormie 2014 43 1.8 (3.67) 19 0.4 (3.49) 38.7 % 0.38 [ -0.16, 0.93 ]
Irwin 2015 45 0.4 (1.88) 38 0.1 (1.89) 61.3 % 0.16 [ -0.27, 0.59 ]
Subtotal (95% CI) 88 57 100.0 % 0.24 [ -0.09, 0.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
2 Follow-up
Rogers 2009 19 1.5 (2.27) 17 -0.3 (2.38) 100.0 % 0.76 [ 0.08, 1.44 ]
Subtotal (95% CI) 19 17 100.0 % 0.76 [ 0.08, 1.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.18 (P = 0.029)
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Analysis 10.17. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 17
Grip strength right hand (follow-up).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 17 Grip strength right hand (follow-up)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Portela 2008 25 39.26 (12.3) 9 35.6 (13.1) 6.6 % 3.66 [ -6.16, 13.48 ]
Rogers 2009 20 29.2 (6.6) 18 25.4 (5.9) 19.0 % 3.80 [ -0.17, 7.77 ]
Winters-Stone 2011 36 25.7 (5.28) 31 25.3 (5.7) 23.9 % 0.40 [ -2.25, 3.05 ]
Kim 2015 20 22.7 (4.26) 19 23.3 (3.87) 24.3 % -0.60 [ -3.15, 1.95 ]
Kaltsatou 2011 28 27 (3.4) 26 21.7 (4.1) 26.2 % 5.30 [ 3.28, 7.32 ]
Subtotal (95% CI) 129 103 100.0 % 2.30 [ -0.56, 5.16 ]
Heterogeneity: Tau2 = 7.08; Chi2 = 15.95, df = 4 (P = 0.003); I2 =75%
Test for overall effect: Z = 1.58 (P = 0.11)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 10.18. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 18
Grip strength left hand (follow-up).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 18 Grip strength left hand (follow-up)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Rogers 2009 20 26.5 (4.6) 18 23.1 (6.4) 22.2 % 3.40 [ -0.18, 6.98 ]
Winters-Stone 2011 36 24.8 (5.2) 31 23.8 (5.58) 25.6 % 1.00 [ -1.60, 3.60 ]
Kaltsatou 2011 28 27.1 (4.4) 26 21.5 (4.9) 26.0 % 5.60 [ 3.11, 8.09 ]
Kim 2015 20 21.1 (4.16) 19 22.4 (3.52) 26.2 % -1.30 [ -3.71, 1.11 ]
Subtotal (95% CI) 104 94 100.0 % 2.12 [ -1.05, 5.30 ]
Heterogeneity: Tau2 = 8.48; Chi2 = 16.36, df = 3 (P = 0.00096); I2 =82%
Test for overall effect: Z = 1.31 (P = 0.19)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
-20 -10 0 10 20
Favours control Favours physical activity
517Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 10.19. Comparison 10 Comparison: muscular strength, all physical activity vs control, Outcome 19
Elbow flexion (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 10 Comparison: muscular strength, all physical activity vs control
Outcome: 19 Elbow flexion (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 End of intervention
Nikander 2007 14 131 (20) 14 129 (28) 19.0 % 0.08 [ -0.66, 0.82 ]
Milne 2008 29 16.8 (3.7) 29 16.8 (4.2) 39.3 % 0.0 [ -0.51, 0.51 ]
Do 2015 32 9.65 (1.67) 30 10.05 (1.68) 41.7 % -0.24 [ -0.74, 0.26 ]
Subtotal (95% CI) 75 73 100.0 % -0.08 [ -0.41, 0.24 ]
Heterogeneity: Chi2 = 0.64, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 11.1. Comparison 11 Comparison: bone health, all physical activity vs control, Outcome 1 Bone
mineral content (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 11 Comparison: bone health, all physical activity vs control
Outcome: 1 Bone mineral content (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Cadmus 2009 36 2216 (383) 32 2120 (308) 20.9 % 0.27 [ -0.21, 0.75 ]
Saarto 2012 239 -45.34 (74.45) 218 -43.55 (73.34) 79.1 % -0.02 [ -0.21, 0.16 ]
Subtotal (95% CI) 275 250 100.0 % 0.04 [ -0.20, 0.27 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 0.31 (P = 0.75)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 11.2. Comparison 11 Comparison: bone health, all physical activity vs control, Outcome 2 Bone
mineral density - femoral neck (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 11 Comparison: bone health, all physical activity vs control
Outcome: 2 Bone mineral density - femoral neck (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Kim 2015 20 0.78 (0.08) 19 0.81 (0.08) 16.1 % -0.37 [ -1.00, 0.27 ]
Winters-Stone 2011 36 0.72 (0.1) 31 0.71 (0.08) 21.1 % 0.11 [ -0.37, 0.59 ]
Waltman 2010 (1) 110 0.92 (0.5) 113 0.63 (0.42) 29.8 % 0.63 [ 0.36, 0.90 ]
Saarto 2012 (2) 239 -0.006 (0.025) 218 -0.01 (0.03) 33.1 % 0.18 [ 0.00, 0.37 ]
Subtotal (95% CI) 405 381 100.0 % 0.21 [ -0.13, 0.55 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 11.96, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 1.21 (P = 0.22)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 11.3. Comparison 11 Comparison: bone health, all physical activity vs control, Outcome 3 Bone
mineral density - lumbar spine (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 11 Comparison: bone health, all physical activity vs control
Outcome: 3 Bone mineral density - lumbar spine (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Kim 2015 20 0.97 (0.08) 19 0.99 (0.07) 14.9 % -0.26 [ -0.89, 0.37 ]
Winters-Stone 2011 36 0.99 (0.15) 31 0.95 (0.11) 20.1 % 0.30 [ -0.19, 0.78 ]
Waltman 2010 (1) 110 3.08 (0.44) 113 2.85 (0.4) 30.4 % 0.55 [ 0.28, 0.81 ]
Saarto 2012 (2) 239 -0.018 (0.033) 218 -0.02 (0.034) 34.6 % 0.09 [ -0.09, 0.27 ]
Subtotal (95% CI) 405 381 100.0 % 0.22 [ -0.09, 0.53 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 9.95, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 1.38 (P = 0.17)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 11.4. Comparison 11 Comparison: bone health, all physical activity vs control, Outcome 4 Bone
mineral density - total hip (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 11 Comparison: bone health, all physical activity vs control
Outcome: 4 Bone mineral density - total hip (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Kim 2015 20 0.876 (0.083) 19 0.85 (0.066) 28.6 % 0.40 [ -0.23, 1.04 ]
Winters-Stone 2011 36 0.86 (0.11) 31 0.84 (0.1) 33.0 % 0.19 [ -0.29, 0.67 ]
Waltman 2010 (1) 110 2.15 (0.28) 113 1.81 (0.36) 38.4 % 1.05 [ 0.77, 1.33 ]
Subtotal (95% CI) 166 163 100.0 % 0.58 [ -0.02, 1.18 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 10.71, df = 2 (P = 0.005); I2 =81%
Test for overall effect: Z = 1.88 (P = 0.060)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 11.5. Comparison 11 Comparison: bone health, all physical activity vs control, Outcome 5 Bone
formation - alkaline phosphatase (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 11 Comparison: bone health, all physical activity vs control
Outcome: 5 Bone formation - alkaline phosphatase (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 7 10.21 (2.9) 9 8.12 (3.3) 45.1 % 0.63 [ -0.39, 1.65 ]
Waltman 2010 110 -11.1 (2.3) 113 -8.7 (2.6) 54.9 % -0.97 [ -1.25, -0.70 ]
Subtotal (95% CI) 117 122 100.0 % -0.25 [ -1.81, 1.31 ]
Heterogeneity: Tau2 = 1.14; Chi2 = 8.85, df = 1 (P = 0.003); I2 =89%
Test for overall effect: Z = 0.31 (P = 0.75)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 11.6. Comparison 11 Comparison: bone health, all physical activity vs control, Outcome 6 Bone
resorption - serum NTx (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 11 Comparison: bone health, all physical activity vs control
Outcome: 6 Bone resorption - serum NTx (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 End of intervention
Mustian 2004 7 11.1 (7.7) 9 18.8 (7.5) 31.7 % -0.96 [ -2.02, 0.10 ]
Kim 2015 20 52.3 (17.78) 19 55.7 (26.86) 33.7 % -0.15 [ -0.78, 0.48 ]
Waltman 2010 110 -16.7 (3.3) 113 -23.2 (2.8) 34.6 % 2.12 [ 1.79, 2.45 ]
Subtotal (95% CI) 137 141 100.0 % 0.38 [ -1.58, 2.34 ]
Heterogeneity: Tau2 = 2.85; Chi2 = 60.53, df = 2 (P<0.00001); I2 =97%
Test for overall effect: Z = 0.38 (P = 0.70)
2 Follow-up
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 12.1. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 1 Overall HRQoL
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 1 Overall HRQoL (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Courneya 2003 24 91.3 (11) 28 89.3 (10.9) 29.0 % 0.18 [ -0.37, 0.73 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 29.9 % 0.19 [ -0.35, 0.73 ]
Cadmus 2009 37 91.2 (12.6) 37 86.2 (17.4) 41.1 % 0.33 [ -0.13, 0.78 ]
Subtotal (95% CI) 101 85 100.0 % 0.24 [ -0.05, 0.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.21, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.62 (P = 0.10)
2 Not postmenopausal only
Milne 2008 29 86.4 (8.3) 29 64.1 (10.8) 13.8 % 2.28 [ 1.61, 2.96 ]
Rogers 2009 20 92 (11.4) 18 87.4 (13.1) 14.2 % 0.37 [ -0.27, 1.01 ]
Schmitz 2005 39 -44.2 (8.7) 40 -47.4 (9.4) 16.9 % 0.35 [ -0.09, 0.79 ]
Loh 2014 63 112.4 (14.09) 32 109.29 (13.26) 17.1 % 0.22 [ -0.20, 0.65 ]
Rogers 2015 105 88.1 (12.4) 108 83.2 (15.5) 18.9 % 0.35 [ 0.08, 0.62 ]
Vallance 2007 250 91.54 (11.76) 85 90.55 (12.95) 19.2 % 0.08 [ -0.16, 0.33 ]
Subtotal (95% CI) 506 312 100.0 % 0.55 [ 0.11, 0.98 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 36.76, df = 5 (P<0.00001); I2 =86%
Test for overall effect: Z = 2.44 (P = 0.015)
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Analysis 12.2. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 2 Overall HRQoL
(change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 2 Overall HRQoL (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Courneya 2003 24 5.7 (7.4) 28 0.6 (7.4) 28.1 % 0.68 [ 0.12, 1.24 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 29.8 % 0.52 [ -0.03, 1.06 ]
Cadmus 2009 37 0.6 (7.5) 37 -2.4 (9.8) 42.1 % 0.34 [ -0.12, 0.80 ]
Subtotal (95% CI) 101 85 100.0 % 0.49 [ 0.19, 0.79 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.85, df = 2 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 3.22 (P = 0.0013)
2 Not postmenopausal only
Rogers 2009 20 4.5 (8.4) 18 2.9 (12) 11.3 % 0.15 [ -0.49, 0.79 ]
Schmitz 2005 39 2.3 (4.5) 40 0.6 (4) 18.5 % 0.40 [ -0.05, 0.84 ]
Vallance 2007 250 2.3 (11.08) 85 -0.16 (6.4) 32.1 % 0.24 [ 0.00, 0.49 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 38.2 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 572 380 100.0 % 0.13 [ -0.11, 0.38 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 7.11, df = 3 (P = 0.07); I2 =58%
Test for overall effect: Z = 1.07 (P = 0.28)
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Analysis 12.3. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 3 Overall emotional
function/mental health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 3 Overall emotional function/mental health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Courneya 2003 24 21.5 (3.4) 28 20.7 (3) 41.0 % 0.25 [ -0.30, 0.79 ]
Cadmus 2009 37 20.5 (3) 37 19.8 (4.2) 59.0 % 0.19 [ -0.27, 0.65 ]
Subtotal (95% CI) 61 65 100.0 % 0.21 [ -0.14, 0.56 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.02, df = 1 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.19 (P = 0.23)
2 Not postmenopausal only
Pinto 2003 12 -10.83 (28.1) 12 -27.17 (19.5) 4.5 % 0.65 [ -0.17, 1.48 ]
Rogers 2009 20 20 (3.1) 18 21.1 (2.9) 6.7 % -0.36 [ -1.00, 0.28 ]
Milne 2008 29 19.6 (2.4) 29 16.7 (4.1) 8.6 % 0.85 [ 0.31, 1.39 ]
Cantarero-Villanueva 2013 32 -17175 (4279) 29 -20390 (6113) 9.2 % 0.61 [ 0.09, 1.12 ]
Schmitz 2005 39 -45.6 (8.2) 40 -48.2 (8.2) 11.1 % 0.31 [ -0.13, 0.76 ]
Loh 2014 63 19.87 (2.81) 32 19.98 (3.22) 11.6 % -0.04 [ -0.46, 0.39 ]
Fillion 2008 44 48.54 (7.91) 43 47.49 (9.08) 11.8 % 0.12 [ -0.30, 0.54 ]
Rogers 2015 105 20.6 (2.9) 108 19.7 (3.2) 17.7 % 0.29 [ 0.02, 0.56 ]
Vallance 2007 250 20.28 (3.31) 85 19.92 (3.44) 18.8 % 0.11 [ -0.14, 0.35 ]
Subtotal (95% CI) 594 396 100.0 % 0.25 [ 0.06, 0.44 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 14.46, df = 8 (P = 0.07); I2 =45%
Test for overall effect: Z = 2.57 (P = 0.010)
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Analysis 12.4. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 4 Overall emotional
function/mental health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 4 Overall emotional function/mental health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Courneya 2003 24 2.3 (3.1) 28 0.8 (2.9) 40.6 % 0.49 [ -0.06, 1.05 ]
Cadmus 2009 37 0.3 (2.2) 37 -0.5 (3.3) 59.4 % 0.28 [ -0.18, 0.74 ]
Subtotal (95% CI) 61 65 100.0 % 0.37 [ 0.01, 0.72 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.33, df = 1 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.04 (P = 0.041)
2 Not postmenopausal only
Rogers 2009 20 0.9 (2.5) 18 -0.1 (2.7) 10.6 % 0.38 [ -0.27, 1.02 ]
Cantarero-Villanueva 2013 32 -1445 (4452) 29 353 (3323) 14.4 % -0.45 [ -0.96, 0.06 ]
Schmitz 2005 39 2.5 (4.4) 40 0.3 (3.9) 16.7 % 0.52 [ 0.08, 0.97 ]
Vallance 2007 250 0.47 (3.54) 85 0.08 (2.49) 27.1 % 0.12 [ -0.13, 0.36 ]
Saarto 2012 263 1.2 (17.79) 237 1.9 (18.46) 31.2 % -0.04 [ -0.21, 0.14 ]
Subtotal (95% CI) 604 409 100.0 % 0.08 [ -0.17, 0.33 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 10.22, df = 4 (P = 0.04); I2 =61%
Test for overall effect: Z = 0.65 (P = 0.51)
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Analysis 12.5. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 5 Overall physical
function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 5 Overall physical function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Courneya 2003 24 25.3 (2.5) 28 25.3 (2.8) 28.1 % 0.0 [ -0.55, 0.55 ]
Winters-Stone 2011 36 51.7 (6.2) 25 52.3 (5.9) 32.1 % -0.10 [ -0.61, 0.41 ]
Cadmus 2009 37 25.1 (2.7) 37 24 (4.1) 39.8 % 0.31 [ -0.15, 0.77 ]
Subtotal (95% CI) 97 90 100.0 % 0.09 [ -0.20, 0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.53, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Not postmenopausal only
Pinto 2003 12 32.3 (4.3) 12 25.3 (8.2) 9.0 % 1.03 [ 0.17, 1.89 ]
Milne 2008 29 24 (2.6) 29 15.6 (4.5) 10.9 % 2.26 [ 1.59, 2.92 ]
Rogers 2009 20 23.3 (4.5) 18 25.4 (2.3) 11.0 % -0.57 [ -1.22, 0.08 ]
Schmitz 2005 39 -44.2 (5.6) 40 -48.3 (7.7) 13.0 % 0.60 [ 0.15, 1.05 ]
Loh 2014 63 24.92 (2.54) 32 24.17 (2.23) 13.3 % 0.30 [ -0.12, 0.73 ]
Fillion 2008 44 45.1 (10.42) 43 41.76 (9.76) 13.3 % 0.33 [ -0.10, 0.75 ]
Rogers 2015 105 24.1 (3.5) 108 22.5 (5) 14.6 % 0.37 [ 0.10, 0.64 ]
Vallance 2007 250 25.1 (2.96) 85 24.95 (3.26) 14.8 % 0.05 [ -0.20, 0.30 ]
Subtotal (95% CI) 562 367 100.0 % 0.50 [ 0.10, 0.90 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 48.26, df = 7 (P<0.00001); I2 =85%
Test for overall effect: Z = 2.47 (P = 0.013)
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Analysis 12.6. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 6 Overall physical
function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 6 Overall physical function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Courneya 2003 24 1.9 (2) 28 -0.2 (2.2) 47.9 % 0.98 [ 0.40, 1.56 ]
Cadmus 2009 37 0.1 (6.02) 37 -0.5 (7.42) 52.1 % 0.09 [ -0.37, 0.54 ]
Subtotal (95% CI) 61 65 100.0 % 0.52 [ -0.36, 1.39 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 5.63, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 1.16 (P = 0.25)
2 Not postmenopausal only
Rogers 2009 20 2.3 (5.1) 18 2.6 (6) 10.0 % -0.05 [ -0.69, 0.58 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 17.3 % -0.05 [ -0.49, 0.39 ]
Vallance 2007 247 1 (3.32) 85 0.19 (2.07) 32.4 % 0.26 [ 0.02, 0.51 ]
Saarto 2012 263 1.9 (13.65) 237 3.4 (13.35) 40.3 % -0.11 [ -0.29, 0.06 ]
Subtotal (95% CI) 569 380 100.0 % 0.03 [ -0.20, 0.25 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 6.01, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.23 (P = 0.81)
-10 -5 0 5 10
Favours control Favours physical activity
530Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.7. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 7 Overall role
function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 7 Overall role function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Courneya 2003 24 23.4 (4) 28 23.1 (4) 41.6 % 0.07 [ -0.47, 0.62 ]
Cadmus 2009 37 23.1 (4.7) 37 20.6 (7.2) 58.4 % 0.41 [ -0.05, 0.87 ]
Subtotal (95% CI) 61 65 100.0 % 0.27 [ -0.08, 0.62 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.84, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
2 Not postmenopausal only
Milne 2008 29 22.2 (3) 29 12.5 (4.8) 14.2 % 2.39 [ 1.71, 3.08 ]
Rogers 2009 20 21.4 (4.8) 18 23.8 (3.2) 14.6 % -0.57 [ -1.22, 0.08 ]
Schmitz 2005 39 -49.2 (6.5) 40 -50 (6.2) 16.9 % 0.12 [ -0.32, 0.57 ]
Loh 2014 63 23.37 (4.33) 32 22.22 (4.99) 17.1 % 0.25 [ -0.18, 0.68 ]
Rogers 2015 105 22.3 (4.5) 108 20.3 (5.5) 18.5 % 0.40 [ 0.12, 0.67 ]
Vallance 2007 250 23.22 (3.98) 85 22.72 (4.58) 18.7 % 0.12 [ -0.13, 0.37 ]
Subtotal (95% CI) 506 312 100.0 % 0.42 [ -0.07, 0.90 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 45.91, df = 5 (P<0.00001); I2 =89%
Test for overall effect: Z = 1.67 (P = 0.095)
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Analysis 12.8. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 8 Overall role
function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 8 Overall role function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Courneya 2003 24 0.9 (2.8) 28 0.4 (2.7) 41.0 % 0.18 [ -0.37, 0.73 ]
Cadmus 2009 37 -0.3 (3.7) 37 -0.5 (3.4) 59.0 % 0.06 [ -0.40, 0.51 ]
Subtotal (95% CI) 61 65 100.0 % 0.11 [ -0.24, 0.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
2 Not postmenopausal only
Rogers 2009 20 0.4 (3.3) 18 1.4 (4.3) 4.3 % -0.26 [ -0.90, 0.38 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 9.1 % -0.05 [ -0.49, 0.39 ]
Vallance 2007 250 0.63 (4.14) 85 -0.01 (2.7) 29.2 % 0.17 [ -0.08, 0.41 ]
Saarto 2012 263 2.4 (21.51) 237 3.8 (21.6) 57.4 % -0.06 [ -0.24, 0.11 ]
Subtotal (95% CI) 572 380 100.0 % 0.00 [ -0.14, 0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.96, df = 3 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.95)
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Analysis 12.9. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 9 Overall social well-
being/function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 9 Overall social well-being/function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Rogers 2014 20 7.3 (4.9) 22 3.1 (3.2) 28.5 % 1.01 [ 0.36, 1.65 ]
Courneya 2003 24 21.1 (3.5) 28 20.7 (3.6) 33.4 % 0.11 [ -0.43, 0.66 ]
Cadmus 2009 37 22.3 (4.9) 37 20.6 (7.2) 38.1 % 0.27 [ -0.18, 0.73 ]
Subtotal (95% CI) 81 87 100.0 % 0.43 [ -0.06, 0.91 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 4.74, df = 2 (P = 0.09); I2 =58%
Test for overall effect: Z = 1.73 (P = 0.084)
2 Not postmenopausal only
Rogers 2009 20 22.6 (4.1) 18 21.8 (5.7) 4.9 % 0.16 [ -0.48, 0.80 ]
Loh 2014 63 21.48 (4.88) 32 19.61 (4.9) 10.8 % 0.38 [ -0.05, 0.81 ]
Kiecolt-Glaser 2014 96 95.2 (10.8) 90 93.8 (9.3) 24.0 % 0.14 [ -0.15, 0.43 ]
Rogers 2015 105 21 (5.7) 108 20.7 (5.8) 27.5 % 0.05 [ -0.22, 0.32 ]
Vallance 2007 250 22.94 (4.96) 85 22.96 (5.05) 32.8 % 0.00 [ -0.25, 0.24 ]
Subtotal (95% CI) 534 333 100.0 % 0.09 [ -0.05, 0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.54, df = 4 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
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Analysis 12.10. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 10 Overall social
well-being/function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 10 Overall social well-being/function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Rogers 2014 20 2.1 (3.2) 22 -0.8 (3.5) 23.6 % 0.85 [ 0.21, 1.48 ]
Courneya 2003 24 0.6 (2.4) 28 -0.5 (3.3) 31.5 % 0.37 [ -0.18, 0.92 ]
Cadmus 2009 37 0.6 (4.6) 37 -1 (3.2) 44.9 % 0.40 [ -0.06, 0.86 ]
Subtotal (95% CI) 81 87 100.0 % 0.50 [ 0.19, 0.80 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 3.15 (P = 0.0016)
2 Not postmenopausal only
Rogers 2009 20 0.9 (2.6) 18 -1.2 (2.7) 29.9 % 0.78 [ 0.11, 1.44 ]
Vallance 2007 250 0.21 (4.82) 85 -4.15 (3.34) 34.8 % 0.97 [ 0.71, 1.23 ]
Saarto 2012 263 5 (21.1) 237 8.8 (20.81) 35.3 % -0.18 [ -0.36, -0.01 ]
Subtotal (95% CI) 533 340 100.0 % 0.50 [ -0.39, 1.40 ]
Heterogeneity: Tau2 = 0.58; Chi2 = 55.25, df = 2 (P<0.00001); I2 =96%
Test for overall effect: Z = 1.11 (P = 0.27)
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Analysis 12.11. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 11 Overall cognitive
function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 11 Overall cognitive function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Not postmenopausal only
Pinto 2003 12 -4.33 (2.5) 6 -7.17 (2.1) 12.5 % 1.14 [ 0.07, 2.20 ]
Rogers 2009 19 -124.5 (30.8) 18 -135.5 (19.5) 33.4 % 0.42 [ -0.24, 1.07 ]
Cantarero-Villanueva 2013 32 -37.93 (8.48) 29 -43.03 (10.01) 54.1 % 0.55 [ 0.03, 1.06 ]
Subtotal (95% CI) 63 53 100.0 % 0.58 [ 0.20, 0.95 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.31, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
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Analysis 12.12. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 12 Overall cognitive
function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 12 Overall cognitive function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Not postmenopausal only
Rogers 2009 20 4.2 (16.8) 18 -4.7 (25.9) 23.7 % 0.40 [ -0.24, 1.05 ]
Cantarero-Villanueva 2013 32 2.2 (7.63) 29 -0.18 (5.5471) 29.7 % 0.35 [ -0.16, 0.86 ]
Saarto 2012 263 -1 (18.2) 237 2.2 (18.46) 46.6 % -0.17 [ -0.35, 0.00 ]
Subtotal (95% CI) 315 284 100.0 % 0.12 [ -0.31, 0.55 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 6.03, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 0.54 (P = 0.59)
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Analysis 12.13. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 13 Overall general
health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 13 Overall general health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 43.0 % 0.19 [ -0.35, 0.73 ]
Cadmus 2009 37 50 (8.8) 37 51.7 (8.4) 57.0 % -0.20 [ -0.65, 0.26 ]
Subtotal (95% CI) 77 57 100.0 % -0.03 [ -0.41, 0.35 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.16, df = 1 (P = 0.28); I2 =14%
Test for overall effect: Z = 0.15 (P = 0.88)
2 Not postmenopausal only
Rogers 2009 20 3.5 (0.9) 18 3.8 (0.5) 38.7 % -0.40 [ -1.04, 0.25 ]
Schmitz 2005 39 53.8 (5.3) 40 53.2 (6) 61.3 % 0.10 [ -0.34, 0.55 ]
Subtotal (95% CI) 59 58 100.0 % -0.09 [ -0.57, 0.39 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 0.37 (P = 0.71)
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Analysis 12.14. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 14 Overall general
health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 14 Overall general health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 44.4 % 0.52 [ -0.03, 1.06 ]
Cadmus 2009 37 0.2 (4.4) 37 -0.1 (5.1) 55.6 % 0.06 [ -0.39, 0.52 ]
Subtotal (95% CI) 77 57 100.0 % 0.27 [ -0.18, 0.71 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 1.17 (P = 0.24)
2 Not postmenopausal only
Rogers 2009 20 0.15 (0.6) 18 0.17 (0.7) 10.6 % -0.03 [ -0.67, 0.61 ]
Schmitz 2005 39 0.7 (4.8) 40 -0.6 (3.9) 20.1 % 0.29 [ -0.15, 0.74 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 69.3 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 322 295 100.0 % -0.01 [ -0.22, 0.21 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.48, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 0.05 (P = 0.96)
-100 -50 0 50 100
Favours control Favours physical activity
538Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.15. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 15 Overall sexual
function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 15 Overall sexual function (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postmenopausal only
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Not postmenopausal only
Schmitz 2005 39 -51 (7.5) 40 -53.5 (8) 49.1 % 0.32 [ -0.12, 0.76 ]
Pinto 2003 39 42.45 (9.24) 43 40.12 (6.3) 50.9 % 0.29 [ -0.14, 0.73 ]
Subtotal (95% CI) 78 83 100.0 % 0.31 [ 0.00, 0.62 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 1.93 (P = 0.053)
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Analysis 12.16. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 16 Overall sexual
function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 16 Overall sexual function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Not postmenopausal only
Schmitz 2005 39 1.7 (4.8) 40 0.2 (5.2) 21.8 % 0.30 [ -0.15, 0.74 ]
Saarto 2012 263 4.3 (25.38) 237 3.8 (24.35) 78.2 % 0.02 [ -0.16, 0.20 ]
Subtotal (95% CI) 302 277 100.0 % 0.08 [ -0.14, 0.30 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.29, df = 1 (P = 0.26); I2 =23%
Test for overall effect: Z = 0.70 (P = 0.48)
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Analysis 12.17. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 17 Overall sleep
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 17 Overall sleep (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postmenopausal only
Rogers 2014 20 6.7 (3.7) 22 7.1 (3.2) 100.0 % -0.11 [ -0.72, 0.49 ]
Subtotal (95% CI) 20 22 100.0 % -0.11 [ -0.72, 0.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 Not postmenopausal only
Rogers 2013 11 6.3 (2.7) 9 6.2 (3.2) 22.5 % 0.03 [ -0.85, 0.91 ]
Bower 2011 16 8.1 (2.5) 15 7.7 (2.6) 35.0 % 0.15 [ -0.55, 0.86 ]
Rogers 2009 20 6.65 (4.17) 18 5.5 (4) 42.5 % 0.28 [ -0.36, 0.92 ]
Subtotal (95% CI) 47 42 100.0 % 0.18 [ -0.24, 0.60 ]
Heterogeneity: Chi2 = 0.20, df = 2 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
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Analysis 12.18. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 18 Overall sleep
(change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 18 Overall sleep (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Rogers 2014 20 -1.3 (3.2) 22 -2.2 (4.4) 100.0 % 0.23 [ -0.38, 0.84 ]
Subtotal (95% CI) 20 22 100.0 % 0.23 [ -0.38, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
2 Not postmenopausal only
Rogers 2009 20 0.45 (2.1) 18 0.28 (4.7) 100.0 % 0.05 [ -0.59, 0.68 ]
Subtotal (95% CI) 20 18 100.0 % 0.05 [ -0.59, 0.68 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.14 (P = 0.89)
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Analysis 12.19. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 19 Overall anxiety
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 19 Overall anxiety (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Rogers 2014 20 45.6 (8.9) 22 45.7 (8) 36.2 % -0.01 [ -0.62, 0.59 ]
Cadmus 2009 37 32.1 (12.3) 37 34.1 (15.4) 63.8 % -0.14 [ -0.60, 0.31 ]
Subtotal (95% CI) 57 59 100.0 % -0.09 [ -0.46, 0.27 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Not postmenopausal only
Pinto 2003 12 7.58 (7.3) 6 10.5 (3.7) 21.5 % -0.43 [ -1.43, 0.56 ]
Cantarero-Villanueva 2013 32 42.51 (8.6) 29 49.93 (11.7) 78.5 % -0.72 [ -1.24, -0.20 ]
Subtotal (95% CI) 44 35 100.0 % -0.66 [ -1.12, -0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.80 (P = 0.0051)
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Analysis 12.20. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 20 Overall anxiety
(change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 20 Overall anxiety (change values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Postmenopausal only
Cadmus 2009 37 -0.7 (9.2) 37 0.5 (5.8) 64.2 % -0.15 [ -0.61, 0.30 ]
Rogers 2014 20 -4 (6.5) 22 -1.8 (5) 35.8 % -0.37 [ -0.99, 0.24 ]
Subtotal (95% CI) 57 59 100.0 % -0.23 [ -0.60, 0.13 ]
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
2 Not postmenopausal only
Cantarero-Villanueva 2013 32 -4.2 (9.8) 29 0.75 (5.5) 100.0 % -0.61 [ -1.12, -0.09 ]
Subtotal (95% CI) 32 29 100.0 % -0.61 [ -1.12, -0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
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Analysis 12.21. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 21 Overall self-
esteem/body image (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 21 Overall self-esteem/body image (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Courneya 2003 24 34.8 (4.7) 28 34.6 (4.4) 41.2 % 0.04 [ -0.50, 0.59 ]
Cadmus 2009 37 34.2 (5.5) 37 33.4 (5.9) 58.8 % 0.14 [ -0.32, 0.60 ]
Subtotal (95% CI) 61 65 100.0 % 0.10 [ -0.25, 0.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
2 Not postmenopausal only
Pinto 2003 12 32.3 (4.3) 6 25.3 (8.2) 33.0 % 1.15 [ 0.08, 2.22 ]
Milne 2008 29 -17.9 (6.8) 29 -20.1 (6.3) 67.0 % 0.33 [ -0.19, 0.85 ]
Subtotal (95% CI) 41 35 100.0 % 0.60 [ -0.15, 1.35 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 1.82, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 1.56 (P = 0.12)
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Analysis 12.22. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 22 Overall self-
esteem/body image (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 22 Overall self-esteem/body image (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Courneya 2003 24 2.6 (3.7) 28 -0.1 (3.5) 46.9 % 0.74 [ 0.18, 1.30 ]
Cadmus 2009 37 0.4 (4.4) 37 0.2 (2.9) 53.1 % 0.05 [ -0.40, 0.51 ]
Subtotal (95% CI) 61 65 100.0 % 0.38 [ -0.30, 1.05 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 3.44, df = 1 (P = 0.06); I2 =71%
Test for overall effect: Z = 1.10 (P = 0.27)
2 Not postmenopausal only
Milne 2008 29 1.5 (3.7) 29 0.1 (3.9) 32.6 % 0.36 [ -0.16, 0.88 ]
Saarto 2012 263 10.7 (21.51) 237 12 (21.99) 67.4 % -0.06 [ -0.24, 0.12 ]
Subtotal (95% CI) 292 266 100.0 % 0.08 [ -0.31, 0.47 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 2.29, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 0.39 (P = 0.69)
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Analysis 12.23. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 23 Overall
depression (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 23 Overall depression (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Payne 2008 10 12.7 (8.7) 10 11.4 (7.9) 11.6 % 0.15 [ -0.73, 1.03 ]
Rogers 2014 20 44.2 (8.6) 22 25.1 (44.2) 22.2 % 0.58 [ -0.04, 1.19 ]
Ergun 2013 40 6.88 (6.76) 20 5.15 (5.18) 28.4 % 0.27 [ -0.27, 0.81 ]
Cadmus 2009 37 9.6 (9.3) 37 10.8 (10.1) 37.8 % -0.12 [ -0.58, 0.33 ]
Subtotal (95% CI) 107 89 100.0 % 0.18 [ -0.13, 0.48 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.36, df = 3 (P = 0.34); I2 =11%
Test for overall effect: Z = 1.12 (P = 0.26)
2 Not postmenopausal only
Pinto 2003 12 6.17 (7.2) 6 9.83 (6.8) 10.6 % -0.49 [ -1.49, 0.50 ]
Bower 2011 16 7.7 (5.8) 15 11.6 (7.1) 17.6 % -0.59 [ -1.31, 0.13 ]
Cantarero-Villanueva 2013 32 45.58 (9.68) 29 53.71 (11.6) 26.9 % -0.75 [ -1.28, -0.23 ]
Kiecolt-Glaser 2014 96 8.1 (8.6) 90 9.2 (8.2) 44.8 % -0.13 [ -0.42, 0.16 ]
Subtotal (95% CI) 156 140 100.0 % -0.42 [ -0.77, -0.06 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 4.99, df = 3 (P = 0.17); I2 =40%
Test for overall effect: Z = 2.30 (P = 0.022)
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Analysis 12.24. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 24 Overall
depression (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 24 Overall depression (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Rogers 2014 20 -1.7 (6.9) 22 1.1 (4.2) 24.3 % -0.49 [ -1.10, 0.13 ]
Ergun 2013 40 1.22 (6.19) 20 2.35 (8.03) 31.8 % -0.16 [ -0.70, 0.37 ]
Cadmus 2009 37 0.3 (6.4) 37 1.7 (6.3) 44.0 % -0.22 [ -0.68, 0.24 ]
Subtotal (95% CI) 97 79 100.0 % -0.27 [ -0.57, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 2 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 1.72 (P = 0.086)
2 Not postmenopausal only
Cantarero-Villanueva 2013 32 -2.95 (7.82) 29 1.46 (7.36) 42.4 % -0.57 [ -1.09, -0.06 ]
Saarto 2012 263 -0.3 (3.31) 237 -0.5 (3.38) 57.6 % 0.06 [ -0.12, 0.24 ]
Subtotal (95% CI) 295 266 100.0 % -0.21 [ -0.82, 0.40 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 5.22, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 12.25. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 25 Overall fatigue
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 25 Overall fatigue (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Payne 2008 9 4.7 (2.6) 9 3.5 (1.7) 5.7 % 0.52 [ -0.42, 1.46 ]
Rogers 2014 20 4.1 (2.1) 22 4 (1.8) 13.8 % 0.05 [ -0.56, 0.66 ]
Courneya 2003 24 -8.3 (7.9) 28 -8.8 (8.1) 17.0 % 0.06 [ -0.48, 0.61 ]
Ergun 2013 40 2.94 (2.24) 20 3.3 (1.79) 17.5 % -0.17 [ -0.71, 0.37 ]
Winters-Stone 2011 36 45 (5.3) 31 43.1 (10.3) 21.8 % 0.23 [ -0.25, 0.72 ]
Cadmus 2009 37 -51.9 (9) 37 -50.6 (10) 24.3 % -0.14 [ -0.59, 0.32 ]
Subtotal (95% CI) 166 147 100.0 % 0.04 [ -0.19, 0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.77, df = 5 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
2 Not postmenopausal only
Pinto 2003 12 7.16 (6.4) 6 9 (6.4) 7.0 % -0.27 [ -1.26, 0.71 ]
Rogers 2013 11 4.2 (1.8) 9 4.2 (1.6) 7.9 % 0.0 [ -0.88, 0.88 ]
Bower 2011 16 3.4 (1.8) 15 4.9 (1.3) 9.3 % -0.93 [ -1.67, -0.18 ]
Rogers 2009 20 -12.4 (10.4) 18 -10.1 (6.6) 10.5 % -0.26 [ -0.90, 0.38 ]
Milne 2008 29 11.9 (3.2) 29 17.4 (4.7) 11.2 % -1.35 [ -1.92, -0.78 ]
Cantarero-Villanueva 2013 32 3.78 (1.78) 29 6.23 (1.72) 11.4 % -1.38 [ -1.94, -0.82 ]
Fillion 2008 44 2.65 (0.72) 43 2.86 (0.83) 13.1 % -0.27 [ -0.69, 0.15 ]
Kiecolt-Glaser 2014 96 6.3 (19.6) 90 12.7 (18.97) 14.6 % -0.33 [ -0.62, -0.04 ]
Vallance 2007 250 -42.7 (8.4) 85 -42.6 (8.7) 15.0 % -0.01 [ -0.26, 0.23 ]
Subtotal (95% CI) 510 324 100.0 % -0.53 [ -0.87, -0.18 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 34.94, df = 8 (P = 0.00003); I2 =77%
Test for overall effect: Z = 2.98 (P = 0.0029)
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Analysis 12.26. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 26 Overall fatigue
(change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 26 Overall fatigue (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Payne 2008 9 -0.93 (1.95) 9 0.52 (1.38) 47.0 % -0.82 [ -1.79, 0.15 ]
Courneya 2003 24 9.3 (10.2) 28 2 (7.5) 53.0 % 0.81 [ 0.24, 1.38 ]
Subtotal (95% CI) 33 37 100.0 % 0.05 [ -1.55, 1.64 ]
Heterogeneity: Tau2 = 1.16; Chi2 = 8.05, df = 1 (P = 0.005); I2 =88%
Test for overall effect: Z = 0.06 (P = 0.95)
2 Not postmenopausal only
Rogers 2013 11 4.2 (2) 9 3.9 (1.5) 13.1 % 0.16 [ -0.72, 1.04 ]
Rogers 2009 20 1.9 (9.6) 18 4.2 (12.3) 17.3 % -0.21 [ -0.84, 0.43 ]
Cantarero-Villanueva 2013 32 -2 (1.75) 29 0.34 (1.39) 18.7 % -1.45 [ -2.02, -0.88 ]
Vallance 2007 250 2.49 (8.17) 85 1.15 (6.61) 24.9 % 0.17 [ -0.08, 0.42 ]
Saarto 2012 263 -2.4 (9.06) 237 -2.4 (8.6) 25.9 % 0.0 [ -0.18, 0.18 ]
Subtotal (95% CI) 576 378 100.0 % -0.24 [ -0.69, 0.20 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 27.19, df = 4 (P = 0.00002); I2 =85%
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 12.27. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 27 Overall
pain/disability (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 27 Overall pain/disability (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Cadmus 2009 37 50.3 (9.1) 37 50.8 (9) 100.0 % -0.05 [ -0.51, 0.40 ]
Subtotal (95% CI) 37 37 100.0 % -0.05 [ -0.51, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.24 (P = 0.81)
2 Not postmenopausal only
Rogers 2009 20 -3.03 (2.98) 18 -2.28 (2.76) 100.0 % -0.26 [ -0.89, 0.38 ]
Subtotal (95% CI) 20 18 100.0 % -0.26 [ -0.89, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
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Analysis 12.28. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 28 Overall
pain/disability (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 28 Overall pain/disability (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Cadmus 2009 37 -2.2 (11.3) 37 -0.1 (7) 47.6 % -0.22 [ -0.68, 0.24 ]
Irwin 2015 45 -6 (18.97) 38 0.7 (18.56) 52.4 % -0.35 [ -0.79, 0.08 ]
Subtotal (95% CI) 82 75 100.0 % -0.29 [ -0.61, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.071)
2 Not postmenopausal only
Rogers 2009 19 -0.8 (1.37) 17 -1.8 (6.21) 100.0 % 0.22 [ -0.43, 0.88 ]
Subtotal (95% CI) 19 17 100.0 % 0.22 [ -0.43, 0.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
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Analysis 12.29. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 29 Overall
cardiorespiratory fitness (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 29 Overall cardiorespiratory fitness (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Rogers 2014 20 30.9 (6.3) 22 25.1 (5) 19.7 % 1.01 [ 0.36, 1.65 ]
Kim 2015 20 424.8 (55.8) 19 394.4 (54) 20.0 % 0.54 [ -0.10, 1.18 ]
Courneya 2003 24 21.3 (3.7) 26 18.2 (3.9) 23.7 % 0.80 [ 0.22, 1.38 ]
Irwin 2015 45 24.6 (5.5) 38 23 (4.7) 36.6 % 0.31 [ -0.13, 0.74 ]
Subtotal (95% CI) 109 105 100.0 % 0.61 [ 0.30, 0.92 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.75, df = 3 (P = 0.29); I2 =20%
Test for overall effect: Z = 3.81 (P = 0.00014)
2 Not postmenopausal only
Rogers 2013 12 23.9 (6.2) 10 23.9 (3.8) 5.3 % 0.0 [ -0.84, 0.84 ]
Rogers 2009 20 29.5 (6.6) 18 27.6 (6.1) 9.0 % 0.29 [ -0.35, 0.93 ]
Milne 2008 29 1.49 (0.31) 29 1.48 (0.43) 14.0 % 0.03 [ -0.49, 0.54 ]
Fillion 2008 44 27.04 (4.39) 43 26.53 (5.81) 20.9 % 0.10 [ -0.32, 0.52 ]
Rogers 2015 105 23.6 (4.8) 108 22.7 (0.3) 50.8 % 0.27 [ 0.00, 0.54 ]
Subtotal (95% CI) 210 208 100.0 % 0.19 [ -0.01, 0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.16, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
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Analysis 12.30. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 30 Overall
cardiorespiratory fitness (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 30 Overall cardiorespiratory fitness (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Dolan 2016 23 12.2 (10.2) 10 -5.97 (7.2) 19.8 % 1.88 [ 0.99, 2.77 ]
Courneya 2003 24 2.7 (2.6) 26 -0.6 (1.7) 25.2 % 1.49 [ 0.86, 2.12 ]
Rogers 2014 20 2.8 (4.9) 22 1.1 (4.2) 25.7 % 0.37 [ -0.24, 0.98 ]
Irwin 2015 45 1.5 (2.1) 38 -0.4 (2.7) 29.3 % 0.79 [ 0.34, 1.24 ]
Subtotal (95% CI) 112 96 100.0 % 1.07 [ 0.48, 1.67 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 11.04, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 3.52 (P = 0.00043)
2 Not postmenopausal only
Saarto 2012 262 0.89 (1.15) 236 0.72 (1.01) 100.0 % 0.16 [ -0.02, 0.33 ]
Subtotal (95% CI) 262 236 100.0 % 0.16 [ -0.02, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
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Analysis 12.31. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 31 Overall self-
reported physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 31 Overall self-reported physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Cadmus 2009 34 161.7 (114.7) 33 55.6 (101.9) 21.0 % 0.97 [ 0.46, 1.47 ]
Irwin 2015 45 222.1 (118.6) 38 103.6 (104.6) 22.0 % 1.04 [ 0.58, 1.51 ]
Kim 2015 20 17.6 (16.03) 19 11.8 (11.6) 18.4 % 0.40 [ -0.23, 1.04 ]
Matthews 2007 22 54.2 (34.1) 14 27.2 (22.7) 17.1 % 0.87 [ 0.17, 1.58 ]
Winters-Stone 2011 36 430.8 (281.4) 31 461.7 (346.4) 21.6 % -0.10 [ -0.58, 0.38 ]
Subtotal (95% CI) 157 135 100.0 % 0.63 [ 0.17, 1.10 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 14.52, df = 4 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.67 (P = 0.0075)
2 Not postmenopausal only
Guinan 2013 16 38.7 (26.9) 10 19.9 (11.3) 9.2 % 0.81 [ -0.01, 1.64 ]
Kiecolt-Glaser 2014 96 11.2 (7.6) 90 9.1 (6.1) 25.1 % 0.30 [ 0.01, 0.59 ]
Rogers 2009 20 121.4 (73.2) 18 114.3 (131.5) 13.0 % 0.07 [ -0.57, 0.70 ]
Rogers 2015 110 169 (119) 112 74 (107) 25.7 % 0.84 [ 0.56, 1.11 ]
Vallance 2007 253 207.6 (169) 85 163 (121) 26.9 % 0.28 [ 0.03, 0.53 ]
Subtotal (95% CI) 495 315 100.0 % 0.45 [ 0.16, 0.75 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 12.58, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 2.99 (P = 0.0028)
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Analysis 12.32. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 32 Overall self-
reported physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 32 Overall self-reported physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Cadmus 2009 34 129 (117.9) 33 44.3 (89.4) 36.7 % 0.80 [ 0.30, 1.30 ]
Irwin 2015 45 159 (136) 38 49 (86) 43.9 % 0.94 [ 0.48, 1.40 ]
Matthews 2007 22 21.5 (30.6) 14 5 (13.8) 19.3 % 0.63 [ -0.06, 1.32 ]
Subtotal (95% CI) 101 85 100.0 % 0.83 [ 0.53, 1.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.56, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 5.37 (P < 0.00001)
2 Not postmenopausal only
Guinan 2013 16 15.6 (11.4476) 10 -8.3 (4.1937) 17.8 % 2.46 [ 1.39, 3.53 ]
Saarto 2012 262 3.5 (18.3) 236 3.3 (21.5) 41.7 % 0.01 [ -0.17, 0.19 ]
Vallance 2007 281 82 (168.7) 96 30 (167.8) 40.5 % 0.31 [ 0.08, 0.54 ]
Subtotal (95% CI) 559 342 100.0 % 0.57 [ -0.02, 1.16 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 22.00, df = 2 (P = 0.00002); I2 =91%
Test for overall effect: Z = 1.88 (P = 0.060)
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Analysis 12.33. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 33 Overall objective
physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 33 Overall objective physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Matthews 2007 22 330.8 (114.7) 14 198.5 (55.4) 28.7 % 1.34 [ 0.60, 2.09 ]
Rogers 2014 20 294 (175) 22 154 (75) 32.3 % 1.04 [ 0.39, 1.69 ]
Cadmus 2009 33 6738 (2958) 34 5537 (3352) 39.0 % 0.38 [ -0.11, 0.86 ]
Subtotal (95% CI) 75 70 100.0 % 0.87 [ 0.27, 1.46 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 5.47, df = 2 (P = 0.06); I2 =63%
Test for overall effect: Z = 2.87 (P = 0.0041)
2 Not postmenopausal only
Rogers 2013 12 198.4 (111.7) 10 0 (0) Not estimable
Guinan 2013 16 30.7 (15.6) 9 31 (15.6) 6.9 % -0.02 [ -0.84, 0.80 ]
Rogers 2009 20 252191 (91893) 18 210917 (64078) 10.4 % 0.51 [ -0.14, 1.15 ]
Rogers 2015 110 246 (153) 112 197 (138) 39.7 % 0.34 [ 0.07, 0.60 ]
Vallance 2007 253 8110.5 (4133.9) 85 8028 (3457) 43.1 % 0.02 [ -0.23, 0.27 ]
Subtotal (95% CI) 411 234 100.0 % 0.19 [ -0.03, 0.42 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.13, df = 3 (P = 0.25); I2 =27%
Test for overall effect: Z = 1.70 (P = 0.088)
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Analysis 12.34. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 34 Overall objective
physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 34 Overall objective physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Matthews 2007 22 72.2 (114.6) 14 -16.8 (51.5) 23.9 % 0.91 [ 0.20, 1.62 ]
Rogers 2014 20 114 (109) 22 10 (70) 27.7 % 1.13 [ 0.47, 1.78 ]
Cadmus 2009 33 1621 (2108) 34 -60 (2341) 48.4 % 0.75 [ 0.25, 1.24 ]
Subtotal (95% CI) 75 70 100.0 % 0.89 [ 0.54, 1.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.83, df = 2 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 5.05 (P < 0.00001)
2 Not postmenopausal only
Guinan 2013 16 -1.1 (6.2) 9 -7.9 (5.3) 43.0 % 1.11 [ 0.23, 2.00 ]
Vallance 2007 253 -150 (5173.3) 85 91 (5155.4) 57.0 % -0.05 [ -0.29, 0.20 ]
Subtotal (95% CI) 269 94 100.0 % 0.45 [ -0.67, 1.58 ]
Heterogeneity: Tau2 = 0.56; Chi2 = 6.16, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.79 (P = 0.43)
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Analysis 12.35. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 35 Mass (follow-up
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 35 Mass (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 Postmenopausal only
Matthews 2007 22 74.9 (15.2) 14 78.9 (20.3) 12.8 % -4.00 [ -16.39, 8.39 ]
Courneya 2003 24 78.2 (20.5) 26 80.1 (16.2) 18.6 % -1.90 [ -12.20, 8.40 ]
Cadmus 2009 36 80.73 (16.88) 33 78.51 (20.64) 24.6 % 2.22 [ -6.72, 11.16 ]
Winters-Stone 2011 36 76.5 (15.6) 31 74.2 (12.3) 44.0 % 2.30 [ -4.39, 8.99 ]
Subtotal (95% CI) 118 104 100.0 % 0.69 [ -3.74, 5.13 ]
Heterogeneity: Chi2 = 1.13, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
2 Not postmenopausal only
DeNysschen 2011 30 69.3 (14.2) 34 72.4 (19.6) 0.5 % -3.10 [ -11.42, 5.22 ]
Ligibel 2008 40 80 (17.5) 42 83.3 (18.7) 0.6 % -3.30 [ -11.14, 4.54 ]
Schmitz 2005 39 69.5 (2.22) 40 69.2 (2.2) 38.4 % 0.30 [ -0.67, 1.27 ]
Kiecolt-Glaser 2014 96 75.2 (2.8) 90 75.2 (2.6) 60.5 % 0.0 [ -0.78, 0.78 ]
Subtotal (95% CI) 205 206 100.0 % 0.08 [ -0.52, 0.68 ]
Heterogeneity: Chi2 = 1.51, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.80)
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Analysis 12.36. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 36 Mass (change
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 36 Mass (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Dolan 2016 23 -0.55 (5.04) 10 1.44 (1.62) 14.1 % -1.99 [ -4.28, 0.30 ]
Irwin 2015 45 -2.1 (4.3) 38 0.1 (3.6) 21.8 % -2.20 [ -3.90, -0.50 ]
Matthews 2007 22 0.01 (2.09) 14 0.04 (2.16) 27.1 % -0.03 [ -1.46, 1.40 ]
Courneya 2003 24 0.1 (2) 26 0.7 (1.8) 37.0 % -0.60 [ -1.66, 0.46 ]
Subtotal (95% CI) 114 88 100.0 % -0.99 [ -1.96, -0.02 ]
Heterogeneity: Tau2 = 0.37; Chi2 = 4.85, df = 3 (P = 0.18); I2 =38%
Test for overall effect: Z = 2.00 (P = 0.045)
2 Not postmenopausal only
Ligibel 2008 22 0 (2.3) 14 0.04 (2.16) 1.5 % -0.04 [ -1.52, 1.44 ]
Saarto 2012 262 0.66 (3.68) 236 0.67 (3.84) 7.3 % -0.01 [ -0.67, 0.65 ]
Schmitz 2005 39 0.32 (0.43) 40 0.2 (0.42) 91.2 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 323 290 100.0 % 0.11 [ -0.07, 0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.18, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 1.18 (P = 0.24)
-4 -2 0 2 4
Favours physical activity Favours control
560Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.37. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 37 BMI (follow-up
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 37 BMI (follow-up values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Fixed,95% CI IV,Fixed,95% CI
1 Postmenopausal only
Courneya 2003 24 29.4 (7.4) 26 29.3 (6) 29.0 % 0.10 [ -3.65, 3.85 ]
Rogers 2014 20 29.6 (5) 22 32.2 (6.7) 32.3 % -2.60 [ -6.16, 0.96 ]
Cadmus 2009 36 30.45 (6) 33 29.9 (7.59) 38.7 % 0.55 [ -2.70, 3.80 ]
Subtotal (95% CI) 80 81 100.0 % -0.60 [ -2.62, 1.42 ]
Heterogeneity: Chi2 = 1.83, df = 2 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
2 Not postmenopausal only
Rogers 2013 12 33.6 (7) 10 30.6 (7.28) 0.1 % 3.00 [ -3.00, 9.00 ]
Rogers 2009 20 30.6 (7.6) 18 30.4 (8.3) 0.2 % 0.20 [ -4.88, 5.28 ]
Ligibel 2008 40 30.3 (6.3) 42 31.5 (6.8) 0.6 % -1.20 [ -4.04, 1.64 ]
Vallance 2007 253 27.01 (5.21) 85 27.2 (5.15) 2.8 % -0.19 [ -1.46, 1.08 ]
Schmitz 2005 39 26 (0.74) 40 25.8 (0.73) 43.1 % 0.20 [ -0.12, 0.52 ]
Kiecolt-Glaser 2014 96 27.8 (1.08) 90 27.8 (0.95) 53.2 % 0.0 [ -0.29, 0.29 ]
Subtotal (95% CI) 460 285 100.0 % 0.08 [ -0.13, 0.29 ]
Heterogeneity: Chi2 = 2.68, df = 5 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.72 (P = 0.47)
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Analysis 12.38. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 38 BMI (change
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 38 BMI (change values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Rogers 2014 20 -0.2 (0.9) 22 -0.3 (1.1) 32.4 % 0.10 [ -0.51, 0.71 ]
Courneya 2003 24 0 (0.7) 26 0.3 (0.7) 67.6 % -0.30 [ -0.69, 0.09 ]
Subtotal (95% CI) 44 48 100.0 % -0.17 [ -0.54, 0.20 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.19, df = 1 (P = 0.28); I2 =16%
Test for overall effect: Z = 0.91 (P = 0.36)
2 Not postmenopausal only
Ligibel 2008 40 0 (0.9) 42 0.2 (0.8) 3.7 % -0.20 [ -0.57, 0.17 ]
Schmitz 2005 39 0.06 (0.17) 40 0.07 (0.16) 96.3 % -0.01 [ -0.08, 0.06 ]
Subtotal (95% CI) 79 82 100.0 % -0.02 [ -0.09, 0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.98, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
-4 -2 0 2 4
Favours physical activity Favours control
562Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.39. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 39 Overall body fat
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 39 Overall body fat (follow-up values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Matthews 2007 22 39.7 (6.3) 14 43.1 (6.9) 14.9 % -0.51 [ -1.19, 0.17 ]
Rogers 2014 20 38.6 (6.4) 22 41.5 (7.4) 17.4 % -0.41 [ -1.02, 0.20 ]
Courneya 2003 24 131.9 (46.4) 26 137.1 (44.4) 19.9 % -0.11 [ -0.67, 0.44 ]
Winters-Stone 2011 36 40.5 (6.2) 31 38.5 (5.8) 23.6 % 0.33 [ -0.16, 0.81 ]
Cadmus 2009 36 40.54 (6.55) 33 39.6 (5.97) 24.2 % 0.15 [ -0.33, 0.62 ]
Subtotal (95% CI) 138 126 100.0 % -0.06 [ -0.36, 0.25 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 6.11, df = 4 (P = 0.19); I2 =35%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Not postmenopausal only
Rogers 2013 10 44.2 (6.7) 12 42.3 (7.7) 11.2 % 0.25 [ -0.59, 1.09 ]
Rogers 2009 20 44.3 (7.4) 19 43.5 (7.5) 15.0 % 0.11 [ -0.52, 0.73 ]
DeNysschen 2011 30 36.9 (8.4) 34 38 (10.2) 18.0 % -0.12 [ -0.61, 0.38 ]
Saarto 2012 37 39.9 (7.5) 30 40.2 (8) 18.2 % -0.04 [ -0.52, 0.44 ]
Schmitz 2005 39 40.91 (1.31) 40 42.29 (1.3) 18.4 % -1.05 [ -1.52, -0.58 ]
Ligibel 2008 40 42.9 (7.4) 42 44.7 (8) 19.3 % -0.23 [ -0.67, 0.20 ]
Subtotal (95% CI) 176 177 100.0 % -0.22 [ -0.59, 0.15 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 14.56, df = 5 (P = 0.01); I2 =66%
Test for overall effect: Z = 1.16 (P = 0.24)
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Analysis 12.40. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 40 Overall body fat
(change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 40 Overall body fat (change values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Matthews 2007 22 -0.2 (1.62) 14 0.41 (1.94) 27.2 % -0.34 [ -1.02, 0.33 ]
Rogers 2014 20 -1.1 (2.2) 22 -0.6 (2.4) 33.6 % -0.21 [ -0.82, 0.39 ]
Courneya 2003 24 -4.9 (15.7) 26 5.1 (24.4) 39.1 % -0.48 [ -1.04, 0.09 ]
Subtotal (95% CI) 66 62 100.0 % -0.35 [ -0.70, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
2 Not postmenopausal only
Schmitz 2005 39 -1.15 (0.45) 40 0.23 (0.44) 49.6 % -3.07 [ -3.73, -2.41 ]
Ligibel 2008 40 -0.2 (1.7) 42 0.3 (1.7) 50.4 % -0.29 [ -0.73, 0.14 ]
Subtotal (95% CI) 79 82 100.0 % -1.67 [ -4.39, 1.05 ]
Heterogeneity: Tau2 = 3.78; Chi2 = 47.46, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.20 (P = 0.23)
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Analysis 12.41. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 41 Lower body
strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 41 Lower body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Winters-Stone 2011 36 201.3 (57.4) 31 191 (51.7) 100.0 % 0.19 [ -0.30, 0.67 ]
Subtotal (95% CI) 36 31 100.0 % 0.19 [ -0.30, 0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
2 Not postmenopausal only
Rogers 2013 11 68.4 (15.5) 9 67.1 (16.2) 13.9 % 0.08 [ -0.80, 0.96 ]
Rogers 2009 20 80.3 (27) 18 64.9 (19.7) 19.2 % 0.63 [ -0.02, 1.29 ]
Schmitz 2005 23 296.6 (48.9) 22 238.9 (46.4) 19.6 % 1.19 [ 0.55, 1.83 ]
Milne 2008 29 66.2 (10.2) 29 61.7 (11) 23.0 % 0.42 [ -0.10, 0.94 ]
Saarto 2012 37 136 (23) 30 136 (29) 24.3 % 0.0 [ -0.48, 0.48 ]
Subtotal (95% CI) 120 108 100.0 % 0.46 [ 0.04, 0.88 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 9.46, df = 4 (P = 0.05); I2 =58%
Test for overall effect: Z = 2.14 (P = 0.032)
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Analysis 12.42. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 42 Lower body
strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 42 Lower body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Dolan 2016 23 11.84 (8.89) 10 0.34 (11.1) 36.8 % 1.17 [ 0.37, 1.97 ]
Waltman 2010 110 4.42 (11.48) 113 0.19 (8.38) 63.2 % 0.42 [ 0.15, 0.69 ]
Subtotal (95% CI) 133 123 100.0 % 0.70 [ -0.01, 1.41 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 3.04, df = 1 (P = 0.08); I2 =67%
Test for overall effect: Z = 1.92 (P = 0.054)
2 Not postmenopausal only
Schmitz 2005 23 81.8 (48.92) 22 20.3 (45.97) 100.0 % 1.27 [ 0.63, 1.92 ]
Subtotal (95% CI) 23 22 100.0 % 1.27 [ 0.63, 1.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.86 (P = 0.00011)
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Analysis 12.43. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 43 Upper body
strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 43 Upper body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Winters-Stone 2011 36 63.3 (15.3) 31 61.1 (16.8) 100.0 % 0.14 [ -0.34, 0.62 ]
Subtotal (95% CI) 36 31 100.0 % 0.14 [ -0.34, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
2 Not postmenopausal only
Schmitz 2005 23 83 (13.4) 22 63 (12.7) 24.1 % 1.50 [ 0.84, 2.17 ]
Rogers 2009 20 27.9 (5.04) 18 24.3 (6.18) 24.3 % 0.63 [ -0.03, 1.28 ]
Milne 2008 29 7.6 (2.9) 29 9.4 (2.6) 25.6 % -0.64 [ -1.17, -0.12 ]
Saarto 2012 37 32.7 (5.3) 30 30.8 (5.7) 26.0 % 0.34 [ -0.14, 0.83 ]
Subtotal (95% CI) 109 99 100.0 % 0.44 [ -0.40, 1.28 ]
Heterogeneity: Tau2 = 0.65; Chi2 = 25.69, df = 3 (P = 0.00001); I2 =88%
Test for overall effect: Z = 1.02 (P = 0.31)
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Analysis 12.44. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 44 Upper body
strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 44 Upper body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Irwin 2015 45 0.4 (1.88) 38 0.1 (1.89) 27.1 % 0.16 [ -0.27, 0.59 ]
Waltman 2010 110 1.9 (4.86) 113 0.75 (2.9) 72.9 % 0.29 [ 0.02, 0.55 ]
Subtotal (95% CI) 155 151 100.0 % 0.25 [ 0.03, 0.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.028)
2 Not postmenopausal only
Schmitz 2005 23 32.3 (11.51) 22 6.9 (10.79) 49.3 % 2.24 [ 1.48, 2.99 ]
Rogers 2009 19 1.5 (2.27) 17 -0.3 (2.38) 50.7 % 0.76 [ 0.08, 1.44 ]
Subtotal (95% CI) 42 39 100.0 % 1.49 [ 0.04, 2.93 ]
Heterogeneity: Tau2 = 0.96; Chi2 = 8.08, df = 1 (P = 0.004); I2 =88%
Test for overall effect: Z = 2.01 (P = 0.044)
-4 -2 0 2 4
Favours control Favours physical activity
568Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 12.45. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 45 Bone mineral
density - femoral neck (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 45 Bone mineral density - femoral neck (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Kim 2015 20 0.78 (0.08) 19 0.81 (0.08) 28.0 % -0.37 [ -1.00, 0.27 ]
Winters-Stone 2011 36 0.72 (0.1) 31 0.71 (0.08) 32.9 % 0.11 [ -0.37, 0.59 ]
Waltman 2010 (1) 110 0.92 (0.5) 113 0.63 (0.42) 39.1 % 0.63 [ 0.36, 0.90 ]
Subtotal (95% CI) 166 163 100.0 % 0.18 [ -0.39, 0.75 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 9.77, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 0.61 (P = 0.54)
2 Not postmenopausal only
Saarto 2012 (2) 239 -0.006 (0.025) 218 -0.01 (0.03) 100.0 % 0.18 [ 0.00, 0.37 ]
Subtotal (95% CI) 239 218 100.0 % 0.18 [ 0.00, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
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Analysis 12.46. Comparison 12 Subanalysis: outcomes by menopausal status, Outcome 46 Bone mineral
density - lumbar spine (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 12 Subanalysis: outcomes by menopausal status
Outcome: 46 Bone mineral density - lumbar spine (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Postmenopausal only
Kim 2015 20 0.97 (0.08) 19 0.99 (0.07) 24.6 % -0.26 [ -0.89, 0.37 ]
Winters-Stone 2011 36 0.99 (0.15) 31 0.95 (0.11) 31.6 % 0.30 [ -0.19, 0.78 ]
Waltman 2010 (1) 110 3.08 (0.44) 113 2.85 (0.4) 43.8 % 0.55 [ 0.28, 0.81 ]
Subtotal (95% CI) 166 163 100.0 % 0.27 [ -0.16, 0.70 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 5.52, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 1.23 (P = 0.22)
2 Not postmenopausal only
Saarto 2012 (2) 239 -0.018 (0.033) 218 -0.02 (0.034) 100.0 % 0.09 [ -0.09, 0.27 ]
Subtotal (95% CI) 239 218 100.0 % 0.09 [ -0.09, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 1 Overall HRQoL (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise interventions
Rogers 2015 10 85.23 (4.2) 10 65.89 (14.66) 3.4 % 1.72 [ 0.66, 2.78 ]
Cerulli 2014 10 85.23 (4.2) 10 65.89 (14.66) 3.4 % 1.72 [ 0.66, 2.78 ]
Rogers 2009 20 92 (11.4) 18 87.4 (13.1) 6.9 % 0.37 [ -0.27, 1.01 ]
Ergun 2013 20 68.97 (21.16) 20 67.91 (16.7) 7.2 % 0.05 [ -0.57, 0.67 ]
Courneya 2003 24 91.3 (11) 28 89.3 (10.9) 8.2 % 0.18 [ -0.37, 0.73 ]
Murtezani 2014 30 86.5 (7.3) 32 79.1 (7.5) 8.5 % 0.99 [ 0.46, 1.52 ]
Mehnert 2011 30 74.72 (21.72) 27 65.43 (16.78) 8.5 % 0.47 [ -0.06, 1.00 ]
Cadmus 2009 37 91.2 (12.6) 37 86.2 (17.4) 9.7 % 0.33 [ -0.13, 0.78 ]
Pinto 2015 39 117.79 (12.74) 37 113.98 (18.02) 9.8 % 0.24 [ -0.21, 0.69 ]
Loh 2014 63 112.4 (14.09) 32 109.29 (13.26) 10.2 % 0.22 [ -0.20, 0.65 ]
Daley 2007 33 90.85 (13.47) 69 86.44 (15.07) 10.4 % 0.30 [ -0.12, 0.72 ]
Vallance 2007 250 91.54 (11.76) 85 90.55 (12.95) 13.8 % 0.08 [ -0.16, 0.33 ]
Subtotal (95% CI) 566 405 100.0 % 0.41 [ 0.19, 0.63 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 24.66, df = 11 (P = 0.01); I2 =55%
Test for overall effect: Z = 3.61 (P = 0.00030)
2 Resistance exercise interventions
Schmitz 2005 39 -44.2 (8.7) 40 -47.4 (9.4) 100.0 % 0.35 [ -0.09, 0.79 ]
Subtotal (95% CI) 39 40 100.0 % 0.35 [ -0.09, 0.79 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.54 (P = 0.12)
3 Combined aerobic and resistance exercise
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 10.3 % 1.30 [ 0.19, 2.41 ]
Portela 2008 25 107.2 (28.5) 9 91.6 (28.5) 13.1 % 0.53 [ -0.24, 1.31 ]
Milne 2008 29 86.4 (8.3) 29 64.1 (10.8) 14.0 % 2.28 [ 1.61, 2.96 ]
Ergun 2013 20 74.16 (18.71) 20 67.91 (16.7) 14.4 % 0.35 [ -0.28, 0.97 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 15.4 % 0.28 [ -0.22, 0.79 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Taleghani 2012 40 217.5 (36.3) 40 210.1 (41.5) 15.8 % 0.19 [ -0.25, 0.63 ]
Short 2014 195 106.8 (16.7) 104 108.2 (18.2) 17.0 % -0.08 [ -0.32, 0.16 ]
Subtotal (95% CI) 349 240 100.0 % 0.63 [ 0.08, 1.19 ]
Heterogeneity: Tau2 = 0.46; Chi2 = 46.88, df = 6 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.23 (P = 0.026)
4 Yoga, Tai Chi, and Pilates interventions
Mustian 2004 11 121.7 (22.67) 10 124.3 (25.9) 15.2 % -0.10 [ -0.96, 0.75 ]
Loudon 2014 12 -7.42 (1.24) 11 -7.45 (1.44) 16.6 % 0.02 [ -0.80, 0.84 ]
Littman 2012 30 90.3 (11) 110 87.7 (15) 68.2 % 0.18 [ -0.22, 0.59 ]
Subtotal (95% CI) 53 131 100.0 % 0.11 [ -0.22, 0.45 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.40, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 2 Overall HRQoL (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise interventions
Murtezani 2014 30 9.16 (2.12) 32 -0.56 (2.01) 8.2 % 4.65 [ 3.67, 5.63 ]
Rogers 2009 20 4.5 (8.4) 18 2.9 (12) 10.4 % 0.15 [ -0.49, 0.79 ]
Courneya 2003 24 5.7 (7.4) 28 0.6 (7.4) 10.9 % 0.68 [ 0.12, 1.24 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 11.0 % 0.52 [ -0.03, 1.06 ]
Mehnert 2011 30 9.72 (21.03) 27 5.55 (16.5) 11.1 % 0.22 [ -0.31, 0.74 ]
Cadmus 2009 37 0.6 (7.5) 37 -2.4 (9.8) 11.5 % 0.34 [ -0.12, 0.80 ]
Daley 2007 33 10.22 (11.2) 69 3.2 (11.26) 11.7 % 0.62 [ 0.20, 1.04 ]
Vallance 2007 250 2.3 (11.08) 85 -0.16 (6.4) 12.5 % 0.24 [ 0.00, 0.49 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 12.7 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 727 553 100.0 % 0.68 [ 0.22, 1.15 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 97.57, df = 8 (P<0.00001); I2 =92%
Test for overall effect: Z = 2.88 (P = 0.0040)
2 Resistance exercise interventions
Schmitz 2005 39 2.3 (4.5) 40 0.6 (4) 100.0 % 0.40 [ -0.05, 0.84 ]
Subtotal (95% CI) 39 40 100.0 % 0.40 [ -0.05, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
3 Combined aerobic and resistance exercise
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 16.9 % 1.92 [ 0.68, 3.17 ]
Naumann 2012 11 14.5 (10.6) 10 3.1 (11.4) 22.7 % 1.00 [ 0.08, 1.92 ]
Cuesta-Vargas 2014 22 0.32 (0.18) 20 0.33 (0.09) 29.5 % -0.07 [ -0.67, 0.54 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 30.9 % 0.52 [ -0.03, 1.06 ]
Subtotal (95% CI) 81 58 100.0 % 0.69 [ 0.01, 1.38 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 9.52, df = 3 (P = 0.02); I2 =68%
Test for overall effect: Z = 1.98 (P = 0.048)
4 Yoga, Tai Chi, and Pilates interventions
Mustian 2004 11 15 (5) 10 0 (5) 100.0 % 2.88 [ 1.59, 4.17 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 11 10 100.0 % 2.88 [ 1.59, 4.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.37 (P = 0.000012)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 3 Overall emotional function/mental health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise interventions
Rogers 2009 20 20 (3.1) 18 21.1 (2.9) 2.9 % -0.36 [ -1.00, 0.28 ]
Basen-Enquist 2006 28 78.2 (10.58) 23 77.2 (11.99) 3.9 % 0.09 [ -0.46, 0.64 ]
Courneya 2003 24 21.5 (3.4) 28 20.7 (3) 4.0 % 0.25 [ -0.30, 0.79 ]
Mehnert 2011 30 77.01 (35.75) 28 69.05 (40.5) 4.5 % 0.21 [ -0.31, 0.72 ]
Murtezani 2014 30 19.5 (3.3) 32 18.3 (3.5) 4.7 % 0.35 [ -0.15, 0.85 ]
Daley 2007 33 19.06 (4.18) 33 18.45 (3.31) 5.1 % 0.16 [ -0.32, 0.64 ]
Cadmus 2009 37 20.5 (3) 37 19.8 (4.2) 5.7 % 0.19 [ -0.27, 0.65 ]
Pinto 2015 39 54.21 (9.28) 37 52.48 (9.62) 5.8 % 0.18 [ -0.27, 0.63 ]
Pinto 2005 39 -8.02 (20.69) 43 -16.51 (28.75) 6.2 % 0.33 [ -0.10, 0.77 ]
Loh 2014 63 19.87 (2.81) 32 19.98 (3.22) 6.6 % -0.04 [ -0.46, 0.39 ]
Fillion 2008 44 48.54 (7.91) 43 47.49 (9.08) 6.7 % 0.12 [ -0.30, 0.54 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Duijits 2012 37 73.92 (34.7) 89 77.46 (34.32) 8.1 % -0.10 [ -0.49, 0.28 ]
Rogers 2015 105 20.6 (2.9) 108 19.7 (3.2) 16.3 % 0.29 [ 0.02, 0.56 ]
Vallance 2007 250 20.28 (3.31) 85 19.92 (3.44) 19.6 % 0.11 [ -0.14, 0.35 ]
Subtotal (95% CI) 779 636 100.0 % 0.15 [ 0.04, 0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 7.55, df = 13 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.61 (P = 0.0090)
2 Resistance exercise interventions
Schmitz 2005 39 -45.6 (8.2) 40 -48.2 (8.2) 38.2 % 0.31 [ -0.13, 0.76 ]
Schmitz 2009 112 53.2 (9.6) 120 53.8 (8.7) 61.8 % -0.07 [ -0.32, 0.19 ]
Subtotal (95% CI) 151 160 100.0 % 0.08 [ -0.28, 0.44 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 2.10, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 0.43 (P = 0.67)
3 Combined aerobic and resistance exercise
Herrero 2006 8 90.6 (9.3) 8 83.3 (14.8) 6.2 % 0.56 [ -0.45, 1.56 ]
Pinto 2003 12 -10.83 (28.1) 12 -27.17 (19.5) 9.3 % 0.65 [ -0.17, 1.48 ]
Cuesta-Vargas 2014 22 42.9 (19.17) 20 32.3 (33.33) 16.8 % 0.39 [ -0.22, 1.00 ]
Milne 2008 29 19.6 (2.4) 29 16.7 (4.1) 21.7 % 0.85 [ 0.31, 1.39 ]
Do 2015 32 87.4 (8.8) 30 70.4 (21.5) 22.2 % 1.03 [ 0.50, 1.57 ]
Cantarero-Villanueva 2013 32 -17175 (4279) 29 -20390 (6113) 23.8 % 0.61 [ 0.09, 1.12 ]
Subtotal (95% CI) 135 128 100.0 % 0.72 [ 0.47, 0.97 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.01, df = 5 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 5.62 (P < 0.00001)
4 Yoga, Tai Chi, and Pilates interventions
Banasik 2011 7 0.47 (0.36) 7 0.38 (0.31) 12.3 % 0.25 [ -0.80, 1.30 ]
Mustian 2004 9 24.78 (2.04) 10 24.8 (3.19) 16.9 % -0.01 [ -0.91, 0.89 ]
Loudon 2014 12 -1.58 (0.7) 11 -1.61 (0.49) 20.4 % 0.05 [ -0.77, 0.87 ]
Littman 2012 30 20.3 (4) 27 20.8 (3.1) 50.4 % -0.14 [ -0.66, 0.38 ]
Subtotal (95% CI) 58 55 100.0 % -0.03 [ -0.40, 0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 3 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.88)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 20 0.9 (2.5) 18 -0.1 (2.7) 12.3 % 0.38 [ -0.27, 1.02 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 12.9 % 1.80 [ 1.21, 2.40 ]
Courneya 2003 24 2.3 (3.1) 28 0.8 (2.9) 13.5 % 0.49 [ -0.06, 1.05 ]
Mehnert 2011 30 2.3 (35.5) 28 3.57 (17.6) 14.0 % -0.04 [ -0.56, 0.47 ]
Cadmus 2009 37 0.3 (2.2) 37 -0.5 (3.3) 14.8 % 0.28 [ -0.18, 0.74 ]
Pinto 2005 39 -3.8 (27.7) 43 -11.47 (25.8) 15.1 % 0.28 [ -0.15, 0.72 ]
Vallance 2007 250 0.47 (3.54) 85 0.08 (2.49) 17.5 % 0.12 [ -0.13, 0.36 ]
Subtotal (95% CI) 430 271 100.0 % 0.44 [ 0.06, 0.82 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 28.69, df = 6 (P = 0.00007); I2 =79%
Test for overall effect: Z = 2.28 (P = 0.022)
2 Resistance exercise
Cormie 2014 43 4.4 (9) 19 2.7 (8.6) 25.0 % 0.19 [ -0.35, 0.73 ]
Schmitz 2005 39 2.5 (4.4) 40 0.3 (3.9) 32.4 % 0.52 [ 0.08, 0.97 ]
Schmitz 2009 58 3.3 (23.2) 62 3.1 (17.2) 42.5 % 0.01 [ -0.35, 0.37 ]
Subtotal (95% CI) 140 121 100.0 % 0.22 [ -0.09, 0.54 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.09, df = 2 (P = 0.21); I2 =35%
Test for overall effect: Z = 1.37 (P = 0.17)
3 Combined aerobic and resistance exercise
Herrero 2006 8 9.3 (19.6) 8 -2.1 (5.9) 10.5 % 0.74 [ -0.28, 1.77 ]
Naumann 2012 11 1 (2.69) 10 -0.1 (2.72) 13.6 % 0.39 [ -0.48, 1.26 ]
Cantarero-Villanueva 2013 32 -1445 (4452) 29 353 (3323) 26.9 % -0.45 [ -0.96, 0.06 ]
Saarto 2012 263 1.2 (17.79) 237 1.9 (18.46) 49.0 % -0.04 [ -0.21, 0.14 ]
Subtotal (95% CI) 314 284 100.0 % -0.01 [ -0.38, 0.36 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 5.67, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 0.04 (P = 0.97)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 2.44 (2.52) 10 0.1 (1.68) 100.0 % 1.06 [ 0.08, 2.03 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 9 10 100.0 % 1.06 [ 0.08, 2.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.12 (P = 0.034)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 5 Overall physical function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 20 23.3 (4.5) 18 25.4 (2.3) 3.4 % -0.57 [ -1.22, 0.08 ]
Basen-Enquist 2006 28 82.5 (12.7) 23 77.4 (11.5) 4.5 % 0.41 [ -0.15, 0.97 ]
Courneya 2003 24 25.3 (2.5) 28 25.3 (2.8) 4.7 % 0.0 [ -0.55, 0.55 ]
Mehnert 2011 30 88.96 (9.13) 28 78.12 (21.22) 4.9 % 0.66 [ 0.13, 1.19 ]
Murtezani 2014 30 22.6 (4.4) 32 19.4 (4.4) 5.1 % 0.72 [ 0.20, 1.23 ]
Daley 2007 33 25.61 (2.15) 33 23.61 (5.7) 5.6 % 0.46 [ -0.03, 0.95 ]
Cadmus 2009 37 25.1 (2.7) 37 24 (4.1) 6.2 % 0.31 [ -0.15, 0.77 ]
Pinto 2015 39 87.08 (4.4) 37 84.69 (15.91) 6.4 % 0.21 [ -0.25, 0.66 ]
Pinto 2005 39 30.26 (7.88) 43 27.33 (6.76) 6.7 % 0.40 [ -0.04, 0.83 ]
Loh 2014 63 24.92 (2.54) 32 24.17 (2.23) 6.9 % 0.30 [ -0.12, 0.73 ]
Fillion 2008 44 45.1 (10.42) 43 41.76 (9.76) 7.0 % 0.33 [ -0.10, 0.75 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Duijits 2012 87 84.03 (16.88) 89 80.18 (17.08) 11.5 % 0.23 [ -0.07, 0.52 ]
Rogers 2015 105 24.1 (3.5) 108 22.5 (5) 12.8 % 0.37 [ 0.10, 0.64 ]
Vallance 2007 250 25.1 (2.96) 85 24.95 (3.26) 14.2 % 0.05 [ -0.20, 0.30 ]
Subtotal (95% CI) 829 636 100.0 % 0.28 [ 0.15, 0.41 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 17.34, df = 13 (P = 0.18); I2 =25%
Test for overall effect: Z = 4.24 (P = 0.000022)
2 Resistance exercise
Winters-Stone 2011 36 51.7 (6.2) 25 52.3 (5.9) 25.6 % -0.10 [ -0.61, 0.41 ]
Schmitz 2005 39 -44.2 (5.6) 40 -48.3 (7.7) 29.3 % 0.60 [ 0.15, 1.05 ]
Schmitz 2009 112 50.6 (8.15) 120 49.1 (9.32) 45.1 % 0.17 [ -0.09, 0.43 ]
Subtotal (95% CI) 187 185 100.0 % 0.23 [ -0.11, 0.57 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 4.37, df = 2 (P = 0.11); I2 =54%
Test for overall effect: Z = 1.32 (P = 0.19)
3 Combined aerobic and resistance exercise
Herrero 2006 8 94.1 (7.5) 8 92.5 (6.6) 17.8 % 0.21 [ -0.77, 1.20 ]
Pinto 2003 12 32.3 (4.3) 12 25.3 (8.2) 18.9 % 1.03 [ 0.17, 1.89 ]
Milne 2008 29 24 (2.6) 29 15.6 (4.5) 20.5 % 2.26 [ 1.59, 2.92 ]
Cuesta-Vargas 2014 22 42.9 (4.06) 20 32.4 (32.48) 21.0 % 0.46 [ -0.16, 1.07 ]
Do 2015 32 89.4 (8.4) 30 89 (8.7) 21.8 % 0.05 [ -0.45, 0.54 ]
Subtotal (95% CI) 103 99 100.0 % 0.80 [ -0.04, 1.64 ]
Heterogeneity: Tau2 = 0.78; Chi2 = 29.57, df = 4 (P<0.00001); I2 =86%
Test for overall effect: Z = 1.87 (P = 0.061)
4 Yoga, Tai Chi, and Pilates
Banasik 2011 7 -0.77 (0.94) 7 -0.42 (0.25) 15.2 % -0.48 [ -1.54, 0.59 ]
Mustian 2004 9 26.89 (4.11) 10 26.5 (4.14) 21.4 % 0.09 [ -0.81, 0.99 ]
Littman 2012 30 25.4 (1.7) 27 24.3 (4.4) 63.4 % 0.33 [ -0.19, 0.86 ]
Subtotal (95% CI) 46 44 100.0 % 0.16 [ -0.26, 0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.80, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Murtezani 2014 30 4.43 (1.53) 32 -1.34 (1.15) 11.6 % 4.23 [ 3.31, 5.15 ]
Rogers 2009 20 2.3 (5.1) 18 2.6 (6) 13.6 % -0.05 [ -0.69, 0.58 ]
Courneya 2003 24 1.9 (2) 28 -0.2 (2.2) 14.0 % 0.98 [ 0.40, 1.56 ]
Mehnert 2011 30 3.96 (10.83) 28 -2.15 (16.7) 14.4 % 0.43 [ -0.09, 0.95 ]
Cadmus 2009 37 0.1 (6.02) 37 -0.5 (7.42) 14.8 % 0.09 [ -0.37, 0.54 ]
Vallance 2007 247 1 (3.32) 85 0.19 (2.07) 15.8 % 0.26 [ 0.02, 0.51 ]
Saarto 2012 263 1.9 (13.65) 237 3.4 (13.35) 16.0 % -0.11 [ -0.29, 0.06 ]
Subtotal (95% CI) 651 465 100.0 % 0.72 [ 0.14, 1.30 ]
Heterogeneity: Tau2 = 0.55; Chi2 = 94.83, df = 6 (P<0.00001); I2 =94%
Test for overall effect: Z = 2.42 (P = 0.016)
2 Resistance exercise
Cormie 2014 43 3.49 (5.15) 19 -0.5 (5.67) 27.3 % 0.74 [ 0.19, 1.30 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 33.7 % -0.05 [ -0.49, 0.39 ]
Schmitz 2009 58 6.6 (17.1) 62 4.1 (17.3) 39.0 % 0.14 [ -0.21, 0.50 ]
Subtotal (95% CI) 140 121 100.0 % 0.24 [ -0.17, 0.65 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 4.99, df = 2 (P = 0.08); I2 =60%
Test for overall effect: Z = 1.16 (P = 0.24)
3 Combined aerobic and resistance exercise
Herrero 2006 8 6.7 (5) 8 -1.7 (6.9) 43.6 % 1.32 [ 0.21, 2.43 ]
Naumann 2012 11 1.9 (3.3) 10 0.8 (3.4) 56.4 % 0.32 [ -0.55, 1.18 ]
Subtotal (95% CI) 19 18 100.0 % 0.75 [ -0.22, 1.73 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 1.95, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 1.51 (P = 0.13)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 1.89 (2.61) 10 -0.2 (1.61) 100.0 % 0.93 [ -0.03, 1.89 ]
Subtotal (95% CI) 9 10 100.0 % 0.93 [ -0.03, 1.89 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 7 Overall role function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 20 21.4 (4.8) 18 23.8 (3.2) 5.1 % -0.57 [ -1.22, 0.08 ]
Basen-Enquist 2006 28 86.1 (22.2) 23 73 (24.5) 6.6 % 0.55 [ -0.01, 1.12 ]
Courneya 2003 24 23.4 (4) 28 23.1 (4) 7.0 % 0.07 [ -0.47, 0.62 ]
Mehnert 2011 30 90 (20.34) 27 79.6 (25.04) 7.4 % 0.45 [ -0.07, 0.98 ]
Murtezani 2014 30 24.2 (2.8) 32 23 (2.5) 7.9 % 0.45 [ -0.06, 0.95 ]
Daley 2007 33 22.88 (4.52) 33 20.3 (5.57) 8.2 % 0.50 [ 0.01, 0.99 ]
Cadmus 2009 37 23.1 (4.7) 37 20.6 (7.2) 9.1 % 0.41 [ -0.05, 0.87 ]
Loh 2014 63 23.37 (4.33) 32 22.22 (4.99) 10.2 % 0.25 [ -0.18, 0.68 ]
Rogers 2015 105 22.3 (4.5) 108 20.3 (5.5) 18.3 % 0.40 [ 0.12, 0.67 ]
Vallance 2007 250 23.22 (3.98) 85 22.72 (4.58) 20.2 % 0.12 [ -0.13, 0.37 ]
Subtotal (95% CI) 620 423 100.0 % 0.28 [ 0.12, 0.44 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 12.25, df = 9 (P = 0.20); I2 =27%
Test for overall effect: Z = 3.49 (P = 0.00049)
2 Resistance exercise
Schmitz 2005 39 -49.2 (6.5) 40 -50 (6.2) 100.0 % 0.12 [ -0.32, 0.57 ]
Subtotal (95% CI) 39 40 100.0 % 0.12 [ -0.32, 0.57 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
3 Combined aerobic and resistance exercise
Herrero 2006 8 97.6 (5.9) 8 100 (0.01) 31.8 % -0.54 [ -1.55, 0.46 ]
Milne 2008 29 22.2 (3) 29 12.5 (4.8) 33.7 % 2.39 [ 1.71, 3.08 ]
Do 2015 32 78.1 (19.5) 30 79.2 (14.6) 34.5 % -0.06 [ -0.56, 0.44 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 69 67 100.0 % 0.61 [ -1.15, 2.37 ]
Heterogeneity: Tau2 = 2.28; Chi2 = 38.11, df = 2 (P<0.00001); I2 =95%
Test for overall effect: Z = 0.68 (P = 0.50)
4 Yoga, Tai Chi, and Pilates
Banasik 2011 7 3.46 (0.64) 7 3.24 (0.56) 12.4 % 0.34 [ -0.72, 1.40 ]
Mustian 2004 9 2.44 (1.5) 9 2.8 (1.53) 16.1 % -0.23 [ -1.15, 0.70 ]
Loudon 2014 12 -1.3 (0.31) 11 -1.3 (0.36) 20.7 % 0.0 [ -0.82, 0.82 ]
Littman 2012 30 22.6 (3.9) 27 21.7 (4.7) 50.9 % 0.21 [ -0.31, 0.73 ]
Subtotal (95% CI) 58 54 100.0 % 0.11 [ -0.26, 0.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.89, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 8 Overall role function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 20 0.4 (3.3) 18 1.4 (4.3) 9.8 % -0.26 [ -0.90, 0.38 ]
Courneya 2003 24 0.9 (2.8) 28 0.4 (2.7) 11.7 % 0.18 [ -0.37, 0.73 ]
Murtezani 2014 30 1.66 (0.71) 32 0.87 (0.64) 11.8 % 1.16 [ 0.62, 1.70 ]
Mehnert 2011 30 6.67 (23.84) 27 5.56 (27) 12.2 % 0.04 [ -0.48, 0.56 ]
Cadmus 2009 37 -0.3 (3.7) 37 -0.5 (3.4) 13.8 % 0.06 [ -0.40, 0.51 ]
Vallance 2007 250 0.63 (4.14) 85 -0.01 (2.7) 19.5 % 0.17 [ -0.08, 0.41 ]
Saarto 2012 263 2.4 (21.51) 237 3.8 (21.6) 21.2 % -0.06 [ -0.24, 0.11 ]
Subtotal (95% CI) 654 464 100.0 % 0.16 [ -0.10, 0.43 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 19.53, df = 6 (P = 0.003); I2 =69%
Test for overall effect: Z = 1.22 (P = 0.22)
2 Resistance exercise
Cormie 2014 43 4.9 (7.1) 19 1.7 (7.1) 44.6 % 0.45 [ -0.10, 0.99 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 55.4 % -0.05 [ -0.49, 0.39 ]
Subtotal (95% CI) 82 59 100.0 % 0.17 [ -0.32, 0.65 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 1.93, df = 1 (P = 0.16); I2 =48%
Test for overall effect: Z = 0.68 (P = 0.49)
3 Combined aerobic and resistance exercise
Herrero 2006 8 2.1 (13.9) 8 2.1 (5.9) 43.5 % 0.0 [ -0.98, 0.98 ]
Naumann 2012 11 1.5 (4.41) 10 0.5 (4.49) 56.5 % 0.22 [ -0.64, 1.08 ]
Subtotal (95% CI) 19 18 100.0 % 0.12 [ -0.52, 0.77 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.11, df = 1 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 0.56 (1.59) 10 0.8 (1.55) 100.0 % -0.15 [ -1.05, 0.76 ]
Subtotal (95% CI) 9 10 100.0 % -0.15 [ -1.05, 0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 9 Overall social well-being/function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 20 22.6 (4.1) 18 21.8 (5.7) 4.4 % 0.16 [ -0.48, 0.80 ]
Basen-Enquist 2006 28 84.6 (16.93) 23 84.9 (19.18) 5.8 % -0.02 [ -0.57, 0.54 ]
Courneya 2003 24 21.1 (3.5) 28 20.7 (3.6) 5.9 % 0.11 [ -0.43, 0.66 ]
Mehnert 2011 30 85.35 (20.88) 28 79.91 (22.65) 6.6 % 0.25 [ -0.27, 0.76 ]
Murtezani 2014 30 20.2 (2.8) 32 18.3 (2.7) 6.7 % 0.68 [ 0.17, 1.20 ]
Daley 2007 33 23.3 (4.78) 33 20.4 (6.8) 7.3 % 0.49 [ 0.00, 0.98 ]
Cadmus 2009 37 22.3 (4.9) 37 20.6 (7.2) 8.3 % 0.27 [ -0.18, 0.73 ]
Loh 2014 63 21.48 (4.88) 32 19.61 (4.9) 9.3 % 0.38 [ -0.05, 0.81 ]
Rogers 2015 105 21 (5.7) 108 20.7 (5.8) 21.3 % 0.05 [ -0.22, 0.32 ]
Vallance 2007 250 22.94 (4.96) 85 22.96 (5.05) 24.5 % 0.00 [ -0.25, 0.24 ]
Subtotal (95% CI) 620 424 100.0 % 0.18 [ 0.04, 0.31 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 9.78, df = 9 (P = 0.37); I2 =8%
Test for overall effect: Z = 2.56 (P = 0.011)
2 Resistance exercise
Schmitz 2009 59 14.9 (5.2) 62 14.1 (5.8) 100.0 % 0.14 [ -0.21, 0.50 ]
Subtotal (95% CI) 59 62 100.0 % 0.14 [ -0.21, 0.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.79 (P = 0.43)
3 Combined aerobic and resistance exercise
Herrero 2006 8 87.5 (19.4) 8 91.7 (23.6) 23.2 % -0.18 [ -1.17, 0.80 ]
Rogers 2014 20 7.3 (4.9) 22 3.1 (3.2) 35.4 % 1.01 [ 0.36, 1.65 ]
Milne 2008 29 20.7 (4) 29 19.4 (3.9) 41.4 % 0.32 [ -0.19, 0.84 ]
Subtotal (95% CI) 57 59 100.0 % 0.45 [ -0.16, 1.05 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 4.64, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 1.45 (P = 0.15)
4 Yoga, Tai Chi, and Pilates
Banasik 2011 7 2.8 (0.67) 7 3.16 (0.83) 4.9 % -0.45 [ -1.51, 0.62 ]
-4 -2 0 2 4
Favours control Favours physical activity
(Continued . . . )
583Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Mustian 2004 9 8.63 (1.89) 10 9 (1.83) 6.9 % -0.19 [ -1.09, 0.71 ]
Littman 2012 30 22.1 (5) 27 20.9 (6) 20.6 % 0.22 [ -0.31, 0.74 ]
Kiecolt-Glaser 2014 96 95.2 (10.8) 90 93.8 (9.3) 67.6 % 0.14 [ -0.15, 0.43 ]
Subtotal (95% CI) 142 134 100.0 % 0.10 [ -0.13, 0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.66, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 10 Overall social well-being/function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 20 0.9 (2.6) 18 -1.2 (2.7) 12.9 % 0.78 [ 0.11, 1.44 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 13.4 % 1.80 [ 1.21, 2.40 ]
Courneya 2003 24 0.6 (2.4) 28 -0.5 (3.3) 13.8 % 0.37 [ -0.18, 0.92 ]
Mehnert 2011 30 7.33 (22.33) 28 3.12 (24.3) 14.0 % 0.18 [ -0.34, 0.69 ]
Cadmus 2009 37 0.6 (4.6) 37 -1 (3.2) 14.4 % 0.40 [ -0.06, 0.86 ]
Vallance 2007 250 0.21 (4.82) 85 -4.15 (3.34) 15.6 % 0.97 [ 0.71, 1.23 ]
Saarto 2012 263 5 (21.1) 237 8.8 (20.81) 15.9 % -0.18 [ -0.36, -0.01 ]
Subtotal (95% CI) 654 465 100.0 % 0.60 [ 0.07, 1.13 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.45; Chi2 = 81.52, df = 6 (P<0.00001); I2 =93%
Test for overall effect: Z = 2.21 (P = 0.027)
2 Resistance exercise
Cormie 2014 43 3.5 (8.5) 19 2.5 (8.3) 30.4 % 0.12 [ -0.42, 0.66 ]
Schmitz 2009 59 4.4 (33.8) 62 0.7 (34) 69.6 % 0.11 [ -0.25, 0.47 ]
Subtotal (95% CI) 102 81 100.0 % 0.11 [ -0.19, 0.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
3 Combined aerobic and resistance exercise
Naumann 2012 11 0.9 (3.32) 10 -0.2 (3.32) 35.1 % 0.32 [ -0.54, 1.18 ]
Rogers 2014 20 2.1 (3.2) 22 -0.8 (3.5) 64.9 % 0.85 [ 0.21, 1.48 ]
Subtotal (95% CI) 31 32 100.0 % 0.66 [ 0.15, 1.17 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.94, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.011)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 1.5 (1.5) 10 0.44 (1.17) 100.0 % 0.76 [ -0.18, 1.70 ]
Subtotal (95% CI) 9 10 100.0 % 0.76 [ -0.18, 1.70 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.58 (P = 0.11)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 11 Overall cognitive function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 19 -124.5 (30.8) 18 -135.5 (19.5) 38.9 % 0.42 [ -0.24, 1.07 ]
Mehnert 2011 30 81.1 (16.8) 27 78.4 (24.38) 61.1 % 0.13 [ -0.39, 0.65 ]
Subtotal (95% CI) 49 45 100.0 % 0.24 [ -0.17, 0.65 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.16 (P = 0.25)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Pinto 2003 12 -4.33 (2.5) 6 -7.17 (2.1) 15.4 % 1.14 [ 0.07, 2.20 ]
Herrero 2006 8 91.7 (12.6) 8 89.6 (12.4) 18.1 % 0.16 [ -0.82, 1.14 ]
Cantarero-Villanueva 2013 32 -37.93 (8.48) 29 -43.03 (10.01) 66.5 % 0.55 [ 0.03, 1.06 ]
Subtotal (95% CI) 52 43 100.0 % 0.57 [ 0.15, 0.98 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.76, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.65 (P = 0.0080)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 12 Overall cognitive function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 20 4.2 (16.8) 18 -4.7 (25.9) 44.7 % 0.40 [ -0.24, 1.05 ]
Mehnert 2011 30 1.67 (22.36) 27 6.18 (24.6) 55.3 % -0.19 [ -0.71, 0.33 ]
Subtotal (95% CI) 50 45 100.0 % 0.08 [ -0.50, 0.65 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 1.97, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.26 (P = 0.80)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Herrero 2006 8 6.2 (19.8) 8 8.3 (14.8) 11.4 % -0.11 [ -1.09, 0.87 ]
Cantarero-Villanueva 2013 32 2.2 (7.63) 29 -0.18 (5.5471) 29.3 % 0.35 [ -0.16, 0.86 ]
Saarto 2012 263 -1 (18.2) 237 2.2 (18.46) 59.3 % -0.17 [ -0.35, 0.00 ]
Subtotal (95% CI) 303 274 100.0 % -0.01 [ -0.38, 0.35 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 3.67, df = 2 (P = 0.16); I2 =45%
Test for overall effect: Z = 0.07 (P = 0.94)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 13 Overall general health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Baruth 2013 20 68.1 (0) 12 61.6 (0) Not estimable
Rogers 2009 20 3.5 (0.9) 18 3.8 (0.5) 17.7 % -0.40 [ -1.04, 0.25 ]
Ergun 2013 20 68.97 (21.16) 20 67.91 (16.72) 18.4 % 0.05 [ -0.57, 0.67 ]
Basen-Enquist 2006 28 77.4 (11.64) 23 67.1 (13.43) 19.6 % 0.81 [ 0.24, 1.39 ]
Mehnert 2011 30 74.38 (11.84) 28 70.01 (20.81) 21.2 % 0.26 [ -0.26, 0.77 ]
Cadmus 2009 37 50 (8.8) 37 51.7 (8.4) 23.1 % -0.20 [ -0.65, 0.26 ]
Subtotal (95% CI) 155 138 100.0 % 0.11 [ -0.29, 0.51 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 10.17, df = 4 (P = 0.04); I2 =61%
Test for overall effect: Z = 0.53 (P = 0.59)
2 Resistance exercise
Schmitz 2005 39 53.8 (5.3) 40 53.2 (6) 100.0 % 0.10 [ -0.34, 0.55 ]
Subtotal (95% CI) 39 40 100.0 % 0.10 [ -0.34, 0.55 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
3 Combined aerobic and resistance exercise
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 14.8 % 1.30 [ 0.19, 2.41 ]
Ergun 2013 20 74.16 (18.71) 20 67.91 (16.7) 36.6 % 0.35 [ -0.28, 0.97 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 48.6 % 0.28 [ -0.22, 0.79 ]
Subtotal (95% CI) 60 58 100.0 % 0.46 [ 0.00, 0.91 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 2.76, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 1.96 (P = 0.050)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 18.6 (4.77) 9 19.3 (1.92) 100.0 % -0.18 [ -1.11, 0.74 ]
Subtotal (95% CI) 9 9 100.0 % -0.18 [ -1.11, 0.74 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 14 Overall general health (change values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Aerobic exercise
Rogers 2009 20 0.15 (0.6) 18 0.17 (0.7) 5.4 % -0.03 [ -0.67, 0.61 ]
Ergun 2013 20 4.62 (26.54) 20 -6.66 (25.87) 5.5 % 0.42 [ -0.21, 1.05 ]
Mehnert 2011 30 6.6 (13.7) 28 3.24 (19.7) 8.2 % 0.20 [ -0.32, 0.71 ]
Cadmus 2009 37 0.2 (4.4) 37 -0.1 (5.1) 10.5 % 0.06 [ -0.39, 0.52 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 70.5 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 370 340 100.0 % -0.02 [ -0.17, 0.13 ]
Heterogeneity: Chi2 = 3.29, df = 4 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
2 Resistance exercise
Cormie 2014 43 3.7 (7) 19 2.8 (7.1) 40.3 % 0.13 [ -0.41, 0.67 ]
Schmitz 2005 39 0.7 (4.8) 40 -0.6 (3.9) 59.7 % 0.29 [ -0.15, 0.74 ]
Subtotal (95% CI) 82 59 100.0 % 0.23 [ -0.12, 0.57 ]
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.19)
3 Combined aerobic and resistance exercise
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 16.0 % 1.92 [ 0.68, 3.17 ]
Ergun 2013 40 4.62 (26.54) 20 -6.66 (25.87) 84.0 % 0.42 [ -0.12, 0.97 ]
Subtotal (95% CI) 48 28 100.0 % 0.66 [ 0.17, 1.16 ]
Heterogeneity: Chi2 = 4.68, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 2.61 (P = 0.0090)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 0.22 (1.92) 10 0.68 (2.5) 100.0 % -0.20 [ -1.10, 0.71 ]
Subtotal (95% CI) 9 10 100.0 % -0.20 [ -1.10, 0.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 15 Overall sexual function (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Aerobic exercise
Pinto 2005 12 42.75 (9.2) 6 43.7 (6.1) 12.0 % -0.11 [ -1.09, 0.87 ]
Duijits 2012 53 0.6 (0.79) 65 0.59 (0.79) 88.0 % 0.01 [ -0.35, 0.38 ]
Subtotal (95% CI) 65 71 100.0 % 0.00 [ -0.34, 0.34 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
2 Resistance exercise
Schmitz 2005 39 -51 (7.5) 40 -53.5 (8) 40.7 % 0.32 [ -0.12, 0.76 ]
Schmitz 2009 57 -27.3 (5.3) 57 -28.1 (6.2) 59.3 % 0.14 [ -0.23, 0.51 ]
Subtotal (95% CI) 96 97 100.0 % 0.21 [ -0.07, 0.49 ]
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
3 Combined aerobic and resistance exercise
Pinto 2003 39 42.45 (9.24) 43 40.12 (6.3) 100.0 % 0.29 [ -0.14, 0.73 ]
Subtotal (95% CI) 39 43 100.0 % 0.29 [ -0.14, 0.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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16 Overall sexual function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 16 Overall sexual function (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Saarto 2012 263 4.3 (25.38) 237 3.8 (24.35) 100.0 % 0.50 [ -3.86, 4.86 ]
Subtotal (95% CI) 263 237 100.0 % 0.50 [ -3.86, 4.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
2 Resistance exercise
Schmitz 2009 57 7.2 (14.6) 57 -0.2 (16.7) 39.4 % 7.40 [ 1.64, 13.16 ]
Schmitz 2005 39 1.7 (4.8) 40 0.2 (5.2) 60.6 % 1.50 [ -0.71, 3.71 ]
Subtotal (95% CI) 96 97 100.0 % 3.83 [ -1.83, 9.48 ]
Heterogeneity: Tau2 = 12.46; Chi2 = 3.52, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.33 (P = 0.18)
3 Combined aerobic and resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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17 Overall sleep (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 17 Overall sleep (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Aerobic exercise
Rogers 2009 20 6.65 (4.17) 18 5.5 (4) 40.5 % 0.28 [ -0.36, 0.92 ]
Mehnert 2011 30 23.75 (27) 27 38.27 (31.63) 59.5 % -0.49 [ -1.02, 0.04 ]
Subtotal (95% CI) 50 45 100.0 % -0.18 [ -0.59, 0.23 ]
Heterogeneity: Chi2 = 3.26, df = 1 (P = 0.07); I2 =69%
Test for overall effect: Z = 0.86 (P = 0.39)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Rogers 2013 11 6.3 (2.7) 9 6.2 (3.2) 32.1 % 0.03 [ -0.85, 0.91 ]
Rogers 2014 20 6.7 (3.7) 22 7.1 (3.2) 67.9 % -0.11 [ -0.72, 0.49 ]
Subtotal (95% CI) 31 31 100.0 % -0.07 [ -0.57, 0.43 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
4 Yoga, Tai Chi, and Pilates
Bower 2011 16 8.1 (2.5) 15 7.7 (2.6) 100.0 % 0.15 [ -0.55, 0.86 ]
Subtotal (95% CI) 16 15 100.0 % 0.15 [ -0.55, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.42 (P = 0.67)
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18 Overall sleep (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 18 Overall sleep (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 20 0.45 (2.1) 18 0.28 (4.7) 40.4 % 0.05 [ -0.59, 0.68 ]
Mehnert 2011 29 -5.36 (29.88) 27 -9.88 (33.3) 59.6 % 0.14 [ -0.38, 0.67 ]
Subtotal (95% CI) 49 45 100.0 % 0.10 [ -0.30, 0.51 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Rogers 2014 20 -1.3 (3.2) 22 -2.2 (4.4) 100.0 % 0.23 [ -0.38, 0.84 ]
Subtotal (95% CI) 20 22 100.0 % 0.23 [ -0.38, 0.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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19 Overall anxiety (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 19 Overall anxiety (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Segar 1998 10 28.5 (3) 5 39.5 (6) 11.6 % -2.49 [ -3.98, -1.00 ]
Milne 2008 29 15.3 (6.2) 29 21 (5.7) 28.6 % -0.94 [ -1.49, -0.40 ]
Mehnert 2011 30 4.83 (3.46) 28 7.14 (4.97) 29.1 % -0.54 [ -1.06, -0.01 ]
Cadmus 2009 37 32.1 (12.3) 37 34.1 (15.4) 30.7 % -0.14 [ -0.60, 0.31 ]
Subtotal (95% CI) 106 99 100.0 % -0.76 [ -1.37, -0.14 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 11.56, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 2.42 (P = 0.016)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Pinto 2003 12 7.58 (7.3) 6 10.5 (3.7) 18.3 % -0.43 [ -1.43, 0.56 ]
Rogers 2014 20 45.6 (8.9) 22 45.7 (8) 37.3 % -0.01 [ -0.62, 0.59 ]
Cantarero-Villanueva 2013 32 42.51 (8.6) 29 49.93 (11.7) 44.5 % -0.72 [ -1.24, -0.20 ]
Subtotal (95% CI) 64 57 100.0 % -0.40 [ -0.87, 0.07 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 3.02, df = 2 (P = 0.22); I2 =34%
Test for overall effect: Z = 1.68 (P = 0.093)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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20 Overall anxiety (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 20 Overall anxiety (change values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Aerobic exercise
Mehnert 2011 30 -1.67 (3.68) 28 0.18 (4.89) 43.4 % -0.42 [ -0.95, 0.10 ]
Cadmus 2009 37 -0.7 (9.2) 37 0.5 (5.8) 56.6 % -0.15 [ -0.61, 0.30 ]
Subtotal (95% CI) 67 65 100.0 % -0.27 [ -0.61, 0.07 ]
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.55 (P = 0.12)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Rogers 2014 20 -4 (6.5) 22 -1.8 (5) 41.5 % -0.37 [ -0.99, 0.24 ]
Cantarero-Villanueva 2013 32 -4.2 (9.8) 29 0.75 (5.5) 58.5 % -0.61 [ -1.12, -0.09 ]
Subtotal (95% CI) 52 51 100.0 % -0.51 [ -0.90, -0.12 ]
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.54 (P = 0.011)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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21 Overall depression (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 21 Overall depression (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Segar 1998 10 5.5 (2) 5 10 (2) 7.8 % -2.12 [ -3.51, -0.73 ]
Payne 2008 10 12.7 (8.7) 10 11.4 (7.9) 13.5 % 0.15 [ -0.73, 1.03 ]
Ergun 2013 20 8.88 (10.48) 20 5.15 (5.18) 17.7 % 0.44 [ -0.19, 1.07 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 19.7 % -0.51 [ -1.04, 0.01 ]
Daley 2007 33 6 (6.47) 33 10.33 (7.19) 20.2 % -0.63 [ -1.12, -0.13 ]
Cadmus 2009 37 9.6 (9.3) 37 10.8 (10.1) 21.0 % -0.12 [ -0.58, 0.33 ]
Subtotal (95% CI) 140 133 100.0 % -0.32 [ -0.78, 0.14 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 15.80, df = 5 (P = 0.01); I2 =68%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Pinto 2003 12 6.17 (7.2) 6 9.83 (6.8) 15.4 % -0.49 [ -1.49, 0.50 ]
Kaltsatou 2011 13 16.54 (1.66) 13 22.33 (7.73) 18.1 % -1.00 [ -1.83, -0.18 ]
Ergun 2013 20 4.7 (4.1) 20 5.15 (5.18) 21.6 % -0.09 [ -0.71, 0.53 ]
Rogers 2014 20 44.2 (8.6) 22 25.1 (44.2) 21.6 % 0.58 [ -0.04, 1.19 ]
Cantarero-Villanueva 2013 32 45.58 (9.68) 29 53.71 (11.6) 23.3 % -0.75 [ -1.28, -0.23 ]
Subtotal (95% CI) 97 90 100.0 % -0.33 [ -0.90, 0.24 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 13.96, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 1.12 (P = 0.26)
4 Yoga, Tai Chi, and Pilates
Bower 2011 16 7.7 (5.8) 15 11.6 (7.1) 22.8 % -0.59 [ -1.31, 0.13 ]
Kiecolt-Glaser 2014 96 8.1 (8.6) 90 9.2 (8.2) 77.2 % -0.13 [ -0.42, 0.16 ]
Subtotal (95% CI) 112 105 100.0 % -0.23 [ -0.61, 0.14 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.33, df = 1 (P = 0.25); I2 =25%
Test for overall effect: Z = 1.22 (P = 0.22)
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22 Overall depression (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 22 Overall depression (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Ergun 2013 20 -0.61 (6.66) 20 2.35 (8.03) 15.4 % -0.39 [ -1.02, 0.23 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 19.4 % -0.51 [ -1.04, 0.01 ]
Cadmus 2009 37 0.3 (6.4) 37 1.7 (6.3) 22.7 % -0.22 [ -0.68, 0.24 ]
Saarto 2012 263 -0.3 (3.31) 237 -0.5 (3.38) 42.5 % 0.06 [ -0.12, 0.24 ]
Subtotal (95% CI) 350 322 100.0 % -0.18 [ -0.48, 0.11 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 6.16, df = 3 (P = 0.10); I2 =51%
Test for overall effect: Z = 1.22 (P = 0.22)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Naumann 2012 11 -3.6 (4.34) 10 2 (4.55) 15.7 % -1.21 [ -2.16, -0.26 ]
Ergun 2013 20 3.05 (5.22) 20 2.35 (8.03) 26.4 % 0.10 [ -0.52, 0.72 ]
Rogers 2014 20 -1.7 (6.9) 22 1.1 (4.2) 26.6 % -0.49 [ -1.10, 0.13 ]
Cantarero-Villanueva 2013 32 -2.95 (7.82) 29 1.46 (7.36) 31.3 % -0.57 [ -1.09, -0.06 ]
Subtotal (95% CI) 83 81 100.0 % -0.47 [ -0.92, -0.02 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 5.74, df = 3 (P = 0.12); I2 =48%
Test for overall effect: Z = 2.07 (P = 0.039)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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23 Overall fatigue (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 23 Overall fatigue (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Payne 2008 9 4.7 (2.6) 9 3.5 (1.7) 3.0 % 0.52 [ -0.42, 1.46 ]
Rogers 2009 20 -12.4 (10.4) 18 -10.1 (6.6) 5.9 % -0.26 [ -0.90, 0.38 ]
Ergun 2013 20 3.02 (2.5) 20 3.3 (1.79) 6.2 % -0.13 [ -0.75, 0.49 ]
Courneya 2003 24 -8.3 (7.9) 28 -8.8 (8.1) 7.6 % 0.06 [ -0.48, 0.61 ]
Mehnert 2011 30 28.52 (25.58) 27 39.92 (25.09) 8.0 % -0.44 [ -0.97, 0.08 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 8.7 % -0.71 [ -1.21, -0.21 ]
Cadmus 2009 37 -51.9 (9) 37 -50.6 (10) 9.9 % -0.14 [ -0.59, 0.32 ]
Pinto 2015 39 -43.83 (7.8) 37 -41.22 (8.49) 10.0 % -0.32 [ -0.77, 0.14 ]
Pinto 2005 39 27.08 (21.41) 43 42.28 (26.2) 10.2 % -0.63 [ -1.07, -0.18 ]
Fillion 2008 44 2.65 (0.72) 43 2.86 (0.83) 11.0 % -0.27 [ -0.69, 0.15 ]
Vallance 2007 250 -42.7 (8.4) 85 -42.6 (8.7) 19.4 % -0.01 [ -0.26, 0.23 ]
Subtotal (95% CI) 545 380 100.0 % -0.24 [ -0.41, -0.07 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 14.26, df = 10 (P = 0.16); I2 =30%
Test for overall effect: Z = 2.74 (P = 0.0061)
2 Resistance exercise
Winters-Stone 2011 36 45 (5.3) 31 43.1 (10.3) 100.0 % 0.23 [ -0.25, 0.72 ]
Subtotal (95% CI) 36 31 100.0 % 0.23 [ -0.25, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
3 Combined aerobic and resistance exercise
Pinto 2003 12 7.16 (6.4) 6 9 (6.4) 7.2 % -0.27 [ -1.26, 0.71 ]
Rogers 2013 11 4.2 (1.8) 9 4.2 (1.6) 8.2 % 0.0 [ -0.88, 0.88 ]
Ergun 2013 20 2.86 (2.02) 20 3.3 (1.79) 11.0 % -0.23 [ -0.85, 0.40 ]
Cuesta-Vargas 2014 22 4 (1.8) 20 5.2 (3.2) 11.1 % -0.46 [ -1.07, 0.15 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rogers 2014 20 4.1 (2.1) 22 4 (1.8) 11.2 % 0.05 [ -0.56, 0.66 ]
Milne 2008 29 11.9 (3.2) 29 17.4 (4.7) 11.6 % -1.35 [ -1.92, -0.78 ]
Cantarero-Villanueva 2013 32 3.78 (1.78) 29 6.23 (1.72) 11.7 % -1.38 [ -1.94, -0.82 ]
Do 2015 32 16.8 (13.3) 30 22.3 (15.1) 12.5 % -0.38 [ -0.89, 0.12 ]
Short 2014 195 -41.5 (9.3) 104 -39.8 (10.4) 15.6 % -0.17 [ -0.41, 0.06 ]
Subtotal (95% CI) 373 269 100.0 % -0.48 [ -0.83, -0.13 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 28.92, df = 8 (P = 0.00033); I2 =72%
Test for overall effect: Z = 2.69 (P = 0.0071)
4 Yoga, Tai Chi, and Pilates
Banasik 2011 7 1 (0.89) 7 1.57 (0.98) 4.4 % -0.57 [ -1.65, 0.51 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 7.6 % -0.07 [ -0.89, 0.75 ]
Bower 2011 16 3.4 (1.8) 15 4.9 (1.3) 9.1 % -0.93 [ -1.67, -0.18 ]
Littman 2012 30 -45 (5.3) 27 -43.1 (10.3) 18.6 % -0.23 [ -0.75, 0.29 ]
Kiecolt-Glaser 2014 96 6.3 (19.6) 90 12.7 (18.97) 60.4 % -0.33 [ -0.62, -0.04 ]
Subtotal (95% CI) 161 150 100.0 % -0.36 [ -0.58, -0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.09, df = 4 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 3.11 (P = 0.0019)
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24 Overall fatigue (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 24 Overall fatigue (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 20 1.9 (9.6) 18 4.2 (12.3) 10.8 % -0.21 [ -0.84, 0.43 ]
Courneya 2003 24 9.3 (10.2) 28 2 (7.5) 12.0 % 0.81 [ 0.24, 1.38 ]
Mehnert 2011 30 -0.74 (20.73) 27 -2.88 (25.3) 12.8 % 0.09 [ -0.43, 0.61 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 13.2 % -0.71 [ -1.21, -0.21 ]
Pinto 2005 39 -14.93 (23.54) 43 1.79 (23.48) 14.2 % -0.70 [ -1.15, -0.26 ]
Vallance 2007 250 2.49 (8.17) 85 1.15 (6.61) 18.0 % 0.17 [ -0.08, 0.42 ]
Saarto 2012 263 -2.4 (9.06) 237 -2.4 (8.6) 19.0 % 0.0 [ -0.18, 0.18 ]
Subtotal (95% CI) 659 471 100.0 % -0.08 [ -0.38, 0.23 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 27.53, df = 6 (P = 0.00012); I2 =78%
Test for overall effect: Z = 0.49 (P = 0.62)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Herrero 2006 8 -4.2 (19.6) 8 6.4 (14.5) 22.2 % -0.58 [ -1.59, 0.43 ]
Naumann 2012 11 -3.6 (4.35) 10 2 (4.55) 23.2 % -1.21 [ -2.16, -0.26 ]
Rogers 2013 11 4.2 (2) 9 3.9 (1.5) 24.4 % 0.16 [ -0.72, 1.04 ]
Cantarero-Villanueva 2013 32 -2 (1.75) 29 0.34 (1.39) 30.3 % -1.45 [ -2.02, -0.88 ]
Subtotal (95% CI) 62 56 100.0 % -0.81 [ -1.57, -0.05 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 9.89, df = 3 (P = 0.02); I2 =70%
Test for overall effect: Z = 2.10 (P = 0.036)
4 Yoga, Tai Chi, and Pilates
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 100.0 % -0.07 [ -0.89, 0.75 ]
Subtotal (95% CI) 12 11 100.0 % -0.07 [ -0.89, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.18 (P = 0.86)
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25 Overall pain/disability (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 25 Overall pain/disability (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Rogers 2009 20 -3.03 (2.98) 18 -2.28 (2.76) 12.9 % -0.26 [ -0.89, 0.38 ]
Basen-Enquist 2006 28 79.7 (10.58) 23 72.1 (11.51) 15.4 % 0.68 [ 0.11, 1.25 ]
Mehnert 2011 30 79.4 (23.1) 28 73.5 (24.83) 17.7 % 0.24 [ -0.27, 0.76 ]
Cadmus 2009 37 50.3 (9.1) 37 50.8 (9) 20.9 % -0.05 [ -0.51, 0.40 ]
Duijits 2012 87 79.27 (23.59) 89 78.79 (23.78) 33.1 % 0.02 [ -0.28, 0.32 ]
Subtotal (95% CI) 202 195 100.0 % 0.11 [ -0.15, 0.37 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 6.19, df = 4 (P = 0.19); I2 =35%
Test for overall effect: Z = 0.83 (P = 0.41)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Portela 2008 25 -20.6 (20.2) 9 -20.8 (15.5) 30.0 % 0.01 [ -0.75, 0.77 ]
Do 2015 32 21.1 (24.6) 30 16.5 (26.7) 70.0 % 0.18 [ -0.32, 0.68 ]
Subtotal (95% CI) 57 39 100.0 % 0.13 [ -0.29, 0.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.13, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 9.11 (1.35) 10 9.1 (1.74) 45.6 % 0.01 [ -0.89, 0.91 ]
Loudon 2014 12 0.8 (1.48) 11 1.44 (2.24) 54.4 % -0.33 [ -1.15, 0.50 ]
Subtotal (95% CI) 21 21 100.0 % -0.18 [ -0.78, 0.43 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.29, df = 1 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.57 (P = 0.57)
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26 Overall pain/disability (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 26 Overall pain/disability (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Mehnert 2011 30 -2.4 (24.95) 28 -7.61 (25.2) 45.9 % 0.21 [ -0.31, 0.72 ]
Cadmus 2009 37 -2.2 (11.3) 37 -0.1 (7) 54.1 % -0.22 [ -0.68, 0.24 ]
Subtotal (95% CI) 67 65 100.0 % -0.03 [ -0.44, 0.39 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.47, df = 1 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.12 (P = 0.90)
2 Resistance exercise
Cormie 2014 43 3.4 (6.5) 19 2 (6.2) 100.0 % 0.22 [ -0.33, 0.76 ]
Subtotal (95% CI) 43 19 100.0 % 0.22 [ -0.33, 0.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.44)
3 Combined aerobic and resistance exercise
Irwin 2015 45 -6 (18.97) 38 0.7 (18.56) 100.0 % -0.35 [ -0.79, 0.08 ]
Subtotal (95% CI) 45 38 100.0 % -0.35 [ -0.79, 0.08 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 -0.22 (1.29) 10 0 (1.42) 100.0 % -0.15 [ -1.06, 0.75 ]
Subtotal (95% CI) 9 10 100.0 % -0.15 [ -1.06, 0.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.34 (P = 0.74)
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27 Overall self-esteem/body image (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 27 Overall self-esteem/body image (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Segar 1998 10 33 (1.8) 5 30.5 (2.7) 6.7 % 1.11 [ -0.06, 2.28 ]
Musanti 2012 10 21.7 (4.4) 12 26.33 (3.94) 9.5 % -1.07 [ -1.98, -0.16 ]
Mehnert 2011 27 -5.47 (1.66) 27 -6.82 (2.6) 15.7 % 0.61 [ 0.06, 1.16 ]
Courneya 2003 24 34.8 (4.7) 28 34.6 (4.4) 15.7 % 0.04 [ -0.50, 0.59 ]
Daley 2007 33 2.03 (0.83) 32 1.57 (0.5) 16.7 % 0.66 [ 0.16, 1.16 ]
Cadmus 2009 37 34.2 (5.5) 37 33.4 (5.9) 17.7 % 0.14 [ -0.32, 0.60 ]
Pinto 2005 39 30.26 (7.82) 43 27.23 (6.76) 18.1 % 0.41 [ -0.03, 0.85 ]
Subtotal (95% CI) 180 184 100.0 % 0.29 [ -0.07, 0.64 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 15.40, df = 6 (P = 0.02); I2 =61%
Test for overall effect: Z = 1.58 (P = 0.12)
2 Resistance exercise
Musanti 2012 9 26.44 (2.6) 12 26.33 (3.94) 14.4 % 0.03 [ -0.83, 0.90 ]
Schmitz 2009 59 -70.4 (16.3) 63 -71.5 (18) 85.6 % 0.06 [ -0.29, 0.42 ]
Subtotal (95% CI) 68 75 100.0 % 0.06 [ -0.27, 0.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
3 Combined aerobic and resistance exercise
Pinto 2003 12 32.3 (4.3) 6 25.3 (8.2) 17.5 % 1.15 [ 0.08, 2.22 ]
Musanti 2012 11 23.64 (1.22) 12 26.33 (3.94) 21.6 % -0.87 [ -1.74, -0.01 ]
Milne 2008 29 -17.9 (6.8) 29 -20.1 (6.3) 30.2 % 0.33 [ -0.19, 0.85 ]
Do 2015 (1) 32 37.9 (18.9) 30 36.1 (18.3) 30.7 % 0.10 [ -0.40, 0.59 ]
Subtotal (95% CI) 84 77 100.0 % 0.14 [ -0.46, 0.74 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 9.25, df = 3 (P = 0.03); I2 =68%
Test for overall effect: Z = 0.46 (P = 0.64)
4 Yoga, Tai Chi, and Pilates
Loudon 2014 12 -1.43 (0.33) 11 -1.56 (0.86) 100.0 % 0.20 [ -0.62, 1.02 ]
Subtotal (95% CI) 12 11 100.0 % 0.20 [ -0.62, 1.02 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.47 (P = 0.64)
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28 Overall self-esteem/body image (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 28 Overall self-esteem/body image (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Musanti 2012 10 -1.3 (5.98) 12 0.58 (3.92) 7.2 % -0.37 [ -1.21, 0.48 ]
Courneya 2003 24 2.6 (3.7) 28 -0.1 (3.5) 13.1 % 0.74 [ 0.18, 1.30 ]
Mehnert 2011 30 0.73 (2.12) 27 0.39 (2.12) 14.6 % 0.16 [ -0.36, 0.68 ]
Daley 2007 33 1.79 (0.71) 33 1.56 (0.67) 15.8 % 0.33 [ -0.16, 0.82 ]
Cadmus 2009 37 0.4 (4.4) 37 0.2 (2.9) 17.0 % 0.05 [ -0.40, 0.51 ]
Saarto 2012 263 10.7 (21.51) 237 12 (21.99) 32.2 % -0.06 [ -0.24, 0.12 ]
Subtotal (95% CI) 397 374 100.0 % 0.14 [ -0.12, 0.39 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 9.58, df = 5 (P = 0.09); I2 =48%
Test for overall effect: Z = 1.05 (P = 0.29)
2 Resistance exercise
Musanti 2012 9 1.11 (1.76) 12 0.58 (3.92) 31.1 % 0.16 [ -0.71, 1.03 ]
Schmitz 2009 59 -12 (15.5) 63 -4.1 (16.2) 68.9 % -0.49 [ -0.86, -0.13 ]
Subtotal (95% CI) 68 75 100.0 % -0.29 [ -0.88, 0.30 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 1.87, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.96 (P = 0.34)
3 Combined aerobic and resistance exercise
Musanti 2012 11 -0.82 (4.67) 12 0.58 (3.92) 38.4 % -0.31 [ -1.14, 0.51 ]
Milne 2008 29 1.5 (3.7) 29 0.1 (3.9) 61.6 % 0.36 [ -0.16, 0.88 ]
Subtotal (95% CI) 40 41 100.0 % 0.10 [ -0.54, 0.75 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 1.86, df = 1 (P = 0.17); I2 =46%
Test for overall effect: Z = 0.31 (P = 0.75)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 11 3 (1) 10 -1.5 (1.5) 100.0 % 3.42 [ 1.99, 4.86 ]
Subtotal (95% CI) 11 10 100.0 % 3.42 [ 1.99, 4.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.68 (P < 0.00001)
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29 Overall cardiorespiratory fitness (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 29 Overall cardiorespiratory fitness (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Cerulli 2014 10 31.29 (4.95) 10 32.26 (10.1) 3.2 % -0.12 [ -0.99, 0.76 ]
Musanti 2012 10 24.76 (6.49) 12 23 (4.29) 3.4 % 0.31 [ -0.53, 1.16 ]
Nikander 2007 14 -17.6 (1.3) 14 -17.2 (1.4) 4.3 % -0.29 [ -1.03, 0.46 ]
Rogers 2009 20 29.5 (6.6) 18 27.6 (6.1) 5.7 % 0.29 [ -0.35, 0.93 ]
Courneya 2003 24 21.3 (3.7) 26 18.2 (3.9) 6.8 % 0.80 [ 0.22, 1.38 ]
Mehnert 2011 27 26.9 (4.4) 23 25.7 (4.7) 7.2 % 0.26 [ -0.30, 0.82 ]
Basen-Enquist 2006 35 1643 (122.5) 25 1546 (127.5) 7.8 % 0.77 [ 0.24, 1.30 ]
Murtezani 2014 30 875.1 (86.7) 32 823.5 (87.1) 8.4 % 0.59 [ 0.08, 1.10 ]
Pinto 2005 39 -16.34 (2.09) 43 -17.85 (2.24) 10.3 % 0.69 [ 0.24, 1.14 ]
Fillion 2008 44 27.04 (4.39) 43 26.53 (5.81) 11.3 % 0.10 [ -0.32, 0.52 ]
Daley 2007 33 34.99 (4.42) 69 33.05 (5.3) 11.4 % 0.38 [ -0.04, 0.80 ]
Rogers 2015 105 23.6 (4.8) 108 22.7 (0.3) 20.3 % 0.27 [ 0.00, 0.54 ]
Subtotal (95% CI) 391 423 100.0 % 0.37 [ 0.21, 0.54 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 13.52, df = 11 (P = 0.26); I2 =19%
Test for overall effect: Z = 4.49 (P < 0.00001)
2 Resistance exercise
Musanti 2012 9 24.22 (4.38) 12 23 (4.29) 100.0 % 0.27 [ -0.60, 1.14 ]
Subtotal (95% CI) 9 12 100.0 % 0.27 [ -0.60, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 Combined aerobic and resistance exercise
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Herrero 2006 8 25.9 (4.5) 8 25.7 (3.7) 5.4 % 0.05 [ -0.93, 1.03 ]
Rogers 2013 12 23.9 (6.2) 10 23.9 (3.8) 6.8 % 0.0 [ -0.84, 0.84 ]
Musanti 2012 11 24.71 (4.14) 12 23 (4.29) 7.0 % 0.39 [ -0.44, 1.22 ]
Portela 2008 25 3006.96 (410.8) 9 2416.1 (718.6) 7.1 % 1.14 [ 0.33, 1.96 ]
Kaltsatou 2011 14 483.33 (85.95) 13 403.08 (71.92) 7.2 % 0.98 [ 0.17, 1.78 ]
Rahnama 2010 14 20.65 (5.73) 15 13.85 (5.18) 7.3 % 1.21 [ 0.41, 2.01 ]
Rogers 2014 20 30.9 (6.3) 22 25.1 (5) 9.7 % 1.01 [ 0.36, 1.65 ]
Kim 2015 20 424.8 (55.8) 19 394.4 (54) 9.8 % 0.54 [ -0.10, 1.18 ]
Do 2015 30 31.7 (12.4) 30 24.5 (6.6) 12.4 % 0.72 [ 0.19, 1.24 ]
Milne 2008 29 1.49 (0.31) 29 1.48 (0.43) 12.6 % 0.03 [ -0.49, 0.54 ]
Irwin 2015 45 24.6 (5.5) 38 23 (4.7) 14.7 % 0.31 [ -0.13, 0.74 ]
Subtotal (95% CI) 228 205 100.0 % 0.56 [ 0.30, 0.81 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 15.96, df = 10 (P = 0.10); I2 =37%
Test for overall effect: Z = 4.27 (P = 0.000020)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 11 636.1 (50.6) 10 610.3 (75.9) 100.0 % 0.39 [ -0.48, 1.25 ]
Subtotal (95% CI) 11 10 100.0 % 0.39 [ -0.48, 1.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.88 (P = 0.38)
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30 Overall cardiorespiratory fitness (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 30 Overall cardiorespiratory fitness (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Dolan 2016 23 12.2 (10.2) 10 -5.97 (7.2) 16.6 % 1.88 [ 0.99, 2.77 ]
Musanti 2012 10 0.96 (2.39) 12 0.88 (3.4) 17.2 % 0.03 [ -0.81, 0.87 ]
Courneya 2003 24 2.7 (2.6) 26 -0.6 (1.7) 19.8 % 1.49 [ 0.86, 2.12 ]
Pinto 2005 39 1.35 (2.4) 43 -0.25 (2.5) 22.1 % 0.65 [ 0.20, 1.09 ]
Saarto 2012 262 0.89 (1.15) 236 0.72 (1.01) 24.4 % 0.16 [ -0.02, 0.33 ]
Subtotal (95% CI) 358 327 100.0 % 0.79 [ 0.17, 1.42 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 30.86, df = 4 (P<0.00001); I2 =87%
Test for overall effect: Z = 2.49 (P = 0.013)
2 Resistance exercise
Musanti 2012 9 0.75 (3.69) 12 0.9 (3.4) 100.0 % -0.04 [ -0.91, 0.82 ]
Subtotal (95% CI) 9 12 100.0 % -0.04 [ -0.91, 0.82 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
3 Combined aerobic and resistance exercise
Nieman 1995 6 60.8 (8.4) 6 12 (17.8) 6.9 % 3.24 [ 1.29, 5.18 ]
Naumann 2012 11 3.1 (2.9) 10 -0.1 (3.1) 18.3 % 1.03 [ 0.10, 1.95 ]
Musanti 2012 11 1.16 (2.78) 12 0.9 (3.4) 20.4 % 0.08 [ -0.74, 0.90 ]
Rogers 2014 20 2.8 (4.9) 22 1.1 (4.2) 25.2 % 0.37 [ -0.24, 0.98 ]
Irwin 2015 45 1.5 (2.1) 38 -0.4 (2.7) 29.2 % 0.79 [ 0.34, 1.24 ]
Subtotal (95% CI) 93 88 100.0 % 0.75 [ 0.18, 1.31 ]
Heterogeneity: Tau2 = 0.23; Chi2 = 10.47, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 2.59 (P = 0.0096)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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31 Overall self-reported physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 31 Overall self-reported physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Guinan 2013 16 38.7 (26.9) 10 19.9 (11.3) 5.9 % 0.81 [ -0.01, 1.64 ]
Matthews 2007 22 54.2 (34.1) 14 27.2 (22.7) 7.2 % 0.87 [ 0.17, 1.58 ]
Rogers 2009 20 121.4 (73.2) 18 114.3 (131.5) 8.0 % 0.07 [ -0.57, 0.70 ]
Basen-Enquist 2006 35 428 (254.4) 25 404 (265) 9.8 % 0.09 [ -0.42, 0.61 ]
Cadmus 2009 34 161.7 (114.7) 33 55.6 (101.9) 9.9 % 0.97 [ 0.46, 1.47 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 9.9 % 1.01 [ 0.50, 1.52 ]
Hatchett 2013 38 3.47 (2.19) 36 1.42 (1.67) 10.2 % 1.04 [ 0.55, 1.53 ]
Pinto 2005 39 202.43 (161.65) 43 78.36 (86) 10.7 % 0.96 [ 0.50, 1.42 ]
Rogers 2015 110 169 (119) 112 74 (107) 13.9 % 0.84 [ 0.56, 1.11 ]
Vallance 2007 253 207.6 (169) 85 163 (121) 14.4 % 0.28 [ 0.03, 0.53 ]
Subtotal (95% CI) 603 408 100.0 % 0.69 [ 0.44, 0.94 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 26.28, df = 9 (P = 0.002); I2 =66%
Test for overall effect: Z = 5.40 (P < 0.00001)
2 Resistance exercise
Winters-Stone 2011 36 430.8 (281.4) 31 461.7 (346.4) 20.2 % -0.10 [ -0.58, 0.38 ]
Schmitz 2009 131 3348.8 (9019.4) 133 2339.8 (6213.7) 79.8 % 0.13 [ -0.11, 0.37 ]
Subtotal (95% CI) 167 164 100.0 % 0.08 [ -0.13, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.44)
3 Combined aerobic and resistance exercise
Kim 2015 20 17.6 (16.03) 19 11.8 (11.6) 27.8 % 0.40 [ -0.23, 1.04 ]
Irwin 2015 45 222.1 (118.6) 38 103.6 (104.6) 33.1 % 1.04 [ 0.58, 1.51 ]
Short 2014 195 217.9 (222.9) 104 180.3 (206.9) 39.1 % 0.17 [ -0.07, 0.41 ]
Subtotal (95% CI) 260 161 100.0 % 0.53 [ -0.05, 1.10 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 10.84, df = 2 (P = 0.004); I2 =82%
Test for overall effect: Z = 1.78 (P = 0.074)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
4 Yoga, Tai Chi, and Pilates
Littman 2012 32 19.2 (19.1) 31 12.1 (13.6) 25.1 % 0.42 [ -0.08, 0.92 ]
Kiecolt-Glaser 2014 96 11.2 (7.6) 90 9.1 (6.1) 74.9 % 0.30 [ 0.01, 0.59 ]
Subtotal (95% CI) 128 121 100.0 % 0.33 [ 0.08, 0.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0093)
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32 Overall self-reported physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 32 Overall self-reported physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Guinan 2013 16 15.6 (11.4476) 10 -8.3 (4.1937) 8.4 % 2.46 [ 1.39, 3.53 ]
Matthews 2007 22 21.5 (30.6) 14 5 (13.8) 13.4 % 0.63 [ -0.06, 1.32 ]
Cadmus 2009 34 129 (117.9) 33 44.3 (89.4) 16.8 % 0.80 [ 0.30, 1.30 ]
Pinto 2005 39 84.74 (189.2) 43 -18.27 (200.7) 17.9 % 0.52 [ 0.08, 0.96 ]
Vallance 2007 281 82 (168.7) 96 30 (167.8) 21.4 % 0.31 [ 0.08, 0.54 ]
Saarto 2012 262 3.5 (18.3) 236 3.3 (21.5) 22.2 % 0.01 [ -0.17, 0.19 ]
Subtotal (95% CI) 654 432 100.0 % 0.59 [ 0.20, 0.97 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 30.98, df = 5 (P<0.00001); I2 =84%
Test for overall effect: Z = 2.96 (P = 0.0031)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 Resistance exercise
Schmitz 2009 (1) 48 2.8 (16.8) 57 -0.8 (16.6) 100.0 % 0.21 [ -0.17, 0.60 ]
Subtotal (95% CI) 48 57 100.0 % 0.21 [ -0.17, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
3 Combined aerobic and resistance exercise
Irwin 2015 45 159 (136) 38 49 (86) 100.0 % 0.94 [ 0.48, 1.40 ]
Subtotal (95% CI) 45 38 100.0 % 0.94 [ 0.48, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.04 (P = 0.000053)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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33 Overall objective physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 33 Overall objective physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Guinan 2013 16 30.7 (15.6) 9 31 (15.6) 7.4 % -0.02 [ -0.84, 0.80 ]
Matthews 2007 22 330.8 (114.7) 14 198.5 (55.4) 8.3 % 1.34 [ 0.60, 2.09 ]
Rogers 2009 20 252191 (91893) 18 210917 (64078) 9.8 % 0.51 [ -0.14, 1.15 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 12.3 % 1.01 [ 0.50, 1.52 ]
Cadmus 2009 33 6738 (2958) 34 5537 (3352) 12.8 % 0.38 [ -0.11, 0.86 ]
Pinto 2005 39 37.5 (14.25) 43 33.62 (19.43) 13.8 % 0.22 [ -0.21, 0.66 ]
Rogers 2015 110 246 (153) 112 197 (138) 17.6 % 0.34 [ 0.07, 0.60 ]
Vallance 2007 253 8110.5 (4133.9) 85 8028 (3457) 18.0 % 0.02 [ -0.23, 0.27 ]
Subtotal (95% CI) 529 347 100.0 % 0.43 [ 0.15, 0.70 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 21.18, df = 7 (P = 0.004); I2 =67%
Test for overall effect: Z = 3.01 (P = 0.0026)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Rogers 2013 12 198.4 (111.7) 10 0 (0) Not estimable
Rogers 2014 20 294 (175) 22 154 (75) 43.8 % 1.04 [ 0.39, 1.69 ]
Short 2014 219 9363.07 (7922.79) 111 8301.2 (3373.4) 56.2 % 0.16 [ -0.07, 0.39 ]
Subtotal (95% CI) 251 143 100.0 % 0.54 [ -0.31, 1.40 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 6.30, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 1.24 (P = 0.21)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 34 Overall objective physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Guinan 2013 16 -1.1 (6.2) 9 -7.9 (5.3) 19.5 % 1.11 [ 0.23, 2.00 ]
Matthews 2007 22 72.2 (114.6) 14 -16.8 (51.5) 22.8 % 0.91 [ 0.20, 1.62 ]
Cadmus 2009 33 1621 (2108) 34 -60 (2341) 26.8 % 0.75 [ 0.25, 1.24 ]
Vallance 2007 253 -150 (5173.3) 85 91 (5155.4) 30.9 % -0.05 [ -0.29, 0.20 ]
Subtotal (95% CI) 324 142 100.0 % 0.61 [ -0.01, 1.23 ]
Heterogeneity: Tau2 = 0.30; Chi2 = 16.43, df = 3 (P = 0.00093); I2 =82%
Test for overall effect: Z = 1.94 (P = 0.052)
2 Resistance exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Combined aerobic and resistance exercise
Rogers 2014 20 114 (109) 22 10 (70) 100.0 % 1.13 [ 0.47, 1.78 ]
Subtotal (95% CI) 20 22 100.0 % 1.13 [ 0.47, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.36 (P = 0.00077)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 35 Mass (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 Aerobic exercise
Matthews 2007 22 74.9 (15.2) 14 78.9 (20.3) 5.0 % -4.00 [ -16.39, 8.39 ]
Courneya 2003 24 78.2 (20.5) 26 80.1 (16.2) 7.2 % -1.90 [ -12.20, 8.40 ]
Nikander 2007 14 73.5 (13.3) 14 75.5 (12) 8.7 % -2.00 [ -11.38, 7.38 ]
Cadmus 2009 36 80.73 (16.88) 33 78.51 (20.64) 9.6 % 2.22 [ -6.72, 11.16 ]
DeNysschen 2011 30 69.3 (14.2) 34 72.4 (19.6) 11.0 % -3.10 [ -11.42, 5.22 ]
Daley 2007 33 74.26 (12.49) 69 75.6 (12.5) 28.5 % -1.34 [ -6.52, 3.84 ]
Murtezani 2014 30 71.7 (9.5) 32 72.6 (10.75) 30.1 % -0.90 [ -5.94, 4.14 ]
Subtotal (95% CI) 189 222 100.0 % -1.29 [ -4.06, 1.47 ]
Heterogeneity: Chi2 = 1.02, df = 6 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.92 (P = 0.36)
2 Resistance exercise
Winters-Stone 2011 36 76.5 (15.6) 31 74.2 (12.3) 2.0 % 2.30 [ -4.39, 8.99 ]
Schmitz 2009 131 76.15 (15.66) 133 77.19 (17.02) 5.6 % -1.04 [ -4.98, 2.90 ]
Schmitz 2005 39 69.5 (2.22) 40 69.2 (2.2) 92.4 % 0.30 [ -0.67, 1.27 ]
Subtotal (95% CI) 206 204 100.0 % 0.26 [ -0.67, 1.20 ]
Heterogeneity: Chi2 = 0.78, df = 2 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
3 Combined aerobic and resistance exercise
Herrero 2006 8 65.6 (8.7) 8 67.3 (8.9) 30.8 % -1.70 [ -10.32, 6.92 ]
Rahnama 2010 14 69.4 (13.5) 15 71.6 (9.2) 31.9 % -2.20 [ -10.67, 6.27 ]
Ligibel 2008 40 80 (17.5) 42 83.3 (18.7) 37.3 % -3.30 [ -11.14, 4.54 ]
Subtotal (95% CI) 62 65 100.0 % -2.46 [ -7.24, 2.33 ]
Heterogeneity: Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 1.01 (P = 0.31)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 11 67.1 (10.42) 10 68.6 (13.84) 0.5 % -1.50 [ -12.06, 9.06 ]
Littman 2012 28 81.1 (13.6) 27 81.3 (14.3) 1.1 % -0.20 [ -7.58, 7.18 ]
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N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
Kiecolt-Glaser 2014 96 75.2 (2.8) 90 75.2 (2.6) 98.4 % 0.0 [ -0.78, 0.78 ]
Subtotal (95% CI) 135 127 100.0 % -0.01 [ -0.78, 0.76 ]
Heterogeneity: Chi2 = 0.08, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.98)
-20 -10 0 10 20
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Analysis 13.36. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome
36 Mass (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 36 Mass (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Dolan 2016 23 -0.55 (5.04) 10 1.44 (1.62) 9.7 % -1.99 [ -4.28, 0.30 ]
Matthews 2007 22 0.01 (2.09) 14 0.04 (2.16) 17.6 % -0.03 [ -1.46, 1.40 ]
Murtezani 2014 30 -2.3 (2.4) 32 -0.3 (2.6) 20.1 % -2.00 [ -3.24, -0.76 ]
Courneya 2003 24 0.1 (2) 26 0.7 (1.8) 23.0 % -0.60 [ -1.66, 0.46 ]
Saarto 2012 262 0.66 (3.68) 236 0.67 (3.84) 29.6 % -0.01 [ -0.67, 0.65 ]
Subtotal (95% CI) 361 318 100.0 % -0.74 [ -1.58, 0.09 ]
Heterogeneity: Tau2 = 0.50; Chi2 = 9.76, df = 4 (P = 0.04); I2 =59%
Test for overall effect: Z = 1.74 (P = 0.081)
2 Resistance exercise
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 3.1 % -0.60 [ -1.98, 0.78 ]
Schmitz 2005 39 0.32 (0.43) 40 0.2 (0.42) 96.9 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 104 105 100.0 % 0.10 [ -0.15, 0.34 ]
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N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.01; Chi2 = 1.03, df = 1 (P = 0.31); I2 =3%
Test for overall effect: Z = 0.78 (P = 0.44)
3 Combined aerobic and resistance exercise
Irwin 2015 45 -2.1 (4.3) 38 0.1 (3.6) 29.8 % -2.20 [ -3.90, -0.50 ]
Ligibel 2008 22 0 (2.3) 14 0.04 (2.16) 33.0 % -0.04 [ -1.52, 1.44 ]
Naumann 2012 11 0.45 (1.33) 10 0.12 (1.52) 37.1 % 0.33 [ -0.90, 1.56 ]
Subtotal (95% CI) 78 62 100.0 % -0.55 [ -1.99, 0.90 ]
Heterogeneity: Tau2 = 1.08; Chi2 = 5.89, df = 2 (P = 0.05); I2 =66%
Test for overall effect: Z = 0.74 (P = 0.46)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 -0.3 (1.86) 10 0.6 (1.43) 100.0 % -0.90 [ -2.40, 0.60 ]
Subtotal (95% CI) 9 10 100.0 % -0.90 [ -2.40, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 37 BMI (follow-up values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Fixed,95% CI IV,Fixed,95% CI
1 Aerobic exercise
Rogers 2009 20 30.6 (7.6) 18 30.4 (8.3) 2.7 % 0.20 [ -4.88, 5.28 ]
Courneya 2003 24 29.4 (7.4) 26 29.3 (6) 5.0 % 0.10 [ -3.65, 3.85 ]
Cadmus 2009 36 30.45 (6) 33 29.9 (7.59) 6.7 % 0.55 [ -2.70, 3.80 ]
Pinto 2005 39 27.66 (5.01) 43 29.01 (5.62) 13.4 % -1.35 [ -3.65, 0.95 ]
Murtezani 2014 30 25.1 (2.9) 32 25.8 (3.47) 28.1 % -0.70 [ -2.29, 0.89 ]
Vallance 2007 253 27.01 (5.21) 85 27.2 (5.15) 44.0 % -0.19 [ -1.46, 1.08 ]
Subtotal (95% CI) 402 237 100.0 % -0.41 [ -1.26, 0.43 ]
Heterogeneity: Chi2 = 1.35, df = 5 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Resistance exercise
Schmitz 2009 131 28.46 (5.55) 133 28.94 (6.27) 4.9 % -0.48 [ -1.91, 0.95 ]
Schmitz 2005 39 26 (0.74) 40 25.8 (0.73) 95.1 % 0.20 [ -0.12, 0.52 ]
Subtotal (95% CI) 170 173 100.0 % 0.17 [ -0.15, 0.48 ]
Heterogeneity: Chi2 = 0.83, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
3 Combined aerobic and resistance exercise
Portela 2008 25 29.1 (5.5) 9 34.7 (15) 2.5 % -5.60 [ -15.63, 4.43 ]
Rogers 2013 12 33.6 (7) 10 30.6 (7.28) 7.1 % 3.00 [ -3.00, 9.00 ]
Nikander 2007 14 26.9 (5.6) 14 27.7 (4.9) 16.8 % -0.80 [ -4.70, 3.10 ]
Rogers 2014 20 29.6 (5) 22 32.2 (6.7) 20.1 % -2.60 [ -6.16, 0.96 ]
Rahnama 2010 14 27.74 (4.77) 15 28.04 (4.6) 21.8 % -0.30 [ -3.71, 3.11 ]
Ligibel 2008 40 30.3 (6.3) 42 31.5 (6.8) 31.7 % -1.20 [ -4.04, 1.64 ]
Subtotal (95% CI) 125 112 100.0 % -1.03 [ -2.63, 0.56 ]
Heterogeneity: Chi2 = 3.48, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 11 23.9 (4.17) 10 26.7 (5.59) 0.5 % -2.80 [ -7.05, 1.45 ]
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N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Fixed,95% CI IV,Fixed,95% CI
Littman 2012 28 27.66 (5.01) 27 29.01 (5.62) 1.1 % -1.35 [ -4.17, 1.47 ]
Kiecolt-Glaser 2014 96 27.8 (1.08) 90 27.8 (0.95) 98.5 % 0.0 [ -0.29, 0.29 ]
Subtotal (95% CI) 135 127 100.0 % -0.03 [ -0.32, 0.26 ]
Heterogeneity: Chi2 = 2.51, df = 2 (P = 0.28); I2 =20%
Test for overall effect: Z = 0.18 (P = 0.85)
-20 -10 0 10 20
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Analysis 13.38. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome
38 BMI (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 38 BMI (change values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Courneya 2003 24 0 (0.7) 26 0.3 (0.7) 48.9 % -0.30 [ -0.69, 0.09 ]
Murtezani 2014 30 -0.8 (0.7) 32 -0.14 (0.8) 51.1 % -0.66 [ -1.03, -0.29 ]
Subtotal (95% CI) 54 58 100.0 % -0.48 [ -0.84, -0.13 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.71, df = 1 (P = 0.19); I2 =42%
Test for overall effect: Z = 2.69 (P = 0.0071)
2 Resistance exercise
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 0.3 % -0.60 [ -1.98, 0.78 ]
Schmitz 2005 39 0.06 (0.17) 40 0.07 (0.16) 99.7 % -0.01 [ -0.08, 0.06 ]
Subtotal (95% CI) 104 105 100.0 % -0.01 [ -0.08, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
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N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Random,95% CI IV,Random,95% CI
3 Combined aerobic and resistance exercise
Rogers 2014 20 -0.2 (0.9) 22 -0.3 (1.1) 18.4 % 0.10 [ -0.51, 0.71 ]
Naumann 2012 11 0.1 (0.5) 10 -0.1 (0.57) 31.9 % 0.20 [ -0.26, 0.66 ]
Ligibel 2008 40 0 (0.9) 42 0.2 (0.8) 49.6 % -0.20 [ -0.57, 0.17 ]
Subtotal (95% CI) 71 74 100.0 % -0.02 [ -0.28, 0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.94, df = 2 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 -0.42 (0.75) 10 0.29 (0.61) 100.0 % -0.71 [ -1.33, -0.09 ]
Subtotal (95% CI) 9 10 100.0 % -0.71 [ -1.33, -0.09 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.25 (P = 0.025)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 39 Overall body fat (follow-up values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Cerulli 2014 10 26.72 (5.34) 10 30.55 (4.4) 3.5 % -0.75 [ -1.66, 0.16 ]
Musanti 2012 10 33.8 (7.6) 12 33.7 (5.7) 4.1 % 0.01 [ -0.82, 0.85 ]
Matthews 2007 22 39.7 (6.3) 14 43.1 (6.9) 6.2 % -0.51 [ -1.19, 0.17 ]
Rogers 2009 20 44.3 (7.4) 19 43.5 (7.5) 7.3 % 0.11 [ -0.52, 0.73 ]
Courneya 2003 24 131.9 (46.4) 26 137.1 (44.4) 9.4 % -0.11 [ -0.67, 0.44 ]
DeNysschen 2011 30 36.9 (8.4) 34 38 (10.2) 12.0 % -0.12 [ -0.61, 0.38 ]
Saarto 2012 37 39.9 (7.5) 30 40.2 (8) 12.5 % -0.04 [ -0.52, 0.44 ]
Cadmus 2009 36 40.54 (6.55) 33 39.6 (5.97) 12.9 % 0.15 [ -0.33, 0.62 ]
Pinto 2005 39 37.53 (4.79) 43 38.55 (4.83) 15.3 % -0.21 [ -0.64, 0.22 ]
Daley 2007 33 39.4 (4.74) 69 40.1 (7.4) 16.8 % -0.10 [ -0.52, 0.31 ]
Subtotal (95% CI) 261 290 100.0 % -0.11 [ -0.28, 0.06 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.16, df = 9 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Resistance exercise
Musanti 2012 9 33.3 (7.1) 12 33.7 (5.7) 17.8 % -0.06 [ -0.93, 0.80 ]
Winters-Stone 2011 36 40.5 (6.2) 31 38.5 (5.8) 25.8 % 0.33 [ -0.16, 0.81 ]
Schmitz 2005 39 40.91 (1.31) 40 42.29 (1.3) 26.0 % -1.05 [ -1.52, -0.58 ]
Schmitz 2009 130 38.47 (5.93) 132 39.74 (5.9) 30.4 % -0.21 [ -0.46, 0.03 ]
Subtotal (95% CI) 214 215 100.0 % -0.26 [ -0.81, 0.28 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 16.72, df = 3 (P = 0.00081); I2 =82%
Test for overall effect: Z = 0.95 (P = 0.34)
3 Combined aerobic and resistance exercise
Herrero 2006 8 22 (5) 8 22 (4) 8.8 % 0.0 [ -0.98, 0.98 ]
Rogers 2013 10 44.2 (6.7) 12 42.3 (7.7) 11.8 % 0.25 [ -0.59, 1.09 ]
Musanti 2012 11 35.2 (4.8) 12 33.7 (5.7) 12.4 % 0.27 [ -0.55, 1.10 ]
Rogers 2014 20 38.6 (6.4) 22 41.5 (7.4) 22.4 % -0.41 [ -1.02, 0.20 ]
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N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Ligibel 2008 40 42.9 (7.4) 42 44.7 (8) 44.6 % -0.23 [ -0.67, 0.20 ]
Subtotal (95% CI) 89 96 100.0 % -0.13 [ -0.42, 0.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.79, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.38)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 11 38.5 (4.47) 10 41.7 (4.89) 100.0 % -0.66 [ -1.54, 0.23 ]
Subtotal (95% CI) 11 10 100.0 % -0.66 [ -1.54, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.15)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 40 Overall body fat (change values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Musanti 2012 10 -0.3 (4.82) 12 1.4 (1.57) 20.4 % -0.48 [ -1.33, 0.38 ]
Matthews 2007 22 -0.2 (1.62) 14 0.41 (1.94) 32.6 % -0.34 [ -1.02, 0.33 ]
Courneya 2003 24 -4.9 (15.7) 26 5.1 (24.4) 46.9 % -0.48 [ -1.04, 0.09 ]
Subtotal (95% CI) 56 52 100.0 % -0.43 [ -0.82, -0.05 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.10, df = 2 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.028)
2 Resistance exercise
Musanti 2012 9 -0.7 (2.34) 12 1.4 (1.57) 32.3 % -1.04 [ -1.98, -0.11 ]
Schmitz 2005 39 -1.15 (0.45) 40 0.23 (0.44) 33.4 % -3.07 [ -3.73, -2.41 ]
Schmitz 2009 (1) 65 -0.3 (5.7) 63 -0.1 (3.3) 34.3 % -0.04 [ -0.39, 0.30 ]
Subtotal (95% CI) 113 115 100.0 % -1.38 [ -3.39, 0.63 ]
Heterogeneity: Tau2 = 3.03; Chi2 = 63.85, df = 2 (P<0.00001); I2 =97%
Test for overall effect: Z = 1.34 (P = 0.18)
3 Combined aerobic and resistance exercise
Naumann 2012 11 -0.3 (2.42) 10 0.8 (2.75) 12.3 % -0.41 [ -1.28, 0.46 ]
Musanti 2012 11 0.2 (3.57) 12 1.4 (1.57) 13.5 % -0.43 [ -1.26, 0.40 ]
Rogers 2014 20 -1.1 (2.2) 22 -0.6 (2.4) 25.2 % -0.21 [ -0.82, 0.39 ]
Ligibel 2008 40 -0.2 (1.7) 42 0.3 (1.7) 49.0 % -0.29 [ -0.73, 0.14 ]
Subtotal (95% CI) 82 86 100.0 % -0.30 [ -0.61, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.23, df = 3 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.050)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 9 -0.16 (2.91) 10 0.28 (1.57) 100.0 % -0.18 [ -1.09, 0.72 ]
Subtotal (95% CI) 9 10 100.0 % -0.18 [ -1.09, 0.72 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.40 (P = 0.69)
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Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 41 Lower body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Cerulli 2014 10 114.88 (17.09) 10 79.13 (17.78) 26.7 % 1.96 [ 0.85, 3.07 ]
Rogers 2009 20 80.3 (27) 18 64.9 (19.7) 35.2 % 0.63 [ -0.02, 1.29 ]
Saarto 2012 37 136 (23) 30 136 (29) 38.1 % 0.0 [ -0.48, 0.48 ]
Subtotal (95% CI) 67 58 100.0 % 0.75 [ -0.20, 1.69 ]
Heterogeneity: Tau2 = 0.55; Chi2 = 10.77, df = 2 (P = 0.005); I2 =81%
Test for overall effect: Z = 1.55 (P = 0.12)
2 Resistance exercise
Schmitz 2005 23 296.6 (48.9) 22 238.9 (46.4) 26.6 % 1.19 [ 0.55, 1.83 ]
Winters-Stone 2011 36 201.3 (57.4) 31 191 (51.7) 32.6 % 0.19 [ -0.30, 0.67 ]
Schmitz 2009 113 223.4 (59.6) 119 175.1 (53.5) 40.8 % 0.85 [ 0.58, 1.12 ]
Subtotal (95% CI) 172 172 100.0 % 0.72 [ 0.22, 1.23 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 7.64, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 2.80 (P = 0.0051)
3 Combined aerobic and resistance exercise
Rogers 2013 11 68.4 (15.5) 9 67.1 (16.2) 13.2 % 0.08 [ -0.80, 0.96 ]
Nikander 2007 14 1305 (177) 14 1393 (275) 17.8 % -0.37 [ -1.12, 0.38 ]
Milne 2008 29 66.2 (10.2) 29 61.7 (11) 33.3 % 0.42 [ -0.10, 0.94 ]
Do 2015 32 13 (1.62) 30 13.15 (1.55) 35.8 % -0.09 [ -0.59, 0.41 ]
Subtotal (95% CI) 86 82 100.0 % 0.05 [ -0.28, 0.38 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.45, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 0.30 (P = 0.76)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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42 Lower body strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 42 Lower body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Dolan 2016 23 11.84 (8.89) 10 0.34 (11.1) 100.0 % 1.17 [ 0.37, 1.97 ]
Subtotal (95% CI) 23 10 100.0 % 1.17 [ 0.37, 1.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.86 (P = 0.0042)
2 Resistance exercise
Schmitz 2005 23 81.8 (48.92) 22 20.3 (45.97) 17.6 % 1.27 [ 0.63, 1.92 ]
Cormie 2014 43 37.6 (25.5) 19 6.7 (25.7) 19.6 % 1.19 [ 0.61, 1.78 ]
Schmitz 2009 113 33.2 (33.9) 119 7.9 (26.6) 31.3 % 0.83 [ 0.56, 1.10 ]
Waltman 2010 110 4.42 (11.48) 113 0.19 (8.38) 31.4 % 0.42 [ 0.15, 0.69 ]
Subtotal (95% CI) 289 273 100.0 % 0.85 [ 0.48, 1.22 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 10.89, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 4.47 (P < 0.00001)
3 Combined aerobic and resistance exercise
Nieman 1995 6 28.9 (13.7) 6 3.5 (22.5) 18.4 % 1.26 [ -0.03, 2.55 ]
Naumann 2012 11 7.7 (12.6) 10 3.5 (13.9) 30.5 % 0.30 [ -0.56, 1.17 ]
Do 2015 32 0.9 (0.7) 60 0.95 (0.61) 51.1 % -0.08 [ -0.51, 0.35 ]
Subtotal (95% CI) 49 76 100.0 % 0.28 [ -0.37, 0.93 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 3.98, df = 2 (P = 0.14); I2 =50%
Test for overall effect: Z = 0.86 (P = 0.39)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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43 Upper body strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 43 Upper body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Cerulli 2014 10 16.08 (5.43) 10 17.2 (8.05) 11.8 % -0.16 [ -1.03, 0.72 ]
Musanti 2012 10 52.5 (21) 12 36.75 (20) 11.9 % 0.74 [ -0.13, 1.61 ]
Nikander 2007 14 131 (20) 14 129 (28) 16.5 % 0.08 [ -0.66, 0.82 ]
Rogers 2009 20 27.9 (5.04) 18 24.3 (6.18) 21.2 % 0.63 [ -0.03, 1.28 ]
Saarto 2012 37 32.7 (5.3) 30 30.8 (5.7) 38.6 % 0.34 [ -0.14, 0.83 ]
Subtotal (95% CI) 91 84 100.0 % 0.35 [ 0.05, 0.65 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.25, df = 4 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 2.27 (P = 0.023)
2 Resistance exercise
Musanti 2012 9 56.44 (28) 12 36.75 (20) 17.3 % 0.80 [ -0.11, 1.70 ]
Schmitz 2005 23 83 (13.4) 22 63 (12.7) 22.6 % 1.50 [ 0.84, 2.17 ]
Winters-Stone 2011 36 63.3 (15.3) 31 61.1 (16.8) 27.5 % 0.14 [ -0.34, 0.62 ]
Schmitz 2009 113 52.9 (15.3) 119 40.9 (11.8) 32.6 % 0.88 [ 0.61, 1.15 ]
Subtotal (95% CI) 181 184 100.0 % 0.80 [ 0.28, 1.33 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 11.90, df = 3 (P = 0.01); I2 =75%
Test for overall effect: Z = 3.00 (P = 0.0027)
3 Combined aerobic and resistance exercise
Musanti 2012 11 48.27 (14.8) 12 36.75 (20) 18.0 % 0.63 [ -0.22, 1.47 ]
Portela 2008 25 39.3 (12.3) 9 35.6 (13.1) 18.8 % 0.29 [ -0.48, 1.05 ]
Kaltsatou 2011 28 59.63 (8.49) 26 47.62 (9.83) 20.6 % 1.29 [ 0.70, 1.88 ]
Milne 2008 29 7.6 (2.9) 29 9.4 (2.6) 21.2 % -0.64 [ -1.17, -0.12 ]
Do 2015 32 9.65 (1.67) 30 10.05 (1.68) 21.4 % -0.24 [ -0.74, 0.26 ]
Subtotal (95% CI) 125 106 100.0 % 0.25 [ -0.47, 0.97 ]
Heterogeneity: Tau2 = 0.56; Chi2 = 26.67, df = 4 (P = 0.00002); I2 =85%
Test for overall effect: Z = 0.67 (P = 0.50)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 11 29.6 (3.27) 10 26.7 (5.73) 100.0 % 0.60 [ -0.28, 1.49 ]
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N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 11 10 100.0 % 0.60 [ -0.28, 1.49 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.35 (P = 0.18)
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Analysis 13.44. Comparison 13 Subanalysis: outcomes by mode of physical activity intervention, Outcome
44 Upper body strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 44 Upper body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Musanti 2012 10 5.5 (11.88) 12 0.83 (12.65) 100.0 % 0.36 [ -0.48, 1.21 ]
Subtotal (95% CI) 10 12 100.0 % 0.36 [ -0.48, 1.21 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
2 Resistance exercise
Musanti 2012 9 11.78 (13.69) 12 0.83 (12.65) 14.7 % 0.80 [ -0.10, 1.71 ]
Schmitz 2005 23 32.3 (11.51) 22 6.9 (10.79) 16.9 % 2.24 [ 1.48, 2.99 ]
Cormie 2014 43 5.7 (3.67) 19 1 (3.78) 19.7 % 1.25 [ 0.67, 1.84 ]
Waltman 2010 110 1.9 (4.86) 113 0.75 (2.9) 24.3 % 0.29 [ 0.02, 0.55 ]
Schmitz 2009 113 33.2 (40.8) 119 7.6 (43.7) 24.3 % 0.60 [ 0.34, 0.87 ]
Subtotal (95% CI) 298 285 100.0 % 0.96 [ 0.43, 1.49 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 28.18, df = 4 (P = 0.00001); I2 =86%
Test for overall effect: Z = 3.55 (P = 0.00038)
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N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
3 Combined aerobic and resistance exercise
Musanti 2012 11 6.46 (5.14) 12 0.83 (12.65) 18.5 % 0.55 [ -0.28, 1.39 ]
Do 2015 32 0.3 (0.5) 30 0.55 (1.2) 37.6 % -0.27 [ -0.77, 0.23 ]
Irwin 2015 45 0.4 (1.88) 38 0.1 (1.89) 43.9 % 0.16 [ -0.27, 0.59 ]
Subtotal (95% CI) 88 80 100.0 % 0.07 [ -0.34, 0.48 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 3.21, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.34 (P = 0.74)
4 Yoga, Tai Chi, and Pilates
Mustian 2004 45 4.5 (4.71) 38 -0.85 (3.15) 100.0 % 1.30 [ 0.82, 1.78 ]
Subtotal (95% CI) 45 38 100.0 % 1.30 [ 0.82, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 5.35 (P < 0.00001)
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45 Bone mineral density - femoral neck (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 45 Bone mineral density - femoral neck (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Saarto 2012 (1) 239 -0.006 (0.025) 218 -0.01 (0.03) 100.0 % 0.18 [ 0.00, 0.37 ]
Subtotal (95% CI) 239 218 100.0 % 0.18 [ 0.00, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
2 Resistance exercise
Winters-Stone 2011 36 0.72 (0.1) 31 0.71 (0.08) 42.3 % 0.11 [ -0.37, 0.59 ]
Waltman 2010 (2) 110 0.92 (0.5) 113 0.63 (0.42) 57.7 % 0.63 [ 0.36, 0.90 ]
Subtotal (95% CI) 146 144 100.0 % 0.41 [ -0.09, 0.91 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 3.40, df = 1 (P = 0.07); I2 =71%
Test for overall effect: Z = 1.59 (P = 0.11)
3 Combined aerobic and resistance exercise
Kim 2015 20 0.78 (0.08) 19 0.81 (0.08) 100.0 % -0.37 [ -1.00, 0.27 ]
Subtotal (95% CI) 20 19 100.0 % -0.37 [ -1.00, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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46 Bone mineral density - lumbar spine (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 46 Bone mineral density - lumbar spine (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Saarto 2012 (1) 239 -0.018 (0.033) 218 -0.02 (0.034) 100.0 % 0.09 [ -0.09, 0.27 ]
Subtotal (95% CI) 239 218 100.0 % 0.09 [ -0.09, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
2 Resistance exercise
Winters-Stone 2011 36 0.99 (0.15) 31 0.95 (0.11) 23.5 % 0.30 [ -0.19, 0.78 ]
Waltman 2010 (2) 110 3.08 (0.44) 113 2.85 (0.4) 76.5 % 0.55 [ 0.28, 0.81 ]
Subtotal (95% CI) 146 144 100.0 % 0.49 [ 0.25, 0.72 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.78, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 4.08 (P = 0.000045)
3 Combined aerobic and resistance exercise
Kim 2015 20 0.97 (0.08) 19 0.99 (0.07) 100.0 % -0.26 [ -0.89, 0.37 ]
Subtotal (95% CI) 20 19 100.0 % -0.26 [ -0.89, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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47 Bone mineral density - total hip (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 13 Subanalysis: outcomes by mode of physical activity intervention
Outcome: 47 Bone mineral density - total hip (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Aerobic exercise
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Resistance exercise
Winters-Stone 2011 36 0.86 (0.11) 31 0.84 (0.1) 47.3 % 0.19 [ -0.29, 0.67 ]
Waltman 2010 (1) 110 2.15 (0.28) 113 1.81 (0.36) 52.7 % 1.05 [ 0.77, 1.33 ]
Subtotal (95% CI) 146 144 100.0 % 0.64 [ -0.20, 1.48 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 9.19, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 1.49 (P = 0.14)
3 Combined aerobic and resistance exercise
Kim 2015 20 0.88 (0.08) 19 0.09 (0.07) 100.0 % 10.34 [ 7.84, 12.84 ]
Subtotal (95% CI) 20 19 100.0 % 10.34 [ 7.84, 12.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.11 (P < 0.00001)
4 Yoga, Tai Chi, and Pilates
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 14.1. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome
1 Overall HRQoL (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 1 Overall HRQoL (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Cerulli 2014 10 85.23 (4.2) 10 65.89 (14.66) 3.7 % 1.72 [ 0.66, 2.78 ]
Rogers 2015 10 85.23 (4.2) 10 65.89 (14.66) 3.7 % 1.72 [ 0.66, 2.78 ]
Mustian 2004 11 121.7 (22.67) 10 124.3 (25.9) 4.7 % -0.10 [ -0.96, 0.75 ]
Loudon 2014 12 -7.42 (1.24) 11 -7.45 (1.44) 4.9 % 0.02 [ -0.80, 0.84 ]
Milne 2008 29 86.4 (8.3) 29 64.1 (10.8) 5.8 % 2.28 [ 1.61, 2.96 ]
Rogers 2009 20 92 (11.4) 18 87.4 (13.1) 6.0 % 0.37 [ -0.27, 1.01 ]
Courneya 2003 24 91.3 (11) 28 89.3 (10.9) 6.6 % 0.18 [ -0.37, 0.73 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 6.7 % 0.19 [ -0.35, 0.73 ]
Murtezani 2014 30 86.5 (7.3) 32 79.1 (7.5) 6.7 % 0.99 [ 0.46, 1.52 ]
Mehnert 2011 30 74.72 (21.72) 27 65.43 (16.78) 6.7 % 0.47 [ -0.06, 1.00 ]
Pinto 2015 39 117.79 (12.74) 37 113.98 (18.02) 7.3 % 0.24 [ -0.21, 0.69 ]
Schmitz 2005 39 -44.2 (8.7) 40 -47.4 (9.4) 7.3 % 0.35 [ -0.09, 0.79 ]
Taleghani 2012 40 217.5 (36.3) 40 210.1 (41.5) 7.4 % 0.19 [ -0.25, 0.63 ]
Loh 2014 63 112.4 (14.09) 32 109.29 (13.26) 7.4 % 0.22 [ -0.20, 0.65 ]
Daley 2007 33 90.85 (13.47) 69 86.44 (15.07) 7.5 % 0.30 [ -0.12, 0.72 ]
Littman 2012 30 90.3 (11) 110 87.7 (15) 7.6 % 0.18 [ -0.22, 0.59 ]
Subtotal (95% CI) 460 523 100.0 % 0.51 [ 0.25, 0.77 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 53.65, df = 15 (P<0.00001); I2 =72%
Test for overall effect: Z = 3.80 (P = 0.00015)
2 Moderate-to-high intensity
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 4.2 % 1.30 [ 0.19, 2.41 ]
Portela 2008 25 107.2 (28.5) 9 91.6 (28.5) 7.7 % 0.53 [ -0.24, 1.31 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 14.6 % 0.28 [ -0.22, 0.79 ]
Cadmus 2009 37 91.2 (12.6) 37 86.2 (17.4) 16.2 % 0.33 [ -0.13, 0.78 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vallance 2007 250 91.54 (11.76) 85 90.55 (12.95) 28.4 % 0.08 [ -0.16, 0.33 ]
Short 2014 195 106.8 (16.7) 104 108.2 (18.2) 29.0 % -0.08 [ -0.32, 0.16 ]
Subtotal (95% CI) 547 273 100.0 % 0.19 [ -0.05, 0.43 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 9.41, df = 5 (P = 0.09); I2 =47%
Test for overall effect: Z = 1.56 (P = 0.12)
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2 Overall HRQoL (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 2 Overall HRQoL (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 11 15 (5) 10 0 (5) 7.6 % 2.88 [ 1.59, 4.17 ]
Murtezani 2014 30 9.16 (2.12) 32 -0.56 (2.01) 8.9 % 4.65 [ 3.67, 5.63 ]
Naumann 2012 11 14.5 (10.6) 10 3.1 (11.4) 9.1 % 1.00 [ 0.08, 1.92 ]
Rogers 2009 20 4.5 (8.4) 18 2.9 (12) 10.3 % 0.15 [ -0.49, 0.79 ]
Cuesta-Vargas 2014 22 0.32 (0.18) 20 0.33 (0.09) 10.4 % -0.07 [ -0.67, 0.54 ]
Courneya 2003 24 5.7 (7.4) 28 0.6 (7.4) 10.5 % 0.68 [ 0.12, 1.24 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 10.6 % 0.52 [ -0.03, 1.06 ]
Mehnert 2011 30 9.72 (21.03) 27 5.55 (16.5) 10.7 % 0.22 [ -0.31, 0.74 ]
Schmitz 2005 39 2.3 (4.5) 40 0.6 (4) 10.9 % 0.40 [ -0.05, 0.84 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Daley 2007 33 10.22 (11.2) 69 3.2 (11.26) 11.0 % 0.62 [ 0.20, 1.04 ]
Subtotal (95% CI) 260 274 100.0 % 0.99 [ 0.39, 1.60 ]
Heterogeneity: Tau2 = 0.82; Chi2 = 87.64, df = 9 (P<0.00001); I2 =90%
Test for overall effect: Z = 3.22 (P = 0.0013)
2 Moderate-to-high intensity
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 7.8 % 1.92 [ 0.68, 3.17 ]
Cadmus 2009 37 0.6 (7.5) 37 -2.4 (9.8) 24.7 % 0.34 [ -0.12, 0.80 ]
Vallance 2007 250 2.3 (11.08) 85 -0.16 (6.4) 32.7 % 0.24 [ 0.00, 0.49 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 34.9 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 558 367 100.0 % 0.28 [ -0.11, 0.67 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 14.84, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 1.42 (P = 0.16)
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3 Overall emotional function/mental health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 3 Overall emotional function/mental health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Banasik 2011 7 0.47 (0.36) 7 0.38 (0.31) 1.0 % 0.25 [ -0.80, 1.30 ]
Mustian 2004 9 24.78 (2.04) 10 24.8 (3.19) 1.4 % -0.01 [ -0.91, 0.89 ]
Pinto 2003 12 -10.83 (28.1) 12 -27.17 (19.5) 1.7 % 0.65 [ -0.17, 1.48 ]
Loudon 2014 12 -1.58 (0.7) 11 -1.61 (0.49) 1.7 % 0.05 [ -0.77, 0.87 ]
Rogers 2009 20 20 (3.1) 18 21.1 (2.9) 2.7 % -0.36 [ -1.00, 0.28 ]
Cuesta-Vargas 2014 22 42.9 (19.17) 20 32.3 (33.33) 3.0 % 0.39 [ -0.22, 1.00 ]
Basen-Enquist 2006 28 78.2 (10.58) 23 77.2 (11.99) 3.6 % 0.09 [ -0.46, 0.64 ]
Courneya 2003 24 21.5 (3.4) 28 20.7 (3) 3.7 % 0.25 [ -0.30, 0.79 ]
Milne 2008 29 19.6 (2.4) 29 16.7 (4.1) 3.8 % 0.85 [ 0.31, 1.39 ]
Littman 2012 30 20.3 (4) 27 20.8 (3.1) 4.1 % -0.14 [ -0.66, 0.38 ]
Mehnert 2011 30 77.01 (35.75) 28 69.05 (40.5) 4.1 % 0.21 [ -0.31, 0.72 ]
Cantarero-Villanueva 2013 32 -17175 (4279) 29 -20390 (6113) 4.2 % 0.61 [ 0.09, 1.12 ]
Murtezani 2014 30 19.5 (3.3) 32 18.3 (3.5) 4.4 % 0.35 [ -0.15, 0.85 ]
Daley 2007 33 19.06 (4.18) 33 18.45 (3.31) 4.7 % 0.16 [ -0.32, 0.64 ]
Pinto 2015 39 54.21 (9.28) 37 52.48 (9.62) 5.3 % 0.18 [ -0.27, 0.63 ]
Schmitz 2005 39 -45.6 (8.2) 40 -48.2 (8.2) 5.5 % 0.31 [ -0.13, 0.76 ]
Pinto 2005 39 -8.02 (20.69) 43 -16.51 (28.75) 5.7 % 0.33 [ -0.10, 0.77 ]
Loh 2014 63 19.87 (2.81) 32 19.98 (3.22) 5.9 % -0.04 [ -0.46, 0.39 ]
Fillion 2008 44 48.54 (7.91) 43 47.49 (9.08) 6.1 % 0.12 [ -0.30, 0.54 ]
Rogers 2015 105 20.6 (2.9) 108 19.7 (3.2) 13.2 % 0.29 [ 0.02, 0.56 ]
Schmitz 2009 112 53.2 (9.6) 120 53.8 (8.7) 14.3 % -0.07 [ -0.32, 0.19 ]
Subtotal (95% CI) 759 730 100.0 % 0.19 [ 0.08, 0.30 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 21.35, df = 20 (P = 0.38); I2 =6%
Test for overall effect: Z = 3.49 (P = 0.00049)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 Moderate-to-high intensity
Herrero 2006 8 90.6 (9.3) 8 83.3 (14.8) 9.1 % 0.56 [ -0.45, 1.56 ]
Do 2015 32 87.4 (8.8) 30 70.4 (21.5) 18.8 % 1.03 [ 0.50, 1.57 ]
Cadmus 2009 37 20.5 (3) 37 19.8 (4.2) 21.0 % 0.19 [ -0.27, 0.65 ]
Duijits 2012 37 73.92 (34.7) 89 77.46 (34.32) 23.4 % -0.10 [ -0.49, 0.28 ]
Vallance 2007 250 20.28 (3.31) 85 19.92 (3.44) 27.7 % 0.11 [ -0.14, 0.35 ]
Subtotal (95% CI) 364 249 100.0 % 0.29 [ -0.07, 0.65 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 12.84, df = 4 (P = 0.01); I2 =69%
Test for overall effect: Z = 1.58 (P = 0.11)
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Analysis 14.4. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome
4 Overall emotional function/mental health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 4 Overall emotional function/mental health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 9 2.44 (2.52) 10 0.1 (1.68) 6.9 % 1.06 [ 0.08, 2.03 ]
Naumann 2012 11 1 (2.69) 10 -0.1 (2.72) 7.7 % 0.39 [ -0.48, 1.26 ]
Rogers 2009 20 0.9 (2.5) 18 -0.1 (2.7) 9.5 % 0.38 [ -0.27, 1.02 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 9.9 % 1.80 [ 1.21, 2.40 ]
Courneya 2003 24 2.3 (3.1) 28 0.8 (2.9) 10.3 % 0.49 [ -0.06, 1.05 ]
Mehnert 2011 30 2.3 (35.5) 28 3.57 (17.6) 10.6 % -0.04 [ -0.56, 0.47 ]
Cantarero-Villanueva 2013 32 -1445 (4452) 29 353 (3323) 10.7 % -0.45 [ -0.96, 0.06 ]
Schmitz 2005 39 2.5 (4.4) 40 0.3 (3.9) 11.2 % 0.52 [ 0.08, 0.97 ]
Pinto 2005 39 -3.8 (27.7) 43 -11.47 (25.8) 11.3 % 0.28 [ -0.15, 0.72 ]
Schmitz 2009 58 3.3 (23.2) 62 3.1 (17.2) 11.9 % 0.01 [ -0.35, 0.37 ]
Subtotal (95% CI) 292 300 100.0 % 0.41 [ 0.04, 0.77 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 40.71, df = 9 (P<0.00001); I2 =78%
Test for overall effect: Z = 2.18 (P = 0.029)
2 Moderate-to-high intensity
Herrero 2006 8 9.3 (19.6) 8 -2.1 (5.9) 1.9 % 0.74 [ -0.28, 1.77 ]
Cormie 2014 43 4.4 (9) 19 2.7 (8.6) 6.7 % 0.19 [ -0.35, 0.73 ]
Cadmus 2009 37 0.3 (2.2) 37 -0.5 (3.3) 9.3 % 0.28 [ -0.18, 0.74 ]
Vallance 2007 250 0.47 (3.54) 85 0.08 (2.49) 29.6 % 0.12 [ -0.13, 0.36 ]
Saarto 2012 263 1.2 (17.79) 237 1.9 (18.46) 52.5 % -0.04 [ -0.21, 0.14 ]
Subtotal (95% CI) 601 386 100.0 % 0.07 [ -0.07, 0.21 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.26, df = 4 (P = 0.37); I2 =6%
Test for overall effect: Z = 0.93 (P = 0.35)
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Analysis 14.5. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome
5 Overall physical function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 5 Overall physical function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Banasik 2011 7 -0.77 (0.94) 7 -0.42 (0.25) 2.3 % -0.48 [ -1.54, 0.59 ]
Mustian 2004 9 26.89 (4.11) 10 26.5 (4.14) 2.9 % 0.09 [ -0.81, 0.99 ]
Pinto 2003 12 32.3 (4.3) 12 25.3 (8.2) 3.1 % 1.03 [ 0.17, 1.89 ]
Milne 2008 29 24 (2.6) 29 15.6 (4.5) 4.1 % 2.26 [ 1.59, 2.92 ]
Rogers 2009 20 23.3 (4.5) 18 25.4 (2.3) 4.2 % -0.57 [ -1.22, 0.08 ]
Cuesta-Vargas 2014 22 42.9 (4.06) 20 32.4 (32.48) 4.5 % 0.46 [ -0.16, 1.07 ]
Basen-Enquist 2006 28 82.5 (12.7) 23 77.4 (11.5) 4.9 % 0.41 [ -0.15, 0.97 ]
Courneya 2003 24 25.3 (2.5) 28 25.3 (2.8) 4.9 % 0.0 [ -0.55, 0.55 ]
Mehnert 2011 30 88.96 (9.13) 28 78.12 (21.22) 5.1 % 0.66 [ 0.13, 1.19 ]
Littman 2012 30 25.4 (1.7) 27 24.3 (4.4) 5.1 % 0.33 [ -0.19, 0.86 ]
Murtezani 2014 30 22.6 (4.4) 32 19.4 (4.4) 5.2 % 0.72 [ 0.20, 1.23 ]
Winters-Stone 2011 36 51.7 (6.2) 25 52.3 (5.9) 5.2 % -0.10 [ -0.61, 0.41 ]
Daley 2007 33 25.61 (2.15) 33 23.61 (5.7) 5.4 % 0.46 [ -0.03, 0.95 ]
Schmitz 2005 39 -44.2 (5.6) 40 -48.3 (7.7) 5.7 % 0.60 [ 0.15, 1.05 ]
Pinto 2015 39 87.08 (4.4) 37 84.69 (15.91) 5.7 % 0.21 [ -0.25, 0.66 ]
Pinto 2005 39 30.26 (7.88) 43 27.33 (6.76) 5.8 % 0.40 [ -0.04, 0.83 ]
Loh 2014 63 24.92 (2.54) 32 24.17 (2.23) 5.9 % 0.30 [ -0.12, 0.73 ]
Fillion 2008 44 45.1 (10.42) 43 41.76 (9.76) 5.9 % 0.33 [ -0.10, 0.75 ]
Rogers 2015 105 24.1 (3.5) 108 22.5 (5) 7.1 % 0.37 [ 0.10, 0.64 ]
Schmitz 2009 112 50.6 (8.15) 120 49.1 (9.32) 7.2 % 0.17 [ -0.09, 0.43 ]
Subtotal (95% CI) 751 715 100.0 % 0.38 [ 0.19, 0.58 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 55.68, df = 19 (P = 0.00002); I2 =66%
Test for overall effect: Z = 3.95 (P = 0.000078)
2 Moderate-to-high intensity
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Herrero 2006 8 94.1 (7.5) 8 92.5 (6.6) 2.7 % 0.21 [ -0.77, 1.20 ]
Do 2015 32 89.4 (8.4) 30 89 (8.7) 10.7 % 0.05 [ -0.45, 0.54 ]
Cadmus 2009 37 25.1 (2.7) 37 24 (4.1) 12.6 % 0.31 [ -0.15, 0.77 ]
Duijits 2012 87 84.03 (16.88) 89 80.18 (17.08) 30.2 % 0.23 [ -0.07, 0.52 ]
Vallance 2007 250 25.1 (2.96) 85 24.95 (3.26) 43.8 % 0.05 [ -0.20, 0.30 ]
Subtotal (95% CI) 414 249 100.0 % 0.14 [ -0.02, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.55, df = 4 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.092)
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Analysis 14.6. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome
6 Overall physical function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 6 Overall physical function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 9 1.89 (2.61) 10 -0.2 (1.61) 11.2 % 0.93 [ -0.03, 1.89 ]
Murtezani 2014 30 4.43 (1.53) 32 -1.34 (1.15) 11.4 % 4.23 [ 3.31, 5.15 ]
Naumann 2012 11 1.9 (3.3) 10 0.8 (3.4) 11.7 % 0.32 [ -0.55, 1.18 ]
Rogers 2009 20 2.3 (5.1) 18 2.6 (6) 12.7 % -0.05 [ -0.69, 0.58 ]
Courneya 2003 24 1.9 (2) 28 -0.2 (2.2) 12.9 % 0.98 [ 0.40, 1.56 ]
Mehnert 2011 30 3.96 (10.83) 28 -2.15 (16.7) 13.1 % 0.43 [ -0.09, 0.95 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 13.4 % -0.05 [ -0.49, 0.39 ]
Schmitz 2009 58 6.6 (17.1) 62 4.1 (17.3) 13.7 % 0.14 [ -0.21, 0.50 ]
Subtotal (95% CI) 221 228 100.0 % 0.81 [ 0.11, 1.51 ]
Heterogeneity: Tau2 = 0.90; Chi2 = 79.79, df = 7 (P<0.00001); I2 =91%
Test for overall effect: Z = 2.27 (P = 0.023)
2 Moderate-to-high intensity
Herrero 2006 8 6.7 (5) 8 -1.7 (6.9) 7.3 % 1.32 [ 0.21, 2.43 ]
Cormie 2014 43 3.49 (5.15) 19 -0.5 (5.67) 17.1 % 0.74 [ 0.19, 1.30 ]
Cadmus 2009 37 0.1 (6.02) 37 -0.5 (7.42) 20.1 % 0.09 [ -0.37, 0.54 ]
Vallance 2007 247 1 (3.32) 85 0.19 (2.07) 26.8 % 0.26 [ 0.02, 0.51 ]
Saarto 2012 263 1.9 (13.65) 237 3.4 (13.35) 28.8 % -0.11 [ -0.29, 0.06 ]
Subtotal (95% CI) 598 386 100.0 % 0.28 [ -0.06, 0.62 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 16.88, df = 4 (P = 0.002); I2 =76%
Test for overall effect: Z = 1.60 (P = 0.11)
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7 Overall role function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 7 Overall role function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Banasik 2011 7 3.46 (0.64) 7 3.24 (0.56) 4.2 % 0.34 [ -0.72, 1.40 ]
Mustian 2004 9 2.44 (1.5) 9 2.8 (1.53) 4.8 % -0.23 [ -1.15, 0.70 ]
Loudon 2014 12 -1.3 (0.31) 11 -1.3 (0.36) 5.5 % 0.0 [ -0.82, 0.82 ]
Milne 2008 29 22.2 (3) 29 12.5 (4.8) 6.4 % 2.39 [ 1.71, 3.08 ]
Rogers 2009 20 21.4 (4.8) 18 23.8 (3.2) 6.7 % -0.57 [ -1.22, 0.08 ]
Basen-Enquist 2006 28 86.1 (22.2) 23 73 (24.5) 7.4 % 0.55 [ -0.01, 1.12 ]
Courneya 2003 24 23.4 (4) 28 23.1 (4) 7.5 % 0.07 [ -0.47, 0.62 ]
Mehnert 2011 30 90 (20.34) 27 79.6 (25.04) 7.7 % 0.45 [ -0.07, 0.98 ]
Littman 2012 30 22.6 (3.9) 27 21.7 (4.7) 7.7 % 0.21 [ -0.31, 0.73 ]
Murtezani 2014 30 24.2 (2.8) 32 23 (2.5) 7.8 % 0.45 [ -0.06, 0.95 ]
Daley 2007 33 22.88 (4.52) 33 20.3 (5.57) 7.9 % 0.50 [ 0.01, 0.99 ]
Schmitz 2005 39 -49.2 (6.5) 40 -50 (6.2) 8.3 % 0.12 [ -0.32, 0.57 ]
Loh 2014 63 23.37 (4.33) 32 22.22 (4.99) 8.5 % 0.25 [ -0.18, 0.68 ]
Rogers 2015 105 22.3 (4.5) 108 20.3 (5.5) 9.6 % 0.40 [ 0.12, 0.67 ]
Subtotal (95% CI) 459 424 100.0 % 0.36 [ 0.08, 0.64 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 47.79, df = 13 (P<0.00001); I2 =73%
Test for overall effect: Z = 2.55 (P = 0.011)
2 Moderate-to-high intensity
Herrero 2006 8 97.6 (5.9) 8 100 (0.01) 5.5 % -0.54 [ -1.55, 0.46 ]
Do 2015 32 78.1 (19.5) 30 79.2 (14.6) 19.4 % -0.06 [ -0.56, 0.44 ]
Cadmus 2009 37 23.1 (4.7) 37 20.6 (7.2) 22.1 % 0.41 [ -0.05, 0.87 ]
Vallance 2007 250 23.22 (3.98) 85 22.72 (4.58) 53.0 % 0.12 [ -0.13, 0.37 ]
Subtotal (95% CI) 327 160 100.0 % 0.11 [ -0.13, 0.35 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.69, df = 3 (P = 0.30); I2 =19%
Test for overall effect: Z = 0.92 (P = 0.36)
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Analysis 14.8. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome
8 Overall role function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 8 Overall role function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 9 0.56 (1.59) 10 0.8 (1.55) 10.0 % -0.15 [ -1.05, 0.76 ]
Naumann 2012 11 1.5 (4.41) 10 0.5 (4.49) 10.5 % 0.22 [ -0.64, 1.08 ]
Rogers 2009 20 0.4 (3.3) 18 1.4 (4.3) 14.0 % -0.26 [ -0.90, 0.38 ]
Courneya 2003 24 0.9 (2.8) 28 0.4 (2.7) 15.7 % 0.18 [ -0.37, 0.73 ]
Murtezani 2014 30 1.66 (0.71) 32 0.87 (0.64) 15.8 % 1.16 [ 0.62, 1.70 ]
Mehnert 2011 30 6.67 (23.84) 27 5.56 (27) 16.2 % 0.04 [ -0.48, 0.56 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 17.8 % -0.05 [ -0.49, 0.39 ]
Subtotal (95% CI) 163 165 100.0 % 0.18 [ -0.19, 0.56 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 16.15, df = 6 (P = 0.01); I2 =63%
Test for overall effect: Z = 0.95 (P = 0.34)
2 Moderate-to-high intensity
Herrero 2006 8 2.1 (13.9) 8 2.1 (5.9) 2.3 % 0.0 [ -0.98, 0.98 ]
Cormie 2014 43 4.9 (7.1) 19 1.7 (7.1) 7.3 % 0.45 [ -0.10, 0.99 ]
Cadmus 2009 37 -0.3 (3.7) 37 -0.5 (3.4) 10.2 % 0.06 [ -0.40, 0.51 ]
Vallance 2007 250 0.63 (4.14) 85 -0.01 (2.7) 30.2 % 0.17 [ -0.08, 0.41 ]
Saarto 2012 263 2.4 (21.51) 237 3.8 (21.6) 50.0 % -0.06 [ -0.24, 0.11 ]
Subtotal (95% CI) 601 386 100.0 % 0.06 [ -0.09, 0.21 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 4.51, df = 4 (P = 0.34); I2 =11%
Test for overall effect: Z = 0.73 (P = 0.47)
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Analysis 14.9. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention, Outcome
9 Overall social well-being/function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 9 Overall social well-being/function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Banasik 2011 7 2.8 (0.67) 7 3.16 (0.83) 1.4 % -0.45 [ -1.51, 0.62 ]
Mustian 2004 9 8.63 (1.89) 10 9 (1.83) 2.0 % -0.19 [ -1.09, 0.71 ]
Rogers 2014 20 7.3 (4.9) 22 3.1 (3.2) 3.7 % 1.01 [ 0.36, 1.65 ]
Rogers 2009 20 22.6 (4.1) 18 21.8 (5.7) 3.8 % 0.16 [ -0.48, 0.80 ]
Basen-Enquist 2006 28 84.6 (16.93) 23 84.9 (19.18) 5.0 % -0.02 [ -0.57, 0.54 ]
Courneya 2003 24 21.1 (3.5) 28 20.7 (3.6) 5.1 % 0.11 [ -0.43, 0.66 ]
Littman 2012 30 22.1 (5) 27 20.9 (6) 5.6 % 0.22 [ -0.31, 0.74 ]
Milne 2008 29 20.7 (4) 29 19.4 (3.9) 5.6 % 0.32 [ -0.19, 0.84 ]
Mehnert 2011 30 85.35 (20.88) 28 79.91 (22.65) 5.6 % 0.25 [ -0.27, 0.76 ]
Murtezani 2014 30 20.2 (2.8) 32 18.3 (2.7) 5.7 % 0.68 [ 0.17, 1.20 ]
Daley 2007 33 23.3 (4.78) 33 20.4 (6.8) 6.2 % 0.49 [ 0.00, 0.98 ]
Loh 2014 63 21.48 (4.88) 32 19.61 (4.9) 7.9 % 0.38 [ -0.05, 0.81 ]
Schmitz 2009 59 14.9 (5.2) 62 14.1 (5.8) 10.7 % 0.14 [ -0.21, 0.50 ]
Kiecolt-Glaser 2014 96 95.2 (10.8) 90 93.8 (9.3) 15.0 % 0.14 [ -0.15, 0.43 ]
Rogers 2015 105 21 (5.7) 108 20.7 (5.8) 16.6 % 0.05 [ -0.22, 0.32 ]
Subtotal (95% CI) 583 549 100.0 % 0.23 [ 0.10, 0.36 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 15.82, df = 14 (P = 0.32); I2 =12%
Test for overall effect: Z = 3.44 (P = 0.00059)
2 Moderate-to-high intensity
Herrero 2006 8 87.5 (19.4) 8 91.7 (23.6) 4.6 % -0.18 [ -1.17, 0.80 ]
Cadmus 2009 37 22.3 (4.9) 37 20.6 (7.2) 21.4 % 0.27 [ -0.18, 0.73 ]
Vallance 2007 250 22.94 (4.96) 85 22.96 (5.05) 74.0 % 0.00 [ -0.25, 0.24 ]
Subtotal (95% CI) 295 130 100.0 % 0.05 [ -0.16, 0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.31, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.43 (P = 0.66)
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Analysis 14.10. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 10 Overall social well-being/function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 10 Overall social well-being/function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 9 1.5 (1.5) 10 0.44 (1.17) 9.3 % 0.76 [ -0.18, 1.70 ]
Naumann 2012 11 0.9 (3.32) 10 -0.2 (3.32) 10.0 % 0.32 [ -0.54, 1.18 ]
Rogers 2009 20 0.9 (2.6) 18 -1.2 (2.7) 12.2 % 0.78 [ 0.11, 1.44 ]
Rogers 2014 20 2.1 (3.2) 22 -0.8 (3.5) 12.5 % 0.85 [ 0.21, 1.48 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 13.0 % 1.80 [ 1.21, 2.40 ]
Courneya 2003 24 0.6 (2.4) 28 -0.5 (3.3) 13.5 % 0.37 [ -0.18, 0.92 ]
Mehnert 2011 30 7.33 (22.33) 28 3.12 (24.3) 13.9 % 0.18 [ -0.34, 0.69 ]
Schmitz 2009 59 4.4 (33.8) 62 0.7 (34) 15.7 % 0.11 [ -0.25, 0.47 ]
Subtotal (95% CI) 203 210 100.0 % 0.63 [ 0.21, 1.04 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 26.88, df = 7 (P = 0.00035); I2 =74%
Test for overall effect: Z = 2.97 (P = 0.0029)
2 Moderate-to-high intensity
Cormie 2014 43 3.5 (8.5) 19 2.5 (8.3) 23.0 % 0.12 [ -0.42, 0.66 ]
Cadmus 2009 37 0.6 (4.6) 37 -1 (3.2) 24.0 % 0.40 [ -0.06, 0.86 ]
Vallance 2007 250 0.21 (4.82) 85 -4.15 (3.34) 26.2 % 0.97 [ 0.71, 1.23 ]
Saarto 2012 263 5 (21.1) 237 8.8 (20.81) 26.8 % -0.18 [ -0.36, -0.01 ]
Subtotal (95% CI) 593 378 100.0 % 0.33 [ -0.33, 0.98 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 53.19, df = 3 (P<0.00001); I2 =94%
Test for overall effect: Z = 0.98 (P = 0.32)
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Outcome 11 Overall cognitive function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 11 Overall cognitive function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Pinto 2003 12 -4.33 (2.5) 6 -7.17 (2.1) 8.6 % 1.14 [ 0.07, 2.20 ]
Rogers 2009 19 -124.5 (30.8) 18 -135.5 (19.5) 22.3 % 0.42 [ -0.24, 1.07 ]
Mehnert 2011 30 81.1 (16.8) 27 78.4 (24.38) 34.1 % 0.13 [ -0.39, 0.65 ]
Cantarero-Villanueva 2013 32 -37.93 (8.48) 29 -43.03 (10.01) 35.1 % 0.55 [ 0.03, 1.06 ]
Subtotal (95% CI) 93 80 100.0 % 0.43 [ 0.11, 0.74 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.16, df = 3 (P = 0.37); I2 =5%
Test for overall effect: Z = 2.64 (P = 0.0083)
2 Moderate-to-high intensity
Herrero 2006 8 91.7 (12.6) 8 89.6 (12.4) 100.0 % 0.16 [ -0.82, 1.14 ]
Subtotal (95% CI) 8 8 100.0 % 0.16 [ -0.82, 1.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.32 (P = 0.75)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 12 Overall cognitive function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Rogers 2009 20 4.2 (16.8) 18 -4.7 (25.9) 26.5 % 0.40 [ -0.24, 1.05 ]
Mehnert 2011 30 1.67 (22.36) 27 6.18 (24.6) 36.0 % -0.19 [ -0.71, 0.33 ]
Cantarero-Villanueva 2013 32 2.2 (7.63) 29 -0.18 (5.5471) 37.5 % 0.35 [ -0.16, 0.86 ]
Subtotal (95% CI) 82 74 100.0 % 0.17 [ -0.21, 0.55 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 2.82, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 0.88 (P = 0.38)
2 Moderate-to-high intensity
Herrero 2006 8 6.2 (19.8) 8 8.3 (14.8) 3.1 % -0.11 [ -1.09, 0.87 ]
Saarto 2012 263 -1 (18.2) 237 2.2 (18.46) 96.9 % -0.17 [ -0.35, 0.00 ]
Subtotal (95% CI) 271 245 100.0 % -0.17 [ -0.35, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 1.95 (P = 0.051)
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Analysis 14.13. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 13 Overall general health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 13 Overall general health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 9 18.6 (4.77) 9 19.3 (1.92) 8.7 % -0.18 [ -1.11, 0.74 ]
Rogers 2009 20 3.5 (0.9) 18 3.8 (0.5) 14.7 % -0.40 [ -1.04, 0.25 ]
Basen-Enquist 2006 28 77.4 (11.64) 23 67.1 (13.43) 16.9 % 0.81 [ 0.24, 1.39 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 18.3 % 0.19 [ -0.35, 0.73 ]
Mehnert 2011 30 74.38 (11.84) 28 70.01 (20.81) 19.1 % 0.26 [ -0.26, 0.77 ]
Schmitz 2005 39 53.8 (5.3) 40 53.2 (6) 22.3 % 0.10 [ -0.34, 0.55 ]
Subtotal (95% CI) 166 138 100.0 % 0.17 [ -0.14, 0.48 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 8.53, df = 5 (P = 0.13); I2 =41%
Test for overall effect: Z = 1.08 (P = 0.28)
2 Moderate-to-high intensity
Baruth 2013 20 68.1 (0) 12 61.6 (0) Not estimable
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 20.5 % 1.30 [ 0.19, 2.41 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 39.0 % 0.28 [ -0.22, 0.79 ]
Cadmus 2009 37 50 (8.8) 37 51.7 (8.4) 40.5 % -0.20 [ -0.65, 0.26 ]
Subtotal (95% CI) 97 87 100.0 % 0.30 [ -0.35, 0.95 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 6.60, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 0.90 (P = 0.37)
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Analysis 14.14. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 14 Overall general health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 14 Overall general health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 9 0.22 (1.92) 10 0.68 (2.5) 7.7 % -0.20 [ -1.10, 0.71 ]
Rogers 2009 20 0.15 (0.6) 18 0.17 (0.7) 15.5 % -0.03 [ -0.67, 0.61 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 21.2 % 0.52 [ -0.03, 1.06 ]
Mehnert 2011 30 6.6 (13.7) 28 3.24 (19.7) 23.6 % 0.20 [ -0.32, 0.71 ]
Schmitz 2005 39 0.7 (4.8) 40 -0.6 (3.9) 32.0 % 0.29 [ -0.15, 0.74 ]
Subtotal (95% CI) 138 116 100.0 % 0.23 [ -0.02, 0.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.67, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.80 (P = 0.071)
2 Moderate-to-high intensity
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 9.6 % 1.92 [ 0.68, 3.17 ]
Cormie 2014 43 3.7 (7) 19 2.8 (7.1) 25.0 % 0.13 [ -0.41, 0.67 ]
Cadmus 2009 37 0.2 (4.4) 37 -0.1 (5.1) 28.0 % 0.06 [ -0.39, 0.52 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 37.5 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 351 301 100.0 % 0.20 [ -0.24, 0.64 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 10.34, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 0.89 (P = 0.38)
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Analysis 14.15. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 15 Overall sexual function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 15 Overall sexual function (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Light-to-moderate intensity
Pinto 2005 12 42.75 (9.2) 6 43.7 (6.1) 5.5 % -0.11 [ -1.09, 0.87 ]
Schmitz 2005 39 -51 (7.5) 40 -53.5 (8) 27.0 % 0.32 [ -0.12, 0.76 ]
Pinto 2003 39 42.45 (9.24) 43 40.12 (6.3) 28.0 % 0.29 [ -0.14, 0.73 ]
Schmitz 2009 57 -27.3 (5.3) 57 -28.1 (6.2) 39.4 % 0.14 [ -0.23, 0.51 ]
Subtotal (95% CI) 147 146 100.0 % 0.22 [ -0.01, 0.45 ]
Heterogeneity: Chi2 = 0.93, df = 3 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.065)
2 Moderate-to-high intensity
Duijits 2012 53 0.6 (0.79) 65 0.59 (0.79) 100.0 % 0.01 [ -0.35, 0.38 ]
Subtotal (95% CI) 53 65 100.0 % 0.01 [ -0.35, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
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Analysis 14.16. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 16 Overall sexual function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 16 Overall sexual function (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Schmitz 2009 57 7.2 (14.6) 57 -0.2 (16.7) 39.4 % 7.40 [ 1.64, 13.16 ]
Schmitz 2005 39 1.7 (4.8) 40 0.2 (5.2) 60.6 % 1.50 [ -0.71, 3.71 ]
Subtotal (95% CI) 96 97 100.0 % 3.83 [ -1.83, 9.48 ]
Heterogeneity: Tau2 = 12.46; Chi2 = 3.52, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.33 (P = 0.18)
2 Moderate-to-high intensity
Saarto 2012 263 4.3 (25.38) 237 3.8 (24.35) 100.0 % 0.50 [ -3.86, 4.86 ]
Subtotal (95% CI) 263 237 100.0 % 0.50 [ -3.86, 4.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
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Analysis 14.17. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 17 Overall anxiety (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 17 Overall anxiety (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Pinto 2003 12 7.58 (7.3) 6 10.5 (3.7) 8.8 % -0.43 [ -1.43, 0.56 ]
Rogers 2014 20 45.6 (8.9) 22 45.7 (8) 19.7 % -0.01 [ -0.62, 0.59 ]
Milne 2008 29 15.3 (6.2) 29 21 (5.7) 22.9 % -0.94 [ -1.49, -0.40 ]
Mehnert 2011 30 4.83 (3.46) 28 7.14 (4.97) 24.1 % -0.54 [ -1.06, -0.01 ]
Cantarero-Villanueva 2013 32 42.51 (8.6) 29 49.93 (11.7) 24.5 % -0.72 [ -1.24, -0.20 ]
Subtotal (95% CI) 123 114 100.0 % -0.56 [ -0.88, -0.25 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 5.48, df = 4 (P = 0.24); I2 =27%
Test for overall effect: Z = 3.51 (P = 0.00044)
2 Moderate-to-high intensity
Segar 1998 10 28.5 (3) 5 39.5 (6) 45.2 % -2.49 [ -3.98, -1.00 ]
Cadmus 2009 37 32.1 (12.3) 37 34.1 (15.4) 54.8 % -0.14 [ -0.60, 0.31 ]
Subtotal (95% CI) 47 42 100.0 % -1.20 [ -3.49, 1.09 ]
Heterogeneity: Tau2 = 2.44; Chi2 = 8.68, df = 1 (P = 0.003); I2 =88%
Test for overall effect: Z = 1.03 (P = 0.30)
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Analysis 14.18. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 18 Overall anxiety (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 18 Overall anxiety (change values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Light-to-moderate intensity
Rogers 2014 20 -4 (6.5) 22 -1.8 (5) 26.4 % -0.37 [ -0.99, 0.24 ]
Mehnert 2011 30 -1.67 (3.68) 28 0.18 (4.89) 36.3 % -0.42 [ -0.95, 0.10 ]
Cantarero-Villanueva 2013 32 -4.2 (9.8) 29 0.75 (5.5) 37.3 % -0.61 [ -1.12, -0.09 ]
Subtotal (95% CI) 82 79 100.0 % -0.48 [ -0.79, -0.16 ]
Heterogeneity: Chi2 = 0.39, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
2 Moderate-to-high intensity
Cadmus 2009 37 -0.7 (9.2) 37 0.5 (5.8) 100.0 % -0.15 [ -0.61, 0.30 ]
Subtotal (95% CI) 37 37 100.0 % -0.15 [ -0.61, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
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Analysis 14.19. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 19 Overall depression (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 19 Overall depression (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Pinto 2003 12 6.17 (7.2) 6 9.83 (6.8) 6.1 % -0.49 [ -1.49, 0.50 ]
Payne 2008 10 12.7 (8.7) 10 11.4 (7.9) 7.2 % 0.15 [ -0.73, 1.03 ]
Bower 2011 16 7.7 (5.8) 15 11.6 (7.1) 9.2 % -0.59 [ -1.31, 0.13 ]
Rogers 2014 20 44.2 (8.6) 22 25.1 (44.2) 10.7 % 0.58 [ -0.04, 1.19 ]
Ergun 2013 40 6.88 (6.76) 20 5.15 (5.18) 12.1 % 0.27 [ -0.27, 0.81 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 12.4 % -0.51 [ -1.04, 0.01 ]
Cantarero-Villanueva 2013 32 45.58 (9.68) 29 53.71 (11.6) 12.4 % -0.75 [ -1.28, -0.23 ]
Daley 2007 33 6 (6.47) 33 10.33 (7.19) 12.9 % -0.63 [ -1.12, -0.13 ]
Kiecolt-Glaser 2014 96 8.1 (8.6) 90 9.2 (8.2) 17.0 % -0.13 [ -0.42, 0.16 ]
Subtotal (95% CI) 289 253 100.0 % -0.24 [ -0.53, 0.06 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 19.68, df = 8 (P = 0.01); I2 =59%
Test for overall effect: Z = 1.59 (P = 0.11)
2 Moderate-to-high intensity
Segar 1998 10 5.5 (2) 5 10 (2) 24.5 % -2.12 [ -3.51, -0.73 ]
Kaltsatou 2011 13 16.54 (1.66) 13 22.33 (7.73) 34.6 % -1.00 [ -1.83, -0.18 ]
Cadmus 2009 37 9.6 (9.3) 37 10.8 (10.1) 40.9 % -0.12 [ -0.58, 0.33 ]
Subtotal (95% CI) 60 55 100.0 % -0.92 [ -1.95, 0.11 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 9.24, df = 2 (P = 0.01); I2 =78%
Test for overall effect: Z = 1.75 (P = 0.081)
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Analysis 14.20. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 20 Overall depression (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 20 Overall depression (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Naumann 2012 11 -3.6 (4.34) 10 2 (4.55) 9.9 % -1.21 [ -2.16, -0.26 ]
Rogers 2014 20 -1.7 (6.9) 22 1.1 (4.2) 23.6 % -0.49 [ -1.10, 0.13 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 32.5 % -0.51 [ -1.04, 0.01 ]
Cantarero-Villanueva 2013 32 -2.95 (7.82) 29 1.46 (7.36) 33.9 % -0.57 [ -1.09, -0.06 ]
Subtotal (95% CI) 93 89 100.0 % -0.60 [ -0.89, -0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.84, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.91 (P = 0.000093)
2 Moderate-to-high intensity
Cadmus 2009 37 0.3 (6.4) 37 1.7 (6.3) 20.0 % -0.22 [ -0.68, 0.24 ]
Saarto 2012 263 -0.3 (3.31) 237 -0.5 (3.38) 80.0 % 0.06 [ -0.12, 0.24 ]
Subtotal (95% CI) 300 274 100.0 % 0.00 [ -0.21, 0.22 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.24, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 0.04 (P = 0.97)
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Analysis 14.21. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 21 Overall fatigue (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 21 Overall fatigue (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Banasik 2011 7 1 (0.89) 7 1.57 (0.98) 2.3 % -0.57 [ -1.65, 0.51 ]
Pinto 2003 12 7.16 (6.4) 6 9 (6.4) 2.6 % -0.27 [ -1.26, 0.71 ]
Payne 2008 9 4.7 (2.6) 9 3.5 (1.7) 2.8 % 0.52 [ -0.42, 1.46 ]
Rogers 2013 11 4.2 (1.8) 9 4.2 (1.6) 3.0 % 0.0 [ -0.88, 0.88 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 3.3 % -0.07 [ -0.89, 0.75 ]
Bower 2011 16 3.4 (1.8) 15 4.9 (1.3) 3.7 % -0.93 [ -1.67, -0.18 ]
Rogers 2009 20 -12.4 (10.4) 18 -10.1 (6.6) 4.5 % -0.26 [ -0.90, 0.38 ]
Cuesta-Vargas 2014 22 4 (1.8) 20 5.2 (3.2) 4.6 % -0.46 [ -1.07, 0.15 ]
Rogers 2014 20 4.1 (2.1) 22 4 (1.8) 4.7 % 0.05 [ -0.56, 0.66 ]
Milne 2008 29 11.9 (3.2) 29 17.4 (4.7) 4.9 % -1.35 [ -1.92, -0.78 ]
Cantarero-Villanueva 2013 32 3.78 (1.78) 29 6.23 (1.72) 5.0 % -1.38 [ -1.94, -0.82 ]
Courneya 2003 24 -8.3 (7.9) 28 -8.8 (8.1) 5.2 % 0.06 [ -0.48, 0.61 ]
Ergun 2013 40 2.94 (2.24) 20 3.3 (1.79) 5.2 % -0.17 [ -0.71, 0.37 ]
Mehnert 2011 30 28.52 (25.58) 27 39.92 (25.09) 5.3 % -0.44 [ -0.97, 0.08 ]
Littman 2012 30 -45 (5.3) 27 -43.1 (10.3) 5.4 % -0.23 [ -0.75, 0.29 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 5.6 % -0.71 [ -1.21, -0.21 ]
Winters-Stone 2011 36 45 (5.3) 31 43.1 (10.3) 5.7 % 0.23 [ -0.25, 0.72 ]
Pinto 2015 39 -43.83 (7.8) 37 -41.22 (8.49) 6.0 % -0.32 [ -0.77, 0.14 ]
Pinto 2005 39 27.08 (21.41) 43 42.28 (26.2) 6.1 % -0.63 [ -1.07, -0.18 ]
Fillion 2008 44 2.65 (0.72) 43 2.86 (0.83) 6.3 % -0.27 [ -0.69, 0.15 ]
Kiecolt-Glaser 2014 96 6.3 (19.6) 90 12.7 (18.97) 7.6 % -0.33 [ -0.62, -0.04 ]
Subtotal (95% CI) 601 554 100.0 % -0.38 [ -0.56, -0.19 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 45.29, df = 20 (P = 0.001); I2 =56%
Test for overall effect: Z = 3.94 (P = 0.000081)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 Moderate-to-high intensity
Do 2015 32 16.8 (13.3) 30 22.3 (15.1) 9.2 % -0.38 [ -0.89, 0.12 ]
Cadmus 2009 37 -51.9 (9) 37 -50.6 (10) 11.2 % -0.14 [ -0.59, 0.32 ]
Vallance 2007 250 -42.7 (8.4) 85 -42.6 (8.7) 38.5 % -0.01 [ -0.26, 0.23 ]
Short 2014 195 -41.5 (9.3) 104 -39.8 (10.4) 41.0 % -0.17 [ -0.41, 0.06 ]
Subtotal (95% CI) 514 256 100.0 % -0.13 [ -0.28, 0.03 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.99, df = 3 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.63 (P = 0.10)
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Analysis 14.22. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 22 Overall fatigue (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 22 Overall fatigue (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Naumann 2012 11 -3.6 (4.35) 10 2 (4.55) 9.0 % -1.21 [ -2.16, -0.26 ]
Rogers 2013 11 4.2 (2) 9 3.9 (1.5) 9.5 % 0.16 [ -0.72, 1.04 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 9.9 % -0.07 [ -0.89, 0.75 ]
Rogers 2009 20 1.9 (9.6) 18 4.2 (12.3) 11.2 % -0.21 [ -0.84, 0.43 ]
Courneya 2003 24 9.3 (10.2) 28 2 (7.5) 11.7 % 0.81 [ 0.24, 1.38 ]
Cantarero-Villanueva 2013 32 -2 (1.75) 29 0.34 (1.39) 11.7 % -1.45 [ -2.02, -0.88 ]
Mehnert 2011 30 -0.74 (20.73) 27 -2.88 (25.3) 12.1 % 0.09 [ -0.43, 0.61 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 12.2 % -0.71 [ -1.21, -0.21 ]
Pinto 2005 39 -14.93 (23.54) 43 1.79 (23.48) 12.6 % -0.70 [ -1.15, -0.26 ]
Subtotal (95% CI) 212 208 100.0 % -0.36 [ -0.84, 0.11 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 42.67, df = 8 (P<0.00001); I2 =81%
Test for overall effect: Z = 1.51 (P = 0.13)
2 Moderate-to-high intensity
Herrero 2006 8 -4.2 (19.6) 8 6.4 (14.5) 3.5 % -0.58 [ -1.59, 0.43 ]
Vallance 2007 250 2.49 (8.17) 85 1.15 (6.61) 39.0 % 0.17 [ -0.08, 0.42 ]
Saarto 2012 263 -2.4 (9.06) 237 -2.4 (8.6) 57.6 % 0.0 [ -0.18, 0.18 ]
Subtotal (95% CI) 521 330 100.0 % 0.05 [ -0.14, 0.24 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.75, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 0.48 (P = 0.63)
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Analysis 14.23. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 23 Overall pain/disability (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 23 Overall pain/disability (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 9 9.11 (1.35) 10 9.1 (1.74) 13.1 % 0.01 [ -0.89, 0.91 ]
Loudon 2014 12 0.8 (1.48) 11 1.44 (2.24) 15.0 % -0.33 [ -1.15, 0.50 ]
Rogers 2009 20 -3.03 (2.98) 18 -2.28 (2.76) 21.0 % -0.26 [ -0.89, 0.38 ]
Basen-Enquist 2006 28 79.7 (10.58) 23 72.1 (11.51) 24.1 % 0.68 [ 0.11, 1.25 ]
Mehnert 2011 30 79.4 (23.1) 28 73.5 (24.83) 26.7 % 0.24 [ -0.27, 0.76 ]
Subtotal (95% CI) 99 90 100.0 % 0.13 [ -0.25, 0.50 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 6.39, df = 4 (P = 0.17); I2 =37%
Test for overall effect: Z = 0.66 (P = 0.51)
2 Moderate-to-high intensity
Portela 2008 25 -20.6 (20.2) 9 -20.8 (15.5) 7.8 % 0.01 [ -0.75, 0.77 ]
Do 2015 32 21.1 (24.6) 30 16.5 (26.7) 18.2 % 0.18 [ -0.32, 0.68 ]
Cadmus 2009 37 50.3 (9.1) 37 50.8 (9) 21.9 % -0.05 [ -0.51, 0.40 ]
Duijits 2012 87 79.27 (23.59) 89 78.79 (23.78) 52.0 % 0.02 [ -0.28, 0.32 ]
Subtotal (95% CI) 181 165 100.0 % 0.03 [ -0.18, 0.24 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.47, df = 3 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
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Analysis 14.24. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 24 Overall pain/disability (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 24 Overall pain/disability (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 9 -0.22 (1.29) 10 0 (1.42) 24.7 % -0.15 [ -1.06, 0.75 ]
Mehnert 2011 30 -2.4 (24.95) 28 -7.61 (25.2) 75.3 % 0.21 [ -0.31, 0.72 ]
Subtotal (95% CI) 39 38 100.0 % 0.12 [ -0.33, 0.56 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
2 Moderate-to-high intensity
Cormie 2014 43 3.4 (6.5) 19 2 (6.2) 27.1 % 0.22 [ -0.33, 0.76 ]
Cadmus 2009 37 -2.2 (11.3) 37 -0.1 (7) 35.1 % -0.22 [ -0.68, 0.24 ]
Irwin 2015 45 -6 (18.97) 38 0.7 (18.56) 37.7 % -0.35 [ -0.79, 0.08 ]
Subtotal (95% CI) 125 94 100.0 % -0.15 [ -0.47, 0.16 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.68, df = 2 (P = 0.26); I2 =25%
Test for overall effect: Z = 0.94 (P = 0.35)
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Analysis 14.25. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 25 Overall self-esteem/body image (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 25 Overall self-esteem/body image (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Pinto 2003 12 32.3 (4.3) 6 25.3 (8.2) 3.5 % 1.15 [ 0.08, 2.22 ]
Loudon 2014 12 -1.43 (0.33) 11 -1.56 (0.86) 5.8 % 0.20 [ -0.62, 1.02 ]
Mehnert 2011 27 -5.47 (1.66) 27 -6.82 (2.6) 11.9 % 0.61 [ 0.06, 1.16 ]
Courneya 2003 24 34.8 (4.7) 28 34.6 (4.4) 11.9 % 0.04 [ -0.50, 0.59 ]
Milne 2008 29 -17.9 (6.8) 29 -20.1 (6.3) 13.0 % 0.33 [ -0.19, 0.85 ]
Daley 2007 33 2.03 (0.83) 32 1.57 (0.5) 13.8 % 0.66 [ 0.16, 1.16 ]
Pinto 2005 39 30.26 (7.82) 43 27.23 (6.76) 17.0 % 0.41 [ -0.03, 0.85 ]
Schmitz 2009 59 -70.4 (16.3) 63 -71.5 (18) 23.1 % 0.06 [ -0.29, 0.42 ]
Subtotal (95% CI) 235 239 100.0 % 0.35 [ 0.14, 0.55 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.40, df = 7 (P = 0.30); I2 =17%
Test for overall effect: Z = 3.32 (P = 0.00089)
2 Moderate-to-high intensity
Segar 1998 10 33 (1.8) 5 30.5 (2.7) 13.1 % 1.11 [ -0.06, 2.28 ]
Musanti 2012 30 23.83 (3.48) 12 26.33 (3.94) 24.2 % -0.68 [ -1.37, 0.01 ]
Do 2015 (1) 32 37.9 (18.9) 30 36.1 (18.3) 30.6 % 0.10 [ -0.40, 0.59 ]
Cadmus 2009 37 34.2 (5.5) 37 33.4 (5.9) 32.1 % 0.14 [ -0.32, 0.60 ]
Subtotal (95% CI) 109 84 100.0 % 0.06 [ -0.45, 0.56 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 7.66, df = 3 (P = 0.05); I2 =61%
Test for overall effect: Z = 0.21 (P = 0.83)
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Analysis 14.26. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 26 Overall self-esteem/body image (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 26 Overall self-esteem/body image (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 11 3 (1) 10 -1.5 (1.5) 9.6 % 3.42 [ 1.99, 4.86 ]
Courneya 2003 24 2.6 (3.7) 28 -0.1 (3.5) 17.4 % 0.74 [ 0.18, 1.30 ]
Mehnert 2011 30 0.73 (2.12) 27 0.39 (2.12) 17.8 % 0.16 [ -0.36, 0.68 ]
Milne 2008 29 1.5 (3.7) 29 0.1 (3.9) 17.8 % 0.36 [ -0.16, 0.88 ]
Daley 2007 33 1.79 (0.71) 33 1.56 (0.67) 18.1 % 0.33 [ -0.16, 0.82 ]
Schmitz 2009 59 -12 (15.5) 63 -4.1 (16.2) 19.1 % -0.49 [ -0.86, -0.13 ]
Subtotal (95% CI) 186 190 100.0 % 0.52 [ -0.09, 1.13 ]
Heterogeneity: Tau2 = 0.47; Chi2 = 37.69, df = 5 (P<0.00001); I2 =87%
Test for overall effect: Z = 1.66 (P = 0.097)
2 Moderate-to-high intensity
Musanti 2012 30 -0.4 (4.53) 12 0.58 (3.92) 5.6 % -0.22 [ -0.89, 0.45 ]
Cadmus 2009 37 0.4 (4.4) 37 0.2 (2.9) 12.2 % 0.05 [ -0.40, 0.51 ]
Saarto 2012 263 10.7 (21.51) 237 12 (21.99) 82.2 % -0.06 [ -0.24, 0.12 ]
Subtotal (95% CI) 330 286 100.0 % -0.05 [ -0.21, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.68 (P = 0.50)
-4 -2 0 2 4
Favours control Favours intervention
659Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 14.27. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 27 Overall cardiorespiratory fitness (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 27 Overall cardiorespiratory fitness (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Cerulli 2014 10 31.29 (4.95) 10 32.26 (10.1) 2.9 % -0.12 [ -0.99, 0.76 ]
Mustian 2004 11 636.1 (50.6) 10 610.3 (75.9) 3.0 % 0.39 [ -0.48, 1.25 ]
Rogers 2013 12 23.9 (6.2) 10 23.9 (3.8) 3.1 % 0.0 [ -0.84, 0.84 ]
Rahnama 2010 14 20.65 (5.73) 15 13.85 (5.18) 3.4 % 1.21 [ 0.41, 2.01 ]
Rogers 2014 20 30.9 (6.3) 22 25.1 (5) 4.9 % 1.01 [ 0.36, 1.65 ]
Kim 2015 20 424.8 (55.8) 19 394.4 (54) 4.9 % 0.54 [ -0.10, 1.18 ]
Rogers 2009 20 29.5 (6.6) 18 27.6 (6.1) 4.9 % 0.29 [ -0.35, 0.93 ]
Courneya 2003 24 21.3 (3.7) 26 18.2 (3.9) 5.8 % 0.80 [ 0.22, 1.38 ]
Mehnert 2011 27 26.9 (4.4) 23 25.7 (4.7) 6.1 % 0.26 [ -0.30, 0.82 ]
Basen-Enquist 2006 35 1643 (122.5) 25 1546 (127.5) 6.5 % 0.77 [ 0.24, 1.30 ]
Milne 2008 29 1.49 (0.31) 29 1.48 (0.43) 6.9 % 0.03 [ -0.49, 0.54 ]
Murtezani 2014 30 875.1 (86.7) 32 823.5 (87.1) 7.0 % 0.59 [ 0.08, 1.10 ]
Pinto 2005 39 -16.34 (2.09) 43 -17.85 (2.24) 8.3 % 0.69 [ 0.24, 1.14 ]
Fillion 2008 44 27.04 (4.39) 43 26.53 (5.81) 9.0 % 0.10 [ -0.32, 0.52 ]
Daley 2007 33 34.99 (4.42) 69 33.05 (5.3) 9.1 % 0.38 [ -0.04, 0.80 ]
Rogers 2015 105 23.6 (4.8) 108 22.7 (0.3) 14.2 % 0.27 [ 0.00, 0.54 ]
Subtotal (95% CI) 473 502 100.0 % 0.43 [ 0.27, 0.59 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 20.81, df = 15 (P = 0.14); I2 =28%
Test for overall effect: Z = 5.31 (P < 0.00001)
2 Moderate-to-high intensity
Herrero 2006 8 25.9 (4.5) 8 25.7 (3.7) 8.7 % 0.05 [ -0.93, 1.03 ]
Portela 2008 25 3006.96 (410.8) 9 2416.1 (718.6) 11.4 % 1.14 [ 0.33, 1.96 ]
Kaltsatou 2011 14 483.33 (85.95) 13 403.08 (71.92) 11.6 % 0.98 [ 0.17, 1.78 ]
Nikander 2007 14 -17.6 (1.3) 14 -17.2 (1.4) 12.8 % -0.29 [ -1.03, 0.46 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Musanti 2012 30 24.6 (4.93) 12 23 (4.29) 14.5 % 0.33 [ -0.34, 1.00 ]
Do 2015 30 31.7 (12.4) 30 24.5 (6.6) 18.9 % 0.72 [ 0.19, 1.24 ]
Irwin 2015 45 24.6 (5.5) 38 23 (4.7) 22.1 % 0.31 [ -0.13, 0.74 ]
Subtotal (95% CI) 166 124 100.0 % 0.46 [ 0.13, 0.80 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 10.35, df = 6 (P = 0.11); I2 =42%
Test for overall effect: Z = 2.71 (P = 0.0068)
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Analysis 14.28. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 28 Overall cardiorespiratory fitness (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 28 Overall cardiorespiratory fitness (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Nieman 1995 6 60.8 (8.4) 6 12 (17.8) 6.8 % 3.24 [ 1.29, 5.18 ]
Dolan 2016 11 12.95 (10.4) 10 -5.97 (7.2) 13.8 % 2.01 [ 0.92, 3.10 ]
Naumann 2012 11 3.1 (2.9) 10 -0.1 (3.1) 15.9 % 1.03 [ 0.10, 1.95 ]
Courneya 2003 24 2.7 (2.6) 26 -0.6 (1.7) 20.2 % 1.49 [ 0.86, 2.12 ]
Rogers 2014 20 2.8 (4.9) 22 1.1 (4.2) 20.5 % 0.37 [ -0.24, 0.98 ]
Pinto 2005 39 1.35 (2.4) 43 -0.25 (2.5) 22.9 % 0.65 [ 0.20, 1.09 ]
Subtotal (95% CI) 111 117 100.0 % 1.18 [ 0.60, 1.77 ]
Heterogeneity: Tau2 = 0.34; Chi2 = 17.08, df = 5 (P = 0.004); I2 =71%
-10 -5 0 5 10
Favours control Favours physical activity
(Continued . . . )
661Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 3.95 (P = 0.000078)
2 Moderate-to-high intensity
Dolan 2016 12 11.48 (10.5) 10 -5.97 (7.2) 16.0 % 1.83 [ 0.80, 2.86 ]
Musanti 2012 30 1 (3.1) 12 0.9 (3.4) 23.0 % 0.03 [ -0.64, 0.70 ]
Irwin 2015 45 1.5 (2.1) 38 -0.4 (2.7) 28.0 % 0.79 [ 0.34, 1.24 ]
Saarto 2012 262 0.89 (1.15) 236 0.72 (1.01) 33.0 % 0.16 [ -0.02, 0.33 ]
Subtotal (95% CI) 349 296 100.0 % 0.57 [ 0.01, 1.14 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 16.01, df = 3 (P = 0.001); I2 =81%
Test for overall effect: Z = 1.98 (P = 0.047)
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Analysis 14.29. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 29 Overall self-reported physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 29 Overall self-reported physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Guinan 2013 16 38.7 (26.9) 10 19.9 (11.3) 5.4 % 0.81 [ -0.01, 1.64 ]
Matthews 2007 22 54.2 (34.1) 14 27.2 (22.7) 6.5 % 0.87 [ 0.17, 1.58 ]
Rogers 2009 20 121.4 (73.2) 18 114.3 (131.5) 7.2 % 0.07 [ -0.57, 0.70 ]
Basen-Enquist 2006 35 428 (254.4) 25 404 (265) 8.7 % 0.09 [ -0.42, 0.61 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 8.8 % 1.01 [ 0.50, 1.52 ]
Littman 2012 32 19.2 (19.1) 31 12.1 (13.6) 8.9 % 0.42 [ -0.08, 0.92 ]
Winters-Stone 2011 36 430.8 (281.4) 31 461.7 (346.4) 9.1 % -0.10 [ -0.58, 0.38 ]
Pinto 2005 39 202.43 (161.65) 43 78.36 (86) 9.4 % 0.96 [ 0.50, 1.42 ]
Kiecolt-Glaser 2014 96 11.2 (7.6) 90 9.1 (6.1) 11.7 % 0.30 [ 0.01, 0.59 ]
Rogers 2015 110 169 (119) 112 74 (107) 11.9 % 0.84 [ 0.56, 1.11 ]
Schmitz 2009 131 3348.8 (9019.4) 133 2339.8 (6213.7) 12.4 % 0.13 [ -0.11, 0.37 ]
Subtotal (95% CI) 573 539 100.0 % 0.47 [ 0.23, 0.72 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 35.18, df = 10 (P = 0.00012); I2 =72%
Test for overall effect: Z = 3.78 (P = 0.00016)
2 Moderate-to-high intensity
Baruth 2013 20 0 (0) 12 0 (0) Not estimable
Cadmus 2009 34 161.7 (114.7) 33 55.6 (101.9) 17.5 % 0.97 [ 0.46, 1.47 ]
Hatchett 2013 38 3.47 (2.19) 36 1.42 (1.67) 17.9 % 1.04 [ 0.55, 1.53 ]
Irwin 2015 45 222.1 (118.6) 38 103.6 (104.6) 18.5 % 1.04 [ 0.58, 1.51 ]
Vallance 2007 253 207.6 (169) 85 163 (121) 23.0 % 0.28 [ 0.03, 0.53 ]
Short 2014 195 217.9 (222.9) 104 180.3 (206.9) 23.1 % 0.17 [ -0.07, 0.41 ]
Subtotal (95% CI) 585 308 100.0 % 0.65 [ 0.27, 1.03 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 22.93, df = 4 (P = 0.00013); I2 =83%
Test for overall effect: Z = 3.36 (P = 0.00077)
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Analysis 14.30. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 30 Overall self-reported physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 30 Overall self-reported physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Guinan 2013 16 15.6 (11.4476) 10 -8.3 (4.1937) 17.3 % 2.46 [ 1.39, 3.53 ]
Matthews 2007 22 21.5 (30.6) 14 5 (13.8) 24.1 % 0.63 [ -0.06, 1.32 ]
Pinto 2005 39 84.74 (189.2) 43 -18.27 (200.7) 28.8 % 0.52 [ 0.08, 0.96 ]
Schmitz 2009 (1) 48 2.8 (16.8) 57 -0.8 (16.6) 29.7 % 0.21 [ -0.17, 0.60 ]
Subtotal (95% CI) 125 124 100.0 % 0.79 [ 0.15, 1.44 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 15.08, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 2.41 (P = 0.016)
2 Moderate-to-high intensity
Cadmus 2009 34 129 (117.9) 33 44.3 (89.4) 20.7 % 0.80 [ 0.30, 1.30 ]
Irwin 2015 45 159 (136) 38 49 (86) 21.9 % 0.94 [ 0.48, 1.40 ]
Vallance 2007 281 82 (168.7) 96 30 (167.8) 28.1 % 0.31 [ 0.08, 0.54 ]
Saarto 2012 262 3.5 (18.3) 236 3.3 (21.5) 29.3 % 0.01 [ -0.17, 0.19 ]
Subtotal (95% CI) 622 403 100.0 % 0.46 [ 0.07, 0.85 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 20.76, df = 3 (P = 0.00012); I2 =86%
Test for overall effect: Z = 2.30 (P = 0.022)
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Analysis 14.31. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 31 Overall objective physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 31 Overall objective physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Rogers 2013 12 198.4 (111.7) 10 0 (0) Not estimable
Guinan 2013 16 30.7 (15.6) 9 31 (15.6) 8.3 % -0.02 [ -0.84, 0.80 ]
Matthews 2007 22 330.8 (114.7) 14 198.5 (55.4) 9.3 % 1.34 [ 0.60, 2.09 ]
Rogers 2014 20 294 (175) 22 154 (75) 10.9 % 1.04 [ 0.39, 1.69 ]
Rogers 2009 20 252191 (91893) 18 210917 (64078) 10.9 % 0.51 [ -0.14, 1.15 ]
Kim 2015 20 17.6 (16.03) 19 11.8 (11.6) 11.2 % 0.40 [ -0.23, 1.04 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 13.8 % 1.01 [ 0.50, 1.52 ]
Pinto 2005 39 37.5 (14.25) 43 33.62 (19.43) 15.6 % 0.22 [ -0.21, 0.66 ]
Rogers 2015 110 246 (153) 112 197 (138) 20.0 % 0.34 [ 0.07, 0.60 ]
Subtotal (95% CI) 295 279 100.0 % 0.58 [ 0.29, 0.87 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 16.06, df = 7 (P = 0.02); I2 =56%
Test for overall effect: Z = 3.91 (P = 0.000091)
2 Moderate-to-high intensity
Cadmus 2009 33 6738 (2958) 34 5537 (3352) 10.7 % 0.38 [ -0.11, 0.86 ]
Vallance 2007 253 8110.5 (4133.9) 85 8028 (3457) 41.4 % 0.02 [ -0.23, 0.27 ]
Short 2014 219 9363.07 (7922.79) 111 8301.2 (3373.4) 47.8 % 0.16 [ -0.07, 0.39 ]
Subtotal (95% CI) 505 230 100.0 % 0.12 [ -0.03, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.80, df = 2 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.12)
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Analysis 14.32. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 32 Overall objective physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 32 Overall objective physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Guinan 2013 16 -1.1 (6.2) 9 -7.9 (5.3) 22.9 % 1.11 [ 0.23, 2.00 ]
Matthews 2007 22 72.2 (114.6) 14 -16.8 (51.5) 35.7 % 0.91 [ 0.20, 1.62 ]
Rogers 2014 20 114 (109) 22 10 (70) 41.4 % 1.13 [ 0.47, 1.78 ]
Subtotal (95% CI) 58 45 100.0 % 1.05 [ 0.62, 1.47 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.22, df = 2 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 4.86 (P < 0.00001)
2 Moderate-to-high intensity
Cadmus 2009 33 1621 (2108) 34 -60 (2341) 46.1 % 0.75 [ 0.25, 1.24 ]
Vallance 2007 253 -150 (5173.3) 85 91 (5155.4) 53.9 % -0.05 [ -0.29, 0.20 ]
Subtotal (95% CI) 286 119 100.0 % 0.32 [ -0.45, 1.09 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 7.85, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 0.81 (P = 0.42)
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Analysis 14.33. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 33 Mass (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 33 Mass (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 Light-to-moderate intensity
Matthews 2007 22 74.9 (15.2) 14 78.9 (20.3) 0.2 % -4.00 [ -16.39, 8.39 ]
Mustian 2004 11 67.1 (10.42) 10 68.6 (13.84) 0.3 % -1.50 [ -12.06, 9.06 ]
Courneya 2003 24 78.2 (20.5) 26 80.1 (16.2) 0.3 % -1.90 [ -12.20, 8.40 ]
Rahnama 2010 14 69.4 (13.5) 15 71.6 (9.2) 0.5 % -2.20 [ -10.67, 6.27 ]
DeNysschen 2011 30 69.3 (14.2) 34 72.4 (19.6) 0.5 % -3.10 [ -11.42, 5.22 ]
Littman 2012 28 81.1 (13.6) 27 81.3 (14.3) 0.6 % -0.20 [ -7.58, 7.18 ]
Winters-Stone 2011 36 76.5 (15.6) 31 74.2 (12.3) 0.8 % 2.30 [ -4.39, 8.99 ]
Daley 2007 33 74.26 (12.49) 69 75.6 (12.5) 1.3 % -1.34 [ -6.52, 3.84 ]
Murtezani 2014 30 71.7 (9.5) 32 72.6 (10.75) 1.3 % -0.90 [ -5.94, 4.14 ]
Schmitz 2009 131 76.15 (15.66) 133 77.19 (17.02) 2.2 % -1.04 [ -4.98, 2.90 ]
Schmitz 2005 39 69.5 (2.22) 40 69.2 (2.2) 35.7 % 0.30 [ -0.67, 1.27 ]
Kiecolt-Glaser 2014 96 75.2 (2.8) 90 75.2 (2.6) 56.3 % 0.0 [ -0.78, 0.78 ]
Subtotal (95% CI) 494 521 100.0 % 0.03 [ -0.56, 0.61 ]
Heterogeneity: Chi2 = 2.86, df = 11 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
2 Moderate-to-high intensity
Nikander 2007 14 73.5 (13.3) 14 75.5 (12) 21.2 % -2.00 [ -11.38, 7.38 ]
Cadmus 2009 36 80.73 (16.88) 33 78.51 (20.64) 23.3 % 2.22 [ -6.72, 11.16 ]
Herrero 2006 8 65.6 (8.7) 8 67.3 (8.9) 25.1 % -1.70 [ -10.32, 6.92 ]
Ligibel 2008 40 80 (17.5) 42 83.3 (18.7) 30.4 % -3.30 [ -11.14, 4.54 ]
Subtotal (95% CI) 98 97 100.0 % -1.34 [ -5.66, 2.98 ]
Heterogeneity: Chi2 = 0.87, df = 3 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
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Analysis 14.34. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 34 Mass (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 34 Mass (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Dolan 2016 11 -0.41 (2.08) 10 1.44 (1.62) 9.2 % -1.85 [ -3.44, -0.26 ]
Mustian 2004 9 -0.3 (1.86) 10 0.6 (1.43) 9.8 % -0.90 [ -2.40, 0.60 ]
Matthews 2007 22 0.01 (2.09) 14 0.04 (2.16) 10.4 % -0.03 [ -1.46, 1.40 ]
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 10.8 % -0.60 [ -1.98, 0.78 ]
Murtezani 2014 30 -2.3 (2.4) 32 -0.3 (2.6) 11.9 % -2.00 [ -3.24, -0.76 ]
Naumann 2012 11 0.45 (1.33) 10 0.12 (1.52) 12.1 % 0.33 [ -0.90, 1.56 ]
Courneya 2003 24 0.1 (2) 26 0.7 (1.8) 13.7 % -0.60 [ -1.66, 0.46 ]
Schmitz 2005 39 0.32 (0.43) 40 0.2 (0.42) 22.0 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 211 207 100.0 % -0.58 [ -1.21, 0.05 ]
Heterogeneity: Tau2 = 0.46; Chi2 = 20.32, df = 7 (P = 0.005); I2 =66%
Test for overall effect: Z = 1.81 (P = 0.070)
2 Moderate-to-high intensity
Irwin 2015 45 -2.1 (4.3) 38 0.1 (3.6) 21.0 % -2.20 [ -3.90, -0.50 ]
Ligibel 2008 22 0 (2.3) 14 0.04 (2.16) 23.3 % -0.04 [ -1.52, 1.44 ]
Dolan 2016 12 -0.67 (1.9) 10 1.44 (1.62) 23.4 % -2.11 [ -3.58, -0.64 ]
Saarto 2012 262 0.66 (3.68) 236 0.67 (3.84) 32.3 % -0.01 [ -0.67, 0.65 ]
Subtotal (95% CI) 341 298 100.0 % -0.97 [ -2.18, 0.24 ]
Heterogeneity: Tau2 = 1.07; Chi2 = 10.92, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 1.57 (P = 0.12)
-4 -2 0 2 4
Favours physical activity Favours control
(1) with lymphedema
668Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 14.35. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 35 BMI (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 35 BMI (follow-up values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Fixed,95% CI IV,Fixed,95% CI
1 Light-to-moderate intensity
Rogers 2013 12 33.6 (7) 10 30.6 (7.28) 0.1 % 3.00 [ -3.00, 9.00 ]
Rogers 2009 20 30.6 (7.6) 18 30.4 (8.3) 0.2 % 0.20 [ -4.88, 5.28 ]
Mustian 2004 11 23.9 (4.17) 10 26.7 (5.59) 0.2 % -2.80 [ -7.05, 1.45 ]
Courneya 2003 24 29.4 (7.4) 26 29.3 (6) 0.3 % 0.10 [ -3.65, 3.85 ]
Rogers 2014 20 29.6 (5) 22 32.2 (6.7) 0.3 % -2.60 [ -6.16, 0.96 ]
Rahnama 2010 14 27.74 (4.77) 15 28.04 (4.6) 0.4 % -0.30 [ -3.71, 3.11 ]
Littman 2012 28 27.66 (5.01) 27 29.01 (5.62) 0.6 % -1.35 [ -4.17, 1.47 ]
Pinto 2005 39 27.66 (5.01) 43 29.01 (5.62) 0.8 % -1.35 [ -3.65, 0.95 ]
Murtezani 2014 30 25.1 (2.9) 32 25.8 (3.47) 1.7 % -0.70 [ -2.29, 0.89 ]
Schmitz 2009 131 28.46 (5.55) 133 28.94 (6.27) 2.2 % -0.48 [ -1.91, 0.95 ]
Schmitz 2005 39 26 (0.74) 40 25.8 (0.73) 41.7 % 0.20 [ -0.12, 0.52 ]
Kiecolt-Glaser 2014 96 27.8 (1.08) 90 27.8 (0.95) 51.5 % 0.0 [ -0.29, 0.29 ]
Subtotal (95% CI) 464 466 100.0 % 0.03 [ -0.18, 0.24 ]
Heterogeneity: Chi2 = 9.49, df = 11 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.28 (P = 0.78)
2 Moderate-to-high intensity
Portela 2008 25 29.1 (5.5) 9 34.7 (15) 1.1 % -5.60 [ -15.63, 4.43 ]
Nikander 2007 14 26.9 (5.6) 14 27.7 (4.9) 7.2 % -0.80 [ -4.70, 3.10 ]
Cadmus 2009 36 30.45 (6) 33 29.9 (7.59) 10.4 % 0.55 [ -2.70, 3.80 ]
Ligibel 2008 40 30.3 (6.3) 42 31.5 (6.8) 13.6 % -1.20 [ -4.04, 1.64 ]
Vallance 2007 253 27.01 (5.21) 85 27.2 (5.15) 67.8 % -0.19 [ -1.46, 1.08 ]
Subtotal (95% CI) 368 183 100.0 % -0.35 [ -1.40, 0.69 ]
Heterogeneity: Chi2 = 1.80, df = 4 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.66 (P = 0.51)
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Analysis 14.36. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 36 BMI (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 36 BMI (change values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 3.4 % -0.60 [ -1.98, 0.78 ]
Mustian 2004 9 -0.42 (0.75) 10 0.29 (0.61) 11.1 % -0.71 [ -1.33, -0.09 ]
Rogers 2014 20 -0.2 (0.9) 22 -0.3 (1.1) 11.4 % 0.10 [ -0.51, 0.71 ]
Naumann 2012 11 0.1 (0.5) 10 -0.1 (0.57) 14.8 % 0.20 [ -0.26, 0.66 ]
Courneya 2003 24 0 (0.7) 26 0.3 (0.7) 16.9 % -0.30 [ -0.69, 0.09 ]
Murtezani 2014 30 -0.8 (0.7) 32 -0.14 (0.8) 17.3 % -0.66 [ -1.03, -0.29 ]
Schmitz 2005 39 0.06 (0.17) 40 0.07 (0.16) 25.1 % -0.01 [ -0.08, 0.06 ]
Subtotal (95% CI) 198 205 100.0 % -0.23 [ -0.50, 0.05 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 19.32, df = 6 (P = 0.004); I2 =69%
Test for overall effect: Z = 1.61 (P = 0.11)
2 Moderate-to-high intensity
Ligibel 2008 40 0 (0.9) 42 0.2 (0.8) 100.0 % -0.20 [ -0.57, 0.17 ]
Subtotal (95% CI) 40 42 100.0 % -0.20 [ -0.57, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
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Analysis 14.37. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 37 Overall body fat (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 37 Overall body fat (follow-up values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Cerulli 2014 10 26.72 (5.34) 10 30.55 (4.4) 3.8 % -0.75 [ -1.66, 0.16 ]
Mustian 2004 11 38.5 (4.47) 10 41.7 (4.89) 4.0 % -0.66 [ -1.54, 0.23 ]
Rogers 2013 10 44.2 (6.7) 12 42.3 (7.7) 4.4 % 0.25 [ -0.59, 1.09 ]
Matthews 2007 22 39.7 (6.3) 14 43.1 (6.9) 5.9 % -0.51 [ -1.19, 0.17 ]
Rogers 2009 20 44.3 (7.4) 19 43.5 (7.5) 6.6 % 0.11 [ -0.52, 0.73 ]
Rogers 2014 20 38.6 (6.4) 22 41.5 (7.4) 6.8 % -0.41 [ -1.02, 0.20 ]
Courneya 2003 24 131.9 (46.4) 26 137.1 (44.4) 7.6 % -0.11 [ -0.67, 0.44 ]
DeNysschen 2011 30 36.9 (8.4) 34 38 (10.2) 8.7 % -0.12 [ -0.61, 0.38 ]
Winters-Stone 2011 36 40.5 (6.2) 31 38.5 (5.8) 8.8 % 0.33 [ -0.16, 0.81 ]
Schmitz 2005 39 40.91 (1.31) 40 42.29 (1.3) 9.1 % -1.05 [ -1.52, -0.58 ]
Pinto 2005 39 37.53 (4.79) 43 38.55 (4.83) 9.8 % -0.21 [ -0.64, 0.22 ]
Daley 2007 33 39.4 (4.74) 69 40.1 (7.4) 10.2 % -0.10 [ -0.52, 0.31 ]
Schmitz 2009 130 38.47 (5.93) 132 39.74 (5.9) 14.2 % -0.21 [ -0.46, 0.03 ]
Subtotal (95% CI) 424 462 100.0 % -0.24 [ -0.44, -0.04 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 22.86, df = 12 (P = 0.03); I2 =48%
Test for overall effect: Z = 2.34 (P = 0.019)
2 Moderate-to-high intensity
Herrero 2006 8 22 (5) 8 22 (4) 6.0 % 0.0 [ -0.98, 0.98 ]
Musanti 2012 30 34.13 (6.64) 12 33.7 (5.7) 12.9 % 0.07 [ -0.60, 0.74 ]
Saarto 2012 37 39.9 (7.5) 30 40.2 (8) 24.9 % -0.04 [ -0.52, 0.44 ]
Cadmus 2009 36 40.54 (6.55) 33 39.6 (5.97) 25.8 % 0.15 [ -0.33, 0.62 ]
Ligibel 2008 40 42.9 (7.4) 42 44.7 (8) 30.5 % -0.23 [ -0.67, 0.20 ]
Subtotal (95% CI) 151 125 100.0 % -0.03 [ -0.27, 0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.45, df = 4 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.78)
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Analysis 14.38. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 38 Overall body fat (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 38 Overall body fat (change values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 9 -0.16 (2.91) 10 0.28 (1.57) 13.1 % -0.18 [ -1.09, 0.72 ]
Naumann 2012 11 -0.3 (2.42) 10 0.8 (2.75) 13.3 % -0.41 [ -1.28, 0.46 ]
Matthews 2007 22 -0.2 (1.62) 14 0.41 (1.94) 14.3 % -0.34 [ -1.02, 0.33 ]
Schmitz 2005 39 -1.15 (0.45) 40 0.23 (0.44) 14.4 % -3.07 [ -3.73, -2.41 ]
Rogers 2014 20 -1.1 (2.2) 22 -0.6 (2.4) 14.6 % -0.21 [ -0.82, 0.39 ]
Courneya 2003 24 -4.9 (15.7) 26 5.1 (24.4) 14.8 % -0.48 [ -1.04, 0.09 ]
Schmitz 2009 (1) 65 -0.3 (5.7) 63 -0.1 (3.3) 15.5 % -0.04 [ -0.39, 0.30 ]
Subtotal (95% CI) 190 185 100.0 % -0.68 [ -1.44, 0.09 ]
Heterogeneity: Tau2 = 0.95; Chi2 = 66.52, df = 6 (P<0.00001); I2 =91%
Test for overall effect: Z = 1.73 (P = 0.084)
2 Moderate-to-high intensity
Musanti 2012 30 -0.24 (2.83) 12 1.4 (1.57) 28.8 % -0.63 [ -1.32, 0.05 ]
Ligibel 2008 40 -0.2 (1.7) 42 0.3 (1.7) 71.2 % -0.29 [ -0.73, 0.14 ]
Subtotal (95% CI) 70 54 100.0 % -0.39 [ -0.76, -0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 2.08 (P = 0.038)
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Analysis 14.39. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 39 Lower body strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 39 Lower body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Cerulli 2014 10 114.88 (17.09) 10 79.13 (17.78) 7.2 % 1.96 [ 0.85, 3.07 ]
Rogers 2013 11 68.4 (15.5) 9 67.1 (16.2) 9.8 % 0.08 [ -0.80, 0.96 ]
Rogers 2009 20 80.3 (27) 18 64.9 (19.7) 13.5 % 0.63 [ -0.02, 1.29 ]
Schmitz 2005 23 296.6 (48.9) 22 238.9 (46.4) 13.8 % 1.19 [ 0.55, 1.83 ]
Milne 2008 29 66.2 (10.2) 29 61.7 (11) 16.3 % 0.42 [ -0.10, 0.94 ]
Winters-Stone 2011 36 201.3 (57.4) 31 191 (51.7) 17.2 % 0.19 [ -0.30, 0.67 ]
Schmitz 2009 113 223.4 (59.6) 119 175.1 (53.5) 22.1 % 0.85 [ 0.58, 1.12 ]
Subtotal (95% CI) 242 238 100.0 % 0.69 [ 0.34, 1.04 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 15.91, df = 6 (P = 0.01); I2 =62%
Test for overall effect: Z = 3.84 (P = 0.00012)
2 Moderate-to-high intensity
Nikander 2007 14 1305 (177) 14 1393 (275) 17.6 % -0.37 [ -1.12, 0.38 ]
Do 2015 32 13 (1.62) 30 13.15 (1.55) 39.8 % -0.09 [ -0.59, 0.41 ]
Saarto 2012 37 136 (23) 30 136 (29) 42.6 % 0.0 [ -0.48, 0.48 ]
Subtotal (95% CI) 83 74 100.0 % -0.10 [ -0.42, 0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.66, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
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Analysis 14.40. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 40 Lower body strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 40 Lower body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Nieman 1995 6 28.9 (13.7) 6 3.5 (22.5) 3.1 % 1.26 [ -0.03, 2.55 ]
Dolan 2016 11 10.26 (10) 10 0.34 (11.1) 6.2 % 0.90 [ 0.00, 1.81 ]
Naumann 2012 11 7.7 (12.6) 10 3.5 (13.9) 6.9 % 0.30 [ -0.56, 1.17 ]
Schmitz 2005 23 81.8 (48.92) 22 20.3 (45.97) 12.3 % 1.27 [ 0.63, 1.92 ]
Schmitz 2009 113 33.2 (33.9) 119 7.9 (26.6) 71.4 % 0.83 [ 0.56, 1.10 ]
Subtotal (95% CI) 164 167 100.0 % 0.87 [ 0.64, 1.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.58, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 7.48 (P < 0.00001)
2 Moderate-to-high intensity
Dolan 2016 12 13.28 (7.9) 10 0.34 (11.1) 16.9 % 1.31 [ 0.37, 2.26 ]
Cormie 2014 43 37.6 (25.5) 19 6.7 (25.7) 24.3 % 1.19 [ 0.61, 1.78 ]
Do 2015 32 0.9 (0.7) 60 0.95 (0.61) 27.8 % -0.08 [ -0.51, 0.35 ]
Waltman 2010 110 4.42 (11.48) 113 0.19 (8.38) 31.0 % 0.42 [ 0.15, 0.69 ]
Subtotal (95% CI) 197 202 100.0 % 0.62 [ 0.07, 1.17 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 15.35, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 2.21 (P = 0.027)
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Analysis 14.41. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 41 Upper body strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 41 Upper body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Mustian 2004 11 29.6 (3.27) 10 26.7 (5.73) 12.0 % 0.60 [ -0.28, 1.49 ]
Cerulli 2014 10 16.08 (5.43) 10 17.2 (8.05) 12.0 % -0.16 [ -1.03, 0.72 ]
Schmitz 2005 23 83 (13.4) 22 63 (12.7) 13.9 % 1.50 [ 0.84, 2.17 ]
Rogers 2009 20 27.9 (5.04) 18 24.3 (6.18) 14.1 % 0.63 [ -0.03, 1.28 ]
Milne 2008 29 7.6 (2.9) 29 9.4 (2.6) 15.2 % -0.64 [ -1.17, -0.12 ]
Winters-Stone 2011 36 63.3 (15.3) 31 61.1 (16.8) 15.6 % 0.14 [ -0.34, 0.62 ]
Schmitz 2009 113 52.9 (15.3) 119 40.9 (11.8) 17.1 % 0.88 [ 0.61, 1.15 ]
Subtotal (95% CI) 242 239 100.0 % 0.43 [ -0.11, 0.96 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 38.52, df = 6 (P<0.00001); I2 =84%
Test for overall effect: Z = 1.57 (P = 0.12)
2 Moderate-to-high intensity
Portela 2008 25 39.3 (12.3) 9 35.6 (13.1) 14.4 % 0.29 [ -0.48, 1.05 ]
Nikander 2007 14 131 (20) 14 129 (28) 14.8 % 0.08 [ -0.66, 0.82 ]
Musanti 2012 30 52.13 (20.98) 12 36.75 (20) 15.6 % 0.73 [ 0.04, 1.42 ]
Kaltsatou 2011 28 59.63 (8.49) 26 47.62 (9.83) 17.3 % 1.29 [ 0.70, 1.88 ]
Do 2015 32 9.65 (1.67) 30 10.05 (1.68) 18.8 % -0.24 [ -0.74, 0.26 ]
Saarto 2012 37 32.7 (5.3) 30 30.8 (5.7) 19.1 % 0.34 [ -0.14, 0.83 ]
Subtotal (95% CI) 166 121 100.0 % 0.41 [ -0.05, 0.87 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 16.68, df = 5 (P = 0.01); I2 =70%
Test for overall effect: Z = 1.77 (P = 0.078)
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Analysis 14.42. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 42 Upper body strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 42 Upper body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Schmitz 2005 23 32.3 (11.51) 22 6.9 (10.79) 29.2 % 2.24 [ 1.48, 2.99 ]
Mustian 2004 45 4.5 (4.71) 38 -0.85 (3.15) 34.0 % 1.30 [ 0.82, 1.78 ]
Schmitz 2009 113 33.2 (40.8) 119 7.6 (43.7) 36.8 % 0.60 [ 0.34, 0.87 ]
Subtotal (95% CI) 181 179 100.0 % 1.32 [ 0.47, 2.16 ]
Heterogeneity: Tau2 = 0.49; Chi2 = 19.50, df = 2 (P = 0.00006); I2 =90%
Test for overall effect: Z = 3.05 (P = 0.0023)
2 Moderate-to-high intensity
Musanti 2012 30 7.74 (10.62) 12 0.83 (12.65) 15.9 % 0.60 [ -0.08, 1.29 ]
Cormie 2014 43 5.7 (3.67) 19 1 (3.78) 17.9 % 1.25 [ 0.67, 1.84 ]
Do 2015 32 0.3 (0.5) 30 0.55 (1.2) 19.8 % -0.27 [ -0.77, 0.23 ]
Irwin 2015 45 0.4 (1.88) 38 0.1 (1.89) 21.4 % 0.16 [ -0.27, 0.59 ]
Waltman 2010 110 1.9 (4.86) 113 0.75 (2.9) 24.9 % 0.29 [ 0.02, 0.55 ]
Subtotal (95% CI) 260 212 100.0 % 0.37 [ -0.05, 0.79 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 16.36, df = 4 (P = 0.003); I2 =76%
Test for overall effect: Z = 1.75 (P = 0.081)
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Analysis 14.43. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 43 Bone mineral density - femoral neck (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 43 Bone mineral density - femoral neck (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Kim 2015 20 0.78 (0.08) 19 0.81 (0.08) 40.2 % -0.37 [ -1.00, 0.27 ]
Winters-Stone 2011 36 0.72 (0.1) 31 0.71 (0.08) 59.8 % 0.11 [ -0.37, 0.59 ]
Subtotal (95% CI) 56 50 100.0 % -0.08 [ -0.54, 0.37 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.37, df = 1 (P = 0.24); I2 =27%
Test for overall effect: Z = 0.36 (P = 0.72)
2 Moderate-to-high intensity
Waltman 2010 (1) 110 0.92 (0.5) 113 0.63 (0.42) 47.5 % 0.63 [ 0.36, 0.90 ]
Saarto 2012 (2) 239 -0.006 (0.025) 218 -0.01 (0.03) 52.5 % 0.18 [ 0.00, 0.37 ]
Subtotal (95% CI) 349 331 100.0 % 0.39 [ -0.04, 0.83 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 7.17, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 1.77 (P = 0.077)
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Analysis 14.44. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 44 Bone mineral density - lumbar spine (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 44 Bone mineral density - lumbar spine (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Kim 2015 20 0.97 (0.08) 19 0.99 (0.07) 43.1 % -0.26 [ -0.89, 0.37 ]
Winters-Stone 2011 36 0.99 (0.15) 31 0.95 (0.11) 56.9 % 0.30 [ -0.19, 0.78 ]
Subtotal (95% CI) 56 50 100.0 % 0.06 [ -0.48, 0.60 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 1.89, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.21 (P = 0.84)
2 Moderate-to-high intensity
Waltman 2010 (1) 110 3.08 (0.44) 113 2.85 (0.4) 47.6 % 0.55 [ 0.28, 0.81 ]
Saarto 2012 (2) 239 -0.018 (0.033) 218 -0.02 (0.034) 52.4 % 0.09 [ -0.09, 0.27 ]
Subtotal (95% CI) 349 331 100.0 % 0.31 [ -0.14, 0.75 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 7.59, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 1.35 (P = 0.18)
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Analysis 14.45. Comparison 14 Subanalysis: outcomes by intensity of physical activity intervention,
Outcome 45 Bone mineral density - total hip (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 14 Subanalysis: outcomes by intensity of physical activity intervention
Outcome: 45 Bone mineral density - total hip (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Light-to-moderate intensity
Kim 2015 20 0.88 (0.08) 19 0.09 (0.07) 49.2 % 10.34 [ 7.84, 12.84 ]
Winters-Stone 2011 36 0.86 (0.11) 31 0.84 (0.1) 50.8 % 0.19 [ -0.29, 0.67 ]
Subtotal (95% CI) 56 50 100.0 % 5.19 [ -4.76, 15.14 ]
Heterogeneity: Tau2 = 50.72; Chi2 = 61.08, df = 1 (P<0.00001); I2 =98%
Test for overall effect: Z = 1.02 (P = 0.31)
2 Moderate-to-high intensity
Waltman 2010 (1) 110 2.15 (0.28) 113 1.81 (0.36) 100.0 % 1.05 [ 0.77, 1.33 ]
Subtotal (95% CI) 110 113 100.0 % 1.05 [ 0.77, 1.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.33 (P < 0.00001)
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Analysis 15.1. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome
1 Overall HRQoL (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 1 Overall HRQoL (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 3.4 % 1.30 [ 0.19, 2.41 ]
Rogers 2015 10 85.23 (4.2) 10 65.89 (14.66) 3.6 % 1.72 [ 0.66, 2.78 ]
Mustian 2004 11 121.7 (22.67) 10 124.3 (25.9) 4.5 % -0.10 [ -0.96, 0.75 ]
Loudon 2014 12 -7.42 (1.24) 11 -7.45 (1.44) 4.7 % 0.02 [ -0.80, 0.84 ]
Milne 2008 29 86.4 (8.3) 29 64.1 (10.8) 5.6 % 2.28 [ 1.61, 2.96 ]
Rogers 2009 20 92 (11.4) 18 87.4 (13.1) 5.8 % 0.37 [ -0.27, 1.01 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 6.5 % 0.19 [ -0.35, 0.73 ]
Murtezani 2014 30 86.5 (7.3) 32 79.1 (7.5) 6.6 % 0.99 [ 0.46, 1.52 ]
Mehnert 2011 30 74.72 (21.72) 27 65.43 (16.78) 6.6 % 0.47 [ -0.06, 1.00 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 6.8 % 0.28 [ -0.22, 0.79 ]
Pinto 2015 39 117.79 (12.74) 37 113.98 (18.02) 7.1 % 0.24 [ -0.21, 0.69 ]
Taleghani 2012 40 217.5 (36.3) 40 210.1 (41.5) 7.2 % 0.19 [ -0.25, 0.63 ]
Loh 2014 63 112.4 (14.09) 32 109.29 (13.26) 7.3 % 0.22 [ -0.20, 0.65 ]
Daley 2007 33 90.85 (13.47) 69 86.44 (15.07) 7.4 % 0.30 [ -0.12, 0.72 ]
Vallance 2007 250 91.54 (11.76) 85 90.55 (12.95) 8.4 % 0.08 [ -0.16, 0.33 ]
Short 2014 195 106.8 (16.7) 104 108.2 (18.2) 8.5 % -0.08 [ -0.32, 0.16 ]
Subtotal (95% CI) 842 562 100.0 % 0.45 [ 0.19, 0.70 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 64.72, df = 15 (P<0.00001); I2 =77%
Test for overall effect: Z = 3.43 (P = 0.00060)
2 More than 12 weeks
Cerulli 2014 10 85.23 (4.2) 10 65.89 (14.66) 6.0 % 1.72 [ 0.66, 2.78 ]
Portela 2008 25 107.2 (28.5) 9 91.6 (28.5) 10.2 % 0.53 [ -0.24, 1.31 ]
Courneya 2003 24 91.3 (11) 28 89.3 (10.9) 16.9 % 0.18 [ -0.37, 0.73 ]
Cadmus 2009 37 91.2 (12.6) 37 86.2 (17.4) 21.0 % 0.33 [ -0.13, 0.78 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Schmitz 2005 39 -44.2 (8.7) 40 -47.4 (9.4) 21.8 % 0.35 [ -0.09, 0.79 ]
Littman 2012 30 90.3 (11) 110 87.7 (15) 24.1 % 0.18 [ -0.22, 0.59 ]
Subtotal (95% CI) 165 234 100.0 % 0.38 [ 0.10, 0.65 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 7.67, df = 5 (P = 0.18); I2 =35%
Test for overall effect: Z = 2.66 (P = 0.0077)
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Analysis 15.2. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome
2 Overall HRQoL (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 2 Overall HRQoL (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Mustian 2004 11 15 (5) 10 0 (5) 6.7 % 2.88 [ 1.59, 4.17 ]
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 6.9 % 1.92 [ 0.68, 3.17 ]
Murtezani 2014 30 9.16 (2.12) 32 -0.56 (2.01) 8.0 % 4.65 [ 3.67, 5.63 ]
Naumann 2012 11 14.5 (10.6) 10 3.1 (11.4) 8.3 % 1.00 [ 0.08, 1.92 ]
Rogers 2009 20 4.5 (8.4) 18 2.9 (12) 9.5 % 0.15 [ -0.49, 0.79 ]
Cuesta-Vargas 2014 22 0.32 (0.18) 20 0.33 (0.09) 9.6 % -0.07 [ -0.67, 0.54 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 9.9 % 0.52 [ -0.03, 1.06 ]
Mehnert 2011 30 9.72 (21.03) 27 5.55 (16.5) 9.9 % 0.22 [ -0.31, 0.74 ]
Cadmus 2009 37 0.6 (7.5) 37 -2.4 (9.8) 10.2 % 0.34 [ -0.12, 0.80 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Daley 2007 33 10.22 (11.2) 69 3.2 (11.26) 10.3 % 0.62 [ 0.20, 1.04 ]
Vallance 2007 250 2.3 (11.08) 85 -0.16 (6.4) 10.7 % 0.24 [ 0.00, 0.49 ]
Subtotal (95% CI) 492 336 100.0 % 0.99 [ 0.45, 1.52 ]
Heterogeneity: Tau2 = 0.68; Chi2 = 98.44, df = 10 (P<0.00001); I2 =90%
Test for overall effect: Z = 3.61 (P = 0.00031)
2 More than 12 weeks
Courneya 2003 24 5.7 (7.4) 28 0.6 (7.4) 27.3 % 0.68 [ 0.12, 1.24 ]
Schmitz 2005 39 2.3 (4.5) 40 0.6 (4) 31.7 % 0.40 [ -0.05, 0.84 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 41.0 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 326 305 100.0 % 0.27 [ -0.21, 0.76 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 9.45, df = 2 (P = 0.01); I2 =79%
Test for overall effect: Z = 1.11 (P = 0.26)
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3 Overall emotional function/mental health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 3 Overall emotional function/mental health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Banasik 2011 7 0.47 (0.36) 7 0.38 (0.31) 1.5 % 0.25 [ -0.80, 1.30 ]
Herrero 2006 8 90.6 (9.3) 8 83.3 (14.8) 1.6 % 0.56 [ -0.45, 1.56 ]
Mustian 2004 9 24.78 (2.04) 10 24.8 (3.19) 2.0 % -0.01 [ -0.91, 0.89 ]
Pinto 2003 12 -10.83 (28.1) 12 -27.17 (19.5) 2.3 % 0.65 [ -0.17, 1.48 ]
Loudon 2014 12 -1.58 (0.7) 11 -1.61 (0.49) 2.3 % 0.05 [ -0.77, 0.87 ]
Rogers 2009 20 20 (3.1) 18 21.1 (2.9) 3.5 % -0.36 [ -1.00, 0.28 ]
Cuesta-Vargas 2014 22 42.9 (19.17) 20 32.3 (33.33) 3.8 % 0.39 [ -0.22, 1.00 ]
Milne 2008 29 19.6 (2.4) 29 16.7 (4.1) 4.6 % 0.85 [ 0.31, 1.39 ]
Do 2015 32 87.4 (8.8) 30 70.4 (21.5) 4.7 % 1.03 [ 0.50, 1.57 ]
Mehnert 2011 30 77.01 (35.75) 28 69.05 (40.5) 4.9 % 0.21 [ -0.31, 0.72 ]
Cantarero-Villanueva 2013 32 -17175 (4279) 29 -20390 (6113) 4.9 % 0.61 [ 0.09, 1.12 ]
Murtezani 2014 30 19.5 (3.3) 32 18.3 (3.5) 5.1 % 0.35 [ -0.15, 0.85 ]
Daley 2007 33 19.06 (4.18) 33 18.45 (3.31) 5.4 % 0.16 [ -0.32, 0.64 ]
Pinto 2015 39 54.21 (9.28) 37 52.48 (9.62) 5.9 % 0.18 [ -0.27, 0.63 ]
Pinto 2005 39 -8.02 (20.69) 43 -16.51 (28.75) 6.2 % 0.33 [ -0.10, 0.77 ]
Loh 2014 63 19.87 (2.81) 32 19.98 (3.22) 6.4 % -0.04 [ -0.46, 0.39 ]
Fillion 2008 44 48.54 (7.91) 43 47.49 (9.08) 6.5 % 0.12 [ -0.30, 0.54 ]
Duijits 2012 37 73.92 (34.7) 89 77.46 (34.32) 7.2 % -0.10 [ -0.49, 0.28 ]
Rogers 2015 105 20.6 (2.9) 108 19.7 (3.2) 10.3 % 0.29 [ 0.02, 0.56 ]
Vallance 2007 250 20.28 (3.31) 85 19.92 (3.44) 11.1 % 0.11 [ -0.14, 0.35 ]
Subtotal (95% CI) 853 704 100.0 % 0.26 [ 0.12, 0.39 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 27.63, df = 19 (P = 0.09); I2 =31%
Test for overall effect: Z = 3.74 (P = 0.00019)
2 More than 12 weeks
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Basen-Enquist 2006 28 78.2 (10.58) 23 77.2 (11.99) 9.3 % 0.09 [ -0.46, 0.64 ]
Courneya 2003 24 21.5 (3.4) 28 20.7 (3) 9.5 % 0.25 [ -0.30, 0.79 ]
Littman 2012 30 20.3 (4) 27 20.8 (3.1) 10.5 % -0.14 [ -0.66, 0.38 ]
Cadmus 2009 37 20.5 (3) 37 19.8 (4.2) 13.6 % 0.19 [ -0.27, 0.65 ]
Schmitz 2005 39 -45.6 (8.2) 40 -48.2 (8.2) 14.4 % 0.31 [ -0.13, 0.76 ]
Schmitz 2009 112 53.2 (9.6) 120 53.8 (8.7) 42.8 % -0.07 [ -0.32, 0.19 ]
Subtotal (95% CI) 270 275 100.0 % 0.06 [ -0.11, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.49, df = 5 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.70 (P = 0.48)
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Analysis 15.4. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome
4 Overall emotional function/mental health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 4 Overall emotional function/mental health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Herrero 2006 8 9.3 (19.6) 8 -2.1 (5.9) 6.7 % 0.74 [ -0.28, 1.77 ]
Mustian 2004 9 2.44 (2.52) 10 0.1 (1.68) 7.0 % 1.06 [ 0.08, 2.03 ]
Naumann 2012 11 1 (2.69) 10 -0.1 (2.72) 7.9 % 0.39 [ -0.48, 1.26 ]
Rogers 2009 20 0.9 (2.5) 18 -0.1 (2.7) 9.9 % 0.38 [ -0.27, 1.02 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 10.3 % 1.80 [ 1.21, 2.40 ]
Cormie 2014 43 4.4 (9) 19 2.7 (8.6) 10.8 % 0.19 [ -0.35, 0.73 ]
Mehnert 2011 30 2.3 (35.5) 28 3.57 (17.6) 11.1 % -0.04 [ -0.56, 0.47 ]
Cantarero-Villanueva 2013 32 -1445 (4452) 29 353 (3323) 11.1 % -0.45 [ -0.96, 0.06 ]
Pinto 2005 39 -3.8 (27.7) 43 -11.47 (25.8) 11.8 % 0.28 [ -0.15, 0.72 ]
Vallance 2007 250 0.47 (3.54) 85 0.08 (2.49) 13.4 % 0.12 [ -0.13, 0.36 ]
Subtotal (95% CI) 472 282 100.0 % 0.39 [ 0.03, 0.76 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 39.44, df = 9 (P<0.00001); I2 =77%
Test for overall effect: Z = 2.11 (P = 0.035)
2 More than 12 weeks
Courneya 2003 24 2.3 (3.1) 28 0.8 (2.9) 12.8 % 0.49 [ -0.06, 1.05 ]
Cadmus 2009 37 0.3 (2.2) 37 -0.5 (3.3) 16.3 % 0.28 [ -0.18, 0.74 ]
Schmitz 2005 39 2.5 (4.4) 40 0.3 (3.9) 16.7 % 0.52 [ 0.08, 0.97 ]
Schmitz 2009 58 3.3 (23.2) 62 3.1 (17.2) 21.2 % 0.01 [ -0.35, 0.37 ]
Saarto 2012 263 1.2 (17.79) 237 1.9 (18.46) 32.9 % -0.04 [ -0.21, 0.14 ]
Subtotal (95% CI) 421 404 100.0 % 0.19 [ -0.05, 0.43 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.55, df = 4 (P = 0.07); I2 =53%
Test for overall effect: Z = 1.52 (P = 0.13)
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5 Overall physical function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 5 Overall physical function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Banasik 2011 7 -0.77 (0.94) 7 -0.42 (0.25) 2.7 % -0.48 [ -1.54, 0.59 ]
Herrero 2006 8 94.1 (7.5) 8 92.5 (6.6) 3.0 % 0.21 [ -0.77, 1.20 ]
Mustian 2004 9 26.89 (4.11) 10 26.5 (4.14) 3.3 % 0.09 [ -0.81, 0.99 ]
Pinto 2003 12 32.3 (4.3) 12 25.3 (8.2) 3.5 % 1.03 [ 0.17, 1.89 ]
Milne 2008 29 24 (2.6) 29 15.6 (4.5) 4.7 % 2.26 [ 1.59, 2.92 ]
Rogers 2009 20 23.3 (4.5) 18 25.4 (2.3) 4.8 % -0.57 [ -1.22, 0.08 ]
Cuesta-Vargas 2014 22 42.9 (4.06) 20 32.4 (32.48) 5.1 % 0.46 [ -0.16, 1.07 ]
Mehnert 2011 30 88.96 (9.13) 28 78.12 (21.22) 5.7 % 0.66 [ 0.13, 1.19 ]
Murtezani 2014 30 22.6 (4.4) 32 19.4 (4.4) 5.8 % 0.72 [ 0.20, 1.23 ]
Do 2015 32 89.4 (8.4) 30 89 (8.7) 6.0 % 0.05 [ -0.45, 0.54 ]
Daley 2007 33 25.61 (2.15) 33 23.61 (5.7) 6.0 % 0.46 [ -0.03, 0.95 ]
Pinto 2015 39 87.08 (4.4) 37 84.69 (15.91) 6.3 % 0.21 [ -0.25, 0.66 ]
Pinto 2005 39 30.26 (7.88) 43 27.33 (6.76) 6.5 % 0.40 [ -0.04, 0.83 ]
Loh 2014 63 24.92 (2.54) 32 24.17 (2.23) 6.5 % 0.30 [ -0.12, 0.73 ]
Fillion 2008 44 45.1 (10.42) 43 41.76 (9.76) 6.6 % 0.33 [ -0.10, 0.75 ]
Duijits 2012 87 84.03 (16.88) 89 80.18 (17.08) 7.6 % 0.23 [ -0.07, 0.52 ]
Rogers 2015 105 24.1 (3.5) 108 22.5 (5) 7.9 % 0.37 [ 0.10, 0.64 ]
Vallance 2007 250 25.1 (2.96) 85 24.95 (3.26) 8.0 % 0.05 [ -0.20, 0.30 ]
Subtotal (95% CI) 859 664 100.0 % 0.37 [ 0.17, 0.58 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 55.55, df = 17 (P<0.00001); I2 =69%
Test for overall effect: Z = 3.54 (P = 0.00040)
2 More than 12 weeks
Basen-Enquist 2006 28 82.5 (12.7) 23 77.4 (11.5) 8.3 % 0.41 [ -0.15, 0.97 ]
Courneya 2003 24 25.3 (2.5) 28 25.3 (2.8) 8.7 % 0.0 [ -0.55, 0.55 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Littman 2012 30 25.4 (1.7) 27 24.3 (4.4) 9.4 % 0.33 [ -0.19, 0.86 ]
Winters-Stone 2011 36 51.7 (6.2) 25 52.3 (5.9) 9.9 % -0.10 [ -0.61, 0.41 ]
Cadmus 2009 37 25.1 (2.7) 37 24 (4.1) 12.3 % 0.31 [ -0.15, 0.77 ]
Schmitz 2005 39 -44.2 (5.6) 40 -48.3 (7.7) 12.7 % 0.60 [ 0.15, 1.05 ]
Schmitz 2009 112 50.6 (8.15) 120 49.1 (9.32) 38.8 % 0.17 [ -0.09, 0.43 ]
Subtotal (95% CI) 306 300 100.0 % 0.24 [ 0.08, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.75, df = 6 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 2.89 (P = 0.0039)
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6 Overall physical function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 6 Overall physical function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Herrero 2006 8 6.7 (5) 8 -1.7 (6.9) 10.7 % 1.32 [ 0.21, 2.43 ]
Mustian 2004 9 1.89 (2.61) 10 -0.2 (1.61) 11.4 % 0.93 [ -0.03, 1.89 ]
Murtezani 2014 30 4.43 (1.53) 32 -1.34 (1.15) 11.7 % 4.23 [ 3.31, 5.15 ]
Naumann 2012 11 1.9 (3.3) 10 0.8 (3.4) 11.9 % 0.32 [ -0.55, 1.18 ]
Rogers 2009 20 2.3 (5.1) 18 2.6 (6) 13.0 % -0.05 [ -0.69, 0.58 ]
Cormie 2014 43 3.49 (5.15) 19 -0.5 (5.67) 13.4 % 0.74 [ 0.19, 1.30 ]
Mehnert 2011 30 3.96 (10.83) 28 -2.15 (16.7) 13.5 % 0.43 [ -0.09, 0.95 ]
Vallance 2007 247 1 (3.32) 85 0.19 (2.07) 14.4 % 0.26 [ 0.02, 0.51 ]
Subtotal (95% CI) 398 210 100.0 % 0.97 [ 0.27, 1.66 ]
Heterogeneity: Tau2 = 0.86; Chi2 = 73.76, df = 7 (P<0.00001); I2 =91%
Test for overall effect: Z = 2.72 (P = 0.0065)
2 More than 12 weeks
Courneya 2003 24 1.9 (2) 28 -0.2 (2.2) 14.4 % 0.98 [ 0.40, 1.56 ]
Cadmus 2009 37 0.1 (6.02) 37 -0.5 (7.42) 18.0 % 0.09 [ -0.37, 0.54 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 18.5 % -0.05 [ -0.49, 0.39 ]
Schmitz 2009 58 6.6 (17.1) 62 4.1 (17.3) 21.4 % 0.14 [ -0.21, 0.50 ]
Saarto 2012 263 1.9 (13.65) 237 3.4 (13.35) 27.7 % -0.11 [ -0.29, 0.06 ]
Subtotal (95% CI) 421 404 100.0 % 0.15 [ -0.16, 0.45 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 13.32, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 0.96 (P = 0.34)
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7 Overall role function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 7 Overall role function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Banasik 2011 7 3.46 (0.64) 7 3.24 (0.56) 4.7 % 0.34 [ -0.72, 1.40 ]
Herrero 2006 8 97.6 (5.9) 8 100 (0.01) 5.0 % -0.54 [ -1.55, 0.46 ]
Mustian 2004 9 2.44 (1.5) 9 2.8 (1.53) 5.4 % -0.23 [ -1.15, 0.70 ]
Loudon 2014 12 -1.3 (0.31) 11 -1.3 (0.36) 6.2 % 0.0 [ -0.82, 0.82 ]
Milne 2008 29 22.2 (3) 29 12.5 (4.8) 7.1 % 2.39 [ 1.71, 3.08 ]
Rogers 2009 20 21.4 (4.8) 18 23.8 (3.2) 7.4 % -0.57 [ -1.22, 0.08 ]
Mehnert 2011 30 90 (20.34) 27 79.6 (25.04) 8.4 % 0.45 [ -0.07, 0.98 ]
Murtezani 2014 30 24.2 (2.8) 32 23 (2.5) 8.6 % 0.45 [ -0.06, 0.95 ]
Do 2015 32 78.1 (19.5) 30 79.2 (14.6) 8.6 % -0.06 [ -0.56, 0.44 ]
Daley 2007 33 22.88 (4.52) 33 20.3 (5.57) 8.7 % 0.50 [ 0.01, 0.99 ]
Loh 2014 63 23.37 (4.33) 32 22.22 (4.99) 9.2 % 0.25 [ -0.18, 0.68 ]
Rogers 2015 105 22.3 (4.5) 108 20.3 (5.5) 10.3 % 0.40 [ 0.12, 0.67 ]
Vallance 2007 250 23.22 (3.98) 85 22.72 (4.58) 10.5 % 0.12 [ -0.13, 0.37 ]
Subtotal (95% CI) 628 429 100.0 % 0.30 [ -0.01, 0.60 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 53.08, df = 12 (P<0.00001); I2 =77%
Test for overall effect: Z = 1.92 (P = 0.054)
2 More than 12 weeks
Basen-Enquist 2006 28 86.1 (22.2) 23 73 (24.5) 15.8 % 0.55 [ -0.01, 1.12 ]
Courneya 2003 24 23.4 (4) 28 23.1 (4) 16.8 % 0.07 [ -0.47, 0.62 ]
Littman 2012 30 22.6 (3.9) 27 21.7 (4.7) 18.4 % 0.21 [ -0.31, 0.73 ]
Cadmus 2009 37 23.1 (4.7) 37 20.6 (7.2) 23.5 % 0.41 [ -0.05, 0.87 ]
Schmitz 2005 39 -49.2 (6.5) 40 -50 (6.2) 25.6 % 0.12 [ -0.32, 0.57 ]
Subtotal (95% CI) 158 155 100.0 % 0.27 [ 0.04, 0.49 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.29, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 2.33 (P = 0.020)
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Analysis 15.8. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome
8 Overall role function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 8 Overall role function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Herrero 2006 8 2.1 (13.9) 8 2.1 (5.9) 7.1 % 0.0 [ -0.98, 0.98 ]
Mustian 2004 9 0.56 (1.59) 10 0.8 (1.55) 7.9 % -0.15 [ -1.05, 0.76 ]
Naumann 2012 11 1.5 (4.41) 10 0.5 (4.49) 8.5 % 0.22 [ -0.64, 1.08 ]
Rogers 2009 20 0.4 (3.3) 18 1.4 (4.3) 12.0 % -0.26 [ -0.90, 0.38 ]
Cormie 2014 43 4.9 (7.1) 19 1.7 (7.1) 14.0 % 0.45 [ -0.10, 0.99 ]
Murtezani 2014 30 1.66 (0.71) 32 0.87 (0.64) 14.1 % 1.16 [ 0.62, 1.70 ]
Mehnert 2011 30 6.67 (23.84) 27 5.56 (27) 14.6 % 0.04 [ -0.48, 0.56 ]
Vallance 2007 250 0.63 (4.14) 85 -0.01 (2.7) 21.7 % 0.17 [ -0.08, 0.41 ]
Subtotal (95% CI) 401 209 100.0 % 0.24 [ -0.06, 0.55 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 15.72, df = 7 (P = 0.03); I2 =55%
Test for overall effect: Z = 1.56 (P = 0.12)
2 More than 12 weeks
Courneya 2003 24 0.9 (2.8) 28 0.4 (2.7) 7.3 % 0.18 [ -0.37, 0.73 ]
Cadmus 2009 37 -0.3 (3.7) 37 -0.5 (3.4) 10.5 % 0.06 [ -0.40, 0.51 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 11.2 % -0.05 [ -0.49, 0.39 ]
Saarto 2012 263 2.4 (21.51) 237 3.8 (21.6) 70.9 % -0.06 [ -0.24, 0.11 ]
Subtotal (95% CI) 363 342 100.0 % -0.03 [ -0.18, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.86, df = 3 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
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Analysis 15.9. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention, Outcome
9 Overall social well-being/function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 9 Overall social well-being/function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Banasik 2011 7 2.8 (0.67) 7 3.16 (0.83) 2.1 % -0.45 [ -1.51, 0.62 ]
Herrero 2006 8 87.5 (19.4) 8 91.7 (23.6) 2.4 % -0.18 [ -1.17, 0.80 ]
Mustian 2004 9 8.63 (1.89) 10 9 (1.83) 2.8 % -0.19 [ -1.09, 0.71 ]
Rogers 2014 20 7.3 (4.9) 22 3.1 (3.2) 5.0 % 1.01 [ 0.36, 1.65 ]
Rogers 2009 20 22.6 (4.1) 18 21.8 (5.7) 5.1 % 0.16 [ -0.48, 0.80 ]
Milne 2008 29 20.7 (4) 29 19.4 (3.9) 7.0 % 0.32 [ -0.19, 0.84 ]
Mehnert 2011 30 85.35 (20.88) 28 79.91 (22.65) 7.0 % 0.25 [ -0.27, 0.76 ]
Murtezani 2014 30 20.2 (2.8) 32 18.3 (2.7) 7.1 % 0.68 [ 0.17, 1.20 ]
Daley 2007 33 23.3 (4.78) 33 20.4 (6.8) 7.6 % 0.49 [ 0.00, 0.98 ]
Loh 2014 63 21.48 (4.88) 32 19.61 (4.9) 9.1 % 0.38 [ -0.05, 0.81 ]
Kiecolt-Glaser 2014 96 95.2 (10.8) 90 93.8 (9.3) 14.0 % 0.14 [ -0.15, 0.43 ]
Rogers 2015 105 21 (5.7) 108 20.7 (5.8) 14.9 % 0.05 [ -0.22, 0.32 ]
Vallance 2007 250 22.94 (4.96) 85 22.96 (5.05) 15.9 % 0.00 [ -0.25, 0.24 ]
Subtotal (95% CI) 700 502 100.0 % 0.23 [ 0.06, 0.39 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 18.26, df = 12 (P = 0.11); I2 =34%
Test for overall effect: Z = 2.74 (P = 0.0061)
2 More than 12 weeks
Basen-Enquist 2006 28 84.6 (16.93) 23 84.9 (19.18) 14.3 % -0.02 [ -0.57, 0.54 ]
Courneya 2003 24 21.1 (3.5) 28 20.7 (3.6) 14.6 % 0.11 [ -0.43, 0.66 ]
Littman 2012 30 22.1 (5) 27 20.9 (6) 16.0 % 0.22 [ -0.31, 0.74 ]
Cadmus 2009 37 22.3 (4.9) 37 20.6 (7.2) 20.8 % 0.27 [ -0.18, 0.73 ]
Schmitz 2009 59 14.9 (5.2) 62 14.1 (5.8) 34.2 % 0.14 [ -0.21, 0.50 ]
Subtotal (95% CI) 178 177 100.0 % 0.15 [ -0.05, 0.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.71, df = 4 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
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Analysis 15.10. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 10 Overall social well-being/function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 10 Overall social well-being/function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Mustian 2004 9 1.5 (1.5) 10 0.44 (1.17) 8.7 % 0.76 [ -0.18, 1.70 ]
Naumann 2012 11 0.9 (3.32) 10 -0.2 (3.32) 9.5 % 0.32 [ -0.54, 1.18 ]
Rogers 2009 20 0.9 (2.6) 18 -1.2 (2.7) 11.9 % 0.78 [ 0.11, 1.44 ]
Rogers 2014 20 2.1 (3.2) 22 -0.8 (3.5) 12.3 % 0.85 [ 0.21, 1.48 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 12.8 % 1.80 [ 1.21, 2.40 ]
Cormie 2014 43 3.5 (8.5) 19 2.5 (8.3) 13.6 % 0.12 [ -0.42, 0.66 ]
Mehnert 2011 30 7.33 (22.33) 28 3.12 (24.3) 13.9 % 0.18 [ -0.34, 0.69 ]
Vallance 2007 250 0.21 (4.82) 85 -4.15 (3.34) 17.2 % 0.97 [ 0.71, 1.23 ]
Subtotal (95% CI) 413 224 100.0 % 0.73 [ 0.35, 1.11 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 25.43, df = 7 (P = 0.00064); I2 =72%
Test for overall effect: Z = 3.77 (P = 0.00016)
2 More than 12 weeks
Courneya 2003 24 0.6 (2.4) 28 -0.5 (3.3) 17.5 % 0.37 [ -0.18, 0.92 ]
Cadmus 2009 37 0.6 (4.6) 37 -1 (3.2) 21.1 % 0.40 [ -0.06, 0.86 ]
Schmitz 2009 59 4.4 (33.8) 62 0.7 (34) 26.0 % 0.11 [ -0.25, 0.47 ]
Saarto 2012 263 5 (21.1) 237 8.8 (20.81) 35.4 % -0.18 [ -0.36, -0.01 ]
Subtotal (95% CI) 383 364 100.0 % 0.11 [ -0.19, 0.42 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 8.78, df = 3 (P = 0.03); I2 =66%
Test for overall effect: Z = 0.72 (P = 0.47)
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Analysis 15.11. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 11 Overall cognitive function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 11 Overall cognitive function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Pinto 2003 12 -4.33 (2.5) 6 -7.17 (2.1) 7.5 % 1.14 [ 0.07, 2.20 ]
Herrero 2006 8 91.7 (12.6) 8 89.6 (12.4) 8.8 % 0.16 [ -0.82, 1.14 ]
Rogers 2009 19 -124.5 (30.8) 18 -135.5 (19.5) 20.0 % 0.42 [ -0.24, 1.07 ]
Mehnert 2011 30 81.1 (16.8) 27 78.4 (24.38) 31.4 % 0.13 [ -0.39, 0.65 ]
Cantarero-Villanueva 2013 32 -37.93 (8.48) 29 -43.03 (10.01) 32.4 % 0.55 [ 0.03, 1.06 ]
Subtotal (95% CI) 101 88 100.0 % 0.40 [ 0.11, 0.69 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.41, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.68 (P = 0.0074)
2 More than 12 weeks
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 15.12. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 12 Overall cognitive function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 12 Overall cognitive function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Herrero 2006 8 6.2 (19.8) 8 8.3 (14.8) 9.7 % -0.11 [ -1.09, 0.87 ]
Rogers 2009 20 4.2 (16.8) 18 -4.7 (25.9) 22.1 % 0.40 [ -0.24, 1.05 ]
Mehnert 2011 30 1.67 (22.36) 27 6.18 (24.6) 33.2 % -0.19 [ -0.71, 0.33 ]
Cantarero-Villanueva 2013 32 2.2 (7.63) 29 -0.18 (5.5471) 35.1 % 0.35 [ -0.16, 0.86 ]
Subtotal (95% CI) 90 82 100.0 % 0.14 [ -0.17, 0.44 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 3.10, df = 3 (P = 0.38); I2 =3%
Test for overall effect: Z = 0.88 (P = 0.38)
2 More than 12 weeks
Saarto 2012 263 -1 (18.2) 237 2.2 (18.46) 100.0 % -0.17 [ -0.35, 0.00 ]
Subtotal (95% CI) 263 237 100.0 % -0.17 [ -0.35, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.94 (P = 0.052)
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Analysis 15.13. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 13 Overall general health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 13 Overall general health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 7.5 % 1.30 [ 0.19, 2.41 ]
Mustian 2004 9 18.6 (4.77) 9 19.3 (1.92) 10.0 % -0.18 [ -1.11, 0.74 ]
Rogers 2009 20 3.5 (0.9) 18 3.8 (0.5) 16.9 % -0.40 [ -1.04, 0.25 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 21.0 % 0.19 [ -0.35, 0.73 ]
Mehnert 2011 30 74.38 (11.84) 28 70.01 (20.81) 21.9 % 0.26 [ -0.26, 0.77 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 22.7 % 0.28 [ -0.22, 0.79 ]
Subtotal (95% CI) 139 113 100.0 % 0.17 [ -0.16, 0.50 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 7.85, df = 5 (P = 0.16); I2 =36%
Test for overall effect: Z = 1.03 (P = 0.31)
2 More than 12 weeks
Basen-Enquist 2006 28 77.4 (11.64) 23 67.1 (13.43) 30.2 % 0.81 [ 0.24, 1.39 ]
Cadmus 2009 37 50 (8.8) 37 51.7 (8.4) 34.6 % -0.20 [ -0.65, 0.26 ]
Schmitz 2005 39 53.8 (5.3) 40 53.2 (6) 35.2 % 0.10 [ -0.34, 0.55 ]
Subtotal (95% CI) 104 100 100.0 % 0.21 [ -0.32, 0.75 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 7.33, df = 2 (P = 0.03); I2 =73%
Test for overall effect: Z = 0.78 (P = 0.44)
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Analysis 15.14. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 14 Overall general health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 14 Overall general health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 7.4 % 1.92 [ 0.68, 3.17 ]
Mustian 2004 9 0.22 (1.92) 10 0.68 (2.5) 11.8 % -0.20 [ -1.10, 0.71 ]
Rogers 2009 20 0.15 (0.6) 18 0.17 (0.7) 17.8 % -0.03 [ -0.67, 0.61 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 20.6 % 0.52 [ -0.03, 1.06 ]
Cormie 2014 43 3.7 (7) 19 2.8 (7.1) 20.8 % 0.13 [ -0.41, 0.67 ]
Mehnert 2011 30 6.6 (13.7) 28 3.24 (19.7) 21.5 % 0.20 [ -0.32, 0.71 ]
Subtotal (95% CI) 150 103 100.0 % 0.29 [ -0.09, 0.67 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 9.79, df = 5 (P = 0.08); I2 =49%
Test for overall effect: Z = 1.49 (P = 0.14)
2 More than 12 weeks
Cadmus 2009 37 0.2 (4.4) 37 -0.1 (5.1) 17.9 % 0.06 [ -0.39, 0.52 ]
Schmitz 2005 39 0.7 (4.8) 40 -0.6 (3.9) 18.8 % 0.29 [ -0.15, 0.74 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 63.3 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 339 314 100.0 % 0.01 [ -0.20, 0.22 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.64, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.10 (P = 0.92)
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Analysis 15.15. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 15 Overall sexual function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 15 Overall sexual function (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 12 weeks or less
Pinto 2005 12 42.75 (9.2) 6 43.7 (6.1) 7.5 % -0.11 [ -1.09, 0.87 ]
Pinto 2003 39 42.45 (9.24) 43 40.12 (6.3) 37.9 % 0.29 [ -0.14, 0.73 ]
Duijits 2012 53 0.6 (0.79) 65 0.59 (0.79) 54.7 % 0.01 [ -0.35, 0.38 ]
Subtotal (95% CI) 104 114 100.0 % 0.11 [ -0.16, 0.38 ]
Heterogeneity: Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
2 More than 12 weeks
Schmitz 2005 39 -51 (7.5) 40 -53.5 (8) 40.7 % 0.32 [ -0.12, 0.76 ]
Schmitz 2009 57 -27.3 (5.3) 57 -28.1 (6.2) 59.3 % 0.14 [ -0.23, 0.51 ]
Subtotal (95% CI) 96 97 100.0 % 0.21 [ -0.07, 0.49 ]
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
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Analysis 15.16. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 16 Overall sexual function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 16 Overall sexual function (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 More than 12 weeks
Schmitz 2009 57 7.2 (14.6) 57 -0.2 (16.7) 20.9 % 7.40 [ 1.64, 13.16 ]
Saarto 2012 263 4.3 (25.38) 237 3.8 (24.35) 29.4 % 0.50 [ -3.86, 4.86 ]
Schmitz 2005 39 1.7 (4.8) 40 0.2 (5.2) 49.7 % 1.50 [ -0.71, 3.71 ]
Subtotal (95% CI) 359 334 100.0 % 2.44 [ -0.76, 5.64 ]
Heterogeneity: Tau2 = 4.09; Chi2 = 4.03, df = 2 (P = 0.13); I2 =50%
Test for overall effect: Z = 1.50 (P = 0.13)
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Analysis 15.17. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 17 Overall sleep (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 17 Overall sleep (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 12 weeks or less
Rogers 2013 11 6.3 (2.7) 9 6.2 (3.2) 10.7 % 0.03 [ -0.85, 0.91 ]
Bower 2011 16 8.1 (2.5) 15 7.7 (2.6) 16.7 % 0.15 [ -0.55, 0.86 ]
Rogers 2009 20 6.65 (4.17) 18 5.5 (4) 20.3 % 0.28 [ -0.36, 0.92 ]
Rogers 2014 20 6.7 (3.7) 22 7.1 (3.2) 22.6 % -0.11 [ -0.72, 0.49 ]
Mehnert 2011 30 23.75 (27) 27 38.27 (31.63) 29.8 % -0.49 [ -1.02, 0.04 ]
Subtotal (95% CI) 97 91 100.0 % -0.09 [ -0.37, 0.20 ]
Heterogeneity: Chi2 = 3.98, df = 4 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.56)
2 More than 12 weeks
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 15.18. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 18 Overall sleep (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 18 Overall sleep (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Rogers 2009 20 0.45 (2.1) 18 0.28 (4.7) 28.0 % 0.05 [ -0.59, 0.68 ]
Rogers 2014 20 -1.3 (3.2) 22 -2.2 (4.4) 30.8 % 0.23 [ -0.38, 0.84 ]
Mehnert 2011 29 -5.36 (29.88) 27 -9.88 (33.3) 41.2 % 0.14 [ -0.38, 0.67 ]
Subtotal (95% CI) 69 67 100.0 % 0.14 [ -0.20, 0.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
2 More than 12 weeks
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 15.19. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 19 Overall anxiety (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 19 Overall anxiety (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Segar 1998 10 28.5 (3) 5 39.5 (6) 6.4 % -2.49 [ -3.98, -1.00 ]
Pinto 2003 12 7.58 (7.3) 6 10.5 (3.7) 11.5 % -0.43 [ -1.43, 0.56 ]
Rogers 2014 20 45.6 (8.9) 22 45.7 (8) 19.1 % -0.01 [ -0.62, 0.59 ]
Milne 2008 29 15.3 (6.2) 29 21 (5.7) 20.6 % -0.94 [ -1.49, -0.40 ]
Mehnert 2011 30 4.83 (3.46) 28 7.14 (4.97) 21.2 % -0.54 [ -1.06, -0.01 ]
Cantarero-Villanueva 2013 32 42.51 (8.6) 29 49.93 (11.7) 21.3 % -0.72 [ -1.24, -0.20 ]
Subtotal (95% CI) 133 119 100.0 % -0.67 [ -1.09, -0.25 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 11.63, df = 5 (P = 0.04); I2 =57%
Test for overall effect: Z = 3.12 (P = 0.0018)
2 More than 12 weeks
Cadmus 2009 37 32.1 (12.3) 37 34.1 (15.4) 100.0 % -0.14 [ -0.60, 0.31 ]
Subtotal (95% CI) 37 37 100.0 % -0.14 [ -0.60, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
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Analysis 15.20. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 20 Overall anxiety (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 20 Overall anxiety (change values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 12 weeks or less
Rogers 2014 20 -4 (6.5) 22 -1.8 (5) 26.4 % -0.37 [ -0.99, 0.24 ]
Mehnert 2011 30 -1.67 (3.68) 28 0.18 (4.89) 36.3 % -0.42 [ -0.95, 0.10 ]
Cantarero-Villanueva 2013 32 -4.2 (9.8) 29 0.75 (5.5) 37.3 % -0.61 [ -1.12, -0.09 ]
Subtotal (95% CI) 82 79 100.0 % -0.48 [ -0.79, -0.16 ]
Heterogeneity: Chi2 = 0.39, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 2.99 (P = 0.0028)
2 More than 12 weeks
Cadmus 2009 37 -0.7 (9.2) 37 0.5 (5.8) 100.0 % -0.15 [ -0.61, 0.30 ]
Subtotal (95% CI) 37 37 100.0 % -0.15 [ -0.61, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
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Analysis 15.21. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 21 Overall depression (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 21 Overall depression (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Segar 1998 10 5.5 (2) 5 10 (2) 4.6 % -2.12 [ -3.51, -0.73 ]
Pinto 2003 12 6.17 (7.2) 6 9.83 (6.8) 7.2 % -0.49 [ -1.49, 0.50 ]
Bower 2011 16 7.7 (5.8) 15 11.6 (7.1) 10.1 % -0.59 [ -1.31, 0.13 ]
Rogers 2014 20 44.2 (8.6) 22 25.1 (44.2) 11.4 % 0.58 [ -0.04, 1.19 ]
Ergun 2013 40 6.88 (6.76) 20 5.15 (5.18) 12.5 % 0.27 [ -0.27, 0.81 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 12.7 % -0.51 [ -1.04, 0.01 ]
Cantarero-Villanueva 2013 32 45.58 (9.68) 29 53.71 (11.6) 12.7 % -0.75 [ -1.28, -0.23 ]
Daley 2007 33 6 (6.47) 33 10.33 (7.19) 13.1 % -0.63 [ -1.12, -0.13 ]
Kiecolt-Glaser 2014 96 8.1 (8.6) 90 9.2 (8.2) 15.9 % -0.13 [ -0.42, 0.16 ]
Subtotal (95% CI) 289 248 100.0 % -0.36 [ -0.70, -0.01 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 25.79, df = 8 (P = 0.001); I2 =69%
Test for overall effect: Z = 2.02 (P = 0.044)
2 More than 12 weeks
Payne 2008 10 12.7 (8.7) 10 11.4 (7.9) 26.4 % 0.15 [ -0.73, 1.03 ]
Kaltsatou 2011 13 16.54 (1.66) 13 22.33 (7.73) 28.3 % -1.00 [ -1.83, -0.18 ]
Cadmus 2009 37 9.6 (9.3) 37 10.8 (10.1) 45.3 % -0.12 [ -0.58, 0.33 ]
Subtotal (95% CI) 60 60 100.0 % -0.30 [ -0.90, 0.30 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 4.31, df = 2 (P = 0.12); I2 =54%
Test for overall effect: Z = 0.99 (P = 0.32)
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Analysis 15.22. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 22 Overall depression (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 22 Overall depression (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Naumann 2012 11 -3.6 (4.34) 10 2 (4.55) 9.9 % -1.21 [ -2.16, -0.26 ]
Rogers 2014 20 -1.7 (6.9) 22 1.1 (4.2) 23.6 % -0.49 [ -1.10, 0.13 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 32.5 % -0.51 [ -1.04, 0.01 ]
Cantarero-Villanueva 2013 32 -2.95 (7.82) 29 1.46 (7.36) 33.9 % -0.57 [ -1.09, -0.06 ]
Subtotal (95% CI) 93 89 100.0 % -0.60 [ -0.89, -0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.84, df = 3 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 3.91 (P = 0.000093)
2 More than 12 weeks
Cadmus 2009 37 0.3 (6.4) 37 1.7 (6.3) 20.0 % -0.22 [ -0.68, 0.24 ]
Saarto 2012 263 -0.3 (3.31) 237 -0.5 (3.38) 80.0 % 0.06 [ -0.12, 0.24 ]
Subtotal (95% CI) 300 274 100.0 % 0.00 [ -0.21, 0.22 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.24, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 0.04 (P = 0.97)
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Analysis 15.23. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 23 Overall fatigue (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 23 Overall fatigue (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Banasik 2011 7 1 (0.89) 7 1.57 (0.98) 2.0 % -0.57 [ -1.65, 0.51 ]
Pinto 2003 12 7.16 (6.4) 6 9 (6.4) 2.3 % -0.27 [ -1.26, 0.71 ]
Rogers 2013 11 4.2 (1.8) 9 4.2 (1.6) 2.7 % 0.0 [ -0.88, 0.88 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 3.0 % -0.07 [ -0.89, 0.75 ]
Bower 2011 16 3.4 (1.8) 15 4.9 (1.3) 3.4 % -0.93 [ -1.67, -0.18 ]
Rogers 2009 20 -12.4 (10.4) 18 -10.1 (6.6) 4.2 % -0.26 [ -0.90, 0.38 ]
Cuesta-Vargas 2014 22 4 (1.8) 20 5.2 (3.2) 4.4 % -0.46 [ -1.07, 0.15 ]
Rogers 2014 20 4.1 (2.1) 22 4 (1.8) 4.4 % 0.05 [ -0.56, 0.66 ]
Milne 2008 29 11.9 (3.2) 29 17.4 (4.7) 4.7 % -1.35 [ -1.92, -0.78 ]
Cantarero-Villanueva 2013 32 3.78 (1.78) 29 6.23 (1.72) 4.8 % -1.38 [ -1.94, -0.82 ]
Ergun 2013 40 2.94 (2.24) 20 3.3 (1.79) 5.0 % -0.17 [ -0.71, 0.37 ]
Mehnert 2011 30 28.52 (25.58) 27 39.92 (25.09) 5.1 % -0.44 [ -0.97, 0.08 ]
Do 2015 32 16.8 (13.3) 30 22.3 (15.1) 5.4 % -0.38 [ -0.89, 0.12 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 5.4 % -0.71 [ -1.21, -0.21 ]
Pinto 2015 39 -43.83 (7.8) 37 -41.22 (8.49) 5.9 % -0.32 [ -0.77, 0.14 ]
Pinto 2005 39 27.08 (21.41) 43 42.28 (26.2) 6.0 % -0.63 [ -1.07, -0.18 ]
Fillion 2008 44 2.65 (0.72) 43 2.86 (0.83) 6.3 % -0.27 [ -0.69, 0.15 ]
Kiecolt-Glaser 2014 96 6.3 (19.6) 90 12.7 (18.97) 7.9 % -0.33 [ -0.62, -0.04 ]
Vallance 2007 250 -42.7 (8.4) 85 -42.6 (8.7) 8.4 % -0.01 [ -0.26, 0.23 ]
Short 2014 195 -41.5 (9.3) 104 -39.8 (10.4) 8.5 % -0.17 [ -0.41, 0.06 ]
Subtotal (95% CI) 979 678 100.0 % -0.42 [ -0.59, -0.25 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 43.47, df = 19 (P = 0.001); I2 =56%
Test for overall effect: Z = 4.82 (P < 0.00001)
2 More than 12 weeks
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Payne 2008 9 4.7 (2.6) 9 3.5 (1.7) 6.5 % 0.52 [ -0.42, 1.46 ]
Courneya 2003 24 -8.3 (7.9) 28 -8.8 (8.1) 19.5 % 0.06 [ -0.48, 0.61 ]
Littman 2012 30 -45 (5.3) 27 -43.1 (10.3) 21.3 % -0.23 [ -0.75, 0.29 ]
Winters-Stone 2011 36 45 (5.3) 31 43.1 (10.3) 24.9 % 0.23 [ -0.25, 0.72 ]
Cadmus 2009 37 -51.9 (9) 37 -50.6 (10) 27.8 % -0.14 [ -0.59, 0.32 ]
Subtotal (95% CI) 136 132 100.0 % 0.02 [ -0.22, 0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.21, df = 4 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
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Analysis 15.24. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 24 Overall fatigue (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 24 Overall fatigue (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Herrero 2006 8 -4.2 (19.6) 8 6.4 (14.5) 7.2 % -0.58 [ -1.59, 0.43 ]
Naumann 2012 11 -3.6 (4.35) 10 2 (4.55) 7.6 % -1.21 [ -2.16, -0.26 ]
Rogers 2013 11 4.2 (2) 9 3.9 (1.5) 8.1 % 0.16 [ -0.72, 1.04 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 8.6 % -0.07 [ -0.89, 0.75 ]
Rogers 2009 20 1.9 (9.6) 18 4.2 (12.3) 10.1 % -0.21 [ -0.84, 0.43 ]
Cantarero-Villanueva 2013 32 -2 (1.75) 29 0.34 (1.39) 10.7 % -1.45 [ -2.02, -0.88 ]
Mehnert 2011 30 -0.74 (20.73) 27 -2.88 (25.3) 11.2 % 0.09 [ -0.43, 0.61 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 11.3 % -0.71 [ -1.21, -0.21 ]
Pinto 2005 39 -14.93 (23.54) 43 1.79 (23.48) 11.8 % -0.70 [ -1.15, -0.26 ]
Vallance 2007 250 2.49 (8.17) 85 1.15 (6.61) 13.2 % 0.17 [ -0.08, 0.42 ]
Subtotal (95% CI) 446 273 100.0 % -0.44 [ -0.83, -0.05 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 42.74, df = 9 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.19 (P = 0.029)
2 More than 12 weeks
Courneya 2003 24 9.3 (10.2) 28 2 (7.5) 44.2 % 0.81 [ 0.24, 1.38 ]
Saarto 2012 263 -2.4 (9.06) 237 -2.4 (8.6) 55.8 % 0.0 [ -0.18, 0.18 ]
Subtotal (95% CI) 287 265 100.0 % 0.36 [ -0.43, 1.15 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 7.16, df = 1 (P = 0.01); I2 =86%
Test for overall effect: Z = 0.89 (P = 0.37)
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Analysis 15.25. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 25 Overall pain/disability (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 25 Overall pain/disability (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Mustian 2004 9 9.11 (1.35) 10 9.1 (1.74) 5.1 % 0.01 [ -0.89, 0.91 ]
Loudon 2014 12 0.8 (1.48) 11 1.44 (2.24) 6.0 % -0.33 [ -1.15, 0.50 ]
Rogers 2009 20 -3.03 (2.98) 18 -2.28 (2.76) 10.0 % -0.26 [ -0.89, 0.38 ]
Mehnert 2011 30 79.4 (23.1) 28 73.5 (24.83) 15.4 % 0.24 [ -0.27, 0.76 ]
Do 2015 32 21.1 (24.6) 30 16.5 (26.7) 16.5 % 0.18 [ -0.32, 0.68 ]
Duijits 2012 87 79.27 (23.59) 89 78.79 (23.78) 47.0 % 0.02 [ -0.28, 0.32 ]
Subtotal (95% CI) 190 186 100.0 % 0.03 [ -0.17, 0.23 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.48, df = 5 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.76)
2 More than 12 weeks
Portela 2008 25 -20.6 (20.2) 9 -20.8 (15.5) 24.9 % 0.01 [ -0.75, 0.77 ]
Basen-Enquist 2006 28 79.7 (10.58) 23 72.1 (11.51) 34.1 % 0.68 [ 0.11, 1.25 ]
Cadmus 2009 37 50.3 (9.1) 37 50.8 (9) 41.0 % -0.05 [ -0.51, 0.40 ]
Subtotal (95% CI) 90 69 100.0 % 0.21 [ -0.27, 0.70 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 4.17, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 0.86 (P = 0.39)
-4 -2 0 2 4
Favours control Favours physical activity
708Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 15.26. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 26 Overall pain/disability (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 26 Overall pain/disability (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Mustian 2004 9 -0.22 (1.29) 10 0 (1.42) 14.6 % -0.15 [ -1.06, 0.75 ]
Cormie 2014 43 3.4 (6.5) 19 2 (6.2) 40.7 % 0.22 [ -0.33, 0.76 ]
Mehnert 2011 30 -2.4 (24.95) 28 -7.61 (25.2) 44.7 % 0.21 [ -0.31, 0.72 ]
Subtotal (95% CI) 82 57 100.0 % 0.16 [ -0.19, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
2 More than 12 weeks
Cadmus 2009 37 -2.2 (11.3) 37 -0.1 (7) 47.6 % -0.22 [ -0.68, 0.24 ]
Irwin 2015 45 -6 (18.97) 38 0.7 (18.56) 52.4 % -0.35 [ -0.79, 0.08 ]
Subtotal (95% CI) 82 75 100.0 % -0.29 [ -0.61, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.071)
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Analysis 15.27. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 27 Overall self-esteem/body image (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 27 Overall self-esteem/body image (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Segar 1998 10 33 (1.8) 5 30.5 (2.7) 5.0 % 1.11 [ -0.06, 2.28 ]
Pinto 2003 12 32.3 (4.3) 6 25.3 (8.2) 5.8 % 1.15 [ 0.08, 2.22 ]
Loudon 2014 12 -1.43 (0.33) 11 -1.56 (0.86) 8.3 % 0.20 [ -0.62, 1.02 ]
Musanti 2012 30 23.83 (3.48) 12 26.33 (3.94) 10.4 % -0.68 [ -1.37, 0.01 ]
Mehnert 2011 27 -5.47 (1.66) 27 -6.82 (2.6) 13.1 % 0.61 [ 0.06, 1.16 ]
Milne 2008 29 -17.9 (6.8) 29 -20.1 (6.3) 13.7 % 0.33 [ -0.19, 0.85 ]
Daley 2007 33 2.03 (0.83) 32 1.57 (0.5) 14.1 % 0.66 [ 0.16, 1.16 ]
Do 2015 (1) 32 37.9 (18.9) 30 36.1 (18.3) 14.1 % 0.10 [ -0.40, 0.59 ]
Pinto 2005 39 30.26 (7.82) 43 27.23 (6.76) 15.6 % 0.41 [ -0.03, 0.85 ]
Subtotal (95% CI) 224 195 100.0 % 0.36 [ 0.07, 0.66 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 15.97, df = 8 (P = 0.04); I2 =50%
Test for overall effect: Z = 2.42 (P = 0.015)
2 More than 12 weeks
Courneya 2003 24 34.8 (4.7) 28 34.6 (4.4) 20.9 % 0.04 [ -0.50, 0.59 ]
Cadmus 2009 37 34.2 (5.5) 37 33.4 (5.9) 29.8 % 0.14 [ -0.32, 0.60 ]
Schmitz 2009 59 -70.4 (16.3) 63 -71.5 (18) 49.3 % 0.06 [ -0.29, 0.42 ]
Subtotal (95% CI) 120 128 100.0 % 0.08 [ -0.17, 0.33 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 2 (P = 0.96); I2 =0.0%
Test for overall effect: Z = 0.64 (P = 0.52)
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Analysis 15.28. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 28 Overall self-esteem/body image (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 28 Overall self-esteem/body image (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Mustian 2004 11 3 (1) 10 -1.5 (1.5) 11.4 % 3.42 [ 1.99, 4.86 ]
Musanti 2012 30 -0.4 (4.53) 12 0.58 (3.92) 20.5 % -0.22 [ -0.89, 0.45 ]
Mehnert 2011 30 0.73 (2.12) 27 0.39 (2.12) 22.5 % 0.16 [ -0.36, 0.68 ]
Milne 2008 29 1.5 (3.7) 29 0.1 (3.9) 22.5 % 0.36 [ -0.16, 0.88 ]
Daley 2007 33 1.79 (0.71) 33 1.56 (0.67) 23.0 % 0.33 [ -0.16, 0.82 ]
Subtotal (95% CI) 133 111 100.0 % 0.54 [ -0.10, 1.18 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 20.91, df = 4 (P = 0.00033); I2 =81%
Test for overall effect: Z = 1.64 (P = 0.10)
2 More than 12 weeks
Courneya 2003 24 2.6 (3.7) 28 -0.1 (3.5) 19.5 % 0.74 [ 0.18, 1.30 ]
Cadmus 2009 37 0.4 (4.4) 37 0.2 (2.9) 22.9 % 0.05 [ -0.40, 0.51 ]
Schmitz 2009 59 -12 (15.5) 63 -4.1 (16.2) 26.0 % -0.49 [ -0.86, -0.13 ]
Saarto 2012 263 10.7 (21.51) 237 12 (21.99) 31.6 % -0.06 [ -0.24, 0.12 ]
Subtotal (95% CI) 383 365 100.0 % 0.01 [ -0.37, 0.39 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 13.52, df = 3 (P = 0.004); I2 =78%
Test for overall effect: Z = 0.04 (P = 0.96)
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Analysis 15.29. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 29 Overall cardiorespiratory fitness (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 29 Overall cardiorespiratory fitness (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Herrero 2006 8 25.9 (4.5) 8 25.7 (3.7) 2.2 % 0.05 [ -0.93, 1.03 ]
Mustian 2004 11 636.1 (50.6) 10 610.3 (75.9) 2.7 % 0.39 [ -0.48, 1.25 ]
Rogers 2013 12 23.9 (6.2) 10 23.9 (3.8) 2.9 % 0.0 [ -0.84, 0.84 ]
Nikander 2007 14 -17.6 (1.3) 14 -17.2 (1.4) 3.6 % -0.29 [ -1.03, 0.46 ]
Musanti 2012 30 24.6 (4.93) 12 23 (4.29) 4.4 % 0.33 [ -0.34, 1.00 ]
Rogers 2014 20 30.9 (6.3) 22 25.1 (5) 4.7 % 1.01 [ 0.36, 1.65 ]
Rogers 2009 20 29.5 (6.6) 18 27.6 (6.1) 4.8 % 0.29 [ -0.35, 0.93 ]
Mehnert 2011 27 26.9 (4.4) 23 25.7 (4.7) 6.1 % 0.26 [ -0.30, 0.82 ]
Do 2015 30 31.7 (12.4) 30 24.5 (6.6) 6.8 % 0.72 [ 0.19, 1.24 ]
Milne 2008 29 1.49 (0.31) 29 1.48 (0.43) 7.0 % 0.03 [ -0.49, 0.54 ]
Murtezani 2014 30 875.1 (86.7) 32 823.5 (87.1) 7.2 % 0.59 [ 0.08, 1.10 ]
Pinto 2005 39 -16.34 (2.09) 43 -17.85 (2.24) 8.9 % 0.69 [ 0.24, 1.14 ]
Fillion 2008 44 27.04 (4.39) 43 26.53 (5.81) 9.9 % 0.10 [ -0.32, 0.52 ]
Daley 2007 33 34.99 (4.42) 69 33.05 (5.3) 10.0 % 0.38 [ -0.04, 0.80 ]
Rogers 2015 105 23.6 (4.8) 108 22.7 (0.3) 18.8 % 0.27 [ 0.00, 0.54 ]
Subtotal (95% CI) 452 471 100.0 % 0.35 [ 0.20, 0.49 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 16.15, df = 14 (P = 0.30); I2 =13%
Test for overall effect: Z = 4.60 (P < 0.00001)
2 More than 12 weeks
Cerulli 2014 10 31.29 (4.95) 10 32.26 (10.1) 7.9 % -0.12 [ -0.99, 0.76 ]
Portela 2008 25 3006.96 (410.8) 9 2416.1 (718.6) 8.9 % 1.14 [ 0.33, 1.96 ]
Kaltsatou 2011 14 483.33 (85.95) 13 403.08 (71.92) 9.1 % 0.98 [ 0.17, 1.78 ]
Rahnama 2010 14 20.65 (5.73) 15 13.85 (5.18) 9.1 % 1.21 [ 0.41, 2.01 ]
Kim 2015 20 424.8 (55.8) 19 394.4 (54) 12.8 % 0.54 [ -0.10, 1.18 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Courneya 2003 24 21.3 (3.7) 26 18.2 (3.9) 14.8 % 0.80 [ 0.22, 1.38 ]
Basen-Enquist 2006 35 1643 (122.5) 25 1546 (127.5) 16.5 % 0.77 [ 0.24, 1.30 ]
Irwin 2015 45 24.6 (5.5) 38 23 (4.7) 20.9 % 0.31 [ -0.13, 0.74 ]
Subtotal (95% CI) 187 155 100.0 % 0.67 [ 0.40, 0.94 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 9.80, df = 7 (P = 0.20); I2 =29%
Test for overall effect: Z = 4.84 (P < 0.00001)
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Analysis 15.30. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 30 Overall cardiorespiratory fitness (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 30 Overall cardiorespiratory fitness (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Nieman 1995 6 60.8 (8.4) 6 12 (17.8) 7.0 % 3.24 [ 1.29, 5.18 ]
Naumann 2012 11 3.1 (2.9) 10 -0.1 (3.1) 15.8 % 1.03 [ 0.10, 1.95 ]
Dolan 2016 23 12.2 (10.2) 10 -5.97 (7.2) 16.3 % 1.88 [ 0.99, 2.77 ]
Musanti 2012 30 1 (3.1) 12 0.9 (3.4) 19.1 % 0.03 [ -0.64, 0.70 ]
Rogers 2014 20 2.8 (4.9) 22 1.1 (4.2) 19.9 % 0.37 [ -0.24, 0.98 ]
Pinto 2005 39 1.35 (2.4) 43 -0.25 (2.5) 22.0 % 0.65 [ 0.20, 1.09 ]
Subtotal (95% CI) 129 103 100.0 % 0.91 [ 0.31, 1.52 ]
Heterogeneity: Tau2 = 0.38; Chi2 = 18.87, df = 5 (P = 0.002); I2 =74%
-10 -5 0 5 10
Favours control Favours physical activity
(Continued . . . )
713Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 2.96 (P = 0.0031)
2 More than 12 weeks
Courneya 2003 24 2.7 (2.6) 26 -0.6 (1.7) 29.7 % 1.49 [ 0.86, 2.12 ]
Irwin 2015 45 1.5 (2.1) 38 -0.4 (2.7) 33.3 % 0.79 [ 0.34, 1.24 ]
Saarto 2012 262 0.89 (1.15) 236 0.72 (1.01) 37.0 % 0.16 [ -0.02, 0.33 ]
Subtotal (95% CI) 331 300 100.0 % 0.76 [ 0.02, 1.51 ]
Heterogeneity: Tau2 = 0.38; Chi2 = 20.62, df = 2 (P = 0.00003); I2 =90%
Test for overall effect: Z = 2.01 (P = 0.045)
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Analysis 15.31. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 31 Overall self-reported physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 31 Overall self-reported physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Baruth 2013 20 0 (0) 12 0 (0) Not estimable
Guinan 2013 16 38.7 (26.9) 10 19.9 (11.3) 5.5 % 0.81 [ -0.01, 1.64 ]
Matthews 2007 22 54.2 (34.1) 14 27.2 (22.7) 6.6 % 0.87 [ 0.17, 1.58 ]
Rogers 2009 20 121.4 (73.2) 18 114.3 (131.5) 7.4 % 0.07 [ -0.57, 0.70 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 9.1 % 1.01 [ 0.50, 1.52 ]
Hatchett 2013 38 3.47 (2.19) 36 1.42 (1.67) 9.4 % 1.04 [ 0.55, 1.53 ]
Pinto 2005 39 202.43 (161.65) 43 78.36 (86) 9.9 % 0.96 [ 0.50, 1.42 ]
Kiecolt-Glaser 2014 96 11.2 (7.6) 90 9.1 (6.1) 12.6 % 0.30 [ 0.01, 0.59 ]
Rogers 2015 110 169 (119) 112 74 (107) 12.8 % 0.84 [ 0.56, 1.11 ]
Vallance 2007 253 207.6 (169) 85 163 (121) 13.2 % 0.28 [ 0.03, 0.53 ]
Short 2014 195 217.9 (222.9) 104 180.3 (206.9) 13.4 % 0.17 [ -0.07, 0.41 ]
Subtotal (95% CI) 845 556 100.0 % 0.60 [ 0.36, 0.84 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 33.71, df = 9 (P = 0.00010); I2 =73%
Test for overall effect: Z = 4.87 (P < 0.00001)
2 More than 12 weeks
Kim 2015 20 17.6 (16.03) 19 11.8 (11.6) 11.6 % 0.40 [ -0.23, 1.04 ]
Basen-Enquist 2006 35 428 (254.4) 25 404 (265) 13.6 % 0.09 [ -0.42, 0.61 ]
Cadmus 2009 34 161.7 (114.7) 33 55.6 (101.9) 13.7 % 0.97 [ 0.46, 1.47 ]
Littman 2012 32 19.2 (19.1) 31 12.1 (13.6) 13.9 % 0.42 [ -0.08, 0.92 ]
Winters-Stone 2011 36 430.8 (281.4) 31 461.7 (346.4) 14.2 % -0.10 [ -0.58, 0.38 ]
Irwin 2015 45 222.1 (118.6) 38 103.6 (104.6) 14.6 % 1.04 [ 0.58, 1.51 ]
Schmitz 2009 131 3348.8 (9019.4) 133 2339.8 (6213.7) 18.5 % 0.13 [ -0.11, 0.37 ]
Subtotal (95% CI) 333 310 100.0 % 0.41 [ 0.09, 0.74 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 21.91, df = 6 (P = 0.001); I2 =73%
Test for overall effect: Z = 2.48 (P = 0.013)
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Analysis 15.32. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 32 Overall self-reported physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 32 Overall self-reported physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Guinan 2013 16 15.6 (11.4476) 10 -8.3 (4.1937) 15.8 % 2.46 [ 1.39, 3.53 ]
Matthews 2007 22 21.5 (30.6) 14 5 (13.8) 23.1 % 0.63 [ -0.06, 1.32 ]
Pinto 2005 39 84.74 (189.2) 43 -18.27 (200.7) 28.6 % 0.52 [ 0.08, 0.96 ]
Vallance 2007 281 82 (168.7) 96 30 (167.8) 32.5 % 0.31 [ 0.08, 0.54 ]
Subtotal (95% CI) 358 163 100.0 % 0.78 [ 0.20, 1.36 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 15.29, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 2.65 (P = 0.0080)
2 More than 12 weeks
Cadmus 2009 34 129 (117.9) 33 44.3 (89.4) 22.4 % 0.80 [ 0.30, 1.30 ]
Irwin 2015 45 159 (136) 38 49 (86) 23.4 % 0.94 [ 0.48, 1.40 ]
Schmitz 2009 (1) 48 2.8 (16.8) 57 -0.8 (16.6) 25.1 % 0.21 [ -0.17, 0.60 ]
Saarto 2012 262 3.5 (18.3) 236 3.3 (21.5) 29.1 % 0.01 [ -0.17, 0.19 ]
Subtotal (95% CI) 389 364 100.0 % 0.46 [ -0.01, 0.92 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 20.15, df = 3 (P = 0.00016); I2 =85%
Test for overall effect: Z = 1.93 (P = 0.053)
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Analysis 15.33. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 33 Overall objective physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 33 Overall objective physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Rogers 2013 12 198.4 (111.7) 10 0 (0) Not estimable
Guinan 2013 16 30.7 (15.6) 9 31 (15.6) 6.4 % -0.02 [ -0.84, 0.80 ]
Matthews 2007 22 330.8 (114.7) 14 198.5 (55.4) 7.2 % 1.34 [ 0.60, 2.09 ]
Rogers 2014 20 294 (175) 22 154 (75) 8.4 % 1.04 [ 0.39, 1.69 ]
Rogers 2009 20 252191 (91893) 18 210917 (64078) 8.5 % 0.51 [ -0.14, 1.15 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 10.7 % 1.01 [ 0.50, 1.52 ]
Pinto 2005 39 37.5 (14.25) 43 33.62 (19.43) 12.0 % 0.22 [ -0.21, 0.66 ]
Rogers 2015 110 246 (153) 112 197 (138) 15.3 % 0.34 [ 0.07, 0.60 ]
Vallance 2007 253 8110.5 (4133.9) 85 8028 (3457) 15.6 % 0.02 [ -0.23, 0.27 ]
Short 2014 219 9363.07 (7922.79) 111 8301.2 (3373.4) 15.9 % 0.16 [ -0.07, 0.39 ]
Subtotal (95% CI) 747 456 100.0 % 0.44 [ 0.18, 0.70 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 27.53, df = 8 (P = 0.00057); I2 =71%
Test for overall effect: Z = 3.35 (P = 0.00081)
2 More than 12 weeks
Cadmus 2009 33 6738 (2958) 34 5537 (3352) 100.0 % 0.38 [ -0.11, 0.86 ]
Subtotal (95% CI) 33 34 100.0 % 0.38 [ -0.11, 0.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.52 (P = 0.13)
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Analysis 15.34. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 34 Overall objective physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 34 Overall objective physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Guinan 2013 16 -1.1 (6.2) 9 -7.9 (5.3) 21.4 % 1.11 [ 0.23, 2.00 ]
Matthews 2007 22 72.2 (114.6) 14 -16.8 (51.5) 24.0 % 0.91 [ 0.20, 1.62 ]
Rogers 2014 20 114 (109) 22 10 (70) 24.8 % 1.13 [ 0.47, 1.78 ]
Vallance 2007 253 -150 (5173.3) 85 91 (5155.4) 29.8 % -0.05 [ -0.29, 0.20 ]
Subtotal (95% CI) 311 130 100.0 % 0.72 [ -0.02, 1.46 ]
Heterogeneity: Tau2 = 0.46; Chi2 = 19.44, df = 3 (P = 0.00022); I2 =85%
Test for overall effect: Z = 1.92 (P = 0.055)
2 More than 12 weeks
Cadmus 2009 33 1621 (2108) 34 -60 (2341) 100.0 % 0.75 [ 0.25, 1.24 ]
Subtotal (95% CI) 33 34 100.0 % 0.75 [ 0.25, 1.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.94 (P = 0.0032)
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Analysis 15.35. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 35 Mass (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 35 Mass (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 12 weeks or less
Matthews 2007 22 74.9 (15.2) 14 78.9 (20.3) 0.4 % -4.00 [ -16.39, 8.39 ]
Mustian 2004 11 67.1 (10.42) 10 68.6 (13.84) 0.5 % -1.50 [ -12.06, 9.06 ]
Nikander 2007 14 73.5 (13.3) 14 75.5 (12) 0.6 % -2.00 [ -11.38, 7.38 ]
Herrero 2006 8 65.6 (8.7) 8 67.3 (8.9) 0.8 % -1.70 [ -10.32, 6.92 ]
Daley 2007 33 74.26 (12.49) 69 75.6 (12.5) 2.1 % -1.34 [ -6.52, 3.84 ]
Murtezani 2014 30 71.7 (9.5) 32 72.6 (10.75) 2.2 % -0.90 [ -5.94, 4.14 ]
Kiecolt-Glaser 2014 96 75.2 (2.8) 90 75.2 (2.6) 93.4 % 0.0 [ -0.78, 0.78 ]
Subtotal (95% CI) 214 237 100.0 % -0.10 [ -0.85, 0.65 ]
Heterogeneity: Chi2 = 1.12, df = 6 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.25 (P = 0.80)
2 More than 12 weeks
Courneya 2003 24 78.2 (20.5) 26 80.1 (16.2) 0.8 % -1.90 [ -12.20, 8.40 ]
Cadmus 2009 36 80.73 (16.88) 33 78.51 (20.64) 1.0 % 2.22 [ -6.72, 11.16 ]
Rahnama 2010 14 69.4 (13.5) 15 71.6 (9.2) 1.1 % -2.20 [ -10.67, 6.27 ]
DeNysschen 2011 30 69.3 (14.2) 34 72.4 (19.6) 1.2 % -3.10 [ -11.42, 5.22 ]
Ligibel 2008 40 80 (17.5) 42 83.3 (18.7) 1.3 % -3.30 [ -11.14, 4.54 ]
Littman 2012 28 81.1 (13.6) 27 81.3 (14.3) 1.5 % -0.20 [ -7.58, 7.18 ]
Winters-Stone 2011 36 76.5 (15.6) 31 74.2 (12.3) 1.8 % 2.30 [ -4.39, 8.99 ]
Schmitz 2009 131 76.15 (15.66) 133 77.19 (17.02) 5.3 % -1.04 [ -4.98, 2.90 ]
Schmitz 2005 39 69.5 (2.22) 40 69.2 (2.2) 86.0 % 0.30 [ -0.67, 1.27 ]
Subtotal (95% CI) 378 381 100.0 % 0.14 [ -0.76, 1.05 ]
Heterogeneity: Chi2 = 2.83, df = 8 (P = 0.94); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.75)
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Analysis 15.36. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 36 Mass (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 36 Mass (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Dolan 2016 23 -0.55 (5.04) 10 1.44 (1.62) 12.4 % -1.99 [ -4.28, 0.30 ]
Mustian 2004 9 -0.3 (1.86) 10 0.6 (1.43) 19.9 % -0.90 [ -2.40, 0.60 ]
Matthews 2007 22 0.01 (2.09) 14 0.04 (2.16) 20.8 % -0.03 [ -1.46, 1.40 ]
Murtezani 2014 30 -2.3 (2.4) 32 -0.3 (2.6) 23.3 % -2.00 [ -3.24, -0.76 ]
Naumann 2012 11 0.45 (1.33) 10 0.12 (1.52) 23.6 % 0.33 [ -0.90, 1.56 ]
Subtotal (95% CI) 95 76 100.0 % -0.82 [ -1.81, 0.17 ]
Heterogeneity: Tau2 = 0.69; Chi2 = 8.99, df = 4 (P = 0.06); I2 =55%
Test for overall effect: Z = 1.63 (P = 0.10)
2 More than 12 weeks
Irwin 2015 45 -2.1 (4.3) 38 0.1 (3.6) 6.7 % -2.20 [ -3.90, -0.50 ]
Ligibel 2008 22 0 (2.3) 14 0.04 (2.16) 8.4 % -0.04 [ -1.52, 1.44 ]
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 9.4 % -0.60 [ -1.98, 0.78 ]
Courneya 2003 24 0.1 (2) 26 0.7 (1.8) 13.8 % -0.60 [ -1.66, 0.46 ]
Saarto 2012 262 0.66 (3.68) 236 0.67 (3.84) 23.1 % -0.01 [ -0.67, 0.65 ]
Schmitz 2005 39 0.32 (0.43) 40 0.2 (0.42) 38.7 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 457 419 100.0 % -0.25 [ -0.73, 0.24 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 9.62, df = 5 (P = 0.09); I2 =48%
Test for overall effect: Z = 1.00 (P = 0.32)
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Analysis 15.37. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 37 BMI (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 37 BMI (follow-up values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Fixed,95% CI IV,Fixed,95% CI
1 12 weeks or less
Rogers 2013 12 33.6 (7) 10 30.6 (7.28) 0.2 % 3.00 [ -3.00, 9.00 ]
Rogers 2009 20 30.6 (7.6) 18 30.4 (8.3) 0.3 % 0.20 [ -4.88, 5.28 ]
Mustian 2004 11 23.9 (4.17) 10 26.7 (5.59) 0.4 % -2.80 [ -7.05, 1.45 ]
Nikander 2007 14 26.9 (5.6) 14 27.7 (4.9) 0.5 % -0.80 [ -4.70, 3.10 ]
Rogers 2014 20 29.6 (5) 22 32.2 (6.7) 0.6 % -2.60 [ -6.16, 0.96 ]
Pinto 2005 39 27.66 (5.01) 43 29.01 (5.62) 1.4 % -1.35 [ -3.65, 0.95 ]
Murtezani 2014 30 25.1 (2.9) 32 25.8 (3.47) 3.0 % -0.70 [ -2.29, 0.89 ]
Vallance 2007 253 27.01 (5.21) 85 27.2 (5.15) 4.7 % -0.19 [ -1.46, 1.08 ]
Kiecolt-Glaser 2014 96 27.8 (1.08) 90 27.8 (0.95) 88.9 % 0.0 [ -0.29, 0.29 ]
Subtotal (95% CI) 495 324 100.0 % -0.07 [ -0.35, 0.20 ]
Heterogeneity: Chi2 = 6.73, df = 8 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
2 More than 12 weeks
Portela 2008 25 29.1 (5.5) 9 34.7 (15) 0.1 % -5.60 [ -15.63, 4.43 ]
Courneya 2003 24 29.4 (7.4) 26 29.3 (6) 0.7 % 0.10 [ -3.65, 3.85 ]
Rahnama 2010 14 27.74 (4.77) 15 28.04 (4.6) 0.8 % -0.30 [ -3.71, 3.11 ]
Cadmus 2009 36 30.45 (6) 33 29.9 (7.59) 0.9 % 0.55 [ -2.70, 3.80 ]
Ligibel 2008 40 30.3 (6.3) 42 31.5 (6.8) 1.2 % -1.20 [ -4.04, 1.64 ]
Littman 2012 28 27.66 (5.01) 27 29.01 (5.62) 1.2 % -1.35 [ -4.17, 1.47 ]
Schmitz 2009 131 28.46 (5.55) 133 28.94 (6.27) 4.7 % -0.48 [ -1.91, 0.95 ]
Schmitz 2005 39 26 (0.74) 40 25.8 (0.73) 90.5 % 0.20 [ -0.12, 0.52 ]
Subtotal (95% CI) 337 325 100.0 % 0.13 [ -0.18, 0.43 ]
Heterogeneity: Chi2 = 4.16, df = 7 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.42)
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Analysis 15.38. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 38 BMI (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 38 BMI (change values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Mustian 2004 9 -0.42 (0.75) 10 0.29 (0.61) 22.3 % -0.71 [ -1.33, -0.09 ]
Rogers 2014 20 -0.2 (0.9) 22 -0.3 (1.1) 22.6 % 0.10 [ -0.51, 0.71 ]
Naumann 2012 11 0.1 (0.5) 10 -0.1 (0.57) 26.4 % 0.20 [ -0.26, 0.66 ]
Murtezani 2014 30 -0.8 (0.7) 32 -0.14 (0.8) 28.7 % -0.66 [ -1.03, -0.29 ]
Subtotal (95% CI) 70 74 100.0 % -0.27 [ -0.76, 0.22 ]
Heterogeneity: Tau2 = 0.18; Chi2 = 11.45, df = 3 (P = 0.01); I2 =74%
Test for overall effect: Z = 1.09 (P = 0.28)
2 More than 12 weeks
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 1.1 % -0.60 [ -1.98, 0.78 ]
Courneya 2003 24 0 (0.7) 26 0.3 (0.7) 11.8 % -0.30 [ -0.69, 0.09 ]
Ligibel 2008 40 0 (0.9) 42 0.2 (0.8) 12.9 % -0.20 [ -0.57, 0.17 ]
Schmitz 2005 39 0.06 (0.17) 40 0.07 (0.16) 74.2 % -0.01 [ -0.08, 0.06 ]
Subtotal (95% CI) 168 173 100.0 % -0.08 [ -0.22, 0.07 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 3.61, df = 3 (P = 0.31); I2 =17%
Test for overall effect: Z = 1.03 (P = 0.30)
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Analysis 15.39. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 39 Overall body fat (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 39 Overall body fat (follow-up values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Herrero 2006 8 22 (5) 8 22 (4) 4.3 % 0.0 [ -0.98, 0.98 ]
Mustian 2004 11 38.5 (4.47) 10 41.7 (4.89) 5.2 % -0.66 [ -1.54, 0.23 ]
Rogers 2013 10 44.2 (6.7) 12 42.3 (7.7) 5.8 % 0.25 [ -0.59, 1.09 ]
Matthews 2007 22 39.7 (6.3) 14 43.1 (6.9) 8.8 % -0.51 [ -1.19, 0.17 ]
Musanti 2012 30 34.13 (6.64) 12 33.7 (5.7) 9.1 % 0.07 [ -0.60, 0.74 ]
Rogers 2009 20 44.3 (7.4) 19 43.5 (7.5) 10.4 % 0.11 [ -0.52, 0.73 ]
Rogers 2014 20 38.6 (6.4) 22 41.5 (7.4) 10.9 % -0.41 [ -1.02, 0.20 ]
Pinto 2005 39 37.53 (4.79) 43 38.55 (4.83) 21.7 % -0.21 [ -0.64, 0.22 ]
Daley 2007 33 39.4 (4.74) 69 40.1 (7.4) 23.8 % -0.10 [ -0.52, 0.31 ]
Subtotal (95% CI) 193 209 100.0 % -0.16 [ -0.37, 0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.12, df = 8 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 1.58 (P = 0.11)
2 More than 12 weeks
Cerulli 2014 10 26.72 (5.34) 10 30.55 (4.4) 5.4 % -0.75 [ -1.66, 0.16 ]
Courneya 2003 24 131.9 (46.4) 26 137.1 (44.4) 9.9 % -0.11 [ -0.67, 0.44 ]
DeNysschen 2011 30 36.9 (8.4) 34 38 (10.2) 11.0 % -0.12 [ -0.61, 0.38 ]
Winters-Stone 2011 36 40.5 (6.2) 31 38.5 (5.8) 11.2 % 0.33 [ -0.16, 0.81 ]
Saarto 2012 37 39.9 (7.5) 30 40.2 (8) 11.2 % -0.04 [ -0.52, 0.44 ]
Cadmus 2009 36 40.54 (6.55) 33 39.6 (5.97) 11.4 % 0.15 [ -0.33, 0.62 ]
Schmitz 2005 39 40.91 (1.31) 40 42.29 (1.3) 11.4 % -1.05 [ -1.52, -0.58 ]
Ligibel 2008 40 42.9 (7.4) 42 44.7 (8) 12.2 % -0.23 [ -0.67, 0.20 ]
Schmitz 2009 130 38.47 (5.93) 132 39.74 (5.9) 16.2 % -0.21 [ -0.46, 0.03 ]
Subtotal (95% CI) 382 378 100.0 % -0.20 [ -0.45, 0.05 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 21.11, df = 8 (P = 0.01); I2 =62%
Test for overall effect: Z = 1.54 (P = 0.12)
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Analysis 15.40. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 40 Overall body fat (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 40 Overall body fat (change values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Mustian 2004 9 -0.16 (2.91) 10 0.28 (1.57) 12.8 % -0.18 [ -1.09, 0.72 ]
Naumann 2012 11 -0.3 (2.42) 10 0.8 (2.75) 13.9 % -0.41 [ -1.28, 0.46 ]
Musanti 2012 30 -0.24 (2.83) 12 1.4 (1.57) 22.3 % -0.63 [ -1.32, 0.05 ]
Matthews 2007 22 -0.2 (1.62) 14 0.41 (1.94) 22.9 % -0.34 [ -1.02, 0.33 ]
Rogers 2014 20 -1.1 (2.2) 22 -0.6 (2.4) 28.2 % -0.21 [ -0.82, 0.39 ]
Subtotal (95% CI) 92 68 100.0 % -0.36 [ -0.68, -0.04 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.00, df = 4 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 2.18 (P = 0.029)
2 More than 12 weeks
Schmitz 2005 39 -1.15 (0.45) 40 0.23 (0.44) 24.2 % -3.07 [ -3.73, -2.41 ]
Courneya 2003 24 -4.9 (15.7) 26 5.1 (24.4) 24.7 % -0.48 [ -1.04, 0.09 ]
Ligibel 2008 40 -0.2 (1.7) 42 0.3 (1.7) 25.4 % -0.29 [ -0.73, 0.14 ]
Schmitz 2009 (1) 65 -0.3 (5.7) 63 -0.1 (3.3) 25.7 % -0.04 [ -0.39, 0.30 ]
Subtotal (95% CI) 168 171 100.0 % -0.94 [ -2.07, 0.18 ]
Heterogeneity: Tau2 = 1.24; Chi2 = 65.67, df = 3 (P<0.00001); I2 =95%
Test for overall effect: Z = 1.65 (P = 0.099)
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Outcome 41 Lower body strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 41 Lower body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Rogers 2013 11 68.4 (15.5) 9 67.1 (16.2) 12.2 % 0.08 [ -0.80, 0.96 ]
Nikander 2007 14 1305 (177) 14 1393 (275) 15.8 % -0.37 [ -1.12, 0.38 ]
Rogers 2009 20 80.3 (27) 18 64.9 (19.7) 19.2 % 0.63 [ -0.02, 1.29 ]
Milne 2008 29 66.2 (10.2) 29 61.7 (11) 25.7 % 0.42 [ -0.10, 0.94 ]
Do 2015 32 13 (1.62) 30 13.15 (1.55) 27.1 % -0.09 [ -0.59, 0.41 ]
Subtotal (95% CI) 106 100 100.0 % 0.15 [ -0.19, 0.50 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 5.90, df = 4 (P = 0.21); I2 =32%
Test for overall effect: Z = 0.88 (P = 0.38)
2 More than 12 weeks
Cerulli 2014 10 114.88 (17.09) 10 79.13 (17.78) 12.1 % 1.96 [ 0.85, 3.07 ]
Schmitz 2005 23 296.6 (48.9) 22 238.9 (46.4) 19.1 % 1.19 [ 0.55, 1.83 ]
Saarto 2012 37 136 (23) 30 136 (29) 21.8 % 0.0 [ -0.48, 0.48 ]
Winters-Stone 2011 36 201.3 (57.4) 31 191 (51.7) 21.8 % 0.19 [ -0.30, 0.67 ]
Schmitz 2009 113 223.4 (59.6) 119 175.1 (53.5) 25.0 % 0.85 [ 0.58, 1.12 ]
Subtotal (95% CI) 219 212 100.0 % 0.72 [ 0.20, 1.24 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 20.83, df = 4 (P = 0.00034); I2 =81%
Test for overall effect: Z = 2.70 (P = 0.0069)
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Analysis 15.42. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 42 Lower body strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 42 Lower body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Nieman 1995 6 28.9 (13.7) 6 3.5 (22.5) 13.4 % 1.26 [ -0.03, 2.55 ]
Naumann 2012 11 7.7 (12.6) 10 3.5 (13.9) 18.8 % 0.30 [ -0.56, 1.17 ]
Dolan 2016 23 11.84 (8.89) 10 0.34 (11.1) 19.7 % 1.17 [ 0.37, 1.97 ]
Cormie 2014 43 37.6 (25.5) 19 6.7 (25.7) 23.0 % 1.19 [ 0.61, 1.78 ]
Do 2015 32 0.9 (0.7) 60 0.95 (0.61) 25.0 % -0.08 [ -0.51, 0.35 ]
Subtotal (95% CI) 115 105 100.0 % 0.71 [ 0.06, 1.37 ]
Heterogeneity: Tau2 = 0.40; Chi2 = 16.62, df = 4 (P = 0.002); I2 =76%
Test for overall effect: Z = 2.14 (P = 0.033)
2 More than 12 weeks
Schmitz 2005 23 81.8 (48.92) 22 20.3 (45.97) 21.6 % 1.27 [ 0.63, 1.92 ]
Schmitz 2009 113 33.2 (33.9) 119 7.9 (26.6) 39.1 % 0.83 [ 0.56, 1.10 ]
Waltman 2010 110 4.42 (11.48) 113 0.19 (8.38) 39.3 % 0.42 [ 0.15, 0.69 ]
Subtotal (95% CI) 246 254 100.0 % 0.76 [ 0.36, 1.17 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 8.10, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 3.68 (P = 0.00023)
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Analysis 15.43. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 43 Upper body strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 43 Upper body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Mustian 2004 11 29.6 (3.27) 10 26.7 (5.73) 13.3 % 0.60 [ -0.28, 1.49 ]
Nikander 2007 14 131 (20) 14 129 (28) 15.4 % 0.08 [ -0.66, 0.82 ]
Musanti 2012 30 52.13 (20.98) 12 36.75 (20) 16.2 % 0.73 [ 0.04, 1.42 ]
Rogers 2009 20 27.9 (5.04) 18 24.3 (6.18) 16.8 % 0.63 [ -0.03, 1.28 ]
Milne 2008 29 7.6 (2.9) 29 9.4 (2.6) 18.9 % -0.64 [ -1.17, -0.12 ]
Do 2015 32 9.65 (1.67) 30 10.05 (1.68) 19.4 % -0.24 [ -0.74, 0.26 ]
Subtotal (95% CI) 136 113 100.0 % 0.15 [ -0.32, 0.62 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 16.15, df = 5 (P = 0.01); I2 =69%
Test for overall effect: Z = 0.62 (P = 0.54)
2 More than 12 weeks
Cerulli 2014 10 16.08 (5.43) 10 17.2 (8.05) 10.3 % -0.16 [ -1.03, 0.72 ]
Portela 2008 25 39.3 (12.3) 9 35.6 (13.1) 11.7 % 0.29 [ -0.48, 1.05 ]
Schmitz 2005 23 83 (13.4) 22 63 (12.7) 13.1 % 1.50 [ 0.84, 2.17 ]
Kaltsatou 2011 28 59.63 (8.49) 26 47.62 (9.83) 14.2 % 1.29 [ 0.70, 1.88 ]
Saarto 2012 37 32.7 (5.3) 30 30.8 (5.7) 15.8 % 0.34 [ -0.14, 0.83 ]
Winters-Stone 2011 36 63.3 (15.3) 31 61.1 (16.8) 15.9 % 0.14 [ -0.34, 0.62 ]
Schmitz 2009 113 52.9 (15.3) 119 40.9 (11.8) 18.9 % 0.88 [ 0.61, 1.15 ]
Subtotal (95% CI) 272 247 100.0 % 0.64 [ 0.24, 1.04 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 23.22, df = 6 (P = 0.00073); I2 =74%
Test for overall effect: Z = 3.15 (P = 0.0016)
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Analysis 15.44. Comparison 15 Subanalysis: outcomes by duration of physical activity intervention,
Outcome 44 Upper body strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 15 Subanalysis: outcomes by duration of physical activity intervention
Outcome: 44 Upper body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 12 weeks or less
Musanti 2012 30 7.74 (10.62) 12 0.83 (12.65) 23.6 % 0.60 [ -0.08, 1.29 ]
Cormie 2014 43 5.7 (3.67) 19 1 (3.78) 24.7 % 1.25 [ 0.67, 1.84 ]
Do 2015 32 0.3 (0.5) 30 0.55 (1.2) 25.7 % -0.27 [ -0.77, 0.23 ]
Mustian 2004 45 4.5 (4.71) 38 -0.85 (3.15) 26.0 % 1.30 [ 0.82, 1.78 ]
Subtotal (95% CI) 150 99 100.0 % 0.72 [ -0.06, 1.50 ]
Heterogeneity: Tau2 = 0.56; Chi2 = 24.08, df = 3 (P = 0.00002); I2 =88%
Test for overall effect: Z = 1.80 (P = 0.072)
2 More than 12 weeks
Schmitz 2005 23 32.3 (11.51) 22 6.9 (10.79) 18.8 % 2.24 [ 1.48, 2.99 ]
Irwin 2015 45 0.4 (1.88) 38 0.1 (1.89) 25.2 % 0.16 [ -0.27, 0.59 ]
Waltman 2010 110 1.9 (4.86) 113 0.75 (2.9) 28.0 % 0.29 [ 0.02, 0.55 ]
Schmitz 2009 113 33.2 (40.8) 119 7.6 (43.7) 28.0 % 0.60 [ 0.34, 0.87 ]
Subtotal (95% CI) 291 292 100.0 % 0.71 [ 0.17, 1.25 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 25.58, df = 3 (P = 0.00001); I2 =88%
Test for overall effect: Z = 2.59 (P = 0.0097)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 1 Overall HRQoL (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 16.2 % 1.30 [ 0.19, 2.41 ]
Mustian 2004 11 121.7 (22.67) 10 124.3 (25.9) 18.8 % -0.10 [ -0.96, 0.75 ]
Milne 2008 29 86.4 (8.3) 29 64.1 (10.8) 20.7 % 2.28 [ 1.61, 2.96 ]
Murtezani 2014 30 86.5 (7.3) 32 79.1 (7.5) 22.1 % 0.99 [ 0.46, 1.52 ]
Mehnert 2011 30 74.72 (21.72) 27 65.43 (16.78) 22.1 % 0.47 [ -0.06, 1.00 ]
Subtotal (95% CI) 108 106 100.0 % 0.99 [ 0.22, 1.75 ]
Heterogeneity: Tau2 = 0.62; Chi2 = 24.56, df = 4 (P = 0.00006); I2 =84%
Test for overall effect: Z = 2.53 (P = 0.011)
2 Individual format
Cerulli 2014 10 85.23 (4.2) 10 65.89 (14.66) 2.5 % 1.72 [ 0.66, 2.78 ]
Portela 2008 25 107.2 (28.5) 9 91.6 (28.5) 4.4 % 0.53 [ -0.24, 1.31 ]
Courneya 2003 24 91.3 (11) 28 89.3 (10.9) 7.6 % 0.18 [ -0.37, 0.73 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 7.7 % 0.19 [ -0.35, 0.73 ]
Pinto 2015 39 117.79 (12.74) 37 113.98 (18.02) 9.9 % 0.24 [ -0.21, 0.69 ]
Schmitz 2005 39 -44.2 (8.7) 40 -47.4 (9.4) 10.1 % 0.35 [ -0.09, 0.79 ]
Taleghani 2012 40 217.5 (36.3) 40 210.1 (41.5) 10.2 % 0.19 [ -0.25, 0.63 ]
Daley 2007 33 90.85 (13.47) 69 86.44 (15.07) 10.9 % 0.30 [ -0.12, 0.72 ]
Vallance 2007 250 91.54 (11.76) 85 90.55 (12.95) 18.2 % 0.08 [ -0.16, 0.33 ]
Short 2014 195 106.8 (16.7) 104 108.2 (18.2) 18.6 % -0.08 [ -0.32, 0.16 ]
Subtotal (95% CI) 695 442 100.0 % 0.21 [ 0.03, 0.38 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 14.77, df = 9 (P = 0.10); I2 =39%
Test for overall effect: Z = 2.30 (P = 0.022)
3 Both group and individual formats
Rogers 2015 10 85.23 (4.2) 10 65.89 (14.66) 6.4 % 1.72 [ 0.66, 2.78 ]
Loudon 2014 12 -7.42 (1.24) 11 -7.45 (1.44) 9.8 % 0.02 [ -0.80, 0.84 ]
Rogers 2009 20 92 (11.4) 18 87.4 (13.1) 14.1 % 0.37 [ -0.27, 1.01 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cadmus 2009 37 91.2 (12.6) 37 86.2 (17.4) 21.6 % 0.33 [ -0.13, 0.78 ]
Loh 2014 63 112.4 (14.09) 32 109.29 (13.26) 23.4 % 0.22 [ -0.20, 0.65 ]
Littman 2012 30 90.3 (11) 110 87.7 (15) 24.7 % 0.18 [ -0.22, 0.59 ]
Subtotal (95% CI) 172 218 100.0 % 0.33 [ 0.04, 0.62 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 7.84, df = 5 (P = 0.17); I2 =36%
Test for overall effect: Z = 2.26 (P = 0.024)
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Analysis 16.2. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 2 Overall HRQoL
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 2 Overall HRQoL (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Mustian 2004 11 15 (5) 10 0 (5) 19.0 % 2.88 [ 1.59, 4.17 ]
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 19.2 % 1.92 [ 0.68, 3.17 ]
Murtezani 2014 30 9.16 (2.12) 32 -0.56 (2.01) 20.0 % 4.65 [ 3.67, 5.63 ]
Cuesta-Vargas 2014 22 0.32 (0.18) 20 0.33 (0.09) 20.8 % -0.07 [ -0.67, 0.54 ]
Mehnert 2011 30 9.72 (21.03) 27 5.55 (16.5) 21.0 % 0.22 [ -0.31, 0.74 ]
Subtotal (95% CI) 101 97 100.0 % 1.88 [ 0.19, 3.56 ]
Heterogeneity: Tau2 = 3.43; Chi2 = 83.96, df = 4 (P<0.00001); I2 =95%
Test for overall effect: Z = 2.19 (P = 0.029)
2 Individual format
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Naumann 2012 11 14.5 (10.6) 10 3.1 (11.4) 3.7 % 1.00 [ 0.08, 1.92 ]
Courneya 2003 24 5.7 (7.4) 28 0.6 (7.4) 9.8 % 0.68 [ 0.12, 1.24 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 10.4 % 0.52 [ -0.03, 1.06 ]
Schmitz 2005 39 2.3 (4.5) 40 0.6 (4) 15.3 % 0.40 [ -0.05, 0.84 ]
Daley 2007 33 10.22 (11.2) 69 3.2 (11.26) 16.8 % 0.62 [ 0.20, 1.04 ]
Vallance 2007 250 2.3 (11.08) 85 -0.16 (6.4) 44.1 % 0.24 [ 0.00, 0.49 ]
Subtotal (95% CI) 397 252 100.0 % 0.43 [ 0.25, 0.61 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.29, df = 5 (P = 0.38); I2 =6%
Test for overall effect: Z = 4.69 (P < 0.00001)
3 Both group and individual formats
Rogers 2009 20 4.5 (8.4) 18 2.9 (12) 15.3 % 0.15 [ -0.49, 0.79 ]
Cadmus 2009 37 0.6 (7.5) 37 -2.4 (9.8) 25.0 % 0.34 [ -0.12, 0.80 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 59.7 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 320 292 100.0 % 0.06 [ -0.22, 0.33 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.23, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.39 (P = 0.69)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 3 Overall emotional function/mental health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Banasik 2011 7 0.47 (0.36) 7 0.38 (0.31) 3.5 % 0.25 [ -0.80, 1.30 ]
Herrero 2006 8 90.6 (9.3) 8 83.3 (14.8) 3.8 % 0.56 [ -0.45, 1.56 ]
Mustian 2004 9 24.78 (2.04) 10 24.8 (3.19) 4.7 % -0.01 [ -0.91, 0.89 ]
Cuesta-Vargas 2014 22 42.9 (19.17) 20 32.3 (33.33) 8.6 % 0.39 [ -0.22, 1.00 ]
Milne 2008 29 19.6 (2.4) 29 16.7 (4.1) 10.3 % 0.85 [ 0.31, 1.39 ]
Mehnert 2011 30 77.01 (35.75) 28 69.05 (40.5) 10.9 % 0.21 [ -0.31, 0.72 ]
Cantarero-Villanueva 2013 32 -17175 (4279) 29 -20390 (6113) 11.0 % 0.61 [ 0.09, 1.12 ]
Murtezani 2014 30 19.5 (3.3) 32 18.3 (3.5) 11.3 % 0.35 [ -0.15, 0.85 ]
Fillion 2008 44 48.54 (7.91) 43 47.49 (9.08) 14.1 % 0.12 [ -0.30, 0.54 ]
Schmitz 2009 112 53.2 (9.6) 120 53.8 (8.7) 21.7 % -0.07 [ -0.32, 0.19 ]
Subtotal (95% CI) 323 326 100.0 % 0.28 [ 0.07, 0.49 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 13.58, df = 9 (P = 0.14); I2 =34%
Test for overall effect: Z = 2.64 (P = 0.0083)
2 Individual format
Baruth 2013 20 83.5 (0) 12 68.5 (0) Not estimable
Pinto 2003 12 -10.83 (28.1) 12 -27.17 (19.5) 2.9 % 0.65 [ -0.17, 1.48 ]
Basen-Enquist 2006 28 78.2 (10.58) 23 77.2 (11.99) 6.5 % 0.09 [ -0.46, 0.64 ]
Courneya 2003 24 21.5 (3.4) 28 20.7 (3) 6.6 % 0.25 [ -0.30, 0.79 ]
Daley 2007 33 19.06 (4.18) 33 18.45 (3.31) 8.4 % 0.16 [ -0.32, 0.64 ]
Pinto 2015 39 54.21 (9.28) 37 52.48 (9.62) 9.7 % 0.18 [ -0.27, 0.63 ]
Schmitz 2005 39 -45.6 (8.2) 40 -48.2 (8.2) 10.0 % 0.31 [ -0.13, 0.76 ]
Pinto 2005 39 -8.02 (20.69) 43 -16.51 (28.75) 10.3 % 0.33 [ -0.10, 0.77 ]
Duijits 2012 37 73.92 (34.7) 89 77.46 (34.32) 13.4 % -0.10 [ -0.49, 0.28 ]
Vallance 2007 250 20.28 (3.31) 85 19.92 (3.44) 32.4 % 0.11 [ -0.14, 0.35 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 521 402 100.0 % 0.16 [ 0.02, 0.30 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.57, df = 8 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.027)
3 Both group and individual formats
Loudon 2014 12 -1.58 (0.7) 11 -1.61 (0.49) 5.1 % 0.05 [ -0.77, 0.87 ]
Rogers 2009 20 20 (3.1) 18 21.1 (2.9) 8.2 % -0.36 [ -1.00, 0.28 ]
Littman 2012 30 20.3 (4) 27 20.8 (3.1) 12.2 % -0.14 [ -0.66, 0.38 ]
Cadmus 2009 37 20.5 (3) 37 19.8 (4.2) 15.7 % 0.19 [ -0.27, 0.65 ]
Loh 2014 63 19.87 (2.81) 32 19.98 (3.22) 18.0 % -0.04 [ -0.46, 0.39 ]
Rogers 2015 105 20.6 (2.9) 108 19.7 (3.2) 40.9 % 0.29 [ 0.02, 0.56 ]
Subtotal (95% CI) 267 233 100.0 % 0.10 [ -0.09, 0.29 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 5.27, df = 5 (P = 0.38); I2 =5%
Test for overall effect: Z = 1.05 (P = 0.29)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 4 Overall emotional function/mental health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 9.3 (19.6) 8 -2.1 (5.9) 11.1 % 0.74 [ -0.28, 1.77 ]
Mustian 2004 9 2.44 (2.52) 10 0.1 (1.68) 11.5 % 1.06 [ 0.08, 2.03 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 14.8 % 1.80 [ 1.21, 2.40 ]
Cormie 2014 43 4.4 (9) 19 2.7 (8.6) 15.2 % 0.19 [ -0.35, 0.73 ]
Mehnert 2011 30 2.3 (35.5) 28 3.57 (17.6) 15.4 % -0.04 [ -0.56, 0.47 ]
Cantarero-Villanueva 2013 32 -1445 (4452) 29 353 (3323) 15.5 % -0.45 [ -0.96, 0.06 ]
Schmitz 2009 58 3.3 (23.2) 62 3.1 (17.2) 16.5 % 0.01 [ -0.35, 0.37 ]
Subtotal (95% CI) 210 188 100.0 % 0.42 [ -0.14, 0.99 ]
Heterogeneity: Tau2 = 0.46; Chi2 = 39.78, df = 6 (P<0.00001); I2 =85%
Test for overall effect: Z = 1.48 (P = 0.14)
2 Individual format
Naumann 2012 11 1 (2.69) 10 -0.1 (2.72) 4.3 % 0.39 [ -0.48, 1.26 ]
Courneya 2003 24 2.3 (3.1) 28 0.8 (2.9) 10.4 % 0.49 [ -0.06, 1.05 ]
Schmitz 2005 39 2.5 (4.4) 40 0.3 (3.9) 15.8 % 0.52 [ 0.08, 0.97 ]
Pinto 2005 39 -3.8 (27.7) 43 -11.47 (25.8) 16.8 % 0.28 [ -0.15, 0.72 ]
Vallance 2007 250 0.47 (3.54) 85 0.08 (2.49) 52.7 % 0.12 [ -0.13, 0.36 ]
Subtotal (95% CI) 363 206 100.0 % 0.26 [ 0.08, 0.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.40, df = 4 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 2.86 (P = 0.0042)
3 Both group and individual formats
Rogers 2009 20 0.9 (2.5) 18 -0.1 (2.7) 13.3 % 0.38 [ -0.27, 1.02 ]
Cadmus 2009 37 0.3 (2.2) 37 -0.5 (3.3) 23.0 % 0.28 [ -0.18, 0.74 ]
Saarto 2012 263 1.2 (17.79) 237 1.9 (18.46) 63.7 % -0.04 [ -0.21, 0.14 ]
Subtotal (95% CI) 320 292 100.0 % 0.09 [ -0.16, 0.34 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.87, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 0.70 (P = 0.48)
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Analysis 16.5. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 5 Overall physical
function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 5 Overall physical function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Banasik 2011 7 -0.77 (0.94) 7 -0.42 (0.25) 7.6 % -0.48 [ -1.54, 0.59 ]
Herrero 2006 8 94.1 (7.5) 8 92.5 (6.6) 8.2 % 0.21 [ -0.77, 1.20 ]
Mustian 2004 9 26.89 (4.11) 10 26.5 (4.14) 8.9 % 0.09 [ -0.81, 0.99 ]
Milne 2008 29 24 (2.6) 29 15.6 (4.5) 11.0 % 2.26 [ 1.59, 2.92 ]
Cuesta-Vargas 2014 22 42.9 (4.06) 20 32.4 (32.48) 11.5 % 0.46 [ -0.16, 1.07 ]
Mehnert 2011 30 88.96 (9.13) 28 78.12 (21.22) 12.3 % 0.66 [ 0.13, 1.19 ]
Murtezani 2014 30 22.6 (4.4) 32 19.4 (4.4) 12.5 % 0.72 [ 0.20, 1.23 ]
Fillion 2008 44 45.1 (10.42) 43 41.76 (9.76) 13.3 % 0.33 [ -0.10, 0.75 ]
Schmitz 2009 112 50.6 (8.15) 120 49.1 (9.32) 14.6 % 0.17 [ -0.09, 0.43 ]
Subtotal (95% CI) 291 297 100.0 % 0.53 [ 0.12, 0.94 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 38.27, df = 8 (P<0.00001); I2 =79%
Test for overall effect: Z = 2.52 (P = 0.012)
2 Individual format
Pinto 2003 12 32.3 (4.3) 12 25.3 (8.2) 3.3 % 1.03 [ 0.17, 1.89 ]
Basen-Enquist 2006 28 82.5 (12.7) 23 77.4 (11.5) 7.2 % 0.41 [ -0.15, 0.97 ]
Courneya 2003 24 25.3 (2.5) 28 25.3 (2.8) 7.5 % 0.0 [ -0.55, 0.55 ]
Daley 2007 33 25.61 (2.15) 33 23.61 (5.7) 9.0 % 0.46 [ -0.03, 0.95 ]
Schmitz 2005 39 -44.2 (5.6) 40 -48.3 (7.7) 10.2 % 0.60 [ 0.15, 1.05 ]
Pinto 2015 39 87.08 (4.4) 37 84.69 (15.91) 10.2 % 0.21 [ -0.25, 0.66 ]
Pinto 2005 39 30.26 (7.88) 43 27.33 (6.76) 10.7 % 0.40 [ -0.04, 0.83 ]
Duijits 2012 87 84.03 (16.88) 89 80.18 (17.08) 18.7 % 0.23 [ -0.07, 0.52 ]
Vallance 2007 250 25.1 (2.96) 85 24.95 (3.26) 23.2 % 0.05 [ -0.20, 0.30 ]
Subtotal (95% CI) 551 390 100.0 % 0.28 [ 0.12, 0.45 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 10.38, df = 8 (P = 0.24); I2 =23%
Test for overall effect: Z = 3.44 (P = 0.00059)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
3 Both group and individual formats
Rogers 2009 20 23.3 (4.5) 18 25.4 (2.3) 10.3 % -0.57 [ -1.22, 0.08 ]
Littman 2012 30 25.4 (1.7) 27 24.3 (4.4) 14.0 % 0.33 [ -0.19, 0.86 ]
Winters-Stone 2011 36 51.7 (6.2) 25 52.3 (5.9) 14.5 % -0.10 [ -0.61, 0.41 ]
Cadmus 2009 37 25.1 (2.7) 37 24 (4.1) 16.5 % 0.31 [ -0.15, 0.77 ]
Loh 2014 63 24.92 (2.54) 32 24.17 (2.23) 17.9 % 0.30 [ -0.12, 0.73 ]
Rogers 2015 105 24.1 (3.5) 108 22.5 (5) 26.8 % 0.37 [ 0.10, 0.64 ]
Subtotal (95% CI) 291 247 100.0 % 0.18 [ -0.06, 0.42 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.72, df = 5 (P = 0.12); I2 =43%
Test for overall effect: Z = 1.45 (P = 0.15)
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Analysis 16.6. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 6 Overall physical
function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 6 Overall physical function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 6.7 (5) 8 -1.7 (6.9) 14.9 % 1.32 [ 0.21, 2.43 ]
Mustian 2004 9 1.89 (2.61) 10 -0.2 (1.61) 15.7 % 0.93 [ -0.03, 1.89 ]
Murtezani 2014 30 4.43 (1.53) 32 -1.34 (1.15) 15.9 % 4.23 [ 3.31, 5.15 ]
Cormie 2014 43 3.49 (5.15) 19 -0.5 (5.67) 17.6 % 0.74 [ 0.19, 1.30 ]
Mehnert 2011 30 3.96 (10.83) 28 -2.15 (16.7) 17.7 % 0.43 [ -0.09, 0.95 ]
Schmitz 2009 58 6.6 (17.1) 62 4.1 (17.3) 18.2 % 0.14 [ -0.21, 0.50 ]
Subtotal (95% CI) 178 159 100.0 % 1.25 [ 0.29, 2.21 ]
Heterogeneity: Tau2 = 1.29; Chi2 = 68.65, df = 5 (P<0.00001); I2 =93%
Test for overall effect: Z = 2.55 (P = 0.011)
2 Individual format
Naumann 2012 11 1.9 (3.3) 10 0.8 (3.4) 5.9 % 0.32 [ -0.55, 1.18 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 22.5 % -0.05 [ -0.49, 0.39 ]
Vallance 2007 247 1 (3.32) 85 0.19 (2.07) 71.6 % 0.26 [ 0.02, 0.51 ]
Subtotal (95% CI) 297 135 100.0 % 0.20 [ -0.01, 0.41 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.59, df = 2 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.84 (P = 0.066)
3 Both group and individual formats
Rogers 2009 20 2.3 (5.1) 18 2.6 (6) 20.1 % -0.05 [ -0.69, 0.58 ]
Courneya 2003 24 1.9 (2) 28 -0.2 (2.2) 21.7 % 0.98 [ 0.40, 1.56 ]
Cadmus 2009 37 0.1 (6.02) 37 -0.5 (7.42) 25.3 % 0.09 [ -0.37, 0.54 ]
Saarto 2012 263 1.9 (13.65) 237 3.4 (13.35) 32.8 % -0.11 [ -0.29, 0.06 ]
Subtotal (95% CI) 344 320 100.0 % 0.19 [ -0.25, 0.63 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 12.68, df = 3 (P = 0.01); I2 =76%
Test for overall effect: Z = 0.83 (P = 0.40)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 7 Overall role function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Banasik 2011 7 3.46 (0.64) 7 3.24 (0.56) 14.7 % 0.34 [ -0.72, 1.40 ]
Herrero 2006 8 97.6 (5.9) 8 100 (0.01) 15.1 % -0.54 [ -1.55, 0.46 ]
Mustian 2004 9 2.44 (1.5) 9 2.8 (1.53) 15.7 % -0.23 [ -1.15, 0.70 ]
Milne 2008 29 22.2 (3) 29 12.5 (4.8) 17.4 % 2.39 [ 1.71, 3.08 ]
Mehnert 2011 30 90 (20.34) 27 79.6 (25.04) 18.4 % 0.45 [ -0.07, 0.98 ]
Murtezani 2014 30 24.2 (2.8) 32 23 (2.5) 18.6 % 0.45 [ -0.06, 0.95 ]
Subtotal (95% CI) 113 112 100.0 % 0.52 [ -0.27, 1.30 ]
Heterogeneity: Tau2 = 0.80; Chi2 = 35.20, df = 5 (P<0.00001); I2 =86%
Test for overall effect: Z = 1.29 (P = 0.20)
2 Individual format
Baruth 2013 20 72.9 (0) 12 65.6 (0) Not estimable
Basen-Enquist 2006 28 86.1 (22.2) 23 73 (24.5) 8.5 % 0.55 [ -0.01, 1.12 ]
Courneya 2003 24 23.4 (4) 28 23.1 (4) 9.1 % 0.07 [ -0.47, 0.62 ]
Daley 2007 33 22.88 (4.52) 33 20.3 (5.57) 11.2 % 0.50 [ 0.01, 0.99 ]
Cadmus 2009 37 23.1 (4.7) 37 20.6 (7.2) 12.7 % 0.41 [ -0.05, 0.87 ]
Schmitz 2005 39 -49.2 (6.5) 40 -50 (6.2) 13.9 % 0.12 [ -0.32, 0.57 ]
Vallance 2007 250 23.22 (3.98) 85 22.72 (4.58) 44.6 % 0.12 [ -0.13, 0.37 ]
Subtotal (95% CI) 431 258 100.0 % 0.23 [ 0.07, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.32, df = 5 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 2.78 (P = 0.0054)
3 Both group and individual formats
Loudon 2014 12 -1.3 (0.31) 11 -1.3 (0.36) 10.3 % 0.0 [ -0.82, 0.82 ]
Rogers 2009 20 21.4 (4.8) 18 23.8 (3.2) 14.4 % -0.57 [ -1.22, 0.08 ]
Littman 2012 30 22.6 (3.9) 27 21.7 (4.7) 19.0 % 0.21 [ -0.31, 0.73 ]
Loh 2014 63 23.37 (4.33) 32 22.22 (4.99) 23.5 % 0.25 [ -0.18, 0.68 ]
Rogers 2015 105 22.3 (4.5) 108 20.3 (5.5) 32.8 % 0.40 [ 0.12, 0.67 ]
-4 -2 0 2 4
Favours control Favours physical activity
(Continued . . . )
738Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 230 196 100.0 % 0.15 [ -0.15, 0.45 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 7.56, df = 4 (P = 0.11); I2 =47%
Test for overall effect: Z = 0.95 (P = 0.34)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 8 Overall role function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 2.1 (13.9) 8 2.1 (5.9) 14.2 % 0.0 [ -0.98, 0.98 ]
Mustian 2004 9 0.56 (1.59) 10 0.8 (1.55) 15.6 % -0.15 [ -1.05, 0.76 ]
Cormie 2014 43 4.9 (7.1) 19 1.7 (7.1) 23.1 % 0.45 [ -0.10, 0.99 ]
Murtezani 2014 30 1.66 (0.71) 32 0.87 (0.64) 23.3 % 1.16 [ 0.62, 1.70 ]
Mehnert 2011 30 6.67 (23.84) 27 5.56 (27) 23.8 % 0.04 [ -0.48, 0.56 ]
Subtotal (95% CI) 120 96 100.0 % 0.36 [ -0.14, 0.85 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 11.36, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 1.42 (P = 0.15)
2 Individual format
Naumann 2012 11 1.5 (4.41) 10 0.5 (4.49) 5.1 % 0.22 [ -0.64, 1.08 ]
Courneya 2003 24 0.9 (2.8) 28 0.4 (2.7) 12.7 % 0.18 [ -0.37, 0.73 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 19.5 % -0.05 [ -0.49, 0.39 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vallance 2007 250 0.63 (4.14) 85 -0.01 (2.7) 62.6 % 0.17 [ -0.08, 0.41 ]
Subtotal (95% CI) 324 163 100.0 % 0.13 [ -0.07, 0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.81, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 1.29 (P = 0.20)
3 Both group and individual formats
Rogers 2009 20 0.4 (3.3) 18 1.4 (4.3) 6.2 % -0.26 [ -0.90, 0.38 ]
Cadmus 2009 37 -0.3 (3.7) 37 -0.5 (3.4) 12.1 % 0.06 [ -0.40, 0.51 ]
Saarto 2012 263 2.4 (21.51) 237 3.8 (21.6) 81.7 % -0.06 [ -0.24, 0.11 ]
Subtotal (95% CI) 320 292 100.0 % -0.06 [ -0.22, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 9 Overall social well-being/function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Banasik 2011 7 2.8 (0.67) 7 3.16 (0.83) 4.3 % -0.45 [ -1.51, 0.62 ]
Herrero 2006 8 87.5 (19.4) 8 91.7 (23.6) 5.0 % -0.18 [ -1.17, 0.80 ]
Mustian 2004 9 8.63 (1.89) 10 9 (1.83) 5.9 % -0.19 [ -1.09, 0.71 ]
Milne 2008 29 20.7 (4) 29 19.4 (3.9) 17.1 % 0.32 [ -0.19, 0.84 ]
Mehnert 2011 30 85.35 (20.88) 28 79.91 (22.65) 17.2 % 0.25 [ -0.27, 0.76 ]
Murtezani 2014 30 20.2 (2.8) 32 18.3 (2.7) 17.4 % 0.68 [ 0.17, 1.20 ]
Schmitz 2009 59 14.9 (5.2) 62 14.1 (5.8) 33.1 % 0.14 [ -0.21, 0.50 ]
Subtotal (95% CI) 172 176 100.0 % 0.22 [ 0.00, 0.45 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 6.40, df = 6 (P = 0.38); I2 =6%
Test for overall effect: Z = 1.97 (P = 0.049)
2 Individual format
Rogers 2014 20 7.3 (4.9) 22 3.1 (3.2) 15.2 % 1.01 [ 0.36, 1.65 ]
Basen-Enquist 2006 28 84.6 (16.93) 23 84.9 (19.18) 17.9 % -0.02 [ -0.57, 0.54 ]
Courneya 2003 24 21.1 (3.5) 28 20.7 (3.6) 18.1 % 0.11 [ -0.43, 0.66 ]
Daley 2007 33 23.3 (4.78) 33 20.4 (6.8) 19.9 % 0.49 [ 0.00, 0.98 ]
Vallance 2007 250 22.94 (4.96) 85 22.96 (5.05) 28.9 % 0.00 [ -0.25, 0.24 ]
Subtotal (95% CI) 355 191 100.0 % 0.27 [ -0.07, 0.61 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 10.43, df = 4 (P = 0.03); I2 =62%
Test for overall effect: Z = 1.54 (P = 0.12)
3 Both group and individual formats
Rogers 2009 20 22.6 (4.1) 18 21.8 (5.7) 5.8 % 0.16 [ -0.48, 0.80 ]
Littman 2012 30 22.1 (5) 27 20.9 (6) 8.7 % 0.22 [ -0.31, 0.74 ]
Cadmus 2009 37 22.3 (4.9) 37 20.6 (7.2) 11.3 % 0.27 [ -0.18, 0.73 ]
Loh 2014 63 21.48 (4.88) 32 19.61 (4.9) 12.9 % 0.38 [ -0.05, 0.81 ]
Kiecolt-Glaser 2014 96 95.2 (10.8) 90 93.8 (9.3) 28.5 % 0.14 [ -0.15, 0.43 ]
Rogers 2015 105 21 (5.7) 108 20.7 (5.8) 32.8 % 0.05 [ -0.22, 0.32 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 351 312 100.0 % 0.16 [ 0.01, 0.32 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.92, df = 5 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 2.09 (P = 0.037)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 10 Overall social well-being/function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Mustian 2004 9 1.5 (1.5) 10 0.44 (1.17) 15.7 % 0.76 [ -0.18, 1.70 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 20.0 % 1.80 [ 1.21, 2.40 ]
Cormie 2014 43 3.5 (8.5) 19 2.5 (8.3) 20.7 % 0.12 [ -0.42, 0.66 ]
Mehnert 2011 30 7.33 (22.33) 28 3.12 (24.3) 21.0 % 0.18 [ -0.34, 0.69 ]
Schmitz 2009 59 4.4 (33.8) 62 0.7 (34) 22.7 % 0.11 [ -0.25, 0.47 ]
Subtotal (95% CI) 171 151 100.0 % 0.57 [ -0.06, 1.19 ]
Heterogeneity: Tau2 = 0.41; Chi2 = 26.10, df = 4 (P = 0.00003); I2 =85%
Test for overall effect: Z = 1.78 (P = 0.076)
2 Individual format
Naumann 2012 11 0.9 (3.32) 10 -0.2 (3.32) 12.4 % 0.32 [ -0.54, 1.18 ]
Rogers 2014 20 2.1 (3.2) 22 -0.8 (3.5) 19.4 % 0.85 [ 0.21, 1.48 ]
Courneya 2003 24 0.6 (2.4) 28 -0.5 (3.3) 23.4 % 0.37 [ -0.18, 0.92 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vallance 2007 250 0.21 (4.82) 85 -4.15 (3.34) 44.8 % 0.97 [ 0.71, 1.23 ]
Subtotal (95% CI) 305 145 100.0 % 0.72 [ 0.38, 1.06 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 5.14, df = 3 (P = 0.16); I2 =42%
Test for overall effect: Z = 4.17 (P = 0.000030)
3 Both group and individual formats
Rogers 2009 20 0.9 (2.6) 18 -1.2 (2.7) 27.0 % 0.78 [ 0.11, 1.44 ]
Cadmus 2009 37 0.6 (4.6) 37 -1 (3.2) 33.0 % 0.40 [ -0.06, 0.86 ]
Saarto 2012 263 5 (21.1) 237 8.8 (20.81) 40.1 % -0.18 [ -0.36, -0.01 ]
Subtotal (95% CI) 320 292 100.0 % 0.27 [ -0.31, 0.85 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 11.76, df = 2 (P = 0.003); I2 =83%
Test for overall effect: Z = 0.91 (P = 0.36)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 11 Overall cognitive function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 91.7 (12.6) 8 89.6 (12.4) 12.1 % 0.16 [ -0.82, 1.14 ]
Mehnert 2011 30 81.1 (16.8) 27 78.4 (24.38) 43.2 % 0.13 [ -0.39, 0.65 ]
Cantarero-Villanueva 2013 32 -37.93 (8.48) 29 -43.03 (10.01) 44.6 % 0.55 [ 0.03, 1.06 ]
Subtotal (95% CI) 70 64 100.0 % 0.32 [ -0.02, 0.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
2 Individual format
Pinto 2003 12 -4.33 (2.5) 6 -7.17 (2.1) 100.0 % 1.14 [ 0.07, 2.20 ]
Subtotal (95% CI) 12 6 100.0 % 1.14 [ 0.07, 2.20 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
3 Both group and individual formats
Rogers 2009 19 -124.5 (30.8) 18 -135.5 (19.5) 100.0 % 0.42 [ -0.24, 1.07 ]
Subtotal (95% CI) 19 18 100.0 % 0.42 [ -0.24, 1.07 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.25 (P = 0.21)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 12 Overall cognitive function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 6.2 (19.8) 8 8.3 (14.8) 13.4 % -0.11 [ -1.09, 0.87 ]
Mehnert 2011 30 1.67 (22.36) 27 6.18 (24.6) 42.3 % -0.19 [ -0.71, 0.33 ]
Cantarero-Villanueva 2013 32 2.2 (7.63) 29 -0.18 (5.5471) 44.3 % 0.35 [ -0.16, 0.86 ]
Subtotal (95% CI) 70 64 100.0 % 0.06 [ -0.31, 0.43 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.26, df = 2 (P = 0.32); I2 =11%
Test for overall effect: Z = 0.32 (P = 0.75)
2 Individual format
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Both group and individual formats
Rogers 2009 20 4.2 (16.8) 18 -4.7 (25.9) 35.1 % 0.40 [ -0.24, 1.05 ]
Saarto 2012 263 -1 (18.2) 237 2.2 (18.46) 64.9 % -0.17 [ -0.35, 0.00 ]
Subtotal (95% CI) 283 255 100.0 % 0.03 [ -0.51, 0.57 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 2.88, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.10 (P = 0.92)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 13 Overall general health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 24.0 % 1.30 [ 0.19, 2.41 ]
Mustian 2004 9 18.6 (4.77) 9 19.3 (1.92) 29.5 % -0.18 [ -1.11, 0.74 ]
Mehnert 2011 30 74.38 (11.84) 28 70.01 (20.81) 46.6 % 0.26 [ -0.26, 0.77 ]
Subtotal (95% CI) 47 45 100.0 % 0.38 [ -0.31, 1.07 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 4.19, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 1.07 (P = 0.28)
2 Individual format
Baruth 2013 20 68.1 (0) 12 61.6 (0) Not estimable
Basen-Enquist 2006 28 77.4 (11.64) 23 67.1 (13.43) 29.6 % 0.81 [ 0.24, 1.39 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 31.9 % 0.19 [ -0.35, 0.73 ]
Schmitz 2005 39 53.8 (5.3) 40 53.2 (6) 38.5 % 0.10 [ -0.34, 0.55 ]
Subtotal (95% CI) 127 95 100.0 % 0.34 [ -0.08, 0.76 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 3.94, df = 2 (P = 0.14); I2 =49%
Test for overall effect: Z = 1.61 (P = 0.11)
3 Both group and individual formats
Rogers 2009 20 3.5 (0.9) 18 3.8 (0.5) 33.5 % -0.40 [ -1.04, 0.25 ]
Cadmus 2009 37 50 (8.8) 37 51.7 (8.4) 66.5 % -0.20 [ -0.65, 0.26 ]
Subtotal (95% CI) 57 55 100.0 % -0.26 [ -0.64, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
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Analysis 16.14. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 14 Overall
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 14 Overall general health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 15.0 % 1.92 [ 0.68, 3.17 ]
Mustian 2004 9 0.22 (1.92) 10 0.68 (2.5) 21.5 % -0.20 [ -1.10, 0.71 ]
Cormie 2014 43 3.7 (7) 19 2.8 (7.1) 31.4 % 0.13 [ -0.41, 0.67 ]
Mehnert 2011 30 6.6 (13.7) 28 3.24 (19.7) 32.1 % 0.20 [ -0.32, 0.71 ]
Subtotal (95% CI) 90 65 100.0 % 0.35 [ -0.25, 0.95 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 8.11, df = 3 (P = 0.04); I2 =63%
Test for overall effect: Z = 1.14 (P = 0.25)
2 Individual format
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 39.8 % 0.52 [ -0.03, 1.06 ]
Schmitz 2005 39 0.7 (4.8) 40 -0.6 (3.9) 60.2 % 0.29 [ -0.15, 0.74 ]
Subtotal (95% CI) 79 60 100.0 % 0.38 [ 0.04, 0.73 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 1 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.029)
3 Both group and individual formats
Rogers 2009 20 0.15 (0.6) 18 0.17 (0.7) 6.2 % -0.03 [ -0.67, 0.61 ]
Cadmus 2009 37 0.2 (4.4) 37 -0.1 (5.1) 12.1 % 0.06 [ -0.39, 0.52 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 81.7 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 320 292 100.0 % -0.07 [ -0.23, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
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sexual function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 15 Overall sexual function (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Group format
Schmitz 2009 57 -27.3 (5.3) 57 -28.1 (6.2) 100.0 % 0.14 [ -0.23, 0.51 ]
Subtotal (95% CI) 57 57 100.0 % 0.14 [ -0.23, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
2 Individual format
Pinto 2005 12 42.75 (9.2) 6 43.7 (6.1) 5.5 % -0.11 [ -1.09, 0.87 ]
Schmitz 2005 39 -51 (7.5) 40 -53.5 (8) 26.7 % 0.32 [ -0.12, 0.76 ]
Pinto 2003 39 42.45 (9.24) 43 40.12 (6.3) 27.7 % 0.29 [ -0.14, 0.73 ]
Duijits 2012 53 0.6 (0.79) 65 0.59 (0.79) 40.0 % 0.01 [ -0.35, 0.38 ]
Subtotal (95% CI) 143 154 100.0 % 0.17 [ -0.06, 0.40 ]
Heterogeneity: Chi2 = 1.78, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
3 Both group and individual formats
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 16 Overall sleep (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Group format
Bower 2011 16 8.1 (2.5) 15 7.7 (2.6) 35.9 % 0.15 [ -0.55, 0.86 ]
Mehnert 2011 30 23.75 (27) 27 38.27 (31.63) 64.1 % -0.49 [ -1.02, 0.04 ]
Subtotal (95% CI) 46 42 100.0 % -0.26 [ -0.68, 0.16 ]
Heterogeneity: Chi2 = 2.04, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 1.20 (P = 0.23)
2 Individual format
Rogers 2013 11 6.3 (2.7) 9 6.2 (3.2) 32.1 % 0.03 [ -0.85, 0.91 ]
Rogers 2014 20 6.7 (3.7) 22 7.1 (3.2) 67.9 % -0.11 [ -0.72, 0.49 ]
Subtotal (95% CI) 31 31 100.0 % -0.07 [ -0.57, 0.43 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 0.26 (P = 0.79)
3 Both group and individual formats
Rogers 2009 20 6.65 (4.17) 18 5.5 (4) 100.0 % 0.28 [ -0.36, 0.92 ]
Subtotal (95% CI) 20 18 100.0 % 0.28 [ -0.36, 0.92 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.84 (P = 0.40)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 17 Overall anxiety (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Milne 2008 29 15.3 (6.2) 29 21 (5.7) 31.5 % -0.94 [ -1.49, -0.40 ]
Mehnert 2011 30 4.83 (3.46) 28 7.14 (4.97) 33.9 % -0.54 [ -1.06, -0.01 ]
Cantarero-Villanueva 2013 32 42.51 (8.6) 29 49.93 (11.7) 34.6 % -0.72 [ -1.24, -0.20 ]
Subtotal (95% CI) 91 86 100.0 % -0.73 [ -1.03, -0.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 4.67 (P < 0.00001)
2 Individual format
Pinto 2003 12 7.58 (7.3) 6 10.5 (3.7) 27.1 % -0.43 [ -1.43, 0.56 ]
Rogers 2014 20 45.6 (8.9) 22 45.7 (8) 72.9 % -0.01 [ -0.62, 0.59 ]
Subtotal (95% CI) 32 28 100.0 % -0.13 [ -0.64, 0.39 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.48 (P = 0.63)
3 Both group and individual formats
Cadmus 2009 37 32.1 (12.3) 37 34.1 (15.4) 100.0 % -0.14 [ -0.60, 0.31 ]
Subtotal (95% CI) 37 37 100.0 % -0.14 [ -0.60, 0.31 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 18 Overall anxiety (change values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Group format
Mehnert 2011 30 -1.67 (3.68) 28 0.18 (4.89) 49.4 % -0.42 [ -0.95, 0.10 ]
Cantarero-Villanueva 2013 32 -4.2 (9.8) 29 0.75 (5.5) 50.6 % -0.61 [ -1.12, -0.09 ]
Subtotal (95% CI) 62 57 100.0 % -0.52 [ -0.88, -0.15 ]
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0057)
2 Individual format
Rogers 2014 20 -4 (6.5) 22 -1.8 (5) 100.0 % -0.37 [ -0.99, 0.24 ]
Subtotal (95% CI) 20 22 100.0 % -0.37 [ -0.99, 0.24 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.20 (P = 0.23)
3 Both group and individual formats
Cadmus 2009 37 -0.7 (9.2) 37 0.5 (5.8) 100.0 % -0.15 [ -0.61, 0.30 ]
Subtotal (95% CI) 37 37 100.0 % -0.15 [ -0.61, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
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Analysis 16.19. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 19 Overall
depression (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 19 Overall depression (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 49.0 % -0.51 [ -1.04, 0.01 ]
Cantarero-Villanueva 2013 32 -2.95 (7.82) 29 1.46 (7.36) 51.0 % -0.57 [ -1.09, -0.06 ]
Subtotal (95% CI) 62 57 100.0 % -0.54 [ -0.91, -0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.90 (P = 0.0037)
2 Individual format
Naumann 2012 11 -3.6 (4.34) 10 2 (4.55) 21.5 % -1.21 [ -2.16, -0.26 ]
Rogers 2014 20 -1.7 (6.9) 22 1.1 (4.2) 36.7 % -0.49 [ -1.10, 0.13 ]
Ergun 2013 40 1.22 (6.19) 20 2.35 (8.03) 41.8 % -0.16 [ -0.70, 0.37 ]
Subtotal (95% CI) 71 52 100.0 % -0.51 [ -1.03, 0.01 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 3.58, df = 2 (P = 0.17); I2 =44%
Test for overall effect: Z = 1.91 (P = 0.056)
3 Both group and individual formats
Cadmus 2009 37 0.3 (6.4) 37 1.7 (6.3) 20.0 % -0.22 [ -0.68, 0.24 ]
Saarto 2012 263 -0.3 (3.31) 237 -0.5 (3.38) 80.0 % 0.06 [ -0.12, 0.24 ]
Subtotal (95% CI) 300 274 100.0 % 0.00 [ -0.21, 0.22 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.24, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 0.04 (P = 0.97)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 20 Overall depression (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Kaltsatou 2011 13 16.54 (1.66) 13 22.33 (7.73) 13.8 % -1.00 [ -1.83, -0.18 ]
Bower 2011 16 7.7 (5.8) 15 11.6 (7.1) 17.9 % -0.59 [ -1.31, 0.13 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 34.0 % -0.51 [ -1.04, 0.01 ]
Cantarero-Villanueva 2013 32 45.58 (9.68) 29 53.71 (11.6) 34.3 % -0.75 [ -1.28, -0.23 ]
Subtotal (95% CI) 91 85 100.0 % -0.68 [ -0.98, -0.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.13, df = 3 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.34 (P = 0.000014)
2 Individual format
Pinto 2003 12 6.17 (7.2) 6 9.83 (6.8) 14.2 % -0.49 [ -1.49, 0.50 ]
Payne 2008 10 12.7 (8.7) 10 11.4 (7.9) 16.2 % 0.15 [ -0.73, 1.03 ]
Rogers 2014 20 44.2 (8.6) 22 25.1 (44.2) 21.6 % 0.58 [ -0.04, 1.19 ]
Ergun 2013 40 6.88 (6.76) 20 5.15 (5.18) 23.5 % 0.27 [ -0.27, 0.81 ]
Daley 2007 33 6 (6.47) 33 10.33 (7.19) 24.5 % -0.63 [ -1.12, -0.13 ]
Subtotal (95% CI) 115 91 100.0 % -0.01 [ -0.51, 0.49 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 11.43, df = 4 (P = 0.02); I2 =65%
Test for overall effect: Z = 0.04 (P = 0.97)
3 Both group and individual formats
Cadmus 2009 37 9.6 (9.3) 37 10.8 (10.1) 28.5 % -0.12 [ -0.58, 0.33 ]
Kiecolt-Glaser 2014 96 8.1 (8.6) 90 9.2 (8.2) 71.5 % -0.13 [ -0.42, 0.16 ]
Subtotal (95% CI) 133 127 100.0 % -0.13 [ -0.37, 0.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 21 Overall fatigue (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Banasik 2011 7 1 (0.89) 7 1.57 (0.98) 8.1 % -0.57 [ -1.65, 0.51 ]
Bower 2011 16 3.4 (1.8) 15 4.9 (1.3) 12.3 % -0.93 [ -1.67, -0.18 ]
Cuesta-Vargas 2014 22 4 (1.8) 20 5.2 (3.2) 14.5 % -0.46 [ -1.07, 0.15 ]
Milne 2008 29 11.9 (3.2) 29 17.4 (4.7) 15.3 % -1.35 [ -1.92, -0.78 ]
Cantarero-Villanueva 2013 32 3.78 (1.78) 29 6.23 (1.72) 15.5 % -1.38 [ -1.94, -0.82 ]
Mehnert 2011 30 28.52 (25.58) 27 39.92 (25.09) 16.2 % -0.44 [ -0.97, 0.08 ]
Fillion 2008 44 2.65 (0.72) 43 2.86 (0.83) 18.2 % -0.27 [ -0.69, 0.15 ]
Subtotal (95% CI) 180 170 100.0 % -0.77 [ -1.15, -0.39 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 16.43, df = 6 (P = 0.01); I2 =63%
Test for overall effect: Z = 3.97 (P = 0.000072)
2 Individual format
Pinto 2003 12 7.16 (6.4) 6 9 (6.4) 2.7 % -0.27 [ -1.26, 0.71 ]
Payne 2008 9 4.7 (2.6) 9 3.5 (1.7) 2.9 % 0.52 [ -0.42, 1.46 ]
Rogers 2013 11 4.2 (1.8) 9 4.2 (1.6) 3.3 % 0.0 [ -0.88, 0.88 ]
Rogers 2014 20 4.1 (2.1) 22 4 (1.8) 6.3 % 0.05 [ -0.56, 0.66 ]
Courneya 2003 24 -8.3 (7.9) 28 -8.8 (8.1) 7.5 % 0.06 [ -0.48, 0.61 ]
Ergun 2013 40 2.94 (2.24) 20 3.3 (1.79) 7.7 % -0.17 [ -0.71, 0.37 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 8.6 % -0.71 [ -1.21, -0.21 ]
Pinto 2015 39 -43.83 (7.8) 37 -41.22 (8.49) 9.9 % -0.32 [ -0.77, 0.14 ]
Pinto 2005 39 27.08 (21.41) 43 42.28 (26.2) 10.2 % -0.63 [ -1.07, -0.18 ]
Vallance 2007 250 -42.7 (8.4) 85 -42.6 (8.7) 20.1 % -0.01 [ -0.26, 0.23 ]
Short 2014 195 -41.5 (9.3) 104 -39.8 (10.4) 20.6 % -0.17 [ -0.41, 0.06 ]
Subtotal (95% CI) 672 396 100.0 % -0.19 [ -0.36, -0.02 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 14.04, df = 10 (P = 0.17); I2 =29%
Test for overall effect: Z = 2.24 (P = 0.025)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
3 Both group and individual formats
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 5.2 % -0.07 [ -0.89, 0.75 ]
Rogers 2009 20 -12.4 (10.4) 18 -10.1 (6.6) 8.5 % -0.26 [ -0.90, 0.38 ]
Littman 2012 30 -45 (5.3) 27 -43.1 (10.3) 12.8 % -0.23 [ -0.75, 0.29 ]
Winters-Stone 2011 36 45 (5.3) 31 43.1 (10.3) 15.0 % 0.23 [ -0.25, 0.72 ]
Cadmus 2009 37 -51.9 (9) 37 -50.6 (10) 16.8 % -0.14 [ -0.59, 0.32 ]
Kiecolt-Glaser 2014 96 6.3 (19.6) 90 12.7 (18.97) 41.6 % -0.33 [ -0.62, -0.04 ]
Subtotal (95% CI) 231 214 100.0 % -0.18 [ -0.37, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.07, df = 5 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.058)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 22 Overall fatigue (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 -4.2 (19.6) 8 6.4 (14.5) 28.6 % -0.58 [ -1.59, 0.43 ]
Mehnert 2011 30 -0.74 (20.73) 27 -2.88 (25.3) 71.4 % 0.09 [ -0.43, 0.61 ]
Subtotal (95% CI) 38 35 100.0 % -0.10 [ -0.70, 0.50 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 1.35, df = 1 (P = 0.24); I2 =26%
Test for overall effect: Z = 0.33 (P = 0.74)
2 Individual format
Naumann 2012 11 -3.6 (4.35) 10 2 (4.55) 11.7 % -1.21 [ -2.16, -0.26 ]
Rogers 2013 11 4.2 (2) 9 3.9 (1.5) 12.2 % 0.16 [ -0.72, 1.04 ]
Courneya 2003 24 9.3 (10.2) 28 2 (7.5) 14.6 % 0.81 [ 0.24, 1.38 ]
Cantarero-Villanueva 2013 32 -2 (1.75) 29 0.34 (1.39) 14.6 % -1.45 [ -2.02, -0.88 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 15.1 % -0.71 [ -1.21, -0.21 ]
Pinto 2005 39 -14.93 (23.54) 43 1.79 (23.48) 15.4 % -0.70 [ -1.15, -0.26 ]
Vallance 2007 250 2.49 (8.17) 85 1.15 (6.61) 16.5 % 0.17 [ -0.08, 0.42 ]
Subtotal (95% CI) 400 237 100.0 % -0.40 [ -0.98, 0.17 ]
Heterogeneity: Tau2 = 0.51; Chi2 = 53.50, df = 6 (P<0.00001); I2 =89%
Test for overall effect: Z = 1.37 (P = 0.17)
3 Both group and individual formats
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 4.1 % -0.07 [ -0.89, 0.75 ]
Rogers 2009 20 1.9 (9.6) 18 4.2 (12.3) 6.7 % -0.21 [ -0.84, 0.43 ]
Saarto 2012 263 -2.4 (9.06) 237 -2.4 (8.6) 89.2 % 0.0 [ -0.18, 0.18 ]
Subtotal (95% CI) 295 266 100.0 % -0.02 [ -0.18, 0.15 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.39, df = 2 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 23 Overall pain/disability (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Mustian 2004 9 9.11 (1.35) 10 9.1 (1.74) 24.8 % 0.01 [ -0.89, 0.91 ]
Mehnert 2011 30 79.4 (23.1) 28 73.5 (24.83) 75.2 % 0.24 [ -0.27, 0.76 ]
Subtotal (95% CI) 39 38 100.0 % 0.18 [ -0.26, 0.63 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
2 Individual format
Portela 2008 25 -20.6 (20.2) 9 -20.8 (15.5) 21.3 % 0.01 [ -0.75, 0.77 ]
Basen-Enquist 2006 28 79.7 (10.58) 23 72.1 (11.51) 30.1 % 0.68 [ 0.11, 1.25 ]
Duijits 2012 87 79.27 (23.59) 89 78.79 (23.78) 48.6 % 0.02 [ -0.28, 0.32 ]
Subtotal (95% CI) 140 121 100.0 % 0.22 [ -0.22, 0.65 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 4.21, df = 2 (P = 0.12); I2 =52%
Test for overall effect: Z = 0.98 (P = 0.33)
3 Both group and individual formats
Loudon 2014 12 0.8 (1.48) 11 1.44 (2.24) 16.8 % -0.33 [ -1.15, 0.50 ]
Rogers 2009 20 -3.03 (2.98) 18 -2.28 (2.76) 28.0 % -0.26 [ -0.89, 0.38 ]
Cadmus 2009 37 50.3 (9.1) 37 50.8 (9) 55.2 % -0.05 [ -0.51, 0.40 ]
Subtotal (95% CI) 69 66 100.0 % -0.16 [ -0.50, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.45, df = 2 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
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Analysis 16.24. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 24 Overall
pain/disability (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 24 Overall pain/disability (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Mustian 2004 9 -0.22 (1.29) 10 0 (1.42) 14.6 % -0.15 [ -1.06, 0.75 ]
Cormie 2014 43 3.4 (6.5) 19 2 (6.2) 40.7 % 0.22 [ -0.33, 0.76 ]
Mehnert 2011 30 -2.4 (24.95) 28 -7.61 (25.2) 44.7 % 0.21 [ -0.31, 0.72 ]
Subtotal (95% CI) 82 57 100.0 % 0.16 [ -0.19, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
2 Individual format
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Both group and individual formats
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 16.25. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 25 Overall self-
esteem/body image (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 25 Overall self-esteem/body image (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Mehnert 2011 27 -5.47 (1.66) 27 -6.82 (2.6) 25.7 % 0.61 [ 0.06, 1.16 ]
Milne 2008 29 -17.9 (6.8) 29 -20.1 (6.3) 27.9 % 0.33 [ -0.19, 0.85 ]
Schmitz 2009 59 -70.4 (16.3) 63 -71.5 (18) 46.4 % 0.06 [ -0.29, 0.42 ]
Subtotal (95% CI) 115 119 100.0 % 0.28 [ -0.04, 0.60 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.82, df = 2 (P = 0.24); I2 =29%
Test for overall effect: Z = 1.73 (P = 0.084)
2 Individual format
Pinto 2003 12 32.3 (4.3) 6 25.3 (8.2) 12.3 % 1.15 [ 0.08, 2.22 ]
Musanti 2012 30 23.83 (3.48) 12 26.33 (3.94) 18.8 % -0.68 [ -1.37, 0.01 ]
Courneya 2003 24 34.8 (4.7) 28 34.6 (4.4) 21.8 % 0.04 [ -0.50, 0.59 ]
Daley 2007 33 2.03 (0.83) 32 1.57 (0.5) 22.8 % 0.66 [ 0.16, 1.16 ]
Pinto 2005 39 30.26 (7.82) 43 27.23 (6.76) 24.2 % 0.41 [ -0.03, 0.85 ]
Subtotal (95% CI) 138 121 100.0 % 0.27 [ -0.21, 0.76 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 13.33, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 1.10 (P = 0.27)
3 Both group and individual formats
Loudon 2014 12 -1.43 (0.33) 11 -1.56 (0.86) 23.6 % 0.20 [ -0.62, 1.02 ]
Cadmus 2009 37 34.2 (5.5) 37 33.4 (5.9) 76.4 % 0.14 [ -0.32, 0.60 ]
Subtotal (95% CI) 49 48 100.0 % 0.15 [ -0.25, 0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.75 (P = 0.45)
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Analysis 16.26. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 26 Overall self-
esteem/body image (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 26 Overall self-esteem/body image (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Mustian 2004 11 3 (1) 10 -1.5 (1.5) 17.3 % 3.42 [ 1.99, 4.86 ]
Mehnert 2011 30 0.73 (2.12) 27 0.39 (2.12) 27.1 % 0.16 [ -0.36, 0.68 ]
Milne 2008 29 1.5 (3.7) 29 0.1 (3.9) 27.2 % 0.36 [ -0.16, 0.88 ]
Schmitz 2009 59 -12 (15.5) 63 -4.1 (16.2) 28.4 % -0.49 [ -0.86, -0.13 ]
Subtotal (95% CI) 129 129 100.0 % 0.59 [ -0.33, 1.51 ]
Heterogeneity: Tau2 = 0.74; Chi2 = 31.39, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.26 (P = 0.21)
2 Individual format
Musanti 2012 30 -0.4 (4.53) 12 0.58 (3.92) 28.5 % -0.22 [ -0.89, 0.45 ]
Courneya 2003 24 2.6 (3.7) 28 -0.1 (3.5) 33.6 % 0.74 [ 0.18, 1.30 ]
Daley 2007 33 1.79 (0.71) 33 1.56 (0.67) 37.9 % 0.33 [ -0.16, 0.82 ]
Subtotal (95% CI) 87 73 100.0 % 0.31 [ -0.19, 0.81 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 4.60, df = 2 (P = 0.10); I2 =57%
Test for overall effect: Z = 1.22 (P = 0.22)
3 Both group and individual formats
Cadmus 2009 37 0.4 (4.4) 37 0.2 (2.9) 12.9 % 0.05 [ -0.40, 0.51 ]
Saarto 2012 263 10.7 (21.51) 237 12 (21.99) 87.1 % -0.06 [ -0.24, 0.12 ]
Subtotal (95% CI) 300 274 100.0 % -0.05 [ -0.21, 0.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
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Analysis 16.27. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 27 Overall
cardiorespiratory fitness (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 27 Overall cardiorespiratory fitness (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 25.9 (4.5) 8 25.7 (3.7) 5.3 % 0.05 [ -0.93, 1.03 ]
Mustian 2004 11 636.1 (50.6) 10 610.3 (75.9) 6.7 % 0.39 [ -0.48, 1.25 ]
Kaltsatou 2011 14 483.33 (85.95) 13 403.08 (71.92) 7.7 % 0.98 [ 0.17, 1.78 ]
Mehnert 2011 27 26.9 (4.4) 23 25.7 (4.7) 15.8 % 0.26 [ -0.30, 0.82 ]
Milne 2008 29 1.49 (0.31) 29 1.48 (0.43) 18.5 % 0.03 [ -0.49, 0.54 ]
Murtezani 2014 30 875.1 (86.7) 32 823.5 (87.1) 18.9 % 0.59 [ 0.08, 1.10 ]
Fillion 2008 44 27.04 (4.39) 43 26.53 (5.81) 27.1 % 0.10 [ -0.32, 0.52 ]
Subtotal (95% CI) 163 158 100.0 % 0.29 [ 0.06, 0.51 ]
Heterogeneity: Tau2 = 0.00; Chi2 = 6.21, df = 6 (P = 0.40); I2 =3%
Test for overall effect: Z = 2.49 (P = 0.013)
2 Individual format
Cerulli 2014 10 31.29 (4.95) 10 32.26 (10.1) 5.1 % -0.12 [ -0.99, 0.76 ]
Rogers 2013 12 23.9 (6.2) 10 23.9 (3.8) 5.5 % 0.0 [ -0.84, 0.84 ]
Portela 2008 25 3006.96 (410.8) 9 2416.1 (718.6) 5.8 % 1.14 [ 0.33, 1.96 ]
Musanti 2012 30 24.6 (4.93) 12 23 (4.29) 8.2 % 0.33 [ -0.34, 1.00 ]
Rogers 2014 20 30.9 (6.3) 22 25.1 (5) 8.8 % 1.01 [ 0.36, 1.65 ]
Kim 2015 20 424.8 (55.8) 19 394.4 (54) 9.0 % 0.54 [ -0.10, 1.18 ]
Courneya 2003 24 21.3 (3.7) 26 18.2 (3.9) 10.7 % 0.80 [ 0.22, 1.38 ]
Basen-Enquist 2006 35 1643 (122.5) 25 1546 (127.5) 12.3 % 0.77 [ 0.24, 1.30 ]
Pinto 2005 39 -16.34 (2.09) 43 -17.85 (2.24) 16.4 % 0.69 [ 0.24, 1.14 ]
Daley 2007 33 34.99 (4.42) 69 33.05 (5.3) 18.1 % 0.38 [ -0.04, 0.80 ]
Subtotal (95% CI) 248 245 100.0 % 0.59 [ 0.38, 0.79 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 10.42, df = 9 (P = 0.32); I2 =14%
Test for overall effect: Z = 5.63 (P < 0.00001)
3 Both group and individual formats
Nikander 2007 14 -17.6 (1.3) 14 -17.2 (1.4) 7.7 % -0.29 [ -1.03, 0.46 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Rogers 2009 20 29.5 (6.6) 18 27.6 (6.1) 10.5 % 0.29 [ -0.35, 0.93 ]
Irwin 2015 45 24.6 (5.5) 38 23 (4.7) 22.8 % 0.31 [ -0.13, 0.74 ]
Rogers 2015 105 23.6 (4.8) 108 22.7 (0.3) 59.0 % 0.27 [ 0.00, 0.54 ]
Subtotal (95% CI) 184 178 100.0 % 0.24 [ 0.03, 0.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.08, df = 3 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 2.22 (P = 0.026)
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Analysis 16.28. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 28 Overall
cardiorespiratory fitness (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 28 Overall cardiorespiratory fitness (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Individual format
Musanti 2012 30 1 (3.1) 12 0.9 (3.4) 23.1 % 0.03 [ -0.64, 0.70 ]
Courneya 2003 24 2.7 (2.6) 26 -0.6 (1.7) 24.0 % 1.49 [ 0.86, 2.12 ]
Rogers 2014 20 2.8 (4.9) 22 1.1 (4.2) 24.5 % 0.37 [ -0.24, 0.98 ]
Pinto 2005 39 1.35 (2.4) 43 -0.25 (2.5) 28.4 % 0.65 [ 0.20, 1.09 ]
Subtotal (95% CI) 113 103 100.0 % 0.64 [ 0.08, 1.19 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 0.23; Chi2 = 10.90, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 2.25 (P = 0.024)
3 Both group and individual formats
Irwin 2015 45 1.5 (2.1) 38 -0.4 (2.7) 44.4 % 0.79 [ 0.34, 1.24 ]
Saarto 2012 262 0.89 (1.15) 236 0.72 (1.01) 55.6 % 0.16 [ -0.02, 0.33 ]
Subtotal (95% CI) 307 274 100.0 % 0.44 [ -0.18, 1.05 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 6.56, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 1.39 (P = 0.16)
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Analysis 16.29. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 29 Overall self-
reported physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 29 Overall self-reported physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Schmitz 2009 131 3348.8 (9019.4) 133 2339.8 (6213.7) 100.0 % 0.13 [ -0.11, 0.37 ]
Subtotal (95% CI) 131 133 100.0 % 0.13 [ -0.11, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.06 (P = 0.29)
2 Individual format
Baruth 2013 20 0 (0) 12 0 (0) Not estimable
Matthews 2007 22 54.2 (34.1) 14 27.2 (22.7) 10.0 % 0.87 [ 0.17, 1.58 ]
Basen-Enquist 2006 35 428 (254.4) 25 404 (265) 13.1 % 0.09 [ -0.42, 0.61 ]
-4 -2 0 2 4
Favours control Favours physical activity
(Continued . . . )
763Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 13.2 % 1.01 [ 0.50, 1.52 ]
Hatchett 2013 38 3.47 (2.19) 36 1.42 (1.67) 13.6 % 1.04 [ 0.55, 1.53 ]
Pinto 2005 39 202.43 (161.65) 43 78.36 (86) 14.1 % 0.96 [ 0.50, 1.42 ]
Vallance 2007 253 207.6 (169) 85 163 (121) 18.0 % 0.28 [ 0.03, 0.53 ]
Short 2014 195 217.9 (222.9) 104 180.3 (206.9) 18.1 % 0.17 [ -0.07, 0.41 ]
Subtotal (95% CI) 638 351 100.0 % 0.59 [ 0.28, 0.90 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 25.23, df = 6 (P = 0.00031); I2 =76%
Test for overall effect: Z = 3.72 (P = 0.00020)
3 Both group and individual formats
Guinan 2013 16 38.7 (26.9) 10 19.9 (11.3) 7.6 % 0.81 [ -0.01, 1.64 ]
Rogers 2009 20 121.4 (73.2) 18 114.3 (131.5) 10.0 % 0.07 [ -0.57, 0.70 ]
Cadmus 2009 34 161.7 (114.7) 33 55.6 (101.9) 12.1 % 0.97 [ 0.46, 1.47 ]
Littman 2012 32 19.2 (19.1) 31 12.1 (13.6) 12.3 % 0.42 [ -0.08, 0.92 ]
Winters-Stone 2011 36 430.8 (281.4) 31 461.7 (346.4) 12.6 % -0.10 [ -0.58, 0.38 ]
Irwin 2015 45 222.1 (118.6) 38 103.6 (104.6) 12.9 % 1.04 [ 0.58, 1.51 ]
Kiecolt-Glaser 2014 96 11.2 (7.6) 90 9.1 (6.1) 16.1 % 0.30 [ 0.01, 0.59 ]
Rogers 2015 110 169 (119) 112 74 (107) 16.3 % 0.84 [ 0.56, 1.11 ]
Subtotal (95% CI) 389 363 100.0 % 0.55 [ 0.25, 0.84 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 23.80, df = 7 (P = 0.001); I2 =71%
Test for overall effect: Z = 3.65 (P = 0.00026)
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Analysis 16.30. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 30 Overall self-
reported physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 30 Overall self-reported physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Schmitz 2009 (1) 48 2.8 (16.8) 57 -0.8 (16.6) 100.0 % 0.21 [ -0.17, 0.60 ]
Subtotal (95% CI) 48 57 100.0 % 0.21 [ -0.17, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
2 Individual format
Matthews 2007 22 21.5 (30.6) 14 5 (13.8) 8.2 % 0.63 [ -0.06, 1.32 ]
Pinto 2005 39 84.74 (189.2) 43 -18.27 (200.7) 20.0 % 0.52 [ 0.08, 0.96 ]
Vallance 2007 281 82 (168.7) 96 30 (167.8) 71.8 % 0.31 [ 0.08, 0.54 ]
Subtotal (95% CI) 342 153 100.0 % 0.38 [ 0.18, 0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.28, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.75 (P = 0.00018)
3 Both group and individual formats
Guinan 2013 16 15.6 (11.4476) 10 -8.3 (4.1937) 18.8 % 2.46 [ 1.39, 3.53 ]
Cadmus 2009 34 129 (117.9) 33 44.3 (89.4) 26.0 % 0.80 [ 0.30, 1.30 ]
Irwin 2015 45 159 (136) 38 49 (86) 26.5 % 0.94 [ 0.48, 1.40 ]
Saarto 2012 262 3.5 (18.3) 236 3.3 (21.5) 28.7 % 0.01 [ -0.17, 0.19 ]
Subtotal (95% CI) 357 317 100.0 % 0.92 [ 0.14, 1.70 ]
Heterogeneity: Tau2 = 0.54; Chi2 = 36.90, df = 3 (P<0.00001); I2 =92%
Test for overall effect: Z = 2.32 (P = 0.021)
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Analysis 16.31. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 31 Overall
objective physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 31 Overall objective physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Individual format
Rogers 2013 12 198.4 (111.7) 10 0 (0) Not estimable
Matthews 2007 22 330.8 (114.7) 14 198.5 (55.4) 10.1 % 1.34 [ 0.60, 2.09 ]
Rogers 2014 20 294 (175) 22 154 (75) 11.6 % 1.04 [ 0.39, 1.69 ]
Kim 2015 20 17.6 (16.03) 19 11.8 (11.6) 11.8 % 0.40 [ -0.23, 1.04 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 14.0 % 1.01 [ 0.50, 1.52 ]
Pinto 2005 39 37.5 (14.25) 43 33.62 (19.43) 15.3 % 0.22 [ -0.21, 0.66 ]
Vallance 2007 253 8110.5 (4133.9) 85 8028 (3457) 18.5 % 0.02 [ -0.23, 0.27 ]
Short 2014 219 9363.07 (7922.79) 111 8301.2 (3373.4) 18.8 % 0.16 [ -0.07, 0.39 ]
Subtotal (95% CI) 621 336 100.0 % 0.51 [ 0.18, 0.85 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 26.54, df = 6 (P = 0.00018); I2 =77%
Test for overall effect: Z = 3.01 (P = 0.0026)
3 Both group and individual formats
Guinan 2013 16 30.7 (15.6) 9 31 (15.6) 6.7 % -0.02 [ -0.84, 0.80 ]
Rogers 2009 20 252191 (91893) 18 210917 (64078) 10.6 % 0.51 [ -0.14, 1.15 ]
Cadmus 2009 33 6738 (2958) 34 5537 (3352) 19.1 % 0.38 [ -0.11, 0.86 ]
Rogers 2015 110 246 (153) 112 197 (138) 63.6 % 0.34 [ 0.07, 0.60 ]
Subtotal (95% CI) 179 173 100.0 % 0.34 [ 0.13, 0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.01, df = 3 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 3.13 (P = 0.0018)
-4 -2 0 2 4
Favours control Favours physical activity
766Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 16.32. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 32 Overall
objective physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 32 Overall objective physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Group format
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Individual format
Matthews 2007 22 72.2 (114.6) 14 -16.8 (51.5) 30.7 % 0.91 [ 0.20, 1.62 ]
Rogers 2014 20 114 (109) 22 10 (70) 31.6 % 1.13 [ 0.47, 1.78 ]
Vallance 2007 253 -150 (5173.3) 85 91 (5155.4) 37.8 % -0.05 [ -0.29, 0.20 ]
Subtotal (95% CI) 295 121 100.0 % 0.62 [ -0.23, 1.46 ]
Heterogeneity: Tau2 = 0.48; Chi2 = 15.36, df = 2 (P = 0.00046); I2 =87%
Test for overall effect: Z = 1.43 (P = 0.15)
3 Both group and individual formats
Guinan 2013 16 -1.1 (6.2) 9 -7.9 (5.3) 24.0 % 1.11 [ 0.23, 2.00 ]
Cadmus 2009 33 1621 (2108) 34 -60 (2341) 76.0 % 0.75 [ 0.25, 1.24 ]
Subtotal (95% CI) 49 43 100.0 % 0.83 [ 0.40, 1.27 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 3.78 (P = 0.00016)
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Analysis 16.33. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 33 Mass (follow-
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 33 Mass (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 Group format
Mustian 2004 11 67.1 (10.42) 10 68.6 (13.84) 7.1 % -1.50 [ -12.06, 9.06 ]
Herrero 2006 8 65.6 (8.7) 8 67.3 (8.9) 10.7 % -1.70 [ -10.32, 6.92 ]
Murtezani 2014 30 71.7 (9.5) 32 72.6 (10.75) 31.2 % -0.90 [ -5.94, 4.14 ]
Schmitz 2009 131 76.15 (15.66) 133 77.19 (17.02) 51.0 % -1.04 [ -4.98, 2.90 ]
Subtotal (95% CI) 180 183 100.0 % -1.10 [ -3.92, 1.72 ]
Heterogeneity: Chi2 = 0.03, df = 3 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.44)
2 Individual format
Matthews 2007 22 74.9 (15.2) 14 78.9 (20.3) 0.6 % -4.00 [ -16.39, 8.39 ]
Courneya 2003 24 78.2 (20.5) 26 80.1 (16.2) 0.8 % -1.90 [ -12.20, 8.40 ]
DeNysschen 2011 30 69.3 (14.2) 34 72.4 (19.6) 1.3 % -3.10 [ -11.42, 5.22 ]
Daley 2007 33 74.26 (12.49) 69 75.6 (12.5) 3.3 % -1.34 [ -6.52, 3.84 ]
Schmitz 2005 39 69.5 (2.22) 40 69.2 (2.2) 94.0 % 0.30 [ -0.67, 1.27 ]
Subtotal (95% CI) 148 183 100.0 % 0.16 [ -0.79, 1.10 ]
Heterogeneity: Chi2 = 1.58, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.33 (P = 0.74)
3 Both group and individual formats
Nikander 2007 14 73.5 (13.3) 14 75.5 (12) 0.7 % -2.00 [ -11.38, 7.38 ]
Cadmus 2009 36 80.73 (16.88) 33 78.51 (20.64) 0.7 % 2.22 [ -6.72, 11.16 ]
Ligibel 2008 40 80 (17.5) 42 83.3 (18.7) 0.9 % -3.30 [ -11.14, 4.54 ]
Littman 2012 28 81.1 (13.6) 27 81.3 (14.3) 1.1 % -0.20 [ -7.58, 7.18 ]
Winters-Stone 2011 36 76.5 (15.6) 31 74.2 (12.3) 1.3 % 2.30 [ -4.39, 8.99 ]
Kiecolt-Glaser 2014 96 75.2 (2.8) 90 75.2 (2.6) 95.4 % 0.0 [ -0.78, 0.78 ]
Subtotal (95% CI) 250 237 100.0 % 0.00 [ -0.76, 0.76 ]
Heterogeneity: Chi2 = 1.55, df = 5 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.00 (P = 1.0)
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Analysis 16.34. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 34 Mass (change
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 34 Mass (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Group format
Mustian 2004 9 -0.3 (1.86) 10 0.6 (1.43) 28.4 % -0.90 [ -2.40, 0.60 ]
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 32.8 % -0.60 [ -1.98, 0.78 ]
Murtezani 2014 30 -2.3 (2.4) 32 -0.3 (2.6) 38.7 % -2.00 [ -3.24, -0.76 ]
Subtotal (95% CI) 104 107 100.0 % -1.23 [ -2.10, -0.35 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 2.46, df = 2 (P = 0.29); I2 =19%
Test for overall effect: Z = 2.75 (P = 0.0060)
2 Individual format
Matthews 2007 22 0.01 (2.09) 14 0.04 (2.16) 1.6 % -0.03 [ -1.46, 1.40 ]
Naumann 2012 11 0.45 (1.33) 10 0.12 (1.52) 2.2 % 0.33 [ -0.90, 1.56 ]
Courneya 2003 24 0.1 (2) 26 0.7 (1.8) 2.9 % -0.60 [ -1.66, 0.46 ]
Schmitz 2005 39 0.32 (0.43) 40 0.2 (0.42) 93.3 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 96 90 100.0 % 0.10 [ -0.08, 0.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.89, df = 3 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.27)
3 Both group and individual formats
Irwin 2015 45 -2.1 (4.3) 38 0.1 (3.6) 25.7 % -2.20 [ -3.90, -0.50 ]
Ligibel 2008 22 0 (2.3) 14 0.04 (2.16) 29.2 % -0.04 [ -1.52, 1.44 ]
Saarto 2012 262 0.66 (3.68) 236 0.67 (3.84) 45.0 % -0.01 [ -0.67, 0.65 ]
Subtotal (95% CI) 329 288 100.0 % -0.58 [ -1.80, 0.63 ]
Heterogeneity: Tau2 = 0.74; Chi2 = 5.64, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.94 (P = 0.35)
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Analysis 16.35. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 35 BMI (follow-
up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 35 BMI (follow-up values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Fixed,95% CI IV,Fixed,95% CI
1 Group format
Mustian 2004 11 23.9 (4.17) 10 26.7 (5.59) 5.9 % -2.80 [ -7.05, 1.45 ]
Murtezani 2014 30 25.1 (2.9) 32 25.8 (3.47) 42.1 % -0.70 [ -2.29, 0.89 ]
Schmitz 2009 131 28.46 (5.55) 133 28.94 (6.27) 52.1 % -0.48 [ -1.91, 0.95 ]
Subtotal (95% CI) 172 175 100.0 % -0.71 [ -1.74, 0.32 ]
Heterogeneity: Chi2 = 1.03, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.35 (P = 0.18)
2 Individual format
Portela 2008 25 29.1 (5.5) 9 34.7 (15) 0.1 % -5.60 [ -15.63, 4.43 ]
Rogers 2013 12 33.6 (7) 10 30.6 (7.28) 0.3 % 3.00 [ -3.00, 9.00 ]
Courneya 2003 24 29.4 (7.4) 26 29.3 (6) 0.7 % 0.10 [ -3.65, 3.85 ]
Rogers 2014 20 29.6 (5) 22 32.2 (6.7) 0.8 % -2.60 [ -6.16, 0.96 ]
Pinto 2005 39 27.66 (5.01) 43 29.01 (5.62) 1.8 % -1.35 [ -3.65, 0.95 ]
Vallance 2007 253 27.01 (5.21) 85 27.2 (5.15) 5.9 % -0.19 [ -1.46, 1.08 ]
Schmitz 2005 39 26 (0.74) 40 25.8 (0.73) 90.5 % 0.20 [ -0.12, 0.52 ]
Subtotal (95% CI) 412 235 100.0 % 0.13 [ -0.18, 0.44 ]
Heterogeneity: Chi2 = 6.41, df = 6 (P = 0.38); I2 =6%
Test for overall effect: Z = 0.82 (P = 0.41)
3 Both group and individual formats
Rogers 2009 20 30.6 (7.6) 18 30.4 (8.3) 0.3 % 0.20 [ -4.88, 5.28 ]
Nikander 2007 14 26.9 (5.6) 14 27.7 (4.9) 0.5 % -0.80 [ -4.70, 3.10 ]
Cadmus 2009 36 30.45 (6) 33 29.9 (7.59) 0.8 % 0.55 [ -2.70, 3.80 ]
Ligibel 2008 40 30.3 (6.3) 42 31.5 (6.8) 1.0 % -1.20 [ -4.04, 1.64 ]
Littman 2012 28 27.66 (5.01) 27 29.01 (5.62) 1.0 % -1.35 [ -4.17, 1.47 ]
Kiecolt-Glaser 2014 96 27.8 (1.08) 90 27.8 (0.95) 96.3 % 0.0 [ -0.29, 0.29 ]
Subtotal (95% CI) 234 224 100.0 % -0.03 [ -0.31, 0.26 ]
Heterogeneity: Chi2 = 1.82, df = 5 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
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Analysis 16.36. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 36 BMI (change
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 36 BMI (change values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Group format
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 5.1 % -0.60 [ -1.98, 0.78 ]
Mustian 2004 9 -0.42 (0.75) 10 0.29 (0.61) 25.3 % -0.71 [ -1.33, -0.09 ]
Murtezani 2014 30 -0.8 (0.7) 32 -0.14 (0.8) 69.6 % -0.66 [ -1.03, -0.29 ]
Subtotal (95% CI) 104 107 100.0 % -0.67 [ -0.98, -0.36 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.03, df = 2 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 4.21 (P = 0.000025)
2 Individual format
Naumann 2012 11 0.1 (0.5) 10 -0.1 (0.57) 13.1 % 0.20 [ -0.26, 0.66 ]
Courneya 2003 24 0 (0.7) 26 0.3 (0.7) 17.2 % -0.30 [ -0.69, 0.09 ]
Schmitz 2005 39 0.06 (0.17) 40 0.07 (0.16) 69.7 % -0.01 [ -0.08, 0.06 ]
Subtotal (95% CI) 74 76 100.0 % -0.03 [ -0.22, 0.15 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.92, df = 2 (P = 0.23); I2 =32%
Test for overall effect: Z = 0.35 (P = 0.73)
3 Both group and individual formats
Rogers 2014 20 -0.2 (0.9) 22 -0.3 (1.1) 27.1 % 0.10 [ -0.51, 0.71 ]
Ligibel 2008 40 0 (0.9) 42 0.2 (0.8) 72.9 % -0.20 [ -0.57, 0.17 ]
Subtotal (95% CI) 60 64 100.0 % -0.12 [ -0.43, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
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Analysis 16.37. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 37 Overall body
fat (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 37 Overall body fat (follow-up values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Group format
Herrero 2006 8 22 (5) 8 22 (4) 5.4 % 0.0 [ -0.98, 0.98 ]
Mustian 2004 11 38.5 (4.47) 10 41.7 (4.89) 6.6 % -0.66 [ -1.54, 0.23 ]
Schmitz 2009 130 38.47 (5.93) 132 39.74 (5.9) 88.0 % -0.21 [ -0.46, 0.03 ]
Subtotal (95% CI) 149 150 100.0 % -0.23 [ -0.46, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 2.00 (P = 0.046)
2 Individual format
Cerulli 2014 10 26.72 (5.34) 10 30.55 (4.4) 5.4 % -0.75 [ -1.66, 0.16 ]
Rogers 2013 10 44.2 (6.7) 12 42.3 (7.7) 6.1 % 0.25 [ -0.59, 1.09 ]
Matthews 2007 22 39.7 (6.3) 14 43.1 (6.9) 8.2 % -0.51 [ -1.19, 0.17 ]
Musanti 2012 30 34.13 (6.64) 12 33.7 (5.7) 8.4 % 0.07 [ -0.60, 0.74 ]
Rogers 2014 20 38.6 (6.4) 22 41.5 (7.4) 9.4 % -0.41 [ -1.02, 0.20 ]
Courneya 2003 24 131.9 (46.4) 26 137.1 (44.4) 10.5 % -0.11 [ -0.67, 0.44 ]
DeNysschen 2011 30 36.9 (8.4) 34 38 (10.2) 12.0 % -0.12 [ -0.61, 0.38 ]
Schmitz 2005 39 40.91 (1.31) 40 42.29 (1.3) 12.5 % -1.05 [ -1.52, -0.58 ]
Pinto 2005 39 37.53 (4.79) 43 38.55 (4.83) 13.5 % -0.21 [ -0.64, 0.22 ]
Daley 2007 33 39.4 (4.74) 69 40.1 (7.4) 14.0 % -0.10 [ -0.52, 0.31 ]
Subtotal (95% CI) 257 282 100.0 % -0.30 [ -0.54, -0.06 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 15.84, df = 9 (P = 0.07); I2 =43%
Test for overall effect: Z = 2.44 (P = 0.015)
3 Both group and individual formats
Rogers 2009 20 44.3 (7.4) 19 43.5 (7.5) 12.1 % 0.11 [ -0.52, 0.73 ]
Winters-Stone 2011 36 40.5 (6.2) 31 38.5 (5.8) 20.5 % 0.33 [ -0.16, 0.81 ]
Saarto 2012 37 39.9 (7.5) 30 40.2 (8) 20.6 % -0.04 [ -0.52, 0.44 ]
Cadmus 2009 36 40.54 (6.55) 33 39.6 (5.97) 21.4 % 0.15 [ -0.33, 0.62 ]
Ligibel 2008 40 42.9 (7.4) 42 44.7 (8) 25.4 % -0.23 [ -0.67, 0.20 ]
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N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 169 155 100.0 % 0.05 [ -0.17, 0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.20, df = 4 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.40 (P = 0.69)
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Analysis 16.38. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 38 Overall body
fat (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 38 Overall body fat (change values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Group format
Mustian 2004 9 -0.16 (2.91) 10 0.28 (1.57) 12.8 % -0.18 [ -1.09, 0.72 ]
Schmitz 2009 (1) 65 -0.3 (5.7) 63 -0.1 (3.3) 87.2 % -0.04 [ -0.39, 0.30 ]
Subtotal (95% CI) 74 73 100.0 % -0.06 [ -0.38, 0.26 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
2 Individual format
Naumann 2012 11 -0.3 (2.42) 10 0.8 (2.75) 15.7 % -0.41 [ -1.28, 0.46 ]
Musanti 2012 30 -0.24 (2.83) 12 1.4 (1.57) 16.6 % -0.63 [ -1.32, 0.05 ]
Matthews 2007 22 -0.2 (1.62) 14 0.41 (1.94) 16.7 % -0.34 [ -1.02, 0.33 ]
Schmitz 2005 39 -1.15 (0.45) 40 0.23 (0.44) 16.8 % -3.07 [ -3.73, -2.41 ]
Rogers 2014 20 -1.1 (2.2) 22 -0.6 (2.4) 17.0 % -0.21 [ -0.82, 0.39 ]
Courneya 2003 24 -4.9 (15.7) 26 5.1 (24.4) 17.2 % -0.48 [ -1.04, 0.09 ]
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N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 146 124 100.0 % -0.86 [ -1.74, 0.02 ]
Heterogeneity: Tau2 = 1.10; Chi2 = 52.97, df = 5 (P<0.00001); I2 =91%
Test for overall effect: Z = 1.91 (P = 0.057)
3 Both group and individual formats
Ligibel 2008 40 -0.2 (1.7) 42 0.3 (1.7) 100.0 % -0.29 [ -0.73, 0.14 ]
Subtotal (95% CI) 40 42 100.0 % -0.29 [ -0.73, 0.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
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Analysis 16.39. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 39 Lower body
strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 39 Lower body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Group format
Milne 2008 29 66.2 (10.2) 29 61.7 (11) 36.2 % 0.42 [ -0.10, 0.94 ]
Schmitz 2009 113 223.4 (59.6) 119 175.1 (53.5) 63.8 % 0.85 [ 0.58, 1.12 ]
Subtotal (95% CI) 142 148 100.0 % 0.69 [ 0.29, 1.10 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 2.09, df = 1 (P = 0.15); I2 =52%
Test for overall effect: Z = 3.34 (P = 0.00084)
2 Individual format
Cerulli 2014 10 114.88 (17.09) 10 79.13 (17.78) 28.5 % 1.96 [ 0.85, 3.07 ]
Rogers 2013 11 68.4 (15.5) 9 67.1 (16.2) 33.2 % 0.08 [ -0.80, 0.96 ]
Schmitz 2005 23 296.6 (48.9) 22 238.9 (46.4) 38.3 % 1.19 [ 0.55, 1.83 ]
Subtotal (95% CI) 44 41 100.0 % 1.04 [ 0.08, 2.00 ]
Heterogeneity: Tau2 = 0.52; Chi2 = 7.43, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 2.13 (P = 0.033)
3 Both group and individual formats
Nikander 2007 14 1305 (177) 14 1393 (275) 16.7 % -0.37 [ -1.12, 0.38 ]
Rogers 2009 20 80.3 (27) 18 64.9 (19.7) 20.6 % 0.63 [ -0.02, 1.29 ]
Saarto 2012 37 136 (23) 30 136 (29) 31.3 % 0.0 [ -0.48, 0.48 ]
Winters-Stone 2011 36 201.3 (57.4) 31 191 (51.7) 31.4 % 0.19 [ -0.30, 0.67 ]
Subtotal (95% CI) 107 93 100.0 % 0.13 [ -0.22, 0.47 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 4.31, df = 3 (P = 0.23); I2 =30%
Test for overall effect: Z = 0.72 (P = 0.47)
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Analysis 16.40. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 40 Lower body
strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 40 Lower body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Group format
Cormie 2014 43 37.6 (25.5) 19 6.7 (25.7) 23.7 % 1.19 [ 0.61, 1.78 ]
Schmitz 2009 113 33.2 (33.9) 119 7.9 (26.6) 76.3 % 0.83 [ 0.56, 1.10 ]
Subtotal (95% CI) 156 138 100.0 % 0.92 [ 0.61, 1.22 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 1.24, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 5.93 (P < 0.00001)
2 Individual format
Naumann 2012 11 7.7 (12.6) 10 3.5 (13.9) 23.4 % 0.30 [ -0.56, 1.17 ]
Schmitz 2005 23 81.8 (48.92) 22 20.3 (45.97) 30.7 % 1.27 [ 0.63, 1.92 ]
Waltman 2010 110 4.42 (11.48) 113 0.19 (8.38) 45.8 % 0.42 [ 0.15, 0.69 ]
Subtotal (95% CI) 144 145 100.0 % 0.65 [ 0.09, 1.22 ]
Heterogeneity: Tau2 = 0.17; Chi2 = 5.98, df = 2 (P = 0.05); I2 =67%
Test for overall effect: Z = 2.26 (P = 0.024)
3 Both group and individual formats
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 16.41. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 41 Upper body
strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 41 Upper body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Group format
Mustian 2004 11 29.6 (3.27) 10 26.7 (5.73) 21.6 % 0.60 [ -0.28, 1.49 ]
Kaltsatou 2011 28 59.63 (8.49) 26 47.62 (9.83) 25.0 % 1.29 [ 0.70, 1.88 ]
Milne 2008 29 7.6 (2.9) 29 9.4 (2.6) 25.6 % -0.64 [ -1.17, -0.12 ]
Schmitz 2009 113 52.9 (15.3) 119 40.9 (11.8) 27.8 % 0.88 [ 0.61, 1.15 ]
Subtotal (95% CI) 181 184 100.0 % 0.53 [ -0.29, 1.35 ]
Heterogeneity: Tau2 = 0.61; Chi2 = 30.31, df = 3 (P<0.00001); I2 =90%
Test for overall effect: Z = 1.27 (P = 0.20)
2 Individual format
Cerulli 2014 10 16.08 (5.43) 10 17.2 (8.05) 22.5 % -0.16 [ -1.03, 0.72 ]
Portela 2008 25 39.3 (12.3) 9 35.6 (13.1) 24.7 % 0.29 [ -0.48, 1.05 ]
Musanti 2012 30 52.13 (20.98) 12 36.75 (20) 26.2 % 0.73 [ 0.04, 1.42 ]
Schmitz 2005 23 83 (13.4) 22 63 (12.7) 26.6 % 1.50 [ 0.84, 2.17 ]
Subtotal (95% CI) 88 53 100.0 % 0.63 [ -0.06, 1.32 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 10.32, df = 3 (P = 0.02); I2 =71%
Test for overall effect: Z = 1.78 (P = 0.075)
3 Both group and individual formats
Nikander 2007 14 131 (20) 14 129 (28) 14.3 % 0.08 [ -0.66, 0.82 ]
Rogers 2009 20 27.9 (5.04) 18 24.3 (6.18) 18.4 % 0.63 [ -0.03, 1.28 ]
Saarto 2012 37 32.7 (5.3) 30 30.8 (5.7) 33.4 % 0.34 [ -0.14, 0.83 ]
Winters-Stone 2011 36 63.3 (15.3) 31 61.1 (16.8) 34.0 % 0.14 [ -0.34, 0.62 ]
Subtotal (95% CI) 107 93 100.0 % 0.29 [ 0.01, 0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.78, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
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Analysis 16.42. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 42 Upper body
strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 42 Upper body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Group format
Cormie 2014 43 5.7 (3.67) 19 1 (3.78) 28.2 % 1.25 [ 0.67, 1.84 ]
Mustian 2004 45 4.5 (4.71) 38 -0.85 (3.15) 32.1 % 1.30 [ 0.82, 1.78 ]
Schmitz 2009 113 33.2 (40.8) 119 7.6 (43.7) 39.6 % 0.60 [ 0.34, 0.87 ]
Subtotal (95% CI) 201 176 100.0 % 1.01 [ 0.49, 1.53 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 8.61, df = 2 (P = 0.01); I2 =77%
Test for overall effect: Z = 3.82 (P = 0.00013)
2 Individual format
Schmitz 2005 23 32.3 (11.51) 22 6.9 (10.79) 31.4 % 2.24 [ 1.48, 2.99 ]
Musanti 2012 30 7.74 (10.62) 12 0.83 (12.65) 32.3 % 0.60 [ -0.08, 1.29 ]
Waltman 2010 110 1.9 (4.86) 113 0.75 (2.9) 36.3 % 0.29 [ 0.02, 0.55 ]
Subtotal (95% CI) 163 147 100.0 % 1.00 [ -0.08, 2.09 ]
Heterogeneity: Tau2 = 0.83; Chi2 = 22.68, df = 2 (P = 0.00001); I2 =91%
Test for overall effect: Z = 1.81 (P = 0.070)
3 Both group and individual formats
Irwin 2015 45 0.4 (1.88) 38 0.1 (1.89) 100.0 % 0.16 [ -0.27, 0.59 ]
Subtotal (95% CI) 45 38 100.0 % 0.16 [ -0.27, 0.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.47)
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Analysis 16.43. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 43 Bone
mineral density - femoral neck (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 43 Bone mineral density - femoral neck (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Group format
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Individual format
Kim 2015 20 0.78 (0.08) 19 0.81 (0.08) 45.7 % -0.37 [ -1.00, 0.27 ]
Waltman 2010 (1) 110 0.92 (0.5) 113 0.63 (0.42) 54.3 % 0.63 [ 0.36, 0.90 ]
Subtotal (95% CI) 130 132 100.0 % 0.17 [ -0.80, 1.14 ]
Heterogeneity: Tau2 = 0.43; Chi2 = 8.01, df = 1 (P = 0.005); I2 =88%
Test for overall effect: Z = 0.35 (P = 0.73)
3 Both group and individual formats
Winters-Stone 2011 36 0.72 (0.1) 31 0.71 (0.08) 12.8 % 0.11 [ -0.37, 0.59 ]
Saarto 2012 (2) 239 -0.006 (0.025) 218 -0.01 (0.03) 87.2 % 0.18 [ 0.00, 0.37 ]
Subtotal (95% CI) 275 249 100.0 % 0.17 [ 0.00, 0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.08, df = 1 (P = 0.78); I2 =0.0%
Test for overall effect: Z = 1.96 (P = 0.049)
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Analysis 16.44. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 44 Bone
mineral density - lumbar spine (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 44 Bone mineral density - lumbar spine (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Group format
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Individual format
Kim 2015 20 0.97 (0.08) 19 0.99 (0.07) 43.5 % -0.26 [ -0.89, 0.37 ]
Waltman 2010 (1) 110 3.08 (0.44) 113 2.85 (0.4) 56.5 % 0.55 [ 0.28, 0.81 ]
Subtotal (95% CI) 130 132 100.0 % 0.20 [ -0.59, 0.98 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 5.31, df = 1 (P = 0.02); I2 =81%
Test for overall effect: Z = 0.49 (P = 0.62)
3 Both group and individual formats
Winters-Stone 2011 36 0.99 (0.15) 31 0.95 (0.11) 12.6 % 0.30 [ -0.19, 0.78 ]
Saarto 2012 (2) 239 -0.018 (0.033) 218 -0.02 (0.034) 87.4 % 0.09 [ -0.09, 0.27 ]
Subtotal (95% CI) 275 249 100.0 % 0.12 [ -0.06, 0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
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Analysis 16.45. Comparison 16 Subanalysis: outcomes by format of intervention, Outcome 45 Bone
mineral density - total hip (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 16 Subanalysis: outcomes by format of intervention
Outcome: 45 Bone mineral density - total hip (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Group format
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Individual format
Kim 2015 20 0.88 (0.08) 19 0.09 (0.07) 100.0 % 10.34 [ 7.84, 12.84 ]
Subtotal (95% CI) 20 19 100.0 % 10.34 [ 7.84, 12.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.11 (P < 0.00001)
3 Both group and individual formats
Winters-Stone 2011 36 0.86 (0.11) 31 0.84 (0.1) 47.3 % 0.19 [ -0.29, 0.67 ]
Waltman 2010 (1) 110 2.15 (0.28) 113 1.81 (0.36) 52.7 % 1.05 [ 0.77, 1.33 ]
Subtotal (95% CI) 146 144 100.0 % 0.64 [ -0.20, 1.48 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 9.19, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 1.49 (P = 0.14)
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Analysis 17.1. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 1 Overall HRQoL
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 1 Overall HRQoL (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Portela 2008 13 104.8 (32.1) 9 91.6 (28.5) 3.1 % 0.41 [ -0.45, 1.27 ]
Ergun 2013 40 68.97 (19.89) 20 67.91 (16.7) 7.9 % 0.06 [ -0.48, 0.59 ]
Pinto 2015 39 117.79 (12.74) 37 113.98 (18.02) 11.2 % 0.24 [ -0.21, 0.69 ]
Vallance 2007 250 91.54 (11.76) 85 90.55 (12.95) 37.6 % 0.08 [ -0.16, 0.33 ]
Short 2014 195 106.8 (16.7) 104 108.2 (18.2) 40.2 % -0.08 [ -0.32, 0.16 ]
Subtotal (95% CI) 537 255 100.0 % 0.04 [ -0.11, 0.19 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.60, df = 4 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 0.55 (P = 0.58)
2 Facility-based
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 4.0 % 1.30 [ 0.19, 2.41 ]
Cerulli 2014 10 85.23 (4.2) 10 65.89 (14.66) 4.2 % 1.72 [ 0.66, 2.78 ]
Portela 2008 12 109.8 (25.2) 9 91.6 (28.5) 5.1 % 0.66 [ -0.24, 1.55 ]
Mustian 2004 11 121.7 (22.67) 10 124.3 (25.9) 5.3 % -0.10 [ -0.96, 0.75 ]
Loudon 2014 12 -7.42 (1.24) 11 -7.45 (1.44) 5.5 % 0.02 [ -0.80, 0.84 ]
Milne 2008 29 86.4 (8.3) 29 64.1 (10.8) 6.4 % 2.28 [ 1.61, 2.96 ]
Ergun 2013 20 74.16 (18.71) 20 67.91 (16.7) 6.8 % 0.35 [ -0.28, 0.97 ]
Courneya 2003 24 91.3 (11) 28 89.3 (10.9) 7.3 % 0.18 [ -0.37, 0.73 ]
Murtezani 2014 30 86.5 (7.3) 32 79.1 (7.5) 7.5 % 0.99 [ 0.46, 1.52 ]
Mehnert 2011 30 74.72 (21.72) 27 65.43 (16.78) 7.5 % 0.47 [ -0.06, 1.00 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 7.7 % 0.28 [ -0.22, 0.79 ]
Schmitz 2005 39 -44.2 (8.7) 40 -47.4 (9.4) 8.1 % 0.35 [ -0.09, 0.79 ]
Taleghani 2012 40 217.5 (36.3) 40 210.1 (41.5) 8.1 % 0.19 [ -0.25, 0.63 ]
Daley 2007 33 90.85 (13.47) 69 86.44 (15.07) 8.3 % 0.30 [ -0.12, 0.72 ]
Littman 2012 30 90.3 (11) 110 87.7 (15) 8.4 % 0.18 [ -0.22, 0.59 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 360 473 100.0 % 0.55 [ 0.27, 0.83 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 48.47, df = 14 (P = 0.00001); I2 =71%
Test for overall effect: Z = 3.80 (P = 0.00014)
3 Both home- and facility-based
Rogers 2015 10 85.23 (4.2) 10 65.89 (14.66) 12.6 % 1.72 [ 0.66, 2.78 ]
Rogers 2009 20 92 (11.4) 18 87.4 (13.1) 23.5 % 0.37 [ -0.27, 1.01 ]
Cadmus 2009 37 91.2 (12.6) 37 86.2 (17.4) 31.2 % 0.33 [ -0.13, 0.78 ]
Loh 2014 63 112.4 (14.09) 32 109.29 (13.26) 32.7 % 0.22 [ -0.20, 0.65 ]
Subtotal (95% CI) 130 97 100.0 % 0.48 [ 0.04, 0.92 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 6.70, df = 3 (P = 0.08); I2 =55%
Test for overall effect: Z = 2.14 (P = 0.033)
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Analysis 17.2. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 2 Overall HRQoL
(change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 2 Overall HRQoL (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Ergun 2013 20 4.62 (26.54) 20 -6.66 (25.87) 13.4 % 0.42 [ -0.21, 1.05 ]
Vallance 2007 250 2.3 (11.08) 85 -0.16 (6.4) 86.6 % 0.24 [ 0.00, 0.49 ]
Subtotal (95% CI) 270 105 100.0 % 0.27 [ 0.04, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.27, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.28 (P = 0.023)
2 Facility-based
Mustian 2004 11 15 (5) 10 0 (5) 8.0 % 2.88 [ 1.59, 4.17 ]
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 8.2 % 1.92 [ 0.68, 3.17 ]
Murtezani 2014 30 9.16 (2.12) 32 -0.56 (2.01) 9.2 % 4.65 [ 3.67, 5.63 ]
Naumann 2012 11 14.5 (10.6) 10 3.1 (11.4) 9.5 % 1.00 [ 0.08, 1.92 ]
Ergun 2013 20 6.25 (15.5) 20 -6.66 (25.87) 10.5 % 0.59 [ -0.04, 1.23 ]
Cuesta-Vargas 2014 22 0.32 (0.18) 20 0.33 (0.09) 10.6 % -0.07 [ -0.67, 0.54 ]
Courneya 2003 24 5.7 (7.4) 28 0.6 (7.4) 10.8 % 0.68 [ 0.12, 1.24 ]
Mehnert 2011 30 9.72 (21.03) 27 5.55 (16.5) 10.9 % 0.22 [ -0.31, 0.74 ]
Schmitz 2005 39 2.3 (4.5) 40 0.6 (4) 11.1 % 0.40 [ -0.05, 0.84 ]
Daley 2007 33 10.22 (11.2) 69 3.2 (11.26) 11.2 % 0.62 [ 0.20, 1.04 ]
Subtotal (95% CI) 228 264 100.0 % 1.18 [ 0.53, 1.82 ]
Heterogeneity: Tau2 = 0.93; Chi2 = 88.77, df = 9 (P<0.00001); I2 =90%
Test for overall effect: Z = 3.57 (P = 0.00036)
3 Both home- and facility-based
Rogers 2009 20 4.5 (8.4) 18 2.9 (12) 15.3 % 0.15 [ -0.49, 0.79 ]
Cadmus 2009 37 0.6 (7.5) 37 -2.4 (9.8) 25.0 % 0.34 [ -0.12, 0.80 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 59.7 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 320 292 100.0 % 0.06 [ -0.22, 0.33 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.23, df = 2 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.39 (P = 0.69)
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Analysis 17.3. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 3 Overall
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 3 Overall emotional function/mental health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Basen-Enquist 2006 28 78.2 (10.58) 23 77.2 (11.99) 8.9 % 0.09 [ -0.46, 0.64 ]
Pinto 2015 39 54.21 (9.28) 37 52.48 (9.62) 13.4 % 0.18 [ -0.27, 0.63 ]
Pinto 2005 39 -8.02 (20.69) 43 -16.51 (28.75) 14.3 % 0.33 [ -0.10, 0.77 ]
Duijits 2012 37 73.92 (34.7) 89 77.46 (34.32) 18.5 % -0.10 [ -0.49, 0.28 ]
Vallance 2007 250 20.28 (3.31) 85 19.92 (3.44) 44.9 % 0.11 [ -0.14, 0.35 ]
Subtotal (95% CI) 393 277 100.0 % 0.11 [ -0.06, 0.27 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.28, df = 4 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.30 (P = 0.20)
2 Facility-based
Banasik 2011 7 0.47 (0.36) 7 0.38 (0.31) 2.7 % 0.25 [ -0.80, 1.30 ]
Herrero 2006 8 90.6 (9.3) 8 83.3 (14.8) 2.9 % 0.56 [ -0.45, 1.56 ]
Mustian 2004 9 24.78 (2.04) 10 24.8 (3.19) 3.5 % -0.01 [ -0.91, 0.89 ]
Loudon 2014 12 -1.58 (0.7) 11 -1.61 (0.49) 4.0 % 0.05 [ -0.77, 0.87 ]
Cuesta-Vargas 2014 22 42.9 (19.17) 20 32.3 (33.33) 6.1 % 0.39 [ -0.22, 1.00 ]
Courneya 2003 24 21.5 (3.4) 28 20.7 (3) 7.0 % 0.25 [ -0.30, 0.79 ]
Milne 2008 29 19.6 (2.4) 29 16.7 (4.1) 7.1 % 0.85 [ 0.31, 1.39 ]
Do 2015 32 87.4 (8.8) 30 70.4 (21.5) 7.2 % 1.03 [ 0.50, 1.57 ]
Littman 2012 30 20.3 (4) 27 20.8 (3.1) 7.4 % -0.14 [ -0.66, 0.38 ]
Mehnert 2011 30 77.01 (35.75) 28 69.05 (40.5) 7.4 % 0.21 [ -0.31, 0.72 ]
Cantarero-Villanueva 2013 32 -17175 (4279) 29 -20390 (6113) 7.5 % 0.61 [ 0.09, 1.12 ]
Murtezani 2014 30 19.5 (3.3) 32 18.3 (3.5) 7.7 % 0.35 [ -0.15, 0.85 ]
Daley 2007 33 19.06 (4.18) 33 18.45 (3.31) 8.0 % 0.16 [ -0.32, 0.64 ]
Schmitz 2005 39 -45.6 (8.2) 40 -48.2 (8.2) 8.7 % 0.31 [ -0.13, 0.76 ]
Schmitz 2009 112 53.2 (9.6) 120 53.8 (8.7) 13.0 % -0.07 [ -0.32, 0.19 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 449 452 100.0 % 0.31 [ 0.12, 0.50 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 24.33, df = 14 (P = 0.04); I2 =42%
Test for overall effect: Z = 3.23 (P = 0.0012)
3 Both home- and facility-based
Pinto 2003 12 -10.83 (28.1) 12 -27.17 (19.5) 5.1 % 0.65 [ -0.17, 1.48 ]
Rogers 2009 20 20 (3.1) 18 21.1 (2.9) 8.2 % -0.36 [ -1.00, 0.28 ]
Cadmus 2009 37 20.5 (3) 37 19.8 (4.2) 15.3 % 0.19 [ -0.27, 0.65 ]
Loh 2014 63 19.87 (2.81) 32 19.98 (3.22) 17.4 % -0.04 [ -0.46, 0.39 ]
Fillion 2008 44 48.54 (7.91) 43 47.49 (9.08) 17.7 % 0.12 [ -0.30, 0.54 ]
Rogers 2015 105 20.6 (2.9) 108 19.7 (3.2) 36.2 % 0.29 [ 0.02, 0.56 ]
Subtotal (95% CI) 281 250 100.0 % 0.15 [ -0.04, 0.34 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 5.67, df = 5 (P = 0.34); I2 =12%
Test for overall effect: Z = 1.59 (P = 0.11)
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Analysis 17.4. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 4 Overall
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 4 Overall emotional function/mental health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Pinto 2005 39 -3.8 (27.7) 43 -11.47 (25.8) 24.2 % 0.28 [ -0.15, 0.72 ]
Vallance 2007 250 0.47 (3.54) 85 0.08 (2.49) 75.8 % 0.12 [ -0.13, 0.36 ]
Subtotal (95% CI) 289 128 100.0 % 0.16 [ -0.06, 0.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.44 (P = 0.15)
2 Facility-based
Herrero 2006 8 9.3 (19.6) 8 -2.1 (5.9) 7.0 % 0.74 [ -0.28, 1.77 ]
Mustian 2004 9 2.44 (2.52) 10 0.1 (1.68) 7.4 % 1.06 [ 0.08, 2.03 ]
Naumann 2012 11 1 (2.69) 10 -0.1 (2.72) 8.2 % 0.39 [ -0.48, 1.26 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 10.3 % 1.80 [ 1.21, 2.40 ]
Courneya 2003 24 2.3 (3.1) 28 0.8 (2.9) 10.7 % 0.49 [ -0.06, 1.05 ]
Cormie 2014 43 4.4 (9) 19 2.7 (8.6) 10.8 % 0.19 [ -0.35, 0.73 ]
Mehnert 2011 30 2.3 (35.5) 28 3.57 (17.6) 11.0 % -0.04 [ -0.56, 0.47 ]
Cantarero-Villanueva 2013 32 -1445 (4452) 29 353 (3323) 11.0 % -0.45 [ -0.96, 0.06 ]
Schmitz 2005 39 2.5 (4.4) 40 0.3 (3.9) 11.5 % 0.52 [ 0.08, 0.97 ]
Schmitz 2009 58 3.3 (23.2) 62 3.1 (17.2) 12.2 % 0.01 [ -0.35, 0.37 ]
Subtotal (95% CI) 284 266 100.0 % 0.43 [ 0.04, 0.82 ]
Heterogeneity: Tau2 = 0.29; Chi2 = 41.54, df = 9 (P<0.00001); I2 =78%
Test for overall effect: Z = 2.14 (P = 0.032)
3 Both home- and facility-based
Rogers 2009 20 0.9 (2.5) 18 -0.1 (2.7) 13.3 % 0.38 [ -0.27, 1.02 ]
Cadmus 2009 37 0.3 (2.2) 37 -0.5 (3.3) 23.0 % 0.28 [ -0.18, 0.74 ]
Saarto 2012 263 1.2 (17.79) 237 1.9 (18.46) 63.7 % -0.04 [ -0.21, 0.14 ]
Subtotal (95% CI) 320 292 100.0 % 0.09 [ -0.16, 0.34 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 2.87, df = 2 (P = 0.24); I2 =30%
Test for overall effect: Z = 0.70 (P = 0.48)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 5 Overall physical function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Basen-Enquist 2006 28 82.5 (12.7) 23 77.4 (11.5) 7.8 % 0.41 [ -0.15, 0.97 ]
Pinto 2015 39 87.08 (4.4) 37 84.69 (15.91) 11.9 % 0.21 [ -0.25, 0.66 ]
Pinto 2005 39 30.26 (7.88) 43 27.33 (6.76) 12.7 % 0.40 [ -0.04, 0.83 ]
Duijits 2012 87 84.03 (16.88) 89 80.18 (17.08) 27.6 % 0.23 [ -0.07, 0.52 ]
Vallance 2007 250 25.1 (2.96) 85 24.95 (3.26) 40.0 % 0.05 [ -0.20, 0.30 ]
Subtotal (95% CI) 443 277 100.0 % 0.19 [ 0.03, 0.34 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.78, df = 4 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
2 Facility-based
Banasik 2011 7 -0.77 (0.94) 7 -0.42 (0.25) 4.5 % -0.48 [ -1.54, 0.59 ]
Herrero 2006 8 94.1 (7.5) 8 92.5 (6.6) 5.0 % 0.21 [ -0.77, 1.20 ]
Mustian 2004 9 2.44 (1.5) 9 2.8 (1.53) 5.3 % -0.23 [ -1.15, 0.70 ]
Milne 2008 29 24 (2.6) 29 15.6 (4.5) 7.2 % 2.26 [ 1.59, 2.92 ]
Cuesta-Vargas 2014 22 42.9 (4.06) 20 32.4 (32.48) 7.6 % 0.46 [ -0.16, 1.07 ]
Courneya 2003 24 25.3 (2.5) 28 25.3 (2.8) 8.2 % 0.0 [ -0.55, 0.55 ]
Mehnert 2011 30 88.96 (9.13) 28 78.12 (21.22) 8.3 % 0.66 [ 0.13, 1.19 ]
Littman 2012 30 25.4 (1.7) 27 24.3 (4.4) 8.4 % 0.33 [ -0.19, 0.86 ]
Murtezani 2014 30 22.6 (4.4) 32 19.4 (4.4) 8.5 % 0.72 [ 0.20, 1.23 ]
Do 2015 32 89.4 (8.4) 30 89 (8.7) 8.6 % 0.05 [ -0.45, 0.54 ]
Daley 2007 33 25.61 (2.15) 33 23.61 (5.7) 8.7 % 0.46 [ -0.03, 0.95 ]
Schmitz 2005 39 -44.2 (5.6) 40 -48.3 (7.7) 9.0 % 0.60 [ 0.15, 1.05 ]
Schmitz 2009 112 50.6 (8.15) 120 49.1 (9.32) 10.5 % 0.17 [ -0.09, 0.43 ]
Subtotal (95% CI) 405 411 100.0 % 0.43 [ 0.14, 0.73 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 44.50, df = 12 (P = 0.00001); I2 =73%
Test for overall effect: Z = 2.91 (P = 0.0037)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
3 Both home- and facility-based
Pinto 2003 12 32.3 (4.3) 12 25.3 (8.2) 6.6 % 1.03 [ 0.17, 1.89 ]
Rogers 2009 20 23.3 (4.5) 18 25.4 (2.3) 10.0 % -0.57 [ -1.22, 0.08 ]
Winters-Stone 2011 36 51.7 (6.2) 25 52.3 (5.9) 13.4 % -0.10 [ -0.61, 0.41 ]
Cadmus 2009 37 25.1 (2.7) 37 24 (4.1) 15.1 % 0.31 [ -0.15, 0.77 ]
Loh 2014 63 24.92 (2.54) 32 24.17 (2.23) 16.1 % 0.30 [ -0.12, 0.73 ]
Fillion 2008 44 45.1 (10.42) 43 41.76 (9.76) 16.3 % 0.33 [ -0.10, 0.75 ]
Rogers 2015 105 24.1 (3.5) 108 22.5 (5) 22.5 % 0.37 [ 0.10, 0.64 ]
Subtotal (95% CI) 317 275 100.0 % 0.23 [ -0.02, 0.48 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 11.97, df = 6 (P = 0.06); I2 =50%
Test for overall effect: Z = 1.81 (P = 0.070)
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Analysis 17.6. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 6 Overall physical
function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 6 Overall physical function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Vallance 2007 247 1 (3.32) 85 0.19 (2.07) 100.0 % 0.26 [ 0.02, 0.51 ]
Subtotal (95% CI) 247 85 100.0 % 0.26 [ 0.02, 0.51 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.10 (P = 0.036)
2 Facility-based
Herrero 2006 8 6.7 (5) 8 -1.7 (6.9) 9.3 % 1.32 [ 0.21, 2.43 ]
Mustian 2004 9 1.89 (2.61) 10 -0.2 (1.61) 10.0 % 0.93 [ -0.03, 1.89 ]
Murtezani 2014 30 4.43 (1.53) 32 -1.34 (1.15) 10.2 % 4.23 [ 3.31, 5.15 ]
Naumann 2012 11 1.9 (3.3) 10 0.8 (3.4) 10.5 % 0.32 [ -0.55, 1.18 ]
Courneya 2003 24 1.9 (2) 28 -0.2 (2.2) 11.7 % 0.98 [ 0.40, 1.56 ]
Cormie 2014 43 3.49 (5.15) 19 -0.5 (5.67) 11.8 % 0.74 [ 0.19, 1.30 ]
Mehnert 2011 30 3.96 (10.83) 28 -2.15 (16.7) 11.9 % 0.43 [ -0.09, 0.95 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 12.2 % -0.05 [ -0.49, 0.39 ]
Schmitz 2009 58 6.6 (17.1) 62 4.1 (17.3) 12.4 % 0.14 [ -0.21, 0.50 ]
Subtotal (95% CI) 252 237 100.0 % 0.95 [ 0.31, 1.59 ]
Heterogeneity: Tau2 = 0.82; Chi2 = 79.49, df = 8 (P<0.00001); I2 =90%
Test for overall effect: Z = 2.90 (P = 0.0037)
3 Both home- and facility-based
Rogers 2009 20 2.3 (5.1) 18 2.6 (6) 6.2 % -0.05 [ -0.69, 0.58 ]
Cadmus 2009 37 0.1 (6.02) 37 -0.5 (7.42) 12.1 % 0.09 [ -0.37, 0.54 ]
Saarto 2012 263 1.9 (13.65) 237 3.4 (13.35) 81.7 % -0.11 [ -0.29, 0.06 ]
Subtotal (95% CI) 320 292 100.0 % -0.08 [ -0.24, 0.08 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.64, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
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Analysis 17.7. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 7 Overall role
function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 7 Overall role function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Basen-Enquist 2006 28 86.1 (22.2) 23 73 (24.5) 32.3 % 0.55 [ -0.01, 1.12 ]
Vallance 2007 250 23.22 (3.98) 85 22.72 (4.58) 67.7 % 0.12 [ -0.13, 0.37 ]
Subtotal (95% CI) 278 108 100.0 % 0.26 [ -0.14, 0.66 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 1.92, df = 1 (P = 0.17); I2 =48%
Test for overall effect: Z = 1.28 (P = 0.20)
2 Facility-based
Banasik 2011 7 3.46 (0.64) 7 3.24 (0.56) 5.8 % 0.34 [ -0.72, 1.40 ]
Herrero 2006 8 97.6 (5.9) 8 100 (0.01) 6.1 % -0.54 [ -1.55, 0.46 ]
Mustian 2004 9 2.44 (1.5) 9 2.8 (1.53) 6.5 % -0.23 [ -1.15, 0.70 ]
Loudon 2014 12 -1.3 (0.31) 11 -1.3 (0.36) 7.2 % 0.0 [ -0.82, 0.82 ]
Milne 2008 29 22.2 (3) 29 12.5 (4.8) 8.2 % 2.39 [ 1.71, 3.08 ]
Courneya 2003 24 23.4 (4) 28 23.1 (4) 9.2 % 0.07 [ -0.47, 0.62 ]
Mehnert 2011 30 90 (20.34) 27 79.6 (25.04) 9.3 % 0.45 [ -0.07, 0.98 ]
Littman 2012 30 22.6 (3.9) 27 21.7 (4.7) 9.3 % 0.21 [ -0.31, 0.73 ]
Murtezani 2014 30 24.2 (2.8) 32 23 (2.5) 9.5 % 0.45 [ -0.06, 0.95 ]
Do 2015 32 78.1 (19.5) 30 79.2 (14.6) 9.5 % -0.06 [ -0.56, 0.44 ]
Daley 2007 33 22.88 (4.52) 33 20.3 (5.57) 9.6 % 0.50 [ 0.01, 0.99 ]
Schmitz 2005 39 -49.2 (6.5) 40 -50 (6.2) 9.9 % 0.12 [ -0.32, 0.57 ]
Subtotal (95% CI) 283 281 100.0 % 0.33 [ -0.03, 0.69 ]
Heterogeneity: Tau2 = 0.29; Chi2 = 44.95, df = 11 (P<0.00001); I2 =76%
Test for overall effect: Z = 1.82 (P = 0.069)
3 Both home- and facility-based
Rogers 2009 20 21.4 (4.8) 18 23.8 (3.2) 16.7 % -0.57 [ -1.22, 0.08 ]
Cadmus 2009 37 23.1 (4.7) 37 20.6 (7.2) 24.0 % 0.41 [ -0.05, 0.87 ]
Loh 2014 63 23.37 (4.33) 32 22.22 (4.99) 25.6 % 0.25 [ -0.18, 0.68 ]
Rogers 2015 105 22.3 (4.5) 108 20.3 (5.5) 33.7 % 0.40 [ 0.12, 0.67 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 225 195 100.0 % 0.20 [ -0.14, 0.54 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 7.56, df = 3 (P = 0.06); I2 =60%
Test for overall effect: Z = 1.15 (P = 0.25)
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Analysis 17.8. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 8 Overall role
function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 8 Overall role function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Vallance 2007 250 0.63 (4.14) 85 -0.01 (2.7) 100.0 % 0.17 [ -0.08, 0.41 ]
Subtotal (95% CI) 250 85 100.0 % 0.17 [ -0.08, 0.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.18)
2 Facility-based
Herrero 2006 8 2.1 (13.9) 8 2.1 (5.9) 7.4 % 0.0 [ -0.98, 0.98 ]
Mustian 2004 9 0.56 (1.59) 10 0.8 (1.55) 8.3 % -0.15 [ -1.05, 0.76 ]
Naumann 2012 11 1.5 (4.41) 10 0.5 (4.49) 8.9 % 0.22 [ -0.64, 1.08 ]
Courneya 2003 24 0.9 (2.8) 28 0.4 (2.7) 14.4 % 0.18 [ -0.37, 0.73 ]
Cormie 2014 43 4.9 (7.1) 19 1.7 (7.1) 14.4 % 0.45 [ -0.10, 0.99 ]
Murtezani 2014 30 1.66 (0.71) 32 0.87 (0.64) 14.6 % 1.16 [ 0.62, 1.70 ]
Mehnert 2011 30 6.67 (23.84) 27 5.56 (27) 15.0 % 0.04 [ -0.48, 0.56 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 16.9 % -0.05 [ -0.49, 0.39 ]
Subtotal (95% CI) 194 174 100.0 % 0.26 [ -0.06, 0.58 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 14.73, df = 7 (P = 0.04); I2 =52%
Test for overall effect: Z = 1.62 (P = 0.11)
3 Both home- and facility-based
Rogers 2009 20 0.4 (3.3) 18 1.4 (4.3) 6.2 % -0.26 [ -0.90, 0.38 ]
Cadmus 2009 37 -0.3 (3.7) 37 -0.5 (3.4) 12.1 % 0.06 [ -0.40, 0.51 ]
Saarto 2012 263 2.4 (21.51) 237 3.8 (21.6) 81.7 % -0.06 [ -0.24, 0.11 ]
Subtotal (95% CI) 320 292 100.0 % -0.06 [ -0.22, 0.10 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
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Analysis 17.9. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 9 Overall social
well-being/function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 9 Overall social well-being/function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Basen-Enquist 2006 28 84.6 (16.93) 23 84.9 (19.18) 16.6 % -0.02 [ -0.57, 0.54 ]
Vallance 2007 250 22.94 (4.96) 85 22.96 (5.05) 83.4 % 0.00 [ -0.25, 0.24 ]
Subtotal (95% CI) 278 108 100.0 % -0.01 [ -0.23, 0.22 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.05 (P = 0.96)
2 Facility-based
Banasik 2011 7 2.8 (0.67) 7 3.16 (0.83) 1.9 % -0.45 [ -1.51, 0.62 ]
Herrero 2006 8 87.5 (19.4) 8 91.7 (23.6) 2.3 % -0.18 [ -1.17, 0.80 ]
Mustian 2004 9 8.63 (1.89) 10 9 (1.83) 2.7 % -0.19 [ -1.09, 0.71 ]
Courneya 2003 24 21.1 (3.5) 28 20.7 (3.6) 7.4 % 0.11 [ -0.43, 0.66 ]
Littman 2012 30 22.1 (5) 27 20.9 (6) 8.1 % 0.22 [ -0.31, 0.74 ]
Milne 2008 29 20.7 (4) 29 19.4 (3.9) 8.2 % 0.32 [ -0.19, 0.84 ]
Mehnert 2011 30 85.35 (20.88) 28 79.91 (22.65) 8.2 % 0.25 [ -0.27, 0.76 ]
Murtezani 2014 30 20.2 (2.8) 32 18.3 (2.7) 8.3 % 0.68 [ 0.17, 1.20 ]
Daley 2007 33 23.3 (4.78) 33 20.4 (6.8) 9.1 % 0.49 [ 0.00, 0.98 ]
Schmitz 2009 59 14.9 (5.2) 62 14.1 (5.8) 17.2 % 0.14 [ -0.21, 0.50 ]
Kiecolt-Glaser 2014 96 95.2 (10.8) 90 93.8 (9.3) 26.5 % 0.14 [ -0.15, 0.43 ]
Subtotal (95% CI) 355 354 100.0 % 0.22 [ 0.07, 0.37 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 8.01, df = 10 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 2.87 (P = 0.0040)
3 Both home- and facility-based
Rogers 2014 20 7.3 (4.9) 22 3.1 (3.2) 13.3 % 1.01 [ 0.36, 1.65 ]
Rogers 2009 20 22.6 (4.1) 18 21.8 (5.7) 13.6 % 0.16 [ -0.48, 0.80 ]
Cadmus 2009 37 22.3 (4.9) 37 20.6 (7.2) 20.3 % 0.27 [ -0.18, 0.73 ]
Loh 2014 63 21.48 (4.88) 32 19.61 (4.9) 21.7 % 0.38 [ -0.05, 0.81 ]
Rogers 2015 105 21 (5.7) 108 20.7 (5.8) 31.1 % 0.05 [ -0.22, 0.32 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 245 217 100.0 % 0.31 [ 0.03, 0.59 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 7.76, df = 4 (P = 0.10); I2 =48%
Test for overall effect: Z = 2.14 (P = 0.033)
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well-being/function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 10 Overall social well-being/function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Vallance 2007 250 0.21 (4.82) 85 -4.15 (3.34) 100.0 % 0.97 [ 0.71, 1.23 ]
Subtotal (95% CI) 250 85 100.0 % 0.97 [ 0.71, 1.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.39 (P < 0.00001)
2 Facility-based
Mustian 2004 9 1.5 (1.5) 10 0.44 (1.17) 10.6 % 0.76 [ -0.18, 1.70 ]
Naumann 2012 11 0.9 (3.32) 10 -0.2 (3.32) 11.4 % 0.32 [ -0.54, 1.18 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 14.6 % 1.80 [ 1.21, 2.40 ]
Courneya 2003 24 0.6 (2.4) 28 -0.5 (3.3) 15.1 % 0.37 [ -0.18, 0.92 ]
Cormie 2014 43 3.5 (8.5) 19 2.5 (8.3) 15.3 % 0.12 [ -0.42, 0.66 ]
Mehnert 2011 30 7.33 (22.33) 28 3.12 (24.3) 15.6 % 0.18 [ -0.34, 0.69 ]
Schmitz 2009 59 4.4 (33.8) 62 0.7 (34) 17.4 % 0.11 [ -0.25, 0.47 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 206 189 100.0 % 0.50 [ 0.05, 0.95 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 26.16, df = 6 (P = 0.00021); I2 =77%
Test for overall effect: Z = 2.16 (P = 0.031)
3 Both home- and facility-based
Rogers 2009 20 0.9 (2.6) 18 -1.2 (2.7) 21.7 % 0.78 [ 0.11, 1.44 ]
Rogers 2014 20 2.1 (3.2) 22 -0.8 (3.5) 22.3 % 0.85 [ 0.21, 1.48 ]
Cadmus 2009 37 0.6 (4.6) 37 -1 (3.2) 25.8 % 0.40 [ -0.06, 0.86 ]
Saarto 2012 263 5 (21.1) 237 8.8 (20.81) 30.3 % -0.18 [ -0.36, -0.01 ]
Subtotal (95% CI) 340 314 100.0 % 0.41 [ -0.15, 0.96 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 19.06, df = 3 (P = 0.00027); I2 =84%
Test for overall effect: Z = 1.42 (P = 0.16)
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Analysis 17.11. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 11 Overall
cognitive function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 11 Overall cognitive function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Herrero 2006 8 91.7 (12.6) 8 89.6 (12.4) 12.1 % 0.16 [ -0.82, 1.14 ]
Mehnert 2011 30 81.1 (16.8) 27 78.4 (24.38) 43.2 % 0.13 [ -0.39, 0.65 ]
Cantarero-Villanueva 2013 32 -37.93 (8.48) 29 -43.03 (10.01) 44.6 % 0.55 [ 0.03, 1.06 ]
Subtotal (95% CI) 70 64 100.0 % 0.32 [ -0.02, 0.66 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.36, df = 2 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.82 (P = 0.069)
3 Both home- and facility-based
Pinto 2003 12 -4.33 (2.5) 6 -7.17 (2.1) 32.2 % 1.14 [ 0.07, 2.20 ]
Rogers 2009 19 -124.5 (30.8) 18 -135.5 (19.5) 67.8 % 0.42 [ -0.24, 1.07 ]
Subtotal (95% CI) 31 24 100.0 % 0.65 [ -0.01, 1.31 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 1.28, df = 1 (P = 0.26); I2 =22%
Test for overall effect: Z = 1.92 (P = 0.055)
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cognitive function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 12 Overall cognitive function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Herrero 2006 8 6.2 (19.8) 8 8.3 (14.8) 13.4 % -0.11 [ -1.09, 0.87 ]
Mehnert 2011 30 1.67 (22.36) 27 6.18 (24.6) 42.3 % -0.19 [ -0.71, 0.33 ]
Cantarero-Villanueva 2013 32 2.2 (7.63) 29 -0.18 (5.5471) 44.3 % 0.35 [ -0.16, 0.86 ]
Subtotal (95% CI) 70 64 100.0 % 0.06 [ -0.31, 0.43 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.26, df = 2 (P = 0.32); I2 =11%
Test for overall effect: Z = 0.32 (P = 0.75)
3 Both home- and facility-based
Rogers 2009 20 4.2 (16.8) 18 -4.7 (25.9) 35.1 % 0.40 [ -0.24, 1.05 ]
Saarto 2012 263 -1 (18.2) 237 2.2 (18.46) 64.9 % -0.17 [ -0.35, 0.00 ]
Subtotal (95% CI) 283 255 100.0 % 0.03 [ -0.51, 0.57 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 2.88, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 0.10 (P = 0.92)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 13 Overall general health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Basen-Enquist 2006 28 77.4 (11.64) 23 67.1 (13.43) 49.0 % 0.81 [ 0.24, 1.39 ]
Ergun 2013 40 68.97 (19.89) 20 67.91 (16.7) 51.0 % 0.06 [ -0.48, 0.59 ]
Subtotal (95% CI) 68 43 100.0 % 0.43 [ -0.32, 1.17 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 3.56, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.13 (P = 0.26)
2 Facility-based
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 4.7 % 1.30 [ 0.19, 2.41 ]
Mustian 2004 9 18.6 (4.77) 9 19.3 (1.92) 6.7 % -0.18 [ -1.11, 0.74 ]
Ergun 2013 20 74.16 (18.71) 20 67.91 (16.7) 14.7 % 0.35 [ -0.28, 0.97 ]
Mehnert 2011 30 74.38 (11.84) 28 70.01 (20.81) 21.5 % 0.26 [ -0.26, 0.77 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 22.9 % 0.28 [ -0.22, 0.79 ]
Schmitz 2005 39 53.8 (5.3) 40 53.2 (6) 29.5 % 0.10 [ -0.34, 0.55 ]
Subtotal (95% CI) 138 135 100.0 % 0.25 [ 0.01, 0.49 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.81, df = 5 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.040)
3 Both home- and facility-based
Rogers 2009 20 3.5 (0.9) 18 3.8 (0.5) 33.5 % -0.40 [ -1.04, 0.25 ]
Cadmus 2009 37 50 (8.8) 37 51.7 (8.4) 66.5 % -0.20 [ -0.65, 0.26 ]
Subtotal (95% CI) 57 55 100.0 % -0.26 [ -0.64, 0.11 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 1.38 (P = 0.17)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 14 Overall general health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Ergun 2013 20 4.62 (26.54) 20 -6.66 (25.87) 100.0 % 0.42 [ -0.21, 1.05 ]
Subtotal (95% CI) 20 20 100.0 % 0.42 [ -0.21, 1.05 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 Facility-based
Mustian 2004 9 0.22 (1.92) 10 0.68 (2.5) 41.4 % -0.20 [ -1.10, 0.71 ]
Ergun 2013 20 6.25 (15.5) 20 -6.66 (25.87) 58.6 % 0.59 [ -0.04, 1.23 ]
Subtotal (95% CI) 29 30 100.0 % 0.27 [ -0.49, 1.03 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 1.96, df = 1 (P = 0.16); I2 =49%
Test for overall effect: Z = 0.69 (P = 0.49)
3 Both home- and facility-based
Rogers 2009 20 0.15 (0.6) 18 0.17 (0.7) 6.2 % -0.03 [ -0.67, 0.61 ]
Cadmus 2009 37 0.2 (4.4) 37 -0.1 (5.1) 12.1 % 0.06 [ -0.39, 0.52 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 81.7 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 320 292 100.0 % -0.07 [ -0.23, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
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sexual function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 15 Overall sexual function (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Home-based
Pinto 2005 12 42.75 (9.2) 6 43.7 (6.1) 12.0 % -0.11 [ -1.09, 0.87 ]
Duijits 2012 53 0.6 (0.79) 65 0.59 (0.79) 88.0 % 0.01 [ -0.35, 0.38 ]
Subtotal (95% CI) 65 71 100.0 % 0.00 [ -0.34, 0.34 ]
Heterogeneity: Chi2 = 0.05, df = 1 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.01 (P = 0.99)
2 Facility-based
Schmitz 2005 39 -51 (7.5) 40 -53.5 (8) 40.7 % 0.32 [ -0.12, 0.76 ]
Schmitz 2009 57 -27.3 (5.3) 57 -28.1 (6.2) 59.3 % 0.14 [ -0.23, 0.51 ]
Subtotal (95% CI) 96 97 100.0 % 0.21 [ -0.07, 0.49 ]
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
3 Both home- and facility-based
Pinto 2003 39 42.45 (9.24) 43 40.12 (6.3) 100.0 % 0.29 [ -0.14, 0.73 ]
Subtotal (95% CI) 39 43 100.0 % 0.29 [ -0.14, 0.73 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
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Analysis 17.16. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 16 Overall
sexual function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 16 Overall sexual function (change values)





N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Schmitz 2009 57 7.2 (14.6) 57 -0.2 (16.7) 39.4 % 7.40 [ 1.64, 13.16 ]
Schmitz 2005 39 1.7 (4.8) 40 0.2 (5.2) 60.6 % 1.50 [ -0.71, 3.71 ]
Subtotal (95% CI) 96 97 100.0 % 3.83 [ -1.83, 9.48 ]
Heterogeneity: Tau2 = 12.46; Chi2 = 3.52, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.33 (P = 0.18)
3 Both home- and facility-based
Saarto 2012 263 4.3 (25.38) 237 3.8 (24.35) 100.0 % 0.50 [ -3.86, 4.86 ]
Subtotal (95% CI) 263 237 100.0 % 0.50 [ -3.86, 4.86 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.22 (P = 0.82)
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(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 17 Overall sleep (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Bower 2011 16 8.1 (2.5) 15 7.7 (2.6) 35.9 % 0.15 [ -0.55, 0.86 ]
Mehnert 2011 30 23.75 (27) 27 38.27 (31.63) 64.1 % -0.49 [ -1.02, 0.04 ]
Subtotal (95% CI) 46 42 100.0 % -0.26 [ -0.68, 0.16 ]
Heterogeneity: Chi2 = 2.04, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 1.20 (P = 0.23)
3 Both home- and facility-based
Rogers 2013 11 6.3 (2.7) 9 6.2 (3.2) 20.0 % 0.03 [ -0.85, 0.91 ]
Rogers 2009 20 6.65 (4.17) 18 5.5 (4) 37.8 % 0.28 [ -0.36, 0.92 ]
Rogers 2014 20 6.7 (3.7) 22 7.1 (3.2) 42.2 % -0.11 [ -0.72, 0.49 ]
Subtotal (95% CI) 51 49 100.0 % 0.06 [ -0.33, 0.46 ]
Heterogeneity: Chi2 = 0.75, df = 2 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.31 (P = 0.76)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 18 Overall sleep (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Mehnert 2011 29 -5.36 (29.88) 27 -9.88 (33.3) 100.0 % 0.14 [ -0.38, 0.67 ]
Subtotal (95% CI) 29 27 100.0 % 0.14 [ -0.38, 0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
3 Both home- and facility-based
Rogers 2009 20 0.45 (2.1) 18 0.28 (4.7) 47.7 % 0.05 [ -0.59, 0.68 ]
Rogers 2014 20 -1.3 (3.2) 22 -2.2 (4.4) 52.3 % 0.23 [ -0.38, 0.84 ]
Subtotal (95% CI) 40 40 100.0 % 0.14 [ -0.30, 0.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 17.19. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 19 Overall
anxiety (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 19 Overall anxiety (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Segar 1998 10 28.5 (3) 5 39.5 (6) 8.1 % -2.49 [ -3.98, -1.00 ]
Milne 2008 29 15.3 (6.2) 29 21 (5.7) 29.9 % -0.94 [ -1.49, -0.40 ]
Mehnert 2011 30 4.83 (3.46) 28 7.14 (4.97) 30.8 % -0.54 [ -1.06, -0.01 ]
Cantarero-Villanueva 2013 32 42.51 (8.6) 29 49.93 (11.7) 31.1 % -0.72 [ -1.24, -0.20 ]
Subtotal (95% CI) 101 91 100.0 % -0.87 [ -1.34, -0.41 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 6.25, df = 3 (P = 0.10); I2 =52%
Test for overall effect: Z = 3.69 (P = 0.00022)
3 Both home- and facility-based
Pinto 2003 12 7.58 (7.3) 6 10.5 (3.7) 11.9 % -0.43 [ -1.43, 0.56 ]
Rogers 2014 20 45.6 (8.9) 22 45.7 (8) 31.9 % -0.01 [ -0.62, 0.59 ]
Cadmus 2009 37 32.1 (12.3) 37 34.1 (15.4) 56.2 % -0.14 [ -0.60, 0.31 ]
Subtotal (95% CI) 69 65 100.0 % -0.14 [ -0.48, 0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.77 (P = 0.44)
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anxiety (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 20 Overall anxiety (change values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Mehnert 2011 30 -1.67 (3.68) 28 0.18 (4.89) 49.4 % -0.42 [ -0.95, 0.10 ]
Cantarero-Villanueva 2013 32 -4.2 (9.8) 29 0.75 (5.5) 50.6 % -0.61 [ -1.12, -0.09 ]
Subtotal (95% CI) 62 57 100.0 % -0.52 [ -0.88, -0.15 ]
Heterogeneity: Chi2 = 0.24, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.76 (P = 0.0057)
3 Both home- and facility-based
Rogers 2014 20 -4 (6.5) 22 -1.8 (5) 35.8 % -0.37 [ -0.99, 0.24 ]
Cadmus 2009 37 -0.7 (9.2) 37 0.5 (5.8) 64.2 % -0.15 [ -0.61, 0.30 ]
Subtotal (95% CI) 57 59 100.0 % -0.23 [ -0.60, 0.13 ]
Heterogeneity: Chi2 = 0.32, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.25 (P = 0.21)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 21 Overall depression (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Payne 2008 10 12.7 (8.7) 10 11.4 (7.9) 33.9 % 0.15 [ -0.73, 1.03 ]
Ergun 2013 20 8.88 (10.48) 20 5.15 (5.18) 66.1 % 0.44 [ -0.19, 1.07 ]
Subtotal (95% CI) 30 30 100.0 % 0.34 [ -0.17, 0.85 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
2 Facility-based
Segar 1998 10 5.5 (2) 5 10 (2) 3.9 % -2.12 [ -3.51, -0.73 ]
Kaltsatou 2011 13 16.54 (1.66) 13 22.33 (7.73) 8.8 % -1.00 [ -1.83, -0.18 ]
Bower 2011 16 7.7 (5.8) 15 11.6 (7.1) 10.3 % -0.59 [ -1.31, 0.13 ]
Ergun 2013 20 4.7 (4.1) 20 5.15 (5.18) 12.2 % -0.09 [ -0.71, 0.53 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 14.4 % -0.51 [ -1.04, 0.01 ]
Cantarero-Villanueva 2013 32 45.58 (9.68) 29 53.71 (11.6) 14.5 % -0.75 [ -1.28, -0.23 ]
Daley 2007 33 6 (6.47) 33 10.33 (7.19) 15.1 % -0.63 [ -1.12, -0.13 ]
Kiecolt-Glaser 2014 96 8.1 (8.6) 90 9.2 (8.2) 20.7 % -0.13 [ -0.42, 0.16 ]
Subtotal (95% CI) 250 233 100.0 % -0.55 [ -0.85, -0.25 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 15.18, df = 7 (P = 0.03); I2 =54%
Test for overall effect: Z = 3.58 (P = 0.00035)
3 Both home- and facility-based
Pinto 2003 12 6.17 (7.2) 6 9.83 (6.8) 21.0 % -0.49 [ -1.49, 0.50 ]
Rogers 2014 20 44.2 (8.6) 22 25.1 (44.2) 35.2 % 0.58 [ -0.04, 1.19 ]
Cadmus 2009 37 9.6 (9.3) 37 10.8 (10.1) 43.8 % -0.12 [ -0.58, 0.33 ]
Subtotal (95% CI) 69 65 100.0 % 0.05 [ -0.52, 0.61 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 4.45, df = 2 (P = 0.11); I2 =55%
Test for overall effect: Z = 0.16 (P = 0.87)
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Analysis 17.22. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 22 Overall
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 22 Overall depression (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Ergun 2013 20 -0.61 (6.66) 20 2.35 (8.03) 100.0 % -0.39 [ -1.02, 0.23 ]
Subtotal (95% CI) 20 20 100.0 % -0.39 [ -1.02, 0.23 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
2 Facility-based
Naumann 2012 11 -3.6 (4.34) 10 2 (4.55) 13.0 % -1.21 [ -2.16, -0.26 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 42.6 % -0.51 [ -1.04, 0.01 ]
Cantarero-Villanueva 2013 32 -2.95 (7.82) 29 1.46 (7.36) 44.4 % -0.57 [ -1.09, -0.06 ]
Subtotal (95% CI) 73 67 100.0 % -0.63 [ -0.97, -0.29 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.68, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.61 (P = 0.00031)
3 Both home- and facility-based
Rogers 2014 20 -1.7 (6.9) 22 1.1 (4.2) 17.8 % -0.49 [ -1.10, 0.13 ]
Cadmus 2009 37 0.3 (6.4) 37 1.7 (6.3) 26.7 % -0.22 [ -0.68, 0.24 ]
Saarto 2012 263 -0.3 (3.31) 237 -0.5 (3.38) 55.5 % 0.06 [ -0.12, 0.24 ]
Subtotal (95% CI) 320 296 100.0 % -0.11 [ -0.41, 0.19 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.71, df = 2 (P = 0.16); I2 =46%
Test for overall effect: Z = 0.73 (P = 0.47)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 23 Overall fatigue (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Payne 2008 9 4.7 (2.6) 9 3.5 (1.7) 4.4 % 0.52 [ -0.42, 1.46 ]
Ergun 2013 20 3.02 (2.5) 20 3.3 (1.79) 9.0 % -0.13 [ -0.75, 0.49 ]
Pinto 2015 39 -43.83 (7.8) 37 -41.22 (8.49) 14.5 % -0.32 [ -0.77, 0.14 ]
Pinto 2005 39 27.08 (21.41) 43 42.28 (26.2) 14.8 % -0.63 [ -1.07, -0.18 ]
Vallance 2007 250 -42.7 (8.4) 85 -42.6 (8.7) 28.3 % -0.01 [ -0.26, 0.23 ]
Short 2014 195 -41.5 (9.3) 104 -39.8 (10.4) 29.0 % -0.17 [ -0.41, 0.06 ]
Subtotal (95% CI) 552 298 100.0 % -0.18 [ -0.39, 0.03 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 8.11, df = 5 (P = 0.15); I2 =38%
Test for overall effect: Z = 1.72 (P = 0.085)
2 Facility-based
Banasik 2011 7 1 (0.89) 7 1.57 (0.98) 3.7 % -0.57 [ -1.65, 0.51 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 5.3 % -0.07 [ -0.89, 0.75 ]
Bower 2011 16 3.4 (1.8) 15 4.9 (1.3) 6.0 % -0.93 [ -1.67, -0.18 ]
Ergun 2013 20 2.86 (2.02) 20 3.3 (1.79) 7.3 % -0.23 [ -0.85, 0.40 ]
Cuesta-Vargas 2014 22 4 (1.8) 20 5.2 (3.2) 7.4 % -0.46 [ -1.07, 0.15 ]
Milne 2008 29 11.9 (3.2) 29 17.4 (4.7) 7.8 % -1.35 [ -1.92, -0.78 ]
Cantarero-Villanueva 2013 32 3.78 (1.78) 29 6.23 (1.72) 8.0 % -1.38 [ -1.94, -0.82 ]
Courneya 2003 24 -8.3 (7.9) 28 -8.8 (8.1) 8.2 % 0.06 [ -0.48, 0.61 ]
Mehnert 2011 30 28.52 (25.58) 27 39.92 (25.09) 8.4 % -0.44 [ -0.97, 0.08 ]
Littman 2012 30 -45 (5.3) 27 -43.1 (10.3) 8.5 % -0.23 [ -0.75, 0.29 ]
Do 2015 32 16.8 (13.3) 30 22.3 (15.1) 8.8 % -0.38 [ -0.89, 0.12 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 8.8 % -0.71 [ -1.21, -0.21 ]
Kiecolt-Glaser 2014 96 6.3 (19.6) 90 12.7 (18.97) 11.8 % -0.33 [ -0.62, -0.04 ]
Subtotal (95% CI) 383 366 100.0 % -0.53 [ -0.77, -0.29 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 28.25, df = 12 (P = 0.01); I2 =58%
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Test for overall effect: Z = 4.38 (P = 0.000012)
3 Both home- and facility-based
Pinto 2003 12 7.16 (6.4) 6 9 (6.4) 4.6 % -0.27 [ -1.26, 0.71 ]
Rogers 2013 11 4.2 (1.8) 9 4.2 (1.6) 5.8 % 0.0 [ -0.88, 0.88 ]
Rogers 2009 20 -12.4 (10.4) 18 -10.1 (6.6) 11.0 % -0.26 [ -0.90, 0.38 ]
Rogers 2014 20 4.1 (2.1) 22 4 (1.8) 12.3 % 0.05 [ -0.56, 0.66 ]
Winters-Stone 2011 36 45 (5.3) 31 43.1 (10.3) 19.4 % 0.23 [ -0.25, 0.72 ]
Cadmus 2009 37 -51.9 (9) 37 -50.6 (10) 21.6 % -0.14 [ -0.59, 0.32 ]
Fillion 2008 44 2.65 (0.72) 43 2.86 (0.83) 25.3 % -0.27 [ -0.69, 0.15 ]
Subtotal (95% CI) 180 166 100.0 % -0.09 [ -0.30, 0.13 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.10, df = 6 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.80 (P = 0.43)
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Analysis 17.24. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 24 Overall
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 24 Overall fatigue (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Pinto 2005 39 -14.93 (23.54) 43 1.79 (23.48) 47.6 % -0.70 [ -1.15, -0.26 ]
Vallance 2007 250 2.49 (8.17) 85 1.15 (6.61) 52.4 % 0.17 [ -0.08, 0.42 ]
Subtotal (95% CI) 289 128 100.0 % -0.25 [ -1.10, 0.61 ]
Heterogeneity: Tau2 = 0.35; Chi2 = 11.30, df = 1 (P = 0.00078); I2 =91%
Test for overall effect: Z = 0.56 (P = 0.57)
2 Facility-based
Herrero 2006 8 -4.2 (19.6) 8 6.4 (14.5) 12.1 % -0.58 [ -1.59, 0.43 ]
Naumann 2012 11 -3.6 (4.35) 10 2 (4.55) 12.5 % -1.21 [ -2.16, -0.26 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 13.5 % -0.07 [ -0.89, 0.75 ]
Courneya 2003 24 9.3 (10.2) 28 2 (7.5) 15.3 % 0.81 [ 0.24, 1.38 ]
Cantarero-Villanueva 2013 32 -2 (1.75) 29 0.34 (1.39) 15.3 % -1.45 [ -2.02, -0.88 ]
Mehnert 2011 30 -0.74 (20.73) 27 -2.88 (25.3) 15.6 % 0.09 [ -0.43, 0.61 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 15.7 % -0.71 [ -1.21, -0.21 ]
Subtotal (95% CI) 150 146 100.0 % -0.43 [ -1.06, 0.20 ]
Heterogeneity: Tau2 = 0.60; Chi2 = 39.08, df = 6 (P<0.00001); I2 =85%
Test for overall effect: Z = 1.33 (P = 0.19)
3 Both home- and facility-based
Rogers 2013 11 4.2 (2) 9 3.9 (1.5) 3.5 % 0.16 [ -0.72, 1.04 ]
Rogers 2009 20 1.9 (9.6) 18 4.2 (12.3) 6.8 % -0.21 [ -0.84, 0.43 ]
Saarto 2012 263 -2.4 (9.06) 237 -2.4 (8.6) 89.7 % 0.0 [ -0.18, 0.18 ]
Subtotal (95% CI) 294 264 100.0 % -0.01 [ -0.17, 0.16 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.51, df = 2 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.10 (P = 0.92)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 25 Overall pain/disability (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Portela 2008 13 -19.4 (18.2) 9 -20.8 (15.5) 19.0 % 0.08 [ -0.77, 0.93 ]
Basen-Enquist 2006 28 79.7 (10.58) 23 72.1 (11.51) 31.1 % 0.68 [ 0.11, 1.25 ]
Duijits 2012 87 79.27 (23.59) 89 78.79 (23.78) 49.9 % 0.02 [ -0.28, 0.32 ]
Subtotal (95% CI) 128 121 100.0 % 0.24 [ -0.20, 0.68 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 4.11, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 1.05 (P = 0.29)
2 Facility-based
Mustian 2004 9 9.11 (1.35) 10 9.1 (1.74) 10.5 % 0.01 [ -0.89, 0.91 ]
Portela 2008 12 -21.8 (23) 9 -20.8 (15.5) 11.3 % -0.05 [ -0.91, 0.82 ]
Loudon 2014 12 0.8 (1.48) 11 1.44 (2.24) 12.5 % -0.33 [ -1.15, 0.50 ]
Mehnert 2011 30 79.4 (23.1) 28 73.5 (24.83) 31.7 % 0.24 [ -0.27, 0.76 ]
Do 2015 32 21.1 (24.6) 30 16.5 (26.7) 34.0 % 0.18 [ -0.32, 0.68 ]
Subtotal (95% CI) 95 88 100.0 % 0.09 [ -0.20, 0.38 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.57, df = 4 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 0.62 (P = 0.54)
3 Both home- and facility-based
Rogers 2009 20 -3.03 (2.98) 18 -2.28 (2.76) 33.7 % -0.26 [ -0.89, 0.38 ]
Cadmus 2009 37 50.3 (9.1) 37 50.8 (9) 66.3 % -0.05 [ -0.51, 0.40 ]
Subtotal (95% CI) 57 55 100.0 % -0.12 [ -0.49, 0.25 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.65 (P = 0.52)
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Analysis 17.26. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 26 Overall
pain/disability (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 26 Overall pain/disability (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Mustian 2004 9 -0.22 (1.29) 10 0 (1.42) 14.6 % -0.15 [ -1.06, 0.75 ]
Cormie 2014 43 3.4 (6.5) 19 2 (6.2) 40.7 % 0.22 [ -0.33, 0.76 ]
Mehnert 2011 30 -2.4 (24.95) 28 -7.61 (25.2) 44.7 % 0.21 [ -0.31, 0.72 ]
Subtotal (95% CI) 82 57 100.0 % 0.16 [ -0.19, 0.50 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.54, df = 2 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.89 (P = 0.37)
3 Both home- and facility-based
Cadmus 2009 37 -2.2 (11.3) 37 -0.1 (7) 47.6 % -0.22 [ -0.68, 0.24 ]
Irwin 2015 45 -6 (18.97) 38 0.7 (18.56) 52.4 % -0.35 [ -0.79, 0.08 ]
Subtotal (95% CI) 82 75 100.0 % -0.29 [ -0.61, 0.02 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.17, df = 1 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.81 (P = 0.071)
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esteem/body image (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 27 Overall self-esteem/body image (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Musanti 2012 30 23.83 (3.48) 12 26.33 (3.94) 46.9 % -0.68 [ -1.37, 0.01 ]
Pinto 2005 39 30.26 (7.82) 43 27.23 (6.76) 53.1 % 0.41 [ -0.03, 0.85 ]
Subtotal (95% CI) 69 55 100.0 % -0.10 [ -1.17, 0.97 ]
Heterogeneity: Tau2 = 0.51; Chi2 = 6.89, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 0.18 (P = 0.85)
2 Facility-based
Segar 1998 10 33 (1.8) 5 30.5 (2.7) 3.1 % 1.11 [ -0.06, 2.28 ]
Loudon 2014 12 -1.43 (0.33) 11 -1.56 (0.86) 6.0 % 0.20 [ -0.62, 1.02 ]
Mehnert 2011 27 -5.47 (1.66) 27 -6.82 (2.6) 12.3 % 0.61 [ 0.06, 1.16 ]
Courneya 2003 24 34.8 (4.7) 28 34.6 (4.4) 12.4 % 0.04 [ -0.50, 0.59 ]
Milne 2008 29 -17.9 (6.8) 29 -20.1 (6.3) 13.5 % 0.33 [ -0.19, 0.85 ]
Daley 2007 33 2.03 (0.83) 32 1.57 (0.5) 14.3 % 0.66 [ 0.16, 1.16 ]
Do 2015 (1) 32 37.9 (18.9) 30 36.1 (18.3) 14.4 % 0.10 [ -0.40, 0.59 ]
Schmitz 2009 59 -70.4 (16.3) 63 -71.5 (18) 24.1 % 0.06 [ -0.29, 0.42 ]
Subtotal (95% CI) 226 225 100.0 % 0.29 [ 0.09, 0.50 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 8.32, df = 7 (P = 0.31); I2 =16%
Test for overall effect: Z = 2.76 (P = 0.0057)
3 Both home- and facility-based
Pinto 2003 12 32.3 (4.3) 6 25.3 (8.2) 38.1 % 1.15 [ 0.08, 2.22 ]
Cadmus 2009 37 34.2 (5.5) 37 33.4 (5.9) 61.9 % 0.14 [ -0.32, 0.60 ]
Subtotal (95% CI) 49 43 100.0 % 0.52 [ -0.44, 1.48 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 2.90, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 1.07 (P = 0.29)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 28 Overall self-esteem/body image (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Musanti 2012 30 -0.4 (4.53) 12 0.58 (3.92) 100.0 % -0.22 [ -0.89, 0.45 ]
Subtotal (95% CI) 30 12 100.0 % -0.22 [ -0.89, 0.45 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 Facility-based
Mustian 2004 11 3 (1) 10 -1.5 (1.5) 9.6 % 3.42 [ 1.99, 4.86 ]
Courneya 2003 24 2.6 (3.7) 28 -0.1 (3.5) 17.4 % 0.74 [ 0.18, 1.30 ]
Mehnert 2011 30 0.73 (2.12) 27 0.39 (2.12) 17.8 % 0.16 [ -0.36, 0.68 ]
Milne 2008 29 1.5 (3.7) 29 0.1 (3.9) 17.8 % 0.36 [ -0.16, 0.88 ]
Daley 2007 33 1.79 (0.71) 33 1.56 (0.67) 18.1 % 0.33 [ -0.16, 0.82 ]
Schmitz 2009 59 -12 (15.5) 63 -4.1 (16.2) 19.1 % -0.49 [ -0.86, -0.13 ]
Subtotal (95% CI) 186 190 100.0 % 0.52 [ -0.09, 1.13 ]
Heterogeneity: Tau2 = 0.47; Chi2 = 37.69, df = 5 (P<0.00001); I2 =87%
Test for overall effect: Z = 1.66 (P = 0.097)
3 Both home- and facility-based
Cadmus 2009 37 0.4 (4.4) 37 0.2 (2.9) 12.9 % 0.05 [ -0.40, 0.51 ]
Saarto 2012 263 10.7 (21.51) 237 12 (21.99) 87.1 % -0.06 [ -0.24, 0.12 ]
Subtotal (95% CI) 300 274 100.0 % -0.05 [ -0.21, 0.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.54 (P = 0.59)
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cardiorespiratory fitness (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 29 Overall cardiorespiratory fitness (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Portela 2008 13 3044.3 (440.9) 9 2416.1 (718.6) 8.3 % 1.06 [ 0.15, 1.98 ]
Musanti 2012 30 24.6 (4.93) 12 23 (4.29) 15.3 % 0.33 [ -0.34, 1.00 ]
Kim 2015 20 424.8 (55.8) 19 394.4 (54) 17.0 % 0.54 [ -0.10, 1.18 ]
Basen-Enquist 2006 35 1643 (122.5) 25 1546 (127.5) 24.5 % 0.77 [ 0.24, 1.30 ]
Pinto 2005 39 -16.34 (2.09) 43 -17.85 (2.24) 34.9 % 0.69 [ 0.24, 1.14 ]
Subtotal (95% CI) 137 108 100.0 % 0.66 [ 0.40, 0.92 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.97, df = 4 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 4.90 (P < 0.00001)
2 Facility-based
Herrero 2006 8 25.9 (4.5) 8 25.7 (3.7) 3.7 % 0.05 [ -0.93, 1.03 ]
Portela 2008 12 2966.5 (390.7) 9 2416.1 (718.6) 4.1 % 0.96 [ 0.03, 1.88 ]
Cerulli 2014 10 31.29 (4.95) 10 32.26 (10.1) 4.5 % -0.12 [ -0.99, 0.76 ]
Mustian 2004 11 636.1 (50.6) 10 610.3 (75.9) 4.6 % 0.39 [ -0.48, 1.25 ]
Kaltsatou 2011 14 483.33 (85.95) 13 403.08 (71.92) 5.2 % 0.98 [ 0.17, 1.78 ]
Rahnama 2010 14 20.65 (5.73) 15 13.85 (5.18) 5.2 % 1.21 [ 0.41, 2.01 ]
Courneya 2003 24 21.3 (3.7) 26 18.2 (3.9) 8.5 % 0.80 [ 0.22, 1.38 ]
Mehnert 2011 27 26.9 (4.4) 23 25.7 (4.7) 8.9 % 0.26 [ -0.30, 0.82 ]
Do 2015 30 31.7 (12.4) 30 24.5 (6.6) 9.8 % 0.72 [ 0.19, 1.24 ]
Milne 2008 29 1.49 (0.31) 29 1.48 (0.43) 10.0 % 0.03 [ -0.49, 0.54 ]
Murtezani 2014 30 875.1 (86.7) 32 823.5 (87.1) 10.1 % 0.59 [ 0.08, 1.10 ]
Fillion 2008 44 27.04 (4.39) 43 26.53 (5.81) 12.6 % 0.10 [ -0.32, 0.52 ]
Daley 2007 33 34.99 (4.42) 69 33.05 (5.3) 12.7 % 0.38 [ -0.04, 0.80 ]
Subtotal (95% CI) 286 317 100.0 % 0.45 [ 0.25, 0.66 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 17.02, df = 12 (P = 0.15); I2 =30%
Test for overall effect: Z = 4.35 (P = 0.000014)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
3 Both home- and facility-based
Rogers 2013 12 23.9 (6.2) 10 23.9 (3.8) 8.4 % 0.0 [ -0.84, 0.84 ]
Nikander 2007 14 -17.6 (1.3) 14 -17.2 (1.4) 10.2 % -0.29 [ -1.03, 0.46 ]
Rogers 2014 20 30.9 (6.3) 22 25.1 (5) 12.8 % 1.01 [ 0.36, 1.65 ]
Rogers 2009 20 29.5 (6.6) 18 27.6 (6.1) 13.0 % 0.29 [ -0.35, 0.93 ]
Irwin 2015 45 24.6 (5.5) 38 23 (4.7) 21.8 % 0.31 [ -0.13, 0.74 ]
Rogers 2015 105 23.6 (4.8) 108 22.7 (0.3) 33.8 % 0.27 [ 0.00, 0.54 ]
Subtotal (95% CI) 216 210 100.0 % 0.29 [ 0.03, 0.56 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 7.52, df = 5 (P = 0.18); I2 =34%
Test for overall effect: Z = 2.16 (P = 0.030)
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Analysis 17.30. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 30 Overall
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 30 Overall cardiorespiratory fitness (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Musanti 2012 30 1 (3.1) 12 0.9 (3.4) 41.4 % 0.03 [ -0.64, 0.70 ]
Pinto 2005 39 1.35 (2.4) 43 -0.25 (2.5) 58.6 % 0.65 [ 0.20, 1.09 ]
Subtotal (95% CI) 69 55 100.0 % 0.39 [ -0.20, 0.99 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 2.25, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 1.29 (P = 0.20)
2 Facility-based
Nieman 1995 6 60.8 (8.4) 6 12 (17.8) 8.1 % 3.24 [ 1.29, 5.18 ]
Naumann 2012 11 3.1 (2.9) 10 -0.1 (3.1) 25.8 % 1.03 [ 0.10, 1.95 ]
Dolan 2016 23 12.2 (10.2) 10 -5.97 (7.2) 27.2 % 1.88 [ 0.99, 2.77 ]
Courneya 2003 24 2.7 (2.6) 26 -0.6 (1.7) 38.8 % 1.49 [ 0.86, 2.12 ]
Subtotal (95% CI) 64 52 100.0 % 1.62 [ 1.03, 2.21 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 4.69, df = 3 (P = 0.20); I2 =36%
Test for overall effect: Z = 5.38 (P < 0.00001)
3 Both home- and facility-based
Rogers 2014 20 2.8 (4.9) 22 1.1 (4.2) 23.9 % 0.37 [ -0.24, 0.98 ]
Irwin 2015 45 1.5 (2.1) 38 -0.4 (2.7) 31.3 % 0.79 [ 0.34, 1.24 ]
Saarto 2012 262 0.89 (1.15) 236 0.72 (1.01) 44.8 % 0.16 [ -0.02, 0.33 ]
Subtotal (95% CI) 327 296 100.0 % 0.40 [ -0.02, 0.82 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 6.72, df = 2 (P = 0.03); I2 =70%
Test for overall effect: Z = 1.89 (P = 0.059)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 31 Overall self-reported physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Baruth 2013 20 0 (0) 12 0 (0) Not estimable
Matthews 2007 22 54.2 (34.1) 14 27.2 (22.7) 8.7 % 0.87 [ 0.17, 1.58 ]
Kim 2015 20 17.6 (16.03) 19 11.8 (11.6) 9.7 % 0.40 [ -0.23, 1.04 ]
Basen-Enquist 2006 35 428 (254.4) 25 404 (265) 11.7 % 0.09 [ -0.42, 0.61 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 11.8 % 1.01 [ 0.50, 1.52 ]
Hatchett 2013 38 3.47 (2.19) 36 1.42 (1.67) 12.1 % 1.04 [ 0.55, 1.53 ]
Pinto 2005 39 202.43 (161.65) 43 78.36 (86) 12.7 % 0.96 [ 0.50, 1.42 ]
Vallance 2007 253 207.6 (169) 85 163 (121) 16.6 % 0.28 [ 0.03, 0.53 ]
Short 2014 195 217.9 (222.9) 104 180.3 (206.9) 16.7 % 0.17 [ -0.07, 0.41 ]
Subtotal (95% CI) 658 370 100.0 % 0.57 [ 0.29, 0.85 ]
Heterogeneity: Tau2 = 0.11; Chi2 = 25.24, df = 7 (P = 0.00069); I2 =72%
Test for overall effect: Z = 3.94 (P = 0.000083)
2 Facility-based
Littman 2012 32 19.2 (19.1) 31 12.1 (13.6) 12.1 % 0.42 [ -0.08, 0.92 ]
Kiecolt-Glaser 2014 96 11.2 (7.6) 90 9.1 (6.1) 36.1 % 0.30 [ 0.01, 0.59 ]
Schmitz 2009 131 3348.8 (9019.4) 133 2339.8 (6213.7) 51.8 % 0.13 [ -0.11, 0.37 ]
Subtotal (95% CI) 259 254 100.0 % 0.23 [ 0.05, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.46, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
3 Both home- and facility-based
Guinan 2013 16 38.7 (26.9) 10 19.9 (11.3) 11.4 % 0.81 [ -0.01, 1.64 ]
Rogers 2009 20 121.4 (73.2) 18 114.3 (131.5) 14.5 % 0.07 [ -0.57, 0.70 ]
Cadmus 2009 34 161.7 (114.7) 33 55.6 (101.9) 17.0 % 0.97 [ 0.46, 1.47 ]
Winters-Stone 2011 36 430.8 (281.4) 31 461.7 (346.4) 17.6 % -0.10 [ -0.58, 0.38 ]
Irwin 2015 45 222.1 (118.6) 38 103.6 (104.6) 17.9 % 1.04 [ 0.58, 1.51 ]
Rogers 2015 110 169 (119) 112 74 (107) 21.5 % 0.84 [ 0.56, 1.11 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 261 242 100.0 % 0.62 [ 0.23, 1.00 ]
Heterogeneity: Tau2 = 0.16; Chi2 = 18.59, df = 5 (P = 0.002); I2 =73%
Test for overall effect: Z = 3.14 (P = 0.0017)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 32 Overall self-reported physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Matthews 2007 22 21.5 (30.6) 14 5 (13.8) 8.2 % 0.63 [ -0.06, 1.32 ]
Pinto 2005 39 84.74 (189.2) 43 -18.27 (200.7) 20.0 % 0.52 [ 0.08, 0.96 ]
Vallance 2007 281 82 (168.7) 96 30 (167.8) 71.8 % 0.31 [ 0.08, 0.54 ]
Subtotal (95% CI) 342 153 100.0 % 0.38 [ 0.18, 0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.28, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 3.75 (P = 0.00018)
2 Facility-based
Schmitz 2009 (1) 48 2.8 (16.8) 57 -0.8 (16.6) 100.0 % 0.21 [ -0.17, 0.60 ]
Subtotal (95% CI) 48 57 100.0 % 0.21 [ -0.17, 0.60 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.09 (P = 0.28)
3 Both home- and facility-based
Guinan 2013 16 15.6 (11.4476) 10 -8.3 (4.1937) 18.8 % 2.46 [ 1.39, 3.53 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Cadmus 2009 34 129 (117.9) 33 44.3 (89.4) 26.0 % 0.80 [ 0.30, 1.30 ]
Irwin 2015 45 159 (136) 38 49 (86) 26.5 % 0.94 [ 0.48, 1.40 ]
Saarto 2012 262 3.5 (18.3) 236 3.3 (21.5) 28.7 % 0.01 [ -0.17, 0.19 ]
Subtotal (95% CI) 357 317 100.0 % 0.92 [ 0.14, 1.70 ]
Heterogeneity: Tau2 = 0.54; Chi2 = 36.90, df = 3 (P<0.00001); I2 =92%
Test for overall effect: Z = 2.32 (P = 0.021)
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Analysis 17.33. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 33 Overall
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 33 Overall objective physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Matthews 2007 22 330.8 (114.7) 14 198.5 (55.4) 13.1 % 1.34 [ 0.60, 2.09 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 18.1 % 1.01 [ 0.50, 1.52 ]
Pinto 2005 39 37.5 (14.25) 43 33.62 (19.43) 19.9 % 0.22 [ -0.21, 0.66 ]
Vallance 2007 253 8110.5 (4133.9) 85 8028 (3457) 24.3 % 0.02 [ -0.23, 0.27 ]
Short 2014 219 9363.07 (7922.79) 111 8301.2 (3373.4) 24.6 % 0.16 [ -0.07, 0.39 ]
Subtotal (95% CI) 569 285 100.0 % 0.45 [ 0.07, 0.82 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 20.75, df = 4 (P = 0.00035); I2 =81%
Test for overall effect: Z = 2.33 (P = 0.020)
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
2 Facility-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Both home- and facility-based
Rogers 2013 12 198.4 (111.7) 10 0 (0) Not estimable
Guinan 2013 16 30.7 (15.6) 9 31 (15.6) 8.5 % -0.02 [ -0.84, 0.80 ]
Rogers 2014 20 294 (175) 22 154 (75) 12.8 % 1.04 [ 0.39, 1.69 ]
Rogers 2009 20 252191 (91893) 18 210917 (64078) 12.9 % 0.51 [ -0.14, 1.15 ]
Cadmus 2009 33 6738 (2958) 34 5537 (3352) 20.8 % 0.38 [ -0.11, 0.86 ]
Rogers 2015 110 246 (153) 112 197 (138) 45.0 % 0.34 [ 0.07, 0.60 ]
Subtotal (95% CI) 211 205 100.0 % 0.43 [ 0.17, 0.68 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 5.06, df = 4 (P = 0.28); I2 =21%
Test for overall effect: Z = 3.32 (P = 0.00089)
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Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 34 Overall objective physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Home-based
Matthews 2007 22 72.2 (114.6) 14 -16.8 (51.5) 43.8 % 0.91 [ 0.20, 1.62 ]
Vallance 2007 253 -150 (5173.3) 85 91 (5155.4) 56.2 % -0.05 [ -0.29, 0.20 ]
Subtotal (95% CI) 275 99 100.0 % 0.37 [ -0.56, 1.30 ]
Heterogeneity: Tau2 = 0.39; Chi2 = 6.30, df = 1 (P = 0.01); I2 =84%
Test for overall effect: Z = 0.78 (P = 0.43)
2 Facility-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Both home- and facility-based
Guinan 2013 16 -1.1 (6.2) 9 -7.9 (5.3) 16.7 % 1.11 [ 0.23, 2.00 ]
Rogers 2014 20 114 (109) 22 10 (70) 30.3 % 1.13 [ 0.47, 1.78 ]
Cadmus 2009 33 1621 (2108) 34 -60 (2341) 53.0 % 0.75 [ 0.25, 1.24 ]
Subtotal (95% CI) 69 65 100.0 % 0.92 [ 0.56, 1.28 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.04, df = 2 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 5.00 (P < 0.00001)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 35 Mass (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 Home-based
Matthews 2007 22 74.9 (15.2) 14 78.9 (20.3) 31.1 % -4.00 [ -16.39, 8.39 ]
DeNysschen 2011 30 69.3 (14.2) 34 72.4 (19.6) 68.9 % -3.10 [ -11.42, 5.22 ]
Subtotal (95% CI) 52 48 100.0 % -3.38 [ -10.29, 3.53 ]
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.91); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
2 Facility-based
Mustian 2004 11 67.1 (10.42) 10 68.6 (13.84) 0.3 % -1.50 [ -12.06, 9.06 ]
Courneya 2003 24 78.2 (20.5) 26 80.1 (16.2) 0.3 % -1.90 [ -12.20, 8.40 ]
Herrero 2006 8 65.6 (8.7) 8 67.3 (8.9) 0.5 % -1.70 [ -10.32, 6.92 ]
Rahnama 2010 14 69.4 (13.5) 15 71.6 (9.2) 0.5 % -2.20 [ -10.67, 6.27 ]
Littman 2012 28 81.1 (13.6) 27 81.3 (14.3) 0.6 % -0.20 [ -7.58, 7.18 ]
Daley 2007 33 74.26 (12.49) 69 75.6 (12.5) 1.3 % -1.34 [ -6.52, 3.84 ]
Murtezani 2014 30 71.7 (9.5) 32 72.6 (10.75) 1.3 % -0.90 [ -5.94, 4.14 ]
Schmitz 2009 131 76.15 (15.66) 133 77.19 (17.02) 2.2 % -1.04 [ -4.98, 2.90 ]
Schmitz 2005 39 69.5 (2.22) 40 69.2 (2.2) 36.1 % 0.30 [ -0.67, 1.27 ]
Kiecolt-Glaser 2014 96 75.2 (2.8) 90 75.2 (2.6) 56.9 % 0.0 [ -0.78, 0.78 ]
Subtotal (95% CI) 414 450 100.0 % 0.03 [ -0.56, 0.61 ]
Heterogeneity: Chi2 = 1.62, df = 9 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.09 (P = 0.93)
3 Both home- and facility-based
Nikander 2007 14 73.5 (13.3) 14 75.5 (12) 18.2 % -2.00 [ -11.38, 7.38 ]
Cadmus 2009 36 80.73 (16.88) 33 78.51 (20.64) 20.0 % 2.22 [ -6.72, 11.16 ]
Ligibel 2008 40 80 (17.5) 42 83.3 (18.7) 26.1 % -3.30 [ -11.14, 4.54 ]
Winters-Stone 2011 36 76.5 (15.6) 31 74.2 (12.3) 35.8 % 2.30 [ -4.39, 8.99 ]
Subtotal (95% CI) 126 120 100.0 % 0.04 [ -3.96, 4.04 ]
Heterogeneity: Chi2 = 1.55, df = 3 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.98)
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Analysis 17.36. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 36 Mass (change
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 36 Mass (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Matthews 2007 22 0.01 (2.09) 14 0.04 (2.16) 100.0 % -0.03 [ -1.46, 1.40 ]
Subtotal (95% CI) 22 14 100.0 % -0.03 [ -1.46, 1.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
2 Facility-based
Dolan 2016 23 -0.55 (5.04) 10 1.44 (1.62) 6.7 % -1.99 [ -4.28, 0.30 ]
Mustian 2004 9 -0.3 (1.86) 10 0.6 (1.43) 11.6 % -0.90 [ -2.40, 0.60 ]
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 12.7 % -0.60 [ -1.98, 0.78 ]
Murtezani 2014 30 -2.3 (2.4) 32 -0.3 (2.6) 14.0 % -2.00 [ -3.24, -0.76 ]
Naumann 2012 11 0.45 (1.33) 10 0.12 (1.52) 14.2 % 0.33 [ -0.90, 1.56 ]
Courneya 2003 24 0.1 (2) 26 0.7 (1.8) 16.0 % -0.60 [ -1.66, 0.46 ]
Schmitz 2005 39 0.32 (0.43) 40 0.2 (0.42) 24.9 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 201 193 100.0 % -0.61 [ -1.31, 0.08 ]
Heterogeneity: Tau2 = 0.49; Chi2 = 17.95, df = 6 (P = 0.01); I2 =67%
Test for overall effect: Z = 1.73 (P = 0.083)
3 Both home- and facility-based
Irwin 2015 45 -2.1 (4.3) 38 0.1 (3.6) 25.7 % -2.20 [ -3.90, -0.50 ]
Ligibel 2008 22 0 (2.3) 14 0.04 (2.16) 29.2 % -0.04 [ -1.52, 1.44 ]
Saarto 2012 262 0.66 (3.68) 236 0.67 (3.84) 45.0 % -0.01 [ -0.67, 0.65 ]
Subtotal (95% CI) 329 288 100.0 % -0.58 [ -1.80, 0.63 ]
Heterogeneity: Tau2 = 0.74; Chi2 = 5.64, df = 2 (P = 0.06); I2 =65%
Test for overall effect: Z = 0.94 (P = 0.35)
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Analysis 17.37. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 37 BMI (follow-
up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 37 BMI (follow-up values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Fixed,95% CI IV,Fixed,95% CI
1 Home-based
Portela 2008 13 27.8 (6.3) 9 34.7 (15) 1.1 % -6.90 [ -17.28, 3.48 ]
Pinto 2005 39 27.66 (5.01) 43 29.01 (5.62) 23.1 % -1.35 [ -3.65, 0.95 ]
Vallance 2007 253 27.01 (5.21) 85 27.2 (5.15) 75.8 % -0.19 [ -1.46, 1.08 ]
Subtotal (95% CI) 305 137 100.0 % -0.53 [ -1.64, 0.57 ]
Heterogeneity: Chi2 = 2.21, df = 2 (P = 0.33); I2 =10%
Test for overall effect: Z = 0.95 (P = 0.34)
2 Facility-based
Portela 2008 12 30.5 (4.4) 9 34.7 (15) 0.0 % -4.20 [ -14.31, 5.91 ]
Mustian 2004 11 23.9 (4.17) 10 26.7 (5.59) 0.2 % -2.80 [ -7.05, 1.45 ]
Courneya 2003 24 29.4 (7.4) 26 29.3 (6) 0.3 % 0.10 [ -3.65, 3.85 ]
Rahnama 2010 14 27.74 (4.77) 15 28.04 (4.6) 0.4 % -0.30 [ -3.71, 3.11 ]
Littman 2012 28 27.66 (5.01) 27 29.01 (5.62) 0.6 % -1.35 [ -4.17, 1.47 ]
Murtezani 2014 30 25.1 (2.9) 32 25.8 (3.47) 1.8 % -0.70 [ -2.29, 0.89 ]
Schmitz 2009 131 28.46 (5.55) 133 28.94 (6.27) 2.2 % -0.48 [ -1.91, 0.95 ]
Schmitz 2005 39 26 (0.74) 40 25.8 (0.73) 42.3 % 0.20 [ -0.12, 0.52 ]
Kiecolt-Glaser 2014 96 27.8 (1.08) 90 27.8 (0.95) 52.2 % 0.0 [ -0.29, 0.29 ]
Subtotal (95% CI) 385 382 100.0 % 0.04 [ -0.17, 0.26 ]
Heterogeneity: Chi2 = 5.71, df = 8 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.68)
3 Both home- and facility-based
Rogers 2013 12 33.6 (7) 10 30.6 (7.28) 6.4 % 3.00 [ -3.00, 9.00 ]
Rogers 2009 20 30.6 (7.6) 18 30.4 (8.3) 9.0 % 0.20 [ -4.88, 5.28 ]
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N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Fixed,95% CI IV,Fixed,95% CI
Nikander 2007 14 26.9 (5.6) 14 27.7 (4.9) 15.3 % -0.80 [ -4.70, 3.10 ]
Rogers 2014 20 29.6 (5) 22 32.2 (6.7) 18.4 % -2.60 [ -6.16, 0.96 ]
Cadmus 2009 36 30.45 (6) 33 29.9 (7.59) 22.0 % 0.55 [ -2.70, 3.80 ]
Ligibel 2008 40 30.3 (6.3) 42 31.5 (6.8) 28.9 % -1.20 [ -4.04, 1.64 ]
Subtotal (95% CI) 142 139 100.0 % -0.61 [ -2.14, 0.91 ]
Heterogeneity: Chi2 = 3.36, df = 5 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
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Analysis 17.38. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 38 BMI (change
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 38 BMI (change values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 4.2 % -0.60 [ -1.98, 0.78 ]
Mustian 2004 9 -0.42 (0.75) 10 0.29 (0.61) 13.1 % -0.71 [ -1.33, -0.09 ]
Naumann 2012 11 0.1 (0.5) 10 -0.1 (0.57) 17.0 % 0.20 [ -0.26, 0.66 ]
Courneya 2003 24 0 (0.7) 26 0.3 (0.7) 19.1 % -0.30 [ -0.69, 0.09 ]
Murtezani 2014 30 -0.8 (0.7) 32 -0.14 (0.8) 19.6 % -0.66 [ -1.03, -0.29 ]
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N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Random,95% CI IV,Random,95% CI
Schmitz 2005 39 0.06 (0.17) 40 0.07 (0.16) 27.0 % -0.01 [ -0.08, 0.06 ]
Subtotal (95% CI) 178 183 100.0 % -0.27 [ -0.58, 0.04 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 19.09, df = 5 (P = 0.002); I2 =74%
Test for overall effect: Z = 1.73 (P = 0.083)
3 Both home- and facility-based
Rogers 2014 20 -0.2 (0.9) 22 -0.3 (1.1) 27.1 % 0.10 [ -0.51, 0.71 ]
Ligibel 2008 40 0 (0.9) 42 0.2 (0.8) 72.9 % -0.20 [ -0.57, 0.17 ]
Subtotal (95% CI) 60 64 100.0 % -0.12 [ -0.43, 0.20 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.69, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.74 (P = 0.46)
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Analysis 17.39. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 39 Overall body
fat (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 39 Overall body fat (follow-up values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Matthews 2007 22 39.7 (6.3) 14 43.1 (6.9) 15.6 % -0.51 [ -1.19, 0.17 ]
Musanti 2012 30 34.13 (6.64) 12 33.7 (5.7) 16.1 % 0.07 [ -0.60, 0.74 ]
DeNysschen 2011 30 36.9 (8.4) 34 38 (10.2) 30.0 % -0.12 [ -0.61, 0.38 ]
Pinto 2005 39 37.53 (4.79) 43 38.55 (4.83) 38.3 % -0.21 [ -0.64, 0.22 ]
Subtotal (95% CI) 121 103 100.0 % -0.18 [ -0.45, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.50, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.34 (P = 0.18)
2 Facility-based
Herrero 2006 8 22 (5) 8 22 (4) 7.2 % 0.0 [ -0.98, 0.98 ]
Cerulli 2014 10 26.72 (5.34) 10 30.55 (4.4) 8.0 % -0.75 [ -1.66, 0.16 ]
Mustian 2004 11 38.5 (4.47) 10 41.7 (4.89) 8.4 % -0.66 [ -1.54, 0.23 ]
Courneya 2003 24 131.9 (46.4) 26 137.1 (44.4) 14.9 % -0.11 [ -0.67, 0.44 ]
Schmitz 2005 39 40.91 (1.31) 40 42.29 (1.3) 17.3 % -1.05 [ -1.52, -0.58 ]
Daley 2007 33 39.4 (4.74) 69 40.1 (7.4) 19.1 % -0.10 [ -0.52, 0.31 ]
Schmitz 2009 130 38.47 (5.93) 132 39.74 (5.9) 25.0 % -0.21 [ -0.46, 0.03 ]
Subtotal (95% CI) 255 295 100.0 % -0.39 [ -0.69, -0.08 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 13.24, df = 6 (P = 0.04); I2 =55%
Test for overall effect: Z = 2.50 (P = 0.012)
3 Both home- and facility-based
Rogers 2013 10 44.2 (6.7) 12 42.3 (7.7) 5.6 % 0.25 [ -0.59, 1.09 ]
Rogers 2009 20 44.3 (7.4) 19 43.5 (7.5) 10.1 % 0.11 [ -0.52, 0.73 ]
Rogers 2014 20 38.6 (6.4) 22 41.5 (7.4) 10.7 % -0.41 [ -1.02, 0.20 ]
Winters-Stone 2011 36 40.5 (6.2) 31 38.5 (5.8) 17.1 % 0.33 [ -0.16, 0.81 ]
Saarto 2012 37 39.9 (7.5) 30 40.2 (8) 17.3 % -0.04 [ -0.52, 0.44 ]
Cadmus 2009 36 40.54 (6.55) 33 39.6 (5.97) 17.9 % 0.15 [ -0.33, 0.62 ]
Ligibel 2008 40 42.9 (7.4) 42 44.7 (8) 21.2 % -0.23 [ -0.67, 0.20 ]
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N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 199 189 100.0 % 0.01 [ -0.19, 0.21 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 5.42, df = 6 (P = 0.49); I2 =0.0%
Test for overall effect: Z = 0.08 (P = 0.94)
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Analysis 17.40. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 40 Overall body
fat (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 40 Overall body fat (change values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Musanti 2012 30 -0.24 (2.83) 12 1.4 (1.57) 49.3 % -0.63 [ -1.32, 0.05 ]
Matthews 2007 22 -0.2 (1.62) 14 0.41 (1.94) 50.7 % -0.34 [ -1.02, 0.33 ]
Subtotal (95% CI) 52 26 100.0 % -0.48 [ -0.97, 0.00 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.35, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 1.98 (P = 0.048)
2 Facility-based
Mustian 2004 9 -0.16 (2.91) 10 0.28 (1.57) 18.9 % -0.18 [ -1.09, 0.72 ]
Naumann 2012 11 -0.3 (2.42) 10 0.8 (2.75) 19.1 % -0.41 [ -1.28, 0.46 ]
Schmitz 2005 39 -1.15 (0.45) 40 0.23 (0.44) 20.1 % -3.07 [ -3.73, -2.41 ]
Courneya 2003 24 -4.9 (15.7) 26 5.1 (24.4) 20.5 % -0.48 [ -1.04, 0.09 ]
Schmitz 2009 (1) 65 -0.3 (5.7) 63 -0.1 (3.3) 21.3 % -0.04 [ -0.39, 0.30 ]
Subtotal (95% CI) 148 149 100.0 % -0.84 [ -1.94, 0.26 ]
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N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 1.45; Chi2 = 64.94, df = 4 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.49 (P = 0.14)
3 Both home- and facility-based
Rogers 2014 20 -1.1 (2.2) 22 -0.6 (2.4) 33.9 % -0.21 [ -0.82, 0.39 ]
Ligibel 2008 40 -0.2 (1.7) 42 0.3 (1.7) 66.1 % -0.29 [ -0.73, 0.14 ]
Subtotal (95% CI) 60 64 100.0 % -0.26 [ -0.62, 0.09 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
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Analysis 17.41. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 41 Lower body
strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 41 Lower body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Cerulli 2014 10 114.88 (17.09) 10 79.13 (17.78) 12.1 % 1.96 [ 0.85, 3.07 ]
Schmitz 2005 23 296.6 (48.9) 22 238.9 (46.4) 19.3 % 1.19 [ 0.55, 1.83 ]
Milne 2008 29 66.2 (10.2) 29 61.7 (11) 21.4 % 0.42 [ -0.10, 0.94 ]
Do 2015 32 13 (1.62) 30 13.15 (1.55) 21.8 % -0.09 [ -0.59, 0.41 ]
Schmitz 2009 113 223.4 (59.6) 119 175.1 (53.5) 25.4 % 0.85 [ 0.58, 1.12 ]
Subtotal (95% CI) 207 210 100.0 % 0.75 [ 0.24, 1.27 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 19.31, df = 4 (P = 0.00068); I2 =79%
Test for overall effect: Z = 2.85 (P = 0.0043)
3 Both home- and facility-based
Rogers 2013 11 68.4 (15.5) 9 67.1 (16.2) 9.7 % 0.08 [ -0.80, 0.96 ]
Nikander 2007 14 1305 (177) 14 1393 (275) 13.3 % -0.37 [ -1.12, 0.38 ]
Rogers 2009 20 80.3 (27) 18 64.9 (19.7) 17.1 % 0.63 [ -0.02, 1.29 ]
Saarto 2012 37 136 (23) 30 136 (29) 29.9 % 0.0 [ -0.48, 0.48 ]
Winters-Stone 2011 36 201.3 (57.4) 31 191 (51.7) 30.0 % 0.19 [ -0.30, 0.67 ]
Subtotal (95% CI) 118 102 100.0 % 0.12 [ -0.16, 0.40 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 4.32, df = 4 (P = 0.36); I2 =7%
Test for overall effect: Z = 0.86 (P = 0.39)
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Analysis 17.42. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 42 Lower body
strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 42 Lower body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Nieman 1995 6 28.9 (13.7) 6 3.5 (22.5) 7.3 % 1.26 [ -0.03, 2.55 ]
Naumann 2012 11 7.7 (12.6) 10 3.5 (13.9) 11.6 % 0.30 [ -0.56, 1.17 ]
Dolan 2016 23 11.84 (8.89) 10 0.34 (11.1) 12.4 % 1.17 [ 0.37, 1.97 ]
Schmitz 2005 23 81.8 (48.92) 22 20.3 (45.97) 14.7 % 1.27 [ 0.63, 1.92 ]
Cormie 2014 43 37.6 (25.5) 19 6.7 (25.7) 15.6 % 1.19 [ 0.61, 1.78 ]
Do 2015 32 0.9 (0.7) 60 0.95 (0.61) 18.1 % -0.08 [ -0.51, 0.35 ]
Schmitz 2009 113 33.2 (33.9) 119 7.9 (26.6) 20.3 % 0.83 [ 0.56, 1.10 ]
Subtotal (95% CI) 251 246 100.0 % 0.80 [ 0.38, 1.23 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 22.01, df = 6 (P = 0.001); I2 =73%
Test for overall effect: Z = 3.69 (P = 0.00022)
3 Both home- and facility-based
Waltman 2010 110 4.42 (11.48) 113 0.19 (8.38) 100.0 % 0.42 [ 0.15, 0.69 ]
Subtotal (95% CI) 110 113 100.0 % 0.42 [ 0.15, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.10 (P = 0.0019)
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Analysis 17.43. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 43 Upper body
strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 43 Upper body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Portela 2008 13 40.6 (13.5) 9 35.6 (13.1) 39.2 % 0.36 [ -0.50, 1.22 ]
Musanti 2012 30 52.13 (20.98) 12 36.75 (20) 60.8 % 0.73 [ 0.04, 1.42 ]
Subtotal (95% CI) 43 21 100.0 % 0.58 [ 0.05, 1.12 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.43, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 2.13 (P = 0.033)
2 Facility-based
Mustian 2004 11 29.6 (3.27) 10 26.7 (5.73) 11.0 % 0.60 [ -0.28, 1.49 ]
Cerulli 2014 10 16.08 (5.43) 10 17.2 (8.05) 11.0 % -0.16 [ -1.03, 0.72 ]
Portela 2008 12 37.8 (14.4) 9 35.6 (13.1) 11.1 % 0.15 [ -0.71, 1.02 ]
Schmitz 2005 23 83 (13.4) 22 63 (12.7) 12.4 % 1.50 [ 0.84, 2.17 ]
Kaltsatou 2011 28 59.63 (8.49) 26 47.62 (9.83) 13.0 % 1.29 [ 0.70, 1.88 ]
Milne 2008 29 7.6 (2.9) 29 9.4 (2.6) 13.4 % -0.64 [ -1.17, -0.12 ]
Do 2015 32 9.65 (1.67) 30 10.05 (1.68) 13.5 % -0.24 [ -0.74, 0.26 ]
Schmitz 2009 113 52.9 (15.3) 119 40.9 (11.8) 14.7 % 0.88 [ 0.61, 1.15 ]
Subtotal (95% CI) 258 255 100.0 % 0.43 [ -0.12, 0.98 ]
Heterogeneity: Tau2 = 0.52; Chi2 = 51.98, df = 7 (P<0.00001); I2 =87%
Test for overall effect: Z = 1.54 (P = 0.12)
3 Both home- and facility-based
Nikander 2007 14 131 (20) 14 129 (28) 14.3 % 0.08 [ -0.66, 0.82 ]
Rogers 2009 20 27.9 (5.04) 18 24.3 (6.18) 18.4 % 0.63 [ -0.03, 1.28 ]
Saarto 2012 37 32.7 (5.3) 30 30.8 (5.7) 33.4 % 0.34 [ -0.14, 0.83 ]
Winters-Stone 2011 36 63.3 (15.3) 31 61.1 (16.8) 34.0 % 0.14 [ -0.34, 0.62 ]
Subtotal (95% CI) 107 93 100.0 % 0.29 [ 0.01, 0.57 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.78, df = 3 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.01 (P = 0.045)
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Analysis 17.44. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 44 Upper body
strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 44 Upper body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
2 Facility-based
Schmitz 2005 23 32.3 (11.51) 22 6.9 (10.79) 14.7 % 2.24 [ 1.48, 2.99 ]
Musanti 2012 30 7.74 (10.62) 12 0.83 (12.65) 15.4 % 0.60 [ -0.08, 1.29 ]
Cormie 2014 43 5.7 (3.67) 19 1 (3.78) 16.4 % 1.25 [ 0.67, 1.84 ]
Do 2015 32 0.3 (0.5) 30 0.55 (1.2) 17.2 % -0.27 [ -0.77, 0.23 ]
Mustian 2004 45 4.5 (4.71) 38 -0.85 (3.15) 17.4 % 1.30 [ 0.82, 1.78 ]
Schmitz 2009 113 33.2 (40.8) 119 7.6 (43.7) 18.9 % 0.60 [ 0.34, 0.87 ]
Subtotal (95% CI) 286 240 100.0 % 0.92 [ 0.34, 1.50 ]
Heterogeneity: Tau2 = 0.44; Chi2 = 40.07, df = 5 (P<0.00001); I2 =88%
Test for overall effect: Z = 3.13 (P = 0.0017)
3 Both home- and facility-based
Irwin 2015 45 0.4 (1.88) 38 0.1 (1.89) 27.1 % 0.16 [ -0.27, 0.59 ]
Waltman 2010 110 1.9 (4.86) 113 0.75 (2.9) 72.9 % 0.29 [ 0.02, 0.55 ]
Subtotal (95% CI) 155 151 100.0 % 0.25 [ 0.03, 0.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 2.19 (P = 0.028)
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density - femoral neck (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 45 Bone mineral density - femoral neck (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Kim 2015 20 0.78 (0.08) 19 0.81 (0.08) 100.0 % -0.37 [ -1.00, 0.27 ]
Subtotal (95% CI) 20 19 100.0 % -0.37 [ -1.00, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.26)
2 Facility-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Both home- and facility-based
Winters-Stone 2011 36 0.72 (0.1) 31 0.71 (0.08) 23.5 % 0.11 [ -0.37, 0.59 ]
Waltman 2010 (1) 110 0.92 (0.5) 113 0.63 (0.42) 35.7 % 0.63 [ 0.36, 0.90 ]
Saarto 2012 (2) 239 -0.006 (0.025) 218 -0.01 (0.03) 40.8 % 0.18 [ 0.00, 0.37 ]
Subtotal (95% CI) 385 362 100.0 % 0.32 [ -0.01, 0.65 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 7.87, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 1.91 (P = 0.056)
-2 -1 0 1 2
Favours control Favours physical activity
(1) % change values
(2) change values
836Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 17.46. Comparison 17 Subanalysis: outcomes by setting of intervention, Outcome 46 Bone mineral
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Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 46 Bone mineral density - lumbar spine (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Kim 2015 20 0.97 (0.08) 19 0.99 (0.07) 100.0 % -0.26 [ -0.89, 0.37 ]
Subtotal (95% CI) 20 19 100.0 % -0.26 [ -0.89, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
2 Facility-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Both home- and facility-based
Winters-Stone 2011 36 0.99 (0.15) 31 0.95 (0.11) 23.2 % 0.30 [ -0.19, 0.78 ]
Waltman 2010 (1) 110 3.08 (0.44) 113 2.85 (0.4) 35.8 % 0.55 [ 0.28, 0.81 ]
Saarto 2012 (2) 239 -0.018 (0.033) 218 -0.02 (0.034) 41.0 % 0.09 [ -0.09, 0.27 ]
Subtotal (95% CI) 385 362 100.0 % 0.30 [ -0.02, 0.63 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 7.65, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 1.81 (P = 0.070)
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density - total hip (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 17 Subanalysis: outcomes by setting of intervention
Outcome: 47 Bone mineral density - total hip (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Home-based
Kim 2015 20 0.88 (0.08) 19 0.09 (0.07) 100.0 % 10.34 [ 7.84, 12.84 ]
Subtotal (95% CI) 20 19 100.0 % 10.34 [ 7.84, 12.84 ]
Heterogeneity: not applicable
Test for overall effect: Z = 8.11 (P < 0.00001)
2 Facility-based
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
3 Both home- and facility-based
Winters-Stone 2011 36 0.86 (0.11) 31 0.84 (0.1) 47.3 % 0.19 [ -0.29, 0.67 ]
Waltman 2010 (1) 110 2.15 (0.28) 113 1.81 (0.36) 52.7 % 1.05 [ 0.77, 1.33 ]
Subtotal (95% CI) 146 144 100.0 % 0.64 [ -0.20, 1.48 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 9.19, df = 1 (P = 0.002); I2 =89%
Test for overall effect: Z = 1.49 (P = 0.14)
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Analysis 18.1. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 1 Overall HRQoL
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 1 Overall HRQoL (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 3.1 % 1.30 [ 0.19, 2.41 ]
Loudon 2014 12 -7.42 (1.24) 11 -7.45 (1.44) 4.6 % 0.02 [ -0.80, 0.84 ]
Portela 2008 25 107.2 (28.5) 9 91.6 (28.5) 4.8 % 0.53 [ -0.24, 1.31 ]
Milne 2008 29 86.4 (8.3) 29 64.1 (10.8) 5.5 % 2.28 [ 1.61, 2.96 ]
Rogers 2009 20 92 (11.4) 18 87.4 (13.1) 5.7 % 0.37 [ -0.27, 1.01 ]
Courneya 2003 24 91.3 (11) 28 89.3 (10.9) 6.5 % 0.18 [ -0.37, 0.73 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 6.6 % 0.19 [ -0.35, 0.73 ]
Murtezani 2014 30 86.5 (7.3) 32 79.1 (7.5) 6.7 % 0.99 [ 0.46, 1.52 ]
Cadmus 2009 37 91.2 (12.6) 37 86.2 (17.4) 7.3 % 0.33 [ -0.13, 0.78 ]
Pinto 2015 39 117.79 (12.74) 37 113.98 (18.02) 7.3 % 0.24 [ -0.21, 0.69 ]
Schmitz 2005 39 -44.2 (8.7) 40 -47.4 (9.4) 7.4 % 0.35 [ -0.09, 0.79 ]
Daley 2007 33 90.85 (13.47) 69 86.44 (15.07) 7.6 % 0.30 [ -0.12, 0.72 ]
Rogers 2015 105 88.1 (12.4) 108 83.2 (15.5) 8.8 % 0.35 [ 0.08, 0.62 ]
Vallance 2007 250 91.54 (11.76) 85 90.55 (12.95) 9.0 % 0.08 [ -0.16, 0.33 ]
Short 2014 195 106.8 (16.7) 104 108.2 (18.2) 9.1 % -0.08 [ -0.32, 0.16 ]
Subtotal (95% CI) 886 635 100.0 % 0.43 [ 0.19, 0.66 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 57.17, df = 14 (P<0.00001); I2 =76%
Test for overall effect: Z = 3.52 (P = 0.00043)
2 Unclear/high risk of bias
Cerulli 2014 10 85.23 (4.2) 10 65.89 (14.66) 4.8 % 1.72 [ 0.66, 2.78 ]
Mustian 2004 11 121.7 (22.67) 10 124.3 (25.9) 6.9 % -0.10 [ -0.96, 0.75 ]
Mehnert 2011 30 74.72 (21.72) 27 65.43 (16.78) 14.6 % 0.47 [ -0.06, 1.00 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 15.7 % 0.28 [ -0.22, 0.79 ]
Taleghani 2012 40 217.5 (36.3) 40 210.1 (41.5) 18.5 % 0.19 [ -0.25, 0.63 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Loh 2014 63 112.4 (14.09) 32 109.29 (13.26) 19.2 % 0.22 [ -0.20, 0.65 ]
Littman 2012 30 90.3 (11) 110 87.7 (15) 20.4 % 0.18 [ -0.22, 0.59 ]
Subtotal (95% CI) 216 259 100.0 % 0.30 [ 0.06, 0.55 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 8.81, df = 6 (P = 0.18); I2 =32%
Test for overall effect: Z = 2.43 (P = 0.015)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 2 Overall HRQoL (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 5.7 % 1.92 [ 0.68, 3.17 ]
Murtezani 2014 30 9.16 (2.12) 32 -0.56 (2.01) 6.9 % 4.65 [ 3.67, 5.63 ]
Rogers 2009 20 4.5 (8.4) 18 2.9 (12) 8.8 % 0.15 [ -0.49, 0.79 ]
Cuesta-Vargas 2014 22 0.32 (0.18) 20 0.33 (0.09) 9.0 % -0.07 [ -0.67, 0.54 ]
Courneya 2003 24 5.7 (7.4) 28 0.6 (7.4) 9.2 % 0.68 [ 0.12, 1.24 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 9.3 % 0.52 [ -0.03, 1.06 ]
Cadmus 2009 37 0.6 (7.5) 37 -2.4 (9.8) 9.8 % 0.34 [ -0.12, 0.80 ]
Schmitz 2005 39 2.3 (4.5) 40 0.6 (4) 9.8 % 0.40 [ -0.05, 0.84 ]
Daley 2007 33 10.22 (11.2) 69 3.2 (11.26) 9.9 % 0.62 [ 0.20, 1.04 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vallance 2007 250 2.3 (11.08) 85 -0.16 (6.4) 10.6 % 0.24 [ 0.00, 0.49 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 10.8 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 766 594 100.0 % 0.70 [ 0.28, 1.12 ]
Heterogeneity: Tau2 = 0.42; Chi2 = 106.14, df = 10 (P<0.00001); I2 =91%
Test for overall effect: Z = 3.24 (P = 0.0012)
2 Unclear/high risk of bias
Mustian 2004 11 15 (5) 10 0 (5) 29.2 % 2.88 [ 1.59, 4.17 ]
Naumann 2012 11 14.5 (10.6) 10 3.1 (11.4) 33.5 % 1.00 [ 0.08, 1.92 ]
Mehnert 2011 30 9.72 (21.03) 27 5.55 (16.5) 37.3 % 0.22 [ -0.31, 0.74 ]
Subtotal (95% CI) 52 47 100.0 % 1.26 [ -0.11, 2.62 ]
Heterogeneity: Tau2 = 1.24; Chi2 = 14.64, df = 2 (P = 0.00066); I2 =86%
Test for overall effect: Z = 1.80 (P = 0.072)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 3 Overall emotional function/mental health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 90.6 (9.3) 8 83.3 (14.8) 1.5 % 0.56 [ -0.45, 1.56 ]
Loudon 2014 12 -1.58 (0.7) 11 -1.61 (0.49) 2.3 % 0.05 [ -0.77, 0.87 ]
Rogers 2009 20 20 (3.1) 18 21.1 (2.9) 3.6 % -0.36 [ -1.00, 0.28 ]
Cuesta-Vargas 2014 22 42.9 (19.17) 20 32.3 (33.33) 3.9 % 0.39 [ -0.22, 1.00 ]
Courneya 2003 24 21.5 (3.4) 28 20.7 (3) 4.7 % 0.25 [ -0.30, 0.79 ]
Milne 2008 29 19.6 (2.4) 29 16.7 (4.1) 4.8 % 0.85 [ 0.31, 1.39 ]
Cantarero-Villanueva 2013 32 -17175 (4279) 29 -20390 (6113) 5.2 % 0.61 [ 0.09, 1.12 ]
Murtezani 2014 30 19.5 (3.3) 32 18.3 (3.5) 5.5 % 0.35 [ -0.15, 0.85 ]
Daley 2007 33 19.06 (4.18) 33 18.45 (3.31) 5.8 % 0.16 [ -0.32, 0.64 ]
Cadmus 2009 37 20.5 (3) 37 19.8 (4.2) 6.4 % 0.19 [ -0.27, 0.65 ]
Pinto 2015 39 54.21 (9.28) 37 52.48 (9.62) 6.5 % 0.18 [ -0.27, 0.63 ]
Schmitz 2005 39 -45.6 (8.2) 40 -48.2 (8.2) 6.7 % 0.31 [ -0.13, 0.76 ]
Rogers 2015 105 20.6 (2.9) 108 19.7 (3.2) 13.6 % 0.29 [ 0.02, 0.56 ]
Schmitz 2009 112 53.2 (9.6) 120 53.8 (8.7) 14.4 % -0.07 [ -0.32, 0.19 ]
Vallance 2007 250 20.28 (3.31) 85 19.92 (3.44) 15.1 % 0.11 [ -0.14, 0.35 ]
Subtotal (95% CI) 792 635 100.0 % 0.22 [ 0.09, 0.34 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 17.62, df = 14 (P = 0.22); I2 =21%
Test for overall effect: Z = 3.32 (P = 0.00090)
2 Unclear/high risk of bias
Banasik 2011 7 0.47 (0.36) 7 0.38 (0.31) 3.4 % 0.25 [ -0.80, 1.30 ]
Mustian 2004 9 24.78 (2.04) 10 24.8 (3.19) 4.4 % -0.01 [ -0.91, 0.89 ]
Pinto 2003 12 -10.83 (28.1) 12 -27.17 (19.5) 5.0 % 0.65 [ -0.17, 1.48 ]
Basen-Enquist 2006 28 78.2 (10.58) 23 77.2 (11.99) 9.0 % 0.09 [ -0.46, 0.64 ]
Do 2015 32 87.4 (8.8) 30 70.4 (21.5) 9.4 % 1.03 [ 0.50, 1.57 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Littman 2012 30 20.3 (4) 27 20.8 (3.1) 9.7 % -0.14 [ -0.66, 0.38 ]
Mehnert 2011 30 77.01 (35.75) 28 69.05 (40.5) 9.8 % 0.21 [ -0.31, 0.72 ]
Pinto 2005 39 -8.02 (20.69) 43 -16.51 (28.75) 11.8 % 0.33 [ -0.10, 0.77 ]
Loh 2014 63 19.87 (2.81) 32 19.98 (3.22) 12.1 % -0.04 [ -0.46, 0.39 ]
Fillion 2008 44 48.54 (7.91) 43 47.49 (9.08) 12.2 % 0.12 [ -0.30, 0.54 ]
Duijits 2012 37 73.92 (34.7) 89 77.46 (34.32) 13.3 % -0.10 [ -0.49, 0.28 ]
Subtotal (95% CI) 331 344 100.0 % 0.19 [ -0.02, 0.40 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 16.47, df = 10 (P = 0.09); I2 =39%
Test for overall effect: Z = 1.78 (P = 0.075)
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Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 4 Overall emotional function/mental health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 9.3 (19.6) 8 -2.1 (5.9) 4.5 % 0.74 [ -0.28, 1.77 ]
Rogers 2009 20 0.9 (2.5) 18 -0.1 (2.7) 7.5 % 0.38 [ -0.27, 1.02 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 8.0 % 1.80 [ 1.21, 2.40 ]
Courneya 2003 24 2.3 (3.1) 28 0.8 (2.9) 8.4 % 0.49 [ -0.06, 1.05 ]
Cormie 2014 43 4.4 (9) 19 2.7 (8.6) 8.6 % 0.19 [ -0.35, 0.73 ]
Cantarero-Villanueva 2013 32 -1445 (4452) 29 353 (3323) 8.9 % -0.45 [ -0.96, 0.06 ]
Cadmus 2009 37 0.3 (2.2) 37 -0.5 (3.3) 9.5 % 0.28 [ -0.18, 0.74 ]
Schmitz 2005 39 2.5 (4.4) 40 0.3 (3.9) 9.6 % 0.52 [ 0.08, 0.97 ]
Schmitz 2009 58 3.3 (23.2) 62 3.1 (17.2) 10.7 % 0.01 [ -0.35, 0.37 ]
Vallance 2007 250 0.47 (3.54) 85 0.08 (2.49) 11.8 % 0.12 [ -0.13, 0.36 ]
Saarto 2012 263 1.2 (17.79) 237 1.9 (18.46) 12.4 % -0.04 [ -0.21, 0.14 ]
Subtotal (95% CI) 804 595 100.0 % 0.31 [ 0.04, 0.58 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 46.12, df = 10 (P<0.00001); I2 =78%
Test for overall effect: Z = 2.26 (P = 0.024)
2 Unclear/high risk of bias
Mustian 2004 9 2.44 (2.52) 10 0.1 (1.68) 12.0 % 1.06 [ 0.08, 2.03 ]
Naumann 2012 11 1 (2.69) 10 -0.1 (2.72) 14.8 % 0.39 [ -0.48, 1.26 ]
Mehnert 2011 30 2.3 (35.5) 28 3.57 (17.6) 32.8 % -0.04 [ -0.56, 0.47 ]
Pinto 2005 39 -3.8 (27.7) 43 -11.47 (25.8) 40.5 % 0.28 [ -0.15, 0.72 ]
Subtotal (95% CI) 89 91 100.0 % 0.28 [ -0.08, 0.65 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.99, df = 3 (P = 0.26); I2 =25%
Test for overall effect: Z = 1.55 (P = 0.12)
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Outcome: 5 Overall physical function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 94.1 (7.5) 8 92.5 (6.6) 4.1 % 0.21 [ -0.77, 1.20 ]
Milne 2008 29 24 (2.6) 29 15.6 (4.5) 6.2 % 2.26 [ 1.59, 2.92 ]
Rogers 2009 20 23.3 (4.5) 18 25.4 (2.3) 6.3 % -0.57 [ -1.22, 0.08 ]
Cuesta-Vargas 2014 22 42.9 (4.06) 20 32.4 (32.48) 6.7 % 0.46 [ -0.16, 1.07 ]
Courneya 2003 24 25.3 (2.5) 28 25.3 (2.8) 7.3 % 0.0 [ -0.55, 0.55 ]
Murtezani 2014 30 22.6 (4.4) 32 19.4 (4.4) 7.5 % 0.72 [ 0.20, 1.23 ]
Daley 2007 33 25.61 (2.15) 33 23.61 (5.7) 7.8 % 0.46 [ -0.03, 0.95 ]
Cadmus 2009 37 25.1 (2.7) 37 24 (4.1) 8.1 % 0.31 [ -0.15, 0.77 ]
Schmitz 2005 39 -44.2 (5.6) 40 -48.3 (7.7) 8.1 % 0.60 [ 0.15, 1.05 ]
Pinto 2015 39 87.08 (4.4) 37 84.69 (15.91) 8.2 % 0.21 [ -0.25, 0.66 ]
Rogers 2015 105 24.1 (3.5) 108 22.5 (5) 9.8 % 0.37 [ 0.10, 0.64 ]
Schmitz 2009 112 50.6 (8.15) 120 49.1 (9.32) 9.9 % 0.17 [ -0.09, 0.43 ]
Vallance 2007 250 25.1 (2.96) 85 24.95 (3.26) 10.0 % 0.05 [ -0.20, 0.30 ]
Subtotal (95% CI) 748 595 100.0 % 0.38 [ 0.13, 0.63 ]
Heterogeneity: Tau2 = 0.15; Chi2 = 51.23, df = 12 (P<0.00001); I2 =77%
Test for overall effect: Z = 2.99 (P = 0.0028)
2 Unclear/high risk of bias
Banasik 2011 7 -0.77 (0.94) 7 -0.42 (0.25) 1.8 % -0.48 [ -1.54, 0.59 ]
Mustian 2004 9 26.89 (4.11) 10 26.5 (4.14) 2.5 % 0.09 [ -0.81, 0.99 ]
Pinto 2003 12 32.3 (4.3) 12 25.3 (8.2) 2.7 % 1.03 [ 0.17, 1.89 ]
Basen-Enquist 2006 28 82.5 (12.7) 23 77.4 (11.5) 6.5 % 0.41 [ -0.15, 0.97 ]
Mehnert 2011 30 88.96 (9.13) 28 78.12 (21.22) 7.2 % 0.66 [ 0.13, 1.19 ]
Littman 2012 30 25.4 (1.7) 27 24.3 (4.4) 7.4 % 0.33 [ -0.19, 0.86 ]
Winters-Stone 2011 36 51.7 (6.2) 25 52.3 (5.9) 7.8 % -0.10 [ -0.61, 0.41 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Do 2015 32 89.4 (8.4) 30 89 (8.7) 8.2 % 0.05 [ -0.45, 0.54 ]
Pinto 2005 39 30.26 (7.88) 43 27.33 (6.76) 10.6 % 0.40 [ -0.04, 0.83 ]
Loh 2014 63 24.92 (2.54) 32 24.17 (2.23) 11.1 % 0.30 [ -0.12, 0.73 ]
Fillion 2008 44 45.1 (10.42) 43 41.76 (9.76) 11.3 % 0.33 [ -0.10, 0.75 ]
Duijits 2012 87 84.03 (16.88) 89 80.18 (17.08) 23.0 % 0.23 [ -0.07, 0.52 ]
Subtotal (95% CI) 417 369 100.0 % 0.28 [ 0.14, 0.42 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 10.69, df = 11 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 3.88 (P = 0.00010)
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Analysis 18.6. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 6 Overall physical
function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 6 Overall physical function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 6.7 (5) 8 -1.7 (6.9) 6.8 % 1.32 [ 0.21, 2.43 ]
Murtezani 2014 30 4.43 (1.53) 32 -1.34 (1.15) 7.9 % 4.23 [ 3.31, 5.15 ]
Rogers 2009 20 2.3 (5.1) 18 2.6 (6) 9.6 % -0.05 [ -0.69, 0.58 ]
Courneya 2003 24 1.9 (2) 28 -0.2 (2.2) 9.9 % 0.98 [ 0.40, 1.56 ]
Cormie 2014 43 3.49 (5.15) 19 -0.5 (5.67) 10.1 % 0.74 [ 0.19, 1.30 ]
Cadmus 2009 37 0.1 (6.02) 37 -0.5 (7.42) 10.6 % 0.09 [ -0.37, 0.54 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 10.7 % -0.05 [ -0.49, 0.39 ]
Schmitz 2009 58 6.6 (17.1) 62 4.1 (17.3) 11.1 % 0.14 [ -0.21, 0.50 ]
Vallance 2007 247 1 (3.32) 85 0.19 (2.07) 11.6 % 0.26 [ 0.02, 0.51 ]
Saarto 2012 263 1.9 (13.65) 237 3.4 (13.35) 11.8 % -0.11 [ -0.29, 0.06 ]
Subtotal (95% CI) 769 566 100.0 % 0.63 [ 0.19, 1.07 ]
Heterogeneity: Tau2 = 0.42; Chi2 = 103.01, df = 9 (P<0.00001); I2 =91%
Test for overall effect: Z = 2.80 (P = 0.0052)
2 Unclear/high risk of bias
Mustian 2004 9 1.89 (2.61) 10 -0.2 (1.61) 17.8 % 0.93 [ -0.03, 1.89 ]
Naumann 2012 11 1.9 (3.3) 10 0.8 (3.4) 22.0 % 0.32 [ -0.55, 1.18 ]
Mehnert 2011 30 3.96 (10.83) 28 -2.15 (16.7) 60.2 % 0.43 [ -0.09, 0.95 ]
Subtotal (95% CI) 50 48 100.0 % 0.50 [ 0.09, 0.90 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.02, df = 2 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 2.40 (P = 0.017)
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Analysis 18.7. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 7 Overall role
function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 7 Overall role function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 97.6 (5.9) 8 100 (0.01) 4.9 % -0.54 [ -1.55, 0.46 ]
Loudon 2014 12 -1.3 (0.31) 11 -1.3 (0.36) 6.1 % 0.0 [ -0.82, 0.82 ]
Milne 2008 29 22.2 (3) 29 12.5 (4.8) 7.1 % 2.39 [ 1.71, 3.08 ]
Rogers 2009 20 21.4 (4.8) 18 23.8 (3.2) 7.4 % -0.57 [ -1.22, 0.08 ]
Courneya 2003 24 23.4 (4) 28 23.1 (4) 8.3 % 0.07 [ -0.47, 0.62 ]
Murtezani 2014 30 24.2 (2.8) 32 23 (2.5) 8.6 % 0.45 [ -0.06, 0.95 ]
Daley 2007 33 22.88 (4.52) 33 20.3 (5.57) 8.8 % 0.50 [ 0.01, 0.99 ]
Cadmus 2009 37 23.1 (4.7) 37 20.6 (7.2) 9.0 % 0.41 [ -0.05, 0.87 ]
Schmitz 2005 39 -49.2 (6.5) 40 -50 (6.2) 9.2 % 0.12 [ -0.32, 0.57 ]
Loh 2014 63 23.37 (4.33) 32 22.22 (4.99) 9.3 % 0.25 [ -0.18, 0.68 ]
Rogers 2015 105 22.3 (4.5) 108 20.3 (5.5) 10.6 % 0.40 [ 0.12, 0.67 ]
Vallance 2007 250 23.22 (3.98) 85 22.72 (4.58) 10.7 % 0.12 [ -0.13, 0.37 ]
Subtotal (95% CI) 650 461 100.0 % 0.32 [ 0.02, 0.61 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 50.99, df = 11 (P<0.00001); I2 =78%
Test for overall effect: Z = 2.12 (P = 0.034)
2 Unclear/high risk of bias
Banasik 2011 7 3.46 (0.64) 7 3.24 (0.56) 5.4 % 0.34 [ -0.72, 1.40 ]
Mustian 2004 9 2.44 (1.5) 9 2.8 (1.53) 7.0 % -0.23 [ -1.15, 0.70 ]
Basen-Enquist 2006 28 86.1 (22.2) 23 73 (24.5) 19.1 % 0.55 [ -0.01, 1.12 ]
Mehnert 2011 30 90 (20.34) 27 79.6 (25.04) 21.8 % 0.45 [ -0.07, 0.98 ]
Littman 2012 30 22.6 (3.9) 27 21.7 (4.7) 22.3 % 0.21 [ -0.31, 0.73 ]
Do 2015 32 78.1 (19.5) 30 79.2 (14.6) 24.4 % -0.06 [ -0.56, 0.44 ]
Subtotal (95% CI) 136 123 100.0 % 0.24 [ -0.01, 0.48 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 4.26, df = 5 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.058)
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Analysis 18.8. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 8 Overall role
function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 8 Overall role function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 2.1 (13.9) 8 2.1 (5.9) 4.4 % 0.0 [ -0.98, 0.98 ]
Rogers 2009 20 0.4 (3.3) 18 1.4 (4.3) 8.0 % -0.26 [ -0.90, 0.38 ]
Courneya 2003 24 0.9 (2.8) 28 0.4 (2.7) 9.6 % 0.18 [ -0.37, 0.73 ]
Cormie 2014 43 4.9 (7.1) 19 1.7 (7.1) 9.6 % 0.45 [ -0.10, 0.99 ]
Murtezani 2014 30 1.66 (0.71) 32 0.87 (0.64) 9.7 % 1.16 [ 0.62, 1.70 ]
Cadmus 2009 37 -0.3 (3.7) 37 -0.5 (3.4) 11.5 % 0.06 [ -0.40, 0.51 ]
Schmitz 2005 39 1.2 (4.2) 40 1.5 (6.8) 11.8 % -0.05 [ -0.49, 0.39 ]
Vallance 2007 250 0.63 (4.14) 85 -0.01 (2.7) 16.8 % 0.17 [ -0.08, 0.41 ]
Saarto 2012 263 2.4 (21.51) 237 3.8 (21.6) 18.6 % -0.06 [ -0.24, 0.11 ]
Subtotal (95% CI) 714 504 100.0 % 0.17 [ -0.06, 0.40 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 21.60, df = 8 (P = 0.01); I2 =63%
Test for overall effect: Z = 1.43 (P = 0.15)
2 Unclear/high risk of bias
Mustian 2004 9 0.56 (1.59) 10 0.8 (1.55) 19.6 % -0.15 [ -1.05, 0.76 ]
Naumann 2012 11 1.5 (4.41) 10 0.5 (4.49) 21.6 % 0.22 [ -0.64, 1.08 ]
Mehnert 2011 30 6.67 (23.84) 27 5.56 (27) 58.9 % 0.04 [ -0.48, 0.56 ]
Subtotal (95% CI) 50 47 100.0 % 0.04 [ -0.36, 0.44 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.32, df = 2 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
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Analysis 18.9. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 9 Overall social well-
being/function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 9 Overall social well-being/function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 87.5 (19.4) 8 91.7 (23.6) 2.1 % -0.18 [ -1.17, 0.80 ]
Rogers 2014 20 7.3 (4.9) 22 3.1 (3.2) 4.4 % 1.01 [ 0.36, 1.65 ]
Rogers 2009 20 22.6 (4.1) 18 21.8 (5.7) 4.5 % 0.16 [ -0.48, 0.80 ]
Courneya 2003 24 21.1 (3.5) 28 20.7 (3.6) 5.8 % 0.11 [ -0.43, 0.66 ]
Milne 2008 29 20.7 (4) 29 19.4 (3.9) 6.3 % 0.32 [ -0.19, 0.84 ]
Murtezani 2014 30 20.2 (2.8) 32 18.3 (2.7) 6.4 % 0.68 [ 0.17, 1.20 ]
Daley 2007 33 23.3 (4.78) 33 20.4 (6.8) 6.9 % 0.49 [ 0.00, 0.98 ]
Cadmus 2009 37 22.3 (4.9) 37 20.6 (7.2) 7.6 % 0.27 [ -0.18, 0.73 ]
Schmitz 2009 59 14.9 (5.2) 62 14.1 (5.8) 10.8 % 0.14 [ -0.21, 0.50 ]
Kiecolt-Glaser 2014 96 95.2 (10.8) 90 93.8 (9.3) 13.9 % 0.14 [ -0.15, 0.43 ]
Rogers 2015 105 21 (5.7) 108 20.7 (5.8) 15.0 % 0.05 [ -0.22, 0.32 ]
Vallance 2007 250 22.94 (4.96) 85 22.96 (5.05) 16.3 % 0.00 [ -0.25, 0.24 ]
Subtotal (95% CI) 711 552 100.0 % 0.21 [ 0.07, 0.36 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 15.66, df = 11 (P = 0.15); I2 =30%
Test for overall effect: Z = 2.87 (P = 0.0041)
2 Unclear/high risk of bias
Banasik 2011 7 2.8 (0.67) 7 3.16 (0.83) 4.8 % -0.45 [ -1.51, 0.62 ]
Mustian 2004 9 8.63 (1.89) 10 9 (1.83) 6.7 % -0.19 [ -1.09, 0.71 ]
Basen-Enquist 2006 28 84.6 (16.93) 23 84.9 (19.18) 18.0 % -0.02 [ -0.57, 0.54 ]
Littman 2012 30 22.1 (5) 27 20.9 (6) 20.2 % 0.22 [ -0.31, 0.74 ]
Mehnert 2011 30 85.35 (20.88) 28 79.91 (22.65) 20.5 % 0.25 [ -0.27, 0.76 ]
Loh 2014 63 21.48 (4.88) 32 19.61 (4.9) 29.8 % 0.38 [ -0.05, 0.81 ]
Subtotal (95% CI) 167 127 100.0 % 0.17 [ -0.06, 0.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 3.37, df = 5 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
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Analysis 18.10. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 10 Overall social
well-being/function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 10 Overall social well-being/function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Rogers 2009 20 0.9 (2.6) 18 -1.2 (2.7) 9.9 % 0.78 [ 0.11, 1.44 ]
Rogers 2014 20 2.1 (3.2) 22 -0.8 (3.5) 10.1 % 0.85 [ 0.21, 1.48 ]
Murtezani 2014 30 2.06 (0.78) 32 0.53 (0.89) 10.4 % 1.80 [ 1.21, 2.40 ]
Courneya 2003 24 0.6 (2.4) 28 -0.5 (3.3) 10.7 % 0.37 [ -0.18, 0.92 ]
Cormie 2014 43 3.5 (8.5) 19 2.5 (8.3) 10.7 % 0.12 [ -0.42, 0.66 ]
Cadmus 2009 37 0.6 (4.6) 37 -1 (3.2) 11.3 % 0.40 [ -0.06, 0.86 ]
Schmitz 2009 59 4.4 (33.8) 62 0.7 (34) 11.9 % 0.11 [ -0.25, 0.47 ]
Vallance 2007 250 0.21 (4.82) 85 -4.15 (3.34) 12.4 % 0.97 [ 0.71, 1.23 ]
Saarto 2012 263 5 (21.1) 237 8.8 (20.81) 12.7 % -0.18 [ -0.36, -0.01 ]
Subtotal (95% CI) 746 540 100.0 % 0.56 [ 0.13, 0.98 ]
Heterogeneity: Tau2 = 0.36; Chi2 = 85.70, df = 8 (P<0.00001); I2 =91%
Test for overall effect: Z = 2.56 (P = 0.011)
2 Unclear/high risk of bias
Mustian 2004 9 1.5 (1.5) 10 0.44 (1.17) 18.2 % 0.76 [ -0.18, 1.70 ]
Naumann 2012 11 0.9 (3.32) 10 -0.2 (3.32) 21.6 % 0.32 [ -0.54, 1.18 ]
Mehnert 2011 30 7.33 (22.33) 28 3.12 (24.3) 60.3 % 0.18 [ -0.34, 0.69 ]
Subtotal (95% CI) 50 48 100.0 % 0.31 [ -0.09, 0.71 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 1.12, df = 2 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 1.53 (P = 0.12)
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Analysis 18.11. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 11 Overall cognitive
function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 11 Overall cognitive function (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 91.7 (12.6) 8 89.6 (12.4) 14.4 % 0.16 [ -0.82, 1.14 ]
Rogers 2009 19 -124.5 (30.8) 18 -135.5 (19.5) 32.7 % 0.42 [ -0.24, 1.07 ]
Cantarero-Villanueva 2013 32 -37.93 (8.48) 29 -43.03 (10.01) 52.9 % 0.55 [ 0.03, 1.06 ]
Subtotal (95% CI) 59 55 100.0 % 0.45 [ 0.07, 0.82 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.48, df = 2 (P = 0.79); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
2 Unclear/high risk of bias
Pinto 2003 12 -4.33 (2.5) 6 -7.17 (2.1) 38.9 % 1.14 [ 0.07, 2.20 ]
Mehnert 2011 30 81.1 (16.8) 27 78.4 (24.38) 61.1 % 0.13 [ -0.39, 0.65 ]
Subtotal (95% CI) 42 33 100.0 % 0.52 [ -0.44, 1.48 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 2.77, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 1.06 (P = 0.29)
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Analysis 18.12. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 12 Overall cognitive
function (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 12 Overall cognitive function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 6.2 (19.8) 8 8.3 (14.8) 10.3 % -0.11 [ -1.09, 0.87 ]
Rogers 2009 20 4.2 (16.8) 18 -4.7 (25.9) 18.9 % 0.40 [ -0.24, 1.05 ]
Cantarero-Villanueva 2013 32 2.2 (7.63) 29 -0.18 (5.5471) 24.9 % 0.35 [ -0.16, 0.86 ]
Saarto 2012 263 -1 (18.2) 237 2.2 (18.46) 45.9 % -0.17 [ -0.35, 0.00 ]
Subtotal (95% CI) 323 292 100.0 % 0.07 [ -0.28, 0.42 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 6.03, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 0.40 (P = 0.69)
2 Unclear/high risk of bias
Mehnert 2011 30 1.67 (22.36) 27 6.18 (24.6) 100.0 % -0.19 [ -0.71, 0.33 ]
Subtotal (95% CI) 30 27 100.0 % -0.19 [ -0.71, 0.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
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Analysis 18.13. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 13 Overall general
health (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 13 Overall general health (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 81.3 (10.7) 8 62.5 (16.1) 8.7 % 1.30 [ 0.19, 2.41 ]
Rogers 2009 20 3.5 (0.9) 18 3.8 (0.5) 18.2 % -0.40 [ -1.04, 0.25 ]
Ergun 2013 40 71.6 (19.89) 20 67.91 (16.7) 21.9 % 0.19 [ -0.35, 0.73 ]
Cadmus 2009 37 50 (8.8) 37 51.7 (8.4) 25.2 % -0.20 [ -0.65, 0.26 ]
Schmitz 2005 39 53.8 (5.3) 40 53.2 (6) 25.9 % 0.10 [ -0.34, 0.55 ]
Subtotal (95% CI) 144 123 100.0 % 0.06 [ -0.31, 0.43 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 8.13, df = 4 (P = 0.09); I2 =51%
Test for overall effect: Z = 0.32 (P = 0.75)
2 Unclear/high risk of bias
Mustian 2004 9 18.6 (4.77) 9 19.3 (1.92) 11.8 % -0.18 [ -1.11, 0.74 ]
Basen-Enquist 2006 28 77.4 (11.64) 23 67.1 (13.43) 26.0 % 0.81 [ 0.24, 1.39 ]
Mehnert 2011 30 74.38 (11.84) 28 70.01 (20.81) 30.4 % 0.26 [ -0.26, 0.77 ]
Do 2015 32 87.3 (13.7) 30 82.4 (19.9) 31.8 % 0.28 [ -0.22, 0.79 ]
Subtotal (95% CI) 99 90 100.0 % 0.36 [ 0.02, 0.70 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 3.94, df = 3 (P = 0.27); I2 =24%
Test for overall effect: Z = 2.07 (P = 0.038)
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Analysis 18.14. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 14 Overall general
health (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 14 Overall general health (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 17.7 (8.3) 8 -10.4 (17.7) 4.4 % 1.92 [ 0.68, 3.17 ]
Rogers 2009 20 0.15 (0.6) 18 0.17 (0.7) 11.5 % -0.03 [ -0.67, 0.61 ]
Ergun 2013 40 5.44 (21.47) 20 -6.66 (25.87) 13.6 % 0.52 [ -0.03, 1.06 ]
Cormie 2014 43 3.7 (7) 19 2.8 (7.1) 13.7 % 0.13 [ -0.41, 0.67 ]
Cadmus 2009 37 0.2 (4.4) 37 -0.1 (5.1) 16.0 % 0.06 [ -0.39, 0.52 ]
Schmitz 2005 39 0.7 (4.8) 40 -0.6 (3.9) 16.3 % 0.29 [ -0.15, 0.74 ]
Saarto 2012 263 4.2 (16.22) 237 5.6 (15.39) 24.5 % -0.09 [ -0.26, 0.09 ]
Subtotal (95% CI) 450 379 100.0 % 0.21 [ -0.08, 0.49 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 15.22, df = 6 (P = 0.02); I2 =61%
Test for overall effect: Z = 1.41 (P = 0.16)
2 Unclear/high risk of bias
Mustian 2004 9 0.22 (1.92) 10 0.68 (2.5) 24.6 % -0.20 [ -1.10, 0.71 ]
Mehnert 2011 30 6.6 (13.7) 28 3.24 (19.7) 75.4 % 0.20 [ -0.32, 0.71 ]
Subtotal (95% CI) 39 38 100.0 % 0.10 [ -0.35, 0.55 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.55, df = 1 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
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Analysis 18.15. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 15 Overall sexual
function (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 15 Overall sexual function (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low risk of bias
Schmitz 2005 39 -51 (7.5) 40 -53.5 (8) 40.7 % 0.32 [ -0.12, 0.76 ]
Schmitz 2009 57 -27.3 (5.3) 57 -28.1 (6.2) 59.3 % 0.14 [ -0.23, 0.51 ]
Subtotal (95% CI) 96 97 100.0 % 0.21 [ -0.07, 0.49 ]
Heterogeneity: Chi2 = 0.38, df = 1 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
2 Unclear/high risk of bias
Pinto 2005 12 42.75 (9.2) 6 43.7 (6.1) 7.5 % -0.11 [ -1.09, 0.87 ]
Pinto 2003 39 42.45 (9.24) 43 40.12 (6.3) 37.9 % 0.29 [ -0.14, 0.73 ]
Duijits 2012 53 0.6 (0.79) 65 0.59 (0.79) 54.7 % 0.01 [ -0.35, 0.38 ]
Subtotal (95% CI) 104 114 100.0 % 0.11 [ -0.16, 0.38 ]
Heterogeneity: Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.81 (P = 0.42)
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Analysis 18.16. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 16 Overall sexual
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 16 Overall sexual function (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Schmitz 2005 39 1.7 (4.8) 40 0.2 (5.2) 24.8 % 0.30 [ -0.15, 0.74 ]
Schmitz 2009 57 7.2 (14.6) 57 -0.2 (16.7) 29.5 % 0.47 [ 0.10, 0.84 ]
Saarto 2012 263 4.3 (25.38) 237 3.8 (24.35) 45.7 % 0.02 [ -0.16, 0.20 ]
Subtotal (95% CI) 359 334 100.0 % 0.22 [ -0.08, 0.52 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 5.22, df = 2 (P = 0.07); I2 =62%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Unclear/high risk of bias
Subtotal (95% CI) 0 0 Not estimable
Heterogeneity: not applicable
Test for overall effect: not applicable
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Analysis 18.17. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 17 Overall sleep
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 17 Overall sleep (follow-up values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low risk of bias
Bower 2011 16 8.1 (2.5) 15 7.7 (2.6) 28.0 % 0.15 [ -0.55, 0.86 ]
Rogers 2009 20 6.65 (4.17) 18 5.5 (4) 34.0 % 0.28 [ -0.36, 0.92 ]
Rogers 2014 20 6.7 (3.7) 22 7.1 (3.2) 38.0 % -0.11 [ -0.72, 0.49 ]
Subtotal (95% CI) 56 55 100.0 % 0.09 [ -0.28, 0.47 ]
Heterogeneity: Chi2 = 0.79, df = 2 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.49 (P = 0.62)
2 Unclear/high risk of bias
Rogers 2013 11 6.3 (2.7) 9 6.2 (3.2) 26.4 % 0.03 [ -0.85, 0.91 ]
Mehnert 2011 30 23.75 (27) 27 38.27 (31.63) 73.6 % -0.49 [ -1.02, 0.04 ]
Subtotal (95% CI) 41 36 100.0 % -0.35 [ -0.80, 0.10 ]
Heterogeneity: Chi2 = 0.99, df = 1 (P = 0.32); I2 =0.0%
Test for overall effect: Z = 1.52 (P = 0.13)
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Analysis 18.18. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 18 Overall sleep
(change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 18 Overall sleep (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Rogers 2009 20 0.45 (2.1) 18 0.28 (4.7) 47.7 % 0.05 [ -0.59, 0.68 ]
Rogers 2014 20 -1.3 (3.2) 22 -2.2 (4.4) 52.3 % 0.23 [ -0.38, 0.84 ]
Subtotal (95% CI) 40 40 100.0 % 0.14 [ -0.30, 0.58 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
2 Unclear/high risk of bias
Mehnert 2011 29 -5.36 (29.88) 27 -9.88 (33.3) 100.0 % 0.14 [ -0.38, 0.67 ]
Subtotal (95% CI) 29 27 100.0 % 0.14 [ -0.38, 0.67 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.60)
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Analysis 18.19. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 19 Overall anxiety
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 19 Overall anxiety (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Rogers 2014 20 45.6 (8.9) 22 45.7 (8) 22.4 % -0.01 [ -0.62, 0.59 ]
Milne 2008 29 15.3 (6.2) 29 21 (5.7) 24.5 % -0.94 [ -1.49, -0.40 ]
Cantarero-Villanueva 2013 32 42.51 (8.6) 29 49.93 (11.7) 25.4 % -0.72 [ -1.24, -0.20 ]
Cadmus 2009 37 32.1 (12.3) 37 34.1 (15.4) 27.7 % -0.14 [ -0.60, 0.31 ]
Subtotal (95% CI) 118 117 100.0 % -0.46 [ -0.89, -0.03 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 7.96, df = 3 (P = 0.05); I2 =62%
Test for overall effect: Z = 2.08 (P = 0.038)
2 Unclear/high risk of bias
Segar 1998 10 28.5 (3) 5 39.5 (6) 22.9 % -2.49 [ -3.98, -1.00 ]
Pinto 2003 12 7.58 (7.3) 6 10.5 (3.7) 33.0 % -0.43 [ -1.43, 0.56 ]
Mehnert 2011 30 4.83 (3.46) 28 7.14 (4.97) 44.1 % -0.54 [ -1.06, -0.01 ]
Subtotal (95% CI) 52 39 100.0 % -0.95 [ -1.92, 0.02 ]
Heterogeneity: Tau2 = 0.48; Chi2 = 6.16, df = 2 (P = 0.05); I2 =68%
Test for overall effect: Z = 1.93 (P = 0.054)
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Analysis 18.20. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 20 Overall anxiety
(change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 20 Overall anxiety (change values)







N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Low risk of bias
Cadmus 2009 37 -0.7 (9.2) 37 0.5 (5.8) 42.7 % -0.15 [ -0.61, 0.30 ]
Cantarero-Villanueva 2013 32 -4.2 (9.8) 29 0.75 (5.5) 33.6 % -0.61 [ -1.12, -0.09 ]
Rogers 2014 20 -4 (6.5) 22 -1.8 (5) 23.8 % -0.37 [ -0.99, 0.24 ]
Subtotal (95% CI) 89 88 100.0 % -0.36 [ -0.66, -0.06 ]
Heterogeneity: Chi2 = 1.67, df = 2 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 2.36 (P = 0.018)
2 Unclear/high risk of bias
Mehnert 2011 30 -1.67 (3.68) 28 0.18 (4.89) 100.0 % -0.42 [ -0.95, 0.10 ]
Subtotal (95% CI) 30 28 100.0 % -0.42 [ -0.95, 0.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.59 (P = 0.11)
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Analysis 18.21. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 21 Overall self-
esteem/body image (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 21 Overall self-esteem/body image (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Loudon 2014 12 -1.43 (0.33) 11 -1.56 (0.86) 7.9 % 0.20 [ -0.62, 1.02 ]
Musanti 2012 30 23.83 (3.48) 12 26.33 (3.94) 10.2 % -0.68 [ -1.37, 0.01 ]
Courneya 2003 24 34.8 (4.7) 28 34.6 (4.4) 13.8 % 0.04 [ -0.50, 0.59 ]
Milne 2008 29 -17.9 (6.8) 29 -20.1 (6.3) 14.7 % 0.33 [ -0.19, 0.85 ]
Daley 2007 33 2.03 (0.83) 32 1.57 (0.5) 15.3 % 0.66 [ 0.16, 1.16 ]
Cadmus 2009 37 34.2 (5.5) 37 33.4 (5.9) 16.9 % 0.14 [ -0.32, 0.60 ]
Schmitz 2009 59 -70.4 (16.3) 63 -71.5 (18) 21.2 % 0.06 [ -0.29, 0.42 ]
Subtotal (95% CI) 224 212 100.0 % 0.14 [ -0.12, 0.40 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 10.46, df = 6 (P = 0.11); I2 =43%
Test for overall effect: Z = 1.04 (P = 0.30)
2 Unclear/high risk of bias
Segar 1998 10 33 (1.8) 5 30.5 (2.7) 6.8 % 1.11 [ -0.06, 2.28 ]
Pinto 2003 12 32.3 (4.3) 6 25.3 (8.2) 8.0 % 1.15 [ 0.08, 2.22 ]
Mehnert 2011 27 -5.47 (1.66) 27 -6.82 (2.6) 24.4 % 0.61 [ 0.06, 1.16 ]
Do 2015 (1) 32 37.9 (18.9) 30 36.1 (18.3) 27.8 % 0.10 [ -0.40, 0.59 ]
Pinto 2005 39 30.26 (7.82) 43 27.23 (6.76) 32.9 % 0.41 [ -0.03, 0.85 ]
Subtotal (95% CI) 120 111 100.0 % 0.48 [ 0.16, 0.80 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 5.17, df = 4 (P = 0.27); I2 =23%
Test for overall effect: Z = 2.96 (P = 0.0031)
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Analysis 18.22. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 22 Overall self-
esteem/body image (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 22 Overall self-esteem/body image (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Musanti 2012 30 -0.4 (4.53) 12 0.58 (3.92) 9.8 % -0.22 [ -0.89, 0.45 ]
Courneya 2003 24 2.6 (3.7) 28 -0.1 (3.5) 11.8 % 0.74 [ 0.18, 1.30 ]
Milne 2008 29 1.5 (3.7) 29 0.1 (3.9) 12.7 % 0.36 [ -0.16, 0.88 ]
Daley 2007 33 1.79 (0.71) 33 1.56 (0.67) 13.5 % 0.33 [ -0.16, 0.82 ]
Cadmus 2009 37 0.4 (4.4) 37 0.2 (2.9) 14.2 % 0.05 [ -0.40, 0.51 ]
Schmitz 2009 59 -12 (15.5) 63 -4.1 (16.2) 16.7 % -0.49 [ -0.86, -0.13 ]
Saarto 2012 263 10.7 (21.51) 237 12 (21.99) 21.3 % -0.06 [ -0.24, 0.12 ]
Subtotal (95% CI) 475 439 100.0 % 0.07 [ -0.21, 0.34 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 18.32, df = 6 (P = 0.01); I2 =67%
Test for overall effect: Z = 0.49 (P = 0.62)
2 Unclear/high risk of bias
Mustian 2004 11 3 (1) 10 -1.5 (1.5) 47.8 % 3.42 [ 1.99, 4.86 ]
Mehnert 2011 30 0.73 (2.12) 27 0.39 (2.12) 52.2 % 0.16 [ -0.36, 0.68 ]
Subtotal (95% CI) 41 37 100.0 % 1.72 [ -1.48, 4.92 ]
Heterogeneity: Tau2 = 5.03; Chi2 = 17.62, df = 1 (P = 0.00003); I2 =94%
Test for overall effect: Z = 1.05 (P = 0.29)
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Analysis 18.23. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 23 Overall
depression (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 23 Overall depression (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Bower 2011 16 7.7 (5.8) 15 11.6 (7.1) 10.5 % -0.59 [ -1.31, 0.13 ]
Rogers 2014 20 44.2 (8.6) 22 25.1 (44.2) 12.2 % 0.58 [ -0.04, 1.19 ]
Ergun 2013 40 6.88 (6.76) 20 5.15 (5.18) 13.8 % 0.27 [ -0.27, 0.81 ]
Cantarero-Villanueva 2013 32 45.58 (9.68) 29 53.71 (11.6) 14.1 % -0.75 [ -1.28, -0.23 ]
Daley 2007 33 6 (6.47) 33 10.33 (7.19) 14.7 % -0.63 [ -1.12, -0.13 ]
Cadmus 2009 37 9.6 (9.3) 37 10.8 (10.1) 15.5 % -0.12 [ -0.58, 0.33 ]
Kiecolt-Glaser 2014 96 8.1 (8.6) 90 9.2 (8.2) 19.2 % -0.13 [ -0.42, 0.16 ]
Subtotal (95% CI) 274 246 100.0 % -0.20 [ -0.52, 0.12 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 17.59, df = 6 (P = 0.01); I2 =66%
Test for overall effect: Z = 1.21 (P = 0.23)
2 Unclear/high risk of bias
Segar 1998 10 5.5 (2) 5 10 (2) 11.5 % -2.12 [ -3.51, -0.73 ]
Pinto 2003 12 6.17 (7.2) 6 9.83 (6.8) 17.6 % -0.49 [ -1.49, 0.50 ]
Payne 2008 10 12.7 (8.7) 10 11.4 (7.9) 20.1 % 0.15 [ -0.73, 1.03 ]
Kaltsatou 2011 13 16.54 (1.66) 13 22.33 (7.73) 21.4 % -1.00 [ -1.83, -0.18 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 29.4 % -0.51 [ -1.04, 0.01 ]
Subtotal (95% CI) 75 62 100.0 % -0.67 [ -1.23, -0.11 ]
Heterogeneity: Tau2 = 0.21; Chi2 = 8.45, df = 4 (P = 0.08); I2 =53%
Test for overall effect: Z = 2.33 (P = 0.020)
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Analysis 18.24. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 24 Overall
depression (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 24 Overall depression (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Rogers 2014 20 -1.7 (6.9) 22 1.1 (4.2) 13.1 % -0.49 [ -1.10, 0.13 ]
Ergun 2013 40 1.22 (6.19) 20 2.35 (8.03) 15.7 % -0.16 [ -0.70, 0.37 ]
Cantarero-Villanueva 2013 32 -2.95 (7.82) 29 1.46 (7.36) 16.6 % -0.57 [ -1.09, -0.06 ]
Cadmus 2009 37 0.3 (6.4) 37 1.7 (6.3) 19.0 % -0.22 [ -0.68, 0.24 ]
Saarto 2012 263 -0.3 (3.31) 237 -0.5 (3.38) 35.6 % 0.06 [ -0.12, 0.24 ]
Subtotal (95% CI) 392 345 100.0 % -0.20 [ -0.47, 0.06 ]
Heterogeneity: Tau2 = 0.04; Chi2 = 8.05, df = 4 (P = 0.09); I2 =50%
Test for overall effect: Z = 1.49 (P = 0.14)
2 Unclear/high risk of bias
Naumann 2012 11 -3.6 (4.34) 10 2 (4.55) 33.4 % -1.21 [ -2.16, -0.26 ]
Mehnert 2011 30 2.7 (2.95) 28 4.64 (4.43) 66.6 % -0.51 [ -1.04, 0.01 ]
Subtotal (95% CI) 41 38 100.0 % -0.75 [ -1.39, -0.10 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 1.60, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 2.26 (P = 0.024)
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Analysis 18.25. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 25 Overall fatigue
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 25 Overall fatigue (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 4.1 % -0.07 [ -0.89, 0.75 ]
Bower 2011 16 3.4 (1.8) 15 4.9 (1.3) 4.6 % -0.93 [ -1.67, -0.18 ]
Rogers 2009 20 -12.4 (10.4) 18 -10.1 (6.6) 5.4 % -0.26 [ -0.90, 0.38 ]
Cuesta-Vargas 2014 22 4 (1.8) 20 5.2 (3.2) 5.6 % -0.46 [ -1.07, 0.15 ]
Rogers 2014 20 4.1 (2.1) 22 4 (1.8) 5.7 % 0.05 [ -0.56, 0.66 ]
Milne 2008 29 11.9 (3.2) 29 17.4 (4.7) 6.0 % -1.35 [ -1.92, -0.78 ]
Cantarero-Villanueva 2013 32 3.78 (1.78) 29 6.23 (1.72) 6.1 % -1.38 [ -1.94, -0.82 ]
Courneya 2003 24 -8.3 (7.9) 28 -8.8 (8.1) 6.3 % 0.06 [ -0.48, 0.61 ]
Ergun 2013 40 2.94 (2.24) 20 3.3 (1.79) 6.4 % -0.17 [ -0.71, 0.37 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 6.8 % -0.71 [ -1.21, -0.21 ]
Cadmus 2009 37 -51.9 (9) 37 -50.6 (10) 7.2 % -0.14 [ -0.59, 0.32 ]
Pinto 2015 39 -43.83 (7.8) 37 -41.22 (8.49) 7.3 % -0.32 [ -0.77, 0.14 ]
Kiecolt-Glaser 2014 96 6.3 (19.6) 90 12.7 (18.97) 9.1 % -0.33 [ -0.62, -0.04 ]
Vallance 2007 250 -42.7 (8.4) 85 -42.6 (8.7) 9.6 % -0.01 [ -0.26, 0.23 ]
Short 2014 195 -41.5 (9.3) 104 -39.8 (10.4) 9.7 % -0.17 [ -0.41, 0.06 ]
Subtotal (95% CI) 865 578 100.0 % -0.38 [ -0.59, -0.18 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 42.98, df = 14 (P = 0.00009); I2 =67%
Test for overall effect: Z = 3.61 (P = 0.00030)
2 Unclear/high risk of bias
Banasik 2011 7 1 (0.89) 7 1.57 (0.98) 3.3 % -0.57 [ -1.65, 0.51 ]
Pinto 2003 12 7.16 (6.4) 6 9 (6.4) 3.9 % -0.27 [ -1.26, 0.71 ]
Payne 2008 9 4.7 (2.6) 9 3.5 (1.7) 4.3 % 0.52 [ -0.42, 1.46 ]
Rogers 2013 11 4.2 (1.8) 9 4.2 (1.6) 4.9 % 0.0 [ -0.88, 0.88 ]
Mehnert 2011 30 28.52 (25.58) 27 39.92 (25.09) 12.0 % -0.44 [ -0.97, 0.08 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Littman 2012 30 -45 (5.3) 27 -43.1 (10.3) 12.2 % -0.23 [ -0.75, 0.29 ]
Do 2015 32 16.8 (13.3) 30 22.3 (15.1) 12.9 % -0.38 [ -0.89, 0.12 ]
Winters-Stone 2011 36 45 (5.3) 31 43.1 (10.3) 13.8 % 0.23 [ -0.25, 0.72 ]
Pinto 2005 39 27.08 (21.41) 43 42.28 (26.2) 15.7 % -0.63 [ -1.07, -0.18 ]
Fillion 2008 44 2.65 (0.72) 43 2.86 (0.83) 16.9 % -0.27 [ -0.69, 0.15 ]
Subtotal (95% CI) 250 232 100.0 % -0.25 [ -0.45, -0.05 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 10.64, df = 9 (P = 0.30); I2 =15%
Test for overall effect: Z = 2.43 (P = 0.015)
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Analysis 18.26. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 26 Overall fatigue
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 26 Overall fatigue (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 -4.2 (19.6) 8 6.4 (14.5) 7.9 % -0.58 [ -1.59, 0.43 ]
Loudon 2014 12 1.88 (2.23) 11 2.06 (2.52) 9.6 % -0.07 [ -0.89, 0.75 ]
Rogers 2009 20 1.9 (9.6) 18 4.2 (12.3) 11.6 % -0.21 [ -0.84, 0.43 ]
Courneya 2003 24 9.3 (10.2) 28 2 (7.5) 12.5 % 0.81 [ 0.24, 1.38 ]
Cantarero-Villanueva 2013 32 -2 (1.75) 29 0.34 (1.39) 12.5 % -1.45 [ -2.02, -0.88 ]
Daley 2007 33 2.14 (1.75) 33 3.44 (1.85) 13.3 % -0.71 [ -1.21, -0.21 ]
Vallance 2007 250 2.49 (8.17) 85 1.15 (6.61) 16.0 % 0.17 [ -0.08, 0.42 ]
Saarto 2012 263 -2.4 (9.06) 237 -2.4 (8.6) 16.6 % 0.0 [ -0.18, 0.18 ]
Subtotal (95% CI) 642 449 100.0 % -0.22 [ -0.61, 0.16 ]
Heterogeneity: Tau2 = 0.22; Chi2 = 43.73, df = 7 (P<0.00001); I2 =84%
Test for overall effect: Z = 1.14 (P = 0.25)
2 Unclear/high risk of bias
Payne 2008 9 -0.93 (1.95) 9 0.52 (1.38) 15.1 % -0.82 [ -1.79, 0.15 ]
Naumann 2012 11 -3.6 (4.35) 10 2 (4.55) 15.5 % -1.21 [ -2.16, -0.26 ]
Rogers 2013 11 4.2 (2) 9 3.9 (1.5) 16.8 % 0.16 [ -0.72, 1.04 ]
Mehnert 2011 30 -0.74 (20.73) 27 -2.88 (25.3) 25.3 % 0.09 [ -0.43, 0.61 ]
Pinto 2005 39 -14.93 (23.54) 43 1.79 (23.48) 27.3 % -0.70 [ -1.15, -0.26 ]
Subtotal (95% CI) 100 98 100.0 % -0.45 [ -0.95, 0.05 ]
Heterogeneity: Tau2 = 0.19; Chi2 = 10.24, df = 4 (P = 0.04); I2 =61%
Test for overall effect: Z = 1.77 (P = 0.076)
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Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 27 Overall pain/disability (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Loudon 2014 12 0.8 (1.48) 11 1.44 (2.24) 14.1 % -0.33 [ -1.15, 0.50 ]
Portela 2008 25 -20.6 (20.2) 9 -20.8 (15.5) 16.5 % 0.01 [ -0.75, 0.77 ]
Rogers 2009 20 -3.03 (2.98) 18 -2.28 (2.76) 23.4 % -0.26 [ -0.89, 0.38 ]
Cadmus 2009 37 50.3 (9.1) 37 50.8 (9) 46.1 % -0.05 [ -0.51, 0.40 ]
Subtotal (95% CI) 94 75 100.0 % -0.13 [ -0.44, 0.18 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.60, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
2 Unclear/high risk of bias
Mustian 2004 9 9.11 (1.35) 10 9.1 (1.74) 5.5 % 0.01 [ -0.89, 0.91 ]
Basen-Enquist 2006 28 79.7 (10.58) 23 72.1 (11.51) 13.7 % 0.68 [ 0.11, 1.25 ]
Mehnert 2011 30 79.4 (23.1) 28 73.5 (24.83) 16.6 % 0.24 [ -0.27, 0.76 ]
Do 2015 32 21.1 (24.6) 30 16.5 (26.7) 17.8 % 0.18 [ -0.32, 0.68 ]
Duijits 2012 79 79.07 (23.41) 83 74.62 (23.68) 46.5 % 0.19 [ -0.12, 0.50 ]
Subtotal (95% CI) 178 174 100.0 % 0.25 [ 0.04, 0.46 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 2.71, df = 4 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.35 (P = 0.019)
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Analysis 18.28. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 28 Overall
pain/disability (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 28 Overall pain/disability (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Cormie 2014 43 3.4 (6.5) 19 2 (6.2) 44.3 % 0.22 [ -0.33, 0.76 ]
Cadmus 2009 37 -2.2 (11.3) 37 -0.1 (7) 55.7 % -0.22 [ -0.68, 0.24 ]
Subtotal (95% CI) 80 56 100.0 % -0.03 [ -0.45, 0.40 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 1.46, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 0.13 (P = 0.90)
2 Unclear/high risk of bias
Mustian 2004 9 -0.22 (1.29) 10 0 (1.42) 11.1 % -0.15 [ -1.06, 0.75 ]
Rogers 2009 19 -0.8 (1.37) 17 -1.8 (6.21) 19.9 % 0.22 [ -0.43, 0.88 ]
Mehnert 2011 30 -2.4 (24.95) 28 -7.61 (25.2) 29.9 % 0.21 [ -0.31, 0.72 ]
Irwin 2015 45 -6 (18.97) 38 0.7 (18.56) 39.1 % -0.35 [ -0.79, 0.08 ]
Subtotal (95% CI) 103 93 100.0 % -0.05 [ -0.36, 0.26 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 3.51, df = 3 (P = 0.32); I2 =15%
Test for overall effect: Z = 0.31 (P = 0.75)
-4 -2 0 2 4
Favours physical activity Favours control
870Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 18.29. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 29 Overall
cardiorespiratory fitness (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 29 Overall cardiorespiratory fitness (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 25.9 (4.5) 8 25.7 (3.7) 3.8 % 0.05 [ -0.93, 1.03 ]
Portela 2008 25 3006.96 (410.8) 9 2416.1 (718.6) 5.3 % 1.14 [ 0.33, 1.96 ]
Musanti 2012 30 24.6 (4.93) 12 23 (4.29) 7.3 % 0.33 [ -0.34, 1.00 ]
Rogers 2014 20 30.9 (6.3) 22 25.1 (5) 7.7 % 1.01 [ 0.36, 1.65 ]
Rogers 2009 20 29.5 (6.6) 18 27.6 (6.1) 7.9 % 0.29 [ -0.35, 0.93 ]
Courneya 2003 24 21.3 (3.7) 26 18.2 (3.9) 9.2 % 0.80 [ 0.22, 1.38 ]
Milne 2008 29 1.49 (0.31) 29 1.48 (0.43) 10.9 % 0.03 [ -0.49, 0.54 ]
Murtezani 2014 30 875.1 (86.7) 32 823.5 (87.1) 11.1 % 0.59 [ 0.08, 1.10 ]
Daley 2007 33 34.99 (4.42) 69 33.05 (5.3) 14.4 % 0.38 [ -0.04, 0.80 ]
Rogers 2015 105 23.6 (4.8) 108 22.7 (0.3) 22.5 % 0.27 [ 0.00, 0.54 ]
Subtotal (95% CI) 324 333 100.0 % 0.44 [ 0.24, 0.65 ]
Heterogeneity: Tau2 = 0.03; Chi2 = 12.55, df = 9 (P = 0.18); I2 =28%
Test for overall effect: Z = 4.30 (P = 0.000017)
2 Unclear/high risk of bias
Cerulli 2014 10 31.29 (4.95) 10 32.26 (10.1) 4.6 % -0.12 [ -0.99, 0.76 ]
Mustian 2004 11 636.1 (50.6) 10 610.3 (75.9) 4.7 % 0.39 [ -0.48, 1.25 ]
Rogers 2013 12 23.9 (6.2) 10 23.9 (3.8) 4.9 % 0.0 [ -0.84, 0.84 ]
Kaltsatou 2011 14 483.33 (85.95) 13 403.08 (71.92) 5.2 % 0.98 [ 0.17, 1.78 ]
Rahnama 2010 14 20.65 (5.73) 15 13.85 (5.18) 5.3 % 1.21 [ 0.41, 2.01 ]
Nikander 2007 14 -17.6 (1.3) 14 -17.2 (1.4) 5.9 % -0.29 [ -1.03, 0.46 ]
Kim 2015 20 424.8 (55.8) 19 394.4 (54) 7.3 % 0.54 [ -0.10, 1.18 ]
Mehnert 2011 27 26.9 (4.4) 23 25.7 (4.7) 8.7 % 0.26 [ -0.30, 0.82 ]
Basen-Enquist 2006 35 1643 (122.5) 25 1546 (127.5) 9.2 % 0.77 [ 0.24, 1.30 ]
Do 2015 30 31.7 (12.4) 30 24.5 (6.6) 9.4 % 0.72 [ 0.19, 1.24 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Pinto 2005 39 -16.34 (2.09) 43 -17.85 (2.24) 11.2 % 0.69 [ 0.24, 1.14 ]
Irwin 2015 45 24.6 (5.5) 38 23 (4.7) 11.5 % 0.31 [ -0.13, 0.74 ]
Fillion 2008 44 27.04 (4.39) 43 26.53 (5.81) 11.9 % 0.10 [ -0.32, 0.52 ]
Subtotal (95% CI) 315 293 100.0 % 0.44 [ 0.23, 0.65 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 18.66, df = 12 (P = 0.10); I2 =36%
Test for overall effect: Z = 4.06 (P = 0.000048)
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Analysis 18.30. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 30 Overall
cardiorespiratory fitness (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 30 Overall cardiorespiratory fitness (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Musanti 2012 30 1 (3.1) 12 0.9 (3.4) 22.3 % 0.03 [ -0.64, 0.70 ]
Courneya 2003 24 2.7 (2.6) 26 -0.6 (1.7) 23.1 % 1.49 [ 0.86, 2.12 ]
Rogers 2014 20 2.8 (4.9) 22 1.1 (4.2) 23.5 % 0.37 [ -0.24, 0.98 ]
Saarto 2012 262 0.89 (1.15) 236 0.72 (1.01) 31.1 % 0.16 [ -0.02, 0.33 ]
Subtotal (95% CI) 336 296 100.0 % 0.49 [ -0.09, 1.06 ]
Heterogeneity: Tau2 = 0.27; Chi2 = 16.41, df = 3 (P = 0.00093); I2 =82%
Test for overall effect: Z = 1.65 (P = 0.098)
2 Unclear/high risk of bias
Nieman 1995 6 60.8 (8.4) 6 12 (17.8) 6.7 % 3.24 [ 1.29, 5.18 ]
-10 -5 0 5 10
Favours control Favours physical activity
(Continued . . . )
872Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(. . . Continued)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Naumann 2012 11 3.1 (2.9) 10 -0.1 (3.1) 17.9 % 1.03 [ 0.10, 1.95 ]
Dolan 2016 23 12.2 (10.2) 10 -5.97 (7.2) 18.6 % 1.88 [ 0.99, 2.77 ]
Irwin 2015 45 1.5 (2.1) 38 -0.4 (2.7) 28.3 % 0.79 [ 0.34, 1.24 ]
Pinto 2005 39 1.35 (2.4) 43 -0.25 (2.5) 28.4 % 0.65 [ 0.20, 1.09 ]
Subtotal (95% CI) 124 107 100.0 % 1.16 [ 0.60, 1.72 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 11.81, df = 4 (P = 0.02); I2 =66%
Test for overall effect: Z = 4.04 (P = 0.000054)
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Analysis 18.31. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 31 Overall self-
reported physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 31 Overall self-reported physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Cadmus 2009 34 161.7 (114.7) 33 55.6 (101.9) 9.8 % 0.97 [ 0.46, 1.47 ]
Kiecolt-Glaser 2014 96 11.2 (7.6) 90 9.1 (6.1) 13.9 % 0.30 [ 0.01, 0.59 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 9.8 % 1.01 [ 0.50, 1.52 ]
Rogers 2009 20 121.4 (73.2) 18 114.3 (131.5) 7.8 % 0.07 [ -0.57, 0.70 ]
Rogers 2015 110 169 (119) 112 74 (107) 14.2 % 0.84 [ 0.56, 1.11 ]
Schmitz 2009 131 3348.8 (9019.4) 133 2339.8 (6213.7) 14.9 % 0.13 [ -0.11, 0.37 ]
Short 2014 195 217.9 (222.9) 104 180.3 (206.9) 14.9 % 0.17 [ -0.07, 0.41 ]
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N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Vallance 2007 253 207.6 (169) 85 163 (121) 14.8 % 0.28 [ 0.03, 0.53 ]
Subtotal (95% CI) 875 607 100.0 % 0.45 [ 0.21, 0.68 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 30.50, df = 7 (P = 0.00008); I2 =77%
Test for overall effect: Z = 3.66 (P = 0.00025)
2 Unclear/high risk of bias
Basen-Enquist 2006 35 428 (254.4) 25 404 (265) 11.7 % 0.09 [ -0.42, 0.61 ]
Guinan 2013 16 38.7 (26.9) 10 19.9 (11.3) 7.7 % 0.81 [ -0.01, 1.64 ]
Hatchett 2013 38 3.47 (2.19) 36 1.42 (1.67) 12.2 % 1.04 [ 0.55, 1.53 ]
Irwin 2015 45 222.1 (118.6) 38 103.6 (104.6) 12.6 % 1.04 [ 0.58, 1.51 ]
Kim 2015 20 17.6 (16.03) 19 11.8 (11.6) 10.0 % 0.40 [ -0.23, 1.04 ]
Littman 2012 32 19.2 (19.1) 31 12.1 (13.6) 12.0 % 0.42 [ -0.08, 0.92 ]
Matthews 2007 22 54.2 (34.1) 14 27.2 (22.7) 9.1 % 0.87 [ 0.17, 1.58 ]
Pinto 2005 39 202.43 (161.65) 43 78.36 (86) 12.6 % 0.96 [ 0.50, 1.42 ]
Winters-Stone 2011 36 430.8 (281.4) 31 461.7 (346.4) 12.3 % -0.10 [ -0.58, 0.38 ]
Subtotal (95% CI) 283 247 100.0 % 0.61 [ 0.31, 0.91 ]
Heterogeneity: Tau2 = 0.14; Chi2 = 22.60, df = 8 (P = 0.004); I2 =65%
Test for overall effect: Z = 3.93 (P = 0.000085)
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Analysis 18.32. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 32 Overall self-
reported physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 32 Overall self-reported physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Cadmus 2009 34 129 (117.9) 33 44.3 (89.4) 16.7 % 0.80 [ 0.30, 1.30 ]
Saarto 2012 262 3.5 (18.3) 236 3.3 (21.5) 32.4 % 0.01 [ -0.17, 0.19 ]
Schmitz 2009 (1) 48 2.8 (16.8) 57 -0.8 (16.6) 21.5 % 0.21 [ -0.17, 0.60 ]
Vallance 2007 281 82 (168.7) 96 30 (167.8) 29.4 % 0.31 [ 0.08, 0.54 ]
Subtotal (95% CI) 625 422 100.0 % 0.27 [ 0.00, 0.55 ]
Heterogeneity: Tau2 = 0.05; Chi2 = 10.67, df = 3 (P = 0.01); I2 =72%
Test for overall effect: Z = 1.95 (P = 0.051)
2 Unclear/high risk of bias
Guinan 2013 16 15.6 (11.4476) 10 -8.3 (4.1937) 16.3 % 2.46 [ 1.39, 3.53 ]
Irwin 2015 45 159 (136) 38 49 (86) 29.6 % 0.94 [ 0.48, 1.40 ]
Matthews 2007 22 21.5 (30.6) 14 5 (13.8) 24.1 % 0.63 [ -0.06, 1.32 ]
Pinto 2005 39 84.74 (189.2) 43 -18.27 (200.7) 30.0 % 0.52 [ 0.08, 0.96 ]
Subtotal (95% CI) 122 105 100.0 % 0.99 [ 0.40, 1.58 ]
Heterogeneity: Tau2 = 0.25; Chi2 = 11.28, df = 3 (P = 0.01); I2 =73%
Test for overall effect: Z = 3.31 (P = 0.00094)
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Analysis 18.33. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 33 Overall objective
physical activity (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 33 Overall objective physical activity (follow-up values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Rogers 2014 20 294 (175) 22 154 (75) 9.2 % 1.04 [ 0.39, 1.69 ]
Rogers 2009 20 252191 (91893) 18 210917 (64078) 9.2 % 0.51 [ -0.14, 1.15 ]
Pinto 2015 36 70.3 (65.9) 32 16.5 (31.9) 12.0 % 1.01 [ 0.50, 1.52 ]
Cadmus 2009 33 6738 (2958) 34 5537 (3352) 12.6 % 0.38 [ -0.11, 0.86 ]
Rogers 2015 110 246 (153) 112 197 (138) 18.5 % 0.34 [ 0.07, 0.60 ]
Vallance 2007 253 8110.5 (4133.9) 85 8028 (3457) 19.1 % 0.02 [ -0.23, 0.27 ]
Short 2014 219 9363.07 (7922.79) 111 8301.2 (3373.4) 19.5 % 0.16 [ -0.07, 0.39 ]
Subtotal (95% CI) 691 414 100.0 % 0.41 [ 0.15, 0.66 ]
Heterogeneity: Tau2 = 0.07; Chi2 = 19.34, df = 6 (P = 0.004); I2 =69%
Test for overall effect: Z = 3.16 (P = 0.0016)
2 Unclear/high risk of bias
Rogers 2013 12 198.4 (111.7) 10 0 (0) Not estimable
Guinan 2013 16 30.7 (15.6) 9 31 (15.6) 29.4 % -0.02 [ -0.84, 0.80 ]
Matthews 2007 22 330.8 (114.7) 14 198.5 (55.4) 31.2 % 1.34 [ 0.60, 2.09 ]
Pinto 2005 39 37.5 (14.25) 43 33.62 (19.43) 39.4 % 0.22 [ -0.21, 0.66 ]
Subtotal (95% CI) 89 76 100.0 % 0.50 [ -0.24, 1.25 ]
Heterogeneity: Tau2 = 0.32; Chi2 = 7.75, df = 2 (P = 0.02); I2 =74%
Test for overall effect: Z = 1.32 (P = 0.19)
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Analysis 18.34. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 34 Overall objective
physical activity (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 34 Overall objective physical activity (change values)







N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Rogers 2014 20 114 (109) 22 10 (70) 29.7 % 1.13 [ 0.47, 1.78 ]
Cadmus 2009 33 1621 (2108) 34 -60 (2341) 33.0 % 0.75 [ 0.25, 1.24 ]
Vallance 2007 253 -150 (5173.3) 85 91 (5155.4) 37.2 % -0.05 [ -0.29, 0.20 ]
Subtotal (95% CI) 306 141 100.0 % 0.56 [ -0.18, 1.30 ]
Heterogeneity: Tau2 = 0.37; Chi2 = 16.13, df = 2 (P = 0.00031); I2 =88%
Test for overall effect: Z = 1.49 (P = 0.14)
2 Unclear/high risk of bias
Guinan 2013 16 -1.1 (6.2) 9 -7.9 (5.3) 39.0 % 1.11 [ 0.23, 2.00 ]
Matthews 2007 22 72.2 (114.6) 14 -16.8 (51.5) 61.0 % 0.91 [ 0.20, 1.62 ]
Subtotal (95% CI) 38 23 100.0 % 0.99 [ 0.44, 1.54 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.12, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 3.52 (P = 0.00043)
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Analysis 18.35. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 35 Mass (follow-up
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 35 Mass (follow-up values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Fixed,95% CI IV,Fixed,95% CI
1 Low risk of bias
Courneya 2003 24 78.2 (20.5) 26 80.1 (16.2) 0.3 % -1.90 [ -12.20, 8.40 ]
Cadmus 2009 36 80.73 (16.88) 33 78.51 (20.64) 0.4 % 2.22 [ -6.72, 11.16 ]
Herrero 2006 8 65.6 (8.7) 8 67.3 (8.9) 0.5 % -1.70 [ -10.32, 6.92 ]
Daley 2007 33 74.26 (12.49) 69 75.6 (12.5) 1.3 % -1.34 [ -6.52, 3.84 ]
Murtezani 2014 30 71.7 (9.5) 32 72.6 (10.75) 1.4 % -0.90 [ -5.94, 4.14 ]
Schmitz 2009 131 76.15 (15.66) 133 77.19 (17.02) 2.2 % -1.04 [ -4.98, 2.90 ]
Schmitz 2005 39 69.5 (2.22) 40 69.2 (2.2) 36.4 % 0.30 [ -0.67, 1.27 ]
Kiecolt-Glaser 2014 96 75.2 (2.8) 90 75.2 (2.6) 57.5 % 0.0 [ -0.78, 0.78 ]
Subtotal (95% CI) 397 431 100.0 % 0.05 [ -0.54, 0.64 ]
Heterogeneity: Chi2 = 1.50, df = 7 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
2 Unclear/high risk of bias
Matthews 2007 22 74.9 (15.2) 14 78.9 (20.3) 5.8 % -4.00 [ -16.39, 8.39 ]
Mustian 2004 11 67.1 (10.42) 10 68.6 (13.84) 8.0 % -1.50 [ -12.06, 9.06 ]
Nikander 2007 14 73.5 (13.3) 14 75.5 (12) 10.1 % -2.00 [ -11.38, 7.38 ]
Rahnama 2010 14 69.4 (13.5) 15 71.6 (9.2) 12.4 % -2.20 [ -10.67, 6.27 ]
DeNysschen 2011 30 69.3 (14.2) 34 72.4 (19.6) 12.9 % -3.10 [ -11.42, 5.22 ]
Ligibel 2008 40 80 (17.5) 42 83.3 (18.7) 14.5 % -3.30 [ -11.14, 4.54 ]
Littman 2012 28 81.1 (13.6) 27 81.3 (14.3) 16.4 % -0.20 [ -7.58, 7.18 ]
Winters-Stone 2011 36 76.5 (15.6) 31 74.2 (12.3) 19.9 % 2.30 [ -4.39, 8.99 ]
Subtotal (95% CI) 195 187 100.0 % -1.28 [ -4.26, 1.70 ]
Heterogeneity: Chi2 = 1.88, df = 7 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.84 (P = 0.40)
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Analysis 18.36. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 36 Mass (change
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 36 Mass (change values)





N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 12.6 % -0.60 [ -1.98, 0.78 ]
Murtezani 2014 30 -2.3 (2.4) 32 -0.3 (2.6) 14.3 % -2.00 [ -3.24, -0.76 ]
Courneya 2003 24 0.1 (2) 26 0.7 (1.8) 16.9 % -0.60 [ -1.66, 0.46 ]
Saarto 2012 262 0.66 (3.68) 236 0.67 (3.84) 24.1 % -0.01 [ -0.67, 0.65 ]
Schmitz 2005 39 0.32 (0.43) 40 0.2 (0.42) 32.1 % 0.12 [ -0.07, 0.31 ]
Subtotal (95% CI) 420 399 100.0 % -0.43 [ -1.05, 0.20 ]
Heterogeneity: Tau2 = 0.31; Chi2 = 13.27, df = 4 (P = 0.01); I2 =70%
Test for overall effect: Z = 1.34 (P = 0.18)
2 Unclear/high risk of bias
Dolan 2016 23 -0.55 (5.04) 10 1.44 (1.62) 9.8 % -1.99 [ -4.28, 0.30 ]
Irwin 2015 45 -2.1 (4.3) 38 0.1 (3.6) 15.0 % -2.20 [ -3.90, -0.50 ]
Mustian 2004 9 -0.3 (1.86) 10 0.6 (1.43) 17.4 % -0.90 [ -2.40, 0.60 ]
Ligibel 2008 22 0 (2.3) 14 0.04 (2.16) 17.7 % -0.04 [ -1.52, 1.44 ]
Matthews 2007 22 0.01 (2.09) 14 0.04 (2.16) 18.5 % -0.03 [ -1.46, 1.40 ]
Naumann 2012 11 0.45 (1.33) 10 0.12 (1.52) 21.7 % 0.33 [ -0.90, 1.56 ]
Subtotal (95% CI) 132 96 100.0 % -0.62 [ -1.44, 0.19 ]
Heterogeneity: Tau2 = 0.40; Chi2 = 8.28, df = 5 (P = 0.14); I2 =40%
Test for overall effect: Z = 1.49 (P = 0.14)
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Analysis 18.37. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 37 BMI (follow-up
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 37 BMI (follow-up values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Fixed,95% CI IV,Fixed,95% CI
1 Low risk of bias
Portela 2008 25 29.1 (5.5) 9 34.7 (15) 0.0 % -5.60 [ -15.63, 4.43 ]
Rogers 2009 20 30.6 (7.6) 18 30.4 (8.3) 0.2 % 0.20 [ -4.88, 5.28 ]
Courneya 2003 24 29.4 (7.4) 26 29.3 (6) 0.3 % 0.10 [ -3.65, 3.85 ]
Rogers 2014 20 29.6 (5) 22 32.2 (6.7) 0.3 % -2.60 [ -6.16, 0.96 ]
Cadmus 2009 36 30.45 (6) 33 29.9 (7.59) 0.4 % 0.55 [ -2.70, 3.80 ]
Murtezani 2014 30 25.1 (2.9) 32 25.8 (3.47) 1.7 % -0.70 [ -2.29, 0.89 ]
Schmitz 2009 131 28.46 (5.55) 133 28.94 (6.27) 2.1 % -0.48 [ -1.91, 0.95 ]
Vallance 2007 253 27.01 (5.21) 85 27.2 (5.15) 2.7 % -0.19 [ -1.46, 1.08 ]
Schmitz 2005 39 26 (0.74) 40 25.8 (0.73) 41.3 % 0.20 [ -0.12, 0.52 ]
Kiecolt-Glaser 2014 96 27.8 (1.08) 90 27.8 (0.95) 50.9 % 0.0 [ -0.29, 0.29 ]
Subtotal (95% CI) 674 488 100.0 % 0.05 [ -0.16, 0.26 ]
Heterogeneity: Chi2 = 5.90, df = 9 (P = 0.75); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
2 Unclear/high risk of bias
Rogers 2013 12 33.6 (7) 10 30.6 (7.28) 4.1 % 3.00 [ -3.00, 9.00 ]
Mustian 2004 11 23.9 (4.17) 10 26.7 (5.59) 8.2 % -2.80 [ -7.05, 1.45 ]
Nikander 2007 14 26.9 (5.6) 14 27.7 (4.9) 9.8 % -0.80 [ -4.70, 3.10 ]
Rahnama 2010 14 27.74 (4.77) 15 28.04 (4.6) 12.7 % -0.30 [ -3.71, 3.11 ]
Ligibel 2008 40 30.3 (6.3) 42 31.5 (6.8) 18.5 % -1.20 [ -4.04, 1.64 ]
Littman 2012 28 27.66 (5.01) 27 29.01 (5.62) 18.7 % -1.35 [ -4.17, 1.47 ]
Pinto 2005 39 27.66 (5.01) 43 29.01 (5.62) 28.0 % -1.35 [ -3.65, 0.95 ]
Subtotal (95% CI) 158 161 100.0 % -1.07 [ -2.29, 0.14 ]
Heterogeneity: Chi2 = 2.72, df = 6 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.084)
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Analysis 18.38. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 38 BMI (change
values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 38 BMI (change values)





N Mean(SD)[Kg/m2] N Mean(SD)[Kg/m2] IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Schmitz 2009 (1) 65 -1 (3.7) 65 -0.4 (4.3) 4.7 % -0.60 [ -1.98, 0.78 ]
Rogers 2014 20 -0.2 (0.9) 22 -0.3 (1.1) 15.5 % 0.10 [ -0.51, 0.71 ]
Courneya 2003 24 0 (0.7) 26 0.3 (0.7) 22.8 % -0.30 [ -0.69, 0.09 ]
Murtezani 2014 30 -0.8 (0.7) 32 -0.14 (0.8) 23.4 % -0.66 [ -1.03, -0.29 ]
Schmitz 2005 39 0.06 (0.17) 40 0.07 (0.16) 33.6 % -0.01 [ -0.08, 0.06 ]
Subtotal (95% CI) 178 185 100.0 % -0.24 [ -0.56, 0.08 ]
Heterogeneity: Tau2 = 0.08; Chi2 = 13.79, df = 4 (P = 0.01); I2 =71%
Test for overall effect: Z = 1.45 (P = 0.15)
2 Unclear/high risk of bias
Mustian 2004 9 -0.42 (0.75) 10 0.29 (0.61) 26.6 % -0.71 [ -1.33, -0.09 ]
Naumann 2012 11 0.1 (0.5) 10 -0.1 (0.57) 34.2 % 0.20 [ -0.26, 0.66 ]
Ligibel 2008 40 0 (0.9) 42 0.2 (0.8) 39.2 % -0.20 [ -0.57, 0.17 ]
Subtotal (95% CI) 60 62 100.0 % -0.20 [ -0.65, 0.25 ]
Heterogeneity: Tau2 = 0.10; Chi2 = 5.43, df = 2 (P = 0.07); I2 =63%
Test for overall effect: Z = 0.86 (P = 0.39)
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Analysis 18.39. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 39 Overall body fat
(follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 39 Overall body fat (follow-up values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Herrero 2006 8 22 (5) 8 22 (4) 4.1 % 0.0 [ -0.98, 0.98 ]
Musanti 2012 30 34.13 (6.64) 12 33.7 (5.7) 7.3 % 0.07 [ -0.60, 0.74 ]
Rogers 2009 20 44.3 (7.4) 19 43.5 (7.5) 7.9 % 0.11 [ -0.52, 0.73 ]
Rogers 2014 20 38.6 (6.4) 22 41.5 (7.4) 8.2 % -0.41 [ -1.02, 0.20 ]
Courneya 2003 24 131.9 (46.4) 26 137.1 (44.4) 9.3 % -0.11 [ -0.67, 0.44 ]
Saarto 2012 37 39.9 (7.5) 30 40.2 (8) 10.8 % -0.04 [ -0.52, 0.44 ]
Cadmus 2009 36 40.54 (6.55) 33 39.6 (5.97) 11.0 % 0.15 [ -0.33, 0.62 ]
Schmitz 2005 39 40.91 (1.31) 40 42.29 (1.3) 11.1 % -1.05 [ -1.52, -0.58 ]
Daley 2007 33 39.4 (4.74) 69 40.1 (7.4) 12.5 % -0.10 [ -0.52, 0.31 ]
Schmitz 2009 130 38.47 (5.93) 132 39.74 (5.9) 17.7 % -0.21 [ -0.46, 0.03 ]
Subtotal (95% CI) 377 391 100.0 % -0.19 [ -0.41, 0.03 ]
Heterogeneity: Tau2 = 0.06; Chi2 = 17.33, df = 9 (P = 0.04); I2 =48%
Test for overall effect: Z = 1.66 (P = 0.097)
2 Unclear/high risk of bias
Cerulli 2014 10 26.72 (5.34) 10 30.55 (4.4) 5.8 % -0.75 [ -1.66, 0.16 ]
Mustian 2004 11 38.5 (4.47) 10 41.7 (4.89) 6.2 % -0.66 [ -1.54, 0.23 ]
Rogers 2013 10 44.2 (6.7) 12 42.3 (7.7) 6.7 % 0.25 [ -0.59, 1.09 ]
Matthews 2007 22 39.7 (6.3) 14 43.1 (6.9) 9.7 % -0.51 [ -1.19, 0.17 ]
DeNysschen 2011 30 36.9 (8.4) 34 38 (10.2) 16.3 % -0.12 [ -0.61, 0.38 ]
Winters-Stone 2011 36 40.5 (6.2) 31 38.5 (5.8) 16.7 % 0.33 [ -0.16, 0.81 ]
Pinto 2005 39 37.53 (4.79) 43 38.55 (4.83) 19.4 % -0.21 [ -0.64, 0.22 ]
Ligibel 2008 40 42.9 (7.4) 42 44.7 (8) 19.4 % -0.23 [ -0.67, 0.20 ]
Subtotal (95% CI) 198 196 100.0 % -0.17 [ -0.40, 0.07 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 8.84, df = 7 (P = 0.26); I2 =21%
Test for overall effect: Z = 1.41 (P = 0.16)
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Analysis 18.40. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 40 Overall body fat
(change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 40 Overall body fat (change values)







N Mean(SD)[%] N Mean(SD)[%] IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Musanti 2012 30 -0.24 (2.83) 12 1.4 (1.57) 19.5 % -0.63 [ -1.32, 0.05 ]
Schmitz 2005 39 -1.15 (0.45) 40 0.23 (0.44) 19.6 % -3.07 [ -3.73, -2.41 ]
Rogers 2014 20 -1.1 (2.2) 22 -0.6 (2.4) 19.9 % -0.21 [ -0.82, 0.39 ]
Courneya 2003 24 -4.9 (15.7) 26 5.1 (24.4) 20.1 % -0.48 [ -1.04, 0.09 ]
Schmitz 2009 (1) 65 -0.3 (5.7) 63 -0.1 (3.3) 20.9 % -0.04 [ -0.39, 0.30 ]
Subtotal (95% CI) 178 163 100.0 % -0.87 [ -1.86, 0.12 ]
Heterogeneity: Tau2 = 1.19; Chi2 = 65.49, df = 4 (P<0.00001); I2 =94%
Test for overall effect: Z = 1.72 (P = 0.085)
2 Unclear/high risk of bias
Mustian 2004 9 -0.16 (2.91) 10 0.28 (1.57) 12.2 % -0.18 [ -1.09, 0.72 ]
Naumann 2012 11 -0.3 (2.42) 10 0.8 (2.75) 13.3 % -0.41 [ -1.28, 0.46 ]
Matthews 2007 22 -0.2 (1.62) 14 0.41 (1.94) 21.9 % -0.34 [ -1.02, 0.33 ]
Ligibel 2008 40 -0.2 (1.7) 42 0.3 (1.7) 52.6 % -0.29 [ -0.73, 0.14 ]
Subtotal (95% CI) 82 76 100.0 % -0.30 [ -0.62, 0.01 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.14, df = 3 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
-4 -2 0 2 4
Favours physical activity Favours control
(1) with lymphedema
883Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 18.41. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 41 Lower body
strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 41 Lower body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Rogers 2009 20 80.3 (27) 18 64.9 (19.7) 16.3 % 0.63 [ -0.02, 1.29 ]
Schmitz 2005 23 296.6 (48.9) 22 238.9 (46.4) 16.7 % 1.19 [ 0.55, 1.83 ]
Milne 2008 29 66.2 (10.2) 29 61.7 (11) 19.7 % 0.42 [ -0.10, 0.94 ]
Saarto 2012 37 136 (23) 30 136 (29) 20.7 % 0.0 [ -0.48, 0.48 ]
Schmitz 2009 113 223.4 (59.6) 119 175.1 (53.5) 26.7 % 0.85 [ 0.58, 1.12 ]
Subtotal (95% CI) 222 218 100.0 % 0.61 [ 0.22, 1.00 ]
Heterogeneity: Tau2 = 0.13; Chi2 = 12.62, df = 4 (P = 0.01); I2 =68%
Test for overall effect: Z = 3.10 (P = 0.0019)
2 Unclear/high risk of bias
Cerulli 2014 10 114.88 (17.09) 10 79.13 (17.78) 13.8 % 1.96 [ 0.85, 3.07 ]
Rogers 2013 11 68.4 (15.5) 9 67.1 (16.2) 17.3 % 0.08 [ -0.80, 0.96 ]
Nikander 2007 14 1305 (177) 14 1393 (275) 19.6 % -0.37 [ -1.12, 0.38 ]
Do 2015 32 13 (1.62) 30 13.15 (1.55) 24.5 % -0.09 [ -0.59, 0.41 ]
Winters-Stone 2011 36 201.3 (57.4) 31 191 (51.7) 24.8 % 0.19 [ -0.30, 0.67 ]
Subtotal (95% CI) 103 94 100.0 % 0.23 [ -0.32, 0.79 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 13.05, df = 4 (P = 0.01); I2 =69%
Test for overall effect: Z = 0.83 (P = 0.41)
-4 -2 0 2 4
Favours control Favours physical activity
884Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 18.42. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 42 Lower body
strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 42 Lower body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Schmitz 2005 23 81.8 (48.92) 22 20.3 (45.97) 16.3 % 1.27 [ 0.63, 1.92 ]
Cormie 2014 43 37.6 (25.5) 19 6.7 (25.7) 19.6 % 1.19 [ 0.61, 1.78 ]
Schmitz 2009 113 33.2 (33.9) 119 7.9 (26.6) 64.1 % 0.83 [ 0.56, 1.10 ]
Subtotal (95% CI) 179 160 100.0 % 0.97 [ 0.70, 1.25 ]
Heterogeneity: Tau2 = 0.01; Chi2 = 2.39, df = 2 (P = 0.30); I2 =16%
Test for overall effect: Z = 6.95 (P < 0.00001)
2 Unclear/high risk of bias
Nieman 1995 6 28.9 (13.7) 6 3.5 (22.5) 8.4 % 1.26 [ -0.03, 2.55 ]
Naumann 2012 11 7.7 (12.6) 10 3.5 (13.9) 14.7 % 0.30 [ -0.56, 1.17 ]
Dolan 2016 23 11.84 (8.89) 10 0.34 (11.1) 16.1 % 1.17 [ 0.37, 1.97 ]
Do 2015 32 0.9 (0.7) 60 0.95 (0.61) 27.5 % -0.08 [ -0.51, 0.35 ]
Waltman 2010 110 4.42 (11.48) 113 0.19 (8.38) 33.3 % 0.42 [ 0.15, 0.69 ]
Subtotal (95% CI) 182 199 100.0 % 0.46 [ 0.04, 0.88 ]
Heterogeneity: Tau2 = 0.12; Chi2 = 10.00, df = 4 (P = 0.04); I2 =60%
Test for overall effect: Z = 2.13 (P = 0.033)
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Analysis 18.43. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 43 Upper body
strength (follow-up values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 43 Upper body strength (follow-up values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Portela 2008 25 39.3 (12.3) 9 35.6 (13.1) 12.4 % 0.29 [ -0.48, 1.05 ]
Musanti 2012 30 52.13 (20.98) 12 36.75 (20) 13.2 % 0.73 [ 0.04, 1.42 ]
Schmitz 2005 23 83 (13.4) 22 63 (12.7) 13.4 % 1.50 [ 0.84, 2.17 ]
Rogers 2009 20 27.9 (5.04) 18 24.3 (6.18) 13.6 % 0.63 [ -0.03, 1.28 ]
Milne 2008 29 7.6 (2.9) 29 9.4 (2.6) 14.9 % -0.64 [ -1.17, -0.12 ]
Saarto 2012 37 32.7 (5.3) 30 30.8 (5.7) 15.3 % 0.34 [ -0.14, 0.83 ]
Schmitz 2009 113 52.9 (15.3) 119 40.9 (11.8) 17.1 % 0.88 [ 0.61, 1.15 ]
Subtotal (95% CI) 277 239 100.0 % 0.53 [ 0.04, 1.01 ]
Heterogeneity: Tau2 = 0.33; Chi2 = 34.25, df = 6 (P<0.00001); I2 =82%
Test for overall effect: Z = 2.14 (P = 0.032)
2 Unclear/high risk of bias
Mustian 2004 11 29.6 (3.27) 10 26.7 (5.73) 13.7 % 0.60 [ -0.28, 1.49 ]
Cerulli 2014 10 16.08 (5.43) 10 17.2 (8.05) 13.7 % -0.16 [ -1.03, 0.72 ]
Nikander 2007 14 131 (20) 14 129 (28) 15.6 % 0.08 [ -0.66, 0.82 ]
Kaltsatou 2011 28 59.63 (8.49) 26 47.62 (9.83) 18.0 % 1.29 [ 0.70, 1.88 ]
Do 2015 32 9.65 (1.67) 30 10.05 (1.68) 19.4 % -0.24 [ -0.74, 0.26 ]
Winters-Stone 2011 36 63.3 (15.3) 31 61.1 (16.8) 19.7 % 0.14 [ -0.34, 0.62 ]
Subtotal (95% CI) 131 121 100.0 % 0.29 [ -0.21, 0.78 ]
Heterogeneity: Tau2 = 0.26; Chi2 = 17.44, df = 5 (P = 0.004); I2 =71%
Test for overall effect: Z = 1.14 (P = 0.25)
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Analysis 18.44. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 44 Upper body
strength (change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 44 Upper body strength (change values)







N Mean(SD)[Kg] N Mean(SD)[Kg] IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Schmitz 2005 23 32.3 (11.51) 22 6.9 (10.79) 22.1 % 2.24 [ 1.48, 2.99 ]
Musanti 2012 30 7.74 (10.62) 12 0.83 (12.65) 23.4 % 0.60 [ -0.08, 1.29 ]
Cormie 2014 43 5.7 (3.67) 19 1 (3.78) 25.0 % 1.25 [ 0.67, 1.84 ]
Schmitz 2009 113 33.2 (40.8) 119 7.6 (43.7) 29.5 % 0.60 [ 0.34, 0.87 ]
Subtotal (95% CI) 209 172 100.0 % 1.13 [ 0.46, 1.80 ]
Heterogeneity: Tau2 = 0.38; Chi2 = 18.46, df = 3 (P = 0.00035); I2 =84%
Test for overall effect: Z = 3.30 (P = 0.00097)
2 Unclear/high risk of bias
Rogers 2009 19 1.5 (2.27) 17 -0.3 (2.38) 16.6 % 0.76 [ 0.08, 1.44 ]
Do 2015 32 0.3 (0.5) 30 0.55 (1.2) 19.6 % -0.27 [ -0.77, 0.23 ]
Mustian 2004 45 4.5 (4.71) 38 -0.85 (3.15) 20.0 % 1.30 [ 0.82, 1.78 ]
Irwin 2015 45 0.4 (1.88) 38 0.1 (1.89) 20.7 % 0.16 [ -0.27, 0.59 ]
Waltman 2010 110 1.9 (4.86) 113 0.75 (2.9) 23.2 % 0.29 [ 0.02, 0.55 ]
Subtotal (95% CI) 251 236 100.0 % 0.43 [ -0.05, 0.91 ]
Heterogeneity: Tau2 = 0.24; Chi2 = 23.51, df = 4 (P = 0.00010); I2 =83%
Test for overall effect: Z = 1.77 (P = 0.077)
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Analysis 18.45. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 45 Bone mineral
density - femoral neck (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 45 Bone mineral density - femoral neck (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Saarto 2012 (1) 239 -0.006 (0.025) 218 -0.01 (0.03) 100.0 % 0.18 [ 0.00, 0.37 ]
Subtotal (95% CI) 239 218 100.0 % 0.18 [ 0.00, 0.37 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.93 (P = 0.053)
2 Unclear/high risk of bias
Kim 2015 20 0.78 (0.08) 19 0.81 (0.08) 28.0 % -0.37 [ -1.00, 0.27 ]
Winters-Stone 2011 36 0.72 (0.1) 31 0.71 (0.08) 32.9 % 0.11 [ -0.37, 0.59 ]
Waltman 2010 (2) 110 0.92 (0.5) 113 0.63 (0.42) 39.1 % 0.63 [ 0.36, 0.90 ]
Subtotal (95% CI) 166 163 100.0 % 0.18 [ -0.39, 0.75 ]
Heterogeneity: Tau2 = 0.20; Chi2 = 9.77, df = 2 (P = 0.01); I2 =80%
Test for overall effect: Z = 0.61 (P = 0.54)
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Analysis 18.46. Comparison 18 Sensitivity analysis: outcomes by risk of bias, Outcome 46 Bone mineral
density - lumbar spine (follow-up and change values).
Review: Physical activity for women with breast cancer after adjuvant therapy
Comparison: 18 Sensitivity analysis: outcomes by risk of bias
Outcome: 46 Bone mineral density - lumbar spine (follow-up and change values)







N Mean(SD)[sec] N Mean(SD)[sec] IV,Random,95% CI IV,Random,95% CI
1 Low risk of bias
Saarto 2012 (1) 239 -0.018 (0.033) 218 -0.02 (0.034) 100.0 % 0.09 [ -0.09, 0.27 ]
Subtotal (95% CI) 239 218 100.0 % 0.09 [ -0.09, 0.27 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
2 Unclear/high risk of bias
Kim 2015 20 0.97 (0.08) 19 0.99 (0.07) 24.6 % -0.26 [ -0.89, 0.37 ]
Winters-Stone 2011 36 0.99 (0.15) 31 0.95 (0.11) 31.6 % 0.30 [ -0.19, 0.78 ]
Waltman 2010 (2) 110 3.08 (0.44) 113 2.85 (0.4) 43.8 % 0.55 [ 0.28, 0.81 ]
Subtotal (95% CI) 166 163 100.0 % 0.27 [ -0.16, 0.70 ]
Heterogeneity: Tau2 = 0.09; Chi2 = 5.52, df = 2 (P = 0.06); I2 =64%
Test for overall effect: Z = 1.23 (P = 0.22)
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A D D I T I O N A L T A B L E S
Table 1. HRQoL subscales and HRQoL-related instruments used by investigators
QoL domain and instrument name Direction of response Trials using this scale
Cognitive function
Cognitive problems - Breast Cancer Pre-
vention Trial (BCPT) Symptom Checklist
Higher score indicates worse status. Kiecolt-Glaser 2014
Cognitive function - European Organiza-
tion for Research and Treatment of Can-




Herrero 2006; Mehnert 2011; Saarto 2012
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Table 1. HRQoL subscales and HRQoL-related instruments used by investigators (Continued)
Cognitive function - Functional As-





Confusion - Profile of Mood States
(POMS)
Higher score indicates worse status. Cantarero-Villanueva 2013; Pinto 2003
Emotional function/mental health
Psychosocial global score - Cancer Reha-





Emotional function - EORTC QLQ-C30 Higher score indicates better status. Do 2015; Herrero 2006; Mehnert 2011;
Saarto 2012
Emotional well-being - FACT-General
(FACT-G)
Higher score indicates better status. Banasik 2011; Cadmus 2009; Courneya
2003; Daley 2007; Littman 2012; Loh
2014; Milne 2008; Murtezani 2014;
Naumann 2012; Rogers 2009; Rogers
2015; Vallance 2007





Mental composite - Medical Outcomes
Study Short Form-12 (MOS SF-12) and
MOS SF-36
Higher score indicates better status. SF-12: Cuesta-Vargas 2014; Fillion 2008
SF-36: (Cormie 2014; Kiecolt-Glaser
2014; Pinto 2015; Schmitz 2009
Mental health - MOS SF-12 Higher score indicates better status. Baruth 2013; Basen-Enquist 2006;
Cadmus 2009; Cormie 2014; Duijits
2012; Kiecolt-Glaser 2014; McKenzie
2003; Mehnert 2011; Pinto 2015
Role emotion - MOS SF-36 Higher score indicates better status. Baruth 2013; Basen-Enquist 2006;
Cadmus 2009; Cormie 2014; Duijits
2012; Kiecolt-Glaser 2014; McKenzie
2003; Mehnert 2011
Positive and Negative Affect Scale
(PANAS)
Higher score indicates better status. Pinto 2003
Total mood disturbance score - POMS Higher score indicates worse status. Cantarero-Villanueva 2013; Pinto 2003;
Pinto 2005
Anxiety and depression - POMS Higher score indicates worse status. Fillion 2008
Anger - POMS Higher score indicates worse status. Cantarero-Villanueva 2013; Pinto 2003
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Table 1. HRQoL subscales and HRQoL-related instruments used by investigators (Continued)
General health perspective
Global health - EORTC QLQ-C30 Higher score indicates better status. Do 2015; Ergun 2013; Herrero 2006;
Mehnert 2011; Saarto 2012
Current health - International Breast Can-
cer Study Group (IBCSG)
Higher score indicates better status. Baruth 2013
General health - MOS SF-36 Higher score indicates better status. Baruth 2013; Basen-Enquist 2006;
Cadmus 2009; Cormie 2014; Duijits
2012; Kiecolt-Glaser 2014; McKenzie
2003; Mehnert 2011; Mustian 2004
Single question on perceived general health Higher score indicates better status. Rogers 2009
Perceived physical function
Physical condition - Body Esteem Scale
(BES)
Higher score indicates better status. Pinto 2003; Pinto 2005
Physical strength - Body Image and Rela-
tionships Scale (BIRS)
Higher score indicates worse status. Schmitz 2009
Physical global - CARES-SF Higher score indicates worse status. Schmitz 2005
Physical function - EORTC QLQ-C30 Higher score indicates better status. Do 2015; Herrero 2006; Mehnert 2011;
Saarto 2012
Physical well-being - FACT-G Higher score indicates better status. Banasik 2011; Cadmus 2009; Courneya
2003; Daley 2007; Littman 2012; Loh
2014; Milne 2008; Murtezani 2014;
Naumann 2012; Rogers 2009; Rogers
2015; Vallance 2007
Physical well-being - IBCSG Higher score indicates better status. Baruth 2013
Physical function - MOS SF-12 Higher score indicates better status. Cuesta-Vargas 2014; Fillion 2008
Physical function composite score - MOS
SF-36
Higher score indicates better status. Baruth 2013; Cormie 2014; Duijits 2012;
McKenzie 2003; Mehnert 2011; Mustian
2004; Schmitz 2009; Winters-Stone 2011
Role function
Marital global score - CARES-SF Higher score indicates
worse status.
Schmitz 2005
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Table 1. HRQoL subscales and HRQoL-related instruments used by investigators (Continued)
Role function - EORTC QLQ-C30 Higher score indicates better status. Do 2015; Herrero 2006; Mehnert 2011;
Saarto 2012
Functional well-being - FACT-G Higher score indicates better status. Banasik 2011; Cadmus 2009; Courneya
2003; Daley 2007; Littman 2012; Loh
2014; Milne 2008; Murtezani 2014;
Naumann 2012; Rogers 2009; Rogers
2015; Vallance 2007
Function - LYMQOL Higher score indicates
worse status.
Loudon 2014
Physical role function - MOS SF-36 Higher score indicates better status. Baruth 2013; Basen-Enquist 2006;
Cadmus 2009; Cormie 2014; Duijits
2012; Kiecolt-Glaser 2014; McKenzie
2003; Mehnert 2011; Mustian 2004
Sexuality
Sexual attractiveness - BES Higher score indicates
better status.
Pinto 2003; Pinto 2005
Appearance and sexuality - BIRS Higher score indicates
worse status.
Schmitz 2009





Sexual global - CARES-SF Higher score indicates
worse status.
Schmitz 2005






Pittsburgh Sleep Quality Index (PSI) Higher score indicates
worse status.
Bower 2011; Carson 2009; Kiecolt-Glaser
2014; Payne 2008; Rogers 2009; Rogers
2013; Rogers 2014
Sleep disturbance (0 to 9 scale) Higher score indicates
higher disturbance.
Carson 2009
Sleep objectively via accelerometers Higher sleep time and efficiency indicate
better status.
Rogers 2013; Rogers 2014
Social function
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Table 1. HRQoL subscales and HRQoL-related instruments used by investigators (Continued)
Social functioning - BIRS Higher score indicates
worse status.
Schmitz 2009
Body Image Questionnaire (BIQ) Higher score indicates
worse status.
Mehnert 2011
Social function - EORTC QLQ-C30 Higher score indicates better status. Herrero 2006; Mehnert 2011; Saarto 2012
Social well-being - FACT-G Higher score indicates better status. Banasik 2011; Cadmus 2009; Courneya
2003; Daley 2007; Littman 2012; Loh
2014; Milne 2008; Murtezani 2014;
Naumann 2012; Rogers 2009; Rogers
2015; Vallance 2007
Social support - IBCSG Higher score indicates better status. Baruth 2013
Social functioning - MOS SF-36 Higher score indicates better status. Baruth 2013; Basen-Enquist 2006;
Cadmus 2009; Cormie 2014; Duijits
2012; Kiecolt-Glaser 2014; McKenzie
2003; Mehnert 2011; Mustian 2004














Duijits 2012; Heim 2007; Mehnert 2011;
Musanti 2012
Tension-anxiety - POMS Higher score indicates
worse status.
Cantarero-Villanueva 2013; Fillion 2008;
Pinto 2003
Anxiety - Patient Reported Outcomes Mea-




Social Physique Anxiety Scale-7 (SPAS-7) Higher score indicates
worse status.
Milne 2008
State-Trait Anxiety Index (STAI) Higher score indicates
worse status.
Cadmus 2009; Segar 1998
Cohen’s 10-item perceived stress scale Higher score indicates
worse status.
Bower 2011; Cadmus 2009
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Table 1. HRQoL subscales and HRQoL-related instruments used by investigators (Continued)




Beck Depression Inventory (BDI) Higher score indicates
worse status.
Bower 2011; Daley 2007; Ergun 2013;
Kaltsatou 2011; Naumann 2012; Saarto
2012; Segar 1998




Cadmus 2009; Kiecolt-Glaser 2014; Payne
2008; Schmitz 2005
DASS-21 Higher score indicates
worse status.
Loh 2014
HADS Higher score indicates
worse status.
Duijits 2012; Heim 2007; Mehnert 2011;
Musanti 2012
Depression subscale - POMS Higher score indicates
worse status.
Cantarero-Villanueva 2013; Fillion 2008;
Pinto 2003




Brief Fatigue Inventory Higher score indicates
worse status.
Ergun 2013
Fatigue subscale - FACT-F Higher score indicates
better status.
Baruth 2013; Courneya 2003; Littman
2012; Loh 2014; Peppone 2015; Rogers
2009; Saarto 2012; Short 2014; Vallance
2007
Likert scale responses to fatigue-related




Linear visual analogue scale (VAS) for fa-
tigue (0 to 10)
Higher score indicates
worse status.
Loudon 2014; Pinto 2005




Bower 2011; Fillion 2008; Heim 2007;
Peppone 2015; Rogers 2013; Rogers 2014
Fatigue subscale - POMS Higher score indicates
worse status.
Cantarero-Villanueva 2013; Pinto 2003
Fatigue - PROMIS Higher score indicates
worse status.
Rogers 2014
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Table 1. HRQoL subscales and HRQoL-related instruments used by investigators (Continued)
Revised Piper Fatigue Scale (PFS) Higher score indicates
worse status.
Cantarero-Villanueva 2013; Cuesta-Vargas
2014; Daley 2007; Musanti 2012;
Naumann 2012; Payne 2008
Schwartz Cancer Fatigue Scale (SCFS) Higher score indicates
worse status.
Milne 2008; Winters-Stone 2011




2-Item Fordyce Happiness Measure Higher score indicates
better status.
Cadmus 2009
Happiness measure Higher score indicates
better status.
Courneya 2003
Life Satisfaction Inventory (LSI) Higher score indicates
better status.
Kaltsatou 2011




Brief Pain Inventory (BPI) Higher score indicates
worse status.
Cormie 2014; Fillion 2008; Irwin 2015




Cormie 2014; Irwin 2015; Portela 2008
Pain subscale - EORTC QLQ-C30 Higher score indicates
worse status.
Do 2015; Mehnert 2011
Pain scale - MOS SF-36 Higher score indicates
better status.
Baruth 2013; Basen-Enquist 2006;
Cadmus 2009; Cormie 2014; Duijits
2012; Mehnert 2011; Mustian 2004
University of Rochester Cancer Center




Pain VAS 0 to 10 Higher score indicates
worse status.
Loudon 2014
5-Point Likert scale version of 24-item
Western Ontario and McMaster Universi-
ties Osteoarthritis Index (WOMAC)
Higher score indicates
worse status.
Irwin 2015; Rogers 2009
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Table 1. HRQoL subscales and HRQoL-related instruments used by investigators (Continued)




BES Higher score indicates
better status.
Pinto 2003; Pinto 2005
Body Image Questionnaire (BIQ) Higher score indicates
worse status.
Mehnert 2011









Do 2015; Duijits 2012; Saarto 2012
Physical Self-Perception Profile Higher score indicates
better status.
Daley 2007; Musanti 2012
Rosenberg Self-Esteem Scale (RSE) Higher score indicates
better status.
Cadmus 2009; Courneya 2003; Musanti
2012; Mustian 2004; Segar 1998




Vitality scale - MOS SF-36 Higher score indicates
better status.
Baruth 2013; Basen-Enquist 2006;
Cadmus 2009; Cormie 2014; Duijits
2012; Kiecolt-Glaser 2014; Mehnert 2011;
Mustian 2004
Vigour subscale - POMS Higher score indicates
better status.
Cantarero-Villanueva 2013; Fillion 2008;
Pinto 2003; Pinto 2005
Other psychological measures





Behavioral Regulation for Exercise Ques-
tionnaire 2 (BREQ-2)
Higher score indicates higher status of each
subscale.
Milne 2008




Duijits 2012; Rogers 2009
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Table 1. HRQoL subscales and HRQoL-related instruments used by investigators (Continued)
Exercise role identity - 9-item, 5-point Lik-
ert-type instrument (Anderson and Cy-
chosz)
Higher score indicates
greater exercise role identity.
Hatchett 2013
















Menopausal symptoms 0 to 9 scale Higher score indicates
worse status.
Carson 2009














DeNysschen 2011; Mehnert 2011
Urinary symptoms - Bristol Female Lower





Table 2. Physical fitness, physical activity, and body composition measurement instruments used by investigators
Instrument or test name Outcome Measurement units Trials using this instrument or
test
12-Minute walk test Cardiorespiratory fitness Distance covered in metres Murtezani 2014; Portela 2008
2-Kilometre walking test Cardiorespiratory fitness Time to complete in minutes Nikander 2007; Saarto 2012
6-Minute walk test Cardiorespiratory fitness Distance covered in metres Basen-Enquist 2006; Kaltsatou
2011; Kim 2015; Mustian
2004; Nieman 1995
Aerobic Power Index cycle test Cardiorespiratory fitness Relative power output in W/kg Milne 2008
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Table 2. Physical fitness, physical activity, and body composition measurement instruments used by investigators (Continued)
Astrand-Rhyming cycle test Cardiorespiratory fitness Estimated maximal oxygen up-




Cardiorespiratory fitness Distance covered in metres Daley 2007; Fillion 2008
Graded exercise treadmill test Cardiorespiratory fitness Direct VO max in mL/kg/min DeNysschen 2011; Dolan
2016; Irwin 2015
Graded exercise cycle ergometer
test
Cardiorespiratory fitness Direct VO max in mL/kg/min Courneya 2003; Herrero 2006;
Mehnert 2011
Harvard step test Cardiorespiratory fitness Heart rate in beats per minute
(bpm) post test
Heim 2007
Modified Bruce protocol Cardiorespiratory fitness Estimated VO max in mL/kg/
min




Cardiorespiratory fitness Estimated VO max in mL/kg/
min
Do 2015; Rogers 2009; Rogers
2013; Rogers 2014; Rogers
2015
Rockport 1-mile walk test Cardiorespiratory fitness Time to complete in minutes Pinto 2005
7-Day Physical Activity Recall
(PAR)
Self-reported physical activity Minutes/week Basen-Enquist 2006; Cadmus
2009; Hatchett 2013; Pinto
2005; Pinto 2015
Community Health Activities
Model Programme for Seniors
(CHAMPS)
Self-reported physical activity Metabolic equivalent (MET)-h/
week
Baruth 2013; Kiecolt-Glaser




Self-reported physical activity MET-h/week Schmitz 2009
Physical activity questionnaire Self-reported physical activity Minutes/week Irwin 2015; Kriska 1990
Leisure Score Index (LSI) of
Godin Leisure-Time Exercise
Questionnaire
Self-reported physical activity Minutes/week Courneya 2003; Guinan 2013;
Kim 2015; Rogers 2009; Rogers




Self-reported physical activity MET-h/week Littman 2012
Physical Activity Recall Ques-
tionnaire
Self-reported physical activity MET-h/week Saarto 2012
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Table 2. Physical fitness, physical activity, and body composition measurement instruments used by investigators (Continued)
Accelerometer Objective physical activity Counts per minute/d Guinan 2013; Matthews 2007;
Pinto 2005; Pinto 2015; Rogers
2009; Rogers 2013; Rogers
2014; Rogers 2015
Pedometer Objective physical activity Steps/d Cadmus 2009; Nikander 2007;
Short 2014; Vallance 2007
Body fat via bioelectrical
impedance analysis (BIA)
Body composition % and/or kg Cerulli 2014; Daley 2007;
Guinan 2013; Ligibel 2008;
Matthews 2007; Musanti 2012;
Mustian 2004; Rogers 2013;
Rogers 2014
Body fat and lean mass via
dual-energy X-ray absorptiom-
etry (DEXA)
Body composition % and/or kg Cadmus 2009; DeNysschen
2011; Matthews 2007; Rogers
2009; Saarto 2012; Schmitz
2005; Schmitz 2009; Winters-
Stone 2011
Body fat and muscle mass via
multi-slice magnetic resonance
imaging (MRI)
Body composition % and kg Herrero 2006
Body mass index (BMI) Anthropometric kg/m² Basen-Enquist 2006; Cadmus
2009; Courneya 2003; Daley
2007; Kiecolt-Glaser 2014;
Ligibel 2008; Littman 2012;
Murtezani 2014; Mustian 2004;
Naumann 2012; Nikander
2007; Pinto 2003; Portela 2008;
Rahnama 2010; Rogers 2009;
Rogers 2013; Rogers 2014;
Schmitz 2005; Schmitz 2009
Body mass Anthropometric kg Cadmus 2009; Courneya 2003;
Daley 2007; DeNysschen
2011; Dolan 2016; Guinan
2013; Herrero 2006; Irwin
2015; Kiecolt-Glaser 2014;
Ligibel 2008; Littman 2012;
Matthews 2007; Murtezani
2014; Musanti 2012; Naumann
2012; Nikander 2007; Pinto
2003; Rahnama 2010; Saarto
2012; Schmitz 2005; Schmitz
2009; Winters-Stone 2011
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Table 2. Physical fitness, physical activity, and body composition measurement instruments used by investigators (Continued)
Skinfold thickness Body composition mm and/or % Courneya 2003; Herrero 2006;
Naumann 2012
Hip circumference Anthropometric cm Basen-Enquist 2006; Cadmus
2009; Dolan 2016; Ligibel
2008; Littman 2012; Rahnama
2010; Rogers 2009
Waist circumference Anthropometric cm Basen-Enquist 2006; Cadmus
2009; Dolan 2016; Guinan
2013; Ligibel 2008; Littman
2012; Rahnama 2010; Rogers
2009; Schmitz 2005
Waist-to-hip ratio Anthropometric NA Ligibel 2008; Rahnama 2010;
Rogers 2009; Rogers 2013;
Rogers 2014
Handgrip strength Muscular strength kg Irwin 2015; Kaltsatou 2011;
Kim 2015; Mustian 2004;





Muscular strength kg Cormie 2014; Milne 2008;
Musanti 2012; Naumann 2012;
Schmitz 2005; Schmitz 2009;
Winters-Stone 2011)
RM leg press Muscular strength kg Cerulli 2014; Cormie 2014;
Dolan 2016; Milne 2008;
Musanti 2012; Naumann 2012;
Schmitz 2005; Schmitz 2009;
Winters-Stone 2011
Total bone mineral content
(BMC)
Bone-related outcomes g/cm Cadmus 2009; Saarto 2012
BMC of distal tibia, tibial mid-
shaft, and femoral neck
Bone-related outcomes g/cm Saarto 2012
Bone mineral density (BMD)
via DEXA
Bone-related outcomes g/cm² Cadmus 2009; Kim 2015;
Rogers 2009; Saarto 2012;
Waltman 2010; Winters-Stone
2011
BMD of femoral neck and lum-
bar spine
Bone-related outcomes g/cm² Kim 2015; Rogers 2009; Saarto
2012; Waltman 2010; Winters-
Stone 2011
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Table 2. Physical fitness, physical activity, and body composition measurement instruments used by investigators (Continued)
BMD greater trochanter via
DEXA
Bone-related outcomes g/cm² Winters-Stone 2011
BMD total hip via DEXA Bone-related outcomes g/cm² Kim 2015; Waltman 2010;
Winters-Stone 2011
BMD total radius and 33% ra-
dius via DEXA
Bone-related outcomes g/cm² Waltman 2010
Bone Remodeling Index (BRI) Bone-related outcomes NA Mustian 2004
Serum bone-specific alkaline
phosphatase (BSAP)
Bone-related outcomes µg/L Mustian 2004; Waltman 2010
SerumN-telopeptides of type I
collagen (NTx)
Bone-related outcomes nm bone collagen equivalent
(BCE)
Kim 2015; Mustian 2004;
Waltman 2010
Serum osteocalcin Bone-related outcomes nmol Winters-Stone 2011








to end of intervention
estimate (95% CI)
Change from baseline




Cognitive function SMD: 0.40 (0.11 to 0.
69)
N women (trials): 189
(5)
I² = 0%
SMD: 0.31 (-0.09 to 0.
71)
N women (trials): 97 (2)
I² = 0%
SMD: -0.00 (-0.27 to 0.
26)
N women (trials): 672
(5)
I² = 35%
SMD: 0.20 (-0.20 to 0.
60)




SMD: 0.21 (0.10 to 0.
32)
N women (trials): 2102
(26)
I² = 27%
SMD: 0.20 (0.03 to 0.
36)
N women (trials): 655
(7)
I² = 10%
SMD: 0.31 (0.09 to 0.
53)
N women (trials): 1579
(15)
I² = 72%
SMD: 0.06 (-0.29 to 0.
41)





SMD: 0.18 (-0.08 to 0.
45)
N women (trials): 456
(1)
I² = 47%
NA SMD: 0.17 (-0.07 to 0.
40)
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Table 3. Meta-analysis findings for each HRQoL subscale and secondary outcome (Continued)
Perceived physical func-
tion
SMD: 0.33 (0.18 to 0.
49)
N women (trials): 2129
(25)
I² = 61%
SMD: 0.21 (0.06 to 0.
37)
N women (trials): 637
(6)
I² = 0%
SMD: 0.60 (0.23 to 0.
97)




Role function SMD: 0.29 (0.07 to 0.
51)
N women (trials): 1370
(18)
I² = 69%
SMD: 0.13 (-0.12 to 0.
38)
N women (trials): 249
(2)
I² = 0%
SMD: 0.14 (-0.05 to 0.
33)




Sexual function SMD: 0.16 (-0.04 to 0.
35)
N women (trials): 411
(5)
I² = 0%
NA SMD: 0.22 (-0.08 to 0.
52)




Sleep SMD: -0.09 (-0.37 to 0.
20)
N women (trials): 188
(5)
I² = 0%
NA SMD: 0.14 (-0.20 to 0.
48)




Social function SMD: 0.19 (0.08 to 0.
30)
N women (trials): 1557
(18)
I² = 11%
NA SMD: 0.52 (0.16 to 0.
87)





Anxiety SMD: -0.57 (-0.95 to -
0.19)
N women (trials): 326
(7)
I² = 60%
NA SMD: -0.37 (-0.63 to -
0.12)




Depression SMD: -0.34 (-0.62 to -
0.05)
N women (trials): 657
(12)
I² = 63%
SMD: -0.28 (-0.51 to -
0.05)
N women (trials): 340
(4)
I² = 9%
SMD: -0.34 (-0.63 to -
0.05)




Fatigue SMD: -0.32 (-0.47 to -
0.18)
N women (trials): 2020
(26)
I² = 54%
SMD: -0.43 (-0.60 to -
0.26)
N women (trials): 536
(7)
I² = 0%
SMD:-0.30 (-0.61 to 0.
00)
N women (trials): 1289
(13)
I² = 80%
SMD: -0.47 (-0.84 to -
0.11)
N women (trials): 178
(4)
I² = 23%
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Table 3. Meta-analysis findings for each HRQoL subscale and secondary outcome (Continued)
Happiness/satisfaction
with life
SMD: 0.61 (-0.16 to 1.
37)
N women (studies): 209
(4)
I² = 85%
NA SMD: 0.28 (-0.05 to 0.
62)




Pain/disability SMD: 0.08 (-0.09 to 0.
25)
N women (trials): 535
(9)
I² = 0%
NA SMD: -0.08 (-0.33 to 0.
16)




Self-esteem SMD: 0.27 (0.05 to 0.
48)
N women (trials): 667
(12)
I² = 42%
NA SMD: 0.23 (-0.11 to 0.
58)




Vigour/vitality SMD: 0.36 (0.21 to 0.
50)
N women (trials): 762
(10)
I² = 0%
SMD: 0.26 (0.04 to 0.
48)
N women (trials): 454
(4)
I² = 24%
SMD: 0.23 (0.00 to 0.
45)
N women (trials): 359
(6)
I² = 10%
SMD: 0.20 (-0.06 to 0.
46)






SMD: 0.44 (0.30 to 0.
58)
N women (trials): 1265
(23)
I² = 30%
SMD: 0.36 (0.03 to 0.
69)
N women (trials): 362
(3)
I² = 53%
SMD: 0.83 (0.40 to 1.
27)
N women (trials): 863
(9)
I² = 82%
SMD: 0.42 (0.05 to 0.
79)





MD: 1.89 (0.65 to 3.13)
N women (trials): 199
(4)
I² = 0%
NA MD: 1.31 (0.66 to 1.96)




Peak power output (W) MD: 18.92 (9.64 to 28.
20)
N women (trials): 66 (2)
I² = 0%
NA NA NA
Resting heart rate (bpm) MD: -4.47 (-7.94 to -1.
00)
N women (trials): 82 (2)
I² = 0%
NA MD: -1.05 (-2.22 to 0.
11)





MD: -0.83 (-3.72 to 2.
05)
NA MD: -1.12 (-7.74 to 5.
50)
NA
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Table 3. Meta-analysis findings for each HRQoL subscale and secondary outcome (Continued)
N women (trials): 134
(4)
I² = 0%





MD: 0.66 (-2.89 to 4.
21)
N women (trials): 106
(3)
I² = 22%
NA MD: 0.53 (-1.61 to 2.
68)







SMD: 0.52 (0.33 to 0.
71)
N women (trials): 2012
(17)
I² = 72%
SMD: 0.44 (0.17 to 0.
72)
N women (trials): 683
(4)
I² = 53%
SMD: 0.57 (0.25 to 0.
90)
N women (trials): 1274
(8)
I² = 82%
SMD: 0.51 (0.08 to 0.
93)






OR: 8.44 (2.41 to 29.
56)
N women (trials): 819
(6)
I² = 89%
OR: 3.11 (1.50 to 6.46)






SMD: 0.43 (0.19 to 0.
66)
N women (trials): 1248
(10)
I² = 67%
SMD: 0.22 (-0.21 to 0.
66)
N women (trials): 305
(3)
I² = 58%
SMD: 0.71 (0.14 to 1.
29)
N women (trials): 508
(5)
I² = 83%
SMD: 0.23 (-1.00 to 1.
46)




SMD: -1.45 (-3.68 to 0.
78)
N women (trials): 103
(3)
I² = 95%
NA SMD: -0.01 (-0.63 to 0.
60)





Mass (kg) MD: 0.00 (-0.57 to 0.
58)
N women (trials): 1210
(16)
I² = 0%
NA MD: -0.50 (-0.98 to -0.
01)




BMI (kg/m2) MD: 0.01 (-0.19 to 0.
22)
N women (trials): 1481
(17)
I² = 0%
NA MD: -0.22 (-0.45 to 0.
01)
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Table 3. Meta-analysis findings for each HRQoL subscale and secondary outcome (Continued)
Body fat SMD: -0.18 (-0.34 to -
0.03)
N women (trials): 1162
(18)
I² = 35%
NA SMD: -0.62 (-1.19 to -
0.06)




Lean mass MD: 0.05 (-0.11 to 0.
21)
N women (trials): 612
(8)
I² = 0%
NA MD: 0.80 (-0.13 to 1.
72)




Waist-to-hip ratio MD: -0.03 (-0.06 to 0.
01)
N women (trials): 213
(5)
I² = 54%
NA MD: 0.00 (-0.01 to 0.
01)






MD: -0.50 (-3.18 to 2.
18)
N women (trials): 330
(6)
I² = 0%
NA MD: -1.71 (-2.56 to -0.
86)




Hip circumference (cm) MD: -0.97 (-3.96 to 2.
01)
N women (trials): 249
(4)
I² = 0%
NA MD: -2.37 (-3.31 to -1.
44)





Lower body strength SMD: 0.44 (0.09 to 0.
78)
N women (trials): 637
(10)
I² = 74%
NA SMD: 0.72 (0.38 to 1.
07)




Upper body strength SMD: 0.42 (0.08 to 0.
76)
N women (trials): 13
(768)
I² = 79%
NA SMD: 0.72 (0.30 to 1.
14)




Grip strength MD: 2.37 kg (0.20 to 4.
55)
N women (trials): 320
(7)
I² = 68%
NA SMD: 0.24 (-0.09 to 0.
58)
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SMD: 0.04 (-0.20 to 0.
27)





mineral density - femoral
neck (change and postin-
tervention values)
SMD: 0.21 (-0.13 to 0.
55)




Bone mineral density -
lum-
bar spine (change and
postintervention values)
SMD: 0.22 (-0.09 to 0.
53)




Bone mineral density -
total hip (change and
postintervention values)
SMD: 0.58 (-0.02 to 1.
18)








SMD: -0.25 (-1.81 to 1.
31)





serum NTx (change and
postintervention values)
SMD: 0.38 (-1.58 to 2.
34)








SMD: standardised mean difference.
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A P P E N D I C E S
Appendix 1. MEDLINE
PubMed search:
1. (randomized controlled trial[pt] OR controlled clinical trial[pt] OR randomized[tiab] OR placebo[tw] OR drug therapy[sh] OR
randomly[tiab] OR trial[tiab] OR groups[tiab])
2. (((Breast neoplasms[mh] OR ((breast[mh] OR breast diseases[mh]) AND neoplasms[mh])) AND humans[mh]) OR DCIS[tiab]
OR LCIS[tiab] OR ductal carcinoma in situ[tiab] OR lobular carcinoma in situ[tiab] OR (breast[tiab] AND (ductal carcinoma*[ti]
OR lobular carcinoma*[ti])) OR ((Breast[ti] OR mammary[ti]) AND (cancer*[ti] OR neoplas*[ti] OR tumor*[ti] OR tumour*[ti] OR
carcinoma*[ti] OR malignan*[ti] OR sarcoma[ti] OR lymphoma[ti])))
3. (((Breast neoplasms[mh] OR ((breast[mh] OR breast diseases[mh]) AND neoplasms[mh])) AND humans[mh]) OR DCIS[tiab]
OR LCIS[tiab] OR ductal carcinoma in situ[tiab] OR lobular carcinoma in situ[tiab] OR (breast[tiab] AND (ductal carcinoma*[ti]
OR lobular carcinoma*[ti])) OR ((Breast[ti] OR mammary[ti]) AND (cancer*[ti] OR neoplas*[ti] OR tumor*[ti] OR tumour*[ti]
OR carcinoma*[ti] OR malignan*[ti] OR sarcoma[ti] OR lymphoma[ti]))) AND (Neoplasm Metastasis[Mh] OR secondary[sh] OR
Neoplasm Recurrence, Local[mh] OR metast*[tiab] OR advanced[tiab] OR recurren*[tiab] OR HER-2*[tiab] OR HER2*[tiab] OR
N1[tiab] OR N2[tiab] OR N2a[tiab] OR N2b[tiab] OR N3[tiab] OR N3a[tiab] OR N3b[tiab] OR N3c[tiab] OR M1[tiab] OR
pN1*[tiab] OR pN2*[tiab] OR pN3*[tiab] OR stage IV[tiab] OR stage four[tiab] OR stage 4[tiab] OR local*[tiab] OR loco*[tiab]
OR region*[tiab] OR LABC[tiab] OR T3[tiab] OR T4[tiab] OR Stage III*[tiab] OR Stage three*[tiab] OR stage 3*[tiab])
4. #2 NOT #3
5. (Exercise [mh] OR exercis*[tiab] OR Motor activity[mh] OR Sports[mh] OR sport*[tiab] OR Resistance training[mh] OR train-
ing[tiab] OR fitness[tiab] OR physical activity[tiab] OR physical activities[tiab] OR physical activity intervention*[tiab] OR exercise
intervention* OR active[tiab])
6. #1 AND #4 AND #5
7. Animals [MH] NOT Humans [mh]
8. #6 not #7
Appendix 2. Embase
Embase.com search:
1. random* OR factorial* OR crossover* OR cross NEXT/1 over* OR placebo* OR (doubl* AND blind*) OR (singl* AND blind*)
OR assign*OR allocat* OR volunteer* OR ’crossover procedure’/exp OR ’double blind procedure’/exp OR ’randomized controlled
trial’/exp OR’single blind procedure’/exp
2. ’breast cancer’/exp OR ’breast cancer’
3. ’breast neoplasm’
4. ’breast carcinoma’/exp OR ’breast carcinoma’
5. ’breast tumour’
6. ’breast tumor’/exp OR ’breast tumor’
7. ’mamma carcinoma’/exp OR ’mamma carcinoma’
8. ’mammary neoplasm’
9. ’mammary carcinoma’/exp OR ’mammary carcinoma’
10. ’mammary gland carcinoma’
11. #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10
12. (metastatic OR advance) AND (’breast cancer’/exp OR ’breast neoplasm’ OR ’breast carcinoma’/exp OR ’breast tumour’ OR ’breast
tumor’/exp)
13. #11 NOT #12
14. ’exercise’/exp OR ’exercise’
15. exercis*
16. ’sport’/exp OR ’sport’
17. sport*
18. ’resistance training’/exp OR ’resistance training’
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19. ’training’/exp OR training
20. ’fitness’/exp OR fitness
21. ’physical activity’/exp OR ’physical activity’
22. ’physical activities’
23. physical NEAR/6 activit*
24. ’physical activity intervention’
25. ’physical activity interventions’
26. ’exercise interventions’
27. ’exercise intervention’
28. #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27
29. #1 AND #13 AND #28
30. #29 NOT ([animals]/lim NOT [humans]/lim)
31. #30 AND [embase]/lim
Appendix 3. CENTRAL
The Cochrane Library search:
1. MeSH descriptor: [Breast Neoplasms] explode all trees
2. breast near cancer* or breast near neoplasm* or breast near carcinoma* or breast near tumour* or breast near tumor*
3. #1 or #2
4. (metastatic or advance) and (breast cancer or breast neoplasm or breast carcinoma or breast tumour or breast tumor)
5. #3 not #4
6. MeSH descriptor: [Exercise] explode all trees
7. exercis*
8. MeSH descriptor: [Motor Activity] explode all trees
9. MeSH descriptor: [Sports] explode all trees
10. sport*




15. physical activity intervention*
16. exercise intervention*
17. active
18. #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17
19. #5 and #18
Appendix 4. WHO ICTRP
Basic searches:
1. Physical activity for women with breast cancer after adjuvant therapy
2. Breast cancer AND physical activit*
3. Breast cancer AND physical activity intervention*
4. Breast cancer AND exercise intervention*
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Advanced searches:
1. Title: Physical activity for women with breast cancer after adjuvant therapy
Recruitment: ALL
2. Condition: breast cancer
Intervention: physical activit*
Recruitment: ALL
3. Condition: breast cancer
Intervention: physical activity intervention*
Recruitment: ALL





1. Physical activity for women with breast cancer after adjuvant therapy
2. Breast cancer AND physical activity
3. Breast cancer AND physical activities
4. Breast cancer AND physical activity intervention
5. Breast cancer AND physical activity interventions
6. Breast cancer AND exercise intervention
7. Breast cancer AND exercise interventions
Advanced searches:
1. Title: breast surgery for metastatic breast cancer
Recruitment: All studies
Study Results: All studies
Study Type: All studies
Gender: All studies
2. Condition: breast cancer NOT (advanced breast cancer OR metastatic breast cancer)
Intervention: physical activity intervention OR exercise intervention physical activity interventions OR exercise interventions
Recruitment: All studies
Study Results: All studies
Study Type: All studies
Gender: All studies
3. Condition: breast cancer NOT (advanced breast cancer OR metastatic breast cancer)
Intervention: physical activity OR physical activities
Recruitment: All studies
Study Results: All studies
Study Type: All studies
Gender: All studies
909Physical activity for women with breast cancer after adjuvant therapy (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 6. CINAHL
EBSCOhost search:
S1. (MH “Clinical Trials+”)
S2. PT Clinical trial
S3. TX clinic* n1 trial*
S4. TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S5. TX randomi* control* trial*
S6. (MH “Random Assignment”)
S7. TX random* allocat*
S8. TX placebo*
S9. (MH “Placebos”)
S10. (MH “Quantitative Studies”)
S11. TX allocat* random*
S12. S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11






S19. S13 OR S14 OR S15 OR S16 OR S17 OR S18
S20. “metastatic breast cancer”
S21. “metastatic breast neoplasm”
S22. “metastatic breast carcinoma”
S23. “metastatic breast tumour”
S24. “metastatic breast tumor”
S25. “advanced breast cancer”
S26. “advanced breast neoplasm”
S27. “advanced breast carcinoma”
S28. “advanced breast tumour”
S29. “advanced breast tumor”
S30. S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29
S31. S19 NOT S30
S32. (MH “Exercise+”)
S33. “exercis*”
S34. (MH “Motor Activity+”)
S35. (MH “Sports+”)
S36. “sport*”
S37. (MH “Resistance Training”)
S38. “training”
S39. “fitness”
S40. (MH “Physical Activity”)
S41. “physical activit*”
S42. “physical activity intervention*”
S43. “exercise intervention*”
S44. “active”
S45. S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44
S46. S12 AND S31 AND S45
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Appendix 7. PEDro
1. Abstract & Title: breast cancer AND physical activity
Method: clinical trial
2. Abstract & Title: breast cancer AND exercise
Method: clinical trial
3. Abstract & Title: breast cancer AND physical activity intervention
Method: clinical trial
4. Abstract & Title: breast cancer AND exercise intervention
Method: clinical trial
5. Abstract & Title: breast cancer AND resistance training
Method: clinical trial
6. Abstract & Title: breast cancer AND strength training
Method: clinical trial
7. Abstract & Title: breast cancer AND weight lifting
Method: clinical trial





S4. randomized controlled trial
S5. controlled clinical trial
S6. random*
S7. S1 OR S2 OR S3 OR S4 OR S5 OR S6
S8. breast cancer OR breast neoplasm OR breast carcinoma OR breast tumour OR breast tumor
S9. (metastatic or advance) AND (breast cancer OR breast neoplasm OR breast carcinoma OR breast tumour OR breast tumor)
S10. S8 NOT S9
S11. exercis* OR sport* OR training OR fitness OR physical activit* OR physical activity intervention* OR exercise intervention* OR
active OR resistance training OR strength training OR weight lifting
S12. S7 AND S10 AND S11
Appendix 9. PsycINFO
Searches
1 exp Treatment Effectiveness Evaluation/
2 exp Treatment Outcomes/
3 exp Placebo/
4 exp Followup Studies/
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8 (clinical adj3 trial*).mp.
9 (research adj3 design).mp.
10 (evaluat* adj3 stud*).mp.
11 (clinical adj3 trial*).mp.
12 (research adj3 design).mp.
13 (evaluat* adj3 stud*).mp.
14 (prospectiv* adj3 stud*).mp.
15 ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).mp
16 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15
17 exp Breast Neoplasms/
18 (breast adj6 cancer$).mp.
19 (breast adj6 neoplasm$).mp.
20 (breast adj6 carcinoma$).mp.
21 (breast adj6 tumour$).mp.
22 (breast adj6 tumor$).mp.
23 17 or 18 or 19 or 20 or 21 or 22
24 ((metastatic or advance*) and (breast cancer* or breast neoplasm* or breast carcinoma* or breast tumour* or breast tumor*)).af
25 23 not 24
26 (exercis* or resistance training or training or fitness or physical activit* or physical activity intervention* or exercise intervention*
or active).mp
27 exp Exercise/ or exp Aerobic Exercise/ or exp Physical Activity/ or exp Training/ or exp Physical Fitness/
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(Continued)
28 26 or 27
29 16 and 25 and 28
30 Animals/ not Humans/
31 29 not 30
C O N T R I B U T I O N S O F A U T H O R S
• Drafting the protocol: IML, GSM, ANM, ARC.
• Selecting studies: IML, GSM.
• Extracting data from studies: IML, GSM.
• Entering data into RevMan: IML.
• Carrying out the analysis: IML, GSM, ANM.
• Interpreting the analysis: IML, GSM, ANM.
• Drafting the final review: IML, GSM, ANM, ARC.
• Resolving disagreements: ANM, ARC.
• Updating the review: IML, GSM.
D E C L A R A T I O N S O F I N T E R E S T
None known.
S O U R C E S O F S U P P O R T
Internal sources
• No support provided, UK.
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External sources
• No support provided, UK.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
Review authors did not perform planned analysis of effects of physical activity on blood biomarkers because we considered these
outcomes to be beyond the scope of the current review, and because the prognostic value of blood biomarkers for breast cancer
populations remains uncertain (Ballard-Barbash 2012). We originally planned to conduct a subgroup analysis by treatment regimen
(chemotherapy vs no chemotherapy). However, the numbers of trials conducted with patients who had not undergone chemotherapy
were insufficient for performance of this analysis.
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